--
-- PostgreSQL database dump
--

SET statement_timeout = 0;
SET lock_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SET check_function_bodies = false;
SET client_min_messages = warning;

--
-- Name: plpgsql; Type: EXTENSION; Schema: -; Owner: 
--

CREATE EXTENSION IF NOT EXISTS plpgsql WITH SCHEMA pg_catalog;


--
-- Name: EXTENSION plpgsql; Type: COMMENT; Schema: -; Owner: 
--

COMMENT ON EXTENSION plpgsql IS 'PL/pgSQL procedural language';


--
-- Name: hstore; Type: EXTENSION; Schema: -; Owner: 
--

CREATE EXTENSION IF NOT EXISTS hstore WITH SCHEMA public;


--
-- Name: EXTENSION hstore; Type: COMMENT; Schema: -; Owner: 
--

COMMENT ON EXTENSION hstore IS 'data type for storing sets of (key, value) pairs';


SET search_path = public, pg_catalog;

--
-- Name: get_ancestry(integer); Type: FUNCTION; Schema: public; Owner: documentcloud
--

CREATE FUNCTION get_ancestry(root_id integer) RETURNS TABLE(id integer, parent_id integer, name character varying, extension character varying)
    LANGUAGE sql
    AS $_$
      WITH RECURSIVE ancestry(id, parent_id, name, extension) AS (
        SELECT id, parent_id, name, extension
        FROM groups
        WHERE id = $1
        UNION ALL
        SELECT C.id, C.parent_id, C.name, C.extension
        FROM ancestry P
        INNER JOIN groups C on P.parent_id = C.id
      )

      SELECT * from ancestry ORDER BY id ASC
      $_$;


ALTER FUNCTION public.get_ancestry(root_id integer) OWNER TO documentcloud;

--
-- Name: get_descendants(integer); Type: FUNCTION; Schema: public; Owner: documentcloud
--

CREATE FUNCTION get_descendants(group_id integer) RETURNS TABLE(group_id integer)
    LANGUAGE sql
    AS $_$
        WITH RECURSIVE descendants(group_id) AS (
          SELECT id AS group_id
          FROM groups
          WHERE id=$1
          UNION ALL
          SELECT id AS group_id
          FROM descendants D
          INNER JOIN groups G on G.parent_id = D.group_id
        )

      SELECT * from descendants ORDER BY group_id ASC
      $_$;


ALTER FUNCTION public.get_descendants(group_id integer) OWNER TO documentcloud;

SET default_tablespace = '';

SET default_with_oids = false;

--
-- Name: accounts; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE accounts (
    id integer NOT NULL,
    first_name character varying(40),
    last_name character varying(40),
    email character varying(100),
    hashed_password character varying(255),
    created_at timestamp without time zone,
    updated_at timestamp without time zone,
    identities hstore,
    language character varying(3),
    document_language character varying(3),
    disabled boolean
);


ALTER TABLE public.accounts OWNER TO postgres;

--
-- Name: accounts_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE accounts_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.accounts_id_seq OWNER TO postgres;

--
-- Name: accounts_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE accounts_id_seq OWNED BY accounts.id;


--
-- Name: annotation_groups; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE annotation_groups (
    id integer NOT NULL,
    annotation_id integer,
    group_id integer,
    created_by integer,
    qa_approved_by integer,
    based_on integer,
    approved_count integer,
    iteration integer
);


ALTER TABLE public.annotation_groups OWNER TO documentcloud;

--
-- Name: annotation_groups_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE annotation_groups_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.annotation_groups_id_seq OWNER TO documentcloud;

--
-- Name: annotation_groups_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE annotation_groups_id_seq OWNED BY annotation_groups.id;


--
-- Name: annotation_notes; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE annotation_notes (
    id integer NOT NULL,
    document_id integer,
    annotation_group_id integer,
    note text,
    addressed boolean,
    created_at timestamp without time zone,
    updated_at timestamp without time zone,
    group_id integer,
    iteration integer,
    de_ref integer
);


ALTER TABLE public.annotation_notes OWNER TO documentcloud;

--
-- Name: annotation_notes_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE annotation_notes_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.annotation_notes_id_seq OWNER TO documentcloud;

--
-- Name: annotation_notes_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE annotation_notes_id_seq OWNED BY annotation_notes.id;


--
-- Name: annotations; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE annotations (
    id integer NOT NULL,
    organization_id integer,
    account_id integer NOT NULL,
    document_id integer NOT NULL,
    page_number integer,
    access integer,
    title text NOT NULL,
    content text,
    location character varying(40),
    created_at timestamp without time zone,
    updated_at timestamp without time zone,
    moderation_approval boolean,
    templated boolean DEFAULT false,
    iteration integer,
    match_id integer,
    match_strength integer,
    is_graph_data boolean
);


ALTER TABLE public.annotations OWNER TO postgres;

--
-- Name: annotations_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE annotations_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.annotations_id_seq OWNER TO postgres;

--
-- Name: annotations_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE annotations_id_seq OWNED BY annotations.id;


--
-- Name: app_constants; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE app_constants (
    id integer NOT NULL,
    key character varying(255),
    value character varying(255)
);


ALTER TABLE public.app_constants OWNER TO postgres;

--
-- Name: app_constants_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE app_constants_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.app_constants_id_seq OWNER TO postgres;

--
-- Name: app_constants_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE app_constants_id_seq OWNED BY app_constants.id;


--
-- Name: collaborations; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE collaborations (
    id integer NOT NULL,
    project_id integer NOT NULL,
    account_id integer NOT NULL,
    creator_id integer
);


ALTER TABLE public.collaborations OWNER TO postgres;

--
-- Name: collaborations_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE collaborations_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.collaborations_id_seq OWNER TO postgres;

--
-- Name: collaborations_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE collaborations_id_seq OWNED BY collaborations.id;


--
-- Name: docdata; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE docdata (
    id integer NOT NULL,
    document_id integer NOT NULL,
    data hstore
);


ALTER TABLE public.docdata OWNER TO postgres;

--
-- Name: docdata_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE docdata_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.docdata_id_seq OWNER TO postgres;

--
-- Name: docdata_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE docdata_id_seq OWNED BY docdata.id;


--
-- Name: document_reviewers; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE document_reviewers (
    id integer NOT NULL,
    account_id integer NOT NULL,
    document_id integer NOT NULL,
    created_at timestamp without time zone,
    updated_at timestamp without time zone
);


ALTER TABLE public.document_reviewers OWNER TO postgres;

--
-- Name: document_reviewers_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE document_reviewers_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.document_reviewers_id_seq OWNER TO postgres;

--
-- Name: document_reviewers_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE document_reviewers_id_seq OWNED BY document_reviewers.id;


--
-- Name: documents; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE documents (
    id integer NOT NULL,
    organization_id integer NOT NULL,
    account_id integer NOT NULL,
    access integer NOT NULL,
    page_count integer DEFAULT 0 NOT NULL,
    title character varying(1000) NOT NULL,
    slug character varying(255) NOT NULL,
    source character varying(1000),
    language character varying(3),
    description text,
    calais_id character varying(40),
    publication_date date,
    created_at timestamp without time zone,
    updated_at timestamp without time zone,
    related_article text,
    detected_remote_url text,
    remote_url text,
    publish_at timestamp without time zone,
    text_changed boolean DEFAULT false NOT NULL,
    hit_count integer DEFAULT 0 NOT NULL,
    public_note_count integer DEFAULT 0 NOT NULL,
    reviewer_count integer DEFAULT 0 NOT NULL,
    file_size integer DEFAULT 0 NOT NULL,
    char_count integer DEFAULT 0 NOT NULL,
    original_extension character varying(255),
    file_hash text,
    study text,
    status integer,
    de_one_id integer,
    de_two_id integer,
    qc_id integer,
    qa_id integer,
    de_one_complete boolean,
    de_two_complete boolean,
    qa_note text,
    iteration integer,
    repository_id integer
);


ALTER TABLE public.documents OWNER TO postgres;

--
-- Name: documents_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE documents_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.documents_id_seq OWNER TO postgres;

--
-- Name: documents_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE documents_id_seq OWNED BY documents.id;


--
-- Name: entities; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE entities (
    id integer NOT NULL,
    organization_id integer NOT NULL,
    account_id integer NOT NULL,
    document_id integer NOT NULL,
    access integer NOT NULL,
    kind character varying(40) NOT NULL,
    value character varying(255) NOT NULL,
    relevance double precision DEFAULT 0.0 NOT NULL,
    calais_id character varying(40),
    occurrences text
);


ALTER TABLE public.entities OWNER TO postgres;

--
-- Name: entities_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE entities_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.entities_id_seq OWNER TO postgres;

--
-- Name: entities_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE entities_id_seq OWNED BY entities.id;


--
-- Name: entity_dates; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE entity_dates (
    id integer NOT NULL,
    organization_id integer NOT NULL,
    account_id integer NOT NULL,
    document_id integer NOT NULL,
    access integer NOT NULL,
    date date NOT NULL,
    occurrences text
);


ALTER TABLE public.entity_dates OWNER TO postgres;

--
-- Name: entity_dates_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE entity_dates_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.entity_dates_id_seq OWNER TO postgres;

--
-- Name: entity_dates_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE entity_dates_id_seq OWNED BY entity_dates.id;


--
-- Name: featured_reports; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE featured_reports (
    id integer NOT NULL,
    url character varying(255) NOT NULL,
    title character varying(255) NOT NULL,
    organization character varying(255) NOT NULL,
    article_date date NOT NULL,
    writeup text NOT NULL,
    present_order integer DEFAULT 0,
    created_at timestamp without time zone,
    updated_at timestamp without time zone
);


ALTER TABLE public.featured_reports OWNER TO postgres;

--
-- Name: featured_reports_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE featured_reports_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.featured_reports_id_seq OWNER TO postgres;

--
-- Name: featured_reports_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE featured_reports_id_seq OWNED BY featured_reports.id;


--
-- Name: file_status_histories; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE file_status_histories (
    id integer NOT NULL,
    status integer NOT NULL,
    "user" integer NOT NULL,
    created_at timestamp without time zone,
    updated_at timestamp without time zone
);


ALTER TABLE public.file_status_histories OWNER TO documentcloud;

--
-- Name: file_status_histories_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE file_status_histories_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.file_status_histories_id_seq OWNER TO documentcloud;

--
-- Name: file_status_histories_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE file_status_histories_id_seq OWNED BY file_status_histories.id;


--
-- Name: graph_groups; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE graph_groups (
    id integer NOT NULL,
    graph_id integer,
    group_id integer,
    graph_json text
);


ALTER TABLE public.graph_groups OWNER TO documentcloud;

--
-- Name: graph_groups_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE graph_groups_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.graph_groups_id_seq OWNER TO documentcloud;

--
-- Name: graph_groups_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE graph_groups_id_seq OWNED BY graph_groups.id;


--
-- Name: graphs; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE graphs (
    id integer NOT NULL,
    location text
);


ALTER TABLE public.graphs OWNER TO documentcloud;

--
-- Name: graphs_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE graphs_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.graphs_id_seq OWNER TO documentcloud;

--
-- Name: graphs_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE graphs_id_seq OWNED BY graphs.id;


--
-- Name: group_templates; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE group_templates (
    id integer NOT NULL,
    name text NOT NULL,
    created_at timestamp without time zone,
    updated_at timestamp without time zone,
    help_url text
);


ALTER TABLE public.group_templates OWNER TO documentcloud;

--
-- Name: group_templates_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE group_templates_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.group_templates_id_seq OWNER TO documentcloud;

--
-- Name: group_templates_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE group_templates_id_seq OWNED BY group_templates.id;


--
-- Name: groups; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE groups (
    id integer NOT NULL,
    name text NOT NULL,
    parent_id integer,
    template_id integer,
    document_id integer,
    created_at timestamp without time zone,
    updated_at timestamp without time zone,
    extension text,
    account_id integer,
    base boolean DEFAULT false,
    iteration integer,
    qa_approved_by integer,
    canon boolean,
    is_graph_data boolean
);


ALTER TABLE public.groups OWNER TO documentcloud;

--
-- Name: groups_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE groups_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.groups_id_seq OWNER TO documentcloud;

--
-- Name: groups_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE groups_id_seq OWNED BY groups.id;


--
-- Name: memberships; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE memberships (
    id integer NOT NULL,
    organization_id integer NOT NULL,
    account_id integer NOT NULL,
    role integer NOT NULL,
    "default" boolean DEFAULT false,
    concealed boolean DEFAULT false
);


ALTER TABLE public.memberships OWNER TO postgres;

--
-- Name: memberships_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE memberships_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.memberships_id_seq OWNER TO postgres;

--
-- Name: memberships_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE memberships_id_seq OWNED BY memberships.id;


--
-- Name: organizations; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE organizations (
    id integer NOT NULL,
    name character varying(100) NOT NULL,
    slug character varying(100) NOT NULL,
    created_at timestamp without time zone,
    updated_at timestamp without time zone,
    demo boolean DEFAULT false NOT NULL,
    language character varying(3),
    document_language character varying(3)
);


ALTER TABLE public.organizations OWNER TO postgres;

--
-- Name: organizations_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE organizations_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.organizations_id_seq OWNER TO postgres;

--
-- Name: organizations_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE organizations_id_seq OWNED BY organizations.id;


--
-- Name: pages; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE pages (
    id integer NOT NULL,
    organization_id integer NOT NULL,
    account_id integer NOT NULL,
    document_id integer NOT NULL,
    access integer NOT NULL,
    page_number integer NOT NULL,
    text text NOT NULL,
    start_offset integer,
    end_offset integer
);


ALTER TABLE public.pages OWNER TO postgres;

--
-- Name: pages_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE pages_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.pages_id_seq OWNER TO postgres;

--
-- Name: pages_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE pages_id_seq OWNED BY pages.id;


--
-- Name: pending_memberships; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE pending_memberships (
    id integer NOT NULL,
    first_name character varying(255) NOT NULL,
    last_name character varying(255) NOT NULL,
    email character varying(255) NOT NULL,
    organization_name character varying(255) NOT NULL,
    usage character varying(255) NOT NULL,
    editor character varying(255),
    website character varying(255),
    validated boolean DEFAULT false NOT NULL,
    notes text,
    organization_id integer,
    fields hstore,
    created_at timestamp without time zone,
    updated_at timestamp without time zone
);


ALTER TABLE public.pending_memberships OWNER TO postgres;

--
-- Name: pending_memberships_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE pending_memberships_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.pending_memberships_id_seq OWNER TO postgres;

--
-- Name: pending_memberships_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE pending_memberships_id_seq OWNED BY pending_memberships.id;


--
-- Name: processing_jobs; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE processing_jobs (
    id integer NOT NULL,
    account_id integer NOT NULL,
    cloud_crowd_id integer NOT NULL,
    title character varying(255) NOT NULL,
    document_id integer
);


ALTER TABLE public.processing_jobs OWNER TO postgres;

--
-- Name: processing_jobs_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE processing_jobs_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.processing_jobs_id_seq OWNER TO postgres;

--
-- Name: processing_jobs_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE processing_jobs_id_seq OWNED BY processing_jobs.id;


--
-- Name: project_memberships; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE project_memberships (
    id integer NOT NULL,
    project_id integer NOT NULL,
    document_id integer NOT NULL
);


ALTER TABLE public.project_memberships OWNER TO postgres;

--
-- Name: project_memberships_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE project_memberships_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.project_memberships_id_seq OWNER TO postgres;

--
-- Name: project_memberships_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE project_memberships_id_seq OWNED BY project_memberships.id;


--
-- Name: projects; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE projects (
    id integer NOT NULL,
    account_id integer,
    title character varying(255),
    description text,
    hidden boolean DEFAULT false NOT NULL
);


ALTER TABLE public.projects OWNER TO postgres;

--
-- Name: projects_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE projects_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.projects_id_seq OWNER TO postgres;

--
-- Name: projects_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE projects_id_seq OWNED BY projects.id;


--
-- Name: remote_urls; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE remote_urls (
    id integer NOT NULL,
    document_id integer NOT NULL,
    url character varying(255) NOT NULL,
    hits integer DEFAULT 0 NOT NULL
);


ALTER TABLE public.remote_urls OWNER TO postgres;

--
-- Name: remote_urls_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE remote_urls_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.remote_urls_id_seq OWNER TO postgres;

--
-- Name: remote_urls_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE remote_urls_id_seq OWNED BY remote_urls.id;


--
-- Name: repositories; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE repositories (
    id integer NOT NULL,
    repo_name character varying(255),
    disabled boolean
);


ALTER TABLE public.repositories OWNER TO documentcloud;

--
-- Name: repositories_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE repositories_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.repositories_id_seq OWNER TO documentcloud;

--
-- Name: repositories_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE repositories_id_seq OWNED BY repositories.id;


--
-- Name: reviews; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE reviews (
    id integer NOT NULL,
    document_id integer,
    qc_id integer,
    de_one_id integer,
    de_one_rating integer,
    de_two_id integer,
    de_two_rating integer,
    qc_note text,
    created_at timestamp without time zone,
    updated_at timestamp without time zone,
    qa_id integer,
    qc_rating integer,
    iteration integer,
    qa_note text
);


ALTER TABLE public.reviews OWNER TO documentcloud;

--
-- Name: reviews_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE reviews_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.reviews_id_seq OWNER TO documentcloud;

--
-- Name: reviews_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE reviews_id_seq OWNED BY reviews.id;


--
-- Name: schema_migrations; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE schema_migrations (
    version character varying(255) NOT NULL
);


ALTER TABLE public.schema_migrations OWNER TO postgres;

--
-- Name: sections; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE sections (
    id integer NOT NULL,
    organization_id integer NOT NULL,
    account_id integer NOT NULL,
    document_id integer NOT NULL,
    title text NOT NULL,
    page_number integer NOT NULL,
    access integer NOT NULL
);


ALTER TABLE public.sections OWNER TO postgres;

--
-- Name: sections_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE sections_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.sections_id_seq OWNER TO postgres;

--
-- Name: sections_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE sections_id_seq OWNED BY sections.id;


--
-- Name: security_keys; Type: TABLE; Schema: public; Owner: postgres; Tablespace: 
--

CREATE TABLE security_keys (
    id integer NOT NULL,
    securable_type character varying(40) NOT NULL,
    securable_id integer NOT NULL,
    key character varying(40)
);


ALTER TABLE public.security_keys OWNER TO postgres;

--
-- Name: security_keys_id_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE security_keys_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.security_keys_id_seq OWNER TO postgres;

--
-- Name: security_keys_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE security_keys_id_seq OWNED BY security_keys.id;


--
-- Name: subtemplate_fields; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE subtemplate_fields (
    id integer NOT NULL,
    subtemplate_id integer NOT NULL,
    field_id integer NOT NULL,
    created_at timestamp without time zone,
    updated_at timestamp without time zone
);


ALTER TABLE public.subtemplate_fields OWNER TO documentcloud;

--
-- Name: subtemplate_fields_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE subtemplate_fields_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.subtemplate_fields_id_seq OWNER TO documentcloud;

--
-- Name: subtemplate_fields_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE subtemplate_fields_id_seq OWNED BY subtemplate_fields.id;


--
-- Name: subtemplates; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE subtemplates (
    id integer NOT NULL,
    template_id integer NOT NULL,
    sub_name text NOT NULL,
    created_at timestamp without time zone,
    updated_at timestamp without time zone
);


ALTER TABLE public.subtemplates OWNER TO documentcloud;

--
-- Name: subtemplates_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE subtemplates_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.subtemplates_id_seq OWNER TO documentcloud;

--
-- Name: subtemplates_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE subtemplates_id_seq OWNED BY subtemplates.id;


--
-- Name: template_fields; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE template_fields (
    id integer NOT NULL,
    template_id integer NOT NULL,
    field_name text NOT NULL,
    created_at timestamp without time zone,
    updated_at timestamp without time zone
);


ALTER TABLE public.template_fields OWNER TO documentcloud;

--
-- Name: template_fields_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE template_fields_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.template_fields_id_seq OWNER TO documentcloud;

--
-- Name: template_fields_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE template_fields_id_seq OWNED BY template_fields.id;


--
-- Name: view_only_accesses; Type: TABLE; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE TABLE view_only_accesses (
    id integer NOT NULL,
    document_id integer,
    account_id integer,
    created_at timestamp without time zone,
    updated_at timestamp without time zone
);


ALTER TABLE public.view_only_accesses OWNER TO documentcloud;

--
-- Name: view_only_accesses_id_seq; Type: SEQUENCE; Schema: public; Owner: documentcloud
--

CREATE SEQUENCE view_only_accesses_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.view_only_accesses_id_seq OWNER TO documentcloud;

--
-- Name: view_only_accesses_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: documentcloud
--

ALTER SEQUENCE view_only_accesses_id_seq OWNED BY view_only_accesses.id;


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY accounts ALTER COLUMN id SET DEFAULT nextval('accounts_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY annotation_groups ALTER COLUMN id SET DEFAULT nextval('annotation_groups_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY annotation_notes ALTER COLUMN id SET DEFAULT nextval('annotation_notes_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY annotations ALTER COLUMN id SET DEFAULT nextval('annotations_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY app_constants ALTER COLUMN id SET DEFAULT nextval('app_constants_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY collaborations ALTER COLUMN id SET DEFAULT nextval('collaborations_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY docdata ALTER COLUMN id SET DEFAULT nextval('docdata_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY document_reviewers ALTER COLUMN id SET DEFAULT nextval('document_reviewers_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY documents ALTER COLUMN id SET DEFAULT nextval('documents_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY entities ALTER COLUMN id SET DEFAULT nextval('entities_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY entity_dates ALTER COLUMN id SET DEFAULT nextval('entity_dates_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY featured_reports ALTER COLUMN id SET DEFAULT nextval('featured_reports_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY file_status_histories ALTER COLUMN id SET DEFAULT nextval('file_status_histories_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY graph_groups ALTER COLUMN id SET DEFAULT nextval('graph_groups_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY graphs ALTER COLUMN id SET DEFAULT nextval('graphs_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY group_templates ALTER COLUMN id SET DEFAULT nextval('group_templates_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY groups ALTER COLUMN id SET DEFAULT nextval('groups_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY memberships ALTER COLUMN id SET DEFAULT nextval('memberships_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY organizations ALTER COLUMN id SET DEFAULT nextval('organizations_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY pages ALTER COLUMN id SET DEFAULT nextval('pages_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY pending_memberships ALTER COLUMN id SET DEFAULT nextval('pending_memberships_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY processing_jobs ALTER COLUMN id SET DEFAULT nextval('processing_jobs_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY project_memberships ALTER COLUMN id SET DEFAULT nextval('project_memberships_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY projects ALTER COLUMN id SET DEFAULT nextval('projects_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY remote_urls ALTER COLUMN id SET DEFAULT nextval('remote_urls_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY repositories ALTER COLUMN id SET DEFAULT nextval('repositories_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY reviews ALTER COLUMN id SET DEFAULT nextval('reviews_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY sections ALTER COLUMN id SET DEFAULT nextval('sections_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY security_keys ALTER COLUMN id SET DEFAULT nextval('security_keys_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY subtemplate_fields ALTER COLUMN id SET DEFAULT nextval('subtemplate_fields_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY subtemplates ALTER COLUMN id SET DEFAULT nextval('subtemplates_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY template_fields ALTER COLUMN id SET DEFAULT nextval('template_fields_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: public; Owner: documentcloud
--

ALTER TABLE ONLY view_only_accesses ALTER COLUMN id SET DEFAULT nextval('view_only_accesses_id_seq'::regclass);


--
-- Data for Name: accounts; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY accounts (id, first_name, last_name, email, hashed_password, created_at, updated_at, identities, language, document_language, disabled) FROM stdin;
1	Bill	Denney	admin@denney.ws	$2a$10$vtB9kp5mcTp2vaHekfW9O.eIGNbO1Q4g2Q4957Bp/YcqdEP/nEAtK	2014-04-25 15:38:29.848635	2014-04-25 15:38:29.848635	\N	eng	eng	\N
3	ANother	Test	roberttdev@gmail.com	\N	2014-05-16 17:47:33.089044	2014-05-16 17:47:33.089044	\N	eng	eng	\N
2	R	Will	thisaddresssucks@hotmail.com	$2a$08$Jx7FixZKDHqJJDRmea11jOTRikabjAwm4fi2g3VwOcmZzSqeDACnu	2014-05-15 20:10:46.279399	2014-05-19 22:31:41.288107	\N	eng	eng	\N
4	Administrator	test1	test1@denney.ws	$2a$08$AP7h8XxAGJ829Q3hOwZvs.wtYGk4LxTGvhT/Y67SpopeVSsxgCZ/i	2014-05-30 02:41:29.749052	2014-07-26 18:12:04.902058	\N	eng	eng	\N
5	QA	test2	test2@denney.ws	$2a$08$hLpcjNL6/TTsMiSpRD9EM.zDy1o9Cq75v.bXfxfS0aZ5Cl2XEhUYC	2014-05-30 02:46:32.098086	2014-07-26 18:12:22.09065	\N	eng	eng	\N
6	QC	test3	test3@denney.ws	$2a$08$zfwW4C4yUCFlxxj8qomqeOc0rSsBK4.8WCCFfGla5J0quL0V8K4R.	2014-05-30 02:54:24.19861	2014-07-26 18:12:27.323697	\N	eng	eng	\N
7	DE1	test4	test4@denney.ws	$2a$08$29vK0LcCarR.IXJUnQDYp.Wf7llfF30D0Theusuh7MuZNQH7TUAZq	2014-05-30 02:56:16.675099	2014-07-26 18:12:33.05258	\N	eng	eng	\N
8	Upload	test5	test5@denney.ws	$2a$08$Eq5OAAAQU8g9PUSphNjiW.JLog3Pv/9F9lxqCmZoCF1ignFXWV0TC	2014-05-30 02:59:44.976584	2014-07-26 18:12:39.877771	\N	eng	eng	\N
9	Extraction	test6	test6@denney.ws	$2a$08$OkLA7FtsPtA/8rP9H8XjHebTBAAMZC3toUCNWfRgzsAc6JtCqC93m	2014-05-30 03:00:06.760257	2014-07-26 18:12:49.495015	\N	eng	eng	\N
10	DE2	test7	test7@denney.ws	$2a$08$u5Ir81693lnhdFuIn/0xD.E2uiYaOFt3IlgWh5TaOg87hYS6obQvO	2014-07-26 18:13:06.353769	2014-07-26 18:13:52.933865	\N	eng	eng	\N
11	DE3	test8	test8@denney.ws	$2a$08$VDskJAcYaulDTPFrel8.U.9teGvJxu7l4Zj723bSk4Ns4Ifrn84rG	2014-07-26 18:13:24.76996	2014-07-26 18:14:13.980427	\N	eng	eng	\N
13	Admin	admin2	admin2@denney.ws	$2a$08$NJTYFqs72tLFUbgPqf86s.e/PtXyb9nK9/YbZ1/7n1vn0TEcMGdXq	2014-11-06 21:31:17.78999	2014-11-06 21:59:21.794962	\N	eng	eng	\N
12	Admin	admin1	admin1@denney.ws	$2a$08$m.N.RnG.xHMh9SfkEkgNIeC8cLAzwjLOeet7IPkJBxDnwe6LCdnsu	2014-11-06 21:30:58.406679	2014-11-06 21:59:44.938747	\N	eng	eng	\N
14	DE	DE1	de1@denney.ws	$2a$08$kvk.CcFrhbeWEAcPnOeexeh4TPZhOaJ87Z98iVJyFbTKPxJMyKM4C	2014-11-06 21:31:51.227868	2014-11-06 22:00:04.55846	\N	eng	eng	\N
15	DE	DE2	de2@denney.ws	$2a$08$enoTndhg4ESIQ0V1M8.kAe23q5Yt3t2cll811BFuruya.pBwsWhju	2014-11-06 21:32:02.900488	2014-11-06 22:00:19.295663	\N	eng	eng	\N
16	DE	DE3	de3@denney.ws	$2a$08$LS1IReEfoCMUkywt8DqHH.2HW2jBlHJtOrtQiGLlzQBHFYp7qWI0C	2014-11-06 21:32:15.577964	2014-11-06 22:00:35.425323	\N	eng	eng	\N
17	QC	QC1	qc1@denney.ws	$2a$08$LdKW2cG0HKq3EfSr0J6sPeMMovmrEV56qLMx8i2BnBPR7XKSpU/2m	2014-11-06 21:32:33.506728	2014-11-06 22:00:53.056409	\N	eng	eng	\N
18	QC	QC2	qc2@denney.ws	$2a$08$l0f1ZMvl9P.yjiIxCIt36ueMa3/8fRfDmchpsptvwxLZkOLVHlU1C	2014-11-06 21:32:44.671404	2014-11-06 22:01:05.792213	\N	eng	eng	\N
20	QA	QA1	qa1@denney.ws	$2a$08$oCR3Ee3CpTZP75XQINTEFOwMSMjia/1tyM7xyza8R48epBTcqlCKa	2014-11-06 21:34:41.202288	2014-11-06 22:29:47.9102	\N	eng	eng	\N
21	QA	QA2	qa2@denney.ws	$2a$08$b1qfOMCn8SvcBcVuGzilJ.Pg5rN0wGN8gTjV.LG67pcjqcI/dV6WK	2014-11-06 21:34:56.157402	2014-11-06 22:38:25.349059	\N	eng	eng	\N
22	upload	upload1	upload1@denney.ws	$2a$08$MxhJ0.F3ZpMHmN20PlsVpeK4zhBjhkecc3EHZjiHtS0d/JbFjs1Ji	2014-12-10 02:34:46.789396	2014-12-10 02:45:06.697426	\N	eng	eng	\N
23	View	Only	vo@denney.ws	$2a$08$KDdEaU9ylNjDlyUxVPfxTezZzaRfzNcbheZacLq0FxKAj6HdLTL4i	2015-01-29 20:58:40.57352	2015-01-29 21:08:02.429547	\N	eng	eng	\N
19	QC	QC3	qc3@denney.ws	$2a$08$WD3QtEGwBIhIs3XfwJ67y.CVE4QXp72MyGWHZoMCGxwQtwTmjTd3y	2014-11-06 21:34:16.109675	2015-07-08 20:54:16.10226	\N	eng	eng	f
\.


--
-- Name: accounts_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('accounts_id_seq', 23, true);


--
-- Data for Name: annotation_groups; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY annotation_groups (id, annotation_id, group_id, created_by, qa_approved_by, based_on, approved_count, iteration) FROM stdin;
688	725	251	7	\N	\N	1	1
918	932	327	4	\N	\N	0	1
919	933	327	4	\N	\N	0	1
920	929	327	4	\N	\N	0	1
929	942	330	7	\N	\N	0	1
930	943	330	7	\N	\N	0	1
931	944	329	7	\N	\N	0	1
932	945	329	7	\N	\N	0	1
933	946	329	7	\N	\N	0	1
934	947	319	7	\N	\N	0	1
935	948	319	7	\N	\N	0	1
936	949	319	7	\N	\N	0	1
937	950	319	7	\N	\N	0	1
938	951	319	7	\N	\N	0	1
939	952	319	7	\N	\N	0	1
986	991	340	7	\N	\N	0	1
987	992	340	7	\N	\N	0	1
988	993	340	7	\N	\N	0	1
989	994	340	7	\N	\N	0	1
990	995	341	7	\N	\N	0	1
991	996	341	7	\N	\N	0	1
992	997	341	7	\N	\N	0	1
686	723	251	7	\N	\N	1	1
685	722	251	7	\N	\N	1	1
689	726	251	7	\N	\N	1	1
682	719	251	7	\N	\N	1	1
690	727	251	7	\N	\N	1	1
687	724	251	7	\N	\N	1	1
716	753	260	7	\N	\N	1	1
722	759	264	7	\N	\N	1	1
724	761	265	7	\N	\N	1	1
723	760	265	7	\N	\N	1	1
725	762	266	7	\N	\N	1	1
728	765	267	7	\N	\N	1	1
726	763	267	7	\N	\N	1	1
727	764	268	7	\N	\N	1	1
718	755	262	7	\N	\N	1	1
717	754	262	7	\N	\N	1	1
720	757	263	7	\N	\N	1	1
719	756	263	7	\N	\N	1	1
694	731	252	7	\N	\N	1	1
696	733	252	7	\N	\N	1	1
709	746	252	7	\N	\N	1	1
695	732	252	7	\N	\N	1	1
708	745	254	7	\N	\N	1	1
702	739	254	7	\N	\N	1	1
703	740	254	7	\N	\N	1	1
704	741	254	7	\N	\N	1	1
705	742	254	7	\N	\N	1	1
706	743	254	7	\N	\N	1	1
707	744	254	7	\N	\N	1	1
701	738	253	7	\N	\N	1	1
697	734	253	7	\N	\N	1	1
698	735	253	7	\N	\N	1	1
699	736	253	7	\N	\N	1	1
700	737	253	7	\N	\N	1	1
729	766	256	7	\N	\N	1	1
757	794	277	7	\N	\N	1	1
759	796	277	7	\N	\N	1	1
760	797	277	7	\N	\N	1	1
758	795	277	7	\N	\N	1	1
761	798	278	7	\N	\N	1	1
762	799	278	7	\N	\N	1	1
764	801	278	7	\N	\N	1	1
767	804	279	7	\N	\N	1	1
766	803	279	7	\N	\N	1	1
775	812	280	7	\N	\N	1	1
770	807	280	7	\N	\N	1	1
711	748	257	7	\N	\N	1	1
712	749	257	7	\N	\N	1	1
713	750	257	7	\N	\N	1	1
715	752	257	7	\N	\N	1	1
714	751	257	7	\N	\N	1	1
733	770	270	7	\N	\N	1	1
732	769	270	7	\N	\N	1	1
736	773	272	7	\N	\N	1	1
735	772	272	7	\N	\N	1	1
744	781	273	7	\N	\N	1	1
739	776	273	7	\N	\N	1	1
747	784	274	7	\N	\N	1	1
749	786	274	7	\N	\N	1	1
750	787	274	7	\N	\N	1	1
752	789	275	7	\N	\N	1	1
754	791	275	7	\N	\N	1	1
755	792	275	7	\N	\N	1	1
753	790	275	7	\N	\N	1	1
778	815	281	7	\N	\N	1	1
780	817	281	7	\N	\N	1	1
781	818	281	7	\N	\N	1	1
779	816	281	7	\N	\N	1	1
784	821	282	7	\N	\N	1	1
783	820	282	7	\N	\N	1	1
786	823	283	7	\N	\N	1	1
787	824	283	7	\N	\N	1	1
788	825	284	7	\N	\N	1	1
789	826	284	7	\N	\N	1	1
791	828	285	7	\N	\N	1	1
792	829	286	7	\N	\N	1	1
793	830	286	7	\N	\N	1	1
796	833	287	7	\N	\N	1	1
795	832	287	7	\N	\N	1	1
801	838	288	7	\N	\N	1	1
800	837	288	7	\N	\N	1	1
804	838	290	7	\N	\N	1	1
803	840	290	7	\N	\N	1	1
805	841	291	7	\N	\N	1	1
840	876	308	7	\N	\N	1	1
843	879	308	7	\N	\N	1	1
844	880	309	7	\N	\N	1	1
845	881	309	7	\N	\N	1	1
806	842	293	7	\N	\N	1	1
809	845	294	7	\N	\N	1	1
811	847	295	7	\N	\N	1	1
812	848	296	7	\N	\N	1	1
815	851	296	7	\N	\N	1	1
816	852	297	7	\N	\N	1	1
818	854	297	7	\N	\N	1	1
820	856	298	7	\N	\N	1	1
823	859	298	7	\N	\N	1	1
825	861	299	7	\N	\N	1	1
827	863	300	7	\N	\N	1	1
829	865	301	7	\N	\N	1	1
831	867	302	7	\N	\N	1	1
833	869	303	7	\N	\N	1	1
836	872	305	7	\N	\N	1	1
837	873	305	7	\N	\N	1	1
839	875	306	7	\N	\N	1	1
894	902	316	7	\N	\N	1	1
857	796	308	7	\N	\N	1	1
858	797	308	7	\N	\N	1	1
859	799	309	7	\N	\N	1	1
860	804	310	7	\N	\N	1	1
861	812	311	7	\N	\N	1	1
850	886	311	7	\N	\N	1	1
851	887	312	7	\N	\N	1	1
852	888	312	7	\N	\N	1	1
862	893	312	7	\N	\N	1	1
854	890	312	7	\N	\N	1	1
856	892	312	7	\N	\N	1	1
864	895	313	7	\N	\N	1	1
897	911	318	7	\N	\N	0	1
867	898	313	7	\N	\N	1	1
899	913	318	7	\N	\N	0	1
865	896	313	7	\N	\N	1	1
901	915	318	7	\N	\N	0	1
902	916	318	7	\N	\N	0	1
868	769	293	7	\N	\N	1	1
904	918	318	7	\N	\N	0	1
905	919	318	7	\N	\N	0	1
869	773	294	7	\N	\N	1	1
870	781	295	7	\N	\N	1	1
908	922	319	7	\N	\N	0	1
909	923	324	4	\N	\N	0	1
910	924	324	4	\N	\N	0	1
871	786	296	7	\N	\N	1	1
872	787	296	7	\N	\N	1	1
873	791	297	7	\N	\N	1	1
874	792	297	7	\N	\N	1	1
915	929	324	4	\N	\N	0	1
875	817	298	7	\N	\N	1	1
876	818	298	7	\N	\N	1	1
877	821	299	7	\N	\N	1	1
957	958	335	7	\N	\N	0	1
958	959	335	7	\N	\N	0	1
959	961	335	7	\N	\N	0	1
960	957	335	7	\N	\N	0	1
961	955	335	7	\N	\N	0	1
962	960	335	7	\N	\N	0	1
963	953	335	7	\N	\N	0	1
964	954	335	7	\N	\N	0	1
965	970	336	7	\N	\N	0	1
966	971	336	7	\N	\N	0	1
878	823	300	7	\N	\N	1	1
879	825	301	7	\N	\N	1	1
880	827	302	7	\N	\N	1	1
881	829	303	7	\N	\N	1	1
882	833	304	7	\N	\N	1	1
972	977	336	7	\N	\N	0	1
883	872	306	7	\N	\N	1	1
887	902	315	7	\N	\N	1	1
885	900	315	7	\N	\N	1	1
977	982	338	7	\N	\N	0	1
978	983	338	7	\N	\N	0	1
979	984	338	7	\N	\N	0	1
981	986	338	7	\N	\N	0	1
982	987	339	7	\N	\N	0	1
983	988	339	7	\N	\N	0	1
984	989	339	7	\N	\N	0	1
985	990	339	7	\N	\N	0	1
993	998	341	7	\N	\N	0	1
994	999	342	7	\N	\N	0	1
995	1000	342	7	\N	\N	0	1
996	1001	342	7	\N	\N	0	1
997	1002	342	7	\N	\N	0	1
998	1003	342	7	\N	\N	0	1
1002	1007	346	7	\N	\N	0	1
1004	1009	346	7	\N	\N	0	1
1005	1010	346	7	\N	\N	0	1
1006	1011	345	7	\N	\N	0	1
1007	1004	345	7	\N	\N	0	1
1008	1012	346	7	\N	\N	0	1
1009	1013	346	7	\N	\N	0	1
1010	1014	346	7	\N	\N	0	1
1012	1016	347	7	\N	\N	0	1
1013	1017	347	7	\N	\N	0	1
1014	1018	347	7	\N	\N	0	1
1015	1019	347	7	\N	\N	0	1
1016	1020	347	7	\N	\N	0	1
1017	1007	347	7	\N	\N	0	1
1019	1022	348	7	\N	\N	0	1
1020	1023	348	7	\N	\N	0	1
1021	1024	348	7	\N	\N	0	1
1022	1025	348	7	\N	\N	0	1
1024	1007	348	7	\N	\N	0	1
1025	1017	348	7	\N	\N	0	1
1027	1028	349	7	\N	\N	0	1
1028	1029	349	7	\N	\N	0	1
1029	1030	349	7	\N	\N	0	1
1030	1031	349	7	\N	\N	0	1
1031	1032	349	7	\N	\N	0	1
1032	1007	349	7	\N	\N	0	1
1034	1034	350	7	\N	\N	0	1
1035	1035	350	7	\N	\N	0	1
1036	1036	350	7	\N	\N	0	1
1039	1039	350	7	\N	\N	0	1
1040	1040	350	7	\N	\N	0	1
1041	1041	351	7	\N	\N	0	1
1042	1042	351	7	\N	\N	0	1
1046	1046	352	7	\N	\N	0	1
1047	1047	352	7	\N	\N	0	1
1048	1048	352	7	\N	\N	0	1
1050	1050	353	7	\N	\N	0	1
1051	1051	353	7	\N	\N	0	1
1052	1052	353	7	\N	\N	0	1
1057	1057	354	7	\N	\N	0	1
1058	1058	354	7	\N	\N	0	1
1059	1059	354	7	\N	\N	0	1
1062	1062	355	7	\N	\N	0	1
1063	1063	355	7	\N	\N	0	1
1064	1064	355	7	\N	\N	0	1
1067	1067	356	7	\N	\N	0	1
1070	1070	356	7	\N	\N	0	1
1071	1071	356	7	\N	\N	0	1
1072	1007	352	7	\N	\N	0	1
1073	1009	352	7	\N	\N	0	1
1074	1010	352	7	\N	\N	0	1
1075	1039	356	7	\N	\N	0	1
1076	1040	356	7	\N	\N	0	1
1077	1007	353	7	\N	\N	0	1
1078	1016	353	7	\N	\N	0	1
1079	1017	353	7	\N	\N	0	1
1080	1007	354	7	\N	\N	0	1
1081	1025	354	7	\N	\N	0	1
1082	1017	354	7	\N	\N	0	1
1084	1007	355	7	\N	\N	0	1
1085	1032	355	7	\N	\N	0	1
1086	1028	355	7	\N	\N	0	1
1087	1073	358	7	\N	\N	0	1
1088	1074	358	7	\N	\N	0	1
1254	1007	379	7	\N	\N	0	1
1255	1025	379	7	\N	\N	0	1
1256	1083	379	7	\N	\N	0	1
1092	1078	359	7	\N	\N	0	1
1093	1079	359	7	\N	\N	0	1
1094	1080	359	7	\N	\N	0	1
1257	1136	379	7	\N	\N	0	1
1258	1007	380	7	\N	\N	0	1
1097	1083	360	7	\N	\N	0	1
1098	1084	360	7	\N	\N	0	1
1099	1085	360	7	\N	\N	0	1
1100	1086	360	7	\N	\N	0	1
1259	1032	380	7	\N	\N	0	1
1260	1028	380	7	\N	\N	0	1
1261	1136	380	7	\N	\N	0	1
1104	1090	361	7	\N	\N	0	1
1105	1091	361	7	\N	\N	0	1
1106	1092	361	7	\N	\N	0	1
6159	4137	1318	14	\N	\N	0	1
1110	1096	362	7	\N	\N	0	1
1111	1097	362	7	\N	\N	0	1
1112	1098	362	7	\N	\N	0	1
2033	1796	624	14	\N	\N	1	1
2038	1801	624	14	\N	\N	1	1
1115	1101	363	7	\N	\N	0	1
1116	1102	363	7	\N	\N	0	1
1117	1103	363	7	\N	\N	0	1
1118	1007	359	7	\N	\N	0	1
1119	1009	359	7	\N	\N	0	1
1268	1209	383	7	\N	\N	0	1
1269	1210	383	7	\N	\N	0	1
1270	1211	383	7	\N	\N	0	1
1271	1212	383	7	\N	\N	0	1
1272	1213	383	7	\N	\N	0	1
1273	1214	383	7	\N	\N	0	1
2039	1802	624	14	\N	\N	1	1
2034	1797	624	14	\N	\N	1	1
2052	1815	628	14	\N	\N	1	1
5126	3322	1171	20	\N	\N	1	1
2042	1805	620	14	\N	\N	1	1
2044	1807	626	14	\N	\N	1	1
1274	1215	383	7	\N	\N	0	1
1275	1216	384	7	\N	\N	0	1
1276	1217	384	7	\N	\N	0	1
1277	1218	384	7	\N	\N	0	1
1279	1220	384	7	\N	\N	0	1
1280	1221	384	7	\N	\N	0	1
1281	1222	384	7	\N	\N	0	1
1282	1212	384	7	\N	\N	0	1
1283	1223	386	7	\N	\N	0	1
1284	1224	386	7	\N	\N	0	1
1285	1225	386	7	\N	\N	0	1
1287	1227	386	7	\N	\N	0	1
1153	1039	363	7	\N	\N	0	1
1154	1040	363	7	\N	\N	0	1
1155	1007	360	7	\N	\N	0	1
1156	1016	360	7	\N	\N	0	1
1157	1007	361	7	\N	\N	0	1
1158	1025	361	7	\N	\N	0	1
1159	1083	361	7	\N	\N	0	1
1160	1007	362	7	\N	\N	0	1
1161	1032	362	7	\N	\N	0	1
1162	1028	362	7	\N	\N	0	1
1163	1136	362	7	\N	\N	0	1
1164	1136	361	7	\N	\N	0	1
1165	1137	370	7	\N	\N	0	1
1166	1138	370	7	\N	\N	0	1
1288	1228	386	7	\N	\N	0	1
1289	1229	386	7	\N	\N	0	1
1169	1141	371	7	\N	\N	0	1
1170	1142	371	7	\N	\N	0	1
1171	1143	371	7	\N	\N	0	1
1172	1144	371	7	\N	\N	0	1
1290	1212	386	7	\N	\N	0	1
1291	1230	387	7	\N	\N	0	1
1175	1147	372	7	\N	\N	0	1
1176	1148	372	7	\N	\N	0	1
1177	1149	372	7	\N	\N	0	1
1292	1231	387	7	\N	\N	0	1
1181	1153	373	7	\N	\N	0	1
1182	1154	373	7	\N	\N	0	1
1184	1156	373	7	\N	\N	0	1
1185	1157	373	7	\N	\N	0	1
1189	1161	374	7	\N	\N	0	1
1190	1162	374	7	\N	\N	0	1
1191	1163	374	7	\N	\N	0	1
1195	1167	375	7	\N	\N	0	1
1196	1168	375	7	\N	\N	0	1
1197	1169	375	7	\N	\N	0	1
1198	1009	371	7	\N	\N	0	1
1199	1141	359	7	\N	\N	0	1
1200	1007	371	7	\N	\N	0	1
1201	1039	375	7	\N	\N	0	1
1202	1040	375	7	\N	\N	0	1
1203	1007	372	7	\N	\N	0	1
1204	1016	372	7	\N	\N	0	1
1205	1083	372	7	\N	\N	0	1
1206	1007	373	7	\N	\N	0	1
1207	1025	373	7	\N	\N	0	1
1208	1083	373	7	\N	\N	0	1
1209	1007	374	7	\N	\N	0	1
1210	1032	374	7	\N	\N	0	1
1211	1028	374	7	\N	\N	0	1
1212	1157	374	7	\N	\N	0	1
1213	1170	376	7	\N	\N	0	1
1214	1171	376	7	\N	\N	0	1
1218	1175	377	7	\N	\N	0	1
1219	1176	377	7	\N	\N	0	1
1220	1177	377	7	\N	\N	0	1
1224	1181	378	7	\N	\N	0	1
1225	1182	378	7	\N	\N	0	1
1226	1183	378	7	\N	\N	0	1
1230	1187	379	7	\N	\N	0	1
1231	1188	379	7	\N	\N	0	1
1232	1189	379	7	\N	\N	0	1
1238	1195	380	7	\N	\N	0	1
1239	1196	380	7	\N	\N	0	1
1240	1197	380	7	\N	\N	0	1
1243	1200	381	7	\N	\N	0	1
1244	1201	381	7	\N	\N	0	1
1245	1202	381	7	\N	\N	0	1
1246	1007	377	7	\N	\N	0	1
1247	1009	377	7	\N	\N	0	1
1248	1141	377	7	\N	\N	0	1
1249	1039	381	7	\N	\N	0	1
1250	1040	381	7	\N	\N	0	1
1251	1007	378	7	\N	\N	0	1
1252	1016	378	7	\N	\N	0	1
1253	1083	378	7	\N	\N	0	1
1293	1232	387	7	\N	\N	0	1
2054	1817	628	14	\N	\N	1	1
1295	1234	387	7	\N	\N	0	1
1296	1235	387	7	\N	\N	0	1
1297	1236	387	7	\N	\N	0	1
1298	1212	387	7	\N	\N	0	1
693	730	251	7	\N	\N	1	1
1300	1238	388	7	\N	\N	0	1
1301	1239	388	7	\N	\N	0	1
1302	1240	388	7	\N	\N	0	1
1303	1241	388	7	\N	\N	0	1
1304	1242	388	7	\N	\N	0	1
1305	1243	388	7	\N	\N	0	1
1306	1212	388	7	\N	\N	0	1
1307	1244	389	7	\N	\N	0	1
1308	1245	389	7	\N	\N	0	1
1309	1246	389	7	\N	\N	0	1
1311	1248	389	7	\N	\N	0	1
1312	1249	389	7	\N	\N	0	1
1313	1250	389	7	\N	\N	0	1
1314	1212	389	7	\N	\N	0	1
1316	1252	391	7	\N	\N	0	1
1317	1253	391	7	\N	\N	0	1
1318	1254	391	7	\N	\N	0	1
1322	1258	391	7	\N	\N	0	1
1323	1259	390	7	\N	\N	0	1
1324	1260	390	7	\N	\N	0	1
1325	1261	390	7	\N	\N	0	1
1326	1262	390	7	\N	\N	0	1
1327	1263	392	7	\N	\N	0	1
1328	1264	392	7	\N	\N	0	1
1329	1265	392	7	\N	\N	0	1
1330	1266	392	7	\N	\N	0	1
1331	1267	393	7	\N	\N	0	1
1332	1268	393	7	\N	\N	0	1
1333	1269	394	7	\N	\N	0	1
1335	1271	396	7	\N	\N	0	1
1336	1272	396	7	\N	\N	0	1
1337	1273	396	7	\N	\N	0	1
1338	1274	397	7	\N	\N	0	1
1339	1275	397	7	\N	\N	0	1
1341	1277	396	7	\N	\N	0	1
1342	1278	398	7	\N	\N	0	1
1343	1279	398	7	\N	\N	0	1
710	747	257	7	\N	\N	1	1
748	785	274	7	\N	\N	1	1
1588	725	449	6	5	688	0	1
1589	723	449	6	5	686	0	1
1590	722	449	6	5	685	0	1
1591	726	449	6	5	689	0	1
1592	719	449	6	5	682	0	1
1593	727	449	6	5	690	0	1
1594	724	449	6	5	687	0	1
1607	731	450	6	5	694	0	1
1608	733	450	6	5	696	0	1
1609	746	450	6	5	709	0	1
1610	732	450	6	5	695	0	1
1595	753	453	6	5	716	0	1
1596	759	455	6	5	722	0	1
1597	761	456	6	5	724	0	1
1598	760	456	6	5	723	0	1
1599	762	457	6	5	725	0	1
1600	765	458	6	5	728	0	1
1601	763	458	6	5	726	0	1
1602	764	459	6	5	727	0	1
1603	755	460	6	5	718	0	1
1604	754	460	6	5	717	0	1
1605	757	461	6	5	720	0	1
1606	756	461	6	5	719	0	1
1624	794	467	6	5	757	0	1
1626	797	467	6	5	760	0	1
1627	795	467	6	5	758	0	1
1628	798	468	6	5	761	0	1
1629	799	468	6	5	762	0	1
1630	801	468	6	5	764	0	1
1633	812	470	6	5	775	0	1
1634	807	470	6	5	770	0	1
1631	804	469	6	5	767	0	1
1632	803	469	6	5	766	0	1
1635	747	471	6	5	710	0	1
1636	748	471	6	5	711	0	1
1637	749	471	6	5	712	0	1
1638	750	471	6	5	713	0	1
1639	752	471	6	5	715	0	1
1640	751	471	6	5	714	0	1
1623	766	465	6	5	729	0	1
1642	769	473	6	5	732	0	1
1643	773	474	6	5	736	0	1
1644	772	474	6	5	735	0	1
1645	781	475	6	5	744	0	1
1646	776	475	6	5	739	0	1
1647	784	476	6	5	747	0	1
1648	786	476	6	5	749	0	1
1649	787	476	6	5	750	0	1
1650	785	476	6	5	748	0	1
1651	789	477	6	5	752	0	1
1652	791	477	6	5	754	0	1
1653	792	477	6	5	755	0	1
1654	790	477	6	5	753	0	1
1655	815	478	6	5	778	0	1
1656	817	478	6	5	780	0	1
1657	818	478	6	5	781	0	1
1659	821	480	6	5	784	0	1
1660	820	480	6	5	783	0	1
1661	823	481	6	5	786	0	1
1662	824	481	6	5	787	0	1
1663	825	482	6	5	788	0	1
1664	826	482	6	5	789	0	1
1665	827	483	6	5	790	0	1
1611	745	462	6	5	708	0	1
1612	739	462	6	5	702	0	1
1613	740	462	6	5	703	0	1
1614	741	462	6	5	704	0	1
1615	742	462	6	5	705	0	1
1616	743	462	6	5	706	0	1
1617	744	462	6	5	707	0	1
1618	738	463	6	5	701	0	1
1619	734	463	6	5	697	0	1
1621	736	463	6	5	699	0	1
1622	737	463	6	5	700	0	1
790	827	285	7	\N	\N	1	1
890	905	316	7	\N	\N	1	1
848	884	310	7	\N	\N	1	1
1666	828	483	6	5	791	0	1
1669	833	485	6	5	796	0	1
1670	832	485	6	5	795	0	1
1673	838	487	6	5	804	0	1
1674	840	487	6	5	803	0	1
1675	905	488	6	5	890	0	1
1676	902	488	6	5	894	0	1
1689	887	495	6	5	851	0	1
1690	888	495	6	5	852	0	1
1691	893	495	6	5	862	0	1
1692	890	495	6	5	854	0	1
1693	892	495	6	5	856	0	1
1677	841	489	6	5	805	0	1
1678	876	491	6	5	840	0	1
1679	796	491	6	5	857	0	1
1680	797	491	6	5	858	0	1
1681	879	491	6	5	843	0	1
1682	880	492	6	5	844	0	1
1683	799	492	6	5	859	0	1
1684	881	492	6	5	845	0	1
1685	804	493	6	5	860	0	1
1686	884	493	6	5	848	0	1
1687	812	494	6	5	861	0	1
1688	886	494	6	5	850	0	1
2066	1829	630	14	\N	\N	1	1
2061	1824	629	14	\N	\N	1	1
2060	1823	629	14	\N	\N	1	1
2055	1818	628	14	\N	\N	1	1
2083	1846	634	14	\N	\N	1	1
2086	1849	634	14	\N	\N	1	1
2087	1850	634	14	\N	\N	1	1
2082	1845	634	14	\N	\N	1	1
2107	1870	635	14	\N	\N	1	1
2073	1836	633	14	\N	\N	1	1
2072	1835	633	14	\N	\N	1	1
2090	1853	632	14	\N	\N	1	1
3341	1986	763	14	\N	\N	1	1
3342	1984	763	14	\N	\N	1	1
3343	2032	763	14	\N	\N	1	1
2177	1928	641	14	\N	\N	1	1
2178	1892	641	14	\N	\N	1	1
2179	1893	641	14	\N	\N	1	1
2180	1885	641	14	\N	\N	1	1
2181	1886	641	14	\N	\N	1	1
2304	2025	656	14	\N	\N	1	1
2305	2026	657	14	\N	\N	1	1
2310	2031	657	14	\N	\N	1	1
2306	2027	657	14	\N	\N	1	1
2309	2030	657	14	\N	\N	1	1
2311	2032	657	14	\N	\N	1	1
2251	1990	650	14	\N	\N	1	1
2300	1942	655	14	\N	\N	1	1
2281	2020	655	14	\N	\N	1	1
2282	2021	655	14	\N	\N	1	1
2283	2022	655	14	\N	\N	1	1
2301	1986	655	14	\N	\N	1	1
2302	1984	655	14	\N	\N	1	1
2303	1996	655	14	\N	\N	1	1
2296	1942	654	14	\N	\N	1	1
2275	2014	654	14	\N	\N	1	1
2276	2015	654	14	\N	\N	1	1
2277	2016	654	14	\N	\N	1	1
2297	1982	654	14	\N	\N	1	1
2298	1969	654	14	\N	\N	1	1
2299	1996	654	14	\N	\N	1	1
2292	1942	653	14	\N	\N	1	1
2271	2010	653	14	\N	\N	1	1
2270	2009	653	14	\N	\N	1	1
2269	2008	653	14	\N	\N	1	1
2293	1972	653	14	\N	\N	1	1
2294	1969	653	14	\N	\N	1	1
2295	1996	653	14	\N	\N	1	1
2260	1999	652	14	\N	\N	1	1
2289	1962	652	14	\N	\N	1	1
2290	1959	652	14	\N	\N	1	1
2263	2002	652	14	\N	\N	1	1
2264	2003	652	14	\N	\N	1	1
2291	1996	652	14	\N	\N	1	1
2286	1942	651	14	\N	\N	1	1
2253	1992	651	14	\N	\N	1	1
2258	1997	651	14	\N	\N	1	1
2254	1993	651	14	\N	\N	1	1
2287	1948	651	14	\N	\N	1	1
2288	1945	651	14	\N	\N	1	1
2257	1996	651	14	\N	\N	1	1
2182	1929	643	14	\N	\N	1	1
2249	1942	649	14	\N	\N	1	1
2248	1989	649	14	\N	\N	1	1
2247	1988	649	14	\N	\N	1	1
2246	1987	649	14	\N	\N	1	1
2245	1986	649	14	\N	\N	1	1
2243	1984	649	14	\N	\N	1	1
2250	1939	649	14	\N	\N	1	1
2239	1942	648	14	\N	\N	1	1
2230	1974	648	14	\N	\N	1	1
2231	1975	648	14	\N	\N	1	1
2233	1977	648	14	\N	\N	1	1
2238	1982	648	14	\N	\N	1	1
2240	1969	648	14	\N	\N	1	1
2241	1939	648	14	\N	\N	1	1
2227	1942	647	14	\N	\N	1	1
2218	1964	647	14	\N	\N	1	1
2219	1965	647	14	\N	\N	1	1
2221	1967	647	14	\N	\N	1	1
2226	1972	647	14	\N	\N	1	1
2223	1969	647	14	\N	\N	1	1
2228	1939	647	14	\N	\N	1	1
2208	1955	646	14	\N	\N	1	1
2215	1962	646	14	\N	\N	1	1
2212	1959	646	14	\N	\N	1	1
2206	1953	646	14	\N	\N	1	1
2207	1954	646	14	\N	\N	1	1
2216	1939	646	14	\N	\N	1	1
2195	1942	645	14	\N	\N	1	1
2202	1949	645	14	\N	\N	1	1
2204	1951	645	14	\N	\N	1	1
2203	1950	645	14	\N	\N	1	1
2201	1948	645	14	\N	\N	1	1
2198	1945	645	14	\N	\N	1	1
2192	1939	645	14	\N	\N	1	1
835	871	304	7	\N	\N	1	1
1587	730	449	6	5	693	0	1
1625	796	467	6	5	759	0	1
1641	770	473	6	5	733	0	1
1658	816	478	6	5	779	0	1
1667	829	484	6	5	792	0	1
1668	830	484	6	5	793	0	1
1671	838	486	6	5	801	0	1
1672	837	486	6	5	800	0	1
1694	895	496	6	5	864	0	1
1695	898	496	6	5	867	0	1
1696	896	496	6	5	865	0	1
1697	842	498	6	5	806	0	1
1698	769	498	6	5	868	0	1
1699	773	499	6	5	869	0	1
1700	845	499	6	5	809	0	1
1701	781	500	6	5	870	0	1
1702	847	500	6	5	811	0	1
1703	848	501	6	5	812	0	1
1704	786	501	6	5	871	0	1
1705	787	501	6	5	872	0	1
1706	851	501	6	5	815	0	1
1707	852	502	6	5	816	0	1
1708	791	502	6	5	873	0	1
1709	792	502	6	5	874	0	1
1710	854	502	6	5	818	0	1
1711	856	503	6	5	820	0	1
1712	817	503	6	5	875	0	1
1713	818	503	6	5	876	0	1
1714	859	503	6	5	823	0	1
1715	821	504	6	5	877	0	1
1716	861	504	6	5	825	0	1
1717	823	505	6	5	878	0	1
1718	863	505	6	5	827	0	1
1719	825	506	6	5	879	0	1
1720	865	506	6	5	829	0	1
1721	827	507	6	5	880	0	1
1722	867	507	6	5	831	0	1
1723	829	508	6	5	881	0	1
1724	869	508	6	5	833	0	1
1725	833	509	6	5	882	0	1
1726	871	509	6	5	835	0	1
1727	872	510	6	5	836	0	1
1728	873	510	6	5	837	0	1
1729	872	511	6	5	883	0	1
1730	875	511	6	5	839	0	1
1731	902	512	6	5	887	0	1
1732	900	512	6	5	885	0	1
1620	735	463	6	5	698	0	1
1733	1523	514	7	\N	\N	0	1
1734	1524	514	7	\N	\N	0	1
1735	1525	514	7	\N	\N	0	1
1736	1526	514	7	\N	\N	0	1
1737	1527	514	7	\N	\N	0	1
1738	1528	514	7	\N	\N	0	1
1739	1529	514	7	\N	\N	0	1
1740	1530	514	7	\N	\N	0	1
1741	1531	515	7	\N	\N	0	1
1742	1532	515	7	\N	\N	0	1
1743	1533	515	7	\N	\N	0	1
1746	1536	515	7	\N	\N	0	1
1747	1537	515	7	\N	\N	0	1
1748	1538	515	7	\N	\N	0	1
1749	1526	515	7	\N	\N	0	1
1750	1529	515	7	\N	\N	0	1
1751	1539	516	7	\N	\N	0	1
1752	1540	516	7	\N	\N	0	1
1753	1541	516	7	\N	\N	0	1
1755	1543	516	7	\N	\N	0	1
1756	1544	516	7	\N	\N	0	1
1758	1526	516	7	\N	\N	0	1
1759	1529	516	7	\N	\N	0	1
1760	1546	516	7	\N	\N	0	1
1763	1549	517	7	\N	\N	0	1
1764	1550	517	7	\N	\N	0	1
1765	1551	517	7	\N	\N	0	1
1767	1553	517	7	\N	\N	0	1
1768	1554	517	7	\N	\N	0	1
1769	1526	517	7	\N	\N	0	1
1770	1529	517	7	\N	\N	0	1
1771	1555	517	7	\N	\N	0	1
3344	2061	756	14	\N	\N	1	1
3345	1942	761	14	\N	\N	1	1
3346	1948	761	14	\N	\N	1	1
3347	2030	761	14	\N	\N	1	1
2126	1889	637	14	\N	\N	1	1
2129	1892	637	14	\N	\N	1	1
2122	1885	637	14	\N	\N	1	1
2123	1886	637	14	\N	\N	1	1
2117	1880	636	14	\N	\N	1	1
2118	1881	636	14	\N	\N	1	1
2116	1879	636	14	\N	\N	1	1
2114	1877	636	14	\N	\N	1	1
2121	1884	636	14	\N	\N	1	1
2119	1882	636	14	\N	\N	1	1
2120	1883	636	14	\N	\N	1	1
2112	1875	636	14	\N	\N	1	1
2113	1876	636	14	\N	\N	1	1
6162	3323	1321	17	21	5127	0	1
1803	1587	524	7	\N	\N	0	1
1805	1589	524	7	\N	\N	0	1
1807	1591	524	7	\N	\N	0	1
1810	1526	524	7	\N	\N	0	1
2023	1786	623	14	\N	\N	1	1
2028	1791	623	14	\N	\N	1	1
2029	1792	623	14	\N	\N	1	1
2024	1787	623	14	\N	\N	1	1
2015	1778	621	14	\N	\N	1	1
2019	1782	622	14	\N	\N	1	1
2018	1781	622	14	\N	\N	1	1
2014	1777	620	14	\N	\N	1	1
2012	1775	619	14	\N	\N	1	1
2011	1774	619	14	\N	\N	1	1
2008	1771	618	14	\N	\N	1	1
2002	1765	617	14	\N	\N	1	1
2003	1766	617	14	\N	\N	1	1
2006	1769	617	14	\N	\N	1	1
2007	1770	617	14	\N	\N	1	1
2004	1767	617	14	\N	\N	1	1
1997	1760	616	14	\N	\N	1	1
1999	1762	616	14	\N	\N	1	1
1998	1761	616	14	\N	\N	1	1
3348	2064	761	14	\N	\N	1	1
3349	1962	760	14	\N	\N	1	1
3350	1959	760	14	\N	\N	1	1
3351	2064	760	14	\N	\N	1	1
3352	1942	759	14	\N	\N	1	1
3353	1972	759	14	\N	\N	1	1
3354	2041	759	14	\N	\N	1	1
3355	2064	759	14	\N	\N	1	1
3356	1942	758	14	\N	\N	1	1
3357	1982	758	14	\N	\N	1	1
3358	2041	758	14	\N	\N	1	1
2176	1927	641	14	\N	\N	1	1
2174	1925	641	14	\N	\N	1	1
2175	1926	641	14	\N	\N	1	1
2163	1918	640	14	\N	\N	1	1
2162	1917	640	14	\N	\N	1	1
2165	1920	640	14	\N	\N	1	1
2164	1919	640	14	\N	\N	1	1
2166	1892	640	14	\N	\N	1	1
2167	1893	640	14	\N	\N	1	1
2168	1885	640	14	\N	\N	1	1
2169	1886	640	14	\N	\N	1	1
2152	1911	639	14	\N	\N	1	1
2153	1912	639	14	\N	\N	1	1
2146	1905	639	14	\N	\N	1	1
2147	1906	639	14	\N	\N	1	1
2154	1892	639	14	\N	\N	1	1
2155	1893	639	14	\N	\N	1	1
2156	1885	639	14	\N	\N	1	1
2157	1886	639	14	\N	\N	1	1
2150	1909	638	14	\N	\N	1	1
2151	1910	638	14	\N	\N	1	1
2135	1898	638	14	\N	\N	1	1
2132	1895	638	14	\N	\N	1	1
2138	1892	638	14	\N	\N	1	1
2139	1893	638	14	\N	\N	1	1
2140	1885	638	14	\N	\N	1	1
2141	1886	638	14	\N	\N	1	1
2148	1907	637	14	\N	\N	1	1
2149	1908	637	14	\N	\N	1	1
2131	1894	637	14	\N	\N	1	1
2130	1893	637	14	\N	\N	1	1
3360	1986	757	14	\N	\N	1	1
3361	1984	757	14	\N	\N	1	1
2499	1756	678	14	\N	\N	1	1
2494	2157	678	14	\N	\N	1	1
2493	2156	678	14	\N	\N	1	1
2492	2155	678	14	\N	\N	1	1
2489	2152	678	14	\N	\N	1	1
2498	2161	678	14	\N	\N	1	1
2497	2160	678	14	\N	\N	1	1
2496	2159	678	14	\N	\N	1	1
2491	2154	678	14	\N	\N	1	1
2490	2153	678	14	\N	\N	1	1
2488	1756	677	14	\N	\N	1	1
2483	2147	677	14	\N	\N	1	1
2482	2146	677	14	\N	\N	1	1
2481	2145	677	14	\N	\N	1	1
2478	2142	677	14	\N	\N	1	1
2487	2151	677	14	\N	\N	1	1
2486	2150	677	14	\N	\N	1	1
2485	2149	677	14	\N	\N	1	1
2480	2144	677	14	\N	\N	1	1
2479	2143	677	14	\N	\N	1	1
2470	1756	675	14	\N	\N	1	1
2471	1754	675	14	\N	\N	1	1
2472	1755	675	14	\N	\N	1	1
2473	1757	675	14	\N	\N	1	1
2477	2141	675	14	\N	\N	1	1
2467	2138	675	14	\N	\N	1	1
2468	2139	675	14	\N	\N	1	1
2469	2140	675	14	\N	\N	1	1
2475	1759	675	14	\N	\N	1	1
2476	1753	675	14	\N	\N	1	1
2407	2096	668	14	\N	\N	1	1
2456	1942	673	14	\N	\N	1	1
2439	2128	673	14	\N	\N	1	1
2440	2129	673	14	\N	\N	1	1
2441	2130	673	14	\N	\N	1	1
2457	1986	673	14	\N	\N	1	1
2458	1984	673	14	\N	\N	1	1
2459	2060	673	14	\N	\N	1	1
2452	1942	672	14	\N	\N	1	1
2431	2120	672	14	\N	\N	1	1
2432	2121	672	14	\N	\N	1	1
2433	2122	672	14	\N	\N	1	1
2453	1982	672	14	\N	\N	1	1
2454	2041	672	14	\N	\N	1	1
2455	2060	672	14	\N	\N	1	1
2448	1942	671	14	\N	\N	1	1
2425	2114	671	14	\N	\N	1	1
2426	2115	671	14	\N	\N	1	1
2427	2116	671	14	\N	\N	1	1
2449	1972	671	14	\N	\N	1	1
2450	2041	671	14	\N	\N	1	1
2451	2103	671	14	\N	\N	1	1
2418	2107	670	14	\N	\N	1	1
2445	1962	670	14	\N	\N	1	1
2446	1959	670	14	\N	\N	1	1
2419	2108	670	14	\N	\N	1	1
2420	2109	670	14	\N	\N	1	1
2447	2103	670	14	\N	\N	1	1
2442	1942	669	14	\N	\N	1	1
2411	2100	669	14	\N	\N	1	1
2413	2102	669	14	\N	\N	1	1
2443	1948	669	14	\N	\N	1	1
2444	2030	669	14	\N	\N	1	1
2414	2103	669	14	\N	\N	1	1
2355	2061	662	14	\N	\N	1	1
2403	1942	667	14	\N	\N	1	1
2383	2089	667	14	\N	\N	1	1
2384	2090	667	14	\N	\N	1	1
2385	2091	667	14	\N	\N	1	1
2404	1986	667	14	\N	\N	1	1
2405	1984	667	14	\N	\N	1	1
2406	2088	667	14	\N	\N	1	1
2400	1942	666	14	\N	\N	1	1
2377	2083	666	14	\N	\N	1	1
2379	2085	666	14	\N	\N	1	1
2401	1982	666	14	\N	\N	1	1
2402	2041	666	14	\N	\N	1	1
2382	2088	666	14	\N	\N	1	1
2396	1942	665	14	\N	\N	1	1
2374	2080	665	14	\N	\N	1	1
2371	2077	665	14	\N	\N	1	1
2375	2081	665	14	\N	\N	1	1
2397	1972	665	14	\N	\N	1	1
2398	2041	665	14	\N	\N	1	1
2399	2064	665	14	\N	\N	1	1
2364	2070	664	14	\N	\N	1	1
2393	1962	664	14	\N	\N	1	1
2394	1959	664	14	\N	\N	1	1
2366	2072	664	14	\N	\N	1	1
2395	2064	664	14	\N	\N	1	1
2390	1942	663	14	\N	\N	1	1
2361	2067	663	14	\N	\N	1	1
2356	2062	663	14	\N	\N	1	1
2362	2068	663	14	\N	\N	1	1
2391	1948	663	14	\N	\N	1	1
2392	2030	663	14	\N	\N	1	1
2358	2064	663	14	\N	\N	1	1
2351	1942	661	14	\N	\N	1	1
2335	2056	661	14	\N	\N	1	1
2336	2057	661	14	\N	\N	1	1
2337	2058	661	14	\N	\N	1	1
2352	1986	661	14	\N	\N	1	1
2354	2060	661	14	\N	\N	1	1
2347	1942	660	14	\N	\N	1	1
2328	2049	660	14	\N	\N	1	1
2329	2050	660	14	\N	\N	1	1
2330	2051	660	14	\N	\N	1	1
2348	1982	660	14	\N	\N	1	1
2349	2041	660	14	\N	\N	1	1
2350	2060	660	14	\N	\N	1	1
2344	1942	659	14	\N	\N	1	1
2322	2043	659	14	\N	\N	1	1
2323	2044	659	14	\N	\N	1	1
2324	2045	659	14	\N	\N	1	1
2345	1972	659	14	\N	\N	1	1
2320	2041	659	14	\N	\N	1	1
2315	2036	658	14	\N	\N	1	1
2341	1962	658	14	\N	\N	1	1
2342	1959	658	14	\N	\N	1	1
2316	2037	658	14	\N	\N	1	1
2317	2038	658	14	\N	\N	1	1
2343	2032	658	14	\N	\N	1	1
2339	1942	657	14	\N	\N	1	1
2340	1948	657	14	\N	\N	1	1
3363	2096	750	14	\N	\N	1	1
2642	2290	695	14	\N	\N	1	1
2643	2287	695	14	\N	\N	1	1
2641	2289	695	14	\N	\N	1	1
2632	2280	694	14	\N	\N	1	1
2637	2285	694	14	\N	\N	1	1
2639	2287	694	14	\N	\N	1	1
2625	2273	693	14	\N	\N	1	1
2630	2278	693	14	\N	\N	1	1
2623	2258	692	14	\N	\N	1	1
2621	2270	692	14	\N	\N	1	1
2624	2272	692	14	\N	\N	1	1
2619	2268	692	14	\N	\N	1	1
2620	2269	692	14	\N	\N	1	1
2609	2258	691	14	\N	\N	1	1
2611	2260	691	14	\N	\N	1	1
2610	2259	691	14	\N	\N	1	1
2612	2261	691	14	\N	\N	1	1
2602	2251	690	14	\N	\N	1	1
2608	2257	690	14	\N	\N	1	1
2603	2252	690	14	\N	\N	1	1
2605	2254	690	14	\N	\N	1	1
2606	2255	690	14	\N	\N	1	1
2674	2317	698	14	\N	\N	1	1
2673	2316	698	14	\N	\N	1	1
2672	2315	698	14	\N	\N	1	1
2667	2310	698	14	\N	\N	1	1
2666	2309	698	14	\N	\N	1	1
2671	2314	698	14	\N	\N	1	1
2670	2313	698	14	\N	\N	1	1
2664	2195	697	14	\N	\N	1	1
2663	2308	697	14	\N	\N	1	1
2662	2307	697	14	\N	\N	1	1
2661	2306	697	14	\N	\N	1	1
2657	2302	697	14	\N	\N	1	1
2660	2305	697	14	\N	\N	1	1
2659	2304	697	14	\N	\N	1	1
2665	2202	697	14	\N	\N	1	1
2658	2303	697	14	\N	\N	1	1
2653	2195	696	14	\N	\N	1	1
2647	2294	696	14	\N	\N	1	1
2648	2295	696	14	\N	\N	1	1
2649	2296	696	14	\N	\N	1	1
2650	2297	696	14	\N	\N	1	1
2651	2298	696	14	\N	\N	1	1
2652	2299	696	14	\N	\N	1	1
2654	2202	696	14	\N	\N	1	1
2598	2195	688	14	\N	\N	1	1
2591	2242	688	14	\N	\N	1	1
2592	2243	688	14	\N	\N	1	1
2593	2244	688	14	\N	\N	1	1
2594	2245	688	14	\N	\N	1	1
2595	2246	688	14	\N	\N	1	1
2600	2249	688	14	\N	\N	1	1
2601	2250	688	14	\N	\N	1	1
2596	2247	688	14	\N	\N	1	1
2599	2202	688	14	\N	\N	1	1
2597	2248	688	14	\N	\N	1	1
2587	2195	687	14	\N	\N	1	1
2579	2232	687	14	\N	\N	1	1
2580	2233	687	14	\N	\N	1	1
2586	2239	687	14	\N	\N	1	1
2582	2235	687	14	\N	\N	1	1
2583	2236	687	14	\N	\N	1	1
2588	2202	687	14	\N	\N	1	1
2585	2238	687	14	\N	\N	1	1
2576	2195	686	14	\N	\N	1	1
2569	2224	686	14	\N	\N	1	1
2570	2225	686	14	\N	\N	1	1
2571	2226	686	14	\N	\N	1	1
2572	2227	686	14	\N	\N	1	1
2573	2228	686	14	\N	\N	1	1
2574	2229	686	14	\N	\N	1	1
2577	2202	686	14	\N	\N	1	1
2575	2230	686	14	\N	\N	1	1
2563	2220	685	14	\N	\N	1	1
2562	2219	685	14	\N	\N	1	1
2560	2217	685	14	\N	\N	1	1
2556	2213	685	14	\N	\N	1	1
2559	2216	685	14	\N	\N	1	1
2558	2215	685	14	\N	\N	1	1
2566	2202	685	14	\N	\N	1	1
2564	2221	685	14	\N	\N	1	1
2554	2195	684	14	\N	\N	1	1
2546	2205	684	14	\N	\N	1	1
2547	2206	684	14	\N	\N	1	1
2548	2207	684	14	\N	\N	1	1
2553	2212	684	14	\N	\N	1	1
2549	2208	684	14	\N	\N	1	1
2555	2202	684	14	\N	\N	1	1
2552	2211	684	14	\N	\N	1	1
2536	2195	683	14	\N	\N	1	1
2534	2193	683	14	\N	\N	1	1
2535	2194	683	14	\N	\N	1	1
2537	2196	683	14	\N	\N	1	1
2544	2203	683	14	\N	\N	1	1
2538	2197	683	14	\N	\N	1	1
2542	2201	683	14	\N	\N	1	1
2543	2202	683	14	\N	\N	1	1
2533	2192	683	14	\N	\N	1	1
2532	1756	681	14	\N	\N	1	1
2526	2186	681	14	\N	\N	1	1
2527	2187	681	14	\N	\N	1	1
2531	2191	681	14	\N	\N	1	1
2523	2183	681	14	\N	\N	1	1
2524	2184	681	14	\N	\N	1	1
2525	2185	681	14	\N	\N	1	1
2529	2189	681	14	\N	\N	1	1
2530	2190	681	14	\N	\N	1	1
2521	1756	680	14	\N	\N	1	1
2515	2176	680	14	\N	\N	1	1
2516	2177	680	14	\N	\N	1	1
2517	2178	680	14	\N	\N	1	1
2520	2181	680	14	\N	\N	1	1
2512	2173	680	14	\N	\N	1	1
2513	2174	680	14	\N	\N	1	1
2514	2175	680	14	\N	\N	1	1
2519	2180	680	14	\N	\N	1	1
2510	1756	679	14	\N	\N	1	1
2504	2166	679	14	\N	\N	1	1
2505	2167	679	14	\N	\N	1	1
2506	2168	679	14	\N	\N	1	1
2509	2171	679	14	\N	\N	1	1
2503	2165	679	14	\N	\N	1	1
2507	2169	679	14	\N	\N	1	1
2508	2170	679	14	\N	\N	1	1
2678	2202	698	14	\N	\N	0	1
2791	2414	715	14	\N	\N	1	1
2782	2405	713	14	\N	\N	1	1
2780	2403	713	14	\N	\N	1	1
2784	2407	713	14	\N	\N	1	1
2783	2406	713	14	\N	\N	1	1
2778	2401	712	14	\N	\N	1	1
3364	1942	755	14	\N	\N	1	1
3365	1948	755	14	\N	\N	1	1
3366	2030	755	14	\N	\N	1	1
3367	2103	755	14	\N	\N	1	1
3368	1962	754	14	\N	\N	1	1
3369	1959	754	14	\N	\N	1	1
3370	2103	754	14	\N	\N	1	1
3371	1942	753	14	\N	\N	1	1
3372	1972	753	14	\N	\N	1	1
3373	2041	753	14	\N	\N	1	1
3374	2103	753	14	\N	\N	1	1
3375	1942	752	14	\N	\N	1	1
3376	1982	752	14	\N	\N	1	1
3377	2041	752	14	\N	\N	1	1
3378	1942	751	14	\N	\N	1	1
3379	1986	751	14	\N	\N	1	1
3380	1984	751	14	\N	\N	1	1
3381	2687	751	14	\N	\N	1	1
3382	1756	748	14	\N	\N	1	1
3383	2141	748	14	\N	\N	1	1
3384	2138	748	14	\N	\N	1	1
3385	2139	748	14	\N	\N	1	1
3386	2140	748	14	\N	\N	1	1
3387	1759	748	14	\N	\N	1	1
3389	1756	747	14	\N	\N	1	1
3390	2142	747	14	\N	\N	1	1
3391	2151	747	14	\N	\N	1	1
3392	2150	747	14	\N	\N	1	1
3393	2149	747	14	\N	\N	1	1
3394	2144	747	14	\N	\N	1	1
3395	2143	747	14	\N	\N	1	1
3396	1756	746	14	\N	\N	1	1
3397	2152	746	14	\N	\N	1	1
3398	2161	746	14	\N	\N	1	1
3399	2160	746	14	\N	\N	1	1
3400	2159	746	14	\N	\N	1	1
3401	2154	746	14	\N	\N	1	1
3402	2153	746	14	\N	\N	1	1
3405	2171	745	14	\N	\N	1	1
3407	2165	745	14	\N	\N	1	1
3408	2169	745	14	\N	\N	1	1
3409	2170	745	14	\N	\N	1	1
3411	1756	744	14	\N	\N	1	1
3412	2181	744	14	\N	\N	1	1
3413	2173	744	14	\N	\N	1	1
3414	2174	744	14	\N	\N	1	1
3415	2175	744	14	\N	\N	1	1
3416	2179	744	14	\N	\N	1	1
3417	2180	744	14	\N	\N	1	1
3418	1756	743	14	\N	\N	1	1
3419	2191	743	14	\N	\N	1	1
2765	2391	707	14	\N	\N	1	1
2767	2393	707	14	\N	\N	1	1
2768	2394	707	14	\N	\N	1	1
2769	2353	707	14	\N	\N	1	1
2770	2350	707	14	\N	\N	1	1
2764	2390	707	14	\N	\N	1	1
2771	2355	707	14	\N	\N	1	1
2756	2385	706	14	\N	\N	1	1
2755	2384	706	14	\N	\N	1	1
2754	2383	706	14	\N	\N	1	1
2753	2382	706	14	\N	\N	1	1
2758	2353	706	14	\N	\N	1	1
2759	2350	706	14	\N	\N	1	1
2757	2386	706	14	\N	\N	1	1
2760	2355	706	14	\N	\N	1	1
2744	2376	705	14	\N	\N	1	1
2747	2353	705	14	\N	\N	1	1
2748	2350	705	14	\N	\N	1	1
2746	2378	705	14	\N	\N	1	1
2749	2355	705	14	\N	\N	1	1
2731	2366	704	14	\N	\N	1	1
2732	2367	704	14	\N	\N	1	1
2733	2368	704	14	\N	\N	1	1
2734	2369	704	14	\N	\N	1	1
2736	2353	704	14	\N	\N	1	1
2737	2350	704	14	\N	\N	1	1
2730	2365	704	14	\N	\N	1	1
2738	2355	704	14	\N	\N	1	1
2724	2361	703	14	\N	\N	1	1
2721	2358	703	14	\N	\N	1	1
2720	2357	703	14	\N	\N	1	1
2726	2353	703	14	\N	\N	1	1
2727	2350	703	14	\N	\N	1	1
2725	2362	703	14	\N	\N	1	1
2718	2355	703	14	\N	\N	1	1
2711	2348	702	14	\N	\N	1	1
2712	2349	702	14	\N	\N	1	1
2714	2351	702	14	\N	\N	1	1
2715	2352	702	14	\N	\N	1	1
2716	2353	702	14	\N	\N	1	1
2713	2350	702	14	\N	\N	1	1
2707	2344	702	14	\N	\N	1	1
2717	2354	702	14	\N	\N	1	1
2692	2331	700	14	\N	\N	1	1
2693	2332	700	14	\N	\N	1	1
2694	2333	700	14	\N	\N	1	1
2695	2334	700	14	\N	\N	1	1
2696	2335	700	14	\N	\N	1	1
2699	2338	700	14	\N	\N	1	1
2700	2339	700	14	\N	\N	1	1
2697	2336	700	14	\N	\N	1	1
2689	2202	699	14	\N	\N	0	1
2698	2337	700	14	\N	\N	1	1
2688	2195	699	14	\N	\N	1	1
2681	2322	699	14	\N	\N	1	1
2682	2323	699	14	\N	\N	1	1
2683	2324	699	14	\N	\N	1	1
2684	2325	699	14	\N	\N	1	1
2685	2326	699	14	\N	\N	1	1
2702	2202	700	14	\N	\N	1	1
2686	2327	699	14	\N	\N	1	1
2677	2195	698	14	\N	\N	1	1
2676	2319	698	14	\N	\N	1	1
2675	2318	698	14	\N	\N	1	1
2705	2342	686	14	\N	\N	1	1
2706	2343	686	14	\N	\N	1	1
2703	2340	684	14	\N	\N	1	1
2704	2341	684	14	\N	\N	1	1
2009	1772	618	14	\N	\N	1	1
3276	2251	715	14	\N	\N	1	1
8862	4389	2231	17	20	\N	0	1
8863	4390	2231	17	20	\N	0	1
8864	4394	2232	17	20	\N	0	1
8865	4390	2232	17	20	\N	0	1
8866	4396	2232	17	20	\N	0	1
8867	4395	2232	17	20	\N	0	1
8868	4396	2233	17	20	\N	0	1
8869	4397	2233	17	20	\N	0	1
8870	4391	2234	17	20	\N	0	1
8871	4390	2234	17	20	\N	1	1
8872	4392	2234	17	20	\N	0	1
8873	4392	2235	17	20	\N	0	1
8874	4393	2235	17	20	\N	0	1
8877	4424	2237	14	\N	\N	1	2
2839	2462	721	14	\N	\N	1	1
2834	2457	721	14	\N	\N	1	1
3236	1907	720	14	\N	\N	1	1
3251	1886	719	14	\N	\N	1	1
3266	1885	717	14	\N	\N	1	1
3286	1948	779	14	\N	\N	1	1
3298	1969	776	14	\N	\N	1	1
3199	2822	775	14	\N	\N	1	1
3421	2184	743	14	\N	\N	1	1
3422	2185	743	14	\N	\N	1	1
3423	2189	743	14	\N	\N	1	1
3424	2190	743	14	\N	\N	1	1
2887	2510	729	14	\N	\N	1	1
2888	2511	729	14	\N	\N	1	1
2876	2499	728	14	\N	\N	1	1
2871	2494	727	14	\N	\N	1	1
2872	2495	727	14	\N	\N	1	1
2863	2486	726	14	\N	\N	1	1
2862	2485	726	14	\N	\N	1	1
2855	2478	725	14	\N	\N	1	1
2854	2477	725	14	\N	\N	1	1
2849	2472	724	14	\N	\N	1	1
2850	2473	724	14	\N	\N	1	1
3493	1765	795	17	20	2002	0	1
3494	1766	795	17	20	2003	0	1
3495	1769	795	17	20	2006	0	1
3496	1770	795	17	20	2007	0	1
3485	1775	796	17	20	2012	0	1
3486	1774	796	17	20	2011	0	1
3491	1772	799	17	20	2009	0	1
3492	1771	799	17	20	2008	0	1
3498	1846	802	17	20	2083	0	1
3499	1849	802	17	20	2086	0	1
3500	1850	802	17	20	2087	0	1
3501	1845	802	17	20	2082	0	1
3502	1870	803	17	20	2107	0	1
3509	2251	809	17	20	3276	0	1
3510	2414	809	17	20	2791	0	1
3562	1927	820	17	20	3268	0	1
3563	1928	820	17	20	3269	0	1
3564	1925	820	17	20	3270	0	1
3565	1926	820	17	20	3271	0	1
3566	1892	820	17	20	3272	0	1
3568	1885	820	17	20	3274	0	1
3569	1886	820	17	20	3275	0	1
3554	1918	819	17	20	3260	0	1
3555	1917	819	17	20	3261	0	1
3556	1920	819	17	20	3262	0	1
3557	1919	819	17	20	3263	0	1
3558	1892	819	17	20	3264	0	1
3559	1893	819	17	20	3265	0	1
3560	1885	819	17	20	3266	0	1
3561	1886	819	17	20	3267	0	1
3546	1911	818	17	20	3252	0	1
3547	1912	818	17	20	3253	0	1
3548	1905	818	17	20	3254	0	1
3549	1906	818	17	20	3255	0	1
3550	1892	818	17	20	3256	0	1
3551	1893	818	17	20	3257	0	1
3553	1886	818	17	20	3259	0	1
3538	1909	817	17	20	3244	0	1
3539	1910	817	17	20	3245	0	1
3540	1898	817	17	20	3246	0	1
3541	1895	817	17	20	3247	0	1
3542	1892	817	17	20	3248	0	1
3543	1893	817	17	20	3249	0	1
3544	1885	817	17	20	3250	0	1
3545	1886	817	17	20	3251	0	1
3530	1907	816	17	20	3236	0	1
3531	1908	816	17	20	3237	0	1
3532	1889	816	17	20	3238	0	1
3533	1894	816	17	20	3239	0	1
3534	1892	816	17	20	3240	0	1
3535	1893	816	17	20	3241	0	1
3536	1885	816	17	20	3242	0	1
3523	2462	815	17	20	2839	0	1
3524	1877	815	17	20	3231	0	1
3525	2457	815	17	20	2834	0	1
3526	1882	815	17	20	3232	0	1
3527	1883	815	17	20	3233	0	1
3528	1875	815	17	20	3234	0	1
3529	1876	815	17	20	3235	0	1
6168	3316	1320	17	21	5120	0	1
6169	3317	1320	17	21	5121	0	1
6170	3314	1320	17	21	5118	0	1
8880	4391	2237	14	\N	\N	1	2
8886	4424	2241	17	20	8877	0	2
8887	4391	2241	17	20	8880	0	2
8879	4390	2236	14	\N	\N	0	2
6171	3377	1325	17	21	5181	0	1
6172	3388	1325	17	21	5192	0	1
6173	3379	1325	17	21	5183	0	1
6174	3380	1325	17	21	5184	0	1
6175	3387	1325	17	21	5191	0	1
6176	3378	1325	17	21	5182	0	1
6177	3400	1326	17	21	5204	0	1
6178	3408	1326	17	21	5212	0	1
6179	3402	1326	17	21	5206	0	1
6180	3403	1326	17	21	5207	0	1
6181	3407	1326	17	21	5211	0	1
6182	3401	1326	17	21	5205	0	1
6189	3390	1330	17	21	5194	0	1
6190	3398	1330	17	21	5202	0	1
6191	3392	1330	17	21	5196	0	1
6192	3393	1330	17	21	5197	0	1
6193	3397	1330	17	21	5201	0	1
6194	3391	1330	17	21	5195	0	1
6195	3386	1324	17	21	5190	0	1
6196	3375	1324	17	21	5179	0	1
6197	3385	1324	17	21	5189	0	1
6198	3384	1324	17	21	5188	0	1
6199	3333	1333	17	21	5137	0	1
6200	3336	1333	17	21	5140	0	1
6201	3337	1333	17	21	5141	0	1
6202	3332	1333	17	21	5136	0	1
6210	3345	1336	17	21	5149	0	1
6211	3344	1336	17	21	5148	0	1
6212	3341	1332	17	21	5145	0	1
6213	3420	1331	17	21	5224	0	1
6214	3419	1331	17	21	5223	0	1
6256	4081	1352	17	21	6088	0	1
3082	2705	754	14	\N	\N	1	1
3081	2704	754	14	\N	\N	1	1
3077	2700	753	14	\N	\N	1	1
3076	2699	753	14	\N	\N	1	1
3075	2698	753	14	\N	\N	1	1
3070	2693	752	14	\N	\N	1	1
3069	2692	752	14	\N	\N	1	1
3068	2691	752	14	\N	\N	1	1
3064	2687	752	14	\N	\N	1	1
3063	2686	751	14	\N	\N	1	1
3062	2685	751	14	\N	\N	1	1
3061	2684	751	14	\N	\N	1	1
3051	2674	748	14	\N	\N	1	1
3050	2673	748	14	\N	\N	1	1
3049	2672	748	14	\N	\N	1	1
3040	2663	747	14	\N	\N	1	1
3041	2664	747	14	\N	\N	1	1
3042	2665	747	14	\N	\N	1	1
3030	2653	746	14	\N	\N	1	1
3031	2654	746	14	\N	\N	1	1
3032	2655	746	14	\N	\N	1	1
3024	2647	745	14	\N	\N	1	1
3023	2646	745	14	\N	\N	1	1
3022	2645	745	14	\N	\N	1	1
3014	2637	744	14	\N	\N	1	1
3013	2636	744	14	\N	\N	1	1
3012	2635	744	14	\N	\N	1	1
3004	2627	743	14	\N	\N	1	1
3003	2626	743	14	\N	\N	1	1
3002	2625	743	14	\N	\N	1	1
6257	4082	1352	17	21	6089	0	1
6221	4126	1342	17	21	6143	0	1
6222	4131	1342	17	21	6148	0	1
6223	4120	1342	17	21	6150	0	1
6224	4122	1342	17	21	6151	0	1
8902	4389	2250	17	20	\N	0	1
8903	4390	2250	17	20	\N	0	1
8904	4391	2251	17	20	\N	0	2
8905	4424	2251	17	20	\N	0	2
8906	4390	2252	17	20	\N	0	2
8907	4394	2253	17	20	\N	0	1
8908	4390	2253	17	20	\N	0	1
8909	4396	2253	17	20	\N	0	1
8910	4395	2253	17	20	\N	0	1
8911	4391	2254	17	20	\N	0	1
8912	4390	2254	17	20	\N	1	1
8913	4392	2254	17	20	\N	0	1
8914	4392	2255	17	20	\N	0	1
8915	4393	2255	17	20	\N	0	1
8917	4424	2256	14	\N	\N	0	3
2035	1798	624	14	\N	\N	1	1
2067	1830	630	14	\N	\N	1	1
3217	2840	777	14	\N	\N	1	1
3216	2839	777	14	\N	\N	1	1
3215	2838	777	14	\N	\N	1	1
3210	2833	776	14	\N	\N	1	1
3209	2832	776	14	\N	\N	1	1
3208	2831	776	14	\N	\N	1	1
3200	2823	775	14	\N	\N	1	1
3201	2824	775	14	\N	\N	1	1
3192	2815	773	14	\N	\N	1	1
3194	2817	773	14	\N	\N	1	1
3188	2811	772	14	\N	\N	1	1
3187	2810	772	14	\N	\N	1	1
3186	2809	772	14	\N	\N	1	1
3180	2803	771	14	\N	\N	1	1
3181	2804	771	14	\N	\N	1	1
3182	2805	771	14	\N	\N	1	1
3175	2798	770	14	\N	\N	1	1
3174	2797	770	14	\N	\N	1	1
3173	2796	770	14	\N	\N	1	1
3168	2791	769	14	\N	\N	1	1
3167	2790	769	14	\N	\N	1	1
3166	2789	769	14	\N	\N	1	1
3157	2780	767	14	\N	\N	1	1
3159	2782	767	14	\N	\N	1	1
3153	2776	766	14	\N	\N	1	1
3152	2775	766	14	\N	\N	1	1
3151	2774	766	14	\N	\N	1	1
3146	2769	765	14	\N	\N	1	1
3145	2768	765	14	\N	\N	1	1
3144	2767	765	14	\N	\N	1	1
3140	2763	764	14	\N	\N	1	1
3139	2762	764	14	\N	\N	1	1
3138	2761	764	14	\N	\N	1	1
3133	2756	763	14	\N	\N	1	1
3132	2755	763	14	\N	\N	1	1
3131	2754	763	14	\N	\N	1	1
3125	2748	761	14	\N	\N	1	1
3122	2745	761	14	\N	\N	1	1
3118	2741	760	14	\N	\N	1	1
3117	2740	760	14	\N	\N	1	1
3116	2739	760	14	\N	\N	1	1
3111	2734	759	14	\N	\N	1	1
3112	2735	759	14	\N	\N	1	1
3110	2733	759	14	\N	\N	1	1
3105	2728	758	14	\N	\N	1	1
3104	2727	758	14	\N	\N	1	1
3103	2726	758	14	\N	\N	1	1
3102	2725	758	14	\N	\N	1	1
3098	2721	757	14	\N	\N	1	1
3097	2720	757	14	\N	\N	1	1
3090	2713	755	14	\N	\N	1	1
3089	2712	755	14	\N	\N	1	1
3088	2711	755	14	\N	\N	1	1
3083	2706	754	14	\N	\N	1	1
3428	2353	723	14	\N	\N	1	1
3429	2350	723	14	\N	\N	1	1
3431	2349	729	14	\N	\N	1	1
3432	2351	729	14	\N	\N	1	1
3433	2352	729	14	\N	\N	1	1
3434	2355	729	14	\N	\N	1	1
3435	2360	728	14	\N	\N	1	1
3436	2358	728	14	\N	\N	1	1
3437	2357	728	14	\N	\N	1	1
3438	2355	728	14	\N	\N	1	1
3440	2368	727	14	\N	\N	1	1
3441	2369	727	14	\N	\N	1	1
3442	2354	727	14	\N	\N	1	1
3443	2376	726	14	\N	\N	1	1
3444	2355	726	14	\N	\N	1	1
3445	2384	725	14	\N	\N	1	1
3446	2383	725	14	\N	\N	1	1
3447	2382	725	14	\N	\N	1	1
3448	2355	725	14	\N	\N	1	1
3449	2392	724	14	\N	\N	1	1
3450	2393	724	14	\N	\N	1	1
3451	2394	724	14	\N	\N	1	1
3452	2355	724	14	\N	\N	1	1
3454	1796	782	17	20	2033	0	1
3455	1801	782	17	20	2038	0	1
3456	1802	782	17	20	2039	0	1
3457	1797	782	17	20	2034	0	1
3463	1830	784	17	20	2067	0	1
3464	1829	784	17	20	2066	0	1
3467	1818	786	17	20	2055	0	1
3468	1817	786	17	20	2054	0	1
3469	1815	786	17	20	2052	0	1
3470	1778	787	17	20	2015	0	1
3471	1782	788	17	20	2019	0	1
3472	1781	788	17	20	2018	0	1
3505	1853	801	17	20	2090	0	1
3504	1835	804	17	20	2072	0	1
3506	1760	805	17	20	1997	0	1
3508	1761	805	17	20	1998	0	1
3521	2280	813	17	20	3282	0	1
3522	2285	813	17	20	3283	0	1
3519	2273	812	17	20	3281	0	1
3520	2401	812	17	20	2778	0	1
3514	2258	811	17	20	3280	0	1
3515	2405	811	17	20	2782	0	1
3516	2403	811	17	20	2780	0	1
3517	2407	811	17	20	2784	0	1
3518	2406	811	17	20	2783	0	1
3511	2260	810	17	20	3277	0	1
3512	2259	810	17	20	3278	0	1
3513	2261	810	17	20	3279	0	1
3591	1942	827	17	20	3296	0	1
3592	2833	827	17	20	3210	0	1
3593	2832	827	17	20	3209	0	1
3595	1982	827	17	20	3297	0	1
3578	2844	825	17	20	3221	0	1
3579	1962	825	17	20	3289	0	1
3580	1959	825	17	20	3290	0	1
3581	2846	825	17	20	3223	0	1
3582	2845	825	17	20	3222	0	1
3583	1939	825	17	20	3291	0	1
3465	1824	785	17	20	2061	0	1
3466	1823	785	17	20	2060	0	1
2025	1788	623	14	\N	\N	1	1
2046	1809	626	14	\N	\N	1	1
2045	1808	626	14	\N	\N	1	1
2050	1813	627	14	\N	\N	1	1
2051	1814	627	14	\N	\N	1	1
3277	2260	714	14	\N	\N	1	1
3278	2259	714	14	\N	\N	1	1
3279	2261	714	14	\N	\N	1	1
3280	2258	713	14	\N	\N	1	1
3281	2273	712	14	\N	\N	1	1
3282	2280	711	14	\N	\N	1	1
3283	2285	711	14	\N	\N	1	1
3231	1877	721	14	\N	\N	1	1
3232	1882	721	14	\N	\N	1	1
3233	1883	721	14	\N	\N	1	1
3234	1875	721	14	\N	\N	1	1
3235	1876	721	14	\N	\N	1	1
3237	1908	720	14	\N	\N	1	1
3238	1889	720	14	\N	\N	1	1
3239	1894	720	14	\N	\N	1	1
3240	1892	720	14	\N	\N	1	1
3241	1893	720	14	\N	\N	1	1
3242	1885	720	14	\N	\N	1	1
3243	1886	720	14	\N	\N	1	1
3244	1909	719	14	\N	\N	1	1
3245	1910	719	14	\N	\N	1	1
3246	1898	719	14	\N	\N	1	1
3247	1895	719	14	\N	\N	1	1
3248	1892	719	14	\N	\N	1	1
3249	1893	719	14	\N	\N	1	1
3250	1885	719	14	\N	\N	1	1
3252	1911	718	14	\N	\N	1	1
3253	1912	718	14	\N	\N	1	1
3254	1905	718	14	\N	\N	1	1
3255	1906	718	14	\N	\N	1	1
3256	1892	718	14	\N	\N	1	1
3257	1893	718	14	\N	\N	1	1
3258	1885	718	14	\N	\N	1	1
3259	1886	718	14	\N	\N	1	1
3260	1918	717	14	\N	\N	1	1
3261	1917	717	14	\N	\N	1	1
3262	1920	717	14	\N	\N	1	1
3263	1919	717	14	\N	\N	1	1
3264	1892	717	14	\N	\N	1	1
3265	1893	717	14	\N	\N	1	1
3267	1886	717	14	\N	\N	1	1
3268	1927	716	14	\N	\N	1	1
3269	1928	716	14	\N	\N	1	1
3270	1925	716	14	\N	\N	1	1
3271	1926	716	14	\N	\N	1	1
3272	1892	716	14	\N	\N	1	1
3273	1893	716	14	\N	\N	1	1
3274	1885	716	14	\N	\N	1	1
3275	1886	716	14	\N	\N	1	1
3284	1929	774	14	\N	\N	1	1
3285	1942	779	14	\N	\N	1	1
3226	2849	779	14	\N	\N	1	1
3224	2847	779	14	\N	\N	1	1
3225	2848	779	14	\N	\N	1	1
3287	1945	779	14	\N	\N	1	1
3288	1939	779	14	\N	\N	1	1
3221	2844	778	14	\N	\N	1	1
3289	1962	778	14	\N	\N	1	1
3290	1959	778	14	\N	\N	1	1
3223	2846	778	14	\N	\N	1	1
3222	2845	778	14	\N	\N	1	1
3291	1939	778	14	\N	\N	1	1
3292	1942	777	14	\N	\N	1	1
3293	1972	777	14	\N	\N	1	1
3294	1969	777	14	\N	\N	1	1
3295	1939	777	14	\N	\N	1	1
3296	1942	776	14	\N	\N	1	1
3297	1982	776	14	\N	\N	1	1
3299	2060	776	14	\N	\N	1	1
3300	1942	775	14	\N	\N	1	1
3301	1986	775	14	\N	\N	1	1
3302	1984	775	14	\N	\N	1	1
3303	2060	775	14	\N	\N	1	1
3304	1990	768	14	\N	\N	1	1
3305	1942	773	14	\N	\N	1	1
3306	1948	773	14	\N	\N	1	1
3307	1969	773	14	\N	\N	1	1
3308	1996	773	14	\N	\N	1	1
3309	1962	772	14	\N	\N	1	1
3310	1959	772	14	\N	\N	1	1
3311	1996	772	14	\N	\N	1	1
3312	1942	771	14	\N	\N	1	1
3314	1969	771	14	\N	\N	1	1
3315	1996	771	14	\N	\N	1	1
3316	1942	770	14	\N	\N	1	1
3317	1982	770	14	\N	\N	1	1
3318	1969	770	14	\N	\N	1	1
3319	2060	770	14	\N	\N	1	1
3320	1942	769	14	\N	\N	1	1
3321	1986	769	14	\N	\N	1	1
3322	1984	769	14	\N	\N	1	1
3323	2060	769	14	\N	\N	1	1
3324	2025	762	14	\N	\N	1	1
3325	1942	767	14	\N	\N	1	1
3326	1948	767	14	\N	\N	1	1
3327	2030	767	14	\N	\N	1	1
3329	1962	766	14	\N	\N	1	1
3330	1959	766	14	\N	\N	1	1
3331	2032	766	14	\N	\N	1	1
3332	1942	765	14	\N	\N	1	1
3333	1972	765	14	\N	\N	1	1
3334	2041	765	14	\N	\N	1	1
3335	2032	765	14	\N	\N	1	1
3336	1942	764	14	\N	\N	1	1
3337	1982	764	14	\N	\N	1	1
3338	2041	764	14	\N	\N	1	1
3339	2032	764	14	\N	\N	1	1
3478	1805	781	17	20	2042	0	1
3458	1788	783	17	20	2025	0	1
3459	1786	783	17	20	2023	0	1
3460	1791	783	17	20	2028	0	1
3461	1792	783	17	20	2029	0	1
3462	1787	783	17	20	2024	0	1
3480	1809	794	17	20	2046	0	1
3481	1808	794	17	20	2045	0	1
3482	1807	794	17	20	2044	0	1
3483	1813	793	17	20	2050	0	1
3484	1814	793	17	20	2051	0	1
3503	1836	804	17	20	2073	0	1
3195	2818	773	14	\N	\N	1	1
3313	1972	771	14	\N	\N	1	1
3633	1942	834	17	20	3320	0	1
3634	2791	834	17	20	3168	0	1
3635	2790	834	17	20	3167	0	1
3636	2789	834	17	20	3166	0	1
3637	1986	834	17	20	3321	0	1
3638	1984	834	17	20	3322	0	1
3639	2060	834	17	20	3323	0	1
3619	1942	832	17	20	3312	0	1
3620	2803	832	17	20	3180	0	1
3621	2804	832	17	20	3181	0	1
3622	2805	832	17	20	3182	0	1
3623	1972	832	17	20	3313	0	1
3624	1969	832	17	20	3314	0	1
3625	1996	832	17	20	3315	0	1
3613	2811	831	17	20	3188	0	1
3614	1962	831	17	20	3309	0	1
3615	1959	831	17	20	3310	0	1
3616	2810	831	17	20	3187	0	1
3617	2809	831	17	20	3186	0	1
3618	1996	831	17	20	3311	0	1
3608	2815	830	17	20	3192	0	1
3609	2817	830	17	20	3194	0	1
3610	1948	830	17	20	3306	0	1
3611	1969	830	17	20	3307	0	1
3612	1996	830	17	20	3308	0	1
6203	3367	1334	17	21	5171	0	1
6204	3370	1334	17	21	5174	0	1
6205	3371	1334	17	21	5175	0	1
6206	3366	1334	17	21	5170	0	1
6215	3327	1337	17	21	5131	0	1
6216	3329	1337	17	21	5133	0	1
6258	4080	1352	17	21	6087	0	1
6259	4078	1352	17	21	6085	0	1
6225	4125	1340	17	21	6142	0	1
6226	4120	1340	17	21	6137	0	1
6227	4122	1340	17	21	6139	0	1
6291	3458	1363	17	21	5265	0	1
6292	3455	1361	17	21	5262	0	1
6281	3467	1360	17	21	5277	0	1
6280	3468	1359	17	21	5278	0	1
6282	3465	1358	17	21	5275	0	1
6283	3464	1358	17	21	5274	0	1
6284	3466	1358	17	21	5276	0	1
6285	3479	1358	17	21	5294	0	1
6286	3463	1358	17	21	5273	0	1
6287	3428	1358	17	21	5279	0	1
6288	3429	1358	17	21	5280	0	1
6289	3422	1358	17	21	5281	0	1
8699	4396	2163	14	\N	\N	0	1
8700	4397	2163	14	\N	\N	0	1
8919	4389	2259	17	20	\N	0	1
8920	4390	2259	17	20	\N	0	1
8921	4424	2260	17	20	\N	0	3
8922	4391	2261	17	20	\N	0	2
8923	4424	2261	17	20	\N	0	2
8924	4394	2262	17	20	\N	0	1
8925	4390	2262	17	20	\N	0	1
8926	4396	2262	17	20	\N	0	1
8927	4395	2262	17	20	\N	0	1
8928	4391	2263	17	20	\N	0	1
8929	4390	2263	17	20	\N	1	1
8930	4392	2263	17	20	\N	0	1
8931	4392	2264	17	20	\N	0	1
8932	4393	2264	17	20	\N	0	1
8934	4391	2265	14	\N	\N	1	4
8935	4391	2266	17	20	8934	0	4
8936	4428	2269	14	\N	\N	0	1
8937	4429	2268	14	\N	\N	0	1
8938	4430	2268	14	\N	\N	0	1
8939	4431	2268	14	\N	\N	0	1
8941	4428	2270	14	\N	\N	0	1
8942	4433	2269	14	\N	\N	0	1
8943	4434	2269	14	\N	\N	0	1
8944	4435	2269	14	\N	\N	0	1
8694	4393	2159	1	\N	\N	1	1
8688	4389	2157	1	\N	\N	1	1
8698	4396	2162	14	\N	\N	1	1
8692	4392	2158	1	\N	\N	1	1
8690	4390	2158	1	\N	\N	1	1
8696	4395	2162	14	\N	\N	1	1
8695	4394	2161	14	\N	\N	0	1
8693	4392	2159	1	\N	\N	1	1
8697	4394	2162	14	\N	\N	1	1
8691	4391	2158	1	\N	\N	1	1
8706	4390	2165	17	20	8690	0	1
8707	4389	2165	17	20	8688	0	1
8713	4390	2169	17	20	8703	0	1
8719	4396	2169	17	20	8698	0	1
8720	4395	2169	17	20	8696	0	1
8721	4394	2169	17	20	8697	0	1
3160	2783	767	14	\N	\N	1	1
3328	2032	767	14	\N	\N	1	1
3340	1942	763	14	\N	\N	1	1
3123	2746	761	14	\N	\N	1	1
3359	1942	757	14	\N	\N	1	1
3096	2719	757	14	\N	\N	1	1
3362	2725	757	14	\N	\N	1	1
3738	1942	852	17	20	3378	0	1
3739	2686	852	17	20	3063	0	1
3740	2685	852	17	20	3062	0	1
3741	2684	852	17	20	3061	0	1
3742	1986	852	17	20	3379	0	1
3743	1984	852	17	20	3380	0	1
3744	2687	852	17	20	3381	0	1
3731	1942	851	17	20	3375	0	1
3732	2693	851	17	20	3070	0	1
3733	2692	851	17	20	3069	0	1
3734	2691	851	17	20	3068	0	1
3735	1982	851	17	20	3376	0	1
3736	2041	851	17	20	3377	0	1
3737	2687	851	17	20	3064	0	1
3724	1942	850	17	20	3371	0	1
3725	2700	850	17	20	3077	0	1
3727	2698	850	17	20	3075	0	1
3728	1972	850	17	20	3372	0	1
3729	2041	850	17	20	3373	0	1
3730	2103	850	17	20	3374	0	1
3718	2706	849	17	20	3083	0	1
3719	1962	849	17	20	3368	0	1
3720	1959	849	17	20	3369	0	1
3721	2705	849	17	20	3082	0	1
3722	2704	849	17	20	3081	0	1
3723	2103	849	17	20	3370	0	1
3711	1942	848	17	20	3364	0	1
3712	2713	848	17	20	3090	0	1
3713	2712	848	17	20	3089	0	1
3714	2711	848	17	20	3088	0	1
3715	1948	848	17	20	3365	0	1
3716	2030	848	17	20	3366	0	1
3675	2061	841	17	20	3344	0	1
3703	1942	846	17	20	3359	0	1
3704	2721	846	17	20	3098	0	1
3705	2720	846	17	20	3097	0	1
3706	2719	846	17	20	3096	0	1
3707	1986	846	17	20	3360	0	1
3708	1984	846	17	20	3361	0	1
3709	2725	846	17	20	3362	0	1
3696	1942	845	17	20	3356	0	1
3697	2728	845	17	20	3105	0	1
3698	2727	845	17	20	3104	0	1
3699	2726	845	17	20	3103	0	1
3700	1982	845	17	20	3357	0	1
3701	2041	845	17	20	3358	0	1
3702	2725	845	17	20	3102	0	1
3689	1942	844	17	20	3352	0	1
3691	2735	844	17	20	3112	0	1
3692	2733	844	17	20	3110	0	1
3693	1972	844	17	20	3353	0	1
3694	2041	844	17	20	3354	0	1
3695	2064	844	17	20	3355	0	1
3683	2741	843	17	20	3118	0	1
3684	1962	843	17	20	3349	0	1
3685	1959	843	17	20	3350	0	1
3686	2740	843	17	20	3117	0	1
3687	2739	843	17	20	3116	0	1
3688	2064	843	17	20	3351	0	1
3676	1942	842	17	20	3345	0	1
3677	2746	842	17	20	3123	0	1
3678	2748	842	17	20	3125	0	1
3679	2745	842	17	20	3122	0	1
3680	1948	842	17	20	3346	0	1
3682	2064	842	17	20	3348	0	1
3640	2025	835	17	20	3324	0	1
3668	1942	840	17	20	3340	0	1
3669	2756	840	17	20	3133	0	1
3670	2755	840	17	20	3132	0	1
3671	2754	840	17	20	3131	0	1
3672	1986	840	17	20	3341	0	1
3673	1984	840	17	20	3342	0	1
3674	2032	840	17	20	3343	0	1
3661	1942	839	17	20	3336	0	1
3662	2763	839	17	20	3140	0	1
3663	2762	839	17	20	3139	0	1
3664	2761	839	17	20	3138	0	1
3665	1982	839	17	20	3337	0	1
3666	2041	839	17	20	3338	0	1
3667	2032	839	17	20	3339	0	1
3655	2769	838	17	20	3146	0	1
3656	2768	838	17	20	3145	0	1
3657	2767	838	17	20	3144	0	1
3658	1972	838	17	20	3333	0	1
3659	2041	838	17	20	3334	0	1
3660	2032	838	17	20	3335	0	1
3648	2776	837	17	20	3153	0	1
3649	1962	837	17	20	3329	0	1
3650	1959	837	17	20	3330	0	1
3651	2775	837	17	20	3152	0	1
3652	2774	837	17	20	3151	0	1
3653	2032	837	17	20	3331	0	1
3641	1942	836	17	20	3325	0	1
3642	2783	836	17	20	3160	0	1
3643	2780	836	17	20	3157	0	1
3644	2782	836	17	20	3159	0	1
3646	2030	836	17	20	3327	0	1
3647	2032	836	17	20	3328	0	1
3626	1942	833	17	20	3316	0	1
3627	2798	833	17	20	3175	0	1
3628	2797	833	17	20	3174	0	1
3629	2796	833	17	20	3173	0	1
3630	1982	833	17	20	3317	0	1
3631	1969	833	17	20	3318	0	1
3632	2060	833	17	20	3319	0	1
3745	1756	854	17	20	3382	0	1
3388	1753	748	14	\N	\N	1	1
8703	4390	2167	17	20	8689	1	1
8704	4392	2167	17	20	8693	0	1
8705	4391	2167	17	20	8691	0	1
8701	4392	2166	17	20	8692	0	1
8702	4393	2166	17	20	8694	0	1
3403	1756	745	14	\N	\N	1	1
3803	2353	860	17	20	3428	0	1
3804	2350	860	17	20	3429	0	1
3805	2510	861	17	20	2887	0	1
3806	2349	861	17	20	3431	0	1
3807	2351	861	17	20	3432	0	1
3808	2352	861	17	20	3433	0	1
3809	2511	861	17	20	2888	0	1
3810	2355	861	17	20	3434	0	1
3775	1756	857	17	20	3403	0	1
3776	2647	857	17	20	3024	0	1
3777	2646	857	17	20	3023	0	1
3778	2645	857	17	20	3022	0	1
3779	2171	857	17	20	3405	0	1
3780	2165	857	17	20	3407	0	1
3781	2169	857	17	20	3408	0	1
3782	2170	857	17	20	3409	0	1
3765	1756	856	17	20	3396	0	1
3766	2653	856	17	20	3030	0	1
3767	2654	856	17	20	3031	0	1
3768	2655	856	17	20	3032	0	1
3769	2152	856	17	20	3397	0	1
3770	2161	856	17	20	3398	0	1
3771	2160	856	17	20	3399	0	1
3772	2159	856	17	20	3400	0	1
3773	2154	856	17	20	3401	0	1
3774	2153	856	17	20	3402	0	1
3746	2674	854	17	20	3051	0	1
3747	2673	854	17	20	3050	0	1
3748	2672	854	17	20	3049	0	1
3749	2141	854	17	20	3383	0	1
3750	2138	854	17	20	3384	0	1
3751	2139	854	17	20	3385	0	1
3752	2140	854	17	20	3386	0	1
3753	1759	854	17	20	3387	0	1
3754	1753	854	17	20	3388	0	1
5204	3400	1183	20	\N	\N	1	1
5212	3408	1183	20	\N	\N	1	1
5206	3402	1183	20	\N	\N	1	1
5207	3403	1183	20	\N	\N	1	1
5211	3407	1183	20	\N	\N	1	1
5205	3401	1183	20	\N	\N	1	1
5220	3416	1186	20	\N	\N	1	1
5221	3417	1186	20	\N	\N	1	1
5222	3418	1186	20	\N	\N	1	1
5216	3412	1185	20	\N	\N	1	1
5215	3411	1185	20	\N	\N	1	1
8689	4390	2157	1	\N	\N	1	1
8949	4440	2272	15	\N	\N	0	1
8953	4444	2271	15	\N	\N	0	1
8954	4445	2271	15	\N	\N	0	1
8955	4446	2271	15	\N	\N	0	1
8957	4448	2272	15	\N	\N	0	1
8958	4449	2272	15	\N	\N	0	1
8959	4440	2273	15	\N	\N	0	1
5224	3420	1174	20	\N	\N	1	1
5223	3419	1174	20	\N	\N	1	1
5273	3463	1198	20	\N	\N	1	1
5266	3459	1197	20	\N	\N	1	1
5265	3458	1196	20	\N	\N	1	1
5262	3455	1195	20	\N	\N	1	1
5263	3456	1195	20	\N	\N	1	1
5261	3454	1195	20	\N	\N	1	1
5264	3457	1195	20	\N	\N	1	1
5267	3428	1195	20	\N	\N	1	1
5268	3429	1195	20	\N	\N	1	1
5269	3422	1195	20	\N	\N	1	1
5254	3450	1194	20	\N	\N	1	1
5253	3449	1193	20	\N	\N	1	1
5250	3446	1192	20	\N	\N	1	1
5249	3445	1192	20	\N	\N	1	1
5251	3447	1192	20	\N	\N	1	1
5246	3442	1192	20	\N	\N	1	1
5255	3428	1192	20	\N	\N	1	1
5256	3429	1192	20	\N	\N	1	1
5257	3422	1192	20	\N	\N	1	1
5245	3441	1191	20	\N	\N	1	1
5235	3431	1190	20	\N	\N	1	1
5230	3426	1189	20	\N	\N	1	1
5231	3427	1189	20	\N	\N	1	1
5229	3425	1189	20	\N	\N	1	1
5234	3430	1189	20	\N	\N	1	1
5232	3428	1189	20	\N	\N	1	1
5233	3429	1189	20	\N	\N	1	1
5226	3422	1189	20	\N	\N	1	1
6187	3411	1329	17	21	5215	0	1
6188	3410	1329	17	21	5214	0	1
5214	3410	1185	20	\N	\N	1	1
3420	2183	743	14	\N	\N	1	1
2875	2498	728	14	\N	\N	1	1
3439	2367	727	14	\N	\N	1	1
3857	2257	874	17	20	2608	0	1
3858	2252	874	17	20	2603	0	1
3859	2254	874	17	20	2605	0	1
3860	2255	874	17	20	2606	0	1
3852	2258	873	17	20	2609	0	1
3853	2260	873	17	20	2611	0	1
3854	2259	873	17	20	2610	0	1
3855	2261	873	17	20	2612	0	1
3848	2270	872	17	20	2621	0	1
3849	2272	872	17	20	2624	0	1
3850	2268	872	17	20	2619	0	1
3851	2269	872	17	20	2620	0	1
3845	2273	871	17	20	2625	0	1
3846	2278	871	17	20	2630	0	1
3842	2280	870	17	20	2632	0	1
3843	2285	870	17	20	2637	0	1
3844	2287	870	17	20	2639	0	1
3839	2290	869	17	20	2642	0	1
3840	2287	869	17	20	2643	0	1
3841	2289	869	17	20	2641	0	1
3893	1907	880	17	20	2148	0	1
3894	1908	880	17	20	2149	0	1
3895	1889	880	17	20	2126	0	1
3896	1894	880	17	20	2131	0	1
3885	1909	879	17	20	2150	0	1
3886	1910	879	17	20	2151	0	1
3887	1898	879	17	20	2135	0	1
3888	1895	879	17	20	2132	0	1
3889	1892	879	17	20	2138	0	1
3890	1893	879	17	20	2139	0	1
3891	1885	879	17	20	2140	0	1
3892	1886	879	17	20	2141	0	1
3877	1911	878	17	20	2152	0	1
3878	1912	878	17	20	2153	0	1
3879	1905	878	17	20	2146	0	1
3880	1906	878	17	20	2147	0	1
3881	1892	878	17	20	2154	0	1
3882	1893	878	17	20	2155	0	1
3883	1885	878	17	20	2156	0	1
3884	1886	878	17	20	2157	0	1
3870	1917	877	17	20	2162	0	1
3871	1920	877	17	20	2165	0	1
3872	1919	877	17	20	2164	0	1
3873	1892	877	17	20	2166	0	1
3874	1893	877	17	20	2167	0	1
3875	1885	877	17	20	2168	0	1
3876	1886	877	17	20	2169	0	1
3861	1927	876	17	20	2176	0	1
3862	1928	876	17	20	2177	0	1
3863	1925	876	17	20	2174	0	1
3864	1926	876	17	20	2175	0	1
3865	1892	876	17	20	2178	0	1
3866	1893	876	17	20	2179	0	1
3867	1885	876	17	20	2180	0	1
3868	1886	876	17	20	2181	0	1
3827	2478	865	17	20	2855	0	1
3829	2383	865	17	20	3446	0	1
3830	2382	865	17	20	3447	0	1
3831	2477	865	17	20	2854	0	1
3832	2355	865	17	20	3448	0	1
3833	2472	866	17	20	2849	0	1
3834	2392	866	17	20	3449	0	1
3835	2393	866	17	20	3450	0	1
3836	2394	866	17	20	3451	0	1
3837	2473	866	17	20	2850	0	1
3838	2355	866	17	20	3452	0	1
3823	2486	864	17	20	2863	0	1
3824	2376	864	17	20	3443	0	1
3825	2485	864	17	20	2862	0	1
3826	2355	864	17	20	3444	0	1
3817	2494	863	17	20	2871	0	1
3818	2367	863	17	20	3439	0	1
3820	2369	863	17	20	3441	0	1
3821	2495	863	17	20	2872	0	1
3822	2354	863	17	20	3442	0	1
3811	2499	862	17	20	2876	0	1
3812	2360	862	17	20	3435	0	1
3813	2358	862	17	20	3436	0	1
3814	2357	862	17	20	3437	0	1
3815	2498	862	17	20	2875	0	1
3816	2355	862	17	20	3438	0	1
3793	1756	859	17	20	3418	0	1
3794	2627	859	17	20	3004	0	1
3795	2626	859	17	20	3003	0	1
3796	2625	859	17	20	3002	0	1
3797	2191	859	17	20	3419	0	1
3798	2183	859	17	20	3420	0	1
3799	2184	859	17	20	3421	0	1
3801	2189	859	17	20	3423	0	1
3802	2190	859	17	20	3424	0	1
3783	1756	858	17	20	3411	0	1
3784	2637	858	17	20	3014	0	1
3785	2636	858	17	20	3013	0	1
3786	2635	858	17	20	3012	0	1
3787	2181	858	17	20	3412	0	1
3788	2173	858	17	20	3413	0	1
3789	2174	858	17	20	3414	0	1
3790	2175	858	17	20	3415	0	1
3791	2179	858	17	20	3416	0	1
3792	2180	858	17	20	3417	0	1
3755	1756	855	17	20	3389	0	1
3756	2663	855	17	20	3040	0	1
3757	2664	855	17	20	3041	0	1
3758	2665	855	17	20	3042	0	1
3760	2151	855	17	20	3391	0	1
3761	2150	855	17	20	3392	0	1
3762	2149	855	17	20	3393	0	1
3763	2144	855	17	20	3394	0	1
3764	2143	855	17	20	3395	0	1
2766	2392	707	14	\N	\N	1	1
2745	2377	705	14	\N	\N	1	1
3898	1893	880	17	20	2130	0	1
3899	1885	880	17	20	2122	0	1
3900	1886	880	17	20	2123	0	1
3948	2348	889	17	20	2711	0	1
3949	2349	889	17	20	2712	0	1
3950	2351	889	17	20	2714	0	1
3951	2352	889	17	20	2715	0	1
3952	2353	889	17	20	2716	0	1
3953	2350	889	17	20	2713	0	1
3954	2344	889	17	20	2707	0	1
3955	2354	889	17	20	2717	0	1
3926	2377	886	17	20	2745	0	1
3927	2376	886	17	20	2744	0	1
3928	2353	886	17	20	2747	0	1
3929	2350	886	17	20	2748	0	1
3930	2378	886	17	20	2746	0	1
3931	2355	886	17	20	2749	0	1
3918	2385	885	17	20	2756	0	1
3919	2384	885	17	20	2755	0	1
3920	2383	885	17	20	2754	0	1
3921	2382	885	17	20	2753	0	1
3922	2353	885	17	20	2758	0	1
3923	2350	885	17	20	2759	0	1
3924	2386	885	17	20	2757	0	1
3925	2355	885	17	20	2760	0	1
3910	2391	884	17	20	2765	0	1
3911	2392	884	17	20	2766	0	1
3912	2393	884	17	20	2767	0	1
3913	2394	884	17	20	2768	0	1
3914	2353	884	17	20	2769	0	1
3915	2350	884	17	20	2770	0	1
3916	2390	884	17	20	2764	0	1
3917	2355	884	17	20	2771	0	1
8960	4450	2277	1	\N	\N	0	1
8961	4451	2277	1	\N	\N	0	1
8962	4452	2277	1	\N	\N	0	1
8963	4453	2277	1	\N	\N	0	1
8964	4454	2277	1	\N	\N	0	1
8965	4455	2277	1	\N	\N	0	1
8966	4456	2277	1	\N	\N	0	1
8967	4457	2277	1	\N	\N	0	1
2723	2360	703	14	\N	\N	1	1
2701	2195	700	14	\N	\N	1	1
2687	2328	699	14	\N	\N	1	1
2646	2293	696	14	\N	\N	1	1
2581	2234	687	14	\N	\N	1	1
2565	2195	685	14	\N	\N	1	1
3902	1881	881	17	20	2118	0	1
3903	1879	881	17	20	2116	0	1
3904	1877	881	17	20	2114	0	1
3905	1884	881	17	20	2121	0	1
3906	1882	881	17	20	2119	0	1
3907	1883	881	17	20	2120	0	1
3908	1875	881	17	20	2112	0	1
3909	1876	881	17	20	2113	0	1
3990	2202	896	17	20	2702	0	1
4050	2195	905	17	20	2565	0	1
4039	2195	904	17	20	2576	0	1
4040	2224	904	17	20	2569	0	1
4041	2225	904	17	20	2570	0	1
4042	2226	904	17	20	2571	0	1
4044	2228	904	17	20	2573	0	1
4045	2342	904	17	20	2705	0	1
4046	2343	904	17	20	2706	0	1
4047	2229	904	17	20	2574	0	1
4048	2202	904	17	20	2577	0	1
4049	2230	904	17	20	2575	0	1
4030	2195	903	17	20	2587	0	1
4031	2232	903	17	20	2579	0	1
4032	2233	903	17	20	2580	0	1
4033	2234	903	17	20	2581	0	1
4034	2239	903	17	20	2586	0	1
4035	2235	903	17	20	2582	0	1
4036	2236	903	17	20	2583	0	1
4037	2202	903	17	20	2588	0	1
4038	2238	903	17	20	2585	0	1
4019	2195	902	17	20	2598	0	1
4021	2243	902	17	20	2592	0	1
4022	2244	902	17	20	2593	0	1
4023	2245	902	17	20	2594	0	1
4024	2246	902	17	20	2595	0	1
4025	2249	902	17	20	2600	0	1
4026	2250	902	17	20	2601	0	1
4027	2247	902	17	20	2596	0	1
4028	2202	902	17	20	2599	0	1
4029	2248	902	17	20	2597	0	1
4010	2195	901	17	20	2653	0	1
4011	2294	901	17	20	2647	0	1
4012	2295	901	17	20	2648	0	1
4013	2296	901	17	20	2649	0	1
4014	2297	901	17	20	2650	0	1
4015	2298	901	17	20	2651	0	1
4016	2299	901	17	20	2652	0	1
4018	2293	901	17	20	2646	0	1
4001	2195	900	17	20	2664	0	1
4002	2308	900	17	20	2663	0	1
4003	2307	900	17	20	2662	0	1
4004	2306	900	17	20	2661	0	1
4005	2302	900	17	20	2657	0	1
4006	2305	900	17	20	2660	0	1
4007	2304	900	17	20	2659	0	1
4008	2202	900	17	20	2665	0	1
4009	2303	900	17	20	2658	0	1
3991	2195	899	17	20	2677	0	1
3992	2319	899	17	20	2676	0	1
3993	2318	899	17	20	2675	0	1
3994	2317	899	17	20	2674	0	1
3995	2316	899	17	20	2673	0	1
3996	2315	899	17	20	2672	0	1
3998	2309	899	17	20	2666	0	1
3999	2314	899	17	20	2671	0	1
4000	2313	899	17	20	2670	0	1
3981	2195	898	17	20	2688	0	1
3982	2322	898	17	20	2681	0	1
3983	2323	898	17	20	2682	0	1
3984	2324	898	17	20	2683	0	1
3985	2328	898	17	20	2687	0	1
3986	2325	898	17	20	2684	0	1
3987	2326	898	17	20	2685	0	1
3989	2327	898	17	20	2686	0	1
3970	2195	897	17	20	2701	0	1
3971	2331	897	17	20	2692	0	1
3972	2332	897	17	20	2693	0	1
3973	2333	897	17	20	2694	0	1
3974	2334	897	17	20	2695	0	1
3976	2338	897	17	20	2699	0	1
3977	2339	897	17	20	2700	0	1
3978	2336	897	17	20	2697	0	1
3980	2337	897	17	20	2698	0	1
3940	2361	888	17	20	2724	0	1
3941	2360	888	17	20	2723	0	1
3942	2358	888	17	20	2721	0	1
3943	2357	888	17	20	2720	0	1
3944	2353	888	17	20	2726	0	1
3945	2350	888	17	20	2727	0	1
3946	2362	888	17	20	2725	0	1
3947	2355	888	17	20	2718	0	1
3932	2366	887	17	20	2731	0	1
3933	2367	887	17	20	2732	0	1
3934	2368	887	17	20	2733	0	1
3935	2369	887	17	20	2734	0	1
3937	2350	887	17	20	2737	0	1
3938	2365	887	17	20	2730	0	1
3939	2355	887	17	20	2738	0	1
2528	2188	681	14	\N	\N	1	1
2518	2179	680	14	\N	\N	1	1
4127	1756	914	17	20	2470	0	1
4128	1754	914	17	20	2471	0	1
4129	1755	914	17	20	2472	0	1
4130	1757	914	17	20	2473	0	1
4131	2141	914	17	20	2477	0	1
4132	2138	914	17	20	2467	0	1
4133	2139	914	17	20	2468	0	1
4134	2140	914	17	20	2469	0	1
4135	1759	914	17	20	2475	0	1
4136	1753	914	17	20	2476	0	1
4117	1756	913	17	20	2488	0	1
4118	2147	913	17	20	2483	0	1
4119	2146	913	17	20	2482	0	1
4120	2145	913	17	20	2481	0	1
4121	2142	913	17	20	2478	0	1
4122	2151	913	17	20	2487	0	1
4123	2150	913	17	20	2486	0	1
4124	2149	913	17	20	2485	0	1
4125	2144	913	17	20	2480	0	1
4126	2143	913	17	20	2479	0	1
4107	1756	912	17	20	2499	0	1
4108	2157	912	17	20	2494	0	1
4109	2156	912	17	20	2493	0	1
4110	2155	912	17	20	2492	0	1
4111	2152	912	17	20	2489	0	1
4112	2161	912	17	20	2498	0	1
4113	2160	912	17	20	2497	0	1
4114	2159	912	17	20	2496	0	1
4115	2154	912	17	20	2491	0	1
4116	2153	912	17	20	2490	0	1
4099	1756	911	17	20	2510	0	1
4100	2166	911	17	20	2504	0	1
4101	2167	911	17	20	2505	0	1
4102	2168	911	17	20	2506	0	1
4103	2171	911	17	20	2509	0	1
4104	2165	911	17	20	2503	0	1
4105	2169	911	17	20	2507	0	1
4106	2170	911	17	20	2508	0	1
4089	1756	910	17	20	2521	0	1
4090	2176	910	17	20	2515	0	1
4091	2177	910	17	20	2516	0	1
4092	2178	910	17	20	2517	0	1
4093	2181	910	17	20	2520	0	1
4094	2173	910	17	20	2512	0	1
4095	2174	910	17	20	2513	0	1
4096	2175	910	17	20	2514	0	1
4097	2179	910	17	20	2518	0	1
4098	2180	910	17	20	2519	0	1
4079	1756	909	17	20	2532	0	1
4080	2186	909	17	20	2526	0	1
4081	2187	909	17	20	2527	0	1
4082	2188	909	17	20	2528	0	1
4083	2191	909	17	20	2531	0	1
4084	2183	909	17	20	2523	0	1
4085	2184	909	17	20	2524	0	1
4086	2185	909	17	20	2525	0	1
4087	2189	909	17	20	2529	0	1
4088	2190	909	17	20	2530	0	1
4051	2220	905	17	20	2563	0	1
4052	2219	905	17	20	2562	0	1
4053	2217	905	17	20	2560	0	1
4054	2213	905	17	20	2556	0	1
4055	2216	905	17	20	2559	0	1
4056	2215	905	17	20	2558	0	1
4057	2202	905	17	20	2566	0	1
4058	2221	905	17	20	2564	0	1
5277	3467	1199	20	\N	\N	1	1
2550	2209	684	14	\N	\N	1	1
4059	2195	906	17	20	2554	0	1
4060	2205	906	17	20	2546	0	1
4061	2206	906	17	20	2547	0	1
4062	2207	906	17	20	2548	0	1
4063	2212	906	17	20	2553	0	1
4064	2208	906	17	20	2549	0	1
4065	2340	906	17	20	2703	0	1
4066	2341	906	17	20	2704	0	1
4067	2209	906	17	20	2550	0	1
4068	2202	906	17	20	2555	0	1
4069	2211	906	17	20	2552	0	1
5124	3320	1170	20	\N	\N	1	1
5123	3319	1170	20	\N	\N	1	1
5122	3318	1170	20	\N	\N	1	1
5116	3312	1169	20	\N	\N	1	1
5117	3313	1169	20	\N	\N	1	1
5120	3316	1169	20	\N	\N	1	1
5121	3317	1169	20	\N	\N	1	1
5118	3314	1169	20	\N	\N	1	1
5287	3474	1201	20	\N	\N	1	1
5288	3475	1201	20	\N	\N	1	1
5286	3473	1201	20	\N	\N	1	1
5284	3471	1201	20	\N	\N	1	1
5293	3479	1201	20	\N	\N	1	1
5291	3478	1201	20	\N	\N	1	1
5289	3476	1201	20	\N	\N	1	1
5292	3429	1201	20	\N	\N	1	1
5282	3469	1201	20	\N	\N	1	1
5283	3470	1201	20	\N	\N	1	1
5279	3428	1198	20	\N	\N	1	1
5280	3429	1198	20	\N	\N	1	1
5281	3422	1198	20	\N	\N	1	1
5295	3479	1195	20	\N	\N	1	1
5297	3479	1189	20	\N	\N	1	1
5432	3595	1220	20	\N	\N	1	1
5431	3594	1220	20	\N	\N	1	1
5430	3593	1220	20	\N	\N	1	1
5424	3587	1219	20	\N	\N	1	1
5425	3588	1219	20	\N	\N	1	1
5426	3589	1219	20	\N	\N	1	1
5419	3582	1218	20	\N	\N	1	1
5420	3583	1218	20	\N	\N	1	1
5418	3581	1217	20	\N	\N	1	1
5417	3580	1217	20	\N	\N	1	1
5403	3483	1216	20	\N	\N	1	1
5402	3579	1216	20	\N	\N	1	1
5401	3578	1216	20	\N	\N	1	1
5400	3577	1216	20	\N	\N	1	1
5404	3519	1216	20	\N	\N	1	1
5405	3516	1216	20	\N	\N	1	1
5406	3483	1215	20	\N	\N	1	1
5392	3569	1215	20	\N	\N	1	1
5393	3570	1215	20	\N	\N	1	1
5394	3571	1215	20	\N	\N	1	1
5407	3521	1215	20	\N	\N	1	1
5408	3522	1215	20	\N	\N	1	1
5409	3483	1214	20	\N	\N	1	1
5386	3563	1214	20	\N	\N	1	1
5387	3564	1214	20	\N	\N	1	1
5388	3565	1214	20	\N	\N	1	1
5410	3527	1214	20	\N	\N	1	1
5411	3528	1214	20	\N	\N	1	1
5412	3483	1213	20	\N	\N	1	1
5384	3561	1213	20	\N	\N	1	1
5383	3560	1213	20	\N	\N	1	1
5382	3559	1213	20	\N	\N	1	1
5413	3537	1213	20	\N	\N	1	1
5414	3536	1213	20	\N	\N	1	1
5376	3553	1212	20	\N	\N	1	1
5415	3548	1212	20	\N	\N	1	1
5416	3545	1212	20	\N	\N	1	1
5378	3555	1212	20	\N	\N	1	1
5377	3554	1212	20	\N	\N	1	1
5373	3550	1211	20	\N	\N	1	1
5372	3549	1211	20	\N	\N	1	1
5364	3541	1210	20	\N	\N	1	1
5371	3548	1210	20	\N	\N	1	1
5368	3545	1210	20	\N	\N	1	1
5362	3539	1210	20	\N	\N	1	1
5363	3540	1210	20	\N	\N	1	1
5360	3483	1209	20	\N	\N	1	1
5355	3533	1209	20	\N	\N	1	1
5356	3534	1209	20	\N	\N	1	1
5357	3535	1209	20	\N	\N	1	1
5359	3537	1209	20	\N	\N	1	1
5358	3536	1209	20	\N	\N	1	1
5353	3483	1208	20	\N	\N	1	1
5352	3531	1208	20	\N	\N	1	1
5351	3530	1208	20	\N	\N	1	1
5350	3529	1208	20	\N	\N	1	1
5349	3528	1208	20	\N	\N	1	1
5346	3483	1207	20	\N	\N	1	1
5345	3525	1207	20	\N	\N	1	1
5344	3524	1207	20	\N	\N	1	1
5343	3523	1207	20	\N	\N	1	1
5341	3521	1207	20	\N	\N	1	1
5342	3522	1207	20	\N	\N	1	1
5339	3483	1206	20	\N	\N	1	1
5330	3511	1206	20	\N	\N	1	1
5331	3512	1206	20	\N	\N	1	1
5333	3514	1206	20	\N	\N	1	1
5338	3519	1206	20	\N	\N	1	1
5335	3516	1206	20	\N	\N	1	1
5325	3507	1205	20	\N	\N	1	1
5313	3495	1204	20	\N	\N	1	1
5316	3498	1204	20	\N	\N	1	1
6209	3355	1335	17	21	5159	0	1
6217	4136	1341	17	21	6155	0	1
6218	4131	1341	17	21	6156	0	1
6219	4120	1341	17	21	6157	0	1
6220	4122	1341	17	21	6158	0	1
6293	3456	1361	17	21	5263	0	1
6294	3454	1361	17	21	5261	0	1
6295	3479	1361	17	21	5295	0	1
6296	3457	1361	17	21	5264	0	1
6297	3428	1361	17	21	5267	0	1
2412	2101	669	14	\N	\N	1	1
2378	2084	666	14	\N	\N	1	1
2365	2071	664	14	\N	\N	1	1
2353	1984	661	14	\N	\N	1	1
2346	2032	659	14	\N	\N	1	1
4207	2025	928	17	20	2304	0	1
4235	1942	933	17	20	2339	0	1
4236	2026	933	17	20	2305	0	1
4237	2031	933	17	20	2310	0	1
4238	2027	933	17	20	2306	0	1
4239	1948	933	17	20	2340	0	1
4240	2030	933	17	20	2309	0	1
4241	2032	933	17	20	2311	0	1
4229	2036	932	17	20	2315	0	1
4230	1962	932	17	20	2341	0	1
4231	1959	932	17	20	2342	0	1
4232	2037	932	17	20	2316	0	1
4234	2032	932	17	20	2343	0	1
4222	1942	931	17	20	2344	0	1
4223	2043	931	17	20	2322	0	1
4224	2044	931	17	20	2323	0	1
4225	2045	931	17	20	2324	0	1
4226	1972	931	17	20	2345	0	1
4227	2041	931	17	20	2320	0	1
4228	2032	931	17	20	2346	0	1
4215	1942	930	17	20	2347	0	1
4216	2049	930	17	20	2328	0	1
4217	2050	930	17	20	2329	0	1
4218	2051	930	17	20	2330	0	1
4219	1982	930	17	20	2348	0	1
4220	2041	930	17	20	2349	0	1
4221	2060	930	17	20	2350	0	1
4208	1942	929	17	20	2351	0	1
4210	2057	929	17	20	2336	0	1
4211	2058	929	17	20	2337	0	1
4212	1986	929	17	20	2352	0	1
4213	1984	929	17	20	2353	0	1
4214	2060	929	17	20	2354	0	1
4172	2061	922	17	20	2355	0	1
4200	1942	927	17	20	2390	0	1
4201	2067	927	17	20	2361	0	1
4202	2062	927	17	20	2356	0	1
4203	2068	927	17	20	2362	0	1
4204	1948	927	17	20	2391	0	1
4205	2030	927	17	20	2392	0	1
4206	2064	927	17	20	2358	0	1
4194	2070	926	17	20	2364	0	1
4195	1962	926	17	20	2393	0	1
4196	1959	926	17	20	2394	0	1
4198	2072	926	17	20	2366	0	1
4199	2064	926	17	20	2395	0	1
4187	1942	925	17	20	2396	0	1
4188	2080	925	17	20	2374	0	1
4189	2077	925	17	20	2371	0	1
4190	2081	925	17	20	2375	0	1
4191	1972	925	17	20	2397	0	1
4192	2041	925	17	20	2398	0	1
4193	2064	925	17	20	2399	0	1
4180	1942	924	17	20	2400	0	1
4181	2083	924	17	20	2377	0	1
4182	2084	924	17	20	2378	0	1
4183	2085	924	17	20	2379	0	1
4184	1982	924	17	20	2401	0	1
4185	2041	924	17	20	2402	0	1
4186	2088	924	17	20	2382	0	1
4174	2089	923	17	20	2383	0	1
4175	2090	923	17	20	2384	0	1
4176	2091	923	17	20	2385	0	1
4177	1986	923	17	20	2404	0	1
4178	1984	923	17	20	2405	0	1
4179	2088	923	17	20	2406	0	1
4137	2096	916	17	20	2407	0	1
4165	1942	921	17	20	2442	0	1
4166	2100	921	17	20	2411	0	1
4167	2101	921	17	20	2412	0	1
4168	2102	921	17	20	2413	0	1
4169	1948	921	17	20	2443	0	1
4170	2030	921	17	20	2444	0	1
4171	2103	921	17	20	2414	0	1
4159	2107	920	17	20	2418	0	1
4160	1962	920	17	20	2445	0	1
4162	2108	920	17	20	2419	0	1
4163	2109	920	17	20	2420	0	1
4164	2103	920	17	20	2447	0	1
4152	1942	919	17	20	2448	0	1
4153	2114	919	17	20	2425	0	1
4154	2115	919	17	20	2426	0	1
4155	2116	919	17	20	2427	0	1
4156	1972	919	17	20	2449	0	1
4157	2041	919	17	20	2450	0	1
4158	2103	919	17	20	2451	0	1
4145	1942	918	17	20	2452	0	1
4146	2120	918	17	20	2431	0	1
4147	2121	918	17	20	2432	0	1
4148	2122	918	17	20	2433	0	1
4149	1982	918	17	20	2453	0	1
4150	2041	918	17	20	2454	0	1
4138	1942	917	17	20	2456	0	1
4139	2128	917	17	20	2439	0	1
4140	2129	917	17	20	2440	0	1
4141	2130	917	17	20	2441	0	1
4142	1986	917	17	20	2457	0	1
4143	1984	917	17	20	2458	0	1
4144	2060	917	17	20	2459	0	1
4070	2195	907	17	20	2536	0	1
4071	2193	907	17	20	2534	0	1
4072	2194	907	17	20	2535	0	1
4073	2196	907	17	20	2537	0	1
4074	2203	907	17	20	2544	0	1
4075	2197	907	17	20	2538	0	1
4076	2201	907	17	20	2542	0	1
4077	2202	907	17	20	2543	0	1
4078	2192	907	17	20	2533	0	1
4243	1942	935	17	20	2300	0	1
4244	2020	935	17	20	2281	0	1
4245	2021	935	17	20	2282	0	1
4246	2022	935	17	20	2283	0	1
4247	1986	935	17	20	2301	0	1
4248	1984	935	17	20	2302	0	1
4249	1996	935	17	20	2303	0	1
5125	3321	1171	20	\N	\N	1	1
5127	3323	1171	20	\N	\N	1	1
5128	3324	1172	20	\N	\N	1	1
5129	3325	1172	20	\N	\N	1	1
4277	1929	940	17	20	2182	0	1
4278	1942	941	17	20	2249	0	1
4279	1989	941	17	20	2248	0	1
4280	1988	941	17	20	2247	0	1
4281	1987	941	17	20	2246	0	1
4282	1986	941	17	20	2245	0	1
4283	1984	941	17	20	2243	0	1
4284	1939	941	17	20	2250	0	1
4257	1942	937	17	20	2292	0	1
4258	2010	937	17	20	2271	0	1
4259	2009	937	17	20	2270	0	1
4260	2008	937	17	20	2269	0	1
4261	1972	937	17	20	2293	0	1
4262	1969	937	17	20	2294	0	1
4263	1996	937	17	20	2295	0	1
4250	1942	936	17	20	2296	0	1
4251	2014	936	17	20	2275	0	1
4252	2015	936	17	20	2276	0	1
4253	2016	936	17	20	2277	0	1
4254	1982	936	17	20	2297	0	1
4255	1969	936	17	20	2298	0	1
4256	1996	936	17	20	2299	0	1
5181	3377	1181	20	\N	\N	1	1
5192	3388	1181	20	\N	\N	1	1
5183	3379	1181	20	\N	\N	1	1
5184	3380	1181	20	\N	\N	1	1
5191	3387	1181	20	\N	\N	1	1
5182	3378	1181	20	\N	\N	1	1
5194	3390	1182	20	\N	\N	1	1
5202	3398	1182	20	\N	\N	1	1
5196	3392	1182	20	\N	\N	1	1
5197	3393	1182	20	\N	\N	1	1
5201	3397	1182	20	\N	\N	1	1
5195	3391	1182	20	\N	\N	1	1
5190	3386	1180	20	\N	\N	1	1
5179	3375	1180	20	\N	\N	1	1
5189	3385	1180	20	\N	\N	1	1
5188	3384	1180	20	\N	\N	1	1
5137	3333	1176	20	\N	\N	1	1
5140	3336	1176	20	\N	\N	1	1
5141	3337	1176	20	\N	\N	1	1
5136	3332	1176	20	\N	\N	1	1
5171	3367	1179	20	\N	\N	1	1
5174	3370	1179	20	\N	\N	1	1
5175	3371	1179	20	\N	\N	1	1
5170	3366	1179	20	\N	\N	1	1
5163	3359	1178	20	\N	\N	1	1
5164	3360	1178	20	\N	\N	1	1
5159	3355	1178	20	\N	\N	1	1
5149	3345	1177	20	\N	\N	1	1
5148	3344	1177	20	\N	\N	1	1
5145	3341	1175	20	\N	\N	1	1
5131	3327	1173	20	\N	\N	1	1
5133	3329	1173	20	\N	\N	1	1
3479	1777	781	17	20	2014	0	1
3453	1798	782	17	20	2035	0	1
3497	1767	795	17	20	2004	0	1
3507	1762	805	17	20	1999	0	1
3856	2251	874	17	20	2602	0	1
3847	2258	872	17	20	2623	0	1
3901	1880	881	17	20	2117	0	1
3897	1892	880	17	20	2129	0	1
3869	1918	877	17	20	2163	0	1
4305	1942	945	17	20	2195	0	1
4306	1949	945	17	20	2202	0	1
4307	1951	945	17	20	2204	0	1
4308	1950	945	17	20	2203	0	1
4309	1948	945	17	20	2201	0	1
4310	1945	945	17	20	2198	0	1
4311	1939	945	17	20	2192	0	1
4299	1955	944	17	20	2208	0	1
4300	1962	944	17	20	2215	0	1
4301	1959	944	17	20	2212	0	1
4302	1953	944	17	20	2206	0	1
4303	1954	944	17	20	2207	0	1
4304	1939	944	17	20	2216	0	1
4292	1942	943	17	20	2227	0	1
4293	1964	943	17	20	2218	0	1
4294	1965	943	17	20	2219	0	1
4295	1967	943	17	20	2221	0	1
4296	1972	943	17	20	2226	0	1
4297	1969	943	17	20	2223	0	1
4298	1939	943	17	20	2228	0	1
4285	1942	942	17	20	2239	0	1
4286	1974	942	17	20	2230	0	1
4287	1975	942	17	20	2231	0	1
4288	1977	942	17	20	2233	0	1
4289	1982	942	17	20	2238	0	1
4290	1969	942	17	20	2240	0	1
4291	1939	942	17	20	2241	0	1
4242	1990	934	17	20	2251	0	1
4270	1942	939	17	20	2286	0	1
4271	1992	939	17	20	2253	0	1
4272	1997	939	17	20	2258	0	1
4273	1993	939	17	20	2254	0	1
4274	1948	939	17	20	2287	0	1
4275	1945	939	17	20	2288	0	1
4276	1996	939	17	20	2257	0	1
4264	1999	938	17	20	2260	0	1
4265	1962	938	17	20	2289	0	1
4266	1959	938	17	20	2290	0	1
4267	2002	938	17	20	2263	0	1
4268	2003	938	17	20	2264	0	1
4269	1996	938	17	20	2291	0	1
4233	2038	932	17	20	2317	0	1
4209	2056	929	17	20	2335	0	1
4197	2071	926	17	20	2365	0	1
4173	1942	923	17	20	2403	0	1
4161	1959	920	17	20	2446	0	1
4151	2060	918	17	20	2455	0	1
4043	2227	904	17	20	2572	0	1
4020	2242	902	17	20	2591	0	1
4017	2202	901	17	20	2654	0	1
3997	2310	899	17	20	2667	0	1
3975	2335	897	17	20	2696	0	1
3936	2353	887	17	20	2736	0	1
3828	2384	865	17	20	3445	0	1
3819	2368	863	17	20	3440	0	1
3567	1893	820	17	20	3273	0	1
3552	1885	818	17	20	3258	0	1
3537	1886	816	17	20	3243	0	1
3710	2096	847	17	20	3363	0	1
3726	2699	850	17	20	3076	0	1
3717	2103	848	17	20	3367	0	1
3690	2734	844	17	20	3111	0	1
3681	2030	842	17	20	3347	0	1
3654	1942	838	17	20	3332	0	1
3645	1948	836	17	20	3326	0	1
3605	1990	829	17	20	3304	0	1
3606	1942	830	17	20	3305	0	1
3607	2818	830	17	20	3195	0	1
3570	1929	823	17	20	3284	0	1
3598	1942	828	17	20	3300	0	1
3599	2822	828	17	20	3199	0	1
3600	2823	828	17	20	3200	0	1
3601	2824	828	17	20	3201	0	1
3602	1986	828	17	20	3301	0	1
3603	1984	828	17	20	3302	0	1
3604	2060	828	17	20	3303	0	1
3594	2831	827	17	20	3208	0	1
3596	1969	827	17	20	3298	0	1
3597	2060	827	17	20	3299	0	1
3584	1942	826	17	20	3292	0	1
3585	2840	826	17	20	3217	0	1
3586	2839	826	17	20	3216	0	1
3587	2838	826	17	20	3215	0	1
3588	1972	826	17	20	3293	0	1
3589	1969	826	17	20	3294	0	1
3590	1939	826	17	20	3295	0	1
3571	1942	824	17	20	3285	0	1
3572	2849	824	17	20	3226	0	1
3573	2847	824	17	20	3224	0	1
3574	2848	824	17	20	3225	0	1
3575	1948	824	17	20	3286	0	1
3576	1945	824	17	20	3287	0	1
3577	1939	824	17	20	3288	0	1
3800	2185	859	17	20	3422	0	1
3759	2142	855	17	20	3390	0	1
6229	4118	1343	17	21	6134	0	1
5617	3717	1244	20	\N	\N	1	1
5616	3716	1244	20	\N	\N	1	1
5597	3483	1242	20	\N	\N	1	1
5572	3707	1242	20	\N	\N	1	1
5571	3706	1242	20	\N	\N	1	1
5570	3705	1242	20	\N	\N	1	1
5598	3519	1242	20	\N	\N	1	1
5599	3516	1242	20	\N	\N	1	1
5600	3714	1242	20	\N	\N	1	1
5605	3483	1241	20	\N	\N	1	1
5564	3699	1241	20	\N	\N	1	1
5565	3700	1241	20	\N	\N	1	1
5566	3701	1241	20	\N	\N	1	1
5606	3521	1241	20	\N	\N	1	1
5607	3522	1241	20	\N	\N	1	1
5608	3715	1241	20	\N	\N	1	1
5609	3483	1240	20	\N	\N	1	1
5558	3693	1240	20	\N	\N	1	1
5559	3694	1240	20	\N	\N	1	1
5560	3695	1240	20	\N	\N	1	1
5610	3527	1240	20	\N	\N	1	1
5611	3528	1240	20	\N	\N	1	1
5612	3715	1240	20	\N	\N	1	1
5601	3483	1239	20	\N	\N	1	1
5554	3689	1239	20	\N	\N	1	1
5553	3688	1239	20	\N	\N	1	1
5552	3687	1239	20	\N	\N	1	1
5602	3537	1239	20	\N	\N	1	1
5603	3536	1239	20	\N	\N	1	1
5604	3714	1239	20	\N	\N	1	1
5546	3681	1238	20	\N	\N	1	1
5613	3548	1238	20	\N	\N	1	1
5614	3545	1238	20	\N	\N	1	1
5548	3683	1238	20	\N	\N	1	1
5547	3682	1238	20	\N	\N	1	1
5615	3715	1238	20	\N	\N	1	1
5543	3678	1237	20	\N	\N	1	1
5511	3646	1231	20	\N	\N	1	1
5541	3676	1236	20	\N	\N	1	1
5580	3548	1236	20	\N	\N	1	1
5581	3545	1236	20	\N	\N	1	1
5539	3674	1236	20	\N	\N	1	1
5540	3675	1236	20	\N	\N	1	1
5579	3647	1236	20	\N	\N	1	1
5582	3483	1235	20	\N	\N	1	1
5534	3669	1235	20	\N	\N	1	1
5535	3670	1235	20	\N	\N	1	1
5536	3671	1235	20	\N	\N	1	1
5583	3537	1235	20	\N	\N	1	1
5584	3536	1235	20	\N	\N	1	1
5585	3713	1235	20	\N	\N	1	1
5586	3483	1234	20	\N	\N	1	1
5530	3665	1234	20	\N	\N	1	1
5529	3664	1234	20	\N	\N	1	1
5528	3663	1234	20	\N	\N	1	1
5587	3527	1234	20	\N	\N	1	1
5573	3647	1234	20	\N	\N	1	1
5589	3483	1233	20	\N	\N	1	1
5524	3659	1233	20	\N	\N	1	1
5523	3658	1233	20	\N	\N	1	1
5522	3657	1233	20	\N	\N	1	1
5590	3521	1233	20	\N	\N	1	1
5591	3522	1233	20	\N	\N	1	1
5592	3714	1233	20	\N	\N	1	1
5593	3483	1232	20	\N	\N	1	1
5516	3651	1232	20	\N	\N	1	1
5517	3652	1232	20	\N	\N	1	1
5518	3653	1232	20	\N	\N	1	1
5594	3519	1232	20	\N	\N	1	1
5595	3516	1232	20	\N	\N	1	1
5509	3644	1230	20	\N	\N	1	1
5510	3645	1230	20	\N	\N	1	1
5481	3483	1229	20	\N	\N	1	1
5480	3643	1229	20	\N	\N	1	1
5479	3642	1229	20	\N	\N	1	1
5478	3641	1229	20	\N	\N	1	1
5482	3519	1229	20	\N	\N	1	1
5483	3516	1229	20	\N	\N	1	1
5484	3483	1228	20	\N	\N	1	1
5470	3633	1228	20	\N	\N	1	1
5471	3634	1228	20	\N	\N	1	1
5472	3635	1228	20	\N	\N	1	1
5485	3521	1228	20	\N	\N	1	1
5486	3522	1228	20	\N	\N	1	1
5464	3627	1227	20	\N	\N	1	1
5465	3628	1227	20	\N	\N	1	1
5466	3629	1227	20	\N	\N	1	1
5488	3527	1227	20	\N	\N	1	1
5489	3528	1227	20	\N	\N	1	1
5490	3483	1226	20	\N	\N	1	1
5462	3625	1226	20	\N	\N	1	1
5461	3624	1226	20	\N	\N	1	1
5460	3623	1226	20	\N	\N	1	1
5491	3537	1226	20	\N	\N	1	1
5492	3536	1226	20	\N	\N	1	1
5454	3617	1225	20	\N	\N	1	1
5493	3548	1225	20	\N	\N	1	1
5494	3545	1225	20	\N	\N	1	1
5455	3618	1225	20	\N	\N	1	1
5451	3614	1224	20	\N	\N	1	1
5450	3613	1224	20	\N	\N	1	1
5449	3612	1223	20	\N	\N	1	1
5495	3548	1223	20	\N	\N	1	1
5496	3545	1223	20	\N	\N	1	1
5447	3610	1223	20	\N	\N	1	1
5448	3611	1223	20	\N	\N	1	1
5497	3483	1222	20	\N	\N	1	1
5442	3605	1222	20	\N	\N	1	1
5443	3606	1222	20	\N	\N	1	1
5444	3607	1222	20	\N	\N	1	1
5498	3537	1222	20	\N	\N	1	1
5499	3536	1222	20	\N	\N	1	1
5438	3601	1221	20	\N	\N	1	1
5437	3600	1221	20	\N	\N	1	1
5436	3599	1221	20	\N	\N	1	1
5501	3527	1221	20	\N	\N	1	1
5502	3528	1221	20	\N	\N	1	1
5503	3483	1220	20	\N	\N	1	1
5504	3521	1220	20	\N	\N	1	1
5505	3522	1220	20	\N	\N	1	1
5506	3483	1219	20	\N	\N	1	1
5507	3519	1219	20	\N	\N	1	1
5508	3516	1219	20	\N	\N	1	1
6231	4115	1344	17	21	6130	0	1
6230	4084	1343	17	21	6135	0	1
5278	3468	1200	20	\N	\N	1	1
5275	3465	1198	20	\N	\N	1	1
5274	3464	1198	20	\N	\N	1	1
5276	3466	1198	20	\N	\N	1	1
5294	3479	1198	20	\N	\N	1	1
5296	3479	1192	20	\N	\N	1	1
5756	3821	1264	20	\N	\N	1	1
5755	3820	1263	20	\N	\N	1	1
5753	3818	1263	20	\N	\N	1	1
5754	3819	1263	20	\N	\N	1	1
5748	3813	1262	20	\N	\N	1	1
5749	3814	1262	20	\N	\N	1	1
5750	3815	1262	20	\N	\N	1	1
5744	3809	1261	20	\N	\N	1	1
5743	3808	1261	20	\N	\N	1	1
5742	3807	1261	20	\N	\N	1	1
5737	3802	1260	20	\N	\N	1	1
5736	3801	1260	20	\N	\N	1	1
5730	3795	1259	20	\N	\N	1	1
5731	3796	1259	20	\N	\N	1	1
5732	3797	1259	20	\N	\N	1	1
5725	3790	1258	20	\N	\N	1	1
5726	3791	1258	20	\N	\N	1	1
5724	3789	1257	20	\N	\N	1	1
5723	3788	1257	20	\N	\N	1	1
5688	3483	1256	20	\N	\N	1	1
5687	3787	1256	20	\N	\N	1	1
5686	3786	1256	20	\N	\N	1	1
5685	3785	1256	20	\N	\N	1	1
5689	3519	1256	20	\N	\N	1	1
5681	3781	1256	20	\N	\N	1	1
5691	3483	1255	20	\N	\N	1	1
5678	3778	1255	20	\N	\N	1	1
5679	3779	1255	20	\N	\N	1	1
5680	3780	1255	20	\N	\N	1	1
5692	3521	1255	20	\N	\N	1	1
5693	3522	1255	20	\N	\N	1	1
5694	3714	1255	20	\N	\N	1	1
5695	3483	1254	20	\N	\N	1	1
5671	3771	1254	20	\N	\N	1	1
5672	3772	1254	20	\N	\N	1	1
5673	3773	1254	20	\N	\N	1	1
5696	3527	1254	20	\N	\N	1	1
5697	3528	1254	20	\N	\N	1	1
5698	3483	1253	20	\N	\N	1	1
5666	3766	1253	20	\N	\N	1	1
5665	3765	1253	20	\N	\N	1	1
5664	3764	1253	20	\N	\N	1	1
5699	3537	1253	20	\N	\N	1	1
5700	3536	1253	20	\N	\N	1	1
5701	3781	1253	20	\N	\N	1	1
5657	3757	1252	20	\N	\N	1	1
5702	3548	1252	20	\N	\N	1	1
5703	3545	1252	20	\N	\N	1	1
5659	3759	1252	20	\N	\N	1	1
5658	3758	1252	20	\N	\N	1	1
5704	3770	1252	20	\N	\N	1	1
5653	3753	1251	20	\N	\N	1	1
5705	3548	1250	20	\N	\N	1	1
5706	3545	1250	20	\N	\N	1	1
5650	3750	1250	20	\N	\N	1	1
5651	3751	1250	20	\N	\N	1	1
5647	3747	1250	20	\N	\N	1	1
5707	3483	1249	20	\N	\N	1	1
5644	3744	1249	20	\N	\N	1	1
5645	3745	1249	20	\N	\N	1	1
5646	3746	1249	20	\N	\N	1	1
5708	3537	1249	20	\N	\N	1	1
5709	3536	1249	20	\N	\N	1	1
5710	3713	1249	20	\N	\N	1	1
5711	3483	1248	20	\N	\N	1	1
5639	3739	1248	20	\N	\N	1	1
5637	3737	1248	20	\N	\N	1	1
5712	3527	1248	20	\N	\N	1	1
5713	3528	1248	20	\N	\N	1	1
5714	3747	1248	20	\N	\N	1	1
5715	3483	1247	20	\N	\N	1	1
5632	3732	1247	20	\N	\N	1	1
5631	3731	1247	20	\N	\N	1	1
5630	3730	1247	20	\N	\N	1	1
5716	3521	1247	20	\N	\N	1	1
5717	3522	1247	20	\N	\N	1	1
5718	3747	1247	20	\N	\N	1	1
5719	3483	1246	20	\N	\N	1	1
5623	3723	1246	20	\N	\N	1	1
5624	3724	1246	20	\N	\N	1	1
5720	3519	1246	20	\N	\N	1	1
5721	3516	1246	20	\N	\N	1	1
5722	3713	1246	20	\N	\N	1	1
6240	4105	1348	17	21	6115	0	1
6241	4095	1348	17	21	6116	0	1
6242	4084	1348	17	21	6117	0	1
6237	4108	1347	17	21	6120	0	1
6238	4095	1347	17	21	6121	0	1
6239	4084	1347	17	21	6122	0	1
6233	4084	1344	17	21	6131	0	1
6301	3449	1366	17	21	5253	0	1
6302	3446	1364	17	21	5250	0	1
6304	3447	1364	17	21	5251	0	1
6305	3479	1364	17	21	5296	0	1
6306	3442	1364	17	21	5246	0	1
6307	3428	1364	17	21	5255	0	1
6308	3429	1364	17	21	5256	0	1
6309	3422	1364	17	21	5257	0	1
6290	3459	1362	17	21	5266	0	1
6298	3429	1361	17	21	5268	0	1
6299	3422	1361	17	21	5269	0	1
6320	3938	1373	17	21	6076	0	1
6321	4076	1373	17	21	6075	0	1
6322	4075	1373	17	21	6074	0	1
6323	4074	1373	17	21	6073	0	1
6324	3944	1373	17	21	6077	0	1
6325	3941	1373	17	21	6078	0	1
6326	3938	1374	17	21	6079	0	1
6328	4069	1374	17	21	6068	0	1
6329	4070	1374	17	21	6069	0	1
6330	3945	1374	17	21	6080	0	1
6331	3946	1374	17	21	6081	0	1
6337	4058	1372	17	21	6057	0	1
6338	4057	1372	17	21	6056	0	1
6339	4056	1372	17	21	6055	0	1
5954	3982	1286	20	\N	\N	1	1
5955	3983	1286	20	\N	\N	1	1
5956	3984	1286	20	\N	\N	1	1
5953	3981	1286	20	\N	\N	1	1
5945	3938	1285	20	\N	\N	1	1
5944	3980	1285	20	\N	\N	1	1
5943	3979	1285	20	\N	\N	1	1
5941	3977	1285	20	\N	\N	1	1
5946	3944	1285	20	\N	\N	1	1
5947	3941	1285	20	\N	\N	1	1
5948	3938	1284	20	\N	\N	1	1
5934	3970	1284	20	\N	\N	1	1
5935	3971	1284	20	\N	\N	1	1
5936	3972	1284	20	\N	\N	1	1
5949	3945	1284	20	\N	\N	1	1
5950	3946	1284	20	\N	\N	1	1
5928	3964	1283	20	\N	\N	1	1
5951	3956	1283	20	\N	\N	1	1
5952	3955	1283	20	\N	\N	1	1
5930	3966	1283	20	\N	\N	1	1
5929	3965	1283	20	\N	\N	1	1
5926	3962	1282	20	\N	\N	1	1
5925	3961	1282	20	\N	\N	1	1
5924	3960	1282	20	\N	\N	1	1
5927	3963	1282	20	\N	\N	1	1
5923	3959	1281	20	\N	\N	1	1
5920	3956	1281	20	\N	\N	1	1
5919	3955	1281	20	\N	\N	1	1
5921	3957	1281	20	\N	\N	1	1
5922	3958	1281	20	\N	\N	1	1
5914	3938	1280	20	\N	\N	1	1
5913	3950	1280	20	\N	\N	1	1
5912	3949	1280	20	\N	\N	1	1
5910	3947	1280	20	\N	\N	1	1
5908	3945	1280	20	\N	\N	1	1
5909	3946	1280	20	\N	\N	1	1
5901	3938	1279	20	\N	\N	1	1
5899	3936	1279	20	\N	\N	1	1
5900	3937	1279	20	\N	\N	1	1
5902	3939	1279	20	\N	\N	1	1
5907	3944	1279	20	\N	\N	1	1
5904	3941	1279	20	\N	\N	1	1
5893	3930	1278	20	\N	\N	1	1
5895	3932	1278	20	\N	\N	1	1
5896	3933	1278	20	\N	\N	1	1
5889	3926	1278	20	\N	\N	1	1
5861	3898	1276	20	\N	\N	1	1
5865	3902	1276	20	\N	\N	1	1
5864	3901	1276	20	\N	\N	1	1
5863	3900	1276	20	\N	\N	1	1
5862	3899	1276	20	\N	\N	1	1
5866	3903	1276	20	\N	\N	1	1
5860	3897	1275	20	\N	\N	1	1
5856	3893	1275	20	\N	\N	1	1
5857	3894	1275	20	\N	\N	1	1
5858	3895	1275	20	\N	\N	1	1
5859	3896	1275	20	\N	\N	1	1
5855	3892	1275	20	\N	\N	1	1
5849	3886	1274	20	\N	\N	1	1
5853	3890	1274	20	\N	\N	1	1
5852	3889	1274	20	\N	\N	1	1
5851	3888	1274	20	\N	\N	1	1
5850	3887	1274	20	\N	\N	1	1
5854	3891	1274	20	\N	\N	1	1
5848	3885	1273	20	\N	\N	1	1
5844	3881	1273	20	\N	\N	1	1
5845	3882	1273	20	\N	\N	1	1
5846	3883	1273	20	\N	\N	1	1
5847	3884	1273	20	\N	\N	1	1
5843	3880	1273	20	\N	\N	1	1
5837	3874	1272	20	\N	\N	1	1
5841	3878	1272	20	\N	\N	1	1
5840	3877	1272	20	\N	\N	1	1
5839	3876	1272	20	\N	\N	1	1
5842	3879	1272	20	\N	\N	1	1
5836	3873	1271	20	\N	\N	1	1
5826	3863	1271	20	\N	\N	1	1
5827	3864	1271	20	\N	\N	1	1
5829	3866	1271	20	\N	\N	1	1
5830	3867	1271	20	\N	\N	1	1
5825	3862	1271	20	\N	\N	1	1
5818	3855	1270	20	\N	\N	1	1
5835	3872	1270	20	\N	\N	1	1
5821	3858	1270	20	\N	\N	1	1
5787	3483	1269	20	\N	\N	1	1
5786	3851	1269	20	\N	\N	1	1
5785	3850	1269	20	\N	\N	1	1
5784	3849	1269	20	\N	\N	1	1
5789	3516	1269	20	\N	\N	1	1
5790	3483	1268	20	\N	\N	1	1
5776	3841	1268	20	\N	\N	1	1
5777	3842	1268	20	\N	\N	1	1
5778	3843	1268	20	\N	\N	1	1
5791	3521	1268	20	\N	\N	1	1
5792	3522	1268	20	\N	\N	1	1
5793	3483	1267	20	\N	\N	1	1
5770	3835	1267	20	\N	\N	1	1
5771	3836	1267	20	\N	\N	1	1
5772	3837	1267	20	\N	\N	1	1
5794	3527	1267	20	\N	\N	1	1
5795	3528	1267	20	\N	\N	1	1
5796	3483	1266	20	\N	\N	1	1
5767	3832	1266	20	\N	\N	1	1
5766	3831	1266	20	\N	\N	1	1
5797	3537	1266	20	\N	\N	1	1
5798	3536	1266	20	\N	\N	1	1
5760	3825	1265	20	\N	\N	1	1
5799	3548	1265	20	\N	\N	1	1
5800	3545	1265	20	\N	\N	1	1
5762	3827	1265	20	\N	\N	1	1
5761	3826	1265	20	\N	\N	1	1
5801	3548	1263	20	\N	\N	1	1
5802	3545	1263	20	\N	\N	1	1
5803	3483	1262	20	\N	\N	1	1
5804	3537	1262	20	\N	\N	1	1
5805	3536	1262	20	\N	\N	1	1
5807	3527	1261	20	\N	\N	1	1
5808	3528	1261	20	\N	\N	1	1
5809	3483	1260	20	\N	\N	1	1
5810	3521	1260	20	\N	\N	1	1
5811	3522	1260	20	\N	\N	1	1
5812	3483	1259	20	\N	\N	1	1
5813	3519	1259	20	\N	\N	1	1
5814	3516	1259	20	\N	\N	1	1
6234	4110	1345	17	21	6124	0	1
6235	4111	1345	17	21	6125	0	1
6143	4126	1316	20	\N	\N	1	1
6142	4125	1315	20	\N	\N	1	1
6137	4120	1315	20	\N	\N	1	1
6139	4122	1315	20	\N	\N	1	1
6133	4117	1314	20	\N	\N	1	1
6134	4118	1314	20	\N	\N	1	1
6135	4084	1314	20	\N	\N	1	1
6130	4115	1313	20	\N	\N	1	1
6129	4114	1313	20	\N	\N	1	1
6131	4084	1313	20	\N	\N	1	1
6124	4110	1312	20	\N	\N	1	1
6125	4111	1312	20	\N	\N	1	1
6127	4084	1312	20	\N	\N	1	1
6120	4108	1311	20	\N	\N	1	1
6121	4095	1311	20	\N	\N	1	1
6122	4084	1311	20	\N	\N	1	1
6115	4105	1310	20	\N	\N	1	1
6116	4095	1310	20	\N	\N	1	1
6117	4084	1310	20	\N	\N	1	1
6110	4101	1309	20	\N	\N	1	1
6111	4102	1309	20	\N	\N	1	1
6112	4084	1309	20	\N	\N	1	1
6107	4099	1308	20	\N	\N	1	1
6106	4098	1308	20	\N	\N	1	1
6108	4084	1308	20	\N	\N	1	1
6097	4090	1307	20	\N	\N	1	1
6102	4095	1307	20	\N	\N	1	1
6104	4084	1307	20	\N	\N	1	1
6090	4083	1306	20	\N	\N	1	1
6093	4086	1306	20	\N	\N	1	1
6091	4084	1306	20	\N	\N	1	1
6095	4088	1306	20	\N	\N	1	1
6088	4081	1305	20	\N	\N	1	1
6089	4082	1305	20	\N	\N	1	1
6087	4080	1305	20	\N	\N	1	1
6085	4078	1305	20	\N	\N	1	1
6076	3938	1303	20	\N	\N	1	1
6075	4076	1303	20	\N	\N	1	1
6074	4075	1303	20	\N	\N	1	1
6073	4074	1303	20	\N	\N	1	1
6077	3944	1303	20	\N	\N	1	1
6078	3941	1303	20	\N	\N	1	1
6079	3938	1302	20	\N	\N	1	1
6067	4068	1302	20	\N	\N	1	1
6068	4069	1302	20	\N	\N	1	1
6069	4070	1302	20	\N	\N	1	1
6080	3945	1302	20	\N	\N	1	1
6081	3946	1302	20	\N	\N	1	1
6061	4062	1301	20	\N	\N	1	1
6082	3956	1301	20	\N	\N	1	1
6083	3955	1301	20	\N	\N	1	1
6063	4064	1301	20	\N	\N	1	1
6062	4063	1301	20	\N	\N	1	1
6057	4058	1300	20	\N	\N	1	1
6056	4057	1300	20	\N	\N	1	1
6055	4056	1300	20	\N	\N	1	1
6058	4059	1300	20	\N	\N	1	1
6047	3956	1299	20	\N	\N	1	1
6048	3955	1299	20	\N	\N	1	1
6044	4053	1299	20	\N	\N	1	1
6045	4054	1299	20	\N	\N	1	1
6049	3938	1298	20	\N	\N	1	1
6041	4050	1298	20	\N	\N	1	1
6040	4049	1298	20	\N	\N	1	1
6039	4048	1298	20	\N	\N	1	1
6050	3945	1298	20	\N	\N	1	1
6051	3946	1298	20	\N	\N	1	1
6052	3938	1297	20	\N	\N	1	1
6033	4042	1297	20	\N	\N	1	1
6034	4043	1297	20	\N	\N	1	1
6035	4044	1297	20	\N	\N	1	1
6054	3941	1297	20	\N	\N	1	1
6027	4036	1296	20	\N	\N	1	1
6028	4037	1296	20	\N	\N	1	1
6029	4038	1296	20	\N	\N	1	1
6026	4035	1296	20	\N	\N	1	1
6024	3938	1295	20	\N	\N	1	1
6021	4032	1295	20	\N	\N	1	1
6020	4031	1295	20	\N	\N	1	1
6019	4030	1295	20	\N	\N	1	1
6022	4033	1295	20	\N	\N	1	1
6025	4023	1295	20	\N	\N	1	1
6017	3938	1294	20	\N	\N	1	1
6014	4026	1294	20	\N	\N	1	1
6015	4027	1294	20	\N	\N	1	1
6012	4024	1294	20	\N	\N	1	1
6011	4023	1294	20	\N	\N	1	1
6003	3938	1293	20	\N	\N	1	1
6002	4022	1293	20	\N	\N	1	1
6001	4021	1293	20	\N	\N	1	1
5999	4019	1293	20	\N	\N	1	1
6004	3944	1293	20	\N	\N	1	1
6005	3941	1293	20	\N	\N	1	1
6006	3938	1292	20	\N	\N	1	1
5992	4012	1292	20	\N	\N	1	1
5993	4013	1292	20	\N	\N	1	1
5994	4014	1292	20	\N	\N	1	1
6007	3945	1292	20	\N	\N	1	1
6008	3946	1292	20	\N	\N	1	1
6009	3956	1291	20	\N	\N	1	1
6010	3955	1291	20	\N	\N	1	1
5988	4008	1291	20	\N	\N	1	1
5987	4007	1291	20	\N	\N	1	1
5984	4004	1290	20	\N	\N	1	1
5983	4003	1290	20	\N	\N	1	1
5982	4002	1290	20	\N	\N	1	1
5985	4005	1290	20	\N	\N	1	1
5973	4001	1289	20	\N	\N	1	1
5974	3956	1289	20	\N	\N	1	1
5975	3955	1289	20	\N	\N	1	1
5971	3999	1289	20	\N	\N	1	1
5972	4000	1289	20	\N	\N	1	1
5976	3938	1288	20	\N	\N	1	1
5967	3995	1288	20	\N	\N	1	1
5966	3994	1288	20	\N	\N	1	1
5977	3945	1288	20	\N	\N	1	1
5978	3946	1288	20	\N	\N	1	1
5979	3938	1287	20	\N	\N	1	1
5960	3988	1287	20	\N	\N	1	1
5961	3989	1287	20	\N	\N	1	1
5962	3990	1287	20	\N	\N	1	1
5980	3944	1287	20	\N	\N	1	1
5981	3941	1287	20	\N	\N	1	1
6243	4101	1349	17	21	6110	0	1
6244	4102	1349	17	21	6111	0	1
6155	4136	1317	20	\N	\N	1	1
6156	4131	1317	20	\N	\N	1	1
6157	4120	1317	20	\N	\N	1	1
6158	4122	1317	20	\N	\N	1	1
6148	4131	1316	20	\N	\N	1	1
6150	4120	1316	20	\N	\N	1	1
6151	4122	1316	20	\N	\N	1	1
6046	4055	1299	20	\N	\N	1	1
6053	3944	1297	20	\N	\N	1	1
6016	4028	1294	20	\N	\N	1	1
5986	4006	1291	20	\N	\N	1	1
5968	3996	1288	20	\N	\N	1	1
6250	4095	1351	17	21	6102	0	1
6251	4084	1351	17	21	6104	0	1
6247	4098	1350	17	21	6106	0	1
6248	4084	1350	17	21	6108	0	1
6245	4084	1349	17	21	6112	0	1
6252	4083	1346	17	21	6090	0	1
6253	4086	1346	17	21	6093	0	1
6254	4084	1346	17	21	6091	0	1
6255	4088	1346	17	21	6095	0	1
6311	3431	1369	17	21	5235	0	1
6310	3441	1368	17	21	5245	0	1
6312	3426	1367	17	21	5230	0	1
6313	3427	1367	17	21	5231	0	1
6314	3425	1367	17	21	5229	0	1
6315	3479	1367	17	21	5297	0	1
6316	3430	1367	17	21	5234	0	1
6317	3428	1367	17	21	5232	0	1
6318	3429	1367	17	21	5233	0	1
6300	3450	1365	17	21	5254	0	1
6260	3474	1354	17	21	5287	0	1
6261	3475	1354	17	21	5288	0	1
6262	3473	1354	17	21	5286	0	1
6263	3471	1354	17	21	5284	0	1
6264	3479	1354	17	21	5293	0	1
6265	3478	1354	17	21	5291	0	1
6266	3476	1354	17	21	5289	0	1
6267	3429	1354	17	21	5292	0	1
6268	3469	1354	17	21	5282	0	1
6269	3470	1354	17	21	5283	0	1
6332	4062	1375	17	21	6061	0	1
6333	3956	1375	17	21	6082	0	1
6334	3955	1375	17	21	6083	0	1
6335	4064	1375	17	21	6063	0	1
6336	4063	1375	17	21	6062	0	1
6406	3938	1389	17	21	5979	0	1
6407	3988	1389	17	21	5960	0	1
6408	3989	1389	17	21	5961	0	1
6409	3990	1389	17	21	5962	0	1
6410	3944	1389	17	21	5980	0	1
6411	3941	1389	17	21	5981	0	1
6400	3938	1388	17	21	5976	0	1
6401	3996	1388	17	21	5968	0	1
6402	3995	1388	17	21	5967	0	1
6403	3994	1388	17	21	5966	0	1
6404	3945	1388	17	21	5977	0	1
6405	3946	1388	17	21	5978	0	1
6395	4001	1387	17	21	5973	0	1
6396	3956	1387	17	21	5974	0	1
6397	3955	1387	17	21	5975	0	1
6398	3999	1387	17	21	5971	0	1
6386	4006	1385	17	21	5986	0	1
6387	3956	1385	17	21	6009	0	1
6388	3955	1385	17	21	6010	0	1
6389	4008	1385	17	21	5988	0	1
6390	4007	1385	17	21	5987	0	1
6380	3938	1384	17	21	6006	0	1
6381	4012	1384	17	21	5992	0	1
6382	4013	1384	17	21	5993	0	1
6383	4014	1384	17	21	5994	0	1
6384	3945	1384	17	21	6007	0	1
6385	3946	1384	17	21	6008	0	1
6374	3938	1383	17	21	6003	0	1
6375	4022	1383	17	21	6002	0	1
6376	4021	1383	17	21	6001	0	1
6377	4019	1383	17	21	5999	0	1
6378	3944	1383	17	21	6004	0	1
6368	3938	1382	17	21	6017	0	1
6369	4026	1382	17	21	6014	0	1
6370	4027	1382	17	21	6015	0	1
6371	4028	1382	17	21	6016	0	1
6372	4024	1382	17	21	6012	0	1
6373	4023	1382	17	21	6011	0	1
6362	3938	1381	17	21	6024	0	1
6363	4032	1381	17	21	6021	0	1
6364	4031	1381	17	21	6020	0	1
6365	4030	1381	17	21	6019	0	1
6366	4033	1381	17	21	6022	0	1
6367	4023	1381	17	21	6025	0	1
6391	4004	1380	17	21	5984	0	1
6392	4003	1380	17	21	5983	0	1
6393	4002	1380	17	21	5982	0	1
6394	4005	1380	17	21	5985	0	1
6353	4042	1379	17	21	6033	0	1
6354	4043	1379	17	21	6034	0	1
6355	4044	1379	17	21	6035	0	1
6356	3944	1379	17	21	6053	0	1
6357	3941	1379	17	21	6054	0	1
6346	3938	1378	17	21	6049	0	1
6347	4050	1378	17	21	6041	0	1
6348	4049	1378	17	21	6040	0	1
6349	4048	1378	17	21	6039	0	1
6350	3945	1378	17	21	6050	0	1
6351	3946	1378	17	21	6051	0	1
6341	4055	1377	17	21	6046	0	1
6342	3956	1377	17	21	6047	0	1
6343	3955	1377	17	21	6048	0	1
6344	4053	1377	17	21	6044	0	1
6345	4054	1377	17	21	6045	0	1
6359	4037	1376	17	21	6028	0	1
6360	4038	1376	17	21	6029	0	1
6361	4035	1376	17	21	6026	0	1
5838	3875	1272	20	\N	\N	1	1
6488	3873	1404	17	21	5836	0	1
6489	3863	1404	17	21	5826	0	1
6490	3864	1404	17	21	5827	0	1
6491	3866	1404	17	21	5829	0	1
6492	3867	1404	17	21	5830	0	1
6493	3862	1404	17	21	5825	0	1
6482	3874	1403	17	21	5837	0	1
6483	3878	1403	17	21	5841	0	1
6484	3877	1403	17	21	5840	0	1
6485	3876	1403	17	21	5839	0	1
6486	3875	1403	17	21	5838	0	1
6487	3879	1403	17	21	5842	0	1
6464	3897	1400	17	21	5860	0	1
6465	3893	1400	17	21	5856	0	1
6466	3894	1400	17	21	5857	0	1
6467	3895	1400	17	21	5858	0	1
6468	3896	1400	17	21	5859	0	1
6469	3892	1400	17	21	5855	0	1
6448	3938	1397	17	21	5901	0	1
6449	3936	1397	17	21	5899	0	1
6450	3937	1397	17	21	5900	0	1
6451	3939	1397	17	21	5902	0	1
6452	3944	1397	17	21	5907	0	1
6453	3941	1397	17	21	5904	0	1
6437	3959	1395	17	21	5923	0	1
6438	3956	1395	17	21	5920	0	1
6439	3955	1395	17	21	5919	0	1
6440	3957	1395	17	21	5921	0	1
6441	3958	1395	17	21	5922	0	1
6454	3930	1394	17	21	5893	0	1
6455	3932	1394	17	21	5895	0	1
6456	3933	1394	17	21	5896	0	1
6457	3926	1394	17	21	5889	0	1
6422	3938	1392	17	21	5948	0	1
6423	3970	1392	17	21	5934	0	1
6424	3971	1392	17	21	5935	0	1
6425	3972	1392	17	21	5936	0	1
6426	3945	1392	17	21	5949	0	1
6427	3946	1392	17	21	5950	0	1
6416	3938	1391	17	21	5945	0	1
6417	3980	1391	17	21	5944	0	1
6418	3979	1391	17	21	5943	0	1
6419	3977	1391	17	21	5941	0	1
6420	3944	1391	17	21	5946	0	1
6421	3941	1391	17	21	5947	0	1
6412	3982	1386	17	21	5954	0	1
6413	3983	1386	17	21	5955	0	1
6414	3984	1386	17	21	5956	0	1
6415	3981	1386	17	21	5953	0	1
5788	3519	1269	20	\N	\N	1	1
5768	3833	1266	20	\N	\N	1	1
5757	3822	1264	20	\N	\N	1	1
5806	3483	1261	20	\N	\N	1	1
5738	3803	1260	20	\N	\N	1	1
5690	3516	1256	20	\N	\N	1	1
6569	3778	1422	17	21	5678	0	1
6570	3779	1422	17	21	5679	0	1
6571	3780	1422	17	21	5680	0	1
6572	3521	1422	17	21	5692	0	1
6573	3522	1422	17	21	5693	0	1
6574	3714	1422	17	21	5694	0	1
6561	3483	1421	17	21	5688	0	1
6562	3787	1421	17	21	5687	0	1
6563	3786	1421	17	21	5686	0	1
6564	3785	1421	17	21	5685	0	1
6565	3519	1421	17	21	5689	0	1
6566	3516	1421	17	21	5690	0	1
6567	3781	1421	17	21	5681	0	1
6551	3483	1418	17	21	5812	0	1
6553	3796	1418	17	21	5731	0	1
6554	3797	1418	17	21	5732	0	1
6555	3519	1418	17	21	5813	0	1
6556	3516	1418	17	21	5814	0	1
6545	3483	1417	17	21	5809	0	1
6546	3803	1417	17	21	5738	0	1
6547	3802	1417	17	21	5737	0	1
6548	3801	1417	17	21	5736	0	1
6549	3521	1417	17	21	5810	0	1
6550	3522	1417	17	21	5811	0	1
6539	3483	1416	17	21	5806	0	1
6540	3809	1416	17	21	5744	0	1
6541	3808	1416	17	21	5743	0	1
6542	3807	1416	17	21	5742	0	1
6543	3527	1416	17	21	5807	0	1
6544	3528	1416	17	21	5808	0	1
6534	3813	1415	17	21	5748	0	1
6535	3814	1415	17	21	5749	0	1
6536	3815	1415	17	21	5750	0	1
6537	3537	1415	17	21	5804	0	1
6538	3536	1415	17	21	5805	0	1
6528	3820	1414	17	21	5755	0	1
6529	3548	1414	17	21	5801	0	1
6530	3545	1414	17	21	5802	0	1
6531	3818	1414	17	21	5753	0	1
6532	3819	1414	17	21	5754	0	1
6557	3790	1413	17	21	5725	0	1
6558	3791	1413	17	21	5726	0	1
6521	3825	1412	17	21	5760	0	1
6522	3548	1412	17	21	5799	0	1
6523	3545	1412	17	21	5800	0	1
6524	3827	1412	17	21	5762	0	1
6515	3483	1411	17	21	5796	0	1
6516	3833	1411	17	21	5768	0	1
6517	3832	1411	17	21	5767	0	1
6518	3831	1411	17	21	5766	0	1
6519	3537	1411	17	21	5797	0	1
6520	3536	1411	17	21	5798	0	1
6509	3483	1410	17	21	5793	0	1
6510	3835	1410	17	21	5770	0	1
6511	3836	1410	17	21	5771	0	1
6512	3837	1410	17	21	5772	0	1
6513	3527	1410	17	21	5794	0	1
6514	3528	1410	17	21	5795	0	1
6503	3483	1409	17	21	5790	0	1
6504	3841	1409	17	21	5776	0	1
6505	3842	1409	17	21	5777	0	1
6506	3843	1409	17	21	5778	0	1
6508	3522	1409	17	21	5792	0	1
6497	3483	1408	17	21	5787	0	1
6498	3851	1408	17	21	5786	0	1
6499	3850	1408	17	21	5785	0	1
6500	3849	1408	17	21	5784	0	1
6501	3519	1408	17	21	5788	0	1
6502	3516	1408	17	21	5789	0	1
6526	3822	1407	17	21	5757	0	1
6527	3821	1407	17	21	5756	0	1
6559	3789	1406	17	21	5724	0	1
6560	3788	1406	17	21	5723	0	1
6476	3885	1402	17	21	5848	0	1
6477	3881	1402	17	21	5844	0	1
6478	3882	1402	17	21	5845	0	1
6479	3883	1402	17	21	5846	0	1
6480	3884	1402	17	21	5847	0	1
6470	3886	1401	17	21	5849	0	1
6471	3890	1401	17	21	5853	0	1
6472	3889	1401	17	21	5852	0	1
6473	3888	1401	17	21	5851	0	1
6474	3887	1401	17	21	5850	0	1
6475	3891	1401	17	21	5854	0	1
6458	3898	1399	17	21	5861	0	1
6459	3902	1399	17	21	5865	0	1
6460	3901	1399	17	21	5864	0	1
6461	3900	1399	17	21	5863	0	1
6462	3899	1399	17	21	5862	0	1
6463	3903	1399	17	21	5866	0	1
6494	3855	1398	17	21	5818	0	1
6495	3872	1398	17	21	5835	0	1
6496	3858	1398	17	21	5821	0	1
6442	3938	1396	17	21	5914	0	1
6444	3949	1396	17	21	5912	0	1
6445	3947	1396	17	21	5910	0	1
6446	3945	1396	17	21	5908	0	1
6447	3946	1396	17	21	5909	0	1
6428	3964	1393	17	21	5928	0	1
6429	3956	1393	17	21	5951	0	1
6430	3955	1393	17	21	5952	0	1
6431	3966	1393	17	21	5930	0	1
6432	3965	1393	17	21	5929	0	1
6433	3962	1390	17	21	5926	0	1
6434	3961	1390	17	21	5925	0	1
6435	3960	1390	17	21	5924	0	1
6436	3963	1390	17	21	5927	0	1
5670	3770	1254	20	\N	\N	1	1
5638	3738	1248	20	\N	\N	1	1
5588	3528	1234	20	\N	\N	1	1
6682	3483	1442	17	21	5586	0	1
6683	3665	1442	17	21	5530	0	1
6684	3664	1442	17	21	5529	0	1
6685	3663	1442	17	21	5528	0	1
6686	3527	1442	17	21	5587	0	1
6687	3528	1442	17	21	5588	0	1
6688	3647	1442	17	21	5573	0	1
6669	3676	1440	17	21	5541	0	1
6670	3548	1440	17	21	5580	0	1
6671	3545	1440	17	21	5581	0	1
6672	3674	1440	17	21	5539	0	1
6673	3675	1440	17	21	5540	0	1
6674	3647	1440	17	21	5579	0	1
6668	3646	1439	17	21	5511	0	1
6661	3681	1438	17	21	5546	0	1
6662	3548	1438	17	21	5613	0	1
6663	3545	1438	17	21	5614	0	1
6664	3683	1438	17	21	5548	0	1
6665	3682	1438	17	21	5547	0	1
6666	3715	1438	17	21	5615	0	1
6654	3483	1437	17	21	5601	0	1
6655	3689	1437	17	21	5554	0	1
6656	3688	1437	17	21	5553	0	1
6657	3687	1437	17	21	5552	0	1
6658	3537	1437	17	21	5602	0	1
6659	3536	1437	17	21	5603	0	1
6660	3714	1437	17	21	5604	0	1
6610	3483	1429	17	21	5711	0	1
6611	3739	1429	17	21	5639	0	1
6612	3738	1429	17	21	5638	0	1
6613	3737	1429	17	21	5637	0	1
6614	3527	1429	17	21	5712	0	1
6615	3528	1429	17	21	5713	0	1
6616	3747	1429	17	21	5714	0	1
6589	3757	1425	17	21	5657	0	1
6590	3548	1425	17	21	5702	0	1
6591	3545	1425	17	21	5703	0	1
6592	3759	1425	17	21	5659	0	1
6593	3758	1425	17	21	5658	0	1
6594	3770	1425	17	21	5704	0	1
6575	3483	1423	17	21	5695	0	1
6576	3771	1423	17	21	5671	0	1
6577	3772	1423	17	21	5672	0	1
6578	3773	1423	17	21	5673	0	1
6579	3527	1423	17	21	5696	0	1
6580	3528	1423	17	21	5697	0	1
6581	3770	1423	17	21	5670	0	1
6595	3753	1420	17	21	5653	0	1
6631	3717	1419	17	21	5617	0	1
6632	3716	1419	17	21	5616	0	1
5652	3752	1250	20	\N	\N	1	1
5618	3718	1245	20	\N	\N	1	1
5625	3725	1246	20	\N	\N	1	1
5596	3713	1232	20	\N	\N	1	1
5487	3483	1227	20	\N	\N	1	1
5456	3619	1225	20	\N	\N	1	1
6737	3548	1453	17	21	5495	0	1
6738	3545	1453	17	21	5496	0	1
6729	3617	1451	17	21	5454	0	1
6730	3548	1451	17	21	5493	0	1
6731	3545	1451	17	21	5494	0	1
6732	3619	1451	17	21	5456	0	1
6733	3618	1451	17	21	5455	0	1
6723	3483	1450	17	21	5490	0	1
6724	3625	1450	17	21	5462	0	1
6725	3624	1450	17	21	5461	0	1
6726	3623	1450	17	21	5460	0	1
6727	3537	1450	17	21	5491	0	1
6728	3536	1450	17	21	5492	0	1
6717	3483	1449	17	21	5487	0	1
6719	3628	1449	17	21	5465	0	1
6720	3629	1449	17	21	5466	0	1
6721	3527	1449	17	21	5488	0	1
6722	3528	1449	17	21	5489	0	1
6711	3483	1448	17	21	5484	0	1
6712	3633	1448	17	21	5470	0	1
6713	3634	1448	17	21	5471	0	1
6714	3635	1448	17	21	5472	0	1
6715	3521	1448	17	21	5485	0	1
6716	3522	1448	17	21	5486	0	1
6705	3483	1447	17	21	5481	0	1
6706	3643	1447	17	21	5480	0	1
6707	3642	1447	17	21	5479	0	1
6708	3641	1447	17	21	5478	0	1
6709	3519	1447	17	21	5482	0	1
6710	3516	1447	17	21	5483	0	1
6735	3613	1446	17	21	5450	0	1
6696	3483	1444	17	21	5593	0	1
6697	3651	1444	17	21	5516	0	1
6698	3652	1444	17	21	5517	0	1
6699	3653	1444	17	21	5518	0	1
6700	3519	1444	17	21	5594	0	1
6701	3516	1444	17	21	5595	0	1
6702	3713	1444	17	21	5596	0	1
6689	3483	1443	17	21	5589	0	1
6690	3659	1443	17	21	5524	0	1
6691	3658	1443	17	21	5523	0	1
6692	3657	1443	17	21	5522	0	1
6693	3521	1443	17	21	5590	0	1
6694	3522	1443	17	21	5591	0	1
6695	3714	1443	17	21	5592	0	1
6675	3483	1441	17	21	5582	0	1
6677	3670	1441	17	21	5535	0	1
6678	3671	1441	17	21	5536	0	1
6679	3537	1441	17	21	5583	0	1
6680	3536	1441	17	21	5584	0	1
6681	3713	1441	17	21	5585	0	1
6647	3483	1436	17	21	5609	0	1
6648	3693	1436	17	21	5558	0	1
6649	3694	1436	17	21	5559	0	1
6650	3695	1436	17	21	5560	0	1
6651	3527	1436	17	21	5610	0	1
6652	3528	1436	17	21	5611	0	1
6653	3715	1436	17	21	5612	0	1
6640	3483	1435	17	21	5605	0	1
6641	3699	1435	17	21	5564	0	1
6642	3700	1435	17	21	5565	0	1
6643	3701	1435	17	21	5566	0	1
6645	3522	1435	17	21	5607	0	1
6646	3715	1435	17	21	5608	0	1
6633	3483	1434	17	21	5597	0	1
6634	3707	1434	17	21	5572	0	1
6635	3706	1434	17	21	5571	0	1
6636	3705	1434	17	21	5570	0	1
6637	3519	1434	17	21	5598	0	1
6638	3516	1434	17	21	5599	0	1
6639	3714	1434	17	21	5600	0	1
6667	3678	1433	17	21	5543	0	1
6703	3644	1432	17	21	5509	0	1
6704	3645	1432	17	21	5510	0	1
6624	3483	1431	17	21	5719	0	1
6625	3723	1431	17	21	5623	0	1
6626	3724	1431	17	21	5624	0	1
6627	3725	1431	17	21	5625	0	1
6629	3516	1431	17	21	5721	0	1
6630	3713	1431	17	21	5722	0	1
6617	3483	1430	17	21	5715	0	1
6618	3732	1430	17	21	5632	0	1
6619	3731	1430	17	21	5631	0	1
6620	3730	1430	17	21	5630	0	1
6621	3521	1430	17	21	5716	0	1
6622	3522	1430	17	21	5717	0	1
6623	3747	1430	17	21	5718	0	1
6603	3483	1428	17	21	5707	0	1
6604	3744	1428	17	21	5644	0	1
6605	3745	1428	17	21	5645	0	1
6606	3746	1428	17	21	5646	0	1
6607	3537	1428	17	21	5708	0	1
6608	3536	1428	17	21	5709	0	1
6609	3713	1428	17	21	5710	0	1
6597	3548	1427	17	21	5705	0	1
6598	3545	1427	17	21	5706	0	1
6599	3750	1427	17	21	5650	0	1
6600	3751	1427	17	21	5651	0	1
6601	3747	1427	17	21	5647	0	1
6602	3718	1426	17	21	5618	0	1
6582	3483	1424	17	21	5698	0	1
6583	3766	1424	17	21	5666	0	1
6584	3765	1424	17	21	5665	0	1
6585	3764	1424	17	21	5664	0	1
6586	3537	1424	17	21	5699	0	1
6587	3536	1424	17	21	5700	0	1
6588	3781	1424	17	21	5701	0	1
5500	3483	1221	20	\N	\N	1	1
5348	3527	1208	20	\N	\N	1	1
6160	3322	1321	17	21	5126	0	1
6161	3321	1321	17	21	5125	0	1
6166	3312	1320	17	21	5116	0	1
6167	3313	1320	17	21	5117	0	1
6186	3412	1329	17	21	5216	0	1
6246	4099	1350	17	21	6107	0	1
6236	4084	1345	17	21	6127	0	1
6232	4114	1344	17	21	6129	0	1
6228	4117	1343	17	21	6133	0	1
6319	3422	1367	17	21	5226	0	1
6817	3483	1469	17	21	5346	0	1
6818	3525	1469	17	21	5345	0	1
6819	3524	1469	17	21	5344	0	1
6820	3523	1469	17	21	5343	0	1
6821	3521	1469	17	21	5341	0	1
6822	3522	1469	17	21	5342	0	1
6811	3483	1468	17	21	5353	0	1
6812	3531	1468	17	21	5352	0	1
6813	3530	1468	17	21	5351	0	1
6814	3529	1468	17	21	5350	0	1
6815	3527	1468	17	21	5348	0	1
6816	3528	1468	17	21	5349	0	1
6805	3483	1467	17	21	5360	0	1
6806	3533	1467	17	21	5355	0	1
6807	3534	1467	17	21	5356	0	1
6808	3535	1467	17	21	5357	0	1
6809	3537	1467	17	21	5359	0	1
6810	3536	1467	17	21	5358	0	1
6793	3553	1464	17	21	5376	0	1
6794	3548	1464	17	21	5415	0	1
6795	3545	1464	17	21	5416	0	1
6796	3555	1464	17	21	5378	0	1
6797	3554	1464	17	21	5377	0	1
6787	3483	1463	17	21	5412	0	1
6788	3561	1463	17	21	5384	0	1
6789	3560	1463	17	21	5383	0	1
6790	3559	1463	17	21	5382	0	1
6791	3537	1463	17	21	5413	0	1
6792	3536	1463	17	21	5414	0	1
6781	3483	1462	17	21	5409	0	1
6782	3563	1462	17	21	5386	0	1
6783	3564	1462	17	21	5387	0	1
6784	3565	1462	17	21	5388	0	1
6785	3527	1462	17	21	5410	0	1
6786	3528	1462	17	21	5411	0	1
6798	3550	1459	17	21	5373	0	1
6799	3549	1459	17	21	5372	0	1
6759	3483	1457	17	21	5506	0	1
6760	3587	1457	17	21	5424	0	1
6761	3588	1457	17	21	5425	0	1
6762	3589	1457	17	21	5426	0	1
6763	3519	1457	17	21	5507	0	1
6764	3516	1457	17	21	5508	0	1
6753	3483	1456	17	21	5503	0	1
6754	3595	1456	17	21	5432	0	1
6755	3594	1456	17	21	5431	0	1
6756	3593	1456	17	21	5430	0	1
6757	3521	1456	17	21	5504	0	1
6758	3522	1456	17	21	5505	0	1
6747	3483	1455	17	21	5500	0	1
6748	3601	1455	17	21	5438	0	1
6749	3600	1455	17	21	5437	0	1
6750	3599	1455	17	21	5436	0	1
6751	3527	1455	17	21	5501	0	1
6752	3528	1455	17	21	5502	0	1
6736	3612	1453	17	21	5449	0	1
6739	3610	1453	17	21	5447	0	1
6740	3611	1453	17	21	5448	0	1
6765	3582	1452	17	21	5419	0	1
6766	3583	1452	17	21	5420	0	1
6718	3627	1449	17	21	5464	0	1
6734	3614	1446	17	21	5451	0	1
6767	3581	1445	17	21	5418	0	1
6768	3580	1445	17	21	5417	0	1
6676	3669	1441	17	21	5534	0	1
5328	3490	1205	20	\N	\N	1	1
6163	3320	1322	17	21	5124	0	1
6164	3319	1322	17	21	5123	0	1
6165	3318	1322	17	21	5122	0	1
6183	3416	1328	17	21	5220	0	1
6184	3417	1328	17	21	5221	0	1
6185	3418	1328	17	21	5222	0	1
6207	3359	1335	17	21	5163	0	1
6208	3360	1335	17	21	5164	0	1
6249	4090	1351	17	21	6097	0	1
6303	3445	1364	17	21	5249	0	1
6823	3483	1470	17	21	5339	0	1
6824	3511	1470	17	21	5330	0	1
6825	3512	1470	17	21	5331	0	1
6826	3514	1470	17	21	5333	0	1
6827	3519	1470	17	21	5338	0	1
6828	3516	1470	17	21	5335	0	1
6800	3541	1466	17	21	5364	0	1
6801	3548	1466	17	21	5371	0	1
6802	3545	1466	17	21	5368	0	1
6803	3539	1466	17	21	5362	0	1
6804	3540	1466	17	21	5363	0	1
6829	3507	1465	17	21	5325	0	1
6830	3490	1465	17	21	5328	0	1
6775	3483	1461	17	21	5406	0	1
6776	3569	1461	17	21	5392	0	1
6777	3570	1461	17	21	5393	0	1
6778	3571	1461	17	21	5394	0	1
6779	3521	1461	17	21	5407	0	1
6780	3522	1461	17	21	5408	0	1
6769	3483	1460	17	21	5403	0	1
6770	3579	1460	17	21	5402	0	1
6771	3578	1460	17	21	5401	0	1
6772	3577	1460	17	21	5400	0	1
6773	3519	1460	17	21	5404	0	1
6774	3516	1460	17	21	5405	0	1
6831	3495	1458	17	21	5313	0	1
6832	3498	1458	17	21	5316	0	1
6741	3483	1454	17	21	5497	0	1
6742	3605	1454	17	21	5442	0	1
6743	3606	1454	17	21	5443	0	1
6744	3607	1454	17	21	5444	0	1
6745	3537	1454	17	21	5498	0	1
6746	3536	1454	17	21	5499	0	1
6644	3521	1435	17	21	5606	0	1
6628	3519	1431	17	21	5720	0	1
6596	3752	1427	17	21	5652	0	1
6568	3483	1422	17	21	5691	0	1
6552	3795	1418	17	21	5730	0	1
6533	3483	1415	17	21	5803	0	1
6525	3826	1412	17	21	5761	0	1
6507	3521	1409	17	21	5791	0	1
6481	3880	1402	17	21	5843	0	1
6327	4068	1374	17	21	6067	0	1
6340	4059	1372	17	21	6058	0	1
6443	3950	1396	17	21	5913	0	1
6399	4000	1387	17	21	5972	0	1
6379	3941	1383	17	21	6005	0	1
6352	3938	1379	17	21	6052	0	1
6358	4036	1376	17	21	6027	0	1
6833	3324	1323	17	21	5128	0	1
6834	3325	1323	17	21	5129	0	1
6910	4206	1512	14	\N	\N	0	1
6915	4141	1515	17	\N	6838	0	1
6840	4143	1475	1	\N	\N	0	1
6838	4141	1475	1	\N	\N	1	1
6839	4142	1475	1	\N	\N	0	1
6911	4207	1512	14	\N	\N	0	1
1814	1597	531	15	\N	\N	1	1
1813	1596	530	14	\N	\N	1	1
1815	1596	532	17	\N	1813	0	1
1816	1597	532	17	\N	1814	0	1
\.


--
-- Name: annotation_groups_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('annotation_groups_id_seq', 8967, true);


--
-- Data for Name: annotation_notes; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY annotation_notes (id, document_id, annotation_group_id, note, addressed, created_at, updated_at, group_id, iteration, de_ref) FROM stdin;
69	93	\N	DE3 Maybe?	t	2015-06-15 20:28:34.308666	2015-06-30 20:51:32.957572	2168	1	2233
70	93	8722	DE3 Maybe?	t	2015-06-15 20:28:34.341798	2015-06-30 20:51:33.527063	\N	1	8868
71	93	8723	DE3 Maybe?	t	2015-06-15 20:28:34.360881	2015-06-30 20:51:34.32734	\N	1	8869
72	93	\N	Keep tryin	t	2015-06-30 21:38:16.674927	2015-06-30 21:47:56.420951	2239	2	2252
73	93	8883	Keep tryin	t	2015-06-30 21:38:16.70401	2015-06-30 21:47:57.019188	\N	2	8906
74	93	\N	bah	t	2015-07-07 17:57:39.129903	2015-07-07 20:37:26.013684	2257	3	2260
75	93	8918	bah	t	2015-07-07 17:57:39.152658	2015-07-07 20:37:26.879297	\N	3	8921
76	93	\N	nah	f	2015-07-07 20:48:28.951373	2015-07-07 20:48:28.951373	2266	4	\N
77	93	8935	nah	f	2015-07-07 20:48:28.984231	2015-07-07 20:48:28.984231	\N	4	\N
\.


--
-- Name: annotation_notes_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('annotation_notes_id_seq', 77, true);


--
-- Data for Name: annotations; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY annotations (id, organization_id, account_id, document_id, page_number, access, title, content, location, created_at, updated_at, moderation_approval, templated, iteration, match_id, match_strength, is_graph_data) FROM stdin;
4206	1	14	46	1	4	ref	er	366,233,394,131	2015-05-06 20:21:14.394448	2015-05-06 20:21:14.394448	\N	f	1	\N	\N	\N
4207	1	14	46	1	4	content	alerts	417,239,436,107	2015-05-06 20:21:14.466938	2015-05-06 20:21:14.466938	\N	f	1	\N	\N	\N
4424	1	14	93	1	4	Man2	ligula	302,461,321,421	2015-06-30 20:29:58.725772	2015-06-30 20:51:28.426267	\N	f	\N	\N	\N	\N
4431	1	14	95	1	4	Journal	Tradewatch.org	852,648,873,516	2016-06-27 18:07:30.675013	2016-06-27 18:07:30.675013	\N	f	1	\N	\N	\N
4433	1	14	95	4	4	Link	Tradewatch.org	804,610,819,473	2016-06-27 18:22:28.795477	2016-06-27 18:22:28.795477	\N	f	1	\N	\N	\N
4434	1	14	95	1	4	Organization	WTO	370,449,387,412	2016-06-27 18:22:28.890307	2016-06-27 18:22:28.890307	\N	f	1	\N	\N	\N
4435	1	14	95	1	4	90's	NAFTA	660,399,677,346	2016-06-27 18:22:28.94739	2016-06-27 18:22:28.94739	\N	f	1	\N	\N	\N
4430	1	14	95	1	4	Title	General Agreement	449,282,467,152	2016-06-27 18:07:30.602118	2016-06-27 19:15:57.355763	\N	f	1	4445	1	\N
4429	1	14	95	1	4	Leader	Stiglitz	139,414,154,364	2016-06-27 18:07:30.539268	2016-06-27 19:15:57.382256	\N	f	1	4444	2	\N
4428	1	14	95	2	4	Number of subjects	2	867,649,887,630	2016-06-27 18:07:30.432248	2016-06-27 19:15:57.4047	\N	t	1	4440	1	\N
4450	1	1	96	\N	1	Adverse Event Name	\N	\N	2016-10-07 18:12:57.250574	2016-10-07 18:12:57.250574	\N	t	1	\N	\N	\N
4451	1	1	96	\N	1	Severity (Mild/Moderate/Severe)	\N	\N	2016-10-07 18:12:57.293744	2016-10-07 18:12:57.293744	\N	t	1	\N	\N	\N
4452	1	1	96	\N	1	Serious/SAE	\N	\N	2016-10-07 18:12:57.323697	2016-10-07 18:12:57.323697	\N	t	1	\N	\N	\N
4453	1	1	96	\N	1	Subject Count	\N	\N	2016-10-07 18:12:57.361511	2016-10-07 18:12:57.361511	\N	t	1	\N	\N	\N
4454	1	1	96	\N	1	Subject Percent	\N	\N	2016-10-07 18:12:57.393238	2016-10-07 18:12:57.393238	\N	t	1	\N	\N	\N
4455	1	1	96	\N	1	Event Count	\N	\N	2016-10-07 18:12:57.426417	2016-10-07 18:12:57.426417	\N	t	1	\N	\N	\N
4456	1	1	96	\N	1	Description	\N	\N	2016-10-07 18:12:57.456768	2016-10-07 18:12:57.456768	\N	t	1	\N	\N	\N
4457	1	1	96	\N	1	Related	\N	\N	2016-10-07 18:12:57.488108	2016-10-07 18:12:57.488108	\N	t	1	\N	\N	\N
4391	1	14	93	1	4	Manual	Dincidunt	477,606,498,545	2015-06-09 18:05:21.421151	2015-06-19 19:56:49.721365	\N	f	1	\N	\N	\N
4390	1	14	93	1	4	Clone1	Bibendum	219,330,240,264	2015-06-09 18:04:38.590246	2015-06-30 20:30:17.071546	\N	f	1	\N	\N	\N
4446	1	15	95	1	4	America	Congress	781,165,805,105	2016-06-27 18:41:45.234657	2016-06-27 18:41:45.234657	\N	f	1	\N	\N	\N
4448	1	15	95	3	4	Organization	WTO	246,509,268,469	2016-06-27 18:53:24.486153	2016-06-27 18:53:24.486153	\N	f	1	\N	\N	\N
4449	1	15	95	3	4	90's	NAFTA	243,563,269,511	2016-06-27 18:53:24.68046	2016-06-27 18:53:24.68046	\N	f	1	\N	\N	\N
4445	1	15	95	1	4	Paper	General Agreement	446,282,466,148	2016-06-27 18:41:45.17531	2016-06-27 19:15:57.342865	\N	f	1	4430	1	\N
4444	1	15	95	1	4	Leader	Stiglitz	136,412,155,359	2016-06-27 18:41:45.108939	2016-06-27 19:15:57.369702	\N	f	1	4429	2	\N
4440	1	15	95	2	4	Subject Percent	2	866,651,894,626	2016-06-27 18:41:44.899353	2016-06-27 19:15:57.39325	\N	t	1	4428	1	\N
4389	1	1	93	1	4	Number of subjects	Lorem	118,132,135,81	2015-06-09 18:03:34.064991	2015-06-09 18:04:38.574118	\N	t	1	\N	\N	\N
4392	1	1	93	1	4	Clone2	PDF	81,208,99,178	2015-06-09 18:05:21.478431	2015-06-09 18:05:21.478431	\N	f	1	\N	\N	\N
4394	1	14	93	1	4	Number of subjects	adipiscing	378,156,393,86	2015-06-09 18:07:01.703042	2015-06-09 18:07:29.75798	\N	t	1	\N	\N	\N
4395	1	14	93	1	4	Manual1	Dipibus	240,413,257,354	2015-06-09 18:08:20.943327	2015-06-09 18:08:20.943327	\N	f	1	\N	\N	\N
4396	1	14	93	1	4	Clone2	fringilla	632,405,652,352	2015-06-09 18:08:21.023955	2015-06-09 18:08:21.023955	\N	f	1	\N	\N	\N
4397	1	14	93	1	4	Man2	Quisque	187,501,205,445	2015-06-09 18:08:47.799124	2015-06-09 18:08:47.799124	\N	f	1	\N	\N	\N
4393	1	14	93	1	4	Manual	Curabitur	133,501,153,439	2015-06-09 18:06:35.921257	2015-06-16 21:50:29.549492	\N	f	1	\N	\N	\N
916	1	7	48	1	4	Volume	41	48,592,59,581	2014-10-24 04:31:48.068852	2014-10-24 04:34:34.087436	\N	t	1	\N	\N	\N
1809	1	14	48	3	4	Count	3	523,413,536,387	2015-01-16 01:55:46.550394	2015-01-16 01:56:25.507025	\N	t	1	\N	\N	\N
2245	1	14	48	5	4	Intra-subject CV%	34.3	169,601,177,581	2015-01-18 14:47:19.384206	2015-01-18 14:49:08.134485	\N	f	1	\N	\N	\N
4115	1	20	47	6	4	Adverse Event Name	dizziness	391,592,400,547	2015-01-25 22:13:14.451398	2015-01-25 22:13:38.2384	\N	f	1	\N	\N	\N
922	1	7	48	1	4	Purpose	drug-drug interaction	789,478,800,380	2014-10-24 04:35:50.146164	2014-10-24 04:35:50.146164	\N	f	1	\N	\N	\N
734	1	7	42	2	4	Contractions	fewer than 6 per hour	205,274,217,91	2014-10-22 03:07:55.160075	2014-10-24 01:55:47.9038	\N	f	1	\N	\N	\N
722	1	7	42	1	4	PMID (PubMed Identifier)	11275035	91,42,100,23	2014-10-22 02:57:43.979114	2014-10-22 03:03:26.739663	\N	t	1	\N	\N	\N
727	1	7	42	1	4	Title	A Randomized Comparison of Transcervical Foley Catheter to Intravaginal Misoprostol for Preinduction Cervical Ripening	116,606,209,65	2014-10-22 02:57:44.169907	2014-10-22 03:03:26.775955	\N	t	1	\N	\N	\N
738	1	7	42	2	4	Bishop Score	less than 6	273,344,288,215	2014-10-22 03:07:55.403085	2014-10-24 01:55:47.882462	\N	f	1	\N	\N	\N
724	1	7	42	1	4	Volume	97	843,110,854,95	2014-10-22 02:57:44.077256	2014-10-22 03:03:26.790232	\N	t	1	\N	\N	\N
730	1	7	42	1	4	Authors	Anthony C. Sciscione, DO, Lisa Nguyen, MD, James Manley, MD, Marjorie Pollock, MSN, CRNP, Bridget Maas, BSN, RNC, Garrett Colmorgen, MD	227,565,288,64	2014-10-22 03:03:26.805707	2014-10-22 03:03:26.805707	\N	f	1	\N	\N	\N
731	1	7	42	1	4	End Date	July 1, 1999	783,560,793,497	2014-10-22 03:05:19.528879	2014-10-22 03:05:19.528879	\N	f	1	\N	\N	\N
732	1	7	42	1	4	Start Date	July 1, 1997	781,484,794,421	2014-10-22 03:05:19.621851	2014-10-22 03:05:19.621851	\N	f	1	\N	\N	\N
733	1	7	42	2	4	Purpose	labor induction	95,192,107,113	2014-10-22 03:05:19.694654	2014-10-22 03:05:19.694654	\N	f	1	\N	\N	\N
735	1	7	42	2	4	Gestation	&gt;28 weeks	162,341,176,227	2014-10-22 03:07:55.248395	2014-10-22 03:07:55.248395	\N	f	1	\N	\N	\N
736	1	7	42	2	4	Plurality	singleton	151,319,163,269	2014-10-22 03:07:55.297272	2014-10-22 03:07:55.297272	\N	f	1	\N	\N	\N
737	1	7	42	2	4	Presentation	vertex	165,220,176,119	2014-10-22 03:07:55.338236	2014-10-22 03:07:55.338236	\N	f	1	\N	\N	\N
739	1	7	42	2	4	Fetus	death	330,126,341,70	2014-10-22 03:12:25.176157	2014-10-22 03:12:25.176157	\N	f	1	\N	\N	\N
740	1	7	42	2	4	General	antepartum bleeding	316,180,328,69	2014-10-22 03:12:25.226463	2014-10-22 03:12:25.226463	\N	f	1	\N	\N	\N
741	1	7	42	2	4	Infection	active genital herpes	316,340,327,181	2014-10-22 03:12:25.298739	2014-10-22 03:12:25.298739	\N	f	1	\N	\N	\N
766	1	7	42	3	4	Number Randomized	58	525,169,536,151	2014-10-22 04:03:58.72034	2014-10-22 04:03:58.72034	\N	f	1	\N	\N	\N
742	1	7	42	2	4	Membranes	rupture	304,344,313,221	2014-10-22 03:12:25.46916	2014-10-22 03:12:25.46916	\N	f	1	\N	\N	\N
743	1	7	42	2	4	Placenta	placenta previa	330,207,341,128	2014-10-22 03:12:25.535877	2014-10-22 03:12:25.535877	\N	f	1	\N	\N	\N
744	1	7	42	2	4	Prior Treatment	induction or induction agent	331,342,341,209	2014-10-22 03:12:25.575071	2014-10-22 03:12:25.575071	\N	f	1	\N	\N	\N
745	1	7	42	2	4	Allergy	misoprostol	356,182,368,69	2014-10-22 03:12:25.615297	2014-10-22 03:12:25.615297	\N	f	1	\N	\N	\N
746	1	7	42	2	4	Randomization	randomized	385,342,397,236	2014-10-22 03:14:29.131593	2014-10-22 03:14:29.131593	\N	f	1	\N	\N	\N
747	1	7	42	2	4	Amount	30	699,118,712,103	2014-10-22 03:23:50.023918	2014-10-22 03:23:50.023918	\N	f	1	\N	\N	\N
725	1	7	42	1	4	Issue	4	844,143,854,128	2014-10-22 02:57:44.095679	2014-10-22 02:59:29.504401	\N	t	1	\N	\N	\N
723	1	7	42	2	4	Journal	Obstetrics &amp; Gynecology	841,637,859,525	2014-10-22 02:57:44.033673	2014-10-22 02:59:29.519307	\N	t	1	\N	\N	\N
748	1	7	42	2	4	Amount Units	mL	700,138,712,118	2014-10-22 03:23:50.070872	2014-10-22 03:23:50.070872	\N	f	1	\N	\N	\N
726	1	7	42	1	4	Pages	603-7	843,636,854,610	2014-10-22 02:57:44.149401	2014-10-22 02:59:29.572881	\N	t	1	\N	\N	\N
749	1	7	42	2	4	Device	16F Foley catheter	685,344,698,248	2014-10-22 03:23:50.114352	2014-10-22 03:23:50.114352	\N	f	1	\N	\N	\N
719	1	7	42	1	4	Publication Date	April 2001	842,197,854,141	2014-10-22 02:57:43.883704	2014-10-22 02:59:29.607788	\N	t	1	\N	\N	\N
750	1	7	42	2	4	Frequency	6 hours	110,638,150,356	2014-10-22 03:23:50.177348	2014-10-22 03:23:50.177348	\N	f	1	\N	\N	\N
751	1	7	42	2	4	Traction	taping the end of the catheter to the medial side of the woman's knee or thigh	69,636,108,358	2014-10-22 03:23:50.219283	2014-10-22 03:23:50.219283	\N	f	1	\N	\N	\N
752	1	7	42	2	4	Maximum duration	none	234,637,257,357	2014-10-22 03:23:50.284879	2014-10-22 03:23:50.284879	\N	f	1	\N	\N	\N
753	1	7	42	2	4	Name	change in Bishop score	519,503,533,382	2014-10-22 03:32:48.267366	2014-10-22 03:32:48.267366	\N	f	1	\N	\N	\N
754	1	7	42	2	4	Name	length of time for preinduction cervical ripening	701,637,724,358	2014-10-22 03:50:03.407303	2014-10-22 03:50:03.407303	\N	f	1	\N	\N	\N
944	1	7	48	2	4	Disease state	healthy	211,149,220,115	2014-10-25 03:07:59.177149	2014-10-25 03:07:59.177149	\N	f	1	\N	\N	\N
4114	1	20	47	6	4	Event Count	2	388,621,400,607	2015-01-25 22:13:14.43192	2015-01-25 22:13:38.25436	\N	t	1	\N	\N	\N
4117	1	20	47	6	4	Adverse Event Name	abnormal dreams	405,446,416,362	2015-01-25 22:13:47.229178	2015-01-25 22:14:24.062653	\N	f	1	\N	\N	\N
4118	1	20	47	6	4	Event Count	2	403,475,416,463	2015-01-25 22:13:47.247822	2015-01-25 22:14:24.080507	\N	t	1	\N	\N	\N
4125	1	20	47	6	4	Description	unrelated to study treatment	449,538,460,491	2015-01-25 22:14:38.786126	2015-01-25 22:16:11.677832	\N	t	1	\N	\N	\N
755	1	7	42	2	4	Description	time from placement of preinduction method until extrusion of Foley catheter, or 1 hour after the last dose of misoprostol	717,640,752,358	2014-10-22 03:50:03.460477	2014-10-22 03:50:03.460477	\N	f	1	\N	\N	\N
757	1	7	42	2	4	Description	time of placement of ripening agent until delivery	753,637,769,451	2014-10-22 03:50:07.919666	2014-10-22 03:56:41.677324	\N	f	1	\N	\N	\N
756	1	7	42	2	4	Name	total time for induction	755,453,766,360	2014-10-22 03:50:07.897952	2014-10-22 03:56:41.731866	\N	f	1	\N	\N	\N
759	1	7	42	2	4	Name	delivery route	768,508,779,434	2014-10-22 03:56:45.132576	2014-10-22 03:57:11.513538	\N	f	1	\N	\N	\N
761	1	7	42	2	4	Description	6 contractions in 10 minutes in 2 consecutive 10-minute periods	781,632,808,360	2014-10-22 03:57:26.599892	2014-10-22 03:58:35.406992	\N	f	1	\N	\N	\N
760	1	7	42	2	4	Name	uterine tachysystole	768,609,779,511	2014-10-22 03:57:26.554611	2014-10-22 03:58:35.555996	\N	f	1	\N	\N	\N
762	1	7	42	2	4	Name	side effects	794,550,812,485	2014-10-22 03:59:06.423833	2014-10-22 03:59:43.243667	\N	f	1	\N	\N	\N
763	1	7	42	2	4	Name	subject comfort	794,631,812,546	2014-10-22 03:59:10.453597	2014-10-22 04:00:06.54279	\N	f	1	\N	\N	\N
764	1	7	42	3	4	Name	FHR disturbances	250,186,263,93	2014-10-22 04:00:10.278198	2014-10-22 04:00:46.0223	\N	f	1	\N	\N	\N
765	1	7	42	3	4	Description	0 (no discomfort) to 10 (most pain ever felt) scale on first postpartum day	307,344,344,69	2014-10-22 04:02:34.569174	2014-10-22 04:02:34.569174	\N	f	1	\N	\N	\N
770	1	7	42	3	4	Count	0	338,632,350,614	2014-10-22 04:06:34.581672	2014-10-22 04:07:21.950536	\N	t	1	\N	\N	\N
769	1	7	42	3	4	Measurement Name	spontaneous labor	353,515,361,420	2014-10-22 04:06:34.563803	2014-10-22 04:07:21.966361	\N	t	1	\N	\N	\N
773	1	7	42	3	4	Measurement Name	epidural analgesia	476,535,487,440	2014-10-22 04:08:00.148918	2014-10-22 04:08:54.711305	\N	t	1	\N	\N	\N
772	1	7	42	3	4	Percent	84	461,382,472,358	2014-10-22 04:08:00.106449	2014-10-22 04:08:54.73009	\N	t	1	\N	\N	\N
781	1	7	42	3	4	Measurement Name	Change in Bishop score	114,458,124,358	2014-10-22 04:09:35.569278	2014-10-22 04:10:18.582389	\N	t	1	\N	\N	\N
776	1	7	42	3	4	Median	3.0	115,490,124,473	2014-10-22 04:09:35.471505	2014-10-22 04:10:18.599332	\N	t	1	\N	\N	\N
784	1	7	42	3	4	Arithmetic Mean	8.1	138,490,146,474	2014-10-22 04:10:38.652244	2014-10-22 04:11:29.331735	\N	t	1	\N	\N	\N
786	1	7	42	3	4	Measurement Name	Preinduction cervical ripening time	138,446,157,358	2014-10-22 04:10:38.688436	2014-10-22 04:11:29.349596	\N	t	1	\N	\N	\N
787	1	7	42	3	4	Measurement Unit	h	148,439,160,422	2014-10-22 04:10:38.706631	2014-10-22 04:11:29.365291	\N	t	1	\N	\N	\N
785	1	7	42	3	4	Standard Deviation	6.6	137,514,148,495	2014-10-22 04:10:38.670592	2014-10-22 04:11:29.381113	\N	t	1	\N	\N	\N
789	1	7	42	3	4	Arithmetic Mean	19.1	172,490,179,469	2014-10-22 04:11:41.419756	2014-10-22 04:14:32.840986	\N	t	1	\N	\N	\N
791	1	7	42	3	4	Measurement Name	Total time for induction	172,456,181,359	2014-10-22 04:11:41.489642	2014-10-22 04:14:32.888719	\N	t	1	\N	\N	\N
790	1	7	42	3	4	Standard Deviation	10.1	172,516,180,496	2014-10-22 04:11:41.439684	2014-10-22 04:15:30.521795	\N	t	1	\N	\N	\N
792	1	7	42	3	4	Measurement Unit	h	182,381,196,369	2014-10-22 04:11:41.508448	2014-10-22 04:15:30.334553	\N	t	1	\N	\N	\N
798	1	7	42	3	4	Arithmetic Mean	2.16	745,194,758,170	2014-10-23 10:49:46.581832	2014-10-23 10:53:28.31317	\N	t	1	\N	\N	\N
794	1	7	42	3	4	Arithmetic Mean	25.1	723,188,733,168	2014-10-23 10:48:48.027679	2014-10-23 10:49:41.770699	\N	t	1	\N	\N	\N
796	1	7	42	3	4	Measurement Name	Maternal age	722,126,733,68	2014-10-23 10:48:48.067147	2014-10-23 10:49:41.786892	\N	t	1	\N	\N	\N
797	1	7	42	3	4	Measurement Unit	y	723,139,735,124	2014-10-23 10:48:48.08598	2014-10-23 10:49:41.802132	\N	t	1	\N	\N	\N
795	1	7	42	3	4	Standard Deviation	6.9	723,211,731,193	2014-10-23 10:48:48.044984	2014-10-23 10:49:41.8164	\N	t	1	\N	\N	\N
801	1	7	42	3	4	Standard Deviation	1.2	747,216,755,199	2014-10-23 10:49:46.68774	2014-10-23 10:53:28.339617	\N	t	1	\N	\N	\N
838	1	7	42	4	4	Count	0	686,172,696,151	2014-10-23 11:20:41.862409	2014-10-23 11:21:56.270376	\N	t	1	\N	\N	\N
799	1	7	42	3	4	Measurement Name	Gravidity	746,113,755,70	2014-10-23 10:49:46.64918	2014-10-23 10:52:19.729676	\N	t	1	\N	\N	\N
837	1	7	42	4	4	Measurement Name	hyperstimulation	686,301,697,210	2014-10-23 11:20:41.844221	2014-10-23 11:21:56.287822	\N	t	1	\N	\N	\N
804	1	7	42	3	4	Measurement Name	Nulliparous	769,124,779,71	2014-10-23 10:54:04.25375	2014-10-23 10:54:37.013769	\N	t	1	\N	\N	\N
803	1	7	42	3	4	Percent	70.6	769,191,779,167	2014-10-23 10:54:04.234595	2014-10-23 10:54:37.030496	\N	t	1	\N	\N	\N
812	1	7	42	3	4	Measurement Name	Baseline Bishop score	781,137,800,71	2014-10-23 10:54:56.084019	2014-10-23 10:55:50.944015	\N	t	1	\N	\N	\N
807	1	7	42	3	4	Median	3.0	781,188,790,172	2014-10-23 10:54:55.88553	2014-10-23 10:55:50.959239	\N	t	1	\N	\N	\N
815	1	7	42	3	4	Arithmetic Mean	2979.5	701,485,708,455	2014-10-23 10:56:28.354571	2014-10-23 10:57:26.305018	\N	t	1	\N	\N	\N
817	1	7	42	3	4	Measurement Name	Infant weight	700,418,709,358	2014-10-23 10:56:28.391972	2014-10-23 10:57:26.321689	\N	t	1	\N	\N	\N
818	1	7	42	3	4	Measurement Unit	g	701,429,710,415	2014-10-23 10:56:28.413559	2014-10-23 10:57:26.338118	\N	t	1	\N	\N	\N
816	1	7	42	3	4	Standard Deviation	619.9	701,517,708,490	2014-10-23 10:56:28.372637	2014-10-23 10:57:26.353009	\N	t	1	\N	\N	\N
929	1	4	42	3	4	Measurement Name	Change in Bishop score	115,458,124,355	2014-10-24 19:59:09.713032	2014-10-24 20:00:56.126997	\N	t	1	\N	\N	\N
924	1	4	42	3	4	Median	3.0	115,492,122,470	2014-10-24 19:59:09.543783	2014-10-24 20:00:56.151959	\N	t	1	\N	\N	\N
821	1	7	42	3	4	Measurement Name	Cesarean delivery	712,433,721,359	2014-10-23 10:58:01.563553	2014-10-23 10:58:39.933463	\N	t	1	\N	\N	\N
820	1	7	42	3	4	Percent	31.8	711,485,720,464	2014-10-23 10:58:01.543089	2014-10-23 10:58:39.950917	\N	t	1	\N	\N	\N
823	1	7	42	3	4	Measurement Name	Contractile abnormalities	724,426,743,359	2014-10-23 10:58:49.369062	2014-10-23 11:16:29.006568	\N	t	1	\N	\N	\N
824	1	7	42	3	4	Percent	0	724,478,732,467	2014-10-23 10:58:49.413327	2014-10-23 11:16:29.02444	\N	t	1	\N	\N	\N
825	1	7	42	3	4	Measurement Name	Meconium	745,406,756,358	2014-10-23 10:58:52.04715	2014-10-23 11:16:51.210206	\N	t	1	\N	\N	\N
826	1	7	42	3	4	Percent	5.2	746,485,755,467	2014-10-23 10:58:52.065485	2014-10-23 11:16:51.225989	\N	t	1	\N	\N	\N
827	1	7	42	3	4	Measurement Name	Delivery within 24 hours	757,438,778,359	2014-10-23 10:59:02.356647	2014-10-23 11:17:18.606626	\N	t	1	\N	\N	\N
828	1	7	42	3	4	Percent	54.5	758,485,767,464	2014-10-23 10:59:02.376537	2014-10-23 11:17:18.622589	\N	t	1	\N	\N	\N
829	1	7	42	3	4	Measurement Name	Vaginal delivery within 24 hours	780,457,800,358	2014-10-23 10:59:04.214416	2014-10-23 11:18:17.794436	\N	t	1	\N	\N	\N
830	1	7	42	3	4	Percent	73	781,479,790,463	2014-10-23 10:59:04.234031	2014-10-23 11:18:17.810008	\N	t	1	\N	\N	\N
923	1	4	42	3	4	Number of Subjects Included in Measurement	58	97,510,107,494	2014-10-24 19:59:09.483559	2014-10-24 20:00:56.167457	\N	t	1	\N	\N	\N
833	1	7	42	4	4	Measurement Name	Cesarean delivery for noreassuring fetal testing	84,206,94,68	2014-10-23 11:18:47.736027	2014-10-23 11:20:03.141426	\N	t	1	\N	\N	\N
832	1	7	42	4	4	Percent	12	111,117,121,99	2014-10-23 11:18:47.718145	2014-10-23 11:20:03.16008	\N	t	1	\N	\N	\N
932	1	4	42	3	4	Median	2.0	113,567,124,546	2014-10-24 20:01:20.373456	2014-10-24 20:02:40.16254	\N	t	1	\N	\N	\N
840	1	7	42	4	4	Measurement Name	FHR abnormalities	700,288,713,191	2014-10-23 21:02:07.529569	2014-10-23 21:05:11.532415	\N	t	1	\N	\N	\N
933	1	4	42	3	4	Number of Subjects Included in Measurement	53	97,583,107,568	2014-10-24 20:01:20.392725	2014-10-24 20:02:40.178158	\N	t	1	\N	\N	\N
942	1	7	48	2	4	Minimum	18	209,321,220,309	2014-10-25 03:05:30.864809	2014-10-25 03:05:30.864809	\N	f	1	\N	\N	\N
943	1	7	48	2	4	Maximum	55	209,350,219,335	2014-10-25 03:06:40.240121	2014-10-25 03:06:40.240121	\N	f	1	\N	\N	\N
945	1	7	48	2	4	Sex	male and female	211,214,220,146	2014-10-25 03:07:59.23722	2014-10-25 03:07:59.23722	\N	f	1	\N	\N	\N
876	1	7	42	3	4	Arithmetic Mean	25.9	723,272,732,249	2014-10-23 21:05:22.129665	2014-10-23 21:05:55.677101	\N	t	1	\N	\N	\N
879	1	7	42	3	4	Standard Deviation	6.9	722,294,734,277	2014-10-23 21:05:22.18296	2014-10-23 21:06:19.635877	\N	t	1	\N	\N	\N
880	1	7	42	3	4	Arithmetic Mean	2.1	745,271,756,254	2014-10-23 21:05:22.214556	2014-10-23 21:06:46.786758	\N	t	1	\N	\N	\N
841	1	7	42	3	4	Number Randomized	53	539,107,551,91	2014-10-23 21:05:21.212367	2014-10-23 21:09:55.384209	\N	f	1	\N	\N	\N
842	1	7	42	3	4	Count	21	298,455,310,392	2014-10-23 21:05:21.327573	2014-10-23 21:12:21.776239	\N	t	1	\N	\N	\N
845	1	7	42	3	4	Percent	93	461,525,473,509	2014-10-23 21:05:21.395327	2014-10-23 21:12:39.082981	\N	t	1	\N	\N	\N
847	1	7	42	3	4	Median	2.0	113,568,124,548	2014-10-23 21:05:21.444199	2014-10-23 21:13:08.001887	\N	t	1	\N	\N	\N
848	1	7	42	3	4	Arithmetic Mean	9.0	137,567,148,548	2014-10-23 21:05:21.473695	2014-10-23 21:13:44.661509	\N	t	1	\N	\N	\N
851	1	7	42	3	4	Standard Deviation	4.9	137,590,148,572	2014-10-23 21:05:21.525843	2014-10-23 21:13:44.710752	\N	t	1	\N	\N	\N
852	1	7	42	3	4	Arithmetic Mean	16.3	171,565,182,545	2014-10-23 21:05:21.555404	2014-10-23 21:14:15.857269	\N	t	1	\N	\N	\N
854	1	7	42	3	4	Standard Deviation	7.2	172,589,180,571	2014-10-23 21:05:21.590505	2014-10-23 21:14:15.90298	\N	t	1	\N	\N	\N
856	1	7	42	3	4	Arithmetic Mean	2969.8	700,560,709,529	2014-10-23 21:05:21.637704	2014-10-23 21:14:59.613365	\N	t	1	\N	\N	\N
859	1	7	42	3	4	Standard Deviation	743.7	700,589,709,564	2014-10-23 21:05:21.692914	2014-10-23 21:14:59.662201	\N	t	1	\N	\N	\N
861	1	7	42	3	4	Percent	37.8	712,559,721,538	2014-10-23 21:05:21.741839	2014-10-23 21:15:20.32385	\N	t	1	\N	\N	\N
863	1	7	42	3	4	Percent	20.4	724,559,732,538	2014-10-23 21:05:21.790723	2014-10-23 21:15:42.580626	\N	t	1	\N	\N	\N
865	1	7	42	3	4	Percent	21.5	746,559,755,536	2014-10-23 21:05:21.836035	2014-10-23 21:16:28.653587	\N	t	1	\N	\N	\N
867	1	7	42	3	4	Percent	67.9	758,557,767,538	2014-10-23 21:05:21.883989	2014-10-23 21:16:54.468479	\N	t	1	\N	\N	\N
869	1	7	42	3	4	Percent	84	780,551,788,538	2014-10-23 21:05:21.931871	2014-10-23 21:17:22.606113	\N	t	1	\N	\N	\N
871	1	7	42	4	4	Percent	24	110,173,121,159	2014-10-23 21:05:21.990305	2014-10-23 21:17:46.136736	\N	t	1	\N	\N	\N
872	1	7	42	4	4	Count	2	218,242,232,214	2014-10-23 21:05:22.01947	2014-10-23 21:36:12.689633	\N	t	1	\N	\N	\N
873	1	7	42	4	4	Measurement Name	hyperstimulation	261,134,272,68	2014-10-23 21:05:22.036788	2014-10-23 21:36:12.706279	\N	t	1	\N	\N	\N
875	1	7	42	4	4	Measurement Name	FHR abnormalities	230,307,245,239	2014-10-23 21:05:22.08666	2014-10-23 21:36:58.431289	\N	t	1	\N	\N	\N
1525	1	7	48	5	4	Confidence Interval Upper Bound	0.961	116,566,124,542	2014-11-02 01:24:12.921802	2014-11-02 01:39:03.763303	\N	t	1	\N	\N	\N
881	1	7	42	3	4	Standard Deviation	1.3	747,293,756,278	2014-10-23 21:05:22.231859	2014-10-23 21:06:46.819983	\N	t	1	\N	\N	\N
884	1	7	42	3	4	Percent	71.7	768,272,779,249	2014-10-23 21:05:22.294653	2014-10-23 21:07:05.38988	\N	t	1	\N	\N	\N
886	1	7	42	3	4	Median	2.0	780,274,790,254	2014-10-23 21:05:22.341503	2014-10-23 21:07:25.546242	\N	t	1	\N	\N	\N
887	1	7	42	2	4	Amount	50	287,571,301,554	2014-10-23 21:05:22.371624	2014-10-23 21:09:16.587974	\N	f	1	\N	\N	\N
888	1	7	42	2	4	Amount Units	ug	289,589,301,569	2014-10-23 21:05:22.389452	2014-10-23 21:09:16.604705	\N	f	1	\N	\N	\N
890	1	7	42	2	4	Frequency	every 4 hours	356,636,369,587	2014-10-23 21:05:22.425298	2014-10-23 21:09:16.620572	\N	f	1	\N	\N	\N
892	1	7	42	2	4	Maximum duration	6 doses	370,546,382,492	2014-10-23 21:05:22.461693	2014-10-23 21:09:16.63633	\N	f	1	\N	\N	\N
893	1	7	42	2	4	Drug Name	misoprostol	290,534,298,471	2014-10-23 21:09:16.652571	2014-10-23 21:09:16.652571	\N	f	1	\N	\N	\N
895	1	7	42	3	4	Arithmetic Mean	2	284,370,295,358	2014-10-23 21:10:35.617583	2014-10-23 21:11:45.785806	\N	t	1	\N	\N	\N
898	1	7	42	3	4	Measurement Unit	doses	284,428,295,395	2014-10-23 21:10:35.67285	2014-10-23 21:11:45.802499	\N	t	1	\N	\N	\N
896	1	7	42	3	4	Standard Deviation	1.2	284,395,294,379	2014-10-23 21:10:35.636423	2014-10-23 21:11:45.817982	\N	t	1	\N	\N	\N
900	1	7	42	3	4	Median	5.0	420,532,431,511	2014-10-23 21:37:50.291219	2014-10-23 21:39:01.455318	\N	t	1	\N	\N	\N
902	1	7	42	3	4	Measurement Name	discomfort	392,586,404,527	2014-10-23 21:37:50.364432	2014-10-23 21:39:01.474274	\N	t	1	\N	\N	\N
946	1	7	48	2	4	Race	caucasian	211,257,220,211	2014-10-25 03:07:59.309675	2014-10-25 03:07:59.309675	\N	f	1	\N	\N	\N
947	1	7	48	2	4	Blinding	double-blind	221,258,232,206	2014-10-25 03:11:29.705825	2014-10-25 03:11:29.705825	\N	f	1	\N	\N	\N
948	1	7	48	2	4	Control	placebo	220,346,235,312	2014-10-25 03:11:29.797026	2014-10-25 03:11:29.797026	\N	f	1	\N	\N	\N
949	1	7	48	2	4	Design	crossover	233,173,245,133	2014-10-25 03:11:29.988785	2014-10-25 03:11:29.988785	\N	f	1	\N	\N	\N
905	1	7	42	3	4	Arithmetic Mean	4.0	434,520,443,500	2014-10-23 21:39:16.670136	2014-10-23 21:39:55.748369	\N	t	1	\N	\N	\N
950	1	7	48	2	4	Number of Sites	1	223,205,231,149	2014-10-25 03:11:30.036886	2014-10-25 03:11:30.036886	\N	f	1	\N	\N	\N
951	1	7	48	2	4	Randomization	randomized	221,311,233,261	2014-10-25 03:11:30.118623	2014-10-25 03:11:30.118623	\N	f	1	\N	\N	\N
952	1	7	48	2	4	Number of Periods	2	232,107,246,88	2014-10-25 03:11:30.166935	2014-10-25 03:11:30.166935	\N	f	1	\N	\N	\N
913	1	7	48	1	4	DOI (Digital Object Identifier)	10.1124/dmd.112.050203	39,665,50,573	2014-10-24 04:31:47.991223	2014-10-24 04:34:34.008705	\N	t	1	\N	\N	\N
915	1	7	48	1	4	Journal	Drug Metabolism and Disposition	49,160,59,44	2014-10-24 04:31:48.048854	2014-10-24 04:34:34.025518	\N	t	1	\N	\N	\N
918	1	7	48	1	4	Pages	987-993	47,624,60,593	2014-10-24 04:31:48.106425	2014-10-24 04:34:34.042015	\N	t	1	\N	\N	\N
911	1	7	48	1	4	Publication Date	May 2013	49,668,61,623	2014-10-24 04:31:47.954319	2014-10-24 04:34:34.058562	\N	t	1	\N	\N	\N
919	1	7	48	1	4	Title	Drug Cocktail Interaction Study on the Effect of the Orally Administered Lavender Oil Preparation Silexan on Cytochrome P450 Enzymes in Healthy Volunteers	79,643,154,58	2014-10-24 04:31:48.125043	2014-10-24 04:34:34.073102	\N	t	1	\N	\N	\N
958	1	7	48	2	4	Drug Amount	160	247,142,254,124	2014-10-25 03:14:51.973486	2014-10-25 03:29:37.781306	\N	t	1	\N	\N	\N
959	1	7	48	2	4	Drug Amount Unit	mg	247,157,255,138	2014-10-25 03:14:51.990998	2014-10-25 03:29:37.797728	\N	t	1	\N	\N	\N
957	1	7	48	2	4	Drug Name	silexan	247,186,255,154	2014-10-25 03:14:51.955901	2014-10-25 03:29:37.814524	\N	t	1	\N	\N	\N
955	1	7	48	2	4	End Time	11	258,178,268,164	2014-10-25 03:14:51.921723	2014-10-25 03:29:37.828483	\N	t	1	\N	\N	\N
960	1	7	48	2	4	Frequency	once daily	259,119,267,69	2014-10-25 03:14:52.007933	2014-10-25 03:29:37.846269	\N	t	1	\N	\N	\N
953	1	7	48	2	4	Start Time	1	258,165,267,153	2014-10-25 03:14:51.882416	2014-10-25 03:29:37.868245	\N	t	1	\N	\N	\N
954	1	7	48	2	4	Time Unit	day	257,153,268,132	2014-10-25 03:14:51.904263	2014-10-25 03:29:37.883846	\N	t	1	\N	\N	\N
961	1	7	48	2	4	Drug Description	Essential oil produced from L. angustifolia flowers by steam distillation.  20-45% linalool and 25-46% libnalyl acetate	269,350,327,43	2014-10-25 03:29:37.909091	2014-10-25 03:29:37.909091	\N	f	1	\N	\N	\N
977	1	7	48	2	4	Frequency	single dose	353,209,362,143	2014-10-25 03:31:35.967052	2014-10-25 03:35:09.149827	\N	t	1	\N	\N	\N
970	1	7	48	2	4	Start Time	11	352,251,363,236	2014-10-25 03:31:35.824082	2014-10-25 03:35:09.200687	\N	t	1	\N	\N	\N
971	1	7	48	2	4	Time Unit	day	354,237,362,219	2014-10-25 03:31:35.8435	2014-10-25 03:35:09.220061	\N	t	1	\N	\N	\N
983	1	7	48	2	4	Drug Amount	150	389,223,399,203	2014-10-25 03:35:28.38475	2014-10-25 03:36:33.66449	\N	t	1	\N	\N	\N
984	1	7	48	2	4	Drug Amount Unit	mg	389,240,399,222	2014-10-25 03:35:28.404652	2014-10-25 03:36:33.681177	\N	t	1	\N	\N	\N
982	1	7	48	2	4	Drug Name	caffeine	389,277,399,239	2014-10-25 03:35:28.367556	2014-10-25 03:36:33.697771	\N	t	1	\N	\N	\N
986	1	7	48	2	4	Drug Formulation	tablet	389,338,400,305	2014-10-25 03:36:33.712817	2014-10-25 03:36:33.712817	\N	f	1	\N	\N	\N
987	1	7	48	2	4	Drug Amount	125	398,263,412,246	2014-10-25 03:36:35.88727	2014-10-25 03:37:29.893949	\N	t	1	\N	\N	\N
988	1	7	48	2	4	Drug Amount Unit	mg	403,280,411,263	2014-10-25 03:36:35.90723	2014-10-25 03:37:29.909637	\N	t	1	\N	\N	\N
990	1	7	48	2	4	Drug Formulation	quarter tablet	413,115,421,42	2014-10-25 03:36:35.943752	2014-10-25 03:37:29.923883	\N	f	1	\N	\N	\N
989	1	7	48	2	4	Drug Name	tolbutamide	401,329,410,278	2014-10-25 03:36:35.925844	2014-10-25 03:37:29.938007	\N	t	1	\N	\N	\N
991	1	7	48	2	4	Drug Amount	20	413,290,422,277	2014-10-25 03:37:31.773171	2014-10-25 03:41:41.149984	\N	t	1	\N	\N	\N
992	1	7	48	2	4	Drug Amount Unit	mg	413,305,422,287	2014-10-25 03:37:31.895378	2014-10-25 03:41:41.16885	\N	t	1	\N	\N	\N
993	1	7	48	2	4	Drug Formulation	tablet	424,92,434,65	2014-10-25 03:37:31.91396	2014-10-25 03:41:41.183986	\N	f	1	\N	\N	\N
994	1	7	48	2	4	Drug Name	omeprazole	413,351,422,302	2014-10-25 03:37:31.931206	2014-10-25 03:41:41.197665	\N	t	1	\N	\N	\N
995	1	7	48	2	4	Drug Amount	30	437,78,446,63	2014-10-25 03:41:48.139671	2014-10-25 03:42:57.159895	\N	t	1	\N	\N	\N
996	1	7	48	2	4	Drug Amount Unit	mg	437,97,447,78	2014-10-25 03:41:48.190753	2014-10-25 03:42:57.174725	\N	t	1	\N	\N	\N
997	1	7	48	2	4	Drug Formulation	capsule	437,249,445,212	2014-10-25 03:41:48.207891	2014-10-25 03:42:57.190139	\N	f	1	\N	\N	\N
998	1	7	48	2	4	Drug Name	dextromethorphan-HBr	436,192,445,96	2014-10-25 03:41:48.225548	2014-10-25 03:42:57.206025	\N	t	1	\N	\N	\N
999	1	7	48	2	4	Drug Amount	2	485,87,493,75	2014-10-25 03:43:00.496119	2014-10-25 03:46:46.579549	\N	t	1	\N	\N	\N
1000	1	7	48	2	4	Drug Amount Unit	mg	485,102,494,85	2014-10-25 03:43:00.544928	2014-10-25 03:46:46.596952	\N	t	1	\N	\N	\N
1001	1	7	48	2	4	Drug Formulation	solution	496,116,506,78	2014-10-25 03:43:00.562847	2014-10-25 03:46:46.633801	\N	f	1	\N	\N	\N
1002	1	7	48	2	4	Drug Name	midazolam	485,146,493,98	2014-10-25 03:43:00.581361	2014-10-25 03:46:46.64849	\N	t	1	\N	\N	\N
1003	1	7	48	2	4	Drug Route	oral	486,215,494,187	2014-10-25 03:46:46.663621	2014-10-25 03:46:46.663621	\N	f	1	\N	\N	\N
1011	1	7	48	2	4	Analyte	caffeine	743,442,771,432	2014-10-25 04:02:45.586097	2014-10-25 04:02:45.586097	\N	f	1	\N	\N	\N
1007	1	7	48	2	4	% Confidence Interval	95	702,570,711,557	2014-10-25 04:02:45.449479	2014-10-25 04:04:10.760642	\N	t	1	\N	\N	\N
1009	1	7	48	2	4	Measurement Name	Cmax	849,500,867,489	2014-10-25 04:02:45.485143	2014-10-25 04:04:10.826273	\N	t	1	\N	\N	\N
1010	1	7	48	2	4	Measurement Unit	uM	487,580,500,564	2014-10-25 04:02:45.503595	2014-10-25 04:04:10.840177	\N	t	1	\N	\N	\N
1004	1	7	48	2	4	Number of Subjects Included in Measurement	16	735,466,745,454	2014-10-25 04:02:45.39168	2014-10-25 04:04:10.855202	\N	t	1	\N	\N	\N
1012	1	7	48	2	4	Confidence Interval Upper Bound	24.5	681,500,698,489	2014-10-25 04:15:45.020265	2014-10-25 04:15:45.020265	\N	f	1	\N	\N	\N
1013	1	7	48	2	4	Geometric Mean	21.20	723,500,743,489	2014-10-25 04:15:45.126121	2014-10-25 04:15:45.126121	\N	f	1	\N	\N	\N
1014	1	7	48	2	4	Confidence Interval Lower Bound	18.3	699,502,718,487	2014-10-25 04:15:45.214879	2014-10-25 04:15:45.214879	\N	f	1	\N	\N	\N
1527	1	7	48	5	4	Mean	0.869	116,510,125,484	2014-11-02 01:24:12.957928	2014-11-02 01:35:12.209156	\N	t	1	\N	\N	\N
1020	1	7	48	2	4	Confidence Interval Lower Bound	114	703,520,717,510	2014-10-25 04:15:50.711762	2014-10-25 04:17:27.61732	\N	f	1	\N	\N	\N
1018	1	7	48	2	4	Confidence Interval Upper Bound	198	685,520,698,510	2014-10-25 04:15:50.676968	2014-10-25 04:17:27.63439	\N	f	1	\N	\N	\N
1019	1	7	48	2	4	Geometric Mean	150	722,521,736,508	2014-10-25 04:15:50.695143	2014-10-25 04:17:27.648457	\N	f	1	\N	\N	\N
1016	1	7	48	2	4	Measurement Name	AUC0-last	837,522,869,508	2014-10-25 04:15:50.618322	2014-10-25 04:17:27.662758	\N	t	1	\N	\N	\N
1017	1	7	48	2	4	Measurement Unit	h*uM	88,578,110,565	2014-10-25 04:15:50.658543	2014-10-25 04:17:27.676962	\N	t	1	\N	\N	\N
1084	1	7	48	2	4	Confidence Interval Lower Bound	752	400,521,415,509	2014-10-29 01:15:23.741819	2014-10-29 23:51:37.789524	\N	f	1	\N	\N	\N
1085	1	7	48	2	4	Confidence Interval Upper Bound	1800	379,522,397,508	2014-10-29 01:15:23.759915	2014-10-29 23:51:37.80481	\N	f	1	\N	\N	\N
1022	1	7	48	2	4	Confidence Interval Lower Bound	120	703,529,716,519	2014-10-25 04:17:30.061666	2014-10-25 04:18:44.915953	\N	f	1	\N	\N	\N
1023	1	7	48	2	4	Confidence Interval Upper Bound	213	685,529,699,519	2014-10-25 04:17:30.080789	2014-10-25 04:18:44.931594	\N	f	1	\N	\N	\N
1024	1	7	48	2	4	Geometric Mean	160	721,530,735,518	2014-10-25 04:17:30.09879	2014-10-25 04:18:44.945915	\N	f	1	\N	\N	\N
1025	1	7	48	2	4	Measurement Name	AUC0-inf	836,533,869,518	2014-10-25 04:17:30.116729	2014-10-25 04:18:44.96003	\N	t	1	\N	\N	\N
1086	1	7	48	2	4	Geometric Mean	1164	421,520,440,509	2014-10-29 01:15:23.777186	2014-10-29 23:51:37.819867	\N	f	1	\N	\N	\N
1029	1	7	48	2	4	Confidence Interval Lower Bound	3.63	701,540,718,529	2014-10-25 04:18:46.662452	2014-10-25 04:20:06.102855	\N	f	1	\N	\N	\N
1030	1	7	48	2	4	Confidence Interval Upper Bound	5.09	680,541,697,527	2014-10-25 04:18:46.680779	2014-10-25 04:20:06.15072	\N	f	1	\N	\N	\N
1031	1	7	48	2	4	Geometric Mean	4.30	720,541,741,528	2014-10-25 04:18:46.698204	2014-10-25 04:20:06.17002	\N	f	1	\N	\N	\N
1032	1	7	48	2	4	Measurement Name	t1/2	854,543,872,528	2014-10-25 04:18:46.716977	2014-10-25 04:20:06.260972	\N	t	1	\N	\N	\N
1028	1	7	48	2	4	Measurement Unit	h	844,541,853,530	2014-10-25 04:18:46.644301	2014-10-25 04:20:06.356023	\N	t	1	\N	\N	\N
1091	1	7	48	2	4	Confidence Interval Lower Bound	721	401,531,416,520	2014-10-29 01:15:23.878836	2014-10-29 23:52:37.554712	\N	f	1	\N	\N	\N
1092	1	7	48	2	4	Confidence Interval Upper Bound	1791	380,532,398,518	2014-10-29 01:15:23.897831	2014-10-29 23:52:37.573103	\N	f	1	\N	\N	\N
1083	1	7	48	2	4	Measurement Unit	h*nM	234,579,254,566	2014-10-29 01:15:23.722874	2014-10-29 23:49:05.78119	\N	t	1	\N	\N	\N
1036	1	7	48	2	4	Maximum	3.02	680,510,697,499	2014-10-25 04:20:29.875352	2014-10-25 04:21:39.374008	\N	t	1	\N	\N	\N
1039	1	7	48	2	4	Measurement Name	tmax	850,511,870,500	2014-10-25 04:20:29.95915	2014-10-25 04:21:39.390139	\N	t	1	\N	\N	\N
1040	1	7	48	2	4	Measurement Unit	h	839,510,849,498	2014-10-25 04:20:30.006458	2014-10-25 04:21:39.404353	\N	t	1	\N	\N	\N
1034	1	7	48	2	4	Median	0.76	721,510,739,498	2014-10-25 04:20:29.809184	2014-10-25 04:21:39.418898	\N	t	1	\N	\N	\N
1035	1	7	48	2	4	Minimum	0.17	701,510,718,500	2014-10-25 04:20:29.856324	2014-10-25 04:21:39.4333	\N	t	1	\N	\N	\N
1090	1	7	48	2	4	Geometric Mean	1137	424,531,443,518	2014-10-29 01:15:23.860397	2014-10-29 23:52:37.588853	\N	f	1	\N	\N	\N
1528	1	7	48	5	4	Measurement Name	AUC0-last	115,169,127,132	2014-11-02 01:24:12.975902	2014-11-02 01:35:12.313945	\N	t	1	\N	\N	\N
2472	1	14	48	5	4	Correlation	0.855	810,553,821,528	2015-01-18 16:49:45.46071	2015-01-18 19:38:21.358655	\N	t	1	\N	\N	\N
1171	1	7	48	2	4	Number of Subjects Included in Measurement	16	130,465,139,456	2014-10-30 00:03:14.263751	2014-10-30 00:03:46.127533	\N	t	1	\N	\N	\N
1176	1	7	48	2	4	Confidence Interval Upper Bound	43.5	75,502,95,488	2014-10-30 00:03:14.37064	2014-10-30 00:10:15.512063	\N	f	1	\N	\N	\N
1175	1	7	48	2	4	Confidence Interval Lower Bound	27.2	97,500,114,489	2014-10-30 00:03:14.351957	2014-10-30 00:10:15.494167	\N	f	1	\N	\N	\N
1041	1	7	48	2	4	Analyte	Tolbutamide	593,443,633,432	2014-10-25 04:22:15.92122	2014-10-25 04:22:56.902138	\N	f	1	\N	\N	\N
1042	1	7	48	2	4	Number of Subjects Included in Measurement	16	590,466,600,453	2014-10-25 04:22:15.939921	2014-10-25 04:22:56.916943	\N	t	1	\N	\N	\N
1047	1	7	48	2	4	Geometric Mean	59.3	579,500,599,489	2014-10-25 04:22:16.16637	2014-10-25 04:24:22.608108	\N	f	1	\N	\N	\N
1067	1	7	48	2	4	Maximum	6.00	539,509,555,498	2014-10-25 04:22:16.586625	2014-10-25 04:24:46.852055	\N	t	1	\N	\N	\N
1050	1	7	48	2	4	Confidence Interval Lower Bound	477	561,520,576,509	2014-10-25 04:22:16.235833	2014-10-25 04:26:26.229102	\N	f	1	\N	\N	\N
1051	1	7	48	2	4	Confidence Interval Upper Bound	648	543,520,559,509	2014-10-25 04:22:16.25387	2014-10-25 04:26:26.243353	\N	f	1	\N	\N	\N
1052	1	7	48	2	4	Geometric Mean	556	579,520,595,509	2014-10-25 04:22:16.272545	2014-10-25 04:26:26.258271	\N	f	1	\N	\N	\N
1048	1	7	48	2	4	Confidence Interval Lower Bound	50.8	557,500,575,488	2014-10-25 04:22:16.186697	2014-10-25 04:24:22.577618	\N	f	1	\N	\N	\N
1046	1	7	48	2	4	Confidence Interval Upper Bound	69.3	539,499,556,488	2014-10-25 04:22:16.105578	2014-10-25 04:24:22.592698	\N	f	1	\N	\N	\N
1070	1	7	48	2	4	Median	3.00	580,509,597,499	2014-10-25 04:22:16.64566	2014-10-25 04:25:19.835977	\N	t	1	\N	\N	\N
1071	1	7	48	2	4	Minimum	0.75	559,509,576,499	2014-10-25 04:22:16.664313	2014-10-25 04:25:19.8515	\N	t	1	\N	\N	\N
1059	1	7	48	2	4	Geometric Mean	654	581,529,596,519	2014-10-25 04:22:16.409799	2014-10-26 02:30:35.35778	\N	f	1	\N	\N	\N
1057	1	7	48	2	4	Confidence Interval Lower Bound	539	561,530,576,519	2014-10-25 04:22:16.37554	2014-10-29 00:56:32.69442	\N	f	1	\N	\N	\N
1058	1	7	48	2	4	Confidence Interval Upper Bound	794	542,531,556,519	2014-10-25 04:22:16.392696	2014-10-29 00:56:32.733568	\N	f	1	\N	\N	\N
1062	1	7	48	2	4	Confidence Interval Lower Bound	6.71	560,541,575,529	2014-10-25 04:22:16.4739	2014-10-29 01:15:14.343121	\N	f	1	\N	\N	\N
1063	1	7	48	2	4	Confidence Interval Upper Bound	9.68	538,540,556,530	2014-10-25 04:22:16.490972	2014-10-29 01:15:14.357247	\N	f	1	\N	\N	\N
1064	1	7	48	2	4	Geometric Mean	8.06	578,541,598,529	2014-10-25 04:22:16.509257	2014-10-29 01:15:14.370287	\N	f	1	\N	\N	\N
1079	1	7	48	2	4	Confidence Interval Lower Bound	352	401,501,416,489	2014-10-29 01:15:23.60773	2014-10-29 01:37:39.56786	\N	f	1	\N	\N	\N
1080	1	7	48	2	4	Confidence Interval Upper Bound	895	382,500,398,490	2014-10-29 01:15:23.624154	2014-10-29 01:37:39.585019	\N	f	1	\N	\N	\N
1078	1	7	48	2	4	Geometric Mean	561	421,500,437,489	2014-10-29 01:15:23.590121	2014-10-29 01:37:39.601227	\N	f	1	\N	\N	\N
1526	1	7	48	5	4	% Confidence Interval	90	101,540,109,527	2014-11-02 01:24:12.939986	2014-11-02 01:35:12.155977	\N	t	1	\N	\N	\N
1529	1	7	48	5	4	Measurement Unit	ratio to placebo	100,509,109,485	2014-11-02 01:24:12.994414	2014-11-02 01:35:12.329067	\N	t	1	\N	\N	\N
1523	1	7	48	5	4	Number of Subjects Included in Measurement	16	115,462,125,446	2014-11-02 01:24:12.879626	2014-11-02 01:35:12.34434	\N	t	1	\N	\N	\N
1073	1	7	48	2	4	Analyte	Omeprazole	440,446,479,433	2014-10-29 01:15:23.416682	2014-10-29 01:22:44.575976	\N	f	1	\N	\N	\N
1074	1	7	48	2	4	Number of Subjects Included in Measurement	16	436,468,444,455	2014-10-29 01:15:23.500129	2014-10-29 01:22:44.595524	\N	t	1	\N	\N	\N
1101	1	7	48	2	4	Maximum	6.00	378,510,395,499	2014-10-29 01:15:24.119243	2014-10-29 23:48:27.355975	\N	t	1	\N	\N	\N
1102	1	7	48	2	4	Median	2.00	421,511,438,499	2014-10-29 01:15:24.138751	2014-10-29 23:48:27.404642	\N	t	1	\N	\N	\N
1103	1	7	48	2	4	Minimum	0.50	399,511,418,499	2014-10-29 01:15:24.158232	2014-10-29 23:48:27.419794	\N	t	1	\N	\N	\N
1096	1	7	48	2	4	Confidence Interval Lower Bound	0.703	394,541,416,529	2014-10-29 01:15:24.017117	2014-10-29 23:53:43.692573	\N	f	1	\N	\N	\N
1097	1	7	48	2	4	Confidence Interval Upper Bound	0.938	369,541,391,529	2014-10-29 01:15:24.034772	2014-10-29 23:53:43.706901	\N	f	1	\N	\N	\N
1098	1	7	48	2	4	Geometric Mean	0.812	424,542,446,529	2014-10-29 01:15:24.052415	2014-10-29 23:53:43.720466	\N	f	1	\N	\N	\N
1136	1	7	48	2	4	Number of Subjects Included in Measurement	15	835,595,845,584	2014-10-29 23:55:03.723178	2014-10-29 23:55:03.723178	\N	f	1	\N	\N	\N
1524	1	7	48	5	4	Confidence Interval Lower Bound	0.786	115,542,124,516	2014-11-02 01:24:12.904664	2014-11-02 01:37:39.531725	\N	t	1	\N	\N	\N
1808	1	14	48	3	4	Measurement Name	smoked in the past	526,588,535,502	2015-01-16 01:55:46.5326	2015-01-16 01:56:25.525753	\N	t	1	\N	\N	\N
1807	1	14	48	3	4	Percent	17.6	523,483,534,452	2015-01-16 01:55:46.513797	2015-01-16 01:56:25.542131	\N	t	1	\N	\N	\N
1813	1	14	48	3	4	Measurement Name	nonsmokers at the time of the study	513,667,520,527	2015-01-16 01:56:42.646962	2015-01-16 01:59:18.203687	\N	t	1	\N	\N	\N
1814	1	14	48	3	4	Percent	100	511,466,521,446	2015-01-16 01:56:42.664937	2015-01-16 01:59:18.221347	\N	t	1	\N	\N	\N
1137	1	7	48	2	4	Analyte	Dextromethorphan	271,444,332,432	2014-10-29 23:56:28.462757	2014-10-29 23:57:10.117459	\N	f	1	\N	\N	\N
1138	1	7	48	2	4	Number of Subjects Included in Measurement	15	281,467,289,455	2014-10-29 23:56:28.482177	2014-10-29 23:57:10.136283	\N	t	1	\N	\N	\N
1149	1	7	48	2	4	Geometric Mean	20.2	267,520,284,508	2014-10-29 23:56:28.72055	2014-10-30 00:00:55.199744	\N	f	1	\N	\N	\N
1153	1	7	48	2	4	Confidence Interval Lower Bound	16.5	247,530,263,518	2014-10-29 23:56:28.818686	2014-10-30 00:02:04.894992	\N	f	1	\N	\N	\N
1154	1	7	48	2	4	Confidence Interval Upper Bound	66.6	226,529,243,518	2014-10-29 23:56:28.838274	2014-10-30 00:02:04.90903	\N	f	1	\N	\N	\N
1156	1	7	48	2	4	Geometric Mean	33.1	272,530,289,519	2014-10-29 23:56:28.879233	2014-10-30 00:02:04.922355	\N	f	1	\N	\N	\N
1141	1	7	48	2	4	Measurement Unit	nM	626,580,638,567	2014-10-29 23:56:28.555735	2014-10-29 23:57:51.325263	\N	t	1	\N	\N	\N
1142	1	7	48	2	4	Confidence Interval Lower Bound	1.94	247,500,264,490	2014-10-29 23:56:28.574085	2014-10-29 23:58:58.765412	\N	f	1	\N	\N	\N
1143	1	7	48	2	4	Confidence Interval Upper Bound	6.72	228,500,245,488	2014-10-29 23:56:28.593434	2014-10-29 23:58:58.779108	\N	f	1	\N	\N	\N
1144	1	7	48	2	4	Geometric Mean	3.61	269,501,285,489	2014-10-29 23:56:28.612667	2014-10-29 23:58:58.793691	\N	f	1	\N	\N	\N
1167	1	7	48	2	4	Maximum	5.00	226,510,244,499	2014-10-29 23:56:29.139447	2014-10-29 23:59:53.259624	\N	t	1	\N	\N	\N
1168	1	7	48	2	4	Median	2.50	268,510,285,499	2014-10-29 23:56:29.156059	2014-10-29 23:59:53.301341	\N	t	1	\N	\N	\N
1169	1	7	48	2	4	Minimum	1.00	245,512,263,498	2014-10-29 23:56:29.172738	2014-10-29 23:59:53.315273	\N	t	1	\N	\N	\N
1147	1	7	48	2	4	Confidence Interval Lower Bound	9.40	247,521,263,509	2014-10-29 23:56:28.682285	2014-10-30 00:00:55.168335	\N	f	1	\N	\N	\N
1148	1	7	48	2	4	Confidence Interval Upper Bound	43.3	227,520,244,509	2014-10-29 23:56:28.701556	2014-10-30 00:00:55.184452	\N	f	1	\N	\N	\N
1157	1	7	48	2	4	Number of Subjects Included in Measurement	12	835,622,844,613	2014-10-29 23:56:28.898245	2014-10-30 00:02:04.961879	\N	f	1	\N	\N	\N
1161	1	7	48	2	4	Confidence Interval Lower Bound	5.13	248,540,264,529	2014-10-29 23:56:28.988293	2014-10-30 00:03:01.239807	\N	f	1	\N	\N	\N
1162	1	7	48	2	4	Confidence Interval Upper Bound	8.53	226,540,242,528	2014-10-29 23:56:29.006864	2014-10-30 00:03:01.272756	\N	f	1	\N	\N	\N
1163	1	7	48	2	4	Geometric Mean	6.61	272,540,289,528	2014-10-29 23:56:29.024858	2014-10-30 00:03:01.307726	\N	f	1	\N	\N	\N
1170	1	7	48	2	4	Analyte	Midazolam	134,444,172,433	2014-10-30 00:03:14.214019	2014-10-30 00:03:46.11009	\N	f	1	\N	\N	\N
1177	1	7	48	2	4	Geometric Mean	34.4	119,500,136,487	2014-10-30 00:03:14.387242	2014-10-30 00:07:44.947665	\N	f	1	\N	\N	\N
1201	1	7	48	2	4	Median	0.75	118,510,137,498	2014-10-30 00:03:14.853269	2014-10-30 00:47:12.630609	\N	t	1	\N	\N	\N
1202	1	7	48	2	4	Minimum	0.33	97,511,114,499	2014-10-30 00:03:14.870621	2014-10-30 00:47:12.646873	\N	t	1	\N	\N	\N
1183	1	7	48	2	4	Confidence Interval Upper Bound	110.0	73,522,95,508	2014-10-30 00:03:14.503985	2014-10-30 00:58:43.924871	\N	f	1	\N	\N	\N
1200	1	7	48	2	4	Maximum	2.50	77,511,93,499	2014-10-30 00:03:14.835109	2014-10-30 00:47:12.535013	\N	t	1	\N	\N	\N
1181	1	7	48	2	4	Geometric Mean	88.6	117,521,137,509	2014-10-30 00:03:14.470735	2014-10-30 00:58:43.939526	\N	f	1	\N	\N	\N
1187	1	7	48	2	4	Confidence Interval Lower Bound	74.3	97,530,116,519	2014-10-30 00:03:14.583402	2014-10-30 00:59:53.178997	\N	f	1	\N	\N	\N
1182	1	7	48	2	4	Confidence Interval Lower Bound	71.3	97,521,114,508	2014-10-30 00:03:14.48734	2014-10-30 00:58:43.908173	\N	f	1	\N	\N	\N
1188	1	7	48	2	4	Confidence Interval Upper Bound	121.1	74,532,91,519	2014-10-30 00:03:14.600487	2014-10-30 00:59:53.19483	\N	f	1	\N	\N	\N
1189	1	7	48	2	4	Geometric Mean	94.9	122,530,137,518	2014-10-30 00:03:14.617831	2014-10-30 00:59:53.209688	\N	f	1	\N	\N	\N
1195	1	7	48	2	4	Confidence Interval Lower Bound	2.39	97,540,114,528	2014-10-30 00:03:14.735465	2014-10-30 01:01:51.202667	\N	f	1	\N	\N	\N
1196	1	7	48	2	4	Confidence Interval Upper Bound	5.21	77,541,92,529	2014-10-30 00:03:14.752415	2014-10-30 01:01:51.221276	\N	f	1	\N	\N	\N
1197	1	7	48	2	4	Geometric Mean	3.53	122,541,138,529	2014-10-30 00:03:14.770284	2014-10-30 01:01:51.236754	\N	f	1	\N	\N	\N
1212	1	7	48	3	4	% Confidence Interval	95	100,549,109,539	2014-10-30 01:16:49.45996	2014-10-30 01:19:17.340191	\N	t	1	\N	\N	\N
1210	1	7	48	3	4	Confidence Interval Lower Bound	3.25	216,575,224,554	2014-10-30 01:16:49.422642	2014-10-30 01:19:17.357975	\N	t	1	\N	\N	\N
1211	1	7	48	3	4	Confidence Interval Upper Bound	5.52	216,594,224,574	2014-10-30 01:16:49.440974	2014-10-30 01:19:17.372885	\N	t	1	\N	\N	\N
1213	1	7	48	3	4	Geometric Mean	4.23	215,554,224,532	2014-10-30 01:16:49.482108	2014-10-30 01:19:17.390292	\N	t	1	\N	\N	\N
1214	1	7	48	3	4	Measurement Name	Plasma concentration 6 h post-dose	215,280,224,144	2014-10-30 01:16:49.499898	2014-10-30 01:19:17.405947	\N	t	1	\N	\N	\N
1215	1	7	48	3	4	Measurement Unit	nM	215,431,224,412	2014-10-30 01:16:49.518323	2014-10-30 01:19:17.420502	\N	t	1	\N	\N	\N
1209	1	7	48	3	4	Number of Subjects Included in Measurement	16	215,392,224,379	2014-10-30 01:16:49.401618	2014-10-30 01:19:17.435494	\N	t	1	\N	\N	\N
1530	1	7	48	5	4	Intrasubject Coefficient of Variation	16.2	116,603,125,580	2014-11-02 01:39:03.823682	2014-11-02 01:39:03.823682	\N	f	1	\N	\N	\N
1217	1	7	48	3	4	Confidence Interval Lower Bound	0.93	133,575,142,554	2014-10-30 01:19:59.285368	2014-10-30 01:21:34.575316	\N	t	1	\N	\N	\N
1218	1	7	48	3	4	Confidence Interval Upper Bound	1.73	134,594,143,575	2014-10-30 01:19:59.305963	2014-10-30 01:21:34.591194	\N	t	1	\N	\N	\N
1220	1	7	48	3	4	Geometric Mean	1.27	134,554,143,532	2014-10-30 01:19:59.35224	2014-10-30 01:21:34.605649	\N	t	1	\N	\N	\N
1221	1	7	48	3	4	Measurement Name	Molar paraxanthine/caffeine plasma concentration ratio 6 h post-dose	134,287,152,99	2014-10-30 01:19:59.369113	2014-10-30 01:21:34.619258	\N	t	1	\N	\N	\N
1222	1	7	48	3	4	Measurement Unit	None	132,439,143,411	2014-10-30 01:19:59.498765	2014-10-30 01:21:34.632941	\N	t	1	\N	\N	\N
1216	1	7	48	3	4	Number of Subjects Included in Measurement	16	133,392,143,377	2014-10-30 01:19:59.230222	2014-10-30 01:21:34.649143	\N	t	1	\N	\N	\N
1224	1	7	48	3	4	Confidence Interval Lower Bound	4.98	155,575,163,554	2014-10-30 01:22:52.096104	2014-10-30 01:24:44.081315	\N	t	1	\N	\N	\N
1225	1	7	48	3	4	Confidence Interval Upper Bound	9.31	155,596,163,575	2014-10-30 01:22:52.114467	2014-10-30 01:24:44.09616	\N	t	1	\N	\N	\N
1227	1	7	48	3	4	Geometric Mean	6.81	154,554,163,533	2014-10-30 01:22:52.14773	2014-10-30 01:24:44.110844	\N	t	1	\N	\N	\N
1228	1	7	48	3	4	Measurement Name	plasma concentration 24 h post-dose	155,289,166,151	2014-10-30 01:22:52.165449	2014-10-30 01:24:44.126331	\N	t	1	\N	\N	\N
1229	1	7	48	3	4	Measurement Unit	uM	154,433,165,412	2014-10-30 01:22:52.183074	2014-10-30 01:24:44.142088	\N	t	1	\N	\N	\N
1223	1	7	48	3	4	Number of Subjects Included in Measurement	16	155,393,164,378	2014-10-30 01:22:52.040521	2014-10-30 01:24:44.156843	\N	t	1	\N	\N	\N
1231	1	7	48	3	4	Confidence Interval Lower Bound	0.561	165,581,173,554	2014-10-30 01:25:24.6212	2014-10-30 01:27:11.623142	\N	t	1	\N	\N	\N
1232	1	7	48	3	4	Confidence Interval Upper Bound	1.20	165,600,173,580	2014-10-30 01:25:24.640788	2014-10-30 01:27:11.63913	\N	t	1	\N	\N	\N
1234	1	7	48	3	4	Geometric Mean	8.20	166,554,173,529	2014-10-30 01:25:24.677277	2014-10-30 01:27:11.654183	\N	t	1	\N	\N	\N
1235	1	7	48	3	4	Measurement Name	omeprazole/5-OH-omeprazole plasma concentration ratio 3 h post-dose	165,266,183,101	2014-10-30 01:25:24.697696	2014-10-30 01:27:11.670076	\N	t	1	\N	\N	\N
1236	1	7	48	3	4	Measurement Unit	None	164,436,175,412	2014-10-30 01:25:24.71797	2014-10-30 01:27:11.685204	\N	t	1	\N	\N	\N
1230	1	7	48	3	4	Number of Subjects Included in Measurement	15	251,382,261,103	2014-10-30 01:25:24.564401	2014-10-30 01:27:11.700583	\N	t	1	\N	\N	\N
1238	1	7	48	3	4	Confidence Interval Lower Bound	0.694	186,580,194,555	2014-10-30 01:27:33.117716	2014-10-30 01:29:20.380962	\N	t	1	\N	\N	\N
1239	1	7	48	3	4	Confidence Interval Upper Bound	1.13	185,600,193,580	2014-10-30 01:27:33.135017	2014-10-30 01:29:20.395571	\N	t	1	\N	\N	\N
1240	1	7	48	3	4	Geometric Mean	0.884	186,556,193,527	2014-10-30 01:27:33.152605	2014-10-30 01:29:20.40897	\N	t	1	\N	\N	\N
1241	1	7	48	3	4	Measurement Name	omeprazole/5-OH-omeprazole AUC0-t ratio	185,327,194,99	2014-10-30 01:27:33.171561	2014-10-30 01:29:20.443554	\N	t	1	\N	\N	\N
1242	1	7	48	3	4	Measurement Unit	None	184,438,194,413	2014-10-30 01:27:33.190667	2014-10-30 01:29:20.457841	\N	t	1	\N	\N	\N
1243	1	7	48	3	4	Number of Subjects Included in Measurement	16	185,393,195,378	2014-10-30 01:27:33.208916	2014-10-30 01:29:20.471387	\N	t	1	\N	\N	\N
1245	1	7	48	3	4	Confidence Interval Lower Bound	0.149	196,580,207,555	2014-10-30 01:29:42.290669	2014-10-30 01:38:56.061902	\N	t	1	\N	\N	\N
1246	1	7	48	3	4	Confidence Interval Upper Bound	0.592	193,605,205,579	2014-10-30 01:29:42.309426	2014-10-30 01:38:56.077183	\N	t	1	\N	\N	\N
1248	1	7	48	3	4	Geometric Mean	0.297	194,553,207,529	2014-10-30 01:29:42.344507	2014-10-30 01:38:56.092825	\N	t	1	\N	\N	\N
1249	1	7	48	3	4	Measurement Name	destromethorphan/dextrophan plasma concentration ratio 3 h post-dose	196,271,214,100	2014-10-30 01:29:42.362295	2014-10-30 01:38:56.107413	\N	t	1	\N	\N	\N
1250	1	7	48	3	4	Measurement Unit	None	194,437,207,413	2014-10-30 01:29:42.379074	2014-10-30 01:38:56.121241	\N	t	1	\N	\N	\N
1244	1	7	48	3	4	Number of Subjects Included in Measurement	15	194,394,207,379	2014-10-30 01:29:42.215616	2014-10-30 01:38:56.135077	\N	t	1	\N	\N	\N
1894	1	14	48	2	4	Formulation	three tablets	389,336,398,279	2015-01-16 02:32:52.613378	2015-01-16 02:36:13.782368	\N	t	1	\N	\N	\N
1537	1	7	48	5	4	Confidence Interval Lower Bound	0.956	127,543,134,517	2014-11-02 01:39:06.746577	2014-11-02 01:41:43.174765	\N	t	1	\N	\N	\N
1259	1	7	48	3	4	Number of males	8	472,635,481,624	2014-10-30 01:40:33.390764	2014-10-30 01:40:33.390764	\N	f	1	\N	\N	\N
1260	1	7	48	3	4	Number of subjects	17	471,513,481,497	2014-10-30 01:40:33.483743	2014-10-30 01:40:33.483743	\N	f	1	\N	\N	\N
1261	1	7	48	3	4	Race	white	472,587,481,511	2014-10-30 01:40:33.567804	2014-10-30 01:40:33.567804	\N	f	1	\N	\N	\N
1262	1	7	48	3	4	Number of females	9	485,368,494,358	2014-10-30 01:40:33.663135	2014-10-30 01:40:33.663135	\N	f	1	\N	\N	\N
1254	1	7	48	3	4	Maximum	52	498,586,507,570	2014-10-30 01:40:33.031591	2014-10-30 01:41:24.520327	\N	t	1	\N	\N	\N
1258	1	7	48	3	4	Measurement Unit	years	498,620,509,590	2014-10-30 01:40:33.213439	2014-10-30 01:41:24.538018	\N	t	1	\N	\N	\N
1252	1	7	48	3	4	Mean	37	498,548,508,533	2014-10-30 01:40:32.9894	2014-10-30 01:41:24.552221	\N	t	1	\N	\N	\N
1253	1	7	48	3	4	Minimum	21	496,567,507,552	2014-10-30 01:40:33.0121	2014-10-30 01:41:24.567044	\N	t	1	\N	\N	\N
1263	1	7	48	3	4	Maximum	26.9	512,409,520,388	2014-10-30 01:41:32.664718	2014-10-30 01:42:31.603814	\N	t	1	\N	\N	\N
1265	1	7	48	3	4	Mean	23.5	499,664,508,640	2014-10-30 01:41:32.757778	2014-10-30 01:42:31.623109	\N	t	1	\N	\N	\N
1264	1	7	48	3	4	Measurement Unit	kg/m2	509,444,521,413	2014-10-30 01:41:32.740067	2014-10-30 01:42:31.637762	\N	t	1	\N	\N	\N
1266	1	7	48	3	4	Minimum	19.7	510,384,521,364	2014-10-30 01:41:32.803123	2014-10-30 01:42:31.652042	\N	t	1	\N	\N	\N
1267	1	7	48	3	4	Ex-smokers	3	524,415,534,388	2014-10-30 01:43:48.791771	2014-10-30 01:43:48.791771	\N	f	1	\N	\N	\N
1268	1	7	48	3	4	Current smokers	0	510,584,521,447	2014-10-30 01:43:48.883909	2014-10-30 01:43:48.883909	\N	f	1	\N	\N	\N
1269	1	7	48	3	4	oral contraceptives	6 females	538,510,547,422	2014-10-30 01:48:51.649219	2014-10-30 01:48:51.649219	\N	f	1	\N	\N	\N
1531	1	7	48	5	4	Confidence Interval Upper Bound	1.414	127,567,135,542	2014-11-02 01:39:06.640059	2014-11-02 01:41:43.191598	\N	t	1	\N	\N	\N
1273	1	7	48	4	4	Count	10	603,625,614,608	2014-10-30 01:50:25.834363	2014-10-30 01:51:55.04156	\N	t	1	\N	\N	\N
1272	1	7	48	4	4	Measurement Name	eructation	592,441,600,394	2014-10-30 01:50:25.815147	2014-10-30 01:51:55.057772	\N	t	1	\N	\N	\N
1271	1	7	48	4	4	Percent	58.8	603,661,612,628	2014-10-30 01:50:25.794333	2014-10-30 01:51:55.072089	\N	t	1	\N	\N	\N
1532	1	7	48	5	4	Mean	1.16	126,506,135,484	2014-11-02 01:39:06.659139	2014-11-02 01:41:43.222661	\N	t	1	\N	\N	\N
1274	1	7	48	4	4	Count	1	685,461,691,442	2014-10-30 01:52:15.257934	2014-10-30 01:52:57.633915	\N	t	1	\N	\N	\N
1275	1	7	48	4	4	Measurement Name	diarrhea	682,440,692,398	2014-10-30 01:52:15.309705	2014-10-30 01:52:57.65129	\N	t	1	\N	\N	\N
1277	1	7	48	4	4	Severity	Mild	589,395,599,370	2014-10-30 01:53:35.197904	2014-10-30 01:53:35.197904	\N	f	1	\N	\N	\N
1278	1	7	48	4	4	Count	1	683,583,692,562	2014-10-30 01:53:43.951712	2014-10-30 01:54:30.081114	\N	t	1	\N	\N	\N
1279	1	7	48	4	4	Measurement Name	nausea	682,560,691,526	2014-10-30 01:53:43.970261	2014-10-30 01:54:30.098341	\N	t	1	\N	\N	\N
1536	1	7	48	5	4	Number of Subjects Included in Measurement	16	127,461,136,449	2014-11-02 01:39:06.729955	2014-11-02 01:41:43.266309	\N	t	1	\N	\N	\N
1538	1	7	48	5	4	Intrasubject Coefficient of Variation	32.2	127,602,135,580	2014-11-02 01:39:06.762954	2014-11-02 01:41:43.206747	\N	f	1	\N	\N	\N
1533	1	7	48	5	4	Measurement Name	paraxanthine / caffeine plasma concentration ratio 6 h post-dose	128,396,136,133	2014-11-02 01:39:06.677663	2014-11-02 01:41:43.236968	\N	t	1	\N	\N	\N
1540	1	7	48	5	4	Confidence Interval Lower Bound	0.973	136,542,145,517	2014-11-02 01:42:12.65307	2014-11-02 01:43:54.55778	\N	t	1	\N	\N	\N
1541	1	7	48	5	4	Confidence Interval Upper Bound	1.101	138,566,144,543	2014-11-02 01:42:12.670823	2014-11-02 01:43:54.571935	\N	t	1	\N	\N	\N
1543	1	7	48	5	4	Geometric Mean	1.035	137,510,145,485	2014-11-02 01:42:12.708779	2014-11-02 01:43:54.585562	\N	t	1	\N	\N	\N
1544	1	7	48	5	4	Measurement Name	AUClast ratio to placebo	138,168,146,133	2014-11-02 01:42:12.726051	2014-11-02 01:43:54.59941	\N	t	1	\N	\N	\N
1539	1	7	48	5	4	Number of Subjects Included in Measurement	16	138,462,146,449	2014-11-02 01:42:12.600979	2014-11-02 01:43:54.627355	\N	t	1	\N	\N	\N
1546	1	7	48	5	4	Intrasubject Coefficient of Variation	10.0	137,602,143,579	2014-11-02 01:43:54.642457	2014-11-02 01:43:54.642457	\N	f	1	\N	\N	\N
1549	1	7	48	5	4	Confidence Interval Lower Bound	0.970	147,541,155,517	2014-11-02 01:44:00.262983	2014-11-02 01:46:32.563075	\N	t	1	\N	\N	\N
1550	1	7	48	5	4	Confidence Interval Upper Bound	1.261	147,566,154,542	2014-11-02 01:44:00.282303	2014-11-02 01:46:32.583367	\N	t	1	\N	\N	\N
1551	1	7	48	5	4	Geometric Mean	1.106	147,509,155,484	2014-11-02 01:44:00.3005	2014-11-02 01:46:32.623365	\N	t	1	\N	\N	\N
1554	1	7	48	5	4	Intrasubject Coefficient of Variation	21.3	146,602,155,580	2014-11-02 01:44:00.352984	2014-11-02 01:46:32.637825	\N	f	1	\N	\N	\N
1553	1	7	48	5	4	Number of Subjects Included in Measurement	16	148,462,155,449	2014-11-02 01:44:00.335065	2014-11-02 01:46:32.664481	\N	t	1	\N	\N	\N
1555	1	7	48	5	4	Measurement Name	plasma concentration 24 h post-dose	146,323,158,260	2014-11-02 01:46:32.679025	2014-11-02 01:46:32.679025	\N	f	1	\N	\N	\N
1756	1	14	48	3	4	% Confidence Interval	95	100,552,109,537	2014-12-25 19:05:58.03364	2014-12-25 19:08:47.760437	\N	t	1	\N	\N	\N
1754	1	14	48	3	4	Confidence Interval Lower Bound	0.93	134,575,143,555	2014-12-25 19:05:57.936887	2014-12-25 19:08:47.777286	\N	t	1	\N	\N	\N
1755	1	14	48	3	4	Confidence Interval Upper Bound	1.73	135,595,142,575	2014-12-25 19:05:57.971395	2014-12-25 19:08:47.792799	\N	t	1	\N	\N	\N
1757	1	14	48	3	4	Geometric Mean	1.27	134,554,142,533	2014-12-25 19:05:58.05323	2014-12-25 19:08:47.808895	\N	t	1	\N	\N	\N
1759	1	14	48	3	4	Measurement Unit	None	133,438,143,411	2014-12-25 19:05:58.091358	2014-12-25 19:08:47.838357	\N	t	1	\N	\N	\N
1753	1	14	48	3	4	Number of Subjects Included in Measurement	16	135,392,140,377	2014-12-25 19:05:57.783304	2014-12-25 19:08:47.852771	\N	t	1	\N	\N	\N
1760	1	14	48	1	4	Blinding	double-blind	349,230,359,168	2014-12-25 19:08:58.044696	2015-01-16 01:11:41.931612	\N	t	1	\N	\N	\N
1762	1	14	48	1	4	Cross-over/Parallel	crossover	351,348,358,316	2014-12-25 19:08:58.141832	2015-01-16 01:11:41.949963	\N	t	1	\N	\N	\N
1761	1	14	48	1	4	Randomization	randomized	351,287,358,228	2014-12-25 19:08:58.122341	2015-01-16 01:11:41.96465	\N	t	1	\N	\N	\N
1818	1	14	48	3	4	Count	6	524,608,535,588	2015-01-16 02:00:55.106018	2015-01-16 02:01:42.503782	\N	t	1	\N	\N	\N
1817	1	14	48	3	4	Measurement Name	used oral contraceptives	535,643,550,398	2015-01-16 02:00:55.088593	2015-01-16 02:01:42.519847	\N	t	1	\N	\N	\N
1815	1	14	48	3	4	Number of Subjects Included in Measurement	9	481,369,496,353	2015-01-16 02:00:55.000464	2015-01-16 02:12:21.470057	\N	t	1	\N	\N	\N
1824	1	14	48	3	4	Count	1	721,440,731,417	2015-01-16 02:12:40.528267	2015-01-16 02:13:23.028809	\N	t	1	\N	\N	\N
1823	1	14	48	3	4	Measurement Name	poor metabolizer of CYP2D6	722,666,731,585	2015-01-16 02:12:40.50345	2015-01-16 02:13:23.045527	\N	t	1	\N	\N	\N
3889	1	20	47	6	4	Confidence Interval Upper Bound	0.76	183,589,192,567	2015-01-25 18:22:06.244394	2015-01-25 18:23:08.378654	\N	t	1	\N	\N	\N
1589	1	7	48	5	4	Confidence Interval Upper Bound	1.614	157,568,166,543	2014-11-03 23:10:05.980365	2014-11-03 23:28:56.797038	\N	t	1	\N	\N	\N
1591	1	7	48	5	4	Geometric Mean	1.143	157,509,166,485	2014-11-03 23:10:06.037766	2014-11-03 23:28:56.81217	\N	t	1	\N	\N	\N
1587	1	7	48	5	4	Number of Subjects Included in Measurement	16	157,463,167,448	2014-11-03 23:10:05.921636	2014-11-03 23:28:56.845199	\N	t	1	\N	\N	\N
1596	1	14	50	1	4	Ploo	floo	175,395,268,322	2014-11-06 22:52:49.288158	2014-11-06 22:52:49.288158	\N	f	1	\N	\N	\N
1597	1	15	50	1	4	zoo	foo	294,412,399,313	2014-11-06 22:53:22.688147	2014-11-06 22:53:22.688147	\N	f	1	\N	\N	\N
1830	1	14	48	3	4	Count	0	746,635,757,579	2015-01-16 02:14:13.727493	2015-01-16 02:26:07.069897	\N	t	1	\N	\N	\N
1829	1	14	48	3	4	Measurement Name	two CYP2C19 alleles coding for nonfunctional enzyme	760,541,771,358	2015-01-16 02:14:13.690006	2015-01-16 02:26:07.121036	\N	t	1	\N	\N	\N
2031	1	14	48	2	4	Confidence Interval Upper Bound	895	383,500,398,488	2015-01-16 04:07:21.802769	2015-01-16 04:08:34.400983	\N	f	1	\N	\N	\N
2030	1	14	48	2	4	Measurement Unit	nM	626,578,638,566	2015-01-16 04:07:21.781406	2015-01-16 04:08:34.448352	\N	t	1	\N	\N	\N
2032	1	14	48	2	4	Number of Subjects Included in Measurement	16	435,467,445,455	2015-01-16 04:07:21.823954	2015-01-16 04:08:34.465806	\N	t	1	\N	\N	\N
2036	1	14	48	2	4	Maximum	6.00	378,509,395,498	2015-01-16 04:07:21.916297	2015-01-16 04:09:17.383337	\N	t	1	\N	\N	\N
1836	1	14	48	2	4	Maximum	female	210,214,220,183	2015-01-16 02:27:16.834205	2015-01-16 02:27:51.49566	\N	t	1	\N	\N	\N
1835	1	14	48	2	4	Minimum	male	211,169,218,146	2015-01-16 02:27:16.814526	2015-01-16 02:27:51.545048	\N	t	1	\N	\N	\N
2037	1	14	48	2	4	Median	2.00	420,512,437,497	2015-01-16 04:07:21.935188	2015-01-16 04:09:17.425519	\N	t	1	\N	\N	\N
2038	1	14	48	2	4	Minimum	0.50	400,510,417,498	2015-01-16 04:07:21.954698	2015-01-16 04:09:17.440313	\N	t	1	\N	\N	\N
2041	1	14	48	2	4	Measurement Unit	h*nM	234,578,254,566	2015-01-16 04:07:22.068808	2015-01-16 04:10:11.45619	\N	t	1	\N	\N	\N
1853	1	14	48	2	4	Disease	healthy	210,148,218,115	2015-01-16 02:28:22.689593	2015-01-16 02:28:22.689593	\N	f	1	\N	\N	\N
1846	1	14	48	2	4	Maximum	55	211,350,217,336	2015-01-16 02:28:22.404503	2015-01-16 02:29:04.695172	\N	t	1	\N	\N	\N
1849	1	14	48	2	4	Measurement Name	age	212,277,218,253	2015-01-16 02:28:22.460765	2015-01-16 02:29:04.741083	\N	t	1	\N	\N	\N
1850	1	14	48	2	4	Measurement Unit	years	223,72,233,43	2015-01-16 02:28:22.478909	2015-01-16 02:29:04.804248	\N	t	1	\N	\N	\N
1845	1	14	48	2	4	Minimum	18	210,322,220,308	2015-01-16 02:28:22.386915	2015-01-16 02:29:04.820225	\N	t	1	\N	\N	\N
1870	1	14	48	2	4	Measurement Name	caucasian	210,255,220,212	2015-01-16 02:29:37.461048	2015-01-16 02:30:09.155976	\N	t	1	\N	\N	\N
2044	1	14	48	2	4	Confidence Interval Upper Bound	1800	379,519,397,507	2015-01-16 04:07:22.196848	2015-01-16 04:10:11.413745	\N	t	1	\N	\N	\N
1765	1	14	48	1	4	DOI (Digital Object Identifier)	10.1124/dmd.112.050203	40,676,49,574	2015-01-16 00:56:23.729941	2015-01-16 00:59:04.667775	\N	t	1	\N	\N	\N
1766	1	14	48	1	4	Journal	Drug Metabolism and Disposition	48,162,59,43	2015-01-16 00:56:23.750978	2015-01-16 00:59:04.707642	\N	t	1	\N	\N	\N
1767	1	14	48	1	4	Volume	41	49,592,61,580	2015-01-16 00:56:23.771491	2015-01-16 00:59:04.725581	\N	t	1	\N	\N	\N
1769	1	14	48	1	4	Pages	987	50,607,61,591	2015-01-16 00:56:23.810378	2015-01-16 01:02:21.284556	\N	t	1	\N	\N	\N
1770	1	14	48	1	4	Title	Drug Cocktail Interaction Study on the Effect of the Orally Administered Lavender Oil Preparation Silexan on Cygochrome P450 Enzymes in Healthy Volunteers	77,647,154,60	2015-01-16 00:56:23.829885	2015-01-16 01:02:21.302481	\N	t	1	\N	\N	\N
1893	1	14	48	2	4	Route	oral	378,351,386,328	2015-01-16 02:32:52.594181	2015-01-16 02:36:13.814188	\N	t	1	\N	\N	\N
1898	1	14	48	2	4	Drug Name	tolbutamide	398,329,413,279	2015-01-16 02:36:39.814816	2015-01-16 02:37:45.15735	\N	t	1	\N	\N	\N
1895	1	14	48	2	4	Formulation	one quarter of a tablet	414,174,422,44	2015-01-16 02:36:39.606765	2015-01-16 02:37:45.17176	\N	t	1	\N	\N	\N
1906	1	14	48	2	4	Formulation	one tablet	424,92,435,47	2015-01-16 02:37:48.35679	2015-01-16 02:40:25.273599	\N	t	1	\N	\N	\N
1992	1	14	48	2	4	Confidence Interval Lower Bound	50.8	559,500,577,488	2015-01-16 03:50:25.196632	2015-01-16 03:52:02.469935	\N	f	1	\N	\N	\N
1993	1	14	48	2	4	Geometric Mean	59.3	581,501,598,488	2015-01-16 03:50:25.214023	2015-01-16 03:52:02.501044	\N	f	1	\N	\N	\N
1772	1	14	48	1	4	Month	May	47,642,62,624	2015-01-16 00:59:04.568435	2015-01-16 00:59:30.389687	\N	t	1	\N	\N	\N
1771	1	14	48	1	4	Year	2013	49,668,61,641	2015-01-16 00:59:04.535502	2015-01-16 00:59:30.40705	\N	t	1	\N	\N	\N
3886	1	20	47	6	4	Coefficient of Variation within Subject	42.9	183,646,192,622	2015-01-25 18:22:06.126872	2015-01-25 18:23:08.34276	\N	f	1	\N	\N	\N
1775	1	14	48	1	4	First Name or Initial	Oxana	167,111,182,60	2015-01-16 01:02:21.176011	2015-01-16 01:02:45.563718	\N	t	1	\N	\N	\N
1774	1	14	48	1	4	Last Name	Doroshyenko	164,197,181,107	2015-01-16 01:02:21.156191	2015-01-16 01:02:45.578834	\N	t	1	\N	\N	\N
1777	1	14	48	3	4	Number of subjects	17	471,512,482,498	2015-01-16 01:49:40.986237	2015-01-16 01:50:26.353692	\N	t	1	\N	\N	\N
1778	1	14	48	3	4	White	17	471,540,481,510	2015-01-16 01:50:46.379191	2015-01-16 01:50:46.379191	\N	f	1	\N	\N	\N
1782	1	14	48	3	4	Count	9	484,370,496,357	2015-01-16 01:51:11.879815	2015-01-16 01:51:47.317912	\N	t	1	\N	\N	\N
1781	1	14	48	3	4	Measurement Name	females	485,407,495,367	2015-01-16 01:51:11.860071	2015-01-16 01:51:47.369988	\N	t	1	\N	\N	\N
1788	1	14	48	3	4	Maximum	26.9	512,410,522,387	2015-01-16 01:52:02.420562	2015-01-16 01:53:41.191198	\N	t	1	\N	\N	\N
1791	1	14	48	3	4	Measurement Name	body mass index	497,506,508,419	2015-01-16 01:52:02.52498	2015-01-16 01:53:41.217331	\N	t	1	\N	\N	\N
1792	1	14	48	3	4	Measurement Unit	kg/m2	509,443,523,411	2015-01-16 01:52:02.554101	2015-01-16 01:53:41.276224	\N	t	1	\N	\N	\N
1786	1	14	48	3	4	Mean	23.5	497,665,509,641	2015-01-16 01:52:02.381413	2015-01-16 01:53:41.290712	\N	t	1	\N	\N	\N
1787	1	14	48	3	4	Minimum	19.7	511,386,521,363	2015-01-16 01:52:02.401161	2015-01-16 01:53:41.304812	\N	t	1	\N	\N	\N
1805	1	14	48	3	4	Measurement Time	Demographic	470,436,482,368	2015-01-16 01:54:06.786834	2015-01-16 01:54:06.786834	\N	f	1	\N	\N	\N
1798	1	14	48	3	4	Maximum	52	498,587,511,570	2015-01-16 01:54:06.384692	2015-01-16 01:54:49.84186	\N	t	1	\N	\N	\N
1801	1	14	48	3	4	Measurement Name	age	498,397,509,377	2015-01-16 01:54:06.471815	2015-01-16 01:54:49.859243	\N	t	1	\N	\N	\N
1802	1	14	48	3	4	Measurement Unit	years	499,621,508,588	2015-01-16 01:54:06.530227	2015-01-16 01:54:49.874576	\N	t	1	\N	\N	\N
1796	1	14	48	3	4	Mean	37	498,549,508,531	2015-01-16 01:54:06.345514	2015-01-16 01:54:49.890491	\N	t	1	\N	\N	\N
1797	1	14	48	3	4	Minimum	21	498,568,510,553	2015-01-16 01:54:06.365667	2015-01-16 01:54:49.904929	\N	t	1	\N	\N	\N
1880	1	14	48	2	4	Drug Amount	160	245,141,256,123	2015-01-16 02:31:09.236355	2015-01-16 02:32:41.263891	\N	t	1	\N	\N	\N
1881	1	14	48	2	4	Drug Amount Unit	mg	245,156,256,138	2015-01-16 02:31:09.25693	2015-01-16 02:32:41.282098	\N	t	1	\N	\N	\N
1879	1	14	48	2	4	Drug Name	silexan	245,184,256,154	2015-01-16 02:31:09.217136	2015-01-16 02:32:41.298582	\N	t	1	\N	\N	\N
1877	1	14	48	2	4	End Time	11	257,179,267,164	2015-01-16 02:31:09.179025	2015-01-16 02:32:41.314134	\N	t	1	\N	\N	\N
1884	1	14	48	2	4	Formulation	one soft gelatin capsule	246,283,255,184	2015-01-16 02:31:09.318622	2015-01-16 02:32:41.329021	\N	t	1	\N	\N	\N
1882	1	14	48	2	4	Frequency	once daily	259,119,267,70	2015-01-16 02:31:09.277195	2015-01-16 02:32:41.344272	\N	t	1	\N	\N	\N
1883	1	14	48	2	4	Route	oral	258,74,266,43	2015-01-16 02:31:09.299743	2015-01-16 02:32:41.358015	\N	t	1	\N	\N	\N
1875	1	14	48	2	4	Start Time	1	259,165,268,154	2015-01-16 02:31:09.087448	2015-01-16 02:32:41.373861	\N	t	1	\N	\N	\N
1876	1	14	48	2	4	Start Time Unit	day	260,152,267,132	2015-01-16 02:31:09.159844	2015-01-16 02:32:41.396585	\N	t	1	\N	\N	\N
1889	1	14	48	2	4	Drug Name	caffeine	390,278,398,238	2015-01-16 02:32:52.518112	2015-01-16 02:36:13.765383	\N	t	1	\N	\N	\N
1892	1	14	48	2	4	Frequency	single	353,219,362,206	2015-01-16 02:32:52.575207	2015-01-16 02:36:13.798834	\N	t	1	\N	\N	\N
1885	1	14	48	2	4	Start Time	11	353,251,362,237	2015-01-16 02:32:52.388045	2015-01-16 02:36:13.830881	\N	t	1	\N	\N	\N
1886	1	14	48	2	4	Start Time Unit	day	353,238,363,218	2015-01-16 02:32:52.455931	2015-01-16 02:36:13.846541	\N	t	1	\N	\N	\N
1905	1	14	48	2	4	Drug Name	omeprazole	413,350,424,302	2015-01-16 02:37:48.337949	2015-01-16 02:38:26.080148	\N	t	1	\N	\N	\N
1907	1	14	48	2	4	Drug Amount	150	390,222,398,202	2015-01-16 02:39:06.940754	2015-01-16 02:39:06.940754	\N	f	1	\N	\N	\N
1908	1	14	48	2	4	Drug Amount Unit	mg	389,241,400,221	2015-01-16 02:39:07.023472	2015-01-16 02:39:07.023472	\N	f	1	\N	\N	\N
1909	1	14	48	2	4	Drug Amount	125	399,263,412,246	2015-01-16 02:39:31.428549	2015-01-16 02:39:31.428549	\N	f	1	\N	\N	\N
1910	1	14	48	2	4	Drug Amount Unit	mg	400,277,415,263	2015-01-16 02:39:31.512753	2015-01-16 02:39:31.512753	\N	f	1	\N	\N	\N
1911	1	14	48	2	4	Drug Amount	20	410,288,423,276	2015-01-16 02:40:25.138819	2015-01-16 02:40:25.138819	\N	f	1	\N	\N	\N
1912	1	14	48	2	4	Drug Amount Unit	mg	412,303,424,288	2015-01-16 02:40:25.21238	2015-01-16 02:40:25.21238	\N	f	1	\N	\N	\N
3957	1	20	47	6	4	Median	4.0	618,433,629,414	2015-01-25 18:48:03.848445	2015-01-25 18:48:03.848445	\N	f	1	\N	\N	\N
1918	1	14	48	2	4	Drug Amount	30	436,78,447,64	2015-01-16 02:40:29.305178	2015-01-16 02:41:37.330954	\N	f	1	\N	\N	\N
1917	1	14	48	2	4	Drug Amount Unit	mg	437,93,448,78	2015-01-16 02:40:29.28447	2015-01-16 02:41:37.347755	\N	f	1	\N	\N	\N
1920	1	14	48	2	4	Drug Name	dextromethorphan-HBr	435,191,448,96	2015-01-16 02:40:29.341136	2015-01-16 02:41:37.362919	\N	t	1	\N	\N	\N
1919	1	14	48	2	4	Formulation	one capsule	435,248,449,192	2015-01-16 02:40:29.32319	2015-01-16 02:41:37.376971	\N	t	1	\N	\N	\N
1927	1	14	48	2	4	Drug Amount	2	481,87,496,76	2015-01-16 02:41:40.196254	2015-01-16 02:46:28.675658	\N	f	1	\N	\N	\N
1928	1	14	48	2	4	Drug Amount Unit	mg	484,101,493,85	2015-01-16 02:41:40.214191	2015-01-16 02:46:28.694968	\N	f	1	\N	\N	\N
1925	1	14	48	2	4	Drug Name	midazolam	485,147,494,98	2015-01-16 02:41:40.157581	2015-01-16 02:46:28.712102	\N	t	1	\N	\N	\N
1926	1	14	48	2	4	Formulation	injection solution	494,114,508,42	2015-01-16 02:41:40.176336	2015-01-16 02:46:28.727452	\N	t	1	\N	\N	\N
1929	1	14	48	2	4	Measurement Name	Caffeine	741,444,775,433	2015-01-16 03:35:00.055969	2015-01-16 03:35:21.570959	\N	f	1	\N	\N	\N
2025	1	14	48	2	4	Measurement Name	Omeprazole	440,444,479,432	2015-01-16 04:07:21.613082	2015-01-16 04:07:40.653338	\N	f	1	\N	\N	\N
2049	1	14	48	2	4	Confidence Interval Lower Bound	721	402,530,416,518	2015-01-16 04:07:22.30752	2015-01-16 04:11:25.124673	\N	t	1	\N	\N	\N
2050	1	14	48	2	4	Confidence Interval Upper Bound	1791	379,531,397,518	2015-01-16 04:07:22.328109	2015-01-16 04:11:25.142781	\N	t	1	\N	\N	\N
2051	1	14	48	2	4	Geometric Mean	1137	424,530,445,519	2015-01-16 04:07:22.348438	2015-01-16 04:11:25.158908	\N	t	1	\N	\N	\N
2056	1	14	48	2	4	Confidence Interval Lower Bound	0.703	395,541,415,529	2015-01-16 04:07:22.464341	2015-01-16 04:12:15.56588	\N	t	1	\N	\N	\N
2057	1	14	48	2	4	Confidence Interval Upper Bound	0.938	370,541,392,529	2015-01-16 04:07:22.484273	2015-01-16 04:12:15.624551	\N	t	1	\N	\N	\N
2058	1	14	48	2	4	Geometric Mean	0.812	424,540,448,529	2015-01-16 04:07:22.539332	2015-01-16 04:12:15.670607	\N	t	1	\N	\N	\N
1942	1	14	48	2	4	% Confidence Interval	95	702,569,710,558	2015-01-16 03:40:23.499779	2015-01-16 03:44:16.707795	\N	t	1	\N	\N	\N
1949	1	14	48	2	4	Confidence Interval Lower Bound	18.3	701,503,719,489	2015-01-16 03:44:16.725645	2015-01-16 03:44:16.725645	\N	f	1	\N	\N	\N
1950	1	14	48	2	4	Geometric Mean	21.20	721,502,743,488	2015-01-16 03:44:16.848269	2015-01-16 03:44:16.848269	\N	f	1	\N	\N	\N
1948	1	14	48	2	4	Measurement Type	Cmax	847,502,871,488	2015-01-16 03:40:23.619446	2015-01-16 03:44:16.911293	\N	t	1	\N	\N	\N
1945	1	14	48	2	4	Measurement Unit	uM	487,579,501,566	2015-01-16 03:40:23.560092	2015-01-16 03:44:16.925622	\N	t	1	\N	\N	\N
1939	1	14	48	2	4	Number of Subjects Included in Measurement	16	736,467,745,455	2015-01-16 03:40:23.440517	2015-01-16 03:44:16.939829	\N	t	1	\N	\N	\N
1951	1	14	48	2	4	Confidence Interval Upper Bound	24.5	680,500,697,489	2015-01-16 03:44:16.955177	2015-01-16 03:44:16.955177	\N	f	1	\N	\N	\N
2096	1	14	48	2	4	Measurement Name	midazolam	134,445,173,432	2015-01-16 04:20:18.204948	2015-01-16 04:20:40.333689	\N	f	1	\N	\N	\N
2128	1	14	48	2	4	Confidence Interval Lower Bound	2.39	99,539,115,530	2015-01-16 04:20:19.262888	2015-01-16 04:25:56.360012	\N	t	1	\N	\N	\N
1955	1	14	48	2	4	Maximum	3.02	680,510,695,498	2015-01-16 03:44:29.240273	2015-01-16 03:45:53.105283	\N	t	1	\N	\N	\N
1962	1	14	48	2	4	Measurement Type	Tmax	850,512,870,501	2015-01-16 03:44:29.412584	2015-01-16 03:45:53.12041	\N	t	1	\N	\N	\N
1959	1	14	48	2	4	Measurement Unit	h	841,511,849,499	2015-01-16 03:44:29.31853	2015-01-16 03:45:53.135894	\N	t	1	\N	\N	\N
1953	1	14	48	2	4	Median	0.76	721,509,740,498	2015-01-16 03:44:29.200432	2015-01-16 03:45:53.149867	\N	t	1	\N	\N	\N
1954	1	14	48	2	4	Minimum	0.17	700,512,719,497	2015-01-16 03:44:29.219609	2015-01-16 03:45:53.163391	\N	t	1	\N	\N	\N
2129	1	14	48	2	4	Confidence Interval Upper Bound	5.21	77,540,94,528	2015-01-16 04:20:19.281208	2015-01-16 04:25:56.377719	\N	t	1	\N	\N	\N
2130	1	14	48	2	4	Geometric Mean	3.53	121,544,139,528	2015-01-16 04:20:19.299626	2015-01-16 04:25:56.392834	\N	t	1	\N	\N	\N
1964	1	14	48	2	4	Confidence Interval Lower Bound	114	703,521,719,510	2015-01-16 03:46:13.75703	2015-01-16 03:47:31.113374	\N	t	1	\N	\N	\N
1965	1	14	48	2	4	Confidence Interval Upper Bound	198	683,520,699,509	2015-01-16 03:46:13.776924	2015-01-16 03:47:31.127752	\N	t	1	\N	\N	\N
1967	1	14	48	2	4	Geometric Mean	150	721,521,736,509	2015-01-16 03:46:13.815563	2015-01-16 03:47:31.142303	\N	t	1	\N	\N	\N
1972	1	14	48	2	4	Measurement Type	AUC0-t	835,522,871,509	2015-01-16 03:46:13.906483	2015-01-16 03:47:31.157169	\N	t	1	\N	\N	\N
1969	1	14	48	2	4	Measurement Unit	h*uM	88,580,110,564	2015-01-16 03:46:13.852535	2015-01-16 03:47:31.172524	\N	t	1	\N	\N	\N
1974	1	14	48	2	4	Confidence Interval Lower Bound	120	703,530,717,519	2015-01-16 03:47:44.802527	2015-01-16 03:48:50.429275	\N	t	1	\N	\N	\N
1975	1	14	48	2	4	Confidence Interval Upper Bound	213	685,532,700,518	2015-01-16 03:47:44.82016	2015-01-16 03:48:50.444358	\N	t	1	\N	\N	\N
1977	1	14	48	2	4	Geometric Mean	160	721,531,735,518	2015-01-16 03:47:44.856049	2015-01-16 03:48:50.457843	\N	t	1	\N	\N	\N
1982	1	14	48	2	4	Measurement Type	AUC0-inf	833,531,871,519	2015-01-16 03:47:44.943124	2015-01-16 03:48:50.472892	\N	t	1	\N	\N	\N
2138	1	14	48	3	4	Measurement Time	6	142,140,159,129	2015-01-17 00:21:21.253392	2015-01-17 00:23:42.196531	\N	t	1	\N	\N	\N
1989	1	14	48	2	4	Confidence Interval Lower Bound	3.63	701,544,716,528	2015-01-16 03:49:04.686596	2015-01-16 03:50:11.279723	\N	t	1	\N	\N	\N
1988	1	14	48	2	4	Confidence Interval Upper Bound	5.09	680,542,695,528	2015-01-16 03:49:04.667394	2015-01-16 03:50:11.295879	\N	t	1	\N	\N	\N
1987	1	14	48	2	4	Geometric Mean	4.30	720,541,741,530	2015-01-16 03:49:04.648382	2015-01-16 03:50:11.309942	\N	t	1	\N	\N	\N
1986	1	14	48	2	4	Measurement Type	t1/2	854,543,871,530	2015-01-16 03:49:04.629652	2015-01-16 03:50:11.324498	\N	t	1	\N	\N	\N
1984	1	14	48	2	4	Measurement Unit	h	844,541,852,529	2015-01-16 03:49:04.59153	2015-01-16 03:50:11.338582	\N	t	1	\N	\N	\N
2139	1	14	48	3	4	Measurement Time Unit	h	143,149,160,134	2015-01-17 00:21:21.272536	2015-01-17 00:23:42.21284	\N	t	1	\N	\N	\N
2140	1	14	48	3	4	Measurement Type	concentration ratio	133,296,146,230	2015-01-17 00:21:21.292486	2015-01-17 00:23:42.227905	\N	t	1	\N	\N	\N
2141	1	14	48	3	4	Measurement Name	Molar paraxanthine/caffeine plasma concentration ratio 6 h post-dose	133,210,143,93	2015-01-17 00:23:42.271934	2015-01-17 00:23:42.271934	\N	f	1	\N	\N	\N
2142	1	14	48	3	4	Measurement Name	tolbutamide	154,152,164,99	2015-01-18 13:53:23.0767	2015-01-18 13:55:06.887448	\N	f	1	\N	\N	\N
2144	1	14	48	3	4	Measurement Unit	uM	156,430,164,412	2015-01-18 13:53:23.118105	2015-01-18 13:55:06.947777	\N	t	1	\N	\N	\N
2014	1	14	48	2	4	Confidence Interval Lower Bound	539	562,533,577,516	2015-01-16 03:50:25.655322	2015-01-16 03:59:23.555157	\N	t	1	\N	\N	\N
2015	1	14	48	2	4	Confidence Interval Upper Bound	794	543,531,558,518	2015-01-16 03:50:25.673293	2015-01-16 03:59:23.569161	\N	t	1	\N	\N	\N
2016	1	14	48	2	4	Geometric Mean	654	580,529,598,519	2015-01-16 03:50:25.692459	2015-01-16 03:59:23.584813	\N	t	1	\N	\N	\N
2020	1	14	48	2	4	Confidence Interval Lower Bound	6.71	560,544,574,527	2015-01-16 03:50:25.79385	2015-01-16 04:00:10.251445	\N	t	1	\N	\N	\N
2021	1	14	48	2	4	Confidence Interval Upper Bound	9.68	538,541,556,528	2015-01-16 03:50:25.815678	2015-01-16 04:00:10.267821	\N	t	1	\N	\N	\N
2022	1	14	48	2	4	Geometric Mean	8.06	579,542,597,527	2015-01-16 03:50:25.870543	2015-01-16 04:00:10.28238	\N	t	1	\N	\N	\N
2026	1	14	48	2	4	Confidence Interval Lower Bound	352	401,501,416,488	2015-01-16 04:07:21.699236	2015-01-16 04:08:34.382239	\N	f	1	\N	\N	\N
2027	1	14	48	2	4	Geometric Mean	561	421,501,435,489	2015-01-16 04:07:21.718457	2015-01-16 04:08:34.417121	\N	f	1	\N	\N	\N
2043	1	14	48	2	4	Confidence Interval Lower Bound	752	401,521,417,510	2015-01-16 04:07:22.13814	2015-01-16 04:10:11.396994	\N	t	1	\N	\N	\N
2045	1	14	48	2	4	Geometric Mean	1164	421,521,440,509	2015-01-16 04:07:22.215503	2015-01-16 04:10:11.427889	\N	t	1	\N	\N	\N
2060	1	14	48	2	4	Number of Subjects Included in Measurement	15	835,594,842,585	2015-01-16 04:11:25.206366	2015-01-16 04:11:25.206366	\N	f	1	\N	\N	\N
3890	1	20	47	6	4	Confidence Interval Lower Bound	1.18	184,613,192,591	2015-01-25 18:22:06.26276	2015-01-25 18:23:08.361197	\N	t	1	\N	\N	\N
1990	1	14	48	2	4	Measurement Name	tolbutamide	591,446,634,432	2015-01-16 03:50:25.096058	2015-01-16 03:50:44.080703	\N	f	1	\N	\N	\N
1997	1	14	48	2	4	Confidence Interval Upper Bound	69.3	539,499,557,489	2015-01-16 03:50:25.289641	2015-01-16 03:52:02.485293	\N	f	1	\N	\N	\N
1996	1	14	48	2	4	Number of Subjects Included in Measurement	16	590,467,599,456	2015-01-16 03:50:25.270753	2015-01-16 03:52:02.546244	\N	t	1	\N	\N	\N
1999	1	14	48	2	4	Maximum	6.00	538,510,554,499	2015-01-16 03:50:25.340588	2015-01-16 03:57:43.9161	\N	t	1	\N	\N	\N
2002	1	14	48	2	4	Median	3.00	578,509,600,499	2015-01-16 03:50:25.396549	2015-01-16 03:57:43.961417	\N	t	1	\N	\N	\N
2003	1	14	48	2	4	Minimum	0.75	559,509,575,498	2015-01-16 03:50:25.415422	2015-01-16 03:57:43.976246	\N	t	1	\N	\N	\N
2010	1	14	48	2	4	Confidence Interval Lower Bound	477	561,520,576,509	2015-01-16 03:50:25.566995	2015-01-16 03:58:34.447898	\N	t	1	\N	\N	\N
2009	1	14	48	2	4	Confidence Interval Upper Bound	648	542,521,557,509	2015-01-16 03:50:25.54757	2015-01-16 03:58:34.463674	\N	t	1	\N	\N	\N
2008	1	14	48	2	4	Geometric Mean	556	579,521,595,507	2015-01-16 03:50:25.526328	2015-01-16 03:58:34.478277	\N	t	1	\N	\N	\N
2244	1	14	48	5	4	Geometric Mean	1.044	167,510,177,485	2015-01-18 14:47:19.355218	2015-01-18 14:49:08.119655	\N	t	1	\N	\N	\N
2061	1	14	48	2	4	Measurement Name	Dextromethorphan	271,445,332,431	2015-01-16 04:12:22.960112	2015-01-16 04:15:59.582167	\N	f	1	\N	\N	\N
2067	1	14	48	2	4	Confidence Interval Lower Bound	1.94	247,500,264,488	2015-01-16 04:12:23.183215	2015-01-16 04:17:01.800175	\N	f	1	\N	\N	\N
2062	1	14	48	2	4	Confidence Interval Upper Bound	6.72	228,500,244,488	2015-01-16 04:12:23.081796	2015-01-16 04:17:01.814707	\N	f	1	\N	\N	\N
2068	1	14	48	2	4	Geometric Mean	3.61	269,501,285,487	2015-01-16 04:12:23.202128	2015-01-16 04:17:01.829489	\N	f	1	\N	\N	\N
2064	1	14	48	2	4	Number of Subjects Included in Measurement	15	279,466,290,453	2015-01-16 04:12:23.119962	2015-01-16 04:17:01.872321	\N	t	1	\N	\N	\N
2070	1	14	48	2	4	Maximum	5.00	226,510,244,498	2015-01-16 04:12:23.258066	2015-01-16 04:17:43.910075	\N	t	1	\N	\N	\N
2071	1	14	48	2	4	Median	2.50	268,511,286,499	2015-01-16 04:12:23.27644	2015-01-16 04:17:44.03808	\N	t	1	\N	\N	\N
2072	1	14	48	2	4	Minimum	1.00	248,510,263,499	2015-01-16 04:12:23.294726	2015-01-16 04:17:44.102392	\N	t	1	\N	\N	\N
2080	1	14	48	2	4	Confidence Interval Lower Bound	9.40	247,520,264,510	2015-01-16 04:12:23.468867	2015-01-16 04:18:33.250422	\N	t	1	\N	\N	\N
2077	1	14	48	2	4	Confidence Interval Upper Bound	43.3	226,521,244,507	2015-01-16 04:12:23.4076	2015-01-16 04:18:33.26758	\N	t	1	\N	\N	\N
2081	1	14	48	2	4	Geometric Mean	20.2	268,521,286,509	2015-01-16 04:12:23.489864	2015-01-16 04:18:33.281652	\N	t	1	\N	\N	\N
2083	1	14	48	2	4	Confidence Interval Lower Bound	16.5	246,531,263,518	2015-01-16 04:12:23.545985	2015-01-16 04:19:22.165344	\N	t	1	\N	\N	\N
2084	1	14	48	2	4	Confidence Interval Upper Bound	66.6	226,530,244,518	2015-01-16 04:12:23.567074	2015-01-16 04:19:22.180422	\N	t	1	\N	\N	\N
2085	1	14	48	2	4	Geometric Mean	33.1	272,531,289,519	2015-01-16 04:12:23.586504	2015-01-16 04:19:22.196584	\N	t	1	\N	\N	\N
2088	1	14	48	2	4	Number of Subjects Included in Measurement	12	835,623,844,612	2015-01-16 04:12:23.645046	2015-01-16 04:19:22.239953	\N	f	1	\N	\N	\N
2089	1	14	48	2	4	Confidence Interval Lower Bound	5.13	247,541,265,528	2015-01-16 04:12:23.684613	2015-01-16 04:20:05.768487	\N	t	1	\N	\N	\N
2090	1	14	48	2	4	Confidence Interval Upper Bound	8.53	227,541,245,529	2015-01-16 04:12:23.704864	2015-01-16 04:20:05.784191	\N	t	1	\N	\N	\N
2091	1	14	48	2	4	Geometric Mean	6.61	271,542,290,528	2015-01-16 04:12:23.725917	2015-01-16 04:20:05.800371	\N	t	1	\N	\N	\N
2100	1	14	48	2	4	Confidence Interval Lower Bound	27.2	98,501,114,488	2015-01-16 04:20:18.446398	2015-01-16 04:21:31.514166	\N	f	1	\N	\N	\N
2101	1	14	48	2	4	Confidence Interval Upper Bound	43.5	76,499,94,488	2015-01-16 04:20:18.492553	2015-01-16 04:21:31.530457	\N	f	1	\N	\N	\N
2102	1	14	48	2	4	Geometric Mean	34.4	119,499,136,487	2015-01-16 04:20:18.538837	2015-01-16 04:21:31.546234	\N	f	1	\N	\N	\N
2103	1	14	48	2	4	Number of Subjects Included in Measurement	16	129,466,140,454	2015-01-16 04:20:18.560853	2015-01-16 04:21:31.589763	\N	t	1	\N	\N	\N
2107	1	14	48	2	4	Maximum	2.50	77,509,95,497	2015-01-16 04:20:18.701795	2015-01-16 04:22:15.386474	\N	t	1	\N	\N	\N
2108	1	14	48	2	4	Median	0.75	120,510,137,498	2015-01-16 04:20:18.774985	2015-01-16 04:22:15.431814	\N	t	1	\N	\N	\N
2109	1	14	48	2	4	Minimum	0.33	97,509,115,498	2015-01-16 04:20:18.838741	2015-01-16 04:22:15.447799	\N	t	1	\N	\N	\N
2114	1	14	48	2	4	Confidence Interval Lower Bound	71.3	98,519,114,509	2015-01-16 04:20:18.944224	2015-01-16 04:23:03.293496	\N	t	1	\N	\N	\N
2115	1	14	48	2	4	Confidence Interval Upper Bound	110.0	73,521,95,508	2015-01-16 04:20:18.963477	2015-01-16 04:23:03.309298	\N	t	1	\N	\N	\N
2116	1	14	48	2	4	Geometric Mean	88.6	119,520,137,507	2015-01-16 04:20:18.982075	2015-01-16 04:23:03.3245	\N	t	1	\N	\N	\N
2120	1	14	48	2	4	Confidence Interval Lower Bound	74.3	97,531,115,519	2015-01-16 04:20:19.087168	2015-01-16 04:24:14.595091	\N	t	1	\N	\N	\N
2121	1	14	48	2	4	Confidence Interval Upper Bound	121.1	73,530,92,519	2015-01-16 04:20:19.105327	2015-01-16 04:24:14.614241	\N	t	1	\N	\N	\N
2122	1	14	48	2	4	Geometric Mean	94.9	121,530,140,518	2015-01-16 04:20:19.126475	2015-01-16 04:24:14.629125	\N	t	1	\N	\N	\N
3888	1	20	47	6	4	Geometric Mean	0.95	184,531,193,508	2015-01-25 18:22:06.206496	2015-01-25 18:23:08.393242	\N	t	1	\N	\N	\N
2147	1	14	48	3	4	Confidence Interval Lower Bound	4.98	155,575,162,554	2015-01-18 13:53:23.176351	2015-01-18 13:55:06.840928	\N	t	1	\N	\N	\N
2146	1	14	48	3	4	Confidence Interval Upper Bound	9.31	155,596,164,574	2015-01-18 13:53:23.156059	2015-01-18 13:55:06.856304	\N	t	1	\N	\N	\N
2145	1	14	48	3	4	Geometric Mean	6.81	155,553,163,533	2015-01-18 13:53:23.136638	2015-01-18 13:55:06.870552	\N	t	1	\N	\N	\N
2151	1	14	48	3	4	Measurement Time	24	155,242,164,228	2015-01-18 13:53:23.253041	2015-01-18 13:55:06.90205	\N	t	1	\N	\N	\N
2150	1	14	48	3	4	Measurement Time Unit	h	154,252,164,239	2015-01-18 13:53:23.234373	2015-01-18 13:55:06.916786	\N	t	1	\N	\N	\N
2149	1	14	48	3	4	Measurement Type	plasma concentration	156,230,163,148	2015-01-18 13:53:23.214793	2015-01-18 13:55:06.931462	\N	t	1	\N	\N	\N
2143	1	14	48	3	4	Number of Subjects Included in Measurement	16	154,392,163,378	2015-01-18 13:53:23.097711	2015-01-18 13:55:06.963702	\N	t	1	\N	\N	\N
2157	1	14	48	3	4	Confidence Interval Lower Bound	0.561	164,579,176,555	2015-01-18 13:55:28.60453	2015-01-18 13:57:50.420714	\N	t	1	\N	\N	\N
2156	1	14	48	3	4	Confidence Interval Upper Bound	1.20	165,600,175,580	2015-01-18 13:55:28.584066	2015-01-18 13:57:50.436069	\N	t	1	\N	\N	\N
2155	1	14	48	3	4	Geometric Mean	0.820	164,554,175,528	2015-01-18 13:55:28.540704	2015-01-18 13:57:50.45018	\N	t	1	\N	\N	\N
2152	1	14	48	3	4	Measurement Name	molar omeprazole/5-OH-omepazole plasma concentration ratio	165,237,173,101	2015-01-18 13:55:28.407038	2015-01-18 13:57:50.46482	\N	f	1	\N	\N	\N
2161	1	14	48	3	4	Measurement Time	3	173,190,184,180	2015-01-18 13:55:28.696339	2015-01-18 13:57:50.479637	\N	t	1	\N	\N	\N
2160	1	14	48	3	4	Measurement Time Unit	h	176,198,182,187	2015-01-18 13:55:28.675931	2015-01-18 13:57:50.494292	\N	t	1	\N	\N	\N
2159	1	14	48	3	4	Measurement Type	plasma concentration ratio	176,183,183,109	2015-01-18 13:55:28.656924	2015-01-18 13:57:50.508796	\N	t	1	\N	\N	\N
2154	1	14	48	3	4	Measurement Unit	none	164,438,175,413	2015-01-18 13:55:28.50965	2015-01-18 13:57:50.522788	\N	t	1	\N	\N	\N
2153	1	14	48	3	4	Number of Subjects Included in Measurement	16	164,393,176,378	2015-01-18 13:55:28.488435	2015-01-18 13:57:50.536572	\N	t	1	\N	\N	\N
2166	1	14	48	3	4	Confidence Interval Lower Bound	0.694	185,579,193,554	2015-01-18 13:57:53.184919	2015-01-18 14:00:27.396589	\N	t	1	\N	\N	\N
2167	1	14	48	3	4	Confidence Interval Upper Bound	1.13	185,600,193,579	2015-01-18 13:57:53.246364	2015-01-18 14:00:27.413476	\N	t	1	\N	\N	\N
2168	1	14	48	3	4	Geometric Mean	0.884	185,554,193,528	2015-01-18 13:57:53.282292	2015-01-18 14:00:27.428857	\N	t	1	\N	\N	\N
2171	1	14	48	3	4	Measurement Name	molar omeprazole/5-OH-omepazole AUC0-t ratio	186,237,193,101	2015-01-18 13:57:53.418714	2015-01-18 14:00:27.444709	\N	f	1	\N	\N	\N
2165	1	14	48	3	4	Measurement Type	AUC0-t ratio	185,287,194,234	2015-01-18 13:57:53.161309	2015-01-18 14:00:27.48092	\N	t	1	\N	\N	\N
2169	1	14	48	3	4	Measurement Unit	None	185,439,194,412	2015-01-18 13:57:53.335308	2015-01-18 14:00:27.504525	\N	t	1	\N	\N	\N
2170	1	14	48	3	4	Number of Subjects Included in Measurement	16	185,393,193,380	2015-01-18 13:57:53.399302	2015-01-18 14:00:27.519676	\N	t	1	\N	\N	\N
2176	1	14	48	3	4	Confidence Interval Lower Bound	0.149	194,578,206,555	2015-01-18 14:00:42.048283	2015-01-18 14:04:03.41392	\N	t	1	\N	\N	\N
2177	1	14	48	3	4	Confidence Interval Upper Bound	0.592	194,606,205,579	2015-01-18 14:00:42.067558	2015-01-18 14:04:03.428166	\N	t	1	\N	\N	\N
2178	1	14	48	3	4	Geometric Mean	0.297	196,554,206,529	2015-01-18 14:00:42.085263	2015-01-18 14:04:03.442431	\N	t	1	\N	\N	\N
2181	1	14	48	3	4	Measurement Name	molar dextromethorphan/dextrorphan plasma concentration ratio	195,243,204,100	2015-01-18 14:00:42.188556	2015-01-18 14:04:03.458145	\N	f	1	\N	\N	\N
2173	1	14	48	3	4	Measurement Time	3	205,192,215,180	2015-01-18 14:00:41.916909	2015-01-18 14:04:03.4724	\N	t	1	\N	\N	\N
2174	1	14	48	3	4	Measurement Time Unit	h	205,199,214,188	2015-01-18 14:00:41.972439	2015-01-18 14:04:03.487002	\N	t	1	\N	\N	\N
2175	1	14	48	3	4	Measurement Type	plasma concentration ratio	207,184,214,110	2015-01-18 14:00:42.028216	2015-01-18 14:04:03.501592	\N	t	1	\N	\N	\N
2179	1	14	48	3	4	Measurement Unit	None	194,437,206,414	2015-01-18 14:00:42.13132	2015-01-18 14:04:03.51576	\N	t	1	\N	\N	\N
2180	1	14	48	3	4	Number of Subjects Included in Measurement	15	194,392,207,380	2015-01-18 14:00:42.170158	2015-01-18 14:04:03.530367	\N	t	1	\N	\N	\N
2186	1	14	48	3	4	Confidence Interval Lower Bound	3.25	215,575,223,555	2015-01-18 14:04:14.356878	2015-01-18 14:05:49.948476	\N	t	1	\N	\N	\N
2187	1	14	48	3	4	Confidence Interval Upper Bound	5.52	216,595,225,575	2015-01-18 14:04:14.375543	2015-01-18 14:05:49.963731	\N	t	1	\N	\N	\N
2188	1	14	48	3	4	Geometric Mean	4.23	216,552,224,534	2015-01-18 14:04:14.394322	2015-01-18 14:05:49.977587	\N	t	1	\N	\N	\N
2191	1	14	48	3	4	Measurement Name	midazolam plasma concentration	215,146,225,100	2015-01-18 14:04:14.447527	2015-01-18 14:05:49.991435	\N	f	1	\N	\N	\N
2183	1	14	48	3	4	Measurement Time	6	215,235,224,223	2015-01-18 14:04:14.285198	2015-01-18 14:05:50.007812	\N	t	1	\N	\N	\N
2184	1	14	48	3	4	Measurement Time Unit	h	215,243,223,230	2015-01-18 14:04:14.303787	2015-01-18 14:05:50.070534	\N	t	1	\N	\N	\N
2185	1	14	48	3	4	Measurement Type	plasma concentration	216,225,228,145	2015-01-18 14:04:14.321744	2015-01-18 14:05:50.122594	\N	t	1	\N	\N	\N
2189	1	14	48	3	4	Measurement Unit	nM	215,431,226,412	2015-01-18 14:04:14.412141	2015-01-18 14:05:50.15235	\N	t	1	\N	\N	\N
2190	1	14	48	3	4	Number of Subjects Included in Measurement	16	214,392,224,378	2015-01-18 14:04:14.429953	2015-01-18 14:05:50.167067	\N	t	1	\N	\N	\N
2195	1	14	48	5	4	% Confidence Interval	90	101,545,109,526	2015-01-18 14:33:19.766461	2015-01-18 14:36:51.60209	\N	t	1	\N	\N	\N
2193	1	14	48	5	4	Confidence Interval Lower Bound	0.786	116,542,125,516	2015-01-18 14:33:19.727861	2015-01-18 14:36:51.619211	\N	t	1	\N	\N	\N
2194	1	14	48	5	4	Confidence Interval Upper Bound	0.961	117,566,124,541	2015-01-18 14:33:19.747517	2015-01-18 14:36:51.633987	\N	t	1	\N	\N	\N
2196	1	14	48	5	4	Geometric Mean	0.869	116,511,125,483	2015-01-18 14:33:19.784921	2015-01-18 14:36:51.648531	\N	t	1	\N	\N	\N
2197	1	14	48	5	4	Measurement Name	caffeine in plasma	116,251,125,175	2015-01-18 14:33:19.827264	2015-01-18 14:36:51.664178	\N	t	1	\N	\N	\N
2201	1	14	48	5	4	Measurement Type	AUC0-t	116,167,125,134	2015-01-18 14:33:19.905133	2015-01-18 14:36:51.678286	\N	t	1	\N	\N	\N
2202	1	14	48	5	4	Measurement Unit	ratio for silexan over placebo	80,524,87,407	2015-01-18 14:36:51.707389	2015-01-18 14:36:51.707389	\N	f	1	\N	\N	\N
2192	1	14	48	5	4	Number of Subjects Included in Measurement	16	117,462,124,448	2015-01-18 14:33:19.65085	2015-01-18 14:36:51.782904	\N	t	1	\N	\N	\N
2203	1	14	48	5	4	Intra-subject CV%	16.2	117,603,124,579	2015-01-18 14:36:51.799047	2015-01-18 14:36:51.799047	\N	f	1	\N	\N	\N
2211	1	14	48	5	4	Number of Subjects Included in Measurement	16	127,461,134,448	2015-01-18 14:36:54.826657	2015-01-18 14:37:39.084373	\N	t	1	\N	\N	\N
2205	1	14	48	5	4	Confidence Interval Lower Bound	0.956	127,543,138,518	2015-01-18 14:36:54.696245	2015-01-18 14:39:17.776463	\N	t	1	\N	\N	\N
2206	1	14	48	5	4	Confidence Interval Upper Bound	1.414	124,566,136,542	2015-01-18 14:36:54.733113	2015-01-18 14:39:17.794117	\N	t	1	\N	\N	\N
2207	1	14	48	5	4	Geometric Mean	1.16	126,505,137,485	2015-01-18 14:36:54.752822	2015-01-18 14:39:17.811012	\N	t	1	\N	\N	\N
2212	1	14	48	5	4	Intra-subject CV%	32.2	127,602,135,581	2015-01-18 14:36:54.846163	2015-01-18 14:39:17.826928	\N	f	1	\N	\N	\N
2208	1	14	48	5	4	Measurement Name	molar paraxanthine/caffeine plasma concentration ratio	127,272,136,132	2015-01-18 14:36:54.770934	2015-01-18 14:39:17.84373	\N	t	1	\N	\N	\N
2209	1	14	48	5	4	Measurement Type	concentration ratio	127,345,137,271	2015-01-18 14:36:54.78887	2015-01-18 14:39:17.86074	\N	t	1	\N	\N	\N
2220	1	14	48	5	4	Confidence Interval Lower Bound	0.973	139,542,146,516	2015-01-18 14:39:24.842762	2015-01-18 14:41:03.859507	\N	t	1	\N	\N	\N
2219	1	14	48	5	4	Confidence Interval Upper Bound	1.101	136,566,147,543	2015-01-18 14:39:24.82215	2015-01-18 14:41:03.874371	\N	t	1	\N	\N	\N
2217	1	14	48	5	4	Geometric Mean	1.035	136,509,148,483	2015-01-18 14:39:24.781659	2015-01-18 14:41:03.889414	\N	t	1	\N	\N	\N
2213	1	14	48	5	4	Intra-subject CV%	10.0	136,601,148,581	2015-01-18 14:39:24.655454	2015-01-18 14:41:03.903877	\N	f	1	\N	\N	\N
2216	1	14	48	5	4	Measurement Name	tolbutamide plasma AUC0-t	137,269,149,173	2015-01-18 14:39:24.762366	2015-01-18 14:41:03.921257	\N	t	1	\N	\N	\N
2215	1	14	48	5	4	Measurement Type	AUC0-t	135,168,148,134	2015-01-18 14:39:24.742978	2015-01-18 14:41:03.936556	\N	t	1	\N	\N	\N
2221	1	14	48	5	4	Number of Subjects Included in Measurement	16	136,460,147,449	2015-01-18 14:39:24.861053	2015-01-18 14:41:03.986366	\N	t	1	\N	\N	\N
2224	1	14	48	5	4	Confidence Interval Lower Bound	0.970	146,542,157,517	2015-01-18 14:41:07.410278	2015-01-18 14:43:17.543359	\N	t	1	\N	\N	\N
2225	1	14	48	5	4	Confidence Interval Upper Bound	1.261	143,566,158,542	2015-01-18 14:41:07.429548	2015-01-18 14:43:17.558226	\N	t	1	\N	\N	\N
2226	1	14	48	5	4	Geometric Mean	1.106	146,510,157,485	2015-01-18 14:41:07.448028	2015-01-18 14:43:17.572343	\N	t	1	\N	\N	\N
2227	1	14	48	5	4	Intra-subject CV%	21.3	146,600,157,581	2015-01-18 14:41:07.466731	2015-01-18 14:43:17.587046	\N	f	1	\N	\N	\N
2228	1	14	48	5	4	Measurement Name	tolbutamide plasma concentration	146,184,158,134	2015-01-18 14:41:07.486684	2015-01-18 14:43:17.601606	\N	t	1	\N	\N	\N
2229	1	14	48	5	4	Measurement Type	plasma concentration	145,264,158,183	2015-01-18 14:41:07.504095	2015-01-18 14:43:17.616447	\N	t	1	\N	\N	\N
2230	1	14	48	5	4	Number of Subjects Included in Measurement	16	146,461,157,449	2015-01-18 14:41:07.522747	2015-01-18 14:43:17.644826	\N	t	1	\N	\N	\N
2232	1	14	48	5	4	Confidence Interval Lower Bound	0.810	156,542,167,516	2015-01-18 14:45:44.204453	2015-01-18 14:47:16.485238	\N	t	1	\N	\N	\N
2233	1	14	48	5	4	Confidence Interval Upper Bound	1.614	156,567,168,543	2015-01-18 14:45:44.223566	2015-01-18 14:47:16.500816	\N	t	1	\N	\N	\N
2234	1	14	48	5	4	Geometric Mean	1.143	158,510,167,485	2015-01-18 14:45:44.242176	2015-01-18 14:47:16.516996	\N	t	1	\N	\N	\N
2239	1	14	48	5	4	Intra-subject CV%	59.9	157,603,167,582	2015-01-18 14:45:44.334368	2015-01-18 14:47:16.531758	\N	f	1	\N	\N	\N
2235	1	14	48	5	4	Measurement Name	omeprazole in plasma	154,264,169,176	2015-01-18 14:45:44.260823	2015-01-18 14:47:16.5464	\N	t	1	\N	\N	\N
2236	1	14	48	5	4	Measurement Type	AUC0-t	158,168,168,133	2015-01-18 14:45:44.278468	2015-01-18 14:47:16.560975	\N	t	1	\N	\N	\N
2238	1	14	48	5	4	Number of Subjects Included in Measurement	16	157,462,167,448	2015-01-18 14:45:44.315396	2015-01-18 14:47:16.588172	\N	t	1	\N	\N	\N
2242	1	14	48	5	4	Confidence Interval Lower Bound	0.842	164,541,176,518	2015-01-18 14:47:19.285099	2015-01-18 14:49:08.082282	\N	t	1	\N	\N	\N
2243	1	14	48	5	4	Confidence Interval Upper Bound	1.294	166,566,177,542	2015-01-18 14:47:19.337618	2015-01-18 14:49:08.104475	\N	t	1	\N	\N	\N
2246	1	14	48	5	4	Measurement Name	Molar omeprazole / 5-OH-omeprazole plasma concentration ratio	167,272,179,133	2015-01-18 14:47:19.421044	2015-01-18 14:49:08.150865	\N	t	1	\N	\N	\N
2247	1	14	48	5	4	Measurement Type	plasma concentration ratio	167,373,179,272	2015-01-18 14:47:19.462344	2015-01-18 14:49:08.166478	\N	t	1	\N	\N	\N
2248	1	14	48	5	4	Number of Subjects Included in Measurement	15	167,461,177,449	2015-01-18 14:47:19.54066	2015-01-18 14:49:08.197279	\N	t	1	\N	\N	\N
2249	1	14	48	5	4	Measurement Time	3	167,380,176,371	2015-01-18 14:49:40.862646	2015-01-18 14:49:40.862646	\N	f	1	\N	\N	\N
2250	1	14	48	5	4	Measurement Time Unit	h	167,392,175,377	2015-01-18 14:49:40.972602	2015-01-18 14:49:40.972602	\N	f	1	\N	\N	\N
3407	1	20	47	4	4	Minimum	20.1	626,514,636,490	2015-01-24 13:53:30.652066	2015-01-24 13:53:30.652066	\N	f	1	\N	\N	\N
3412	1	20	47	4	4	Count	16	626,622,637,582	2015-01-24 13:53:54.53891	2015-01-24 13:54:33.663137	\N	t	1	\N	\N	\N
3411	1	20	47	4	4	Measurement Name	Caucasian or of European heritage	640,624,651,453	2015-01-24 13:53:54.518918	2015-01-24 13:54:33.680031	\N	t	1	\N	\N	\N
3410	1	20	47	4	4	Percent	67	640,408,650,390	2015-01-24 13:53:54.498266	2015-01-24 13:54:33.695781	\N	t	1	\N	\N	\N
3416	1	20	47	4	4	Count	8	655,373,667,361	2015-01-24 13:54:37.128255	2015-01-24 13:55:41.097332	\N	t	1	\N	\N	\N
3417	1	20	47	4	4	Measurement Name	African American or of African heritage	654,628,667,433	2015-01-24 13:54:37.230716	2015-01-24 13:55:41.116247	\N	t	1	\N	\N	\N
3418	1	20	47	4	4	Percent	33	655,390,666,375	2015-01-24 13:54:37.285159	2015-01-24 13:55:41.131512	\N	t	1	\N	\N	\N
3419	1	20	47	2	4	Planned Number of Subjects Randomized	24	288,425,300,410	2015-01-24 18:49:47.421137	2015-01-24 18:49:47.421137	\N	f	1	\N	\N	\N
2251	1	14	48	4	4	Adverse Event Name	eructation	591,440,600,394	2015-01-18 15:34:06.347823	2015-01-18 15:36:13.852025	\N	t	1	\N	\N	\N
2257	1	14	48	4	4	Description	shortly after drug intake	591,587,599,479	2015-01-18 15:34:06.476113	2015-01-18 15:36:13.869485	\N	t	1	\N	\N	\N
2252	1	14	48	4	4	Severity (Mild/Moderate/Severe)	mild	588,395,600,369	2015-01-18 15:34:06.376323	2015-01-18 15:36:13.884105	\N	t	1	\N	\N	\N
2254	1	14	48	4	4	Subject Count	10	602,622,613,608	2015-01-18 15:34:06.416123	2015-01-18 15:36:13.897931	\N	t	1	\N	\N	\N
2255	1	14	48	4	4	Subject Percent	58.8	603,658,613,629	2015-01-18 15:34:06.437115	2015-01-18 15:36:13.912418	\N	t	1	\N	\N	\N
2258	1	14	48	4	4	Adverse Event Name	total	550,623,560,579	2015-01-18 15:36:31.669018	2015-01-18 15:38:23.310723	\N	t	1	\N	\N	\N
2260	1	14	48	4	4	Serious/SAE	0	760,466,770,431	2015-01-18 15:36:31.761366	2015-01-18 15:38:23.32743	\N	t	1	\N	\N	\N
2259	1	14	48	4	4	Severity (Mild/Moderate/Severe)	severe	761,419,770,385	2015-01-18 15:36:31.73971	2015-01-18 15:38:23.344995	\N	t	1	\N	\N	\N
2261	1	14	48	4	4	Subject Count	0	760,387,770,369	2015-01-18 15:36:31.780408	2015-01-18 15:38:23.360115	\N	t	1	\N	\N	\N
2270	1	14	48	4	4	Event Count	30	563,471,573,457	2015-01-18 15:39:03.352814	2015-01-18 15:40:53.738332	\N	t	1	\N	\N	\N
2268	1	14	48	4	4	Subject Count	15	564,520,574,507	2015-01-18 15:39:03.315914	2015-01-18 15:40:53.753505	\N	t	1	\N	\N	\N
2269	1	14	48	4	4	Subject Percent	88.2	563,562,574,539	2015-01-18 15:39:03.334391	2015-01-18 15:40:53.76828	\N	t	1	\N	\N	\N
2272	1	14	48	4	4	Number of Subjects Included in Measurement	17	564,534,574,519	2015-01-18 15:40:53.783774	2015-01-18 15:40:53.783774	\N	f	1	\N	\N	\N
3887	1	20	47	6	4	Measurement Name	5-hydroxyomeprazole AUC0-inf	182,355,195,229	2015-01-25 18:22:06.188075	2015-01-25 18:23:08.448528	\N	t	1	\N	\N	\N
2273	1	14	48	4	4	Adverse Event Name	diarrhea	682,439,692,398	2015-01-18 15:42:01.58581	2015-01-18 15:42:56.879136	\N	t	1	\N	\N	\N
2278	1	14	48	4	4	Event Count	1	684,463,692,441	2015-01-18 15:42:01.681722	2015-01-18 15:42:56.895293	\N	t	1	\N	\N	\N
2295	1	14	48	5	4	Confidence Interval Upper Bound	1.237	175,566,188,542	2015-01-18 15:47:04.459547	2015-01-18 15:49:00.257848	\N	t	1	\N	\N	\N
2280	1	14	48	4	4	Adverse Event Name	nausea	683,560,692,525	2015-01-18 15:43:20.384377	2015-01-18 15:43:55.162842	\N	t	1	\N	\N	\N
2285	1	14	48	4	4	Event Count	1	684,583,693,562	2015-01-18 15:43:20.53363	2015-01-18 15:43:55.178735	\N	t	1	\N	\N	\N
2287	1	14	48	4	4	Severity (Mild/Moderate/Severe)	moderate	774,489,783,442	2015-01-18 15:45:18.581335	2015-01-18 15:45:18.581335	\N	f	1	\N	\N	\N
2290	1	14	48	4	4	Adverse Event Name	vomiting	787,421,797,378	2015-01-18 15:45:33.883024	2015-01-18 15:46:51.277534	\N	t	1	\N	\N	\N
2289	1	14	48	4	4	Subject Count	1	760,629,769,608	2015-01-18 15:45:33.862826	2015-01-18 15:46:51.308043	\N	t	1	\N	\N	\N
2294	1	14	48	5	4	Confidence Interval Lower Bound	0.998	175,540,188,516	2015-01-18 15:47:04.441113	2015-01-18 15:49:00.2414	\N	t	1	\N	\N	\N
2296	1	14	48	5	4	Geometric Mean	1.111	176,508,188,484	2015-01-18 15:47:04.479782	2015-01-18 15:49:00.272197	\N	t	1	\N	\N	\N
2297	1	14	48	5	4	Intra-subject CV%	17.4	176,601,188,581	2015-01-18 15:47:04.498301	2015-01-18 15:49:00.286729	\N	f	1	\N	\N	\N
2298	1	14	48	5	4	Measurement Name	Molar omeprazole / 5-OH-omeprazole AUC0-t ratio	176,274,188,133	2015-01-18 15:47:04.516293	2015-01-18 15:49:00.301005	\N	t	1	\N	\N	\N
2299	1	14	48	5	4	Measurement Type	AUC0-t ratio	175,325,187,273	2015-01-18 15:47:04.536165	2015-01-18 15:49:00.315634	\N	t	1	\N	\N	\N
2293	1	14	48	5	4	Number of Subjects Included in Measurement	16	176,461,188,449	2015-01-18 15:47:04.422105	2015-01-18 15:49:00.345746	\N	t	1	\N	\N	\N
2308	1	14	48	5	4	Confidence Interval Lower Bound	0.838	187,540,198,516	2015-01-18 15:49:59.715758	2015-01-18 15:51:28.11897	\N	t	1	\N	\N	\N
2307	1	14	48	5	4	Confidence Interval Upper Bound	1.305	186,566,198,541	2015-01-18 15:49:59.698396	2015-01-18 15:51:28.134427	\N	t	1	\N	\N	\N
2306	1	14	48	5	4	Geometric Mean	1.046	188,508,199,485	2015-01-18 15:49:59.680405	2015-01-18 15:51:28.16777	\N	t	1	\N	\N	\N
2302	1	14	48	5	4	Intra-subject CV%	36.7	188,600,198,581	2015-01-18 15:49:59.608047	2015-01-18 15:51:28.18165	\N	f	1	\N	\N	\N
2305	1	14	48	5	4	Measurement Name	AUC0-t dextromethorphan in plasma	186,293,198,176	2015-01-18 15:49:59.662895	2015-01-18 15:51:28.19611	\N	t	1	\N	\N	\N
2304	1	14	48	5	4	Measurement Type	AUC0-t	188,167,198,133	2015-01-18 15:49:59.645468	2015-01-18 15:51:28.210354	\N	t	1	\N	\N	\N
2303	1	14	48	5	4	Number of Subjects Included in Measurement	15	188,461,198,450	2015-01-18 15:49:59.627583	2015-01-18 15:51:28.240472	\N	t	1	\N	\N	\N
2319	1	14	48	5	4	Confidence Interval Lower Bound	0.962	193,540,208,517	2015-01-18 15:51:36.822221	2015-01-18 15:53:32.734465	\N	t	1	\N	\N	\N
2318	1	14	48	5	4	Confidence Interval Upper Bound	1.328	195,566,208,542	2015-01-18 15:51:36.803391	2015-01-18 15:53:32.748976	\N	t	1	\N	\N	\N
2317	1	14	48	5	4	Geometric Mean	1.131	194,508,208,484	2015-01-18 15:51:36.784624	2015-01-18 15:53:32.763664	\N	t	1	\N	\N	\N
2316	1	14	48	5	4	Intra-subject CV%	25.2	197,601,209,580	2015-01-18 15:51:36.765039	2015-01-18 15:53:32.77863	\N	f	1	\N	\N	\N
2315	1	14	48	5	4	Measurement Name	Molar dextromethorphan/dextrorphan plasma concentration ratio	198,277,207,134	2015-01-18 15:51:36.746786	2015-01-18 15:53:32.793971	\N	t	1	\N	\N	\N
2310	1	14	48	5	4	Measurement Time	3	197,382,206,369	2015-01-18 15:51:36.655761	2015-01-18 15:53:32.809494	\N	f	1	\N	\N	\N
2309	1	14	48	5	4	Measurement Time Unit	h	197,390,206,377	2015-01-18 15:51:36.584209	2015-01-18 15:53:32.825032	\N	f	1	\N	\N	\N
2314	1	14	48	5	4	Measurement Type	plasma concentration ratio	197,373,209,274	2015-01-18 15:51:36.728875	2015-01-18 15:53:32.841133	\N	t	1	\N	\N	\N
2313	1	14	48	5	4	Number of Subjects Included in Measurement	15	198,460,207,449	2015-01-18 15:51:36.71052	2015-01-18 15:53:32.870113	\N	t	1	\N	\N	\N
3891	1	20	47	6	4	Number of Subjects Included in Measurement	21	182,374,193,361	2015-01-25 18:22:06.283789	2015-01-25 18:23:08.463602	\N	t	1	\N	\N	\N
2322	1	14	48	5	4	Confidence Interval Lower Bound	0.894	206,541,218,517	2015-01-18 15:53:35.371412	2015-01-18 16:04:06.149079	\N	t	1	\N	\N	\N
2323	1	14	48	5	4	Confidence Interval Upper Bound	1.159	208,566,217,542	2015-01-18 15:53:35.389425	2015-01-18 16:04:06.163635	\N	t	1	\N	\N	\N
2324	1	14	48	5	4	Geometric Mean	1.018	206,507,218,485	2015-01-18 15:53:35.410295	2015-01-18 16:04:06.17799	\N	t	1	\N	\N	\N
2328	1	14	48	5	4	Intra-subject CV%	21.1	207,601,218,581	2015-01-18 15:53:35.487943	2015-01-18 16:04:06.191808	\N	f	1	\N	\N	\N
2325	1	14	48	5	4	Measurement Name	AUC0-t of midazolam in plasma	207,262,218,175	2015-01-18 15:53:35.429579	2015-01-18 16:04:06.206895	\N	t	1	\N	\N	\N
2326	1	14	48	5	4	Measurement Type	AUC0-t ratio	207,167,218,133	2015-01-18 15:53:35.448994	2015-01-18 16:04:06.221255	\N	t	1	\N	\N	\N
2327	1	14	48	5	4	Number of Subjects Included in Measurement	16	208,461,219,447	2015-01-18 15:53:35.467958	2015-01-18 16:04:06.263219	\N	t	1	\N	\N	\N
2331	1	14	48	5	4	Confidence Interval Lower Bound	0.847	217,540,229,517	2015-01-18 16:04:09.222103	2015-01-18 16:09:30.323174	\N	t	1	\N	\N	\N
2332	1	14	48	5	4	Confidence Interval Upper Bound	1.277	216,568,229,541	2015-01-18 16:04:09.240596	2015-01-18 16:09:30.339846	\N	t	1	\N	\N	\N
2333	1	14	48	5	4	Geometric Mean	1.040	216,510,228,485	2015-01-18 16:04:09.258351	2015-01-18 16:09:30.354671	\N	t	1	\N	\N	\N
2334	1	14	48	5	4	Intra-subject CV%	33.8	216,600,228,581	2015-01-18 16:04:09.276254	2015-01-18 16:09:30.370339	\N	f	1	\N	\N	\N
2335	1	14	48	5	4	Measurement Name	midazolam plasma concentration	216,177,230,133	2015-01-18 16:04:09.295271	2015-01-18 16:09:30.385615	\N	t	1	\N	\N	\N
2338	1	14	48	5	4	Measurement Time	6	218,265,230,256	2015-01-18 16:04:09.351001	2015-01-18 16:09:30.402352	\N	f	1	\N	\N	\N
2339	1	14	48	5	4	Measurement Time Unit	h	216,273,229,264	2015-01-18 16:04:09.369951	2015-01-18 16:09:30.41754	\N	f	1	\N	\N	\N
2336	1	14	48	5	4	Measurement Type	plasma concentration	217,258,230,177	2015-01-18 16:04:09.313682	2015-01-18 16:09:30.434133	\N	t	1	\N	\N	\N
2337	1	14	48	5	4	Number of Subjects Included in Measurement	16	218,461,229,449	2015-01-18 16:04:09.332306	2015-01-18 16:09:30.46643	\N	t	1	\N	\N	\N
2340	1	14	48	5	4	Measurement Time	6	126,350,136,342	2015-01-18 16:10:04.598137	2015-01-18 16:10:04.598137	\N	f	1	\N	\N	\N
2341	1	14	48	5	4	Measurement Time Unit	h	126,359,135,349	2015-01-18 16:10:04.67359	2015-01-18 16:10:04.67359	\N	f	1	\N	\N	\N
2342	1	14	48	5	4	Measurement Time	24	146,276,156,260	2015-01-18 16:12:03.95028	2015-01-18 16:12:03.95028	\N	f	1	\N	\N	\N
2343	1	14	48	5	4	Measurement Time Unit	h	146,283,158,272	2015-01-18 16:12:04.036989	2015-01-18 16:12:04.036989	\N	f	1	\N	\N	\N
2349	1	14	48	5	4	Measurement Name	Molar caffeine/paraxanthine plasma concentration ratio	729,386,742,175	2015-01-18 16:13:16.310672	2015-01-18 16:16:29.510494	\N	t	1	\N	\N	\N
2351	1	14	48	5	4	Measurement Time	6	738,195,750,187	2015-01-18 16:13:16.349094	2015-01-18 16:16:29.527616	\N	t	1	\N	\N	\N
2352	1	14	48	5	4	Measurement Time Unit	h	740,203,751,194	2015-01-18 16:13:16.367548	2015-01-18 16:16:29.544797	\N	t	1	\N	\N	\N
2353	1	14	48	5	4	Measurement Type	correlation to the AUC0-t of the parent substance	675,541,687,168	2015-01-18 16:13:16.385426	2015-01-18 16:16:29.560899	\N	t	1	\N	\N	\N
2350	1	14	48	5	4	Measurement Unit	Pearson's correlation coefficient	858,258,866,153	2015-01-18 16:13:16.329897	2015-01-18 16:16:29.577095	\N	t	1	\N	\N	\N
2344	1	14	48	5	4	Number of Subjects Included in Measurement	16	730,438,739,424	2015-01-18 16:13:16.213196	2015-01-18 16:16:29.591002	\N	t	1	\N	\N	\N
2354	1	14	48	5	4	p-value	=0.05	867,184,876,148	2015-01-18 16:16:29.606534	2015-01-18 16:16:29.606534	\N	f	1	\N	\N	\N
2361	1	14	48	5	4	Correlation	0.842	750,476,759,451	2015-01-18 16:16:31.317182	2015-01-18 16:17:04.04528	\N	t	1	\N	\N	\N
2348	1	14	48	5	4	Correlation	0.531	729,475,739,451	2015-01-18 16:13:16.292213	2015-01-18 16:17:12.656871	\N	t	1	\N	\N	\N
2360	1	14	48	5	4	Measurement Name	tolbutamide plasma concentration	751,307,760,177	2015-01-18 16:16:31.29689	2015-01-18 16:41:12.593238	\N	t	1	\N	\N	\N
2358	1	14	48	5	4	Measurement Time	24	749,318,760,305	2015-01-18 16:16:31.260675	2015-01-18 16:41:12.610229	\N	t	1	\N	\N	\N
2357	1	14	48	5	4	Measurement Time Unit	h	751,328,759,314	2015-01-18 16:16:31.243107	2015-01-18 16:41:12.625212	\N	t	1	\N	\N	\N
2362	1	14	48	5	4	Number of Subjects Included in Measurement	16	750,436,760,423	2015-01-18 16:16:31.338641	2015-01-18 16:42:26.095462	\N	t	1	\N	\N	\N
2355	1	14	48	5	4	p-value	=0.01	865,223,877,184	2015-01-18 16:16:31.206413	2015-01-18 16:42:26.112393	\N	f	1	\N	\N	\N
2366	1	14	48	5	4	Correlation	0.697	760,475,772,451	2015-01-18 16:42:41.086475	2015-01-18 16:44:33.188044	\N	t	1	\N	\N	\N
2367	1	14	48	5	4	Measurement Name	Molar omeprazole/5-OH-omeprazole plasma concentration ratio	761,410,772,176	2015-01-18 16:42:41.105163	2015-01-18 16:44:33.204058	\N	t	1	\N	\N	\N
2368	1	14	48	5	4	Measurement Time	3	771,195,779,186	2015-01-18 16:42:41.125258	2015-01-18 16:44:33.219565	\N	t	1	\N	\N	\N
2369	1	14	48	5	4	Measurement Time Unit	h	771,203,779,193	2015-01-18 16:42:41.143752	2015-01-18 16:44:33.236174	\N	t	1	\N	\N	\N
2365	1	14	48	5	4	Number of Subjects Included in Measurement	15	759,437,772,424	2015-01-18 16:42:41.066815	2015-01-18 16:44:33.281529	\N	t	1	\N	\N	\N
2377	1	14	48	5	4	Correlation	0.905	779,476,791,451	2015-01-18 16:44:46.142667	2015-01-18 16:46:37.383862	\N	t	1	\N	\N	\N
2376	1	14	48	5	4	Measurement Name	Molar omeprazole/5-OH-omepazole AUC0-t ratio	780,363,791,177	2015-01-18 16:44:46.12321	2015-01-18 16:46:37.399472	\N	t	1	\N	\N	\N
2378	1	14	48	5	4	Number of Subjects Included in Measurement	16	780,437,791,424	2015-01-18 16:44:46.162138	2015-01-18 16:46:37.442077	\N	t	1	\N	\N	\N
2385	1	14	48	5	4	Correlation	0.971	791,475,803,452	2015-01-18 16:46:40.419952	2015-01-18 16:47:57.856762	\N	t	1	\N	\N	\N
2384	1	14	48	5	4	Measurement Name	Molar dextromethorphan/dextrorphan plasma concentration	789,397,803,177	2015-01-18 16:46:40.399007	2015-01-18 16:47:57.887445	\N	t	1	\N	\N	\N
2383	1	14	48	5	4	Measurement Time	3	801,214,812,206	2015-01-18 16:46:40.380026	2015-01-18 16:47:57.956171	\N	t	1	\N	\N	\N
2382	1	14	48	5	4	Measurement Time Unit	h	800,222,812,212	2015-01-18 16:46:40.361228	2015-01-18 16:47:57.971142	\N	t	1	\N	\N	\N
2386	1	14	48	5	4	Number of Subjects Included in Measurement	15	791,436,803,425	2015-01-18 16:46:40.438492	2015-01-18 16:47:58.014601	\N	t	1	\N	\N	\N
2391	1	14	48	5	4	Correlation	0.933	811,475,820,451	2015-01-18 16:48:01.621181	2015-01-18 16:49:40.273051	\N	t	1	\N	\N	\N
2392	1	14	48	5	4	Measurement Name	Midazolam plasma concentration	812,302,821,176	2015-01-18 16:48:01.640287	2015-01-18 16:49:40.28841	\N	t	1	\N	\N	\N
2393	1	14	48	5	4	Measurement Time	6	810,310,821,299	2015-01-18 16:48:01.659339	2015-01-18 16:49:40.305164	\N	t	1	\N	\N	\N
2394	1	14	48	5	4	Measurement Time Unit	h	812,319,821,306	2015-01-18 16:48:01.678958	2015-01-18 16:49:40.320214	\N	t	1	\N	\N	\N
2390	1	14	48	5	4	Number of Subjects Included in Measurement	16	811,436,820,422	2015-01-18 16:48:01.601702	2015-01-18 16:49:40.363866	\N	t	1	\N	\N	\N
3895	1	20	47	6	4	Geometric Mean	1.01	197,531,207,510	2015-01-25 18:23:12.105526	2015-01-25 18:24:13.848177	\N	t	1	\N	\N	\N
3441	1	20	47	3	4	Start Time	11	776,93,785,81	2015-01-24 18:54:52.042544	2015-01-25 22:19:42.430033	\N	t	1	\N	\N	\N
3431	1	20	47	3	4	Start Time	1	701,92,711,81	2015-01-24 18:54:34.571481	2015-01-25 22:19:51.973139	\N	t	1	\N	\N	\N
3420	1	20	47	2	4	Planned Number of Subjects Completing the Study	16	289,646,299,632	2015-01-24 18:49:47.490557	2015-01-24 18:49:47.490557	\N	f	1	\N	\N	\N
3426	1	20	47	3	4	Drug Amount	3	172,241,183,231	2015-01-24 18:51:52.442412	2015-01-24 18:54:34.834958	\N	t	1	\N	\N	\N
3427	1	20	47	3	4	Drug Amount Unit	mg	174,259,185,240	2015-01-24 18:51:52.460681	2015-01-24 18:54:34.860304	\N	t	1	\N	\N	\N
3425	1	20	47	3	4	Drug Name	midazolam	173,233,183,177	2015-01-24 18:51:52.422447	2015-01-24 18:54:34.875138	\N	t	1	\N	\N	\N
3430	1	20	47	3	4	Formulation	oral syrup	172,306,183,257	2015-01-24 18:51:52.516233	2015-01-24 18:54:34.889988	\N	t	1	\N	\N	\N
3428	1	20	47	3	4	Frequency	single	157,317,170,286	2015-01-24 18:51:52.479104	2015-01-24 18:54:34.904384	\N	t	1	\N	\N	\N
2462	1	14	48	2	4	Drug Name	placebo	330,108,339,72	2015-01-18 16:49:45.07358	2015-01-18 16:53:42.760201	\N	t	1	\N	\N	\N
2457	1	14	48	2	4	Formulation	capsule	329,143,340,106	2015-01-18 16:49:44.948848	2015-01-18 16:53:42.791234	\N	t	1	\N	\N	\N
2414	1	14	48	4	4	Subject Count	0	630,408,640,392	2015-01-18 16:49:44.035084	2015-01-18 16:57:25.230808	\N	t	1	\N	\N	\N
2405	1	14	48	4	4	Event Count	11	550,527,560,492	2015-01-18 16:49:43.838522	2015-01-18 17:01:31.209532	\N	t	1	\N	\N	\N
2403	1	14	48	4	4	Number of Subjects Included in Measurement	16	551,664,561,650	2015-01-18 16:49:43.801078	2015-01-18 17:01:31.225584	\N	f	1	\N	\N	\N
2407	1	14	48	4	4	Subject Count	5	550,649,560,640	2015-01-18 16:49:43.876247	2015-01-18 17:01:31.24074	\N	t	1	\N	\N	\N
2406	1	14	48	4	4	Subject Percent	31.3	563,385,573,363	2015-01-18 16:49:43.857777	2015-01-18 17:01:31.261818	\N	t	1	\N	\N	\N
2401	1	14	48	4	4	Event Count	0	684,490,690,479	2015-01-18 16:49:43.750542	2015-01-18 18:25:16.373088	\N	t	1	\N	\N	\N
3429	1	20	47	2	4	Route	oral	817,561,827,531	2015-01-24 18:51:52.497628	2015-01-24 18:54:34.918469	\N	t	1	\N	\N	\N
3422	1	20	47	3	4	Start Time Unit	day	160,163,168,139	2015-01-24 18:51:52.363311	2015-01-24 18:54:34.933176	\N	t	1	\N	\N	\N
3446	1	20	47	3	4	Drug Amount	15	187,113,197,96	2015-01-24 18:55:17.920976	2015-01-24 18:56:17.884496	\N	t	1	\N	\N	\N
3445	1	20	47	3	4	Drug Amount Unit	mg	189,134,199,116	2015-01-24 18:55:17.902221	2015-01-24 18:56:17.899324	\N	t	1	\N	\N	\N
3447	1	20	47	3	4	Drug Name	pioglitazone	173,343,183,308	2015-01-24 18:55:17.938694	2015-01-24 18:56:17.912882	\N	t	1	\N	\N	\N
3442	1	20	47	3	4	Formulation	tablet	188,170,197,135	2015-01-24 18:55:17.802826	2015-01-24 18:56:17.926604	\N	t	1	\N	\N	\N
3450	1	20	47	3	4	Start Time	2	718,90,725,81	2015-01-24 18:55:18.049389	2015-01-24 18:56:27.611544	\N	t	1	\N	\N	\N
3449	1	20	47	3	4	Start Time	12	792,96,799,82	2015-01-24 18:55:17.994764	2015-01-24 18:56:36.630666	\N	t	1	\N	\N	\N
3541	1	20	47	5	4	Maximum	2.0	426,639,435,621	2015-01-24 19:18:41.032174	2015-01-24 19:19:45.32802	\N	t	1	\N	\N	\N
3548	1	20	47	5	4	Measurement Type	tmax	375,621,385,599	2015-01-24 19:18:41.162569	2015-01-24 19:19:45.347257	\N	t	1	\N	\N	\N
3545	1	20	47	5	4	Measurement Unit	hr	385,618,399,603	2015-01-24 19:18:41.106953	2015-01-24 19:19:45.361137	\N	t	1	\N	\N	\N
3539	1	20	47	5	4	Median	0.5	410,621,421,599	2015-01-24 19:18:40.996003	2015-01-24 19:19:45.377511	\N	t	1	\N	\N	\N
3540	1	20	47	5	4	Minimum	0.5	422,621,437,604	2015-01-24 19:18:41.014212	2015-01-24 19:19:45.391864	\N	t	1	\N	\N	\N
3549	1	20	47	5	4	Number of Subjects Included in Measurement	24	441,225,450,210	2015-01-24 19:19:51.317875	2015-01-24 19:20:14.192105	\N	t	1	\N	\N	\N
3553	1	20	47	5	4	Maximum	2.0	455,638,464,621	2015-01-24 19:19:51.458122	2015-01-24 19:23:02.162505	\N	t	1	\N	\N	\N
3555	1	20	47	5	4	Median	0.5	441,619,453,600	2015-01-24 19:19:51.495727	2015-01-24 19:23:02.205991	\N	t	1	\N	\N	\N
3554	1	20	47	5	4	Minimum	0.5	454,619,468,604	2015-01-24 19:19:51.477054	2015-01-24 19:23:02.221055	\N	t	1	\N	\N	\N
3455	1	20	47	3	4	Drug Amount	40	189,257,196,240	2015-01-24 18:56:38.85025	2015-01-24 18:57:32.307309	\N	t	1	\N	\N	\N
3456	1	20	47	3	4	Drug Amount Unit	mg	189,277,198,256	2015-01-24 18:56:38.868129	2015-01-24 18:57:32.324979	\N	t	1	\N	\N	\N
3454	1	20	47	3	4	Drug Name	omeprazole	189,238,198,174	2015-01-24 18:56:38.831373	2015-01-24 18:57:32.339655	\N	t	1	\N	\N	\N
3457	1	20	47	3	4	Formulation	capsule	187,322,197,280	2015-01-24 18:56:38.886533	2015-01-24 18:57:32.353673	\N	t	1	\N	\N	\N
3458	1	20	47	3	4	Start Time	3	732,89,741,81	2015-01-24 18:56:38.928163	2015-01-24 18:57:40.780217	\N	t	1	\N	\N	\N
3459	1	20	47	3	4	Start Time	13	805,95,814,81	2015-01-24 18:56:38.960297	2015-01-24 18:58:00.602225	\N	t	1	\N	\N	\N
3465	1	20	47	3	4	Drug Amount	10	202,137,212,122	2015-01-24 18:58:42.94491	2015-01-24 18:59:33.525544	\N	t	1	\N	\N	\N
3464	1	20	47	3	4	Drug Amount Unit	mg	202,158,215,137	2015-01-24 18:58:42.92806	2015-01-24 18:59:33.544246	\N	t	1	\N	\N	\N
3466	1	20	47	3	4	Drug Name	rosuvastatin	202,121,212,59	2015-01-24 18:58:42.962609	2015-01-24 18:59:33.558279	\N	t	1	\N	\N	\N
3463	1	20	47	3	4	Formulation	tablet	203,188,212,157	2015-01-24 18:58:42.910405	2015-01-24 18:59:33.573074	\N	t	1	\N	\N	\N
3468	1	20	47	3	4	Start Time	4	746,91,755,80	2015-01-24 18:58:43.042297	2015-01-24 18:59:44.039046	\N	t	1	\N	\N	\N
3467	1	20	47	3	4	Start Time	14	822,96,832,81	2015-01-24 18:58:42.995029	2015-01-24 18:59:59.315642	\N	t	1	\N	\N	\N
3474	1	20	47	3	4	Drug Amount	500	229,302,239,282	2015-01-24 19:00:09.611898	2015-01-24 19:02:08.574458	\N	t	1	\N	\N	\N
3475	1	20	47	3	4	Drug Amount Unit	mg	232,321,242,302	2015-01-24 19:00:09.631498	2015-01-24 19:02:08.590137	\N	t	1	\N	\N	\N
3473	1	20	47	3	4	Drug Name	vercirnon	231,284,242,232	2015-01-24 19:00:09.593594	2015-01-24 19:02:08.603892	\N	t	1	\N	\N	\N
3471	1	20	47	3	4	End Time	14	232,171,241,155	2015-01-24 19:00:09.556209	2015-01-24 19:02:08.61772	\N	t	1	\N	\N	\N
3478	1	20	47	3	4	Formulation	capsules	218,231,226,188	2015-01-24 19:00:09.687514	2015-01-24 19:02:08.631807	\N	t	1	\N	\N	\N
3476	1	20	47	3	4	Frequency	BID	216,255,227,232	2015-01-24 19:00:09.650173	2015-01-24 19:02:08.645959	\N	t	1	\N	\N	\N
2510	1	14	48	5	4	Correlation	0.698	730,554,738,528	2015-01-18 16:49:46.291191	2015-01-18 19:12:35.46224	\N	t	1	\N	\N	\N
2511	1	14	48	5	4	Number of Subjects Included in Measurement	16	729,512,740,499	2015-01-18 16:49:46.309932	2015-01-18 19:12:35.527229	\N	t	1	\N	\N	\N
2499	1	14	48	5	4	Correlation	0.928	750,553,760,527	2015-01-18 16:49:46.072568	2015-01-18 19:34:53.160196	\N	t	1	\N	\N	\N
2498	1	14	48	5	4	Number of Subjects Included in Measurement	16	751,513,760,500	2015-01-18 16:49:46.035462	2015-01-18 19:34:53.220703	\N	t	1	\N	\N	\N
2494	1	14	48	5	4	Correlation	0.539	759,552,770,528	2015-01-18 16:49:45.948279	2015-01-18 19:35:36.447113	\N	t	1	\N	\N	\N
2495	1	14	48	5	4	Number of Subjects Included in Measurement	16	760,513,772,500	2015-01-18 16:49:45.967774	2015-01-18 19:35:36.516957	\N	t	1	\N	\N	\N
2486	1	14	48	5	4	Correlation	0.771	781,554,789,529	2015-01-18 16:49:45.786289	2015-01-18 19:36:22.414139	\N	t	1	\N	\N	\N
2485	1	14	48	5	4	Number of Subjects Included in Measurement	16	781,514,791,499	2015-01-18 16:49:45.762584	2015-01-18 19:36:22.444799	\N	t	1	\N	\N	\N
2478	1	14	48	5	4	Correlation	0.983	790,552,802,529	2015-01-18 16:49:45.622974	2015-01-18 19:37:42.105562	\N	t	1	\N	\N	\N
2477	1	14	48	5	4	Number of Subjects Included in Measurement	15	790,513,803,501	2015-01-18 16:49:45.604521	2015-01-18 19:37:42.163964	\N	t	1	\N	\N	\N
2473	1	14	48	5	4	Number of Subjects Included in Measurement	16	810,514,822,500	2015-01-18 16:49:45.519765	2015-01-18 19:38:21.425935	\N	t	1	\N	\N	\N
3469	1	20	47	3	4	Start Time	5	216,308,227,298	2015-01-24 19:00:09.471343	2015-01-24 19:02:08.674377	\N	t	1	\N	\N	\N
3470	1	20	47	3	4	Start Time Unit	day	216,296,226,271	2015-01-24 19:00:09.537095	2015-01-24 19:02:08.68915	\N	t	1	\N	\N	\N
3479	1	20	47	3	4	Fasted/Fed	fed	303,133,315,86	2015-01-24 19:02:58.719975	2015-01-24 19:02:58.719975	\N	f	1	\N	\N	\N
3483	1	20	47	5	4	% Confidence Interval	95	773,218,781,205	2015-01-24 19:11:19.378831	2015-01-24 19:12:29.287507	\N	t	1	\N	\N	\N
3495	1	20	47	5	4	Measurement Name	Midazolam	410,110,422,62	2015-01-24 19:12:29.134234	2015-01-24 19:13:36.818213	\N	t	1	\N	\N	\N
3498	1	20	47	5	4	Measurement Time Unit	Day	425,83,437,60	2015-01-24 19:12:29.190572	2015-01-24 19:13:36.834444	\N	t	1	\N	\N	\N
3490	1	20	47	5	4	Number of Subjects Included in Measurement	24	409,227,421,208	2015-01-24 19:12:29.030909	2015-01-24 19:13:36.851345	\N	t	1	\N	\N	\N
3507	1	20	47	5	4	Measurement Time	1	425,91,437,80	2015-01-24 19:13:36.698473	2015-01-24 19:14:04.917746	\N	t	1	\N	\N	\N
3511	1	20	47	5	4	Confidence Interval Lower Bound	31.0	425,278,435,258	2015-01-24 19:14:27.100028	2015-01-24 19:15:52.854042	\N	t	1	\N	\N	\N
3512	1	20	47	5	4	Confidence Interval Upper Bound	41.7	424,304,437,281	2015-01-24 19:14:27.120358	2015-01-24 19:15:52.869564	\N	t	1	\N	\N	\N
3514	1	20	47	5	4	Geometric Mean	35.9	409,279,421,254	2015-01-24 19:14:27.162261	2015-01-24 19:15:52.908485	\N	t	1	\N	\N	\N
3519	1	20	47	5	4	Measurement Type	AUC0-inf	374,295,386,255	2015-01-24 19:14:27.26255	2015-01-24 19:15:52.930999	\N	t	1	\N	\N	\N
3516	1	20	47	5	4	Measurement Unit	ng*hr/mL	386,301,398,257	2015-01-24 19:14:27.20336	2015-01-24 19:15:52.947303	\N	t	1	\N	\N	\N
3523	1	20	47	5	4	Geometric Mean	34.1	409,365,422,341	2015-01-24 19:15:55.113594	2015-01-24 19:16:53.45843	\N	t	1	\N	\N	\N
3522	1	20	47	5	4	Measurement Unit	ng*hr/mL	386,386,399,344	2015-01-24 19:15:55.075336	2015-01-24 19:16:53.489091	\N	t	1	\N	\N	\N
3897	1	20	47	6	4	Coefficient of Variation within Subject	13.7	197,642,206,622	2015-01-25 18:23:12.140322	2015-01-25 18:24:13.78057	\N	f	1	\N	\N	\N
3893	1	20	47	6	4	Confidence Interval Lower Bound	0.93	198,589,206,569	2015-01-25 18:23:12.069109	2015-01-25 18:24:13.798347	\N	t	1	\N	\N	\N
3312	1	20	47	1	4	DOI (Digital Object Identifier)	10.1007/s00228-013-1592-7	52,197,63,82	2015-01-24 02:56:40.354292	2015-01-24 02:57:47.973477	\N	t	1	\N	\N	\N
3313	1	20	47	1	4	Journal	Eur J Clin Pharmacol	39,149,49,60	2015-01-24 02:56:40.391457	2015-01-24 02:57:47.990436	\N	t	1	\N	\N	\N
3316	1	20	47	1	4	Pages	37-45	39,217,49,190	2015-01-24 02:56:40.456481	2015-01-24 02:57:48.010514	\N	t	1	\N	\N	\N
3320	1	20	47	1	4	Day	8	296,364,306,354	2015-01-24 02:57:47.885128	2015-01-24 02:58:10.217999	\N	t	1	\N	\N	\N
3319	1	20	47	1	4	Month	October	294,399,305,362	2015-01-24 02:57:47.865872	2015-01-24 02:58:10.234076	\N	t	1	\N	\N	\N
3318	1	20	47	1	4	Year	2013	295,421,303,395	2015-01-24 02:57:47.845786	2015-01-24 02:58:10.248354	\N	t	1	\N	\N	\N
3317	1	20	47	1	4	Title	Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates	124,597,194,57	2015-01-24 02:56:40.475871	2015-01-24 02:59:22.623245	\N	t	1	\N	\N	\N
3314	1	20	47	1	4	Volume	70	39,189,49,176	2015-01-24 02:56:40.418792	2015-01-24 02:59:22.63734	\N	t	1	\N	\N	\N
3322	1	20	47	1	4	First Name or Initial	Lynda	216,97,227,60	2015-01-24 02:59:22.527901	2015-01-24 02:59:52.455002	\N	t	1	\N	\N	\N
3321	1	20	47	1	4	Last Name	Haberer	216,153,227,108	2015-01-24 02:59:22.508923	2015-01-24 02:59:52.4702	\N	t	1	\N	\N	\N
3323	1	20	47	1	4	Middle Name or Initial(s)	J	216,109,227,96	2015-01-24 02:59:22.546799	2015-01-24 02:59:52.484586	\N	t	1	\N	\N	\N
2627	1	14	48	3	4	Confidence Interval Lower Bound	3.19	213,488,225,470	2015-01-18 16:49:48.825543	2015-01-18 19:10:03.43222	\N	t	1	\N	\N	\N
2626	1	14	48	3	4	Confidence Interval Upper Bound	5.20	213,508,226,491	2015-01-18 16:49:48.787209	2015-01-18 19:10:03.447728	\N	t	1	\N	\N	\N
2625	1	14	48	3	4	Geometric Mean	4.07	215,468,227,448	2015-01-18 16:49:48.767858	2015-01-18 19:10:03.463352	\N	t	1	\N	\N	\N
3324	1	20	47	2	4	ClinicalTrials.gov Identifier	NCT01489943	713,641,725,567	2015-01-24 03:00:01.521804	2015-01-24 03:54:46.357749	\N	t	1	\N	\N	\N
3325	1	20	47	2	4	Sponsor Study Number	CCX114671	714,428,724,365	2015-01-24 03:00:01.585403	2015-01-24 03:54:46.373551	\N	t	1	\N	\N	\N
3327	1	20	47	2	4	Blinding	open-label	701,476,709,424	2015-01-24 03:54:46.228252	2015-01-24 03:56:51.321062	\N	t	1	\N	\N	\N
3329	1	20	47	2	4	Randomization	single-sequence	700,557,710,479	2015-01-24 03:54:46.269697	2015-01-24 03:56:51.337427	\N	t	1	\N	\N	\N
3333	1	20	47	2	4	Maximum	55	333,549,344,534	2015-01-24 04:04:59.494133	2015-01-24 04:05:44.877719	\N	t	1	\N	\N	\N
3332	1	20	47	2	4	Minimum	18	333,530,346,518	2015-01-24 04:04:59.474448	2015-01-24 04:05:44.927525	\N	t	1	\N	\N	\N
3894	1	20	47	6	4	Confidence Interval Upper Bound	1.09	198,612,207,591	2015-01-25 18:23:12.087356	2015-01-25 18:24:13.831552	\N	t	1	\N	\N	\N
3896	1	20	47	6	4	Measurement Name	5-hydroxyomeprazole AUC0-inf/omeprazole AUC0-inf	198,359,220,230	2015-01-25 18:23:12.122761	2015-01-25 18:24:13.863695	\N	t	1	\N	\N	\N
3341	1	20	47	2	4	Patient	healthy	318,533,331,493	2015-01-24 04:04:59.801311	2015-01-24 04:04:59.801311	\N	f	1	\N	\N	\N
2700	1	14	48	2	4	Confidence Interval Lower Bound	72.3	174,519,190,508	2015-01-18 16:49:50.406944	2015-01-18 18:57:18.825967	\N	t	1	\N	\N	\N
2699	1	14	48	2	4	Confidence Interval Upper Bound	104.6	151,519,168,509	2015-01-18 16:49:50.388716	2015-01-18 18:57:18.841523	\N	t	1	\N	\N	\N
2698	1	14	48	2	4	Geometric Mean	87.0	196,520,212,510	2015-01-18 16:49:50.369444	2015-01-18 18:57:18.858919	\N	t	1	\N	\N	\N
2693	1	14	48	2	4	Confidence Interval Lower Bound	75.0	175,529,191,519	2015-01-18 16:49:50.262215	2015-01-18 18:58:18.405549	\N	t	1	\N	\N	\N
2692	1	14	48	2	4	Confidence Interval Upper Bound	120.0	149,529,169,518	2015-01-18 16:49:50.243443	2015-01-18 18:58:18.423394	\N	t	1	\N	\N	\N
2691	1	14	48	2	4	Geometric Mean	95.0	199,529,216,518	2015-01-18 16:49:50.22501	2015-01-18 18:58:18.439221	\N	t	1	\N	\N	\N
2687	1	14	48	2	4	Number of Subjects Included in Measurement	13	835,631,844,621	2015-01-18 16:49:50.097886	2015-01-18 18:58:18.483609	\N	f	1	\N	\N	\N
2686	1	14	48	2	4	Confidence Interval Lower Bound	2.84	174,540,192,529	2015-01-18 16:49:50.034075	2015-01-18 18:59:01.411284	\N	t	1	\N	\N	\N
2685	1	14	48	2	4	Confidence Interval Upper Bound	6.62	153,540,170,528	2015-01-18 16:49:49.998368	2015-01-18 18:59:01.428561	\N	t	1	\N	\N	\N
2684	1	14	48	2	4	Geometric Mean	4.33	199,540,216,528	2015-01-18 16:49:49.980171	2015-01-18 18:59:01.443447	\N	t	1	\N	\N	\N
2674	1	14	48	3	4	Confidence Interval Lower Bound	0.76	135,489,142,469	2015-01-18 16:49:49.756634	2015-01-18 19:00:49.740827	\N	t	1	\N	\N	\N
2673	1	14	48	3	4	Confidence Interval Upper Bound	1.56	134,509,143,490	2015-01-18 16:49:49.737901	2015-01-18 19:00:49.756368	\N	t	1	\N	\N	\N
2672	1	14	48	3	4	Geometric Mean	1.09	134,469,143,448	2015-01-18 16:49:49.71941	2015-01-18 19:00:49.772336	\N	t	1	\N	\N	\N
2663	1	14	48	3	4	Confidence Interval Lower Bound	4.40	155,489,163,469	2015-01-18 16:49:49.535757	2015-01-18 19:02:16.315163	\N	t	1	\N	\N	\N
2664	1	14	48	3	4	Confidence Interval Upper Bound	8.63	155,511,162,489	2015-01-18 16:49:49.554155	2015-01-18 19:02:16.329715	\N	t	1	\N	\N	\N
2665	1	14	48	3	4	Geometric Mean	6.16	155,468,164,447	2015-01-18 16:49:49.574705	2015-01-18 19:02:16.343263	\N	t	1	\N	\N	\N
2653	1	14	48	3	4	Confidence Interval Lower Bound	0.583	165,494,176,470	2015-01-18 16:49:49.343756	2015-01-18 19:03:12.303605	\N	t	1	\N	\N	\N
2654	1	14	48	3	4	Confidence Interval Upper Bound	1.10	163,513,176,494	2015-01-18 16:49:49.36129	2015-01-18 19:03:12.319969	\N	t	1	\N	\N	\N
2655	1	14	48	3	4	Geometric Mean	0.800	162,468,175,443	2015-01-18 16:49:49.378685	2015-01-18 19:03:12.334524	\N	t	1	\N	\N	\N
2647	1	14	48	3	4	Confidence Interval Lower Bound	0.615	185,492,194,469	2015-01-18 16:49:49.221457	2015-01-18 19:07:56.646149	\N	t	1	\N	\N	\N
2646	1	14	48	3	4	Confidence Interval Upper Bound	1.03	186,513,195,494	2015-01-18 16:49:49.202975	2015-01-18 19:07:56.661017	\N	t	1	\N	\N	\N
2645	1	14	48	3	4	Geometric Mean	0.795	186,468,193,444	2015-01-18 16:49:49.184778	2015-01-18 19:07:56.676048	\N	t	1	\N	\N	\N
2637	1	14	48	3	4	Confidence Interval Lower Bound	0.137	194,492,206,471	2015-01-18 16:49:49.019457	2015-01-18 19:09:05.002345	\N	t	1	\N	\N	\N
2636	1	14	48	3	4	Confidence Interval Upper Bound	0.504	194,518,207,494	2015-01-18 16:49:49.001464	2015-01-18 19:09:05.030366	\N	t	1	\N	\N	\N
2635	1	14	48	3	4	Geometric Mean	0.263	193,467,206,444	2015-01-18 16:49:48.983299	2015-01-18 19:09:05.061177	\N	t	1	\N	\N	\N
3336	1	20	47	2	4	Measurement Name	age	335,618,344,599	2015-01-24 04:04:59.552745	2015-01-24 04:05:44.893861	\N	t	1	\N	\N	\N
3337	1	20	47	2	4	Measurement Unit	years	334,580,344,550	2015-01-24 04:04:59.603496	2015-01-24 04:05:44.910422	\N	t	1	\N	\N	\N
3345	1	20	47	2	4	Maximum	female	319,643,329,606	2015-01-24 04:05:53.79268	2015-01-24 04:06:37.462754	\N	t	1	\N	\N	\N
3344	1	20	47	2	4	Minimum	male	321,591,329,563	2015-01-24 04:05:53.775549	2015-01-24 04:06:37.479671	\N	t	1	\N	\N	\N
3958	1	20	47	6	4	Minimum	4	630,428,642,420	2015-01-25 18:48:03.91113	2015-01-25 18:48:03.91113	\N	f	1	\N	\N	\N
2746	1	14	48	2	4	Confidence Interval Lower Bound	2.04	320,499,336,488	2015-01-18 16:49:51.40232	2015-01-18 18:43:51.736143	\N	f	1	\N	\N	\N
3525	1	20	47	5	4	Confidence Interval Lower Bound	29.5	426,367,435,345	2015-01-24 19:15:55.151487	2015-01-24 19:16:53.410499	\N	t	1	\N	\N	\N
3524	1	20	47	5	4	Confidence Interval Upper Bound	39.5	425,388,436,368	2015-01-24 19:15:55.132525	2015-01-24 19:16:53.424828	\N	t	1	\N	\N	\N
2748	1	14	48	2	4	Confidence Interval Upper Bound	5.75	299,500,316,488	2015-01-18 16:49:51.443387	2015-01-18 18:43:51.753352	\N	f	1	\N	\N	\N
2745	1	14	48	2	4	Geometric Mean	3.42	341,499,357,488	2015-01-18 16:49:51.383559	2015-01-18 18:43:51.774265	\N	f	1	\N	\N	\N
2741	1	14	48	2	4	Maximum	4.00	298,508,314,498	2015-01-18 16:49:51.294676	2015-01-18 18:44:36.885222	\N	t	1	\N	\N	\N
2740	1	14	48	2	4	Median	2.50	341,509,357,498	2015-01-18 16:49:51.276583	2015-01-18 18:44:36.930311	\N	t	1	\N	\N	\N
2739	1	14	48	2	4	Minimum	0.50	318,509,336,498	2015-01-18 16:49:51.258107	2015-01-18 18:44:36.944168	\N	t	1	\N	\N	\N
2734	1	14	48	2	4	Confidence Interval Lower Bound	9.8	324,521,336,507	2015-01-18 16:49:51.150617	2015-01-18 18:45:36.010617	\N	t	1	\N	\N	\N
2735	1	14	48	2	4	Confidence Interval Upper Bound	37.7	303,520,320,507	2015-01-18 16:49:51.170817	2015-01-18 18:45:36.028718	\N	t	1	\N	\N	\N
2733	1	14	48	2	4	Geometric Mean	19.2	341,519,357,508	2015-01-18 16:49:51.129931	2015-01-18 18:45:36.044587	\N	t	1	\N	\N	\N
2728	1	14	48	2	4	Confidence Interval Lower Bound	13.7	319,529,335,518	2015-01-18 16:49:51.01498	2015-01-18 18:48:45.965556	\N	t	1	\N	\N	\N
2727	1	14	48	2	4	Confidence Interval Upper Bound	58.0	298,530,314,518	2015-01-18 16:49:50.994037	2015-01-18 18:48:45.980428	\N	t	1	\N	\N	\N
2726	1	14	48	2	4	Geometric Mean	28.2	342,530,360,517	2015-01-18 16:49:50.971813	2015-01-18 18:48:45.996772	\N	t	1	\N	\N	\N
2725	1	14	48	2	4	Number of Subjects Included in Measurement	10	835,613,845,603	2015-01-18 16:49:50.951019	2015-01-18 18:48:46.039552	\N	f	1	\N	\N	\N
2721	1	14	48	2	4	Confidence Interval Lower Bound	4.80	319,540,334,528	2015-01-18 16:49:50.854358	2015-01-18 18:52:45.281924	\N	t	1	\N	\N	\N
2720	1	14	48	2	4	Confidence Interval Upper Bound	8.81	299,541,316,528	2015-01-18 16:49:50.835024	2015-01-18 18:52:45.323154	\N	t	1	\N	\N	\N
2719	1	14	48	2	4	Geometric Mean	6.50	342,540,359,528	2015-01-18 16:49:50.815421	2015-01-18 18:52:45.33771	\N	t	1	\N	\N	\N
2713	1	14	48	2	4	Confidence Interval Lower Bound	31.5	174,499,191,489	2015-01-18 16:49:50.682942	2015-01-18 18:53:41.941994	\N	f	1	\N	\N	\N
2712	1	14	48	2	4	Confidence Interval Upper Bound	43.5	155,499,171,488	2015-01-18 16:49:50.66532	2015-01-18 18:53:42.002647	\N	f	1	\N	\N	\N
2711	1	14	48	2	4	Geometric Mean	37.0	196,500,212,489	2015-01-18 16:49:50.647299	2015-01-18 18:53:42.017645	\N	f	1	\N	\N	\N
2706	1	14	48	2	4	Maximum	1.00	153,509,170,497	2015-01-18 16:49:50.536753	2015-01-18 18:54:28.846659	\N	t	1	\N	\N	\N
2705	1	14	48	2	4	Median	0.75	195,509,213,498	2015-01-18 16:49:50.517885	2015-01-18 18:54:28.893393	\N	t	1	\N	\N	\N
2704	1	14	48	2	4	Minimum	0.50	175,508,190,498	2015-01-18 16:49:50.498857	2015-01-18 18:54:28.909681	\N	t	1	\N	\N	\N
2776	1	14	48	2	4	Maximum	4.00	465,509,480,497	2015-01-18 16:49:52.200651	2015-01-18 18:38:38.086007	\N	t	1	\N	\N	\N
2775	1	14	48	2	4	Median	2.25	507,509,524,498	2015-01-18 16:49:52.18212	2015-01-18 18:38:38.131298	\N	t	1	\N	\N	\N
2774	1	14	48	2	4	Minimum	0.50	485,509,501,498	2015-01-18 16:49:52.16328	2015-01-18 18:38:38.14717	\N	t	1	\N	\N	\N
2769	1	14	48	2	4	Confidence Interval Lower Bound	633	489,519,501,508	2015-01-18 16:49:52.055808	2015-01-18 18:39:27.878102	\N	t	1	\N	\N	\N
2768	1	14	48	2	4	Confidence Interval Upper Bound	1636	465,520,484,509	2015-01-18 16:49:52.037017	2015-01-18 18:39:27.895115	\N	t	1	\N	\N	\N
2767	1	14	48	2	4	Geometric Mean	1018	506,520,525,508	2015-01-18 16:49:52.018747	2015-01-18 18:39:27.91001	\N	t	1	\N	\N	\N
2763	1	14	48	2	4	Confidence Interval Lower Bound	646	487,530,502,519	2015-01-18 16:49:51.851816	2015-01-18 18:40:21.250968	\N	t	1	\N	\N	\N
2762	1	14	48	2	4	Confidence Interval Upper Bound	1661	466,530,482,518	2015-01-18 16:49:51.776769	2015-01-18 18:40:21.26706	\N	t	1	\N	\N	\N
2761	1	14	48	2	4	Geometric Mean	1036	507,532,525,517	2015-01-18 16:49:51.754915	2015-01-18 18:40:21.281124	\N	t	1	\N	\N	\N
2756	1	14	48	2	4	Confidence Interval Lower Bound	0.712	480,540,501,527	2015-01-18 16:49:51.643309	2015-01-18 18:42:51.71797	\N	t	1	\N	\N	\N
2755	1	14	48	2	4	Confidence Interval Upper Bound	0.976	454,539,477,530	2015-01-18 16:49:51.624591	2015-01-18 18:42:51.733626	\N	t	1	\N	\N	\N
2754	1	14	48	2	4	Geometric Mean	0.834	507,542,528,529	2015-01-18 16:49:51.606265	2015-01-18 18:42:51.748934	\N	t	1	\N	\N	\N
3521	1	20	47	5	4	Measurement Type	AUC0-t	372,378,387,341	2015-01-24 19:15:55.056164	2015-01-24 19:16:53.473521	\N	t	1	\N	\N	\N
3531	1	20	47	5	4	Confidence Interval Lower Bound	8.33	425,453,436,431	2015-01-24 19:16:56.687245	2015-01-24 19:17:38.369828	\N	t	1	\N	\N	\N
3530	1	20	47	5	4	Confidence Interval Upper Bound	10.99	425,482,435,455	2015-01-24 19:16:56.667361	2015-01-24 19:17:38.386778	\N	t	1	\N	\N	\N
3529	1	20	47	5	4	Geometric Mean	9.56	408,454,420,428	2015-01-24 19:16:56.645334	2015-01-24 19:17:38.403828	\N	t	1	\N	\N	\N
3527	1	20	47	5	4	Measurement Type	Cmax	373,453,386,426	2015-01-24 19:16:56.606149	2015-01-24 19:17:38.422222	\N	t	1	\N	\N	\N
3528	1	20	47	5	4	Measurement Unit	ng/mL	385,461,399,431	2015-01-24 19:16:56.624656	2015-01-24 19:17:38.438764	\N	t	1	\N	\N	\N
3533	1	20	47	5	4	Confidence Interval Lower Bound	2.97	426,540,436,518	2015-01-24 19:17:41.587481	2015-01-24 19:18:23.858615	\N	t	1	\N	\N	\N
3534	1	20	47	5	4	Confidence Interval Upper Bound	4.12	424,562,435,541	2015-01-24 19:17:41.605107	2015-01-24 19:18:23.873953	\N	t	1	\N	\N	\N
3535	1	20	47	5	4	Geometric Mean	3.50	410,537,420,513	2015-01-24 19:17:41.623263	2015-01-24 19:18:23.888802	\N	t	1	\N	\N	\N
3537	1	20	47	5	4	Measurement Type	t1/2	375,533,385,513	2015-01-24 19:17:41.660143	2015-01-24 19:18:23.903944	\N	t	1	\N	\N	\N
3536	1	20	47	5	4	Measurement Unit	hr	387,531,399,518	2015-01-24 19:17:41.642906	2015-01-24 19:18:23.919074	\N	t	1	\N	\N	\N
3892	1	20	47	6	4	Number of Subjects Included in Measurement	21	198,375,207,360	2015-01-25 18:23:11.969797	2015-01-25 18:24:13.878636	\N	t	1	\N	\N	\N
3359	1	20	47	2	4	Measurement Name	body weight	348,427,358,362	2015-01-24 04:06:58.61094	2015-01-24 04:07:38.255996	\N	t	1	\N	\N	\N
3360	1	20	47	2	4	Measurement Unit	kg	349,461,360,445	2015-01-24 04:06:58.628709	2015-01-24 04:07:38.271327	\N	t	1	\N	\N	\N
3355	1	20	47	2	4	Minimum	60	347,447,357,431	2015-01-24 04:06:58.535299	2015-01-24 04:07:38.28794	\N	t	1	\N	\N	\N
3367	1	20	47	2	4	Maximum	30	363,396,373,378	2015-01-24 04:07:49.183326	2015-01-24 13:48:10.039583	\N	t	1	\N	\N	\N
3370	1	20	47	2	4	Measurement Name	body mass index	347,564,359,481	2015-01-24 04:07:49.236614	2015-01-24 13:48:10.054833	\N	t	1	\N	\N	\N
3371	1	20	47	2	4	Measurement Unit	kg/m2	360,425,376,392	2015-01-24 04:07:49.253546	2015-01-24 13:48:10.072077	\N	t	1	\N	\N	\N
3366	1	20	47	2	4	Minimum	19	361,376,375,363	2015-01-24 04:07:49.166203	2015-01-24 13:48:10.086513	\N	t	1	\N	\N	\N
3375	1	20	47	4	4	Number of subjects	24	566,432,579,414	2015-01-24 13:48:19.379355	2015-01-24 13:48:58.291962	\N	t	1	\N	\N	\N
3384	1	20	47	4	4	males	23	568,495,578,479	2015-01-24 13:48:58.30799	2015-01-24 13:48:58.30799	\N	f	1	\N	\N	\N
3385	1	20	47	4	4	females	1	567,541,579,530	2015-01-24 13:48:58.375282	2015-01-24 13:48:58.375282	\N	f	1	\N	\N	\N
3377	1	20	47	4	4	Arithmetic Mean	33	597,378,608,362	2015-01-24 13:48:58.060547	2015-01-24 13:49:25.79551	\N	t	1	\N	\N	\N
2849	1	14	48	2	4	Confidence Interval Lower Bound	20.5	774,499,790,487	2015-01-18 16:49:53.745402	2015-01-18 18:28:40.908165	\N	f	1	\N	\N	\N
2847	1	14	48	2	4	Confidence Interval Upper Bound	25.4	753,499,771,489	2015-01-18 16:49:53.708331	2015-01-18 18:28:40.944291	\N	f	1	\N	\N	\N
2848	1	14	48	2	4	Geometric Mean	22.81	794,500,819,489	2015-01-18 16:49:53.726965	2015-01-18 18:28:40.968001	\N	f	1	\N	\N	\N
2844	1	14	48	2	4	Maximum	1.50	753,509,771,499	2015-01-18 16:49:53.641036	2015-01-18 18:29:39.464423	\N	t	1	\N	\N	\N
2846	1	14	48	2	4	Median	0.55	796,509,811,497	2015-01-18 16:49:53.677253	2015-01-18 18:29:39.508891	\N	t	1	\N	\N	\N
2845	1	14	48	2	4	Minimum	0.18	776,509,790,498	2015-01-18 16:49:53.659242	2015-01-18 18:29:39.524226	\N	t	1	\N	\N	\N
2840	1	14	48	2	4	Confidence Interval Lower Bound	135	776,520,790,508	2015-01-18 16:49:53.5539	2015-01-18 18:30:27.892656	\N	t	1	\N	\N	\N
2839	1	14	48	2	4	Confidence Interval Upper Bound	221	758,520,773,508	2015-01-18 16:49:53.535428	2015-01-18 18:30:27.908356	\N	t	1	\N	\N	\N
2838	1	14	48	2	4	Geometric Mean	173	795,520,811,509	2015-01-18 16:49:53.51743	2015-01-18 18:30:27.923422	\N	t	1	\N	\N	\N
2833	1	14	48	2	4	Confidence Interval Lower Bound	147	776,529,791,518	2015-01-18 16:49:53.400631	2015-01-18 18:31:19.22794	\N	t	1	\N	\N	\N
2832	1	14	48	2	4	Confidence Interval Upper Bound	250	757,530,773,519	2015-01-18 16:49:53.382124	2015-01-18 18:31:19.24418	\N	t	1	\N	\N	\N
2831	1	14	48	2	4	Geometric Mean	192	799,530,813,519	2015-01-18 16:49:53.363117	2015-01-18 18:31:19.258216	\N	t	1	\N	\N	\N
2822	1	14	48	2	4	Confidence Interval Lower Bound	3.94	774,539,792,529	2015-01-18 16:49:53.185295	2015-01-18 18:32:02.856404	\N	t	1	\N	\N	\N
2823	1	14	48	2	4	Confidence Interval Upper Bound	5.72	754,540,771,528	2015-01-18 16:49:53.204774	2015-01-18 18:32:02.872372	\N	t	1	\N	\N	\N
2824	1	14	48	2	4	Geometric Mean	4.75	799,540,816,529	2015-01-18 16:49:53.224082	2015-01-18 18:32:02.886966	\N	t	1	\N	\N	\N
2818	1	14	48	2	4	Confidence Interval Lower Bound	50.8	628,499,645,488	2015-01-18 16:49:53.084481	2015-01-18 18:33:11.221755	\N	f	1	\N	\N	\N
2815	1	14	48	2	4	Confidence Interval Upper Bound	68.5	607,500,625,488	2015-01-18 16:49:53.027411	2015-01-18 18:33:11.23793	\N	f	1	\N	\N	\N
2817	1	14	48	2	4	Geometric Mean	59.0	649,498,667,489	2015-01-18 16:49:53.066568	2015-01-18 18:33:11.252383	\N	f	1	\N	\N	\N
2811	1	14	48	2	4	Maximum	5.00	608,509,624,498	2015-01-18 16:49:52.939673	2015-01-18 18:33:55.230023	\N	t	1	\N	\N	\N
2810	1	14	48	2	4	Median	3.03	649,510,666,498	2015-01-18 16:49:52.921001	2015-01-18 18:33:55.284286	\N	t	1	\N	\N	\N
2809	1	14	48	2	4	Minimum	1.50	627,510,645,497	2015-01-18 16:49:52.902513	2015-01-18 18:33:55.299703	\N	t	1	\N	\N	\N
2803	1	14	48	2	4	Confidence Interval Lower Bound	458	631,519,645,509	2015-01-18 16:49:52.777111	2015-01-18 18:34:45.165788	\N	t	1	\N	\N	\N
2804	1	14	48	2	4	Confidence Interval Upper Bound	631	613,520,627,509	2015-01-18 16:49:52.796242	2015-01-18 18:34:45.181338	\N	t	1	\N	\N	\N
2805	1	14	48	2	4	Geometric Mean	537	650,520,665,508	2015-01-18 16:49:52.815328	2015-01-18 18:34:45.19718	\N	t	1	\N	\N	\N
2798	1	14	48	2	4	Confidence Interval Lower Bound	492	631,529,645,517	2015-01-18 16:49:52.672011	2015-01-18 18:35:35.337827	\N	t	1	\N	\N	\N
2797	1	14	48	2	4	Confidence Interval Upper Bound	703	613,529,626,518	2015-01-18 16:49:52.65408	2015-01-18 18:35:35.352955	\N	t	1	\N	\N	\N
2796	1	14	48	2	4	Geometric Mean	589	652,530,668,517	2015-01-18 16:49:52.636155	2015-01-18 18:35:35.367599	\N	t	1	\N	\N	\N
2791	1	14	48	2	4	Confidence Interval Lower Bound	6.25	628,540,645,529	2015-01-18 16:49:52.527734	2015-01-18 18:36:22.917184	\N	t	1	\N	\N	\N
2790	1	14	48	2	4	Confidence Interval Upper Bound	8.37	607,540,624,529	2015-01-18 16:49:52.510127	2015-01-18 18:36:22.933358	\N	t	1	\N	\N	\N
2789	1	14	48	2	4	Geometric Mean	7.23	653,539,669,529	2015-01-18 16:49:52.492045	2015-01-18 18:36:22.948174	\N	t	1	\N	\N	\N
2783	1	14	48	2	4	Confidence Interval Lower Bound	314	488,499,502,488	2015-01-18 16:49:52.351007	2015-01-18 18:37:36.835096	\N	f	1	\N	\N	\N
2780	1	14	48	2	4	Confidence Interval Upper Bound	877	470,499,484,488	2015-01-18 16:49:52.29426	2015-01-18 18:37:36.850187	\N	f	1	\N	\N	\N
2782	1	14	48	2	4	Geometric Mean	524	507,500,522,489	2015-01-18 16:49:52.33236	2015-01-18 18:37:36.863897	\N	f	1	\N	\N	\N
3379	1	20	47	4	4	Measurement Name	age	583,630,593,611	2015-01-24 13:48:58.137514	2015-01-24 13:49:25.815745	\N	t	1	\N	\N	\N
3386	1	20	47	4	4	Measurement Time	demographics	569,624,579,583	2015-01-24 13:50:02.622525	2015-01-24 13:50:02.622525	\N	f	1	\N	\N	\N
3380	1	20	47	4	4	Measurement Unit	years	598,434,607,407	2015-01-24 13:48:58.156126	2015-01-24 13:50:47.82395	\N	t	1	\N	\N	\N
3387	1	20	47	4	4	Minimum	19	596,482,608,467	2015-01-24 13:50:47.842108	2015-01-24 13:50:47.842108	\N	f	1	\N	\N	\N
3378	1	20	47	4	4	Standard Deviation	10.6	596,405,607,383	2015-01-24 13:48:58.091358	2015-01-24 13:50:47.911591	\N	t	1	\N	\N	\N
3388	1	20	47	4	4	Maximum	54	598,500,608,485	2015-01-24 13:50:47.926631	2015-01-24 13:50:47.926631	\N	f	1	\N	\N	\N
3390	1	20	47	4	4	Arithmetic Mean	78.7	596,603,608,577	2015-01-24 13:51:00.911385	2015-01-24 13:52:00.600648	\N	t	1	\N	\N	\N
3392	1	20	47	4	4	Measurement Name	weight	597,575,607,535	2015-01-24 13:51:00.94926	2015-01-24 13:52:00.618369	\N	t	1	\N	\N	\N
3393	1	20	47	4	4	Measurement Unit	kg	599,646,608,631	2015-01-24 13:51:00.968247	2015-01-24 13:52:00.632623	\N	t	1	\N	\N	\N
3397	1	20	47	4	4	Minimum	61.0	611,422,621,397	2015-01-24 13:52:00.647434	2015-01-24 13:52:00.647434	\N	f	1	\N	\N	\N
3391	1	20	47	4	4	Standard Deviation	12.8	597,630,607,605	2015-01-24 13:51:00.931107	2015-01-24 13:52:00.708708	\N	t	1	\N	\N	\N
3398	1	20	47	4	4	Maximum	109.9	610,455,622,425	2015-01-24 13:52:00.72425	2015-01-24 13:52:00.72425	\N	f	1	\N	\N	\N
3400	1	20	47	4	4	Arithmetic Mean	25.68	626,391,636,362	2015-01-24 13:52:37.850957	2015-01-24 13:53:30.59428	\N	t	1	\N	\N	\N
3402	1	20	47	4	4	Measurement Name	BMI	609,629,622,603	2015-01-24 13:52:37.890176	2015-01-24 13:53:30.613985	\N	t	1	\N	\N	\N
3403	1	20	47	4	4	Measurement Unit	kg/m2	626,454,638,421	2015-01-24 13:52:37.910437	2015-01-24 13:53:30.631661	\N	t	1	\N	\N	\N
3401	1	20	47	4	4	Standard Deviation	2.77	626,420,636,395	2015-01-24 13:52:37.869827	2015-01-24 13:53:30.749272	\N	t	1	\N	\N	\N
3898	1	20	47	6	4	Coefficient of Variation within Subject	21.7	221,644,230,621	2015-01-25 18:24:16.35083	2015-01-25 18:27:14.596081	\N	f	1	\N	\N	\N
3902	1	20	47	6	4	Confidence Interval Lower Bound	0.88	222,590,230,569	2015-01-25 18:24:16.477655	2015-01-25 18:27:14.618397	\N	t	1	\N	\N	\N
3901	1	20	47	6	4	Confidence Interval Upper Bound	1.09	221,612,232,591	2015-01-25 18:24:16.458911	2015-01-25 18:27:14.632793	\N	t	1	\N	\N	\N
3900	1	20	47	6	4	Geometric Mean	0.98	220,532,231,508	2015-01-25 18:24:16.439264	2015-01-25 18:27:14.646892	\N	t	1	\N	\N	\N
3550	1	20	47	5	4	Measurement Time	11	456,95,467,80	2015-01-24 19:19:51.384061	2015-01-24 19:20:14.172134	\N	t	1	\N	\N	\N
3579	1	20	47	5	4	Confidence Interval Lower Bound	29.5	456,279,465,259	2015-01-24 19:19:52.022219	2015-01-24 19:20:46.866242	\N	t	1	\N	\N	\N
3578	1	20	47	5	4	Confidence Interval Upper Bound	36.8	456,303,466,282	2015-01-24 19:19:51.981314	2015-01-24 19:20:46.881082	\N	t	1	\N	\N	\N
3577	1	20	47	5	4	Geometric Mean	33.0	439,277,450,256	2015-01-24 19:19:51.96261	2015-01-24 19:20:46.895626	\N	t	1	\N	\N	\N
3569	1	20	47	5	4	Confidence Interval Lower Bound	28.1	456,367,465,343	2015-01-24 19:19:51.801495	2015-01-24 19:21:16.721358	\N	t	1	\N	\N	\N
3570	1	20	47	5	4	Confidence Interval Upper Bound	35.2	456,389,464,367	2015-01-24 19:19:51.820054	2015-01-24 19:21:16.736191	\N	t	1	\N	\N	\N
3571	1	20	47	5	4	Geometric Mean	31.4	440,366,450,341	2015-01-24 19:19:51.838558	2015-01-24 19:21:16.750391	\N	t	1	\N	\N	\N
3563	1	20	47	5	4	Confidence Interval Lower Bound	7.52	456,452,465,430	2015-01-24 19:19:51.673483	2015-01-24 19:21:53.670456	\N	t	1	\N	\N	\N
3564	1	20	47	5	4	Confidence Interval Upper Bound	9.83	456,476,464,452	2015-01-24 19:19:51.692882	2015-01-24 19:21:53.687216	\N	t	1	\N	\N	\N
3565	1	20	47	5	4	Geometric Mean	8.60	440,451,452,427	2015-01-24 19:19:51.712105	2015-01-24 19:21:53.701551	\N	t	1	\N	\N	\N
3561	1	20	47	5	4	Confidence Interval Lower Bound	2.99	456,538,464,516	2015-01-24 19:19:51.621197	2015-01-24 19:22:27.156453	\N	t	1	\N	\N	\N
3560	1	20	47	5	4	Confidence Interval Upper Bound	4.18	456,562,465,540	2015-01-24 19:19:51.602065	2015-01-24 19:22:27.17143	\N	t	1	\N	\N	\N
3559	1	20	47	5	4	Geometric Mean	3.54	441,538,450,516	2015-01-24 19:19:51.583109	2015-01-24 19:22:27.185913	\N	t	1	\N	\N	\N
3899	1	20	47	6	4	Measurement Name	Rosuvastatin AUC0-inf	217,322,233,231	2015-01-25 18:24:16.418385	2015-01-25 18:27:14.664824	\N	t	1	\N	\N	\N
3903	1	20	47	6	4	Number of Subjects Included in Measurement	23	221,376,230,361	2015-01-25 18:24:16.496209	2015-01-25 18:27:14.681974	\N	t	1	\N	\N	\N
3580	1	20	47	5	4	Measurement Time Unit	Day	486,83,496,62	2015-01-24 19:23:12.193486	2015-01-24 19:23:45.540897	\N	t	1	\N	\N	\N
3613	1	20	47	5	4	Number of Subjects Included in Measurement	24	470,226,481,210	2015-01-24 19:23:13.221628	2015-01-24 19:24:03.36585	\N	t	1	\N	\N	\N
3633	1	20	47	5	4	Confidence Interval Lower Bound	4068	485,369,495,346	2015-01-24 19:23:13.694436	2015-01-24 19:25:19.544818	\N	t	1	\N	\N	\N
3634	1	20	47	5	4	Confidence Interval Upper Bound	5193	486,394,494,370	2015-01-24 19:23:13.71253	2015-01-24 19:25:19.560362	\N	t	1	\N	\N	\N
3635	1	20	47	5	4	Geometric Mean	4595.9	470,375,480,342	2015-01-24 19:23:13.730768	2015-01-24 19:25:19.574695	\N	t	1	\N	\N	\N
3627	1	20	47	5	4	Confidence Interval Lower Bound	471.7	485,458,494,432	2015-01-24 19:23:13.573106	2015-01-24 19:25:52.512219	\N	t	1	\N	\N	\N
3628	1	20	47	5	4	Confidence Interval Upper Bound	591.7	485,485,495,459	2015-01-24 19:23:13.591967	2015-01-24 19:25:52.528025	\N	t	1	\N	\N	\N
3629	1	20	47	5	4	Geometric Mean	528.3	472,456,480,428	2015-01-24 19:23:13.609653	2015-01-24 19:25:52.543087	\N	t	1	\N	\N	\N
3625	1	20	47	5	4	Confidence Interval Lower Bound	5.8	485,536,496,519	2015-01-24 19:23:13.497842	2015-01-24 19:26:24.043425	\N	t	1	\N	\N	\N
3624	1	20	47	5	4	Confidence Interval Upper Bound	7.4	486,551,495,536	2015-01-24 19:23:13.477409	2015-01-24 19:26:24.059726	\N	t	1	\N	\N	\N
3623	1	20	47	5	4	Geometric Mean	6.6	470,532,480,514	2015-01-24 19:23:13.458289	2015-01-24 19:26:24.073896	\N	t	1	\N	\N	\N
3617	1	20	47	5	4	Maximum	4.0	487,637,496,623	2015-01-24 19:23:13.331072	2015-01-24 19:27:02.404478	\N	t	1	\N	\N	\N
3619	1	20	47	5	4	Median	3.0	471,620,480,602	2015-01-24 19:23:13.3688	2015-01-24 19:27:02.447489	\N	t	1	\N	\N	\N
3618	1	20	47	5	4	Minimum	1.5	485,620,494,604	2015-01-24 19:23:13.349542	2015-01-24 19:27:02.4631	\N	t	1	\N	\N	\N
3582	1	20	47	5	4	Measurement Time	12	515,95,527,82	2015-01-24 19:23:12.369608	2015-01-24 19:27:41.468091	\N	t	1	\N	\N	\N
3583	1	20	47	5	4	Number of Subjects Included in Measurement	24	500,226,509,212	2015-01-24 19:23:12.408224	2015-01-24 19:27:41.484473	\N	t	1	\N	\N	\N
3612	1	20	47	5	4	Maximum	4.0	516,638,525,623	2015-01-24 19:23:13.189859	2015-01-24 19:28:11.136629	\N	t	1	\N	\N	\N
3610	1	20	47	5	4	Median	3.0	501,619,510,601	2015-01-24 19:23:13.151937	2015-01-24 19:28:11.18041	\N	t	1	\N	\N	\N
3611	1	20	47	5	4	Minimum	1.5	515,621,525,605	2015-01-24 19:23:13.170952	2015-01-24 19:28:11.194429	\N	t	1	\N	\N	\N
3605	1	20	47	5	4	Confidence Interval Lower Bound	4.9	516,534,525,519	2015-01-24 19:23:12.972083	2015-01-24 20:03:35.177628	\N	t	1	\N	\N	\N
3606	1	20	47	5	4	Confidence Interval Upper Bound	5.8	516,551,525,535	2015-01-24 19:23:12.991078	2015-01-24 20:03:35.196095	\N	t	1	\N	\N	\N
3607	1	20	47	5	4	Geometric Mean	5.3	501,532,510,515	2015-01-24 19:23:13.018231	2015-01-24 20:03:35.212203	\N	t	1	\N	\N	\N
3601	1	20	47	5	4	Confidence Interval Lower Bound	522.9	516,458,524,432	2015-01-24 19:23:12.886707	2015-01-24 20:09:49.745385	\N	t	1	\N	\N	\N
3600	1	20	47	5	4	Confidence Interval Upper Bound	619.9	515,486,525,460	2015-01-24 19:23:12.867686	2015-01-24 20:09:49.760524	\N	t	1	\N	\N	\N
3599	1	20	47	5	4	Geometric Mean	569.4	500,456,511,428	2015-01-24 19:23:12.849291	2015-01-24 20:09:49.774908	\N	t	1	\N	\N	\N
3595	1	20	47	5	4	Confidence Interval Lower Bound	4230	514,370,525,345	2015-01-24 19:23:12.765931	2015-01-24 20:10:26.935596	\N	t	1	\N	\N	\N
3594	1	20	47	5	4	Confidence Interval Upper Bound	5257	515,395,525,370	2015-01-24 19:23:12.74702	2015-01-24 20:10:26.955166	\N	t	1	\N	\N	\N
3593	1	20	47	5	4	Geometric Mean	4715.8	500,373,510,341	2015-01-24 19:23:12.72736	2015-01-24 20:10:26.974587	\N	t	1	\N	\N	\N
3587	1	20	47	5	4	Confidence Interval Lower Bound	4835	515,283,524,258	2015-01-24 19:23:12.599782	2015-01-24 20:11:28.821441	\N	t	1	\N	\N	\N
3588	1	20	47	5	4	Confidence Interval Upper Bound	5775	514,307,524,284	2015-01-24 19:23:12.619152	2015-01-24 20:11:28.836542	\N	t	1	\N	\N	\N
3589	1	20	47	5	4	Geometric Mean	5284.5	501,287,510,255	2015-01-24 19:23:12.638101	2015-01-24 20:11:28.852032	\N	t	1	\N	\N	\N
3581	1	20	47	5	4	Measurement Name	pioglitazone	471,114,481,62	2015-01-24 19:23:12.290402	2015-01-24 19:23:45.521362	\N	t	1	\N	\N	\N
3614	1	20	47	5	4	Measurement Time	2	484,91,498,81	2015-01-24 19:23:13.242495	2015-01-24 19:24:03.34985	\N	t	1	\N	\N	\N
3643	1	20	47	5	4	Confidence Interval Lower Bound	4685	486,282,493,258	2015-01-24 19:23:13.891594	2015-01-24 19:24:40.286534	\N	t	1	\N	\N	\N
3642	1	20	47	5	4	Confidence Interval Upper Bound	5881	485,306,495,283	2015-01-24 19:23:13.873507	2015-01-24 19:24:40.302183	\N	t	1	\N	\N	\N
3641	1	20	47	5	4	Geometric Mean	5248.9	471,289,480,255	2015-01-24 19:23:13.854221	2015-01-24 19:24:40.317505	\N	t	1	\N	\N	\N
3932	1	20	47	6	4	Measurement Time	5	630,91,642,80	2015-01-25 18:28:18.647559	2015-01-25 18:29:49.172126	\N	t	1	\N	\N	\N
3926	1	20	47	6	4	Number of Subjects Included in Measurement	6	619,164,629,150	2015-01-25 18:28:18.534169	2015-01-25 18:29:49.20275	\N	t	1	\N	\N	\N
3938	1	20	47	6	4	% Confidence Interval	95	818,218,826,204	2015-01-25 18:29:48.937297	2015-01-25 18:45:53.511149	\N	t	1	\N	\N	\N
3936	1	20	47	6	4	Confidence Interval Lower Bound	5554	630,227,638,203	2015-01-25 18:29:48.883846	2015-01-25 18:45:53.527929	\N	t	1	\N	\N	\N
3644	1	20	47	5	4	Measurement Name	omeprazole	530,114,542,60	2015-01-24 20:11:32.569467	2015-01-24 20:12:30.126405	\N	t	1	\N	\N	\N
3645	1	20	47	5	4	Measurement Time Unit	Day	544,84,554,60	2015-01-24 20:11:32.631771	2015-01-24 20:12:30.143119	\N	t	1	\N	\N	\N
3646	1	20	47	5	4	Measurement Time	3	543,92,558,80	2015-01-24 20:11:32.666176	2015-01-24 20:13:47.379096	\N	t	1	\N	\N	\N
3647	1	20	47	5	4	Number of Subjects Included in Measurement	24	531,228,540,208	2015-01-24 20:11:32.68439	2015-01-24 20:13:47.395526	\N	t	1	\N	\N	\N
3937	1	20	47	6	4	Confidence Interval Upper Bound	9404	629,250,639,227	2015-01-25 18:29:48.918911	2015-01-25 18:45:53.543629	\N	t	1	\N	\N	\N
3939	1	20	47	6	4	Geometric Mean	7227	618,224,627,200	2015-01-25 18:29:48.955264	2015-01-25 18:45:53.558908	\N	t	1	\N	\N	\N
3941	1	20	47	6	4	Measurement Unit	ng*hr/mL	572,286,581,241	2015-01-25 18:29:48.990968	2015-01-25 18:45:53.590632	\N	t	1	\N	\N	\N
3676	1	20	47	5	4	Maximum	24.0	545,644,555,622	2015-01-24 20:11:33.378064	2015-01-24 20:37:01.481997	\N	t	1	\N	\N	\N
3674	1	20	47	5	4	Median	4.0	531,619,540,602	2015-01-24 20:11:33.340325	2015-01-24 20:37:01.529628	\N	t	1	\N	\N	\N
3675	1	20	47	5	4	Minimum	1.5	545,620,557,605	2015-01-24 20:11:33.358539	2015-01-24 20:37:01.546039	\N	t	1	\N	\N	\N
3669	1	20	47	5	4	Confidence Interval Lower Bound	0.94	546,539,555,518	2015-01-24 20:11:33.233721	2015-01-24 20:37:55.430192	\N	t	1	\N	\N	\N
3670	1	20	47	5	4	Confidence Interval Upper Bound	1.25	545,561,554,540	2015-01-24 20:11:33.252421	2015-01-24 20:37:55.448008	\N	t	1	\N	\N	\N
3671	1	20	47	5	4	Geometric Mean	1.08	531,537,541,515	2015-01-24 20:11:33.271	2015-01-24 20:37:55.463734	\N	t	1	\N	\N	\N
3713	1	20	47	5	4	Number of Subjects Included in Measurement	21	801,93,811,80	2015-01-24 20:37:55.510626	2015-01-24 20:37:55.510626	\N	f	1	\N	\N	\N
3665	1	20	47	5	4	Confidence Interval Lower Bound	179.6	544,458,556,432	2015-01-24 20:11:33.145228	2015-01-24 20:38:43.675982	\N	t	1	\N	\N	\N
3664	1	20	47	5	4	Confidence Interval Upper Bound	366.5	546,485,555,459	2015-01-24 20:11:33.127032	2015-01-24 20:38:43.692901	\N	t	1	\N	\N	\N
3663	1	20	47	5	4	Geometric Mean	256.5	531,455,540,429	2015-01-24 20:11:33.107942	2015-01-24 20:38:43.7072	\N	t	1	\N	\N	\N
3659	1	20	47	5	4	Confidence Interval Lower Bound	452.9	546,372,555,345	2015-01-24 20:11:32.949544	2015-01-24 20:39:58.805852	\N	t	1	\N	\N	\N
3658	1	20	47	5	4	Confidence Interval Upper Bound	839.1	545,400,555,373	2015-01-24 20:11:32.927569	2015-01-24 20:39:58.820655	\N	t	1	\N	\N	\N
3657	1	20	47	5	4	Geometric Mean	616.4	531,368,540,341	2015-01-24 20:11:32.908005	2015-01-24 20:39:58.835759	\N	t	1	\N	\N	\N
3714	1	20	47	5	4	Number of Subjects Included in Measurement	23	833,94,842,79	2015-01-24 20:39:58.875578	2015-01-24 20:39:58.875578	\N	f	1	\N	\N	\N
3651	1	20	47	5	4	Confidence Interval Lower Bound	453.0	545,285,555,259	2015-01-24 20:11:32.777329	2015-01-24 20:41:04.240419	\N	t	1	\N	\N	\N
3652	1	20	47	5	4	Confidence Interval Upper Bound	889.9	545,312,555,286	2015-01-24 20:11:32.796667	2015-01-24 20:41:04.256497	\N	t	1	\N	\N	\N
3653	1	20	47	5	4	Geometric Mean	634.9	531,282,540,254	2015-01-24 20:11:32.816003	2015-01-24 20:41:04.271599	\N	t	1	\N	\N	\N
3678	1	20	47	5	4	Measurement Time	13	574,96,585,82	2015-01-24 20:11:33.427573	2015-01-24 20:41:36.742183	\N	t	1	\N	\N	\N
3707	1	20	47	5	4	Confidence Interval Lower Bound	466.9	575,284,585,259	2015-01-24 20:11:34.067169	2015-01-24 20:42:24.563191	\N	t	1	\N	\N	\N
3706	1	20	47	5	4	Confidence Interval Upper Bound	841.3	575,311,585,286	2015-01-24 20:11:34.04895	2015-01-24 20:42:24.586978	\N	t	1	\N	\N	\N
3705	1	20	47	5	4	Geometric Mean	626.8	561,281,570,257	2015-01-24 20:11:34.02785	2015-01-24 20:42:24.602502	\N	t	1	\N	\N	\N
3689	1	20	47	5	4	Confidence Interval Lower Bound	0.99	575,540,584,517	2015-01-24 20:11:33.674472	2015-01-24 20:43:33.724792	\N	t	1	\N	\N	\N
3688	1	20	47	5	4	Confidence Interval Upper Bound	1.40	576,561,584,540	2015-01-24 20:11:33.653492	2015-01-24 20:43:33.740022	\N	t	1	\N	\N	\N
3687	1	20	47	5	4	Geometric Mean	1.18	560,538,568,516	2015-01-24 20:11:33.635081	2015-01-24 20:43:33.754597	\N	t	1	\N	\N	\N
3699	1	20	47	5	4	Confidence Interval Lower Bound	465.3	576,371,584,345	2015-01-24 20:11:33.899015	2015-01-24 20:44:22.594394	\N	t	1	\N	\N	\N
3700	1	20	47	5	4	Confidence Interval Upper Bound	819.3	576,397,583,373	2015-01-24 20:11:33.918218	2015-01-24 20:44:22.609409	\N	t	1	\N	\N	\N
3701	1	20	47	5	4	Geometric Mean	617.4	559,371,570,341	2015-01-24 20:11:33.937465	2015-01-24 20:44:22.624656	\N	t	1	\N	\N	\N
3715	1	20	47	5	4	Number of Subjects Included in Measurement	24	561,226,570,210	2015-01-24 20:44:22.665554	2015-01-24 20:44:22.665554	\N	f	1	\N	\N	\N
3693	1	20	47	5	4	Confidence Interval Lower Bound	208.9	574,457,585,431	2015-01-24 20:11:33.765573	2015-01-24 20:45:03.824658	\N	t	1	\N	\N	\N
3694	1	20	47	5	4	Confidence Interval Upper Bound	363.0	577,484,584,461	2015-01-24 20:11:33.785809	2015-01-24 20:45:03.839237	\N	t	1	\N	\N	\N
3695	1	20	47	5	4	Geometric Mean	275.4	560,456,570,429	2015-01-24 20:11:33.805055	2015-01-24 20:45:03.853841	\N	t	1	\N	\N	\N
3681	1	20	47	5	4	Maximum	6.0	576,639,585,622	2015-01-24 20:11:33.504817	2015-01-24 20:49:02.055755	\N	t	1	\N	\N	\N
3683	1	20	47	5	4	Median	4.0	559,619,570,600	2015-01-24 20:11:33.540932	2015-01-24 20:49:02.101328	\N	t	1	\N	\N	\N
3682	1	20	47	5	4	Minimum	1.0	576,619,584,603	2015-01-24 20:11:33.523423	2015-01-24 20:49:02.115623	\N	t	1	\N	\N	\N
3716	1	20	47	5	4	Measurement Time Unit	Day	605,83,615,62	2015-01-24 20:49:20.087198	2015-01-24 20:56:20.845685	\N	t	1	\N	\N	\N
3732	1	20	47	5	4	Confidence Interval Lower Bound	587.3	634,372,645,344	2015-01-24 20:49:20.492212	2015-01-24 21:04:29.214348	\N	t	1	\N	\N	\N
3731	1	20	47	5	4	Confidence Interval Upper Bound	743.8	635,398,643,374	2015-01-24 20:49:20.473038	2015-01-24 21:04:29.229377	\N	t	1	\N	\N	\N
3730	1	20	47	5	4	Geometric Mean	660.9	618,369,629,343	2015-01-24 20:49:20.454289	2015-01-24 21:04:29.244786	\N	t	1	\N	\N	\N
3723	1	20	47	5	4	Confidence Interval Lower Bound	576.4	635,285,644,259	2015-01-24 20:49:20.301634	2015-01-24 21:07:14.479386	\N	t	1	\N	\N	\N
3724	1	20	47	5	4	Confidence Interval Upper Bound	739.8	635,312,644,287	2015-01-24 20:49:20.319689	2015-01-24 21:07:14.496944	\N	t	1	\N	\N	\N
3725	1	20	47	5	4	Geometric Mean	653.0	620,283,628,256	2015-01-24 20:49:20.338353	2015-01-24 21:07:14.511101	\N	t	1	\N	\N	\N
3930	1	20	47	6	4	Measurement Name	vercimon	618,105,629,61	2015-01-25 18:28:18.609333	2015-01-25 18:29:49.154694	\N	t	1	\N	\N	\N
3933	1	20	47	6	4	Measurement Time Unit	Day	629,82,642,62	2015-01-25 18:28:18.667076	2015-01-25 18:29:49.188056	\N	t	1	\N	\N	\N
3944	1	20	47	6	4	Measurement Type	AUC0-t	568,236,582,199	2015-01-25 18:29:49.050056	2015-01-25 18:45:53.573204	\N	t	1	\N	\N	\N
3950	1	20	47	6	4	Confidence Interval Lower Bound	711	630,345,639,326	2015-01-25 18:45:56.57972	2015-01-25 18:46:42.50289	\N	t	1	\N	\N	\N
3949	1	20	47	6	4	Confidence Interval Upper Bound	1219	631,370,639,346	2015-01-25 18:45:56.561411	2015-01-25 18:46:42.520056	\N	t	1	\N	\N	\N
3947	1	20	47	6	4	Geometric Mean	931	619,342,628,322	2015-01-25 18:45:56.523036	2015-01-25 18:46:42.53654	\N	t	1	\N	\N	\N
3945	1	20	47	6	4	Measurement Type	Cmax	569,347,582,320	2015-01-25 18:45:56.440856	2015-01-25 18:46:42.553319	\N	t	1	\N	\N	\N
3946	1	20	47	6	4	Measurement Unit	ng/mL	571,378,580,347	2015-01-25 18:45:56.503674	2015-01-25 18:46:42.568689	\N	t	1	\N	\N	\N
3717	1	20	47	5	4	Measurement Name	5-OH-omeprazole	588,135,600,61	2015-01-24 20:49:20.145785	2015-01-24 20:56:20.827225	\N	t	1	\N	\N	\N
3753	1	20	47	5	4	Measurement Time	3	605,92,615,80	2015-01-24 20:49:20.925326	2015-01-24 20:56:29.223917	\N	t	1	\N	\N	\N
3787	1	20	47	5	4	Confidence Interval Lower Bound	547.3	605,284,615,258	2015-01-24 20:49:21.603322	2015-01-24 20:57:17.776998	\N	t	1	\N	\N	\N
3786	1	20	47	5	4	Confidence Interval Upper Bound	877.0	606,313,614,287	2015-01-24 20:49:21.585616	2015-01-24 20:57:17.791999	\N	t	1	\N	\N	\N
3785	1	20	47	5	4	Geometric Mean	692.8	591,282,600,256	2015-01-24 20:49:21.567719	2015-01-24 20:57:17.805669	\N	t	1	\N	\N	\N
3781	1	20	47	5	4	Number of Subjects Included in Measurement	22	819,95,826,80	2015-01-24 20:49:21.496649	2015-01-24 20:57:17.846466	\N	f	1	\N	\N	\N
3778	1	20	47	5	4	Confidence Interval Lower Bound	535.0	606,371,614,346	2015-01-24 20:49:21.43104	2015-01-24 20:58:24.442402	\N	t	1	\N	\N	\N
3779	1	20	47	5	4	Confidence Interval Upper Bound	843.6	605,399,615,373	2015-01-24 20:49:21.448711	2015-01-24 20:58:24.457714	\N	t	1	\N	\N	\N
3780	1	20	47	5	4	Geometric Mean	671.8	589,369,599,340	2015-01-24 20:49:21.466802	2015-01-24 20:58:24.472447	\N	t	1	\N	\N	\N
3771	1	20	47	5	4	Confidence Interval Lower Bound	151.5	606,457,614,432	2015-01-24 20:49:21.284072	2015-01-24 20:59:13.922709	\N	t	1	\N	\N	\N
3772	1	20	47	5	4	Confidence Interval Upper Bound	291.5	605,485,615,459	2015-01-24 20:49:21.302772	2015-01-24 20:59:13.937299	\N	t	1	\N	\N	\N
3773	1	20	47	5	4	Geometric Mean	210.2	591,454,600,428	2015-01-24 20:49:21.321795	2015-01-24 20:59:13.951406	\N	t	1	\N	\N	\N
3770	1	20	47	5	4	Number of Subjects Included in Measurement	24	590,226,601,211	2015-01-24 20:49:21.265767	2015-01-24 20:59:13.999039	\N	t	1	\N	\N	\N
3766	1	20	47	5	4	Confidence Interval Lower Bound	1.36	604,539,615,518	2015-01-24 20:49:21.18389	2015-01-24 21:00:28.936093	\N	t	1	\N	\N	\N
3765	1	20	47	5	4	Confidence Interval Upper Bound	1.88	604,561,615,540	2015-01-24 20:49:21.166202	2015-01-24 21:00:28.957696	\N	t	1	\N	\N	\N
3764	1	20	47	5	4	Geometric Mean	1.60	589,536,601,516	2015-01-24 20:49:21.148645	2015-01-24 21:00:28.973807	\N	t	1	\N	\N	\N
3757	1	20	47	5	4	Maximum	24.0	605,642,615,622	2015-01-24 20:49:21.0137	2015-01-24 21:01:32.932423	\N	t	1	\N	\N	\N
3759	1	20	47	5	4	Median	4.0	591,617,600,602	2015-01-24 20:49:21.049641	2015-01-24 21:01:32.975465	\N	t	1	\N	\N	\N
3758	1	20	47	5	4	Minimum	1.5	605,621,615,606	2015-01-24 20:49:21.032171	2015-01-24 21:01:32.990343	\N	t	1	\N	\N	\N
3718	1	20	47	5	4	Measurement Time	13	635,97,644,80	2015-01-24 20:49:20.180655	2015-01-24 21:01:47.550725	\N	t	1	\N	\N	\N
3752	1	20	47	5	4	Maximum	6.0	635,638,644,622	2015-01-24 20:49:20.895088	2015-01-24 21:02:23.419441	\N	t	1	\N	\N	\N
3750	1	20	47	5	4	Median	4.0	619,618,630,601	2015-01-24 20:49:20.858848	2015-01-24 21:02:23.483204	\N	t	1	\N	\N	\N
3751	1	20	47	5	4	Minimum	1.0	635,621,645,604	2015-01-24 20:49:20.876822	2015-01-24 21:02:23.496756	\N	t	1	\N	\N	\N
3747	1	20	47	5	4	Number of Subjects Included in Measurement	24	619,227,630,209	2015-01-24 20:49:20.803178	2015-01-24 21:02:23.535143	\N	f	1	\N	\N	\N
3744	1	20	47	5	4	Confidence Interval Lower Bound	1.43	636,540,643,518	2015-01-24 20:49:20.73736	2015-01-24 21:03:06.825229	\N	t	1	\N	\N	\N
3745	1	20	47	5	4	Confidence Interval Upper Bound	2.25	634,563,644,540	2015-01-24 20:49:20.755147	2015-01-24 21:03:06.839769	\N	t	1	\N	\N	\N
3746	1	20	47	5	4	Geometric Mean	1.79	620,536,630,514	2015-01-24 20:49:20.772904	2015-01-24 21:03:06.85424	\N	t	1	\N	\N	\N
3739	1	20	47	5	4	Confidence Interval Lower Bound	194.9	635,458,643,431	2015-01-24 20:49:20.634825	2015-01-24 21:03:50.427156	\N	t	1	\N	\N	\N
3738	1	20	47	5	4	Confidence Interval Upper Bound	292.4	635,485,643,458	2015-01-24 20:49:20.616202	2015-01-24 21:03:50.441883	\N	t	1	\N	\N	\N
3737	1	20	47	5	4	Geometric Mean	238.7	620,455,629,427	2015-01-24 20:49:20.598125	2015-01-24 21:03:50.455279	\N	t	1	\N	\N	\N
3788	1	20	47	5	4	Measurement Time Unit	Day	663,84,675,60	2015-01-24 21:07:22.146074	2015-01-24 21:07:59.829021	\N	t	1	\N	\N	\N
3821	1	20	47	5	4	Number of Subjects Included in Measurement	24	648,226,658,210	2015-01-24 21:07:23.14172	2015-01-24 21:08:17.463867	\N	t	1	\N	\N	\N
3825	1	20	47	5	4	Maximum	6.0	664,639,674,622	2015-01-24 21:07:23.231906	2015-01-24 21:11:30.135695	\N	t	1	\N	\N	\N
3790	1	20	47	5	4	Measurement Time	14	694,97,707,80	2015-01-24 21:07:22.299572	2015-01-25 03:48:45.621798	\N	t	1	\N	\N	\N
3791	1	20	47	5	4	Number of Subjects Included in Measurement	23	679,225,689,210	2015-01-24 21:07:22.333254	2015-01-25 03:48:45.637716	\N	t	1	\N	\N	\N
3820	1	20	47	5	4	Maximum	6.0	696,640,704,622	2015-01-24 21:07:23.086361	2015-01-25 03:49:13.057904	\N	t	1	\N	\N	\N
3818	1	20	47	5	4	Median	3.0	679,617,689,602	2015-01-24 21:07:22.997762	2015-01-25 03:49:13.139049	\N	t	1	\N	\N	\N
3819	1	20	47	5	4	Minimum	1.0	693,619,705,604	2015-01-24 21:07:23.025409	2015-01-25 03:49:13.155609	\N	t	1	\N	\N	\N
3813	1	20	47	5	4	Confidence Interval Lower Bound	10.27	695,543,704,518	2015-01-24 21:07:22.89149	2015-01-25 03:57:16.588161	\N	t	1	\N	\N	\N
3814	1	20	47	5	4	Confidence Interval Upper Bound	13.99	694,571,704,546	2015-01-24 21:07:22.910431	2015-01-25 03:57:16.603726	\N	t	1	\N	\N	\N
3815	1	20	47	5	4	Geometric Mean	11.99	679,542,688,517	2015-01-24 21:07:22.929553	2015-01-25 03:57:16.618764	\N	t	1	\N	\N	\N
3809	1	20	47	5	4	Confidence Interval Lower Bound	1.97	695,454,704,431	2015-01-24 21:07:22.784611	2015-01-25 03:57:55.140957	\N	t	1	\N	\N	\N
3808	1	20	47	5	4	Confidence Interval Upper Bound	3.18	695,474,704,455	2015-01-24 21:07:22.765119	2015-01-25 03:57:55.156856	\N	t	1	\N	\N	\N
3807	1	20	47	5	4	Geometric Mean	2.50	679,452,689,428	2015-01-24 21:07:22.745974	2015-01-25 03:57:55.172952	\N	t	1	\N	\N	\N
3803	1	20	47	5	4	Confidence Interval Lower Bound	19.9	694,366,705,345	2015-01-24 21:07:22.660378	2015-01-25 03:58:29.707606	\N	t	1	\N	\N	\N
3802	1	20	47	5	4	Confidence Interval Upper Bound	31.7	694,388,705,368	2015-01-24 21:07:22.642678	2015-01-25 03:58:29.726286	\N	t	1	\N	\N	\N
3801	1	20	47	5	4	Geometric Mean	25.1	679,364,689,341	2015-01-24 21:07:22.624002	2015-01-25 03:58:29.741706	\N	t	1	\N	\N	\N
3795	1	20	47	5	4	Confidence Interval Lower Bound	23.0	694,279,705,257	2015-01-24 21:07:22.500362	2015-01-25 03:59:10.443348	\N	t	1	\N	\N	\N
3796	1	20	47	5	4	Confidence Interval Upper Bound	35.0	693,302,704,281	2015-01-24 21:07:22.518034	2015-01-25 03:59:10.458658	\N	t	1	\N	\N	\N
3797	1	20	47	5	4	Geometric Mean	28.4	680,278,688,255	2015-01-24 21:07:22.537205	2015-01-25 03:59:10.47408	\N	t	1	\N	\N	\N
3885	1	20	47	6	4	Coefficient of Variation within Subject	54.3	167,643,178,622	2015-01-25 18:18:16.890535	2015-01-25 18:20:54.014942	\N	f	1	\N	\N	\N
3881	1	20	47	6	4	Confidence Interval Lower Bound	0.76	167,589,177,569	2015-01-25 18:18:16.645786	2015-01-25 18:20:54.030319	\N	t	1	\N	\N	\N
3882	1	20	47	6	4	Confidence Interval Upper Bound	1.31	168,613,177,590	2015-01-25 18:18:16.724535	2015-01-25 18:20:54.044828	\N	t	1	\N	\N	\N
3883	1	20	47	6	4	Geometric Mean	0.99	168,533,177,510	2015-01-25 18:18:16.758764	2015-01-25 18:20:54.059331	\N	t	1	\N	\N	\N
3884	1	20	47	6	4	Measurement Name	Omeprazole AUC0-inf	166,320,179,229	2015-01-25 18:18:16.822576	2015-01-25 18:20:54.074158	\N	t	1	\N	\N	\N
3880	1	20	47	6	4	Number of Subjects Included in Measurement	21	166,452,178,435	2015-01-25 18:18:16.555753	2015-01-25 18:20:54.089711	\N	t	1	\N	\N	\N
3956	1	20	47	6	4	Measurement Type	tmax	570,435,581,415	2015-01-25 18:46:46.56497	2015-01-25 18:48:03.816014	\N	t	1	\N	\N	\N
3955	1	20	47	6	4	Measurement Unit	hr	582,433,595,418	2015-01-25 18:46:46.547061	2015-01-25 18:48:03.833688	\N	t	1	\N	\N	\N
3789	1	20	47	5	4	Measurement Name	Rosuvastatin	649,116,659,63	2015-01-24 21:07:22.214628	2015-01-24 21:07:59.812159	\N	t	1	\N	\N	\N
3822	1	20	47	5	4	Measurement Time	4	665,92,674,81	2015-01-24 21:07:23.162002	2015-01-24 21:08:17.446912	\N	t	1	\N	\N	\N
3851	1	20	47	5	4	Confidence Interval Lower Bound	22.9	666,280,674,259	2015-01-24 21:07:23.769374	2015-01-24 21:09:02.373083	\N	t	1	\N	\N	\N
3850	1	20	47	5	4	Confidence Interval Upper Bound	35.7	665,303,673,281	2015-01-24 21:07:23.742975	2015-01-24 21:09:02.389213	\N	t	1	\N	\N	\N
3849	1	20	47	5	4	Geometric Mean	28.6	649,277,659,255	2015-01-24 21:07:23.724997	2015-01-24 21:09:02.40427	\N	t	1	\N	\N	\N
3841	1	20	47	5	4	Confidence Interval Lower Bound	20.1	666,368,675,345	2015-01-24 21:07:23.562744	2015-01-24 21:09:47.555841	\N	t	1	\N	\N	\N
3842	1	20	47	5	4	Confidence Interval Upper Bound	31.8	665,388,673,367	2015-01-24 21:07:23.580561	2015-01-24 21:09:47.571122	\N	t	1	\N	\N	\N
3843	1	20	47	5	4	Geometric Mean	25.3	649,363,659,340	2015-01-24 21:07:23.599533	2015-01-24 21:09:47.586558	\N	t	1	\N	\N	\N
3835	1	20	47	5	4	Confidence Interval Lower Bound	1.95	665,452,674,432	2015-01-24 21:07:23.440052	2015-01-24 21:10:21.81882	\N	t	1	\N	\N	\N
3836	1	20	47	5	4	Confidence Interval Upper Bound	2.90	666,474,674,454	2015-01-24 21:07:23.458299	2015-01-24 21:10:21.834226	\N	t	1	\N	\N	\N
3837	1	20	47	5	4	Geometric Mean	2.38	649,452,659,429	2015-01-24 21:07:23.476754	2015-01-24 21:10:21.857225	\N	t	1	\N	\N	\N
3833	1	20	47	5	4	Confidence Interval Lower Bound	10.96	666,544,674,518	2015-01-24 21:07:23.389152	2015-01-24 21:11:00.811248	\N	t	1	\N	\N	\N
3832	1	20	47	5	4	Confidence Interval Upper Bound	15.79	664,571,674,546	2015-01-24 21:07:23.371134	2015-01-24 21:11:00.828777	\N	t	1	\N	\N	\N
3831	1	20	47	5	4	Geometric Mean	13.15	650,542,658,516	2015-01-24 21:07:23.353194	2015-01-24 21:11:00.844852	\N	t	1	\N	\N	\N
3827	1	20	47	5	4	Median	4.0	650,622,660,602	2015-01-24 21:07:23.269566	2015-01-24 21:11:30.177788	\N	t	1	\N	\N	\N
3826	1	20	47	5	4	Minimum	1.0	665,620,674,604	2015-01-24 21:07:23.249889	2015-01-24 21:11:30.192895	\N	t	1	\N	\N	\N
3959	1	20	47	6	4	Maximum	6	630,438,642,429	2015-01-25 18:48:03.966794	2015-01-25 18:48:03.966794	\N	f	1	\N	\N	\N
3855	1	20	47	6	4	% Confidence Interval	90	89,580,100,564	2015-01-25 18:05:33.862926	2015-01-25 18:15:31.392394	\N	t	1	\N	\N	\N
3858	1	20	47	6	4	Measurement Unit	Geometric LS Mean Ratio	90,560,111,508	2015-01-25 18:05:33.916718	2015-01-25 18:15:31.430193	\N	t	1	\N	\N	\N
3872	1	20	47	6	4	Measurement Type	AUC0-inf ratio	68,256,78,218	2015-01-25 18:15:31.446713	2015-01-25 18:15:31.446713	\N	f	1	\N	\N	\N
3863	1	20	47	6	4	Confidence Interval Lower Bound	0.85	139,591,146,569	2015-01-25 18:15:31.109221	2015-01-25 18:17:08.942235	\N	t	1	\N	\N	\N
3864	1	20	47	6	4	Confidence Interval Upper Bound	0.99	138,612,147,592	2015-01-25 18:15:31.131281	2015-01-25 18:17:08.957992	\N	t	1	\N	\N	\N
3866	1	20	47	6	4	Geometric Mean	0.92	138,533,146,509	2015-01-25 18:15:31.202139	2015-01-25 18:17:08.971541	\N	t	1	\N	\N	\N
3867	1	20	47	6	4	Measurement Name	Midazolam AUC0-inf	136,316,149,230	2015-01-25 18:15:31.224239	2015-01-25 18:17:08.985096	\N	t	1	\N	\N	\N
3862	1	20	47	6	4	Number of Subjects Included in Measurement	24	138,376,147,361	2015-01-25 18:15:31.087305	2015-01-25 18:17:08.999482	\N	t	1	\N	\N	\N
3873	1	20	47	6	4	Coefficient of Variation within Subject	16.0	137,644,147,622	2015-01-25 18:17:09.014494	2015-01-25 18:17:09.014494	\N	f	1	\N	\N	\N
3874	1	20	47	6	4	Coefficient of Variation within Subject	11.6	154,643,162,623	2015-01-25 18:17:12.366069	2015-01-25 18:18:11.274737	\N	f	1	\N	\N	\N
3878	1	20	47	6	4	Confidence Interval Lower Bound	1.07	153,612,161,592	2015-01-25 18:17:12.465345	2015-01-25 18:18:11.29069	\N	t	1	\N	\N	\N
3877	1	20	47	6	4	Confidence Interval Upper Bound	0.95	153,589,163,570	2015-01-25 18:17:12.445878	2015-01-25 18:18:11.304776	\N	t	1	\N	\N	\N
3876	1	20	47	6	4	Geometric Mean	1.01	153,532,163,509	2015-01-25 18:17:12.40389	2015-01-25 18:18:11.318073	\N	t	1	\N	\N	\N
3875	1	20	47	6	4	Measurement Name	pioglitazone AUC0-inf	153,318,165,232	2015-01-25 18:17:12.384854	2015-01-25 18:18:11.331588	\N	t	1	\N	\N	\N
3879	1	20	47	6	4	Number of Subjects Included in Measurement	24	153,377,162,361	2015-01-25 18:17:12.484822	2015-01-25 18:18:11.345707	\N	t	1	\N	\N	\N
3962	1	20	47	6	4	Measurement Name	GSK2635622	673,121,685,59	2015-01-25 18:48:06.807813	2015-01-25 18:48:54.655691	\N	t	1	\N	\N	\N
3961	1	20	47	6	4	Measurement Time	5	687,93,697,81	2015-01-25 18:48:06.788391	2015-01-25 18:48:54.690628	\N	t	1	\N	\N	\N
3960	1	20	47	6	4	Measurement Time Unit	Day	684,82,700,63	2015-01-25 18:48:06.769783	2015-01-25 18:48:54.73291	\N	t	1	\N	\N	\N
3963	1	20	47	6	4	Number of Subjects Included in Measurement	5	673,167,687,152	2015-01-25 18:48:06.82654	2015-01-25 18:48:54.778268	\N	t	1	\N	\N	\N
3980	1	20	47	6	4	Confidence Interval Lower Bound	1.57	688,226,696,202	2015-01-25 18:48:07.228397	2015-01-25 18:49:26.813301	\N	t	1	\N	\N	\N
3979	1	20	47	6	4	Confidence Interval Upper Bound	24.9	688,247,696,223	2015-01-25 18:48:07.209449	2015-01-25 18:49:26.83044	\N	t	1	\N	\N	\N
3977	1	20	47	6	4	Geometric Mean	6.25	675,223,686,198	2015-01-25 18:48:07.17113	2015-01-25 18:49:26.845871	\N	t	1	\N	\N	\N
3970	1	20	47	6	4	Confidence Interval Lower Bound	1.11	687,347,697,326	2015-01-25 18:48:07.006366	2015-01-25 18:50:00.578595	\N	t	1	\N	\N	\N
3971	1	20	47	6	4	Confidence Interval Upper Bound	6.28	687,370,696,348	2015-01-25 18:48:07.043581	2015-01-25 18:50:00.594036	\N	t	1	\N	\N	\N
3972	1	20	47	6	4	Geometric Mean	2.64	675,345,685,322	2015-01-25 18:48:07.063413	2015-01-25 18:50:00.632375	\N	t	1	\N	\N	\N
3964	1	20	47	6	4	Maximum	11.9	686,465,696,445	2015-01-25 18:48:06.882385	2015-01-25 18:50:34.299614	\N	f	1	\N	\N	\N
3966	1	20	47	6	4	Median	11.92	674,443,685,414	2015-01-25 18:48:06.91898	2015-01-25 18:50:34.344681	\N	f	1	\N	\N	\N
3965	1	20	47	6	4	Minimum	10.0	685,439,699,419	2015-01-25 18:48:06.901051	2015-01-25 18:50:34.361291	\N	f	1	\N	\N	\N
3984	1	20	47	6	4	Measurement Time Unit	Day	738,82,750,61	2015-01-25 18:50:39.729766	2015-01-25 18:51:28.22896	\N	t	1	\N	\N	\N
3981	1	20	47	6	4	Number of Subjects Included in Measurement	6	727,164,741,151	2015-01-25 18:50:39.602249	2015-01-25 18:51:28.244632	\N	t	1	\N	\N	\N
3988	1	20	47	6	4	Confidence Interval Lower Bound	1.73	739,225,749,201	2015-01-25 18:50:39.824581	2015-01-25 18:53:28.791489	\N	t	1	\N	\N	\N
3982	1	20	47	6	4	Measurement Name	GSK2656694	728,122,737,62	2015-01-25 18:50:39.678721	2015-01-25 18:51:28.19463	\N	t	1	\N	\N	\N
3983	1	20	47	6	4	Measurement Time	5	739,95,753,77	2015-01-25 18:50:39.696948	2015-01-25 18:51:28.213061	\N	t	1	\N	\N	\N
4001	1	20	47	6	4	Maximum	11.9	740,463,750,442	2015-01-25 18:50:40.149973	2015-01-25 18:52:09.690573	\N	f	1	\N	\N	\N
3999	1	20	47	6	4	Median	11.92	728,443,738,415	2015-01-25 18:50:40.097639	2015-01-25 18:52:09.734342	\N	f	1	\N	\N	\N
4000	1	20	47	6	4	Minimum	10.0	739,441,754,419	2015-01-25 18:50:40.116542	2015-01-25 18:52:09.748396	\N	f	1	\N	\N	\N
3996	1	20	47	6	4	Confidence Interval Lower Bound	1.46	740,348,750,325	2015-01-25 18:50:40.02958	2015-01-25 18:52:50.398266	\N	t	1	\N	\N	\N
3995	1	20	47	6	4	Confidence Interval Upper Bound	5.54	740,370,750,349	2015-01-25 18:50:39.991112	2015-01-25 18:52:50.413307	\N	t	1	\N	\N	\N
3994	1	20	47	6	4	Geometric Mean	2.85	729,346,737,321	2015-01-25 18:50:39.972113	2015-01-25 18:52:50.426898	\N	t	1	\N	\N	\N
3989	1	20	47	6	4	Confidence Interval Upper Bound	12.88	740,253,750,225	2015-01-25 18:50:39.844966	2015-01-25 18:53:28.807208	\N	t	1	\N	\N	\N
3990	1	20	47	6	4	Geometric Mean	4.72	729,222,737,199	2015-01-25 18:50:39.864005	2015-01-25 18:53:28.823619	\N	t	1	\N	\N	\N
4004	1	20	47	6	4	Measurement Name	vercimon	643,106,658,61	2015-01-25 18:55:17.625724	2015-01-25 18:56:00.446087	\N	t	1	\N	\N	\N
4003	1	20	47	6	4	Measurement Time	10	659,95,670,79	2015-01-25 18:55:17.606496	2015-01-25 18:56:00.464358	\N	t	1	\N	\N	\N
4002	1	20	47	6	4	Measurement Time Unit	Day	660,82,669,62	2015-01-25 18:55:17.548623	2015-01-25 18:56:00.480954	\N	t	1	\N	\N	\N
4005	1	20	47	6	4	Number of Subjects Included in Measurement	6	645,164,655,150	2015-01-25 18:55:17.644271	2015-01-25 18:56:00.501255	\N	t	1	\N	\N	\N
4022	1	20	47	6	4	Confidence Interval Lower Bound	6657	660,228,670,202	2015-01-25 18:55:18.102553	2015-01-25 18:56:33.628103	\N	t	1	\N	\N	\N
4021	1	20	47	6	4	Confidence Interval Upper Bound	10177	660,258,669,227	2015-01-25 18:55:18.054923	2015-01-25 18:56:33.643241	\N	t	1	\N	\N	\N
4019	1	20	47	6	4	Geometric Mean	8231	644,223,656,199	2015-01-25 18:55:17.990361	2015-01-25 18:56:33.657809	\N	t	1	\N	\N	\N
4012	1	20	47	6	4	Confidence Interval Lower Bound	783	659,344,670,325	2015-01-25 18:55:17.826735	2015-01-25 18:57:08.233473	\N	t	1	\N	\N	\N
4013	1	20	47	6	4	Confidence Interval Upper Bound	1174	660,369,670,346	2015-01-25 18:55:17.847175	2015-01-25 18:57:08.2489	\N	t	1	\N	\N	\N
4014	1	20	47	6	4	Geometric Mean	959	645,343,654,321	2015-01-25 18:55:17.867919	2015-01-25 18:57:08.262436	\N	t	1	\N	\N	\N
4006	1	20	47	6	4	Maximum	4	661,439,669,428	2015-01-25 18:55:17.678543	2015-01-25 18:57:36.401775	\N	f	1	\N	\N	\N
4008	1	20	47	6	4	Median	2.5	645,435,654,415	2015-01-25 18:55:17.736603	2015-01-25 18:57:36.447004	\N	f	1	\N	\N	\N
4007	1	20	47	6	4	Minimum	0	660,429,670,419	2015-01-25 18:55:17.719171	2015-01-25 18:57:36.462208	\N	f	1	\N	\N	\N
4026	1	20	47	6	4	Confidence Interval Lower Bound	0.96	660,528,670,506	2015-01-25 18:57:38.62203	2015-01-25 18:58:54.518959	\N	t	1	\N	\N	\N
4027	1	20	47	6	4	Confidence Interval Upper Bound	1.35	660,550,669,529	2015-01-25 18:57:38.63963	2015-01-25 18:58:54.533846	\N	t	1	\N	\N	\N
4028	1	20	47	6	4	Geometric Mean	1.14	642,526,655,501	2015-01-25 18:57:38.657865	2015-01-25 18:58:54.561822	\N	t	1	\N	\N	\N
4024	1	20	47	6	4	Measurement Type	Accumulation ratio AUC0-t	569,541,594,502	2015-01-25 18:57:38.550871	2015-01-25 18:58:54.576089	\N	t	1	\N	\N	\N
4023	1	20	47	6	4	Measurement Unit	ratio	803,154,812,132	2015-01-25 18:57:38.484589	2015-01-25 18:58:54.592205	\N	t	1	\N	\N	\N
4032	1	20	47	6	4	Confidence Interval Lower Bound	0.89	659,615,669,594	2015-01-25 18:59:00.154896	2015-01-25 18:59:50.333077	\N	t	1	\N	\N	\N
4031	1	20	47	6	4	Confidence Interval Upper Bound	1.19	660,638,669,616	2015-01-25 18:59:00.136413	2015-01-25 18:59:50.367089	\N	t	1	\N	\N	\N
4030	1	20	47	6	4	Geometric Mean	1.03	644,613,655,592	2015-01-25 18:59:00.118375	2015-01-25 18:59:50.38199	\N	t	1	\N	\N	\N
4033	1	20	47	6	4	Measurement Type	Accumulation Ratio Cmax	571,617,593,590	2015-01-25 18:59:00.173321	2015-01-25 18:59:50.396262	\N	t	1	\N	\N	\N
4036	1	20	47	6	4	Measurement Name	GSK2635622	700,120,713,61	2015-01-25 18:59:58.25434	2015-01-25 19:00:42.046307	\N	t	1	\N	\N	\N
4037	1	20	47	6	4	Measurement Time	10	713,95,725,81	2015-01-25 18:59:58.29981	2015-01-25 19:00:42.062124	\N	t	1	\N	\N	\N
4038	1	20	47	6	4	Measurement Time Unit	Day	712,81,725,61	2015-01-25 18:59:58.319061	2015-01-25 19:00:42.07748	\N	t	1	\N	\N	\N
4035	1	20	47	6	4	Number of Subjects Included in Measurement	6	701,168,710,153	2015-01-25 18:59:58.181453	2015-01-25 19:00:42.092842	\N	t	1	\N	\N	\N
4055	1	20	47	6	4	Maximum	11.9	714,458,723,438	2015-01-25 18:59:58.735672	2015-01-25 19:01:13.41074	\N	f	1	\N	\N	\N
4053	1	20	47	6	4	Median	3.50	700,439,711,415	2015-01-25 18:59:58.696798	2015-01-25 19:01:13.470297	\N	f	1	\N	\N	\N
4054	1	20	47	6	4	Minimum	0.0	712,437,724,417	2015-01-25 18:59:58.716115	2015-01-25 19:01:13.485692	\N	f	1	\N	\N	\N
4050	1	20	47	6	4	Confidence Interval Lower Bound	3.36	714,347,723,325	2015-01-25 18:59:58.59121	2015-01-25 19:01:46.07294	\N	t	1	\N	\N	\N
4049	1	20	47	6	4	Confidence Interval Upper Bound	16.06	714,375,723,349	2015-01-25 18:59:58.572911	2015-01-25 19:01:46.088817	\N	t	1	\N	\N	\N
4048	1	20	47	6	4	Geometric Mean	7.35	701,344,711,323	2015-01-25 18:59:58.553517	2015-01-25 19:01:46.103625	\N	t	1	\N	\N	\N
4042	1	20	47	6	4	Confidence Interval Lower Bound	28.5	714,225,724,201	2015-01-25 18:59:58.40858	2015-01-25 19:02:18.471852	\N	t	1	\N	\N	\N
4043	1	20	47	6	4	Confidence Interval Upper Bound	152.5	714,252,721,227	2015-01-25 18:59:58.444238	2015-01-25 19:02:18.486228	\N	t	1	\N	\N	\N
4044	1	20	47	6	4	Geometric Mean	65.8	701,222,711,199	2015-01-25 18:59:58.463129	2015-01-25 19:02:18.499583	\N	t	1	\N	\N	\N
4057	1	20	47	6	4	Measurement Time	10	765,95,779,82	2015-01-25 19:02:53.649298	2015-01-25 19:03:42.245766	\N	t	1	\N	\N	\N
4056	1	20	47	6	4	Measurement Time Unit	day	764,82,778,62	2015-01-25 19:02:53.582528	2015-01-25 19:03:42.261979	\N	t	1	\N	\N	\N
4074	1	20	47	6	4	Geometric Mean	185.0	755,226,764,200	2015-01-25 19:02:54.062612	2015-01-25 19:04:13.720667	\N	t	1	\N	\N	\N
4068	1	20	47	6	4	Confidence Interval Lower Bound	13.63	765,351,776,326	2015-01-25 19:02:53.932342	2015-01-25 19:04:47.307236	\N	t	1	\N	\N	\N
4069	1	20	47	6	4	Confidence Interval Upper Bound	32.82	767,380,775,353	2015-01-25 19:02:53.951017	2015-01-25 19:04:47.324917	\N	t	1	\N	\N	\N
4070	1	20	47	6	4	Geometric Mean	21.15	756,348,763,321	2015-01-25 19:02:53.971308	2015-01-25 19:04:47.341763	\N	t	1	\N	\N	\N
4062	1	20	47	6	4	Maximum	10.0	767,457,775,438	2015-01-25 19:02:53.77693	2015-01-25 19:06:31.680312	\N	f	1	\N	\N	\N
4064	1	20	47	6	4	Median	0.50	755,440,763,415	2015-01-25 19:02:53.814852	2015-01-25 19:06:31.726418	\N	f	1	\N	\N	\N
4063	1	20	47	6	4	Minimum	0.0	766,435,775,418	2015-01-25 19:02:53.795863	2015-01-25 19:06:31.7441	\N	f	1	\N	\N	\N
4058	1	20	47	6	4	Measurement Name	GSK2656694	755,120,764,61	2015-01-25 19:02:53.667945	2015-01-25 19:03:42.228821	\N	t	1	\N	\N	\N
4059	1	20	47	6	4	Number of Subjects Included in Measurement	6	755,166,764,153	2015-01-25 19:02:53.685335	2015-01-25 19:03:42.277389	\N	t	1	\N	\N	\N
4076	1	20	47	6	4	Confidence Interval Lower Bound	112.1	766,228,776,202	2015-01-25 19:02:54.101848	2015-01-25 19:04:13.567775	\N	t	1	\N	\N	\N
4075	1	20	47	6	4	Confidence Interval Upper Bound	305.2	767,255,775,230	2015-01-25 19:02:54.081846	2015-01-25 19:04:13.678471	\N	t	1	\N	\N	\N
4081	1	20	47	6	4	Adverse Event Name	somnolence	478,223,488,166	2015-01-25 20:52:55.522204	2015-01-25 20:52:55.522204	\N	f	1	\N	\N	\N
4080	1	20	47	6	4	Event Count	19	492,135,504,119	2015-01-25 20:50:23.985255	2015-01-25 20:52:55.587092	\N	t	1	\N	\N	\N
4078	1	20	47	6	4	Subject Count	13	476,346,488,331	2015-01-25 20:50:23.949248	2015-01-25 20:52:55.621047	\N	t	1	\N	\N	\N
4082	1	20	47	6	4	Description	with midazolam alone or combination	272,503,284,446	2015-01-25 20:52:55.635898	2015-01-25 20:52:55.635898	\N	f	1	\N	\N	\N
4083	1	20	47	6	4	Adverse Event System	gastrointestinal	288,570,300,498	2015-01-25 20:53:08.523641	2015-01-25 22:09:09.250979	\N	t	1	\N	\N	\N
4088	1	20	47	6	4	Subject Count	7	318,649,327,615	2015-01-25 20:53:08.62061	2015-01-25 22:09:09.267531	\N	t	1	\N	\N	\N
4084	1	20	47	6	4	Severity (Mild/Moderate/Severe)	mild	403,634,415,607	2015-01-25 20:53:08.542305	2015-01-25 22:09:09.282357	\N	t	1	\N	\N	\N
4086	1	20	47	6	4	Event Count	8	287,499,299,469	2015-01-25 20:53:08.580195	2015-01-25 22:09:09.297504	\N	t	1	\N	\N	\N
4090	1	20	47	6	4	Adverse Event Name	abdominal pain	302,617,314,544	2015-01-25 22:09:09.041921	2015-01-25 22:09:44.673431	\N	t	1	\N	\N	\N
4095	1	20	47	6	4	Event Count	1	304,508,315,486	2015-01-25 22:09:09.134729	2015-01-25 22:09:44.688946	\N	t	1	\N	\N	\N
4099	1	20	47	6	4	Adverse Event Name	dyspepsia	287,644,299,598	2015-01-25 22:09:53.462986	2015-01-25 22:10:21.039078	\N	t	1	\N	\N	\N
4098	1	20	47	6	4	Event Count	3	302,390,311,379	2015-01-25 22:09:53.443595	2015-01-25 22:10:21.053649	\N	t	1	\N	\N	\N
4101	1	20	47	6	4	Adverse Event Name	nausea	303,431,313,394	2015-01-25 22:10:24.849607	2015-01-25 22:10:53.911312	\N	t	1	\N	\N	\N
4102	1	20	47	6	4	Event Count	2	303,461,314,450	2015-01-25 22:10:24.86745	2015-01-25 22:10:53.957389	\N	t	1	\N	\N	\N
4105	1	20	47	6	4	Adverse Event Name	diarrhoea	302,647,313,621	2015-01-25 22:10:56.726407	2015-01-25 22:11:23.546611	\N	t	1	\N	\N	\N
4108	1	20	47	6	4	Adverse Event Name	gastro-oesophageal reflux	316,529,331,409	2015-01-25 22:11:27.154464	2015-01-25 22:12:20.400234	\N	t	1	\N	\N	\N
4110	1	20	47	6	4	Adverse Event Name	headache	388,512,401,466	2015-01-25 22:12:28.601504	2015-01-25 22:13:12.43507	\N	f	1	\N	\N	\N
4111	1	20	47	6	4	Event Count	4	390,541,400,529	2015-01-25 22:12:28.664268	2015-01-25 22:13:12.450247	\N	t	1	\N	\N	\N
4120	1	20	47	6	4	Severity (Mild/Moderate/Severe)	severe	450,433,457,400	2015-01-25 22:14:38.687434	2015-01-25 22:16:11.69361	\N	t	1	\N	\N	\N
4122	1	20	47	6	4	Subject Count	1	437,438,444,416	2015-01-25 22:14:38.725577	2015-01-25 22:16:11.71419	\N	t	1	\N	\N	\N
4126	1	20	47	6	4	Adverse Event Name	elevated ALT	492,626,503,563	2015-01-25 22:16:11.465524	2015-01-25 22:17:10.336738	\N	t	1	\N	\N	\N
4131	1	20	47	6	4	Event Count	1	420,529,429,505	2015-01-25 22:16:11.561353	2015-01-25 22:17:10.351587	\N	t	1	\N	\N	\N
4136	1	20	47	7	4	Adverse Event Name	elevated AST	334,87,344,62	2015-01-25 22:17:14.56692	2015-01-25 22:18:21.349602	\N	t	1	\N	\N	\N
3408	1	20	47	4	4	Maximum	30.2	625,540,636,517	2015-01-24 13:53:30.766276	2015-01-25 22:19:14.652035	\N	f	1	\N	\N	\N
4137	1	14	47	4	4	not	done	323,575,354,545	2015-01-25 22:26:24.487208	2015-01-25 22:26:24.487208	\N	f	1	\N	\N	\N
4141	1	1	46	3	4	ClinicalTrials.gov Identifier	ma	77,116,92,51	2015-03-24 19:00:12.47802	2015-04-07 19:36:40.294182	\N	t	1	\N	\N	\N
4142	1	1	46	1	4	Sponsor Study Number	11	371,390,388,356	2015-03-24 19:00:12.50061	2015-05-06 20:19:37.902563	\N	t	1	\N	\N	\N
4143	1	1	46	1	4	Study Name	Journals.ASM.org	818,435,848,279	2015-03-24 19:00:12.530026	2015-05-06 20:19:37.917953	\N	t	1	\N	\N	\N
\.


--
-- Name: annotations_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('annotations_id_seq', 4457, true);


--
-- Data for Name: app_constants; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY app_constants (id, key, value) FROM stdin;
\.


--
-- Name: app_constants_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('app_constants_id_seq', 1, false);


--
-- Data for Name: collaborations; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY collaborations (id, project_id, account_id, creator_id) FROM stdin;
\.


--
-- Name: collaborations_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('collaborations_id_seq', 1, false);


--
-- Data for Name: docdata; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY docdata (id, document_id, data) FROM stdin;
\.


--
-- Name: docdata_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('docdata_id_seq', 1, false);


--
-- Data for Name: document_reviewers; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY document_reviewers (id, account_id, document_id, created_at, updated_at) FROM stdin;
1	23	47	2015-03-18 00:00:00	2015-03-18 00:00:00
2	23	48	2015-03-18 00:00:00	2015-03-18 00:00:00
\.


--
-- Name: document_reviewers_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('document_reviewers_id_seq', 2, true);


--
-- Data for Name: documents; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY documents (id, organization_id, account_id, access, page_count, title, slug, source, language, description, calais_id, publication_date, created_at, updated_at, related_article, detected_remote_url, remote_url, publish_at, text_changed, hit_count, public_note_count, reviewer_count, file_size, char_count, original_extension, file_hash, study, status, de_one_id, de_two_id, qc_id, qa_id, de_one_complete, de_two_complete, qa_note, iteration, repository_id) FROM stdin;
46	1	4	1	6	Antimicrob Agents Chemother 2013 Winter 3699 703	antimicrob_agents_chemother_2013_winter_3699_703		eng		\N	\N	2014-10-22 02:53:35.322346	2015-06-15 20:28:13.289234		\N	\N	\N	f	0	5	0	365673	31491	pdf	653dc675b67165573c1efff9126be995e75e54d6		6	1	14	17	\N	t	t	\N	1	\N
42	1	4	1	5	A Randomized Comparison of Transcervical Foley 22	a_randomized_comparison_of_transcervical_foley_22	\N	eng	\N	\N	\N	2014-10-19 20:31:01.93599	2016-06-22 20:21:23.731047	\N	\N	\N	\N	f	0	126	0	164084	23538	pdf	1d5b75b210002d58c968f152e2de428c646c5587	\N	8	7	4	6	5	t	t	\N	1	\N
48	1	4	1	7	Drug Metab Dispos 2013 Doroshyenko 987 93	drug_metab_dispos_2013_doroshyenko_987_93	\N	eng	\N	\N	\N	2014-10-22 02:53:37.987366	2016-06-22 20:27:44.027132	\N	\N	\N	\N	f	0	726	0	707131	44768	pdf	572ecc984a98f4d54fa592344dae89121b21c3e7	\N	8	7	14	17	20	t	t	\N	1	\N
47	1	4	1	9	Art%3A10 1007%2Fs00228 013 1592 7	art_3a10_1007_2fs00228_013_1592_7	\N	eng	\N	\N	\N	2014-10-22 02:53:36.219299	2016-06-23 15:57:31.483432	\N	\N	\N	\N	f	0	451	0	198166	38734	pdf	4ea408e561b885fc5379342c13e85eb822214669	\N	8	20	14	17	21	t	t	\N	1	\N
93	1	1	1	1	Test	test	\N	eng	\N	\N	\N	2015-05-19 17:36:04.836888	2016-06-23 16:53:47.013551	\N	\N	\N	\N	f	0	10	0	77123	3877	pdf	c761fbad13ceab42294314b2cab8643332f7225b	\N	8	\N	\N	\N	\N	\N	\N	\N	5	8
81	1	1	1	1	Denney Invoice 014	denney_invoice_014		eng		\N	\N	2015-04-23 20:02:44.382584	2016-06-27 17:50:06.467094		\N	\N	\N	f	0	0	0	9670	317	docx	a69501fb73a0cbaf223f3be1bf2ce71fddb9ad7b		2	14	\N	\N	\N	\N	\N	\N	1	\N
95	1	1	1	4	FinanceReregulationFactSheetFINAL	financereregulationfactsheetfinal		eng		\N	\N	2015-07-16 19:59:56.528115	2016-06-27 19:26:54.695333		\N	\N	\N	f	0	13	0	207936	15615	pdf	381d018d917807b2a6f9a8e8257893eda6a2f862		5	14	15	17	\N	t	t	\N	1	\N
50	1	4	1	33	Dmd 114 060558 Full	dmd_114_060558_full		eng		\N	\N	2014-11-06 21:21:50.220756	2015-05-11 19:34:52.724351		\N	\N	\N	f	0	2	0	445152	34077	pdf	25ce1fe0581f8607654beab8c6afe7954d420a21		7	14	15	17	1	t	t	\N	1	\N
96	1	1	1	1	ASCPT2016 HbA1c LongitudinalMBMA 02MAR2016	ascpt2016_hba1c_longitudinalmbma_02mar2016		eng		\N	\N	2016-08-02 18:38:45.883817	2016-08-02 18:40:32.023365		\N	\N	\N	f	0	0	0	498975	7670	pdf	620efc7a398ff6a012522ff38111d3e7f26f36e5		2	1	\N	\N	\N	\N	\N	\N	1	\N
87	1	1	1	1	Denney Invoice 015	denney_invoice_015		eng		\N	\N	2015-05-01 20:03:44.75733	2015-06-05 19:31:48.074558		\N	\N	\N	f	0	0	0	9642	287	docx	ca88174040aaa358b3f2a183b0d5bd6034f2d455		1	\N	\N	\N	\N	\N	\N	\N	1	\N
\.


--
-- Name: documents_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('documents_id_seq', 96, true);


--
-- Data for Name: entities; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY entities (id, organization_id, account_id, document_id, access, kind, value, relevance, calais_id, occurrences) FROM stdin;
\.


--
-- Name: entities_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('entities_id_seq', 1, false);


--
-- Data for Name: entity_dates; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY entity_dates (id, organization_id, account_id, document_id, access, date, occurrences) FROM stdin;
4	1	1	9	5	2011-11-01	795:10
5	1	1	9	5	2014-01-31	1227:10,2104:10,4922:10
9	1	1	15	2	2013-05-20	329:11
10	1	1	15	2	2014-05-14	803:12,863:12,5457:12,11365:12,20276:12,26090:12,29830:12
11	1	1	15	2	2013-01-17	5081:15
12	1	2	16	5	2009-10-26	350:11,4450:11,5741:11,5919:11
13	1	2	16	5	2009-06-25	5501:11,6071:11,345800:11
14	1	2	16	5	2009-11-01	5989:10
15	1	2	16	5	2009-08-08	6414:10
16	1	2	16	5	2008-05-23	9000:12,331167:11,339976:11,413523:11
17	1	2	16	5	2009-08-07	21354:10
18	1	2	16	5	2009-08-12	21501:11
19	1	2	16	5	1216-01-06	25173:8
20	1	2	16	5	1259-03-02	28312:8
21	1	2	16	5	2004-05-04	53803:11,281951:11
22	1	2	16	5	1573-06-01	101573:8
23	1	2	16	5	1697-06-01	114765:8
24	1	2	16	5	2006-09-01	127186:16,127287:16
25	1	2	16	5	2006-09-17	142277:17,142720:17
26	1	2	16	5	2009-07-23	143950:11
27	1	2	16	5	2009-07-29	144518:11
28	1	2	16	5	2009-06-01	267415:12,267630:12,272859:12
29	1	2	16	5	2009-08-06	283169:8
30	1	2	16	5	2009-08-26	293971:11
31	1	2	16	5	1457-01-05	295903:8
32	1	2	16	5	1457-01-06	295936:8
33	1	2	16	5	1607-01-07	295975:8
34	1	2	16	5	1617-01-08	296006:8
35	1	2	16	5	1667-01-09	296029:8
36	1	2	16	5	1697-01-10	296067:9
37	1	2	16	5	1717-01-01	296093:8
38	1	2	16	5	1807-01-12	296128:9
39	1	2	16	5	1847-01-14	296219:9
40	1	2	16	5	1857-01-16	296432:9
41	1	2	16	5	1857-01-17	296464:9
42	1	2	16	5	1857-02-02	296687:8
43	1	2	16	5	1947-02-03	296769:8
44	1	2	16	5	1947-02-04	296820:8
45	1	2	16	5	1947-02-05	296883:8
46	1	2	16	5	1947-02-06	296931:8
47	1	2	16	5	1947-02-07	296999:8
48	1	2	16	5	1957-02-08	297181:8
49	1	2	16	5	1957-02-09	297239:8
50	1	2	16	5	2008-12-29	327046:11
51	1	2	16	5	2009-04-17	327062:11,327286:11
52	1	2	16	5	2009-07-08	328032:10,345815:10
53	1	2	16	5	2008-01-31	331276:11
54	1	2	16	5	2008-09-23	331499:11
55	1	2	16	5	2009-07-21	346894:11
56	1	2	16	5	2009-06-29	358084:11
57	1	2	16	5	2008-10-07	405602:10
58	1	2	16	5	2009-01-11	405797:11
59	1	2	16	5	2009-01-21	427722:11,430357:11,430479:11,431430:11,431552:11
169	1	4	42	5	1997-07-01	3580:12
170	1	4	42	5	1999-07-01	3597:12
171	1	4	42	5	1019-04-09	11062:8
172	1	4	42	5	2000-09-06	23310:17
173	1	4	42	5	2000-11-09	23352:16
174	1	4	42	5	2000-11-29	23379:17
181	1	4	46	5	2013-05-20	329:11
182	1	4	46	5	2014-10-21	807:16,871:16,5469:16,11381:16,20296:16,26114:16,29858:16
183	1	4	46	5	2013-01-17	5089:15
184	1	4	47	5	2013-05-10	292:11
185	1	4	47	5	2013-09-20	322:17
186	1	4	47	5	2013-10-08	357:14
187	1	4	48	5	2012-11-19	876:17
188	1	4	48	5	2012-06-21	42119:13
\.


--
-- Name: entity_dates_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('entity_dates_id_seq', 190, true);


--
-- Data for Name: featured_reports; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY featured_reports (id, url, title, organization, article_date, writeup, present_order, created_at, updated_at) FROM stdin;
\.


--
-- Name: featured_reports_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('featured_reports_id_seq', 1, false);


--
-- Data for Name: file_status_histories; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY file_status_histories (id, status, "user", created_at, updated_at) FROM stdin;
1	2	4	2014-09-26 02:41:23.357788	2014-09-26 02:41:23.357788
2	3	6	2014-10-19 21:34:29.799351	2014-10-19 21:34:29.799351
3	2	5	2014-10-19 21:35:16.645852	2014-10-19 21:35:16.645852
4	6	8	2014-10-20 00:28:49.979866	2014-10-20 00:28:49.979866
5	2	7	2014-10-24 01:55:48.120563	2014-10-24 01:55:48.120563
6	3	4	2014-10-24 20:03:14.165161	2014-10-24 20:03:14.165161
7	6	6	2014-10-30 02:42:18.293392	2014-10-30 02:42:18.293392
8	9	5	2014-10-30 02:55:11.876424	2014-10-30 02:55:11.876424
9	2	10	2014-11-03 22:57:49.87671	2014-11-03 22:57:49.87671
10	3	11	2014-11-03 22:58:22.874122	2014-11-03 22:58:22.874122
11	2	5	2014-11-06 21:26:59.447815	2014-11-06 21:26:59.447815
12	3	10	2014-11-06 21:28:27.975298	2014-11-06 21:28:27.975298
13	2	14	2014-11-06 22:52:53.553395	2014-11-06 22:52:53.553395
14	3	15	2014-11-06 22:53:22.900765	2014-11-06 22:53:22.900765
15	6	17	2014-11-06 22:54:05.032235	2014-11-06 22:54:05.032235
16	2	16	2014-12-17 02:21:34.384395	2014-12-17 02:21:34.384395
17	3	15	2014-12-17 02:34:09.315446	2014-12-17 02:34:09.315446
18	10	17	2014-12-22 02:31:42.227352	2014-12-22 02:31:42.227352
19	10	17	2014-12-22 02:31:55.073313	2014-12-22 02:31:55.073313
20	2	14	2014-12-22 02:37:33.825572	2014-12-22 02:37:33.825572
21	3	15	2014-12-22 02:39:04.791468	2014-12-22 02:39:04.791468
22	6	17	2014-12-22 03:25:16.974432	2014-12-22 03:25:16.974432
23	8	20	2014-12-22 03:34:37.361105	2014-12-22 03:34:37.361105
24	10	14	2015-01-17 00:38:47.332338	2015-01-17 00:38:47.332338
25	10	14	2015-01-17 00:39:02.855281	2015-01-17 00:39:02.855281
26	3	14	2015-01-18 19:45:55.389356	2015-01-18 19:45:55.389356
27	2	7	2015-01-18 19:59:27.677973	2015-01-18 19:59:27.677973
28	6	17	2015-01-21 02:22:04.128856	2015-01-21 02:22:04.128856
29	8	20	2015-01-21 02:42:23.681263	2015-01-21 02:42:23.681263
30	2	14	2015-01-23 03:23:27.405621	2015-01-23 03:23:27.405621
31	3	15	2015-01-23 03:24:04.428924	2015-01-23 03:24:04.428924
32	6	17	2015-01-23 03:36:15.916952	2015-01-23 03:36:15.916952
33	9	20	2015-01-23 12:18:36.520448	2015-01-23 12:18:36.520448
34	2	20	2015-01-25 22:19:52.12229	2015-01-25 22:19:52.12229
35	3	14	2015-01-25 22:26:24.726371	2015-01-25 22:26:24.726371
36	6	17	2015-01-26 22:14:35.648318	2015-01-26 22:14:35.648318
37	8	21	2015-01-26 22:28:36.91884	2015-01-26 22:28:36.91884
38	2	1	2015-03-31 18:50:48.072339	2015-03-31 18:50:48.072339
39	3	14	2015-03-31 18:51:29.938676	2015-03-31 18:51:29.938676
40	6	17	2015-03-31 18:52:22.985238	2015-03-31 18:52:22.985238
41	11	14	2015-05-01 21:50:57.924395	2015-05-01 21:50:57.924395
42	2	1	2015-05-06 20:20:35.644776	2015-05-06 20:20:35.644776
43	3	14	2015-05-06 20:21:43.198359	2015-05-06 20:21:43.198359
44	2	14	2015-05-06 20:22:17.554189	2015-05-06 20:22:17.554189
45	2	14	2015-05-06 20:22:59.990744	2015-05-06 20:22:59.990744
46	9	20	2015-05-07 13:59:52.267195	2015-05-07 13:59:52.267195
47	11	14	2015-05-11 19:57:48.365925	2015-05-11 19:57:48.365925
48	11	14	2015-05-11 20:01:01.593314	2015-05-11 20:01:01.593314
49	11	14	2015-05-11 20:31:27.457317	2015-05-11 20:31:27.457317
50	11	14	2015-05-12 17:48:13.759541	2015-05-12 17:48:13.759541
51	12	17	2015-05-12 18:05:13.520351	2015-05-12 18:05:13.520351
52	13	17	2015-05-12 18:06:54.848006	2015-05-12 18:06:54.848006
53	6	17	2015-05-12 18:07:21.545392	2015-05-12 18:07:21.545392
54	3	14	2015-05-18 19:18:47.219984	2015-05-18 19:18:47.219984
55	14	20	2015-05-26 18:48:14.796742	2015-05-26 18:48:14.796742
56	14	20	2015-05-26 18:58:15.80285	2015-05-26 18:58:15.80285
57	14	20	2015-05-26 19:41:22.359541	2015-05-26 19:41:22.359541
58	9	20	2015-05-26 19:42:19.631872	2015-05-26 19:42:19.631872
59	11	14	2015-05-26 19:44:20.401874	2015-05-26 19:44:20.401874
60	11	14	2015-05-26 19:50:28.033441	2015-05-26 19:50:28.033441
61	13	17	2015-05-29 20:29:26.856389	2015-05-29 20:29:26.856389
62	2	16	2015-05-29 20:55:14.677904	2015-05-29 20:55:14.677904
63	3	14	2015-05-29 20:57:04.258888	2015-05-29 20:57:04.258888
64	6	17	2015-05-29 21:02:31.163988	2015-05-29 21:02:31.163988
65	9	20	2015-05-29 21:06:13.719853	2015-05-29 21:06:13.719853
66	11	14	2015-06-05 20:18:50.817355	2015-06-05 20:18:50.817355
67	2	1	2015-06-09 18:06:43.700445	2015-06-09 18:06:43.700445
68	3	14	2015-06-09 18:09:19.99556	2015-06-09 18:09:19.99556
69	6	17	2015-06-15 20:11:44.74885	2015-06-15 20:11:44.74885
70	9	20	2015-06-15 20:30:30.757669	2015-06-15 20:30:30.757669
71	11	14	2015-06-18 21:21:34.277144	2015-06-18 21:21:34.277144
72	11	14	2015-06-19 19:57:27.113459	2015-06-19 19:57:27.113459
73	11	14	2015-06-19 20:24:59.775466	2015-06-19 20:24:59.775466
74	11	14	2015-06-30 20:51:44.89456	2015-06-30 20:51:44.89456
75	13	17	2015-06-30 21:35:14.937539	2015-06-30 21:35:14.937539
76	9	20	2015-06-30 21:45:41.969897	2015-06-30 21:45:41.969897
77	11	14	2015-06-30 21:48:00.743898	2015-06-30 21:48:00.743898
78	13	17	2015-06-30 21:48:32.418999	2015-06-30 21:48:32.418999
79	9	20	2015-07-07 20:33:01.746796	2015-07-07 20:33:01.746796
80	11	14	2015-07-07 20:37:40.168957	2015-07-07 20:37:40.168957
81	13	17	2015-07-07 20:38:24.556702	2015-07-07 20:38:24.556702
82	8	20	2015-07-07 21:16:56.112929	2015-07-07 21:16:56.112929
83	2	14	2016-06-27 18:23:33.535396	2016-06-27 18:23:33.535396
84	3	15	2016-06-27 19:24:20.639599	2016-06-27 19:24:20.639599
\.


--
-- Name: file_status_histories_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('file_status_histories_id_seq', 84, true);


--
-- Data for Name: graph_groups; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY graph_groups (id, graph_id, group_id, graph_json) FROM stdin;
\.


--
-- Name: graph_groups_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('graph_groups_id_seq', 1, false);


--
-- Data for Name: graphs; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY graphs (id, location) FROM stdin;
\.


--
-- Name: graphs_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('graphs_id_seq', 1, false);


--
-- Data for Name: group_templates; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY group_templates (id, name, created_at, updated_at, help_url) FROM stdin;
10	Date	2014-12-20 23:49:31.891514	2015-01-10 13:36:33.591635	https://www.denney.ws/wiki/DACTYL/Templates/Date
8	Demographics	2014-07-03 19:03:20.392046	2015-01-10 14:08:26.962962	https://www.denney.ws/wiki/DACTYL/Templates/Demographics
9	Intervention	2014-07-03 19:06:02.048392	2015-01-10 14:38:27.864871	https://www.denney.ws/wiki/DACTYL/Templates/Intervention
6	Document Reference	2014-06-29 02:23:31.780616	2015-01-10 14:55:36.077784	https://www.denney.ws/wiki/DACTYL/Templates/Document Reference
7	Person's Name	2014-06-29 02:31:52.337788	2015-01-10 14:58:57.370303	https://www.denney.ws/wiki/DACTYL/Templates/Person%27s_Name
1	Measurement	2014-05-02 11:04:17.004909	2015-01-10 17:09:49.619974	https://www.denney.ws/wiki/DACTYL/Templates/Measurement
12	Study	2014-12-21 00:40:42.422399	2015-01-10 18:55:52.527027	https://www.denney.ws/wiki/DACTYL/Templates/Study
11	Study Design	2014-12-20 23:50:28.534754	2015-01-10 18:59:50.102713	https://www.denney.ws/wiki/DACTYL/Templates/Study_Design
13	Treatment	2014-12-21 00:40:52.94908	2015-01-10 19:00:27.414227	\N
15	Results	2015-01-10 19:39:19.099226	2015-01-12 00:58:31.249678	https://www.denney.ws/wiki/DACTYL/Templates/Results
16	Adverse Event	2015-01-18 15:10:23.698302	2015-01-18 15:10:23.698302	https://www.denney.ws/wiki/DACTYL/Templates/Adverse_Event
17	Inclusion and Exclusion Criteria	2015-01-24 17:39:43.320377	2015-01-24 17:39:43.320377	https://www.denney.ws/wiki/DACTYL/Templates/Inclusion_and_Exclusion_Criteria
18	Inclusion	2015-01-24 18:45:02.472302	2015-01-24 18:45:02.472302	https://www.denney.ws/wiki/DACTYL/Templates/Inclusion
\.


--
-- Name: group_templates_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('group_templates_id_seq', 19, true);


--
-- Data for Name: groups; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY groups (id, name, parent_id, template_id, document_id, created_at, updated_at, extension, account_id, base, iteration, qa_approved_by, canon, is_graph_data) FROM stdin;
264	Endpoint	261	\N	42	2014-10-22 03:56:45.067732	2014-10-22 03:57:18.165764	route	7	f	1	\N	\N	\N
265	Endpoint	261	\N	42	2014-10-22 03:57:26.541286	2014-10-22 03:57:35.060239	uterine	7	f	1	\N	\N	\N
266	Endpoint	261	\N	42	2014-10-22 03:59:06.410045	2014-10-22 03:59:18.394122	side	7	f	1	\N	\N	\N
267	Endpoint	261	\N	42	2014-10-22 03:59:10.440259	2014-10-22 03:59:28.907391	comfort	7	f	1	\N	\N	\N
312	Intervention	291	\N	42	2014-10-23 21:05:22.358668	2014-10-23 21:05:22.358668	\N	7	f	1	\N	\N	\N
268	Endpoint	261	\N	42	2014-10-22 04:00:10.26304	2014-10-22 04:01:12.281175	FHR	7	f	1	\N	\N	\N
269	Results	256	\N	42	2014-10-22 04:03:58.59969	2014-10-22 04:03:58.59969	\N	7	f	1	\N	\N	\N
270	Result	269	1	42	2014-10-22 04:06:34.508859	2014-10-22 04:06:34.508859	spont labo	7	f	1	\N	\N	\N
272	Result	269	1	42	2014-10-22 04:08:00.021211	2014-10-22 04:08:00.021211	epidural	7	f	1	\N	\N	\N
273	Result	269	1	42	2014-10-22 04:09:35.382077	2014-10-22 04:09:35.382077	Bishop	7	f	1	\N	\N	\N
274	Result	269	1	42	2014-10-22 04:10:38.593159	2014-10-22 04:10:38.593159	ripe time	7	f	1	\N	\N	\N
275	Result	269	1	42	2014-10-22 04:11:41.353026	2014-10-22 04:11:41.353026	tot time	7	f	1	\N	\N	\N
276	Demographics	256	8	42	2014-10-22 04:15:46.754823	2014-10-22 04:15:46.754823	\N	7	f	1	\N	\N	\N
277	Measurement	276	1	42	2014-10-23 10:48:47.909689	2014-10-23 10:48:47.909689	Mat age	7	f	1	\N	\N	\N
278	Measurement	276	1	42	2014-10-23 10:49:46.56588	2014-10-23 10:49:57.621098	Gravidity	7	f	1	\N	\N	\N
279	Measurement	276	1	42	2014-10-23 10:54:04.174916	2014-10-23 10:54:04.174916	Nullip	7	f	1	\N	\N	\N
280	Measurement	276	1	42	2014-10-23 10:54:55.794616	2014-10-23 10:54:55.794616	Base Bisho	7	f	1	\N	\N	\N
281	Result	269	1	42	2014-10-23 10:56:28.289945	2014-10-23 10:56:28.289945	Infant wt	7	f	1	\N	\N	\N
282	Result	269	1	42	2014-10-23 10:58:01.449753	2014-10-23 10:58:01.449753	Cesarean	7	f	1	\N	\N	\N
283	Result	269	1	42	2014-10-23 10:58:49.355237	2014-10-23 11:15:16.937412	Contract	7	f	1	\N	\N	\N
284	Result	269	1	42	2014-10-23 10:58:52.034158	2014-10-23 11:15:29.24207	Meconium	7	f	1	\N	\N	\N
285	Result	269	1	42	2014-10-23 10:59:02.342184	2014-10-23 11:15:54.949331	Deliv 24	7	f	1	\N	\N	\N
286	Result	269	1	42	2014-10-23 10:59:04.200266	2014-10-23 11:16:03.350544	V Deliv 24	7	f	1	\N	\N	\N
287	Result	269	1	42	2014-10-23 11:18:47.651243	2014-10-23 11:18:47.651243	Ces fet t	7	f	1	\N	\N	\N
288	Result	269	1	42	2014-10-23 11:20:41.726287	2014-10-23 11:20:41.726287	Hyperstim	7	f	1	\N	\N	\N
290	Result	269	1	42	2014-10-23 21:02:07.466198	2014-10-23 21:02:26.255248	FHR abnorm	7	f	1	\N	\N	\N
292	Results	291	\N	42	2014-10-23 21:05:21.297744	2014-10-23 21:05:21.297744	\N	7	f	1	\N	\N	\N
293	Result	292	1	42	2014-10-23 21:05:21.314631	2014-10-23 21:05:21.314631	spont labo	7	f	1	\N	\N	\N
294	Result	292	1	42	2014-10-23 21:05:21.364307	2014-10-23 21:05:21.364307	epidural	7	f	1	\N	\N	\N
295	Result	292	1	42	2014-10-23 21:05:21.412685	2014-10-23 21:05:21.412685	Bishop	7	f	1	\N	\N	\N
296	Result	292	1	42	2014-10-23 21:05:21.461552	2014-10-23 21:05:21.461552	ripe time	7	f	1	\N	\N	\N
297	Result	292	1	42	2014-10-23 21:05:21.542998	2014-10-23 21:05:21.542998	tot time	7	f	1	\N	\N	\N
298	Result	292	1	42	2014-10-23 21:05:21.625623	2014-10-23 21:05:21.625623	Infant wt	7	f	1	\N	\N	\N
299	Result	292	1	42	2014-10-23 21:05:21.710081	2014-10-23 21:05:21.710081	Cesarean	7	f	1	\N	\N	\N
300	Result	292	1	42	2014-10-23 21:05:21.759763	2014-10-23 21:05:21.759763	Contract	7	f	1	\N	\N	\N
301	Result	292	1	42	2014-10-23 21:05:21.807098	2014-10-23 21:05:21.807098	Meconium	7	f	1	\N	\N	\N
302	Result	292	1	42	2014-10-23 21:05:21.85318	2014-10-23 21:05:21.85318	Deliv 24	7	f	1	\N	\N	\N
303	Result	292	1	42	2014-10-23 21:05:21.902164	2014-10-23 21:05:21.902164	V Deliv 24	7	f	1	\N	\N	\N
304	Result	292	1	42	2014-10-23 21:05:21.949307	2014-10-23 21:05:21.949307	Ces fet t	7	f	1	\N	\N	\N
305	Result	292	1	42	2014-10-23 21:05:22.007636	2014-10-23 21:05:22.007636	Hyperstim	7	f	1	\N	\N	\N
306	Result	292	1	42	2014-10-23 21:05:22.055068	2014-10-23 21:05:22.055068	FHR abnorm	7	f	1	\N	\N	\N
250	Home	\N	\N	42	2014-10-22 02:54:18.17456	2014-10-22 02:54:18.17456	\N	7	t	1	\N	\N	\N
251	Source	250	6	42	2014-10-22 02:57:43.763208	2014-10-22 02:57:43.763208	\N	7	f	1	\N	\N	\N
252	Study	250	\N	42	2014-10-22 03:03:33.655147	2014-10-22 03:03:33.655147	\N	7	f	1	\N	\N	\N
253	Inclusion Criteria	252	\N	42	2014-10-22 03:05:19.443811	2014-10-22 03:05:19.443811	\N	7	f	1	\N	\N	\N
254	Exclusion Criteria	252	\N	42	2014-10-22 03:08:04.609058	2014-10-22 03:08:04.609058	\N	7	f	1	\N	\N	\N
255	Treatments	250	\N	42	2014-10-22 03:14:47.584207	2014-10-22 03:14:47.584207	\N	7	f	1	\N	\N	\N
256	Treatment	255	\N	42	2014-10-22 03:14:59.777342	2014-10-22 03:14:59.777342	Foley	7	f	1	\N	\N	\N
257	Intervention	256	\N	42	2014-10-22 03:15:13.464582	2014-10-22 03:15:13.464582	\N	7	f	1	\N	\N	\N
258	Endpoints	252	\N	42	2014-10-22 03:24:16.643151	2014-10-22 03:24:16.643151	\N	7	f	1	\N	\N	\N
259	Primary	258	\N	42	2014-10-22 03:24:43.967974	2014-10-22 03:24:43.967974	\N	7	f	1	\N	\N	\N
260	Endpoint	259	\N	42	2014-10-22 03:25:04.291108	2014-10-22 03:25:04.291108	\N	7	f	1	\N	\N	\N
261	Secondary	258	\N	42	2014-10-22 03:48:31.560693	2014-10-22 03:48:31.560693	\N	7	f	1	\N	\N	\N
262	Endpoint	261	\N	42	2014-10-22 03:48:44.062267	2014-10-22 03:48:44.062267	\N	7	f	1	\N	\N	\N
263	Endpoint	261	\N	42	2014-10-22 03:50:07.881494	2014-10-22 03:50:14.574712	\N	7	f	1	\N	\N	\N
307	Demographics	291	8	42	2014-10-23 21:05:22.103915	2014-10-23 21:05:22.103915	\N	7	f	1	\N	\N	\N
308	Measurement	307	1	42	2014-10-23 21:05:22.117783	2014-10-23 21:05:22.117783	Mat age	7	f	1	\N	\N	\N
309	Measurement	307	1	42	2014-10-23 21:05:22.20143	2014-10-23 21:05:22.20143	Gravidity	7	f	1	\N	\N	\N
310	Measurement	307	1	42	2014-10-23 21:05:22.266016	2014-10-23 21:05:22.266016	Nullip	7	f	1	\N	\N	\N
311	Measurement	307	1	42	2014-10-23 21:05:22.311821	2014-10-23 21:05:22.311821	Base Bisho	7	f	1	\N	\N	\N
291	Treatment	255	\N	42	2014-10-23 21:05:21.198004	2014-10-23 21:05:30.385317	Miso	7	f	1	\N	\N	\N
313	Number of doses	312	1	42	2014-10-23 21:10:35.518807	2014-10-23 21:10:35.518807	\N	7	f	1	\N	\N	\N
315	Result	292	1	42	2014-10-23 21:37:50.222148	2014-10-23 21:37:50.222148	discomfort	7	f	1	\N	\N	\N
316	Result	269	1	42	2014-10-23 21:39:16.606301	2014-10-23 21:39:16.606301	discomfort	7	f	1	\N	\N	\N
317	Home	\N	\N	48	2014-10-24 02:12:13.312838	2014-10-24 02:12:13.312838	\N	7	t	1	\N	\N	\N
318	Source	317	6	48	2014-10-24 04:31:47.89779	2014-10-24 04:31:47.89779	\N	7	f	1	\N	\N	\N
319	Study	317	\N	48	2014-10-24 04:34:46.48105	2014-10-24 04:34:46.48105	\N	7	f	1	\N	\N	\N
320	Home	\N	\N	42	2014-10-24 19:56:35.781354	2014-10-24 19:56:35.781354	\N	4	t	1	\N	\N	\N
321	Treatments	320	\N	42	2014-10-24 19:57:53.699453	2014-10-24 19:57:53.699453	\N	4	f	1	\N	\N	\N
322	Treatment	321	\N	42	2014-10-24 19:58:08.897218	2014-10-24 19:58:08.897218	Foley	4	f	1	\N	\N	\N
323	Results	322	\N	42	2014-10-24 19:58:20.335954	2014-10-24 19:58:20.335954	\N	4	f	1	\N	\N	\N
324	Result	323	1	42	2014-10-24 19:59:09.429167	2014-10-24 19:59:09.429167	change bis	4	f	1	\N	\N	\N
326	Results	325	\N	42	2014-10-24 20:01:20.275336	2014-10-24 20:01:20.275336	\N	4	f	1	\N	\N	\N
327	Result	326	1	42	2014-10-24 20:01:20.288957	2014-10-24 20:01:20.288957	change bis	4	f	1	\N	\N	\N
325	Treatment	321	\N	42	2014-10-24 20:01:20.254392	2014-10-24 20:01:32.072668	Miso	4	f	1	\N	\N	\N
328	Home	\N	\N	42	2014-10-24 20:05:04.137426	2014-10-24 20:05:04.137426	\N	6	t	1	\N	\N	\N
329	Inclusion Criteria	319	\N	48	2014-10-25 03:00:45.447425	2014-10-25 03:00:45.447425	\N	7	f	1	\N	\N	\N
330	Age	329	1	48	2014-10-25 03:01:06.386512	2014-10-25 03:01:06.386512	\N	7	f	1	\N	\N	\N
331	Treatments	317	\N	48	2014-10-25 03:11:35.888417	2014-10-25 03:11:35.888417	\N	7	f	1	\N	\N	\N
332	Treatment	331	\N	48	2014-10-25 03:12:12.379049	2014-10-25 03:12:12.379049	silexan	7	f	1	\N	\N	\N
334	Interventions	332	\N	48	2014-10-25 03:29:46.423726	2014-10-25 03:29:46.423726	\N	7	f	1	\N	\N	\N
335	Intervention	334	9	48	2014-10-25 03:29:59.542491	2014-10-25 03:29:59.542491	Silexan	7	f	1	\N	\N	\N
336	Intervention	334	9	48	2014-10-25 03:31:35.810725	2014-10-25 03:31:35.810725	cocktail	7	f	1	\N	\N	\N
338	Intervention	336	9	48	2014-10-25 03:35:28.247017	2014-10-25 03:35:28.247017	caffeine	7	f	1	\N	\N	\N
339	Intervention	336	9	48	2014-10-25 03:36:35.871401	2014-10-25 03:36:46.965906	tolbut	7	f	1	\N	\N	\N
340	Intervention	336	9	48	2014-10-25 03:37:31.759852	2014-10-25 03:38:08.336937	omepra	7	f	1	\N	\N	\N
341	Intervention	336	9	48	2014-10-25 03:41:48.125134	2014-10-25 03:42:02.589566	dextrome	7	f	1	\N	\N	\N
342	Intervention	336	9	48	2014-10-25 03:43:00.482018	2014-10-25 03:43:11.020034	midaz	7	f	1	\N	\N	\N
345	Result	344	\N	48	2014-10-25 04:01:02.103784	2014-10-25 04:01:02.103784	Caffeine	7	f	1	\N	\N	\N
346	Result	345	1	48	2014-10-25 04:02:45.34203	2014-10-25 04:02:45.34203	Cmax	7	f	1	\N	\N	\N
347	Result	345	1	48	2014-10-25 04:15:50.532511	2014-10-25 04:16:02.031968	AUClast	7	f	1	\N	\N	\N
348	Result	345	1	48	2014-10-25 04:17:29.975078	2014-10-25 04:17:39.668601	AUCinf	7	f	1	\N	\N	\N
394	Background Medication	317	\N	48	2014-10-30 01:45:53.061362	2014-10-30 01:45:53.061362	\N	7	f	1	\N	\N	\N
349	Result	345	1	48	2014-10-25 04:18:46.582099	2014-10-25 04:19:01.035989	t1/2	7	f	1	\N	\N	\N
350	Result	345	1	48	2014-10-25 04:20:29.719922	2014-10-25 04:20:29.719922	Tmax	7	f	1	\N	\N	\N
352	Result	351	1	48	2014-10-25 04:22:15.961742	2014-10-25 04:22:15.961742	Cmax	7	f	1	\N	\N	\N
353	Result	351	1	48	2014-10-25 04:22:16.204323	2014-10-25 04:22:16.204323	AUClast	7	f	1	\N	\N	\N
354	Result	351	1	48	2014-10-25 04:22:16.326594	2014-10-25 04:22:16.326594	AUCinf	7	f	1	\N	\N	\N
355	Result	351	1	48	2014-10-25 04:22:16.443332	2014-10-25 04:22:16.443332	t1/2	7	f	1	\N	\N	\N
356	Result	351	1	48	2014-10-25 04:22:16.575001	2014-10-25 04:22:16.575001	Tmax	7	f	1	\N	\N	\N
351	Result	344	\N	48	2014-10-25 04:22:15.908007	2014-10-25 04:22:28.981368	Tolbut	7	f	1	\N	\N	\N
359	Result	358	1	48	2014-10-29 01:15:23.524852	2014-10-29 01:15:23.524852	Cmax	7	f	1	\N	\N	\N
360	Result	358	1	48	2014-10-29 01:15:23.670831	2014-10-29 01:15:23.670831	AUClast	7	f	1	\N	\N	\N
361	Result	358	1	48	2014-10-29 01:15:23.794576	2014-10-29 01:15:23.794576	AUCinf	7	f	1	\N	\N	\N
362	Result	358	1	48	2014-10-29 01:15:23.915754	2014-10-29 01:15:23.915754	t1/2	7	f	1	\N	\N	\N
363	Result	358	1	48	2014-10-29 01:15:24.070698	2014-10-29 01:15:24.070698	Tmax	7	f	1	\N	\N	\N
358	Result	344	\N	48	2014-10-29 01:15:23.397754	2014-10-29 01:16:05.701655	Omeprazole	7	f	1	\N	\N	\N
371	Result	370	1	48	2014-10-29 23:56:28.502809	2014-10-29 23:56:28.502809	Cmax	7	f	1	\N	\N	\N
372	Result	370	1	48	2014-10-29 23:56:28.631765	2014-10-29 23:56:28.631765	AUClast	7	f	1	\N	\N	\N
373	Result	370	1	48	2014-10-29 23:56:28.758778	2014-10-29 23:56:28.758778	AUCinf	7	f	1	\N	\N	\N
374	Result	370	1	48	2014-10-29 23:56:28.917932	2014-10-29 23:56:28.917932	t1/2	7	f	1	\N	\N	\N
375	Result	370	1	48	2014-10-29 23:56:29.06521	2014-10-29 23:56:29.06521	Tmax	7	f	1	\N	\N	\N
370	Result	344	\N	48	2014-10-29 23:56:28.442537	2014-10-29 23:56:36.439628	Dextro	7	f	1	\N	\N	\N
377	Result	376	1	48	2014-10-30 00:03:14.284918	2014-10-30 00:03:14.284918	Cmax	7	f	1	\N	\N	\N
378	Result	376	1	48	2014-10-30 00:03:14.404176	2014-10-30 00:03:14.404176	AUClast	7	f	1	\N	\N	\N
379	Result	376	1	48	2014-10-30 00:03:14.520869	2014-10-30 00:03:14.520869	AUCinf	7	f	1	\N	\N	\N
380	Result	376	1	48	2014-10-30 00:03:14.651737	2014-10-30 00:03:14.651737	t1/2	7	f	1	\N	\N	\N
381	Result	376	1	48	2014-10-30 00:03:14.787466	2014-10-30 00:03:14.787466	Tmax	7	f	1	\N	\N	\N
376	Result	344	\N	48	2014-10-30 00:03:14.198433	2014-10-30 00:03:23.435063	Midaz	7	f	1	\N	\N	\N
383	Result	376	1	48	2014-10-30 01:16:49.385489	2014-10-30 01:16:49.385489	C6h	7	f	1	\N	\N	\N
384	Result	345	1	48	2014-10-30 01:19:59.213597	2014-10-30 01:19:59.213597	parax/caf	7	f	1	\N	\N	\N
386	Result	351	1	48	2014-10-30 01:22:52.024318	2014-10-30 01:22:52.024318	C24h	7	f	1	\N	\N	\N
387	Result	358	1	48	2014-10-30 01:25:24.54907	2014-10-30 01:27:26.923041	ome/5oh 3h	7	f	1	\N	\N	\N
388	Result	358	1	48	2014-10-30 01:27:32.940612	2014-10-30 01:27:48.805385	auc om/5oh	7	f	1	\N	\N	\N
389	Result	370	1	48	2014-10-30 01:29:42.200513	2014-10-30 01:29:42.200513	C3h	7	f	1	\N	\N	\N
390	Demographics	317	8	48	2014-10-30 01:39:05.959623	2014-10-30 01:39:05.959623	\N	7	f	1	\N	\N	\N
391	Age	390	1	48	2014-10-30 01:40:32.835269	2014-10-30 01:40:32.835269	\N	7	f	1	\N	\N	\N
392	BMI	390	1	48	2014-10-30 01:41:32.650379	2014-10-30 01:41:40.328319	\N	7	f	1	\N	\N	\N
393	Smoking	390	\N	48	2014-10-30 01:42:36.963655	2014-10-30 01:42:36.963655	\N	7	f	1	\N	\N	\N
344	Pharmacokinetics	332	\N	48	2014-10-25 04:00:26.476931	2014-10-30 01:49:28.735429	\N	7	f	1	\N	\N	\N
395	Adverse Events	332	\N	48	2014-10-30 01:49:37.791649	2014-10-30 01:49:37.791649	\N	7	f	1	\N	\N	\N
396	Result	395	1	48	2014-10-30 01:50:25.755261	2014-10-30 01:50:25.755261	eructation	7	f	1	\N	\N	\N
397	Result	395	1	48	2014-10-30 01:52:15.244348	2014-10-30 01:52:23.147901	diar	7	f	1	\N	\N	\N
398	Result	395	1	48	2014-10-30 01:53:43.936008	2014-10-30 01:53:56.71095	nausea	7	f	1	\N	\N	\N
2169	DE2Man	2165	\N	93	2015-06-09 18:10:22.11959	2015-06-15 20:28:21.065065	1	17	f	1	20	f	\N
2167	Manual	2165	\N	93	2015-06-09 18:09:50.722133	2015-06-15 20:28:21.880145	1	17	f	1	20	f	\N
2166	Manual	2165	\N	93	2015-06-09 18:09:45.918844	2015-06-15 20:28:22.695629	2	17	f	1	20	f	\N
449	Source	328	6	42	2014-10-30 02:02:02.659164	2014-10-30 02:42:47.522789	\N	6	f	1	5	\N	\N
450	Study	328	\N	42	2014-10-30 02:02:21.626271	2014-10-30 02:42:48.535522	\N	6	f	1	5	\N	\N
464	Treatments	328	\N	42	2014-10-30 02:16:35.85433	2014-10-30 02:42:49.096071	\N	6	f	1	5	\N	\N
451	Endpoints	450	\N	42	2014-10-30 02:02:24.108909	2014-10-30 02:43:04.125603	\N	6	f	1	5	\N	\N
462	Exclusion Criteria	450	\N	42	2014-10-30 02:08:08.070379	2014-10-30 02:43:04.837401	\N	6	f	1	5	\N	\N
463	Inclusion Criteria	450	\N	42	2014-10-30 02:13:50.139062	2014-10-30 02:43:05.191192	\N	6	f	1	5	\N	\N
453	Endpoint	452	\N	42	2014-10-30 02:02:25.942455	2014-10-30 02:43:17.203358	\N	6	f	1	5	\N	\N
452	Primary	451	\N	42	2014-10-30 02:02:25.098899	2014-10-30 02:43:19.360871	\N	6	f	1	5	\N	\N
454	Secondary	451	\N	42	2014-10-30 02:02:37.578306	2014-10-30 02:43:20.314028	\N	6	f	1	5	\N	\N
455	Endpoint	454	\N	42	2014-10-30 02:02:39.326972	2014-10-30 02:43:22.184956	route	6	f	1	5	\N	\N
456	Endpoint	454	\N	42	2014-10-30 02:03:27.298371	2014-10-30 02:43:22.474574	uterine	6	f	1	5	\N	\N
457	Endpoint	454	\N	42	2014-10-30 02:03:57.097905	2014-10-30 02:43:22.889155	side	6	f	1	5	\N	\N
458	Endpoint	454	\N	42	2014-10-30 02:04:11.043802	2014-10-30 02:43:23.306866	comfort	6	f	1	5	\N	\N
459	Endpoint	454	\N	42	2014-10-30 02:04:21.292924	2014-10-30 02:43:23.76301	FHR	6	f	1	5	\N	\N
460	Endpoint	454	\N	42	2014-10-30 02:04:37.441221	2014-10-30 02:43:24.153447	\N	6	f	1	5	\N	\N
461	Endpoint	454	\N	42	2014-10-30 02:06:20.700696	2014-10-30 02:43:24.593193	tot time	6	f	1	5	\N	\N
467	Measurement	466	1	42	2014-10-30 02:16:44.975045	2014-10-30 02:48:38.157833	Mat age	6	f	1	5	\N	\N
468	Measurement	466	1	42	2014-10-30 02:22:26.919245	2014-10-30 02:48:38.968024	Gravidity	6	f	1	5	\N	\N
470	Measurement	466	1	42	2014-10-30 02:22:38.358867	2014-10-30 02:48:47.950616	Base Bisho	6	f	1	5	\N	\N
469	Measurement	466	1	42	2014-10-30 02:22:32.967081	2014-10-30 02:48:53.20472	Nullip	6	f	1	5	\N	\N
466	Demographics	465	8	42	2014-10-30 02:16:43.594411	2014-10-30 02:49:01.686237	\N	6	f	1	5	\N	\N
471	Intervention	465	\N	42	2014-10-30 02:26:16.63788	2014-10-30 02:49:02.434857	\N	6	f	1	5	\N	\N
472	Results	465	\N	42	2014-10-30 02:26:24.569416	2014-10-30 02:49:28.103621	\N	6	f	1	5	\N	\N
473	Result	472	1	42	2014-10-30 02:26:26.366859	2014-10-30 02:49:32.462974	spont labo	6	f	1	5	\N	\N
474	Result	472	1	42	2014-10-30 02:26:32.146222	2014-10-30 02:49:37.196327	epidural	6	f	1	5	\N	\N
475	Result	472	1	42	2014-10-30 02:26:39.480682	2014-10-30 02:49:41.68517	Bishop	6	f	1	5	\N	\N
476	Result	472	1	42	2014-10-30 02:26:51.065825	2014-10-30 02:49:45.800938	ripe time	6	f	1	5	\N	\N
477	Result	472	1	42	2014-10-30 02:28:14.197717	2014-10-30 02:49:51.099189	tot time	6	f	1	5	\N	\N
478	Result	472	1	42	2014-10-30 02:28:22.492185	2014-10-30 02:49:56.13538	Infant wt	6	f	1	5	\N	\N
480	Result	472	1	42	2014-10-30 02:28:45.358447	2014-10-30 02:50:01.59362	Cesarean	6	f	1	5	\N	\N
481	Result	472	1	42	2014-10-30 02:31:55.635688	2014-10-30 02:50:07.298497	Contract	6	f	1	5	\N	\N
482	Result	472	1	42	2014-10-30 02:32:05.528941	2014-10-30 02:50:12.021284	Meconium	6	f	1	5	\N	\N
483	Result	472	1	42	2014-10-30 02:32:13.656618	2014-10-30 02:50:15.98202	Deliv 24	6	f	1	5	\N	\N
484	Result	472	1	42	2014-10-30 02:32:53.203272	2014-10-30 02:50:19.849198	V Deliv 24	6	f	1	5	\N	\N
485	Result	472	1	42	2014-10-30 02:33:03.974594	2014-10-30 02:50:24.028303	Ces fet t	6	f	1	5	\N	\N
486	Result	472	1	42	2014-10-30 02:33:16.690161	2014-10-30 02:50:32.102892	Hyperstim	6	f	1	5	\N	\N
487	Result	472	1	42	2014-10-30 02:33:22.241557	2014-10-30 02:50:32.582401	FHR abnorm	6	f	1	5	\N	\N
488	Result	472	1	42	2014-10-30 02:33:30.459678	2014-10-30 02:50:36.590759	discomfort	6	f	1	5	\N	\N
465	Treatment	464	\N	42	2014-10-30 02:16:39.839248	2014-10-30 02:52:22.233556	Foley	6	f	1	5	\N	\N
489	Treatment	464	\N	42	2014-10-30 02:34:09.192403	2014-10-30 02:52:22.996475	Miso	6	f	1	5	\N	\N
490	Demographics	489	8	42	2014-10-30 02:34:14.057389	2014-10-30 02:52:24.713457	\N	6	f	1	5	\N	\N
491	Measurement	490	1	42	2014-10-30 02:34:17.813935	2014-10-30 02:52:25.922703	Mat age	6	f	1	5	\N	\N
492	Measurement	490	1	42	2014-10-30 02:34:23.260083	2014-10-30 02:52:26.213295	Gravidity	6	f	1	5	\N	\N
493	Measurement	490	1	42	2014-10-30 02:34:47.667042	2014-10-30 02:52:26.524389	Nullip	6	f	1	5	\N	\N
494	Measurement	490	1	42	2014-10-30 02:34:52.762934	2014-10-30 02:52:26.841557	Base Bisho	6	f	1	5	\N	\N
495	Intervention	489	\N	42	2014-10-30 02:35:07.402369	2014-10-30 02:52:31.601926	\N	6	f	1	5	\N	\N
496	Number of doses	495	1	42	2014-10-30 02:35:10.452549	2014-10-30 02:52:33.152141	\N	6	f	1	5	\N	\N
497	Results	489	\N	42	2014-10-30 02:35:20.90313	2014-10-30 02:52:45.627498	\N	6	f	1	5	\N	\N
498	Result	497	1	42	2014-10-30 02:35:22.250256	2014-10-30 02:52:47.311629	spont labo	6	f	1	5	\N	\N
499	Result	497	1	42	2014-10-30 02:35:27.939636	2014-10-30 02:52:51.217521	epidural	6	f	1	5	\N	\N
500	Result	497	1	42	2014-10-30 02:35:33.942353	2014-10-30 02:52:55.280525	Bishop	6	f	1	5	\N	\N
501	Result	497	1	42	2014-10-30 02:35:40.638955	2014-10-30 02:52:59.243972	ripe time	6	f	1	5	\N	\N
502	Result	497	1	42	2014-10-30 02:35:47.072242	2014-10-30 02:53:04.519047	tot time	6	f	1	5	\N	\N
503	Result	497	1	42	2014-10-30 02:35:51.769339	2014-10-30 02:53:09.157161	Infant wt	6	f	1	5	\N	\N
504	Result	497	1	42	2014-10-30 02:35:58.733916	2014-10-30 02:53:13.742394	Cesarean	6	f	1	5	\N	\N
505	Result	497	1	42	2014-10-30 02:36:05.030259	2014-10-30 02:53:17.071677	Contract	6	f	1	5	\N	\N
506	Result	497	1	42	2014-10-30 02:36:16.560106	2014-10-30 02:53:20.664752	Meconium	6	f	1	5	\N	\N
507	Result	497	1	42	2014-10-30 02:36:23.1054	2014-10-30 02:53:24.683163	Deliv 24	6	f	1	5	\N	\N
508	Result	497	1	42	2014-10-30 02:36:30.279862	2014-10-30 02:53:29.301487	V Deliv 24	6	f	1	5	\N	\N
509	Result	497	1	42	2014-10-30 02:39:29.121075	2014-10-30 02:53:32.846625	Ces fet t	6	f	1	5	\N	\N
510	Result	497	1	42	2014-10-30 02:39:36.861732	2014-10-30 02:53:40.100945	Hyperstim	6	f	1	5	\N	\N
511	Result	497	1	42	2014-10-30 02:39:43.138785	2014-10-30 02:53:40.613739	FHR abnorm	6	f	1	5	\N	\N
512	Result	497	1	42	2014-10-30 02:39:47.807509	2014-10-30 02:53:45.393836	discomfort	6	f	1	5	\N	\N
514	Result	345	1	48	2014-11-02 01:24:12.837139	2014-11-02 01:24:12.837139	AUC ratio	7	f	1	\N	\N	\N
515	Result	345	1	48	2014-11-02 01:39:06.618737	2014-11-02 01:39:30.083255	pa/caf pbo	7	f	1	\N	\N	\N
516	Result	351	1	48	2014-11-02 01:42:12.564837	2014-11-02 01:42:12.564837	auc ratio	7	f	1	\N	\N	\N
517	Result	351	1	48	2014-11-02 01:44:00.211975	2014-11-02 01:44:10.805042	C24h ratio	7	f	1	\N	\N	\N
524	Result	358	1	48	2014-11-03 23:10:05.904416	2014-11-03 23:10:05.904416	AUC ratio	7	f	1	\N	\N	\N
530	Home	\N	\N	50	2014-11-06 22:52:39.357236	2014-11-06 22:52:39.357236	\N	14	t	1	\N	\N	\N
531	Home	\N	\N	50	2014-11-06 22:53:10.397147	2014-11-06 22:53:10.397147	\N	15	t	1	\N	\N	\N
532	Home	\N	\N	50	2014-11-06 22:53:39.406462	2014-11-06 22:53:39.406462	\N	17	t	1	\N	\N	\N
2164	Home	\N	\N	93	2015-06-09 18:09:37.908611	2015-06-09 18:09:37.908611	\N	17	t	1	\N	t	\N
2163	DE2Man	2161	\N	93	2015-06-09 18:08:29.180059	2015-06-09 18:08:29.180059	2	14	f	1	\N	\N	\N
2162	DE2Man	2161	\N	93	2015-06-09 18:07:29.693539	2015-06-09 18:07:29.693539	1	14	f	1	\N	\N	\N
2161	Demographics	2160	8	93	2015-06-09 18:07:01.681627	2015-06-09 18:07:01.681627	\N	14	f	1	\N	\N	\N
2160	Home	\N	\N	93	2015-06-09 18:06:53.011678	2015-06-09 18:06:53.011678	\N	14	t	1	\N	f	\N
2159	Manual	2157	\N	93	2015-06-09 18:05:28.876285	2015-06-09 18:05:28.876285	2	1	f	1	\N	\N	\N
2158	Manual	2157	\N	93	2015-06-09 18:04:38.495392	2015-06-09 18:04:38.495392	1	1	f	1	\N	\N	\N
2157	Demographics	2156	8	93	2015-06-09 18:03:34.031777	2015-06-09 18:03:34.031777	\N	1	f	1	\N	\N	\N
2165	Demographics	2164	8	93	2015-06-09 18:09:41.809653	2015-06-15 20:28:18.42855	\N	17	f	1	20	f	\N
611	Home	\N	\N	48	2014-12-25 19:04:22.97889	2014-12-25 19:04:22.97889	\N	14	t	1	\N	\N	\N
612	Treatments	611	13	48	2014-12-25 19:04:45.732232	2014-12-25 19:04:45.732232	\N	14	f	1	\N	\N	\N
613	Treatment	612	5	48	2014-12-25 19:05:07.092426	2014-12-25 19:05:07.092426	silexan	14	f	1	\N	\N	\N
614	Results	613	\N	48	2014-12-25 19:05:22.199202	2014-12-25 19:05:22.199202	\N	14	f	1	\N	\N	\N
618	Publication Date	617	10	48	2015-01-16 00:59:04.491501	2015-01-16 00:59:04.491501	\N	14	f	1	\N	\N	\N
619	First Author	617	7	48	2015-01-16 01:02:21.143701	2015-01-16 01:02:21.143701	\N	14	f	1	\N	\N	\N
616	Study Design	611	11	48	2014-12-25 19:08:58.032806	2015-01-16 01:48:19.747027	\N	14	f	1	\N	\N	\N
617	Document Reference	611	6	48	2015-01-16 00:56:23.649759	2015-01-16 01:48:29.320118	\N	14	f	1	\N	\N	\N
620	Demographics	611	8	48	2015-01-16 01:49:40.970664	2015-01-16 01:49:40.970664	\N	14	f	1	\N	\N	\N
621	Race	620	\N	48	2015-01-16 01:50:26.279179	2015-01-16 01:50:26.279179	\N	14	f	1	\N	\N	\N
622	Sex	620	1	48	2015-01-16 01:51:11.80723	2015-01-16 01:51:11.80723	\N	14	f	1	\N	\N	\N
623	Body Mass Index	620	1	48	2015-01-16 01:52:02.285258	2015-01-16 01:52:02.285258	\N	14	f	1	\N	\N	\N
624	Age	620	1	48	2015-01-16 01:54:06.259241	2015-01-16 01:54:06.259241	\N	14	f	1	\N	\N	\N
625	Smokers	620	\N	48	2015-01-16 01:55:23.883513	2015-01-16 01:55:23.883513	\N	14	f	1	\N	\N	\N
626	Smokers	625	1	48	2015-01-16 01:55:46.429653	2015-01-16 01:56:35.110003	Ex-smoker	14	f	1	\N	\N	\N
627	Smokers	625	1	48	2015-01-16 01:56:42.557701	2015-01-16 01:58:44.351079	Nonsmoker	14	f	1	\N	\N	\N
628	Oral Contraceptive Use	620	1	48	2015-01-16 02:00:54.984858	2015-01-16 02:00:54.984858	\N	14	f	1	\N	\N	\N
629	CYP2D6 Poor Metabolizer	620	1	48	2015-01-16 02:12:40.392771	2015-01-16 02:12:40.392771	\N	14	f	1	\N	\N	\N
630	CYP2C19	620	1	48	2015-01-16 02:14:13.407767	2015-01-16 02:14:13.407767	\N	14	f	1	\N	\N	\N
631	Inclusion and Exclusion Criteria	611	\N	48	2015-01-16 02:26:45.700284	2015-01-16 02:26:45.700284	\N	14	f	1	\N	\N	\N
632	Inclusion	631	\N	48	2015-01-16 02:27:10.284783	2015-01-16 02:27:10.284783	\N	14	f	1	\N	\N	\N
633	Sex	632	1	48	2015-01-16 02:27:16.702969	2015-01-16 02:27:16.702969	\N	14	f	1	\N	\N	\N
634	Age	632	1	48	2015-01-16 02:28:22.26366	2015-01-16 02:28:22.26366	\N	14	f	1	\N	\N	\N
635	Race	632	1	48	2015-01-16 02:29:36.987733	2015-01-16 02:29:36.987733	\N	14	f	1	\N	\N	\N
636	Intervention	613	9	48	2015-01-16 02:31:09.074491	2015-01-16 02:36:26.635302	silexan	14	f	1	\N	\N	\N
637	Intervention	613	9	48	2015-01-16 02:32:52.373977	2015-01-16 02:36:34.54113	caffeine	14	f	1	\N	\N	\N
638	Intervention	613	9	48	2015-01-16 02:36:39.56023	2015-01-16 02:36:50.830156	tolbutamid	14	f	1	\N	\N	\N
639	Intervention	613	9	48	2015-01-16 02:37:48.196597	2015-01-16 02:37:53.880073	omepra	14	f	1	\N	\N	\N
640	Intervention	613	9	48	2015-01-16 02:40:29.135029	2015-01-16 02:40:35.337208	dextro	14	f	1	\N	\N	\N
641	Intervention	613	9	48	2015-01-16 02:41:39.83028	2015-01-16 02:41:47.704795	midaz	14	f	1	\N	\N	\N
642	Result	614	\N	48	2015-01-16 02:47:20.967041	2015-01-16 02:47:20.967041	Table 1	14	f	1	\N	\N	\N
643	Result	642	\N	48	2015-01-16 03:34:15.684071	2015-01-16 03:34:15.684071	Caffeine	14	f	1	\N	\N	\N
645	Result	643	1	48	2015-01-16 03:40:23.422826	2015-01-16 03:40:23.422826	Cmax	14	f	1	\N	\N	\N
646	Result	643	1	48	2015-01-16 03:44:29.157401	2015-01-16 03:44:29.157401	Tmax	14	f	1	\N	\N	\N
647	Result	643	1	48	2015-01-16 03:46:13.650892	2015-01-16 03:46:13.650892	AUCt	14	f	1	\N	\N	\N
648	Result	643	1	48	2015-01-16 03:47:44.71734	2015-01-16 03:47:44.71734	AUCinf	14	f	1	\N	\N	\N
662	Result	642	\N	48	2015-01-16 04:12:22.943501	2015-01-16 04:15:47.267491	dextro	14	f	1	\N	\N	\N
649	Result	643	1	48	2015-01-16 03:49:04.508564	2015-01-16 03:49:17.703732	halflife	14	f	1	\N	\N	\N
651	Result	650	1	48	2015-01-16 03:50:25.165066	2015-01-16 03:50:25.165066	Cmax	14	f	1	\N	\N	\N
652	Result	650	1	48	2015-01-16 03:50:25.308566	2015-01-16 03:50:25.308566	Tmax	14	f	1	\N	\N	\N
653	Result	650	1	48	2015-01-16 03:50:25.43438	2015-01-16 03:50:25.43438	AUCt	14	f	1	\N	\N	\N
654	Result	650	1	48	2015-01-16 03:50:25.585408	2015-01-16 03:50:25.585408	AUCinf	14	f	1	\N	\N	\N
655	Result	650	1	48	2015-01-16 03:50:25.732348	2015-01-16 03:50:25.732348	halflife	14	f	1	\N	\N	\N
650	Result	642	\N	48	2015-01-16 03:50:25.081822	2015-01-16 03:50:30.77065	tolbut	14	f	1	\N	\N	\N
657	Result	656	1	48	2015-01-16 04:07:21.68427	2015-01-16 04:07:21.68427	Cmax	14	f	1	\N	\N	\N
658	Result	656	1	48	2015-01-16 04:07:21.84368	2015-01-16 04:07:21.84368	Tmax	14	f	1	\N	\N	\N
659	Result	656	1	48	2015-01-16 04:07:21.973316	2015-01-16 04:07:21.973316	AUCt	14	f	1	\N	\N	\N
660	Result	656	1	48	2015-01-16 04:07:22.236562	2015-01-16 04:07:22.236562	AUCinf	14	f	1	\N	\N	\N
661	Result	656	1	48	2015-01-16 04:07:22.388801	2015-01-16 04:07:22.388801	halflife	14	f	1	\N	\N	\N
656	Result	642	\N	48	2015-01-16 04:07:21.594448	2015-01-16 04:07:28.625964	omepra	14	f	1	\N	\N	\N
663	Result	662	1	48	2015-01-16 04:12:23.067543	2015-01-16 04:12:23.067543	Cmax	14	f	1	\N	\N	\N
664	Result	662	1	48	2015-01-16 04:12:23.223729	2015-01-16 04:12:23.223729	Tmax	14	f	1	\N	\N	\N
665	Result	662	1	48	2015-01-16 04:12:23.355344	2015-01-16 04:12:23.355344	AUCt	14	f	1	\N	\N	\N
666	Result	662	1	48	2015-01-16 04:12:23.509983	2015-01-16 04:12:23.509983	AUCinf	14	f	1	\N	\N	\N
667	Result	662	1	48	2015-01-16 04:12:23.668085	2015-01-16 04:12:23.668085	halflife	14	f	1	\N	\N	\N
669	Result	668	1	48	2015-01-16 04:20:18.287282	2015-01-16 04:20:18.287282	Cmax	14	f	1	\N	\N	\N
670	Result	668	1	48	2015-01-16 04:20:18.581367	2015-01-16 04:20:18.581367	Tmax	14	f	1	\N	\N	\N
671	Result	668	1	48	2015-01-16 04:20:18.859054	2015-01-16 04:20:18.859054	AUCt	14	f	1	\N	\N	\N
672	Result	668	1	48	2015-01-16 04:20:19.000735	2015-01-16 04:20:19.000735	AUCinf	14	f	1	\N	\N	\N
673	Result	668	1	48	2015-01-16 04:20:19.166826	2015-01-16 04:20:19.166826	halflife	14	f	1	\N	\N	\N
668	Result	642	\N	48	2015-01-16 04:20:18.189863	2015-01-16 04:20:24.720496	midaz	14	f	1	\N	\N	\N
674	Result	614	\N	48	2015-01-17 00:20:41.06262	2015-01-17 00:20:41.06262	Table 2	14	f	1	\N	\N	\N
675	Result	674	1	48	2015-01-17 00:21:20.9086	2015-01-17 00:21:20.9086	Molar Para	14	f	1	\N	\N	\N
677	Result	674	1	48	2015-01-18 13:53:23.051488	2015-01-18 13:53:33.851702	tolbut	14	f	1	\N	\N	\N
678	Result	674	1	48	2015-01-18 13:55:28.390677	2015-01-18 13:56:00.323527	omepr plas	14	f	1	\N	\N	\N
679	Result	674	1	48	2015-01-18 13:57:52.990623	2015-01-18 13:58:02.980279	omepr auct	14	f	1	\N	\N	\N
689	Adverse Events	613	\N	48	2015-01-18 15:33:36.453681	2015-01-18 15:33:36.453681	\N	14	f	1	\N	\N	\N
680	Result	674	1	48	2015-01-18 14:00:41.77042	2015-01-18 14:00:55.524573	dextro pla	14	f	1	\N	\N	\N
681	Result	674	1	48	2015-01-18 14:04:14.202452	2015-01-18 14:04:23.40608	midaz plas	14	f	1	\N	\N	\N
682	Result	614	\N	48	2015-01-18 14:32:35.267431	2015-01-18 14:32:35.267431	Table 3	14	f	1	\N	\N	\N
683	Result	682	1	48	2015-01-18 14:33:19.633426	2015-01-18 14:33:19.633426	caf AUCt	14	f	1	\N	\N	\N
684	Result	682	1	48	2015-01-18 14:36:54.659381	2015-01-18 14:37:02.105659	caf molar	14	f	1	\N	\N	\N
685	Result	682	1	48	2015-01-18 14:39:24.638996	2015-01-18 14:39:36.9697	tolb AUCt	14	f	1	\N	\N	\N
686	Result	682	1	48	2015-01-18 14:41:07.264626	2015-01-18 14:41:21.620807	tolb plasm	14	f	1	\N	\N	\N
687	Result	682	1	48	2015-01-18 14:45:44.121622	2015-01-18 14:45:57.094882	ome AUCt	14	f	1	\N	\N	\N
688	Result	682	1	48	2015-01-18 14:47:19.181573	2015-01-18 14:47:32.386356	ome 3h	14	f	1	\N	\N	\N
690	Adverse Event	689	16	48	2015-01-18 15:34:06.333494	2015-01-18 15:34:06.333494	eructation	14	f	1	\N	\N	\N
691	Adverse Event	689	16	48	2015-01-18 15:36:31.652198	2015-01-18 15:38:50.29812	severe/ser	14	f	1	\N	\N	\N
692	Adverse Event	689	16	48	2015-01-18 15:39:03.196078	2015-01-18 15:39:03.196078	total	14	f	1	\N	\N	\N
693	Adverse Event	689	16	48	2015-01-18 15:42:01.571124	2015-01-18 15:42:01.571124	diarrhea	14	f	1	\N	\N	\N
694	Adverse Event	689	16	48	2015-01-18 15:43:20.370999	2015-01-18 15:43:20.370999	nausea	14	f	1	\N	\N	\N
695	Adverse Event	689	16	48	2015-01-18 15:45:33.820664	2015-01-18 15:45:42.128055	vomiting	14	f	1	\N	\N	\N
696	Result	682	1	48	2015-01-18 15:47:04.316723	2015-01-18 15:47:23.384022	ome AUCt r	14	f	1	\N	\N	\N
697	Result	682	1	48	2015-01-18 15:49:59.503113	2015-01-18 15:50:09.616771	dex AUCt	14	f	1	\N	\N	\N
698	Result	682	1	48	2015-01-18 15:51:36.569998	2015-01-18 15:51:42.82758	dex 3h	14	f	1	\N	\N	\N
699	Result	682	1	48	2015-01-18 15:53:35.265916	2015-01-18 15:53:45.055528	midaz AUCt	14	f	1	\N	\N	\N
700	Result	682	1	48	2015-01-18 16:04:09.104662	2015-01-18 16:04:17.474504	midaz 6h	14	f	1	\N	\N	\N
701	Result	614	\N	48	2015-01-18 16:12:30.146441	2015-01-18 16:12:30.146441	Table 4	14	f	1	\N	\N	\N
702	Result	701	1	48	2015-01-18 16:13:16.18449	2015-01-18 16:13:16.18449	caf corr	14	f	1	\N	\N	\N
703	Result	701	1	48	2015-01-18 16:16:31.190993	2015-01-18 16:16:38.471657	tolb corr	14	f	1	\N	\N	\N
704	Result	701	1	48	2015-01-18 16:42:40.961887	2015-01-18 16:43:09.305511	ome conc	14	f	1	\N	\N	\N
705	Result	701	1	48	2015-01-18 16:44:45.96445	2015-01-18 16:44:57.475231	ome/5 AUCt	14	f	1	\N	\N	\N
706	Result	701	1	48	2015-01-18 16:46:40.243861	2015-01-18 16:46:49.447284	dex conc	14	f	1	\N	\N	\N
707	Result	701	1	48	2015-01-18 16:48:01.473785	2015-01-18 16:48:18.578928	midaz conc	14	f	1	\N	\N	\N
709	Adverse Events	708	\N	48	2015-01-18 16:49:43.536803	2015-01-18 16:49:43.536803	\N	14	f	1	\N	\N	\N
711	Adverse Event	709	16	48	2015-01-18 16:49:43.670389	2015-01-18 16:49:43.670389	nausea	14	f	1	\N	\N	\N
712	Adverse Event	709	16	48	2015-01-18 16:49:43.738546	2015-01-18 16:49:43.738546	diarrhea	14	f	1	\N	\N	\N
713	Adverse Event	709	16	48	2015-01-18 16:49:43.788959	2015-01-18 16:49:43.788959	total	14	f	1	\N	\N	\N
714	Adverse Event	709	16	48	2015-01-18 16:49:43.89532	2015-01-18 16:49:43.89532	severe/ser	14	f	1	\N	\N	\N
715	Adverse Event	709	16	48	2015-01-18 16:49:43.983352	2015-01-18 16:49:43.983352	eructation	14	f	1	\N	\N	\N
716	Intervention	708	9	48	2015-01-18 16:49:44.091967	2015-01-18 16:49:44.091967	midaz	14	f	1	\N	\N	\N
717	Intervention	708	9	48	2015-01-18 16:49:44.256268	2015-01-18 16:49:44.256268	dextro	14	f	1	\N	\N	\N
718	Intervention	708	9	48	2015-01-18 16:49:44.415113	2015-01-18 16:49:44.415113	omepra	14	f	1	\N	\N	\N
719	Intervention	708	9	48	2015-01-18 16:49:44.602574	2015-01-18 16:49:44.602574	tolbutamid	14	f	1	\N	\N	\N
720	Intervention	708	9	48	2015-01-18 16:49:44.766218	2015-01-18 16:49:44.766218	caffeine	14	f	1	\N	\N	\N
721	Intervention	708	9	48	2015-01-18 16:49:44.936455	2015-01-18 16:49:44.936455	silexan	14	f	1	\N	\N	\N
722	Results	708	\N	48	2015-01-18 16:49:45.208401	2015-01-18 16:49:45.208401	\N	14	f	1	\N	\N	\N
723	Result	722	\N	48	2015-01-18 16:49:45.22318	2015-01-18 16:49:45.22318	Table 4	14	f	1	\N	\N	\N
724	Result	723	1	48	2015-01-18 16:49:45.23705	2015-01-18 16:49:45.23705	midaz conc	14	f	1	\N	\N	\N
725	Result	723	1	48	2015-01-18 16:49:45.538772	2015-01-18 16:49:45.538772	dex conc	14	f	1	\N	\N	\N
726	Result	723	1	48	2015-01-18 16:49:45.695515	2015-01-18 16:49:45.695515	ome/5 AUCt	14	f	1	\N	\N	\N
727	Result	723	1	48	2015-01-18 16:49:45.822887	2015-01-18 16:49:45.822887	ome conc	14	f	1	\N	\N	\N
728	Result	723	1	48	2015-01-18 16:49:45.986545	2015-01-18 16:49:45.986545	tolb corr	14	f	1	\N	\N	\N
729	Result	723	1	48	2015-01-18 16:49:46.168796	2015-01-18 16:49:46.168796	caf corr	14	f	1	\N	\N	\N
742	Result	722	\N	48	2015-01-18 16:49:48.493507	2015-01-18 16:49:48.493507	Table 2	14	f	1	\N	\N	\N
743	Result	742	1	48	2015-01-18 16:49:48.508554	2015-01-18 16:49:48.508554	midaz plas	14	f	1	\N	\N	\N
744	Result	742	1	48	2015-01-18 16:49:48.898908	2015-01-18 16:49:48.898908	dextro pla	14	f	1	\N	\N	\N
745	Result	742	1	48	2015-01-18 16:49:49.091904	2015-01-18 16:49:49.091904	omepr auct	14	f	1	\N	\N	\N
746	Result	742	1	48	2015-01-18 16:49:49.258117	2015-01-18 16:49:49.258117	omepr plas	14	f	1	\N	\N	\N
747	Result	742	1	48	2015-01-18 16:49:49.450807	2015-01-18 16:49:49.450807	tolbut	14	f	1	\N	\N	\N
748	Result	742	1	48	2015-01-18 16:49:49.648912	2015-01-18 16:49:49.648912	Molar Para	14	f	1	\N	\N	\N
749	Result	722	\N	48	2015-01-18 16:49:49.846583	2015-01-18 16:49:49.846583	Table 1	14	f	1	\N	\N	\N
750	Result	749	\N	48	2015-01-18 16:49:49.861052	2015-01-18 16:49:49.861052	midaz	14	f	1	\N	\N	\N
751	Result	750	1	48	2015-01-18 16:49:49.894257	2015-01-18 16:49:49.894257	halflife	14	f	1	\N	\N	\N
752	Result	750	1	48	2015-01-18 16:49:50.078299	2015-01-18 16:49:50.078299	AUCinf	14	f	1	\N	\N	\N
753	Result	750	1	48	2015-01-18 16:49:50.280633	2015-01-18 16:49:50.280633	AUCt	14	f	1	\N	\N	\N
754	Result	750	1	48	2015-01-18 16:49:50.433091	2015-01-18 16:49:50.433091	Tmax	14	f	1	\N	\N	\N
755	Result	750	1	48	2015-01-18 16:49:50.555155	2015-01-18 16:49:50.555155	Cmax	14	f	1	\N	\N	\N
756	Result	749	\N	48	2015-01-18 16:49:50.70036	2015-01-18 16:49:50.70036	dextro	14	f	1	\N	\N	\N
757	Result	756	1	48	2015-01-18 16:49:50.732062	2015-01-18 16:49:50.732062	halflife	14	f	1	\N	\N	\N
708	Treatment	612	5	48	2015-01-18 16:49:43.518815	2015-01-18 16:52:36.657242	placebo	14	f	1	\N	\N	\N
758	Result	756	1	48	2015-01-18 16:49:50.877399	2015-01-18 16:49:50.877399	AUCinf	14	f	1	\N	\N	\N
759	Result	756	1	48	2015-01-18 16:49:51.035865	2015-01-18 16:49:51.035865	AUCt	14	f	1	\N	\N	\N
760	Result	756	1	48	2015-01-18 16:49:51.190072	2015-01-18 16:49:51.190072	Tmax	14	f	1	\N	\N	\N
761	Result	756	1	48	2015-01-18 16:49:51.312558	2015-01-18 16:49:51.312558	Cmax	14	f	1	\N	\N	\N
762	Result	749	\N	48	2015-01-18 16:49:51.484269	2015-01-18 16:49:51.484269	omepra	14	f	1	\N	\N	\N
763	Result	762	1	48	2015-01-18 16:49:51.518208	2015-01-18 16:49:51.518208	halflife	14	f	1	\N	\N	\N
764	Result	762	1	48	2015-01-18 16:49:51.662135	2015-01-18 16:49:51.662135	AUCinf	14	f	1	\N	\N	\N
765	Result	762	1	48	2015-01-18 16:49:51.889518	2015-01-18 16:49:51.889518	AUCt	14	f	1	\N	\N	\N
766	Result	762	1	48	2015-01-18 16:49:52.093911	2015-01-18 16:49:52.093911	Tmax	14	f	1	\N	\N	\N
767	Result	762	1	48	2015-01-18 16:49:52.219626	2015-01-18 16:49:52.219626	Cmax	14	f	1	\N	\N	\N
768	Result	749	\N	48	2015-01-18 16:49:52.370277	2015-01-18 16:49:52.370277	tolbut	14	f	1	\N	\N	\N
769	Result	768	1	48	2015-01-18 16:49:52.404908	2015-01-18 16:49:52.404908	halflife	14	f	1	\N	\N	\N
770	Result	768	1	48	2015-01-18 16:49:52.54678	2015-01-18 16:49:52.54678	AUCinf	14	f	1	\N	\N	\N
771	Result	768	1	48	2015-01-18 16:49:52.690214	2015-01-18 16:49:52.690214	AUCt	14	f	1	\N	\N	\N
772	Result	768	1	48	2015-01-18 16:49:52.833947	2015-01-18 16:49:52.833947	Tmax	14	f	1	\N	\N	\N
773	Result	768	1	48	2015-01-18 16:49:52.958121	2015-01-18 16:49:52.958121	Cmax	14	f	1	\N	\N	\N
774	Result	749	\N	48	2015-01-18 16:49:53.102461	2015-01-18 16:49:53.102461	Caffeine	14	f	1	\N	\N	\N
775	Result	774	1	48	2015-01-18 16:49:53.135336	2015-01-18 16:49:53.135336	halflife	14	f	1	\N	\N	\N
776	Result	774	1	48	2015-01-18 16:49:53.277876	2015-01-18 16:49:53.277876	AUCinf	14	f	1	\N	\N	\N
777	Result	774	1	48	2015-01-18 16:49:53.427039	2015-01-18 16:49:53.427039	AUCt	14	f	1	\N	\N	\N
778	Result	774	1	48	2015-01-18 16:49:53.573942	2015-01-18 16:49:53.573942	Tmax	14	f	1	\N	\N	\N
779	Result	774	1	48	2015-01-18 16:49:53.696372	2015-01-18 16:49:53.696372	Cmax	14	f	1	\N	\N	\N
780	Home	\N	\N	48	2015-01-18 19:59:50.770581	2015-01-18 19:59:50.770581	\N	17	t	1	\N	\N	\N
800	Inclusion and Exclusion Criteria	780	\N	48	2015-01-18 20:04:08.777428	2015-01-21 02:22:58.017572	\N	17	f	1	20	\N	\N
805	Study Design	780	11	48	2015-01-18 20:04:51.715459	2015-01-21 02:22:58.400307	\N	17	f	1	20	\N	\N
806	Treatments	780	13	48	2015-01-18 20:05:00.383581	2015-01-21 02:22:58.791786	\N	17	f	1	20	\N	\N
782	Age	781	1	48	2015-01-18 20:00:01.30796	2015-01-21 02:23:01.287483	\N	17	f	1	20	\N	\N
783	Body Mass Index	781	1	48	2015-01-18 20:00:22.812086	2015-01-21 02:23:01.613033	\N	17	f	1	20	\N	\N
784	CYP2C19	781	1	48	2015-01-18 20:00:30.778633	2015-01-21 02:23:02.328708	\N	17	f	1	20	\N	\N
785	CYP2D6 Poor Metabolizer	781	1	48	2015-01-18 20:01:05.713139	2015-01-21 02:23:02.600408	\N	17	f	1	20	\N	\N
786	Oral Contraceptive Use	781	1	48	2015-01-18 20:01:10.421567	2015-01-21 02:23:08.162653	\N	17	f	1	20	\N	\N
787	Race	781	\N	48	2015-01-18 20:01:15.752508	2015-01-21 02:23:08.429957	\N	17	f	1	20	\N	\N
788	Sex	781	1	48	2015-01-18 20:01:42.228298	2015-01-21 02:23:09.081222	\N	17	f	1	20	\N	\N
792	Smokers	781	\N	48	2015-01-18 20:02:36.902992	2015-01-21 02:23:09.512163	\N	17	f	1	20	\N	\N
794	Smokers	792	1	48	2015-01-18 20:02:45.725328	2015-01-21 02:23:45.880466	Ex-smoker	17	f	1	20	\N	\N
793	Smokers	792	1	48	2015-01-18 20:02:38.526932	2015-01-21 02:23:46.117521	Nonsmoker	17	f	1	20	\N	\N
796	First Author	795	7	48	2015-01-18 20:03:12.728127	2015-01-21 02:24:00.924161	\N	17	f	1	20	\N	\N
799	Publication Date	795	10	48	2015-01-18 20:03:35.314381	2015-01-21 02:24:01.144551	\N	17	f	1	20	\N	\N
802	Age	801	1	48	2015-01-18 20:04:12.23008	2015-01-21 02:24:21.309935	\N	17	f	1	20	\N	\N
803	Race	801	1	48	2015-01-18 20:04:17.77488	2015-01-21 02:24:24.189576	\N	17	f	1	20	\N	\N
804	Sex	801	1	48	2015-01-18 20:04:27.378356	2015-01-21 02:24:26.146389	\N	17	f	1	20	\N	\N
801	Inclusion	800	\N	48	2015-01-18 20:04:10.653552	2015-01-21 02:24:30.131715	\N	17	f	1	20	\N	\N
808	Adverse Events	807	\N	48	2015-01-18 20:05:04.011041	2015-01-21 02:37:37.484702	\N	17	f	1	20	\N	\N
813	Adverse Event	808	16	48	2015-01-18 20:08:25.247462	2015-01-21 02:37:40.787389	nausea	17	f	1	20	\N	\N
812	Adverse Event	808	16	48	2015-01-18 20:08:21.269623	2015-01-21 02:37:46.830674	diarrhea	17	f	1	20	\N	\N
811	Adverse Event	808	16	48	2015-01-18 20:08:14.97889	2015-01-21 02:37:49.683541	total	17	f	1	20	\N	\N
810	Adverse Event	808	16	48	2015-01-18 20:08:08.115907	2015-01-21 02:37:53.390159	severe/ser	17	f	1	20	\N	\N
809	Adverse Event	808	16	48	2015-01-18 20:05:04.83463	2015-01-21 02:37:55.804291	eructation	17	f	1	20	\N	\N
820	Intervention	814	9	48	2015-01-18 20:11:07.220394	2015-01-21 02:38:08.571322	midaz	17	f	1	20	\N	\N
819	Intervention	814	9	48	2015-01-18 20:11:02.688926	2015-01-21 02:38:14.621193	dextro	17	f	1	20	\N	\N
818	Intervention	814	9	48	2015-01-18 20:10:57.928109	2015-01-21 02:38:17.388895	omepra	17	f	1	20	\N	\N
817	Intervention	814	9	48	2015-01-18 20:10:54.220014	2015-01-21 02:38:20.011341	tolbutamid	17	f	1	20	\N	\N
816	Intervention	814	9	48	2015-01-18 20:10:49.450925	2015-01-21 02:38:22.381504	caffeine	17	f	1	20	\N	\N
815	Intervention	814	9	48	2015-01-18 20:10:43.834849	2015-01-21 02:38:25.062906	silexan	17	f	1	20	\N	\N
814	Interventions	807	\N	48	2015-01-18 20:10:41.811807	2015-01-21 02:38:39.682876	\N	17	f	1	20	\N	\N
841	Result	822	\N	48	2015-01-18 20:13:13.753324	2015-01-21 02:39:13.176612	dextro	17	f	1	20	\N	\N
843	Result	841	1	48	2015-01-18 20:13:22.037858	2015-01-21 02:39:24.187629	Tmax	17	f	1	20	\N	\N
842	Result	841	1	48	2015-01-18 20:13:17.140857	2015-01-21 02:39:26.27259	Cmax	17	f	1	20	\N	\N
840	Result	835	1	48	2015-01-18 20:13:02.089555	2015-01-21 02:39:34.886509	halflife	17	f	1	20	\N	\N
839	Result	835	1	48	2015-01-18 20:12:58.630231	2015-01-21 02:39:37.016519	AUCinf	17	f	1	20	\N	\N
838	Result	835	1	48	2015-01-18 20:12:54.074161	2015-01-21 02:39:39.321778	AUCt	17	f	1	20	\N	\N
837	Result	835	1	48	2015-01-18 20:12:46.922618	2015-01-21 02:39:41.07564	Tmax	17	f	1	20	\N	\N
836	Result	835	1	48	2015-01-18 20:12:43.397996	2015-01-21 02:39:42.914478	Cmax	17	f	1	20	\N	\N
835	Result	822	\N	48	2015-01-18 20:12:40.355943	2015-01-21 02:39:48.082654	omepra	17	f	1	20	\N	\N
834	Result	829	1	48	2015-01-18 20:12:22.715183	2015-01-21 02:39:54.008245	halflife	17	f	1	20	\N	\N
833	Result	829	1	48	2015-01-18 20:12:18.170956	2015-01-21 02:39:56.31966	AUCinf	17	f	1	20	\N	\N
832	Result	829	1	48	2015-01-18 20:12:14.746927	2015-01-21 02:39:59.771829	AUCt	17	f	1	20	\N	\N
831	Result	829	1	48	2015-01-18 20:12:11.000741	2015-01-21 02:40:02.298896	Tmax	17	f	1	20	\N	\N
830	Result	829	1	48	2015-01-18 20:12:07.202628	2015-01-21 02:40:04.272146	Cmax	17	f	1	20	\N	\N
829	Result	822	\N	48	2015-01-18 20:12:04.098178	2015-01-21 02:40:11.148729	tolbut	17	f	1	20	\N	\N
823	Result	822	\N	48	2015-01-18 20:11:19.201595	2015-01-21 02:40:13.642301	Caffeine	17	f	1	20	\N	\N
828	Result	823	1	48	2015-01-18 20:11:49.726227	2015-01-21 02:40:19.06761	halflife	17	f	1	20	\N	\N
827	Result	823	1	48	2015-01-18 20:11:44.521185	2015-01-21 02:40:21.330874	AUCinf	17	f	1	20	\N	\N
826	Result	823	1	48	2015-01-18 20:11:39.501448	2015-01-21 02:40:23.561406	AUCt	17	f	1	20	\N	\N
825	Result	823	1	48	2015-01-18 20:11:33.146111	2015-01-21 02:40:25.915991	Tmax	17	f	1	20	\N	\N
824	Result	823	1	48	2015-01-18 20:11:22.491737	2015-01-21 02:40:28.775849	Cmax	17	f	1	20	\N	\N
822	Result	821	\N	48	2015-01-18 20:11:16.640146	2015-01-21 02:40:38.160308	Table 1	17	f	1	20	\N	\N
821	Results	807	\N	48	2015-01-18 20:11:14.750764	2015-01-21 02:41:31.117104	\N	17	f	1	20	\N	\N
807	Treatment	806	5	48	2015-01-18 20:05:02.746454	2015-01-21 02:41:36.721593	placebo	17	f	1	20	\N	\N
852	Result	847	1	48	2015-01-18 20:15:26.834398	2015-01-21 02:38:59.215418	halflife	17	f	1	20	\N	\N
850	Result	847	1	48	2015-01-18 20:15:17.767624	2015-01-21 02:39:03.815596	AUCt	17	f	1	20	\N	\N
849	Result	847	1	48	2015-01-18 20:14:20.886021	2015-01-21 02:39:05.912796	Tmax	17	f	1	20	\N	\N
844	Result	841	1	48	2015-01-18 20:13:30.166403	2015-01-21 02:39:22.239401	AUCt	17	f	1	20	\N	\N
873	Adverse Event	868	16	48	2015-01-18 20:18:12.816023	2015-01-21 02:24:44.07635	severe/ser	17	f	1	20	\N	\N
872	Adverse Event	868	16	48	2015-01-18 20:18:07.902957	2015-01-21 02:24:45.855468	total	17	f	1	20	\N	\N
871	Adverse Event	868	16	48	2015-01-18 20:18:02.43027	2015-01-21 02:24:48.049929	diarrhea	17	f	1	20	\N	\N
870	Adverse Event	868	16	48	2015-01-18 20:17:56.425594	2015-01-21 02:24:49.846743	nausea	17	f	1	20	\N	\N
869	Adverse Event	868	16	48	2015-01-18 20:17:24.268858	2015-01-21 02:24:51.371118	vomiting	17	f	1	20	\N	\N
881	Intervention	875	9	48	2015-01-18 20:19:15.529245	2015-01-21 02:25:02.187453	silexan	17	f	1	20	\N	\N
880	Intervention	875	9	48	2015-01-18 20:19:11.331517	2015-01-21 02:25:05.476916	caffeine	17	f	1	20	\N	\N
878	Intervention	875	9	48	2015-01-18 20:19:05.089951	2015-01-21 02:25:09.981138	omepra	17	f	1	20	\N	\N
877	Intervention	875	9	48	2015-01-18 20:19:00.461043	2015-01-21 02:25:12.053881	dextro	17	f	1	20	\N	\N
876	Intervention	875	9	48	2015-01-18 20:18:52.285399	2015-01-21 02:25:14.442695	midaz	17	f	1	20	\N	\N
875	Interventions	867	\N	48	2015-01-18 20:18:45.530167	2015-01-21 02:25:20.469043	\N	17	f	1	20	\N	\N
868	Adverse Events	867	\N	48	2015-01-18 20:17:22.351204	2015-01-21 02:25:21.685533	\N	17	f	1	20	\N	\N
915	Result	882	\N	48	2015-01-21 02:18:44.781902	2015-01-21 02:25:23.562806	Table 1	17	f	1	20	\N	\N
928	Result	915	\N	48	2015-01-21 02:20:09.235445	2015-01-21 02:26:25.544612	omepra	17	f	1	20	\N	\N
930	Result	928	1	48	2015-01-21 02:20:17.844201	2015-01-21 02:26:35.11203	AUCinf	17	f	1	20	\N	\N
929	Result	928	1	48	2015-01-21 02:20:11.848748	2015-01-21 02:26:36.664955	halflife	17	f	1	20	\N	\N
927	Result	922	1	48	2015-01-21 02:19:57.70481	2015-01-21 02:26:49.403316	Cmax	17	f	1	20	\N	\N
926	Result	922	1	48	2015-01-21 02:19:54.387022	2015-01-21 02:26:51.757262	Tmax	17	f	1	20	\N	\N
925	Result	922	1	48	2015-01-21 02:19:50.278184	2015-01-21 02:26:54.020218	AUCt	17	f	1	20	\N	\N
924	Result	922	1	48	2015-01-21 02:19:46.303975	2015-01-21 02:26:56.246075	AUCinf	17	f	1	20	\N	\N
923	Result	922	1	48	2015-01-21 02:19:41.327223	2015-01-21 02:27:26.742718	halflife	17	f	1	20	\N	\N
922	Result	915	\N	48	2015-01-21 02:19:38.854699	2015-01-21 02:27:39.004888	dextro	17	f	1	20	\N	\N
921	Result	916	1	48	2015-01-21 02:19:30.366433	2015-01-21 02:27:44.376857	Cmax	17	f	1	20	\N	\N
920	Result	916	1	48	2015-01-21 02:19:27.014556	2015-01-21 02:27:46.290114	Tmax	17	f	1	20	\N	\N
919	Result	916	1	48	2015-01-21 02:19:23.217178	2015-01-21 02:27:48.670889	AUCt	17	f	1	20	\N	\N
918	Result	916	1	48	2015-01-21 02:19:18.918435	2015-01-21 02:27:50.355188	AUCinf	17	f	1	20	\N	\N
917	Result	916	1	48	2015-01-21 02:18:48.303619	2015-01-21 02:27:52.337646	halflife	17	f	1	20	\N	\N
916	Result	915	\N	48	2015-01-21 02:18:46.821617	2015-01-21 02:28:17.04457	midaz	17	f	1	20	\N	\N
908	Result	882	\N	48	2015-01-21 02:18:04.874548	2015-01-21 02:30:51.508995	Table 2	17	f	1	20	\N	\N
914	Result	908	1	48	2015-01-21 02:18:36.130188	2015-01-21 02:30:55.455852	Molar Para	17	f	1	20	\N	\N
913	Result	908	1	48	2015-01-21 02:18:32.168248	2015-01-21 02:31:01.51909	tolbut	17	f	1	20	\N	\N
912	Result	908	1	48	2015-01-21 02:18:25.630234	2015-01-21 02:31:05.276385	omepr plas	17	f	1	20	\N	\N
911	Result	908	1	48	2015-01-21 02:18:20.734683	2015-01-21 02:31:08.846674	omepr auct	17	f	1	20	\N	\N
910	Result	908	1	48	2015-01-21 02:18:15.654052	2015-01-21 02:31:11.661589	dextro pla	17	f	1	20	\N	\N
909	Result	908	1	48	2015-01-21 02:18:08.179466	2015-01-21 02:31:14.17437	midaz plas	17	f	1	20	\N	\N
896	Result	882	\N	48	2015-01-21 02:11:41.974314	2015-01-21 02:31:19.168842	Table 3	17	f	1	20	\N	\N
907	Result	896	1	48	2015-01-21 02:17:42.138954	2015-01-21 02:31:57.724688	caf AUCt	17	f	1	20	\N	\N
906	Result	896	1	48	2015-01-21 02:17:21.47458	2015-01-21 02:32:00.314605	caf molar	17	f	1	20	\N	\N
905	Result	896	1	48	2015-01-21 02:17:11.492255	2015-01-21 02:32:02.996756	tolb AUCt	17	f	1	20	\N	\N
904	Result	896	1	48	2015-01-21 02:17:00.020856	2015-01-21 02:32:05.732586	tolb plasm	17	f	1	20	\N	\N
903	Result	896	1	48	2015-01-21 02:16:50.358135	2015-01-21 02:32:07.897089	ome AUCt	17	f	1	20	\N	\N
902	Result	896	1	48	2015-01-21 02:14:34.520042	2015-01-21 02:32:10.339623	ome 3h	17	f	1	20	\N	\N
901	Result	896	1	48	2015-01-21 02:14:17.87967	2015-01-21 02:32:12.855608	ome AUCt r	17	f	1	20	\N	\N
900	Result	896	1	48	2015-01-21 02:14:04.962027	2015-01-21 02:32:15.218399	dex AUCt	17	f	1	20	\N	\N
899	Result	896	1	48	2015-01-21 02:12:57.314843	2015-01-21 02:32:17.348374	dex 3h	17	f	1	20	\N	\N
898	Result	896	1	48	2015-01-21 02:11:55.444604	2015-01-21 02:32:19.446094	midaz AUCt	17	f	1	20	\N	\N
897	Result	896	1	48	2015-01-21 02:11:43.404515	2015-01-21 02:32:21.641494	midaz 6h	17	f	1	20	\N	\N
889	Result	883	1	48	2015-01-18 20:19:53.681481	2015-01-21 02:32:33.20151	caf corr	17	f	1	20	\N	\N
888	Result	883	1	48	2015-01-18 20:19:50.319051	2015-01-21 02:32:36.831542	tolb corr	17	f	1	20	\N	\N
887	Result	883	1	48	2015-01-18 20:19:46.893102	2015-01-21 02:32:39.07285	ome conc	17	f	1	20	\N	\N
886	Result	883	1	48	2015-01-18 20:19:43.315406	2015-01-21 02:32:41.200777	ome/5 AUCt	17	f	1	20	\N	\N
865	Result	860	1	48	2015-01-18 20:16:57.991593	2015-01-21 02:33:26.417015	dex conc	17	f	1	20	\N	\N
866	Result	860	1	48	2015-01-18 20:17:01.448358	2015-01-21 02:33:29.420117	midaz conc	17	f	1	20	\N	\N
864	Result	860	1	48	2015-01-18 20:16:53.015817	2015-01-21 02:33:31.745069	ome/5 AUCt	17	f	1	20	\N	\N
863	Result	860	1	48	2015-01-18 20:16:47.397951	2015-01-21 02:33:37.887035	ome conc	17	f	1	20	\N	\N
862	Result	860	1	48	2015-01-18 20:16:37.930333	2015-01-21 02:33:48.261412	tolb corr	17	f	1	20	\N	\N
861	Result	860	1	48	2015-01-18 20:16:31.842843	2015-01-21 02:33:50.847473	caf corr	17	f	1	20	\N	\N
885	Result	883	1	48	2015-01-18 20:19:39.278144	2015-01-21 02:34:07.30198	dex conc	17	f	1	20	\N	\N
884	Result	883	1	48	2015-01-18 20:19:33.912034	2015-01-21 02:34:09.79187	midaz conc	17	f	1	20	\N	\N
883	Result	882	\N	48	2015-01-18 20:19:31.823577	2015-01-21 02:36:24.383377	Table 4	17	f	1	20	\N	\N
882	Results	867	\N	48	2015-01-18 20:19:29.422549	2015-01-21 02:37:31.268146	\N	17	f	1	20	\N	\N
867	Treatment	806	5	48	2015-01-18 20:17:19.910699	2015-01-21 02:37:35.640648	silexan	17	f	1	20	\N	\N
851	Result	847	1	48	2015-01-18 20:15:23.500893	2015-01-21 02:39:01.602138	AUCinf	17	f	1	20	\N	\N
848	Result	847	1	48	2015-01-18 20:14:15.230263	2015-01-21 02:39:07.946517	Cmax	17	f	1	20	\N	\N
847	Result	822	\N	48	2015-01-18 20:14:10.246079	2015-01-21 02:39:12.432268	midaz	17	f	1	20	\N	\N
846	Result	841	1	48	2015-01-18 20:13:39.450413	2015-01-21 02:39:18.511632	halflife	17	f	1	20	\N	\N
845	Result	841	1	48	2015-01-18 20:13:34.015976	2015-01-21 02:39:20.35902	AUCinf	17	f	1	20	\N	\N
853	Result	821	\N	48	2015-01-18 20:15:41.279159	2015-01-21 02:40:39.118996	Table 2	17	f	1	20	\N	\N
859	Result	853	1	48	2015-01-18 20:16:14.439903	2015-01-21 02:40:44.930953	midaz plas	17	f	1	20	\N	\N
858	Result	853	1	48	2015-01-18 20:16:09.183464	2015-01-21 02:40:48.159879	dextro pla	17	f	1	20	\N	\N
857	Result	853	1	48	2015-01-18 20:16:03.65288	2015-01-21 02:40:50.746577	omepr auct	17	f	1	20	\N	\N
856	Result	853	1	48	2015-01-18 20:15:57.85388	2015-01-21 02:40:53.140629	omepr plas	17	f	1	20	\N	\N
855	Result	853	1	48	2015-01-18 20:15:52.099808	2015-01-21 02:40:55.569275	tolbut	17	f	1	20	\N	\N
854	Result	853	1	48	2015-01-18 20:15:43.010426	2015-01-21 02:40:57.990258	Molar Para	17	f	1	20	\N	\N
860	Result	821	\N	48	2015-01-18 20:16:26.987093	2015-01-21 02:41:05.586202	Table 4	17	f	1	20	\N	\N
942	Result	940	1	48	2015-01-21 02:21:08.35406	2015-01-21 02:25:39.165163	AUCinf	17	f	1	20	\N	\N
938	Result	934	1	48	2015-01-21 02:20:50.426173	2015-01-21 02:25:55.639943	Tmax	17	f	1	20	\N	\N
937	Result	934	1	48	2015-01-21 02:20:47.024574	2015-01-21 02:26:00.727523	AUCt	17	f	1	20	\N	\N
931	Result	928	1	48	2015-01-21 02:20:21.395687	2015-01-21 02:26:33.349607	AUCt	17	f	1	20	\N	\N
940	Result	915	\N	48	2015-01-21 02:21:01.468171	2015-01-21 02:25:25.581067	Caffeine	17	f	1	20	\N	\N
945	Result	940	1	48	2015-01-21 02:21:18.79124	2015-01-21 02:25:30.356168	Cmax	17	f	1	20	\N	\N
944	Result	940	1	48	2015-01-21 02:21:15.51211	2015-01-21 02:25:32.760537	Tmax	17	f	1	20	\N	\N
943	Result	940	1	48	2015-01-21 02:21:11.534372	2015-01-21 02:25:36.825145	AUCt	17	f	1	20	\N	\N
939	Result	934	1	48	2015-01-21 02:20:54.105308	2015-01-21 02:25:53.786572	Cmax	17	f	1	20	\N	\N
932	Result	928	1	48	2015-01-21 02:20:24.814971	2015-01-21 02:26:31.476661	Tmax	17	f	1	20	\N	\N
781	Demographics	780	8	48	2015-01-18 19:59:58.900525	2015-01-21 02:22:56.462388	\N	17	f	1	20	\N	\N
795	Document Reference	780	6	48	2015-01-18 20:03:10.834684	2015-01-21 02:22:56.927029	\N	17	f	1	20	\N	\N
874	Adverse Event	868	16	48	2015-01-18 20:18:16.274252	2015-01-21 02:24:42.238112	eructation	17	f	1	20	\N	\N
879	Intervention	875	9	48	2015-01-18 20:19:08.498397	2015-01-21 02:25:07.751137	tolbutamid	17	f	1	20	\N	\N
941	Result	940	1	48	2015-01-21 02:21:04.151935	2015-01-21 02:25:41.194954	halflife	17	f	1	20	\N	\N
934	Result	915	\N	48	2015-01-21 02:20:37.114005	2015-01-21 02:25:49.711437	tolbut	17	f	1	20	\N	\N
936	Result	934	1	48	2015-01-21 02:20:43.845067	2015-01-21 02:26:02.901311	AUCinf	17	f	1	20	\N	\N
935	Result	934	1	48	2015-01-21 02:20:39.657335	2015-01-21 02:26:08.032224	halflife	17	f	1	20	\N	\N
933	Result	928	1	48	2015-01-21 02:20:28.153934	2015-01-21 02:26:29.858997	Cmax	17	f	1	20	\N	\N
2230	Home	\N	\N	93	2015-06-30 20:29:28.20042	2015-06-30 20:29:28.20042	\N	14	t	2	\N	f	\N
2231	Demographics	2230	8	93	2015-06-30 20:29:28.225815	2015-06-30 20:29:28.225815	\N	14	f	2	20	f	\N
2232	DE2Man	2231	\N	93	2015-06-30 20:29:28.299253	2015-06-30 20:29:28.299253	1	14	f	2	20	f	\N
2233	DE2Man	2231	\N	93	2015-06-30 20:29:28.365528	2015-06-30 20:29:28.365528	2	14	f	2	20	f	\N
2234	Manual	2231	\N	93	2015-06-30 20:29:28.423989	2015-06-30 20:29:28.423989	1	14	f	2	20	f	\N
2235	Manual	2231	\N	93	2015-06-30 20:29:28.484733	2015-06-30 20:29:28.484733	2	14	f	2	20	f	\N
2236	DE3Man	2231	\N	93	2015-06-30 20:29:40.035655	2015-06-30 20:29:53.059597	3	14	f	2	\N	f	\N
2237	DE3Man	2231	\N	93	2015-06-30 20:29:58.702538	2015-06-30 20:30:07.302294	4	14	f	2	\N	f	\N
2241	DE3Man	2165	\N	93	2015-06-30 21:34:41.268175	2015-06-30 21:39:33.31739	4	17	f	2	20	f	\N
2249	Home	\N	\N	93	2015-06-30 21:47:24.694814	2015-06-30 21:47:24.694814	\N	14	t	3	\N	f	\N
2250	Demographics	2249	8	93	2015-06-30 21:47:24.721516	2015-06-30 21:47:24.721516	\N	14	f	3	20	f	\N
2251	DE3Man	2250	\N	93	2015-06-30 21:47:24.773605	2015-06-30 21:47:24.773605	4	14	f	3	20	f	\N
2252	DE3Man	2250	\N	93	2015-06-30 21:47:24.812812	2015-06-30 21:47:24.812812	3	14	f	3	20	f	\N
2253	DE2Man	2250	\N	93	2015-06-30 21:47:24.85786	2015-06-30 21:47:24.85786	1	14	f	3	20	f	\N
2254	Manual	2250	\N	93	2015-06-30 21:47:24.920729	2015-06-30 21:47:24.920729	1	14	f	3	20	f	\N
2255	Manual	2250	\N	93	2015-06-30 21:47:24.976199	2015-06-30 21:47:24.976199	2	14	f	3	20	f	\N
2256	DE3Man	2250	\N	93	2015-06-30 21:47:40.662095	2015-06-30 21:47:40.662095	COPY	14	f	3	\N	f	\N
2258	Home	\N	\N	93	2015-07-07 20:35:55.876591	2015-07-07 20:35:55.876591	\N	14	t	4	\N	f	\N
2259	Demographics	2258	8	93	2015-07-07 20:35:55.90405	2015-07-07 20:35:55.90405	\N	14	f	4	20	f	\N
2260	DE3Man	2259	\N	93	2015-07-07 20:35:55.954738	2015-07-07 20:35:55.954738	COPY	14	f	4	20	f	\N
2261	DE3Man	2259	\N	93	2015-07-07 20:35:56.004978	2015-07-07 20:35:56.004978	4	14	f	4	20	f	\N
2262	DE2Man	2259	\N	93	2015-07-07 20:35:56.051461	2015-07-07 20:35:56.051461	1	14	f	4	20	f	\N
2263	Manual	2259	\N	93	2015-07-07 20:35:56.114923	2015-07-07 20:35:56.114923	1	14	f	4	20	f	\N
2264	Manual	2259	\N	93	2015-07-07 20:35:56.176029	2015-07-07 20:35:56.176029	2	14	f	4	20	f	\N
2265	DE3Man	2259	\N	93	2015-07-07 20:37:01.119254	2015-07-07 20:37:13.024458	LAST	14	f	4	\N	f	\N
2266	DE3Man	2165	\N	93	2015-07-07 20:38:13.327099	2015-07-07 20:48:28.940115	LAST	17	f	4	20	f	\N
2267	Home	\N	\N	81	2016-06-27 17:50:06.829467	2016-06-27 17:50:06.829467	\N	14	t	1	\N	f	\N
2268	Home	\N	\N	95	2016-06-27 17:50:17.684134	2016-06-27 17:50:17.684134	\N	14	t	1	\N	f	\N
2269	Demographics	2268	8	95	2016-06-27 18:07:30.36583	2016-06-27 18:07:30.36583	\N	14	f	1	\N	\N	\N
2270	Demographics	2269	8	95	2016-06-27 18:08:11.144911	2016-06-27 18:08:11.144911	2	14	f	1	\N	\N	\N
2275	Home	\N	\N	96	2016-08-02 18:40:32.10242	2016-08-02 18:40:32.10242	\N	1	t	1	\N	f	\N
2276	Demographics	2274	8	95	2016-08-19 18:54:50.24628	2016-08-19 18:54:50.24628	\N	17	f	1	\N	f	\N
2277	Adverse Event	2275	16	96	2016-10-07 18:12:57.18688	2016-10-07 18:12:57.18688	\N	1	f	1	\N	\N	\N
2271	Home	\N	\N	95	2016-06-27 18:39:47.557821	2016-06-27 18:39:47.557821	\N	15	t	1	\N	f	\N
2272	Adverse Event	2271	16	95	2016-06-27 18:41:44.729505	2016-06-27 18:41:44.729505	\N	15	f	1	\N	\N	\N
2273	Demographics	2272	8	95	2016-06-27 18:53:24.292513	2016-06-27 18:53:24.292513	\N	15	f	1	\N	\N	\N
2274	Home	\N	\N	95	2016-06-27 19:26:54.786068	2016-06-27 19:26:54.786068	\N	17	t	1	\N	t	\N
1168	Home	\N	\N	47	2015-01-24 02:53:52.988435	2015-01-24 02:53:52.988435	\N	20	t	1	\N	\N	\N
1169	Document Reference	1168	6	47	2015-01-24 02:56:40.107379	2015-01-24 02:56:40.107379	\N	20	f	1	\N	\N	\N
1170	Publication Date	1169	10	47	2015-01-24 02:57:47.817207	2015-01-24 02:57:47.817207	\N	20	f	1	\N	\N	\N
1171	First Author	1169	7	47	2015-01-24 02:59:22.496408	2015-01-24 02:59:22.496408	\N	20	f	1	\N	\N	\N
1172	Study	1168	12	47	2015-01-24 03:00:01.508353	2015-01-24 03:00:01.508353	\N	20	f	1	\N	\N	\N
1173	Study Design	1172	11	47	2015-01-24 03:54:46.213058	2015-01-24 03:54:46.213058	\N	20	f	1	\N	\N	\N
1174	Inclusion and Exclusion Criteria	1172	\N	47	2015-01-24 04:03:27.26062	2015-01-24 04:03:27.26062	\N	20	f	1	\N	\N	\N
1175	Inclusion	1174	\N	47	2015-01-24 04:03:41.792296	2015-01-24 04:03:41.792296	\N	20	f	1	\N	\N	\N
1176	Age	1175	1	47	2015-01-24 04:04:59.364687	2015-01-24 04:04:59.364687	\N	20	f	1	\N	\N	\N
1177	Sex	1175	1	47	2015-01-24 04:05:53.677878	2015-01-24 04:05:53.677878	\N	20	f	1	\N	\N	\N
1178	Body Weight	1175	1	47	2015-01-24 04:06:58.269887	2015-01-24 04:06:58.269887	\N	20	f	1	\N	\N	\N
1179	BMI	1175	1	47	2015-01-24 04:07:48.93599	2015-01-24 04:07:48.93599	\N	20	f	1	\N	\N	\N
1180	Demographics	1172	8	47	2015-01-24 13:48:19.366099	2015-01-24 13:48:19.366099	\N	20	f	1	\N	\N	\N
1181	Age	1180	1	47	2015-01-24 13:48:57.995255	2015-01-24 13:48:57.995255	\N	20	f	1	\N	\N	\N
1182	Weight	1180	1	47	2015-01-24 13:51:00.875621	2015-01-24 13:51:00.875621	\N	20	f	1	\N	\N	\N
1183	BMI	1180	1	47	2015-01-24 13:52:37.812315	2015-01-24 13:52:37.812315	\N	20	f	1	\N	\N	\N
1184	Race	1180	\N	47	2015-01-24 13:53:38.101092	2015-01-24 13:53:38.101092	\N	20	f	1	\N	\N	\N
1185	Caucasian	1184	1	47	2015-01-24 13:53:54.461455	2015-01-24 13:53:54.461455	\N	20	f	1	\N	\N	\N
1186	African	1184	1	47	2015-01-24 13:54:37.106747	2015-01-24 13:54:46.412039	\N	20	f	1	\N	\N	\N
1187	Treatment	1172	13	47	2015-01-24 18:51:18.808168	2015-01-24 18:51:18.808168	\N	20	f	1	\N	\N	\N
1188	Interventions	1187	\N	47	2015-01-24 18:51:34.825208	2015-01-24 18:51:34.825208	\N	20	f	1	\N	\N	\N
1189	Intervention	1188	9	47	2015-01-24 18:51:52.331496	2015-01-24 18:51:52.331496	midazolam	20	f	1	\N	\N	\N
1190	Intervention	1189	9	47	2015-01-24 18:54:34.55514	2015-01-24 18:54:34.55514	alone	20	f	1	\N	\N	\N
1191	Intervention	1189	9	47	2015-01-24 18:54:52.029344	2015-01-24 18:55:01.62549	with verc	20	f	1	\N	\N	\N
1193	Intervention	1192	9	47	2015-01-24 18:55:17.98129	2015-01-24 18:55:17.98129	with verc	20	f	1	\N	\N	\N
1194	Intervention	1192	9	47	2015-01-24 18:55:18.020293	2015-01-24 18:55:18.020293	alone	20	f	1	\N	\N	\N
1192	Intervention	1188	9	47	2015-01-24 18:55:17.788727	2015-01-24 18:55:29.492372	pio	20	f	1	\N	\N	\N
1196	Intervention	1195	9	47	2015-01-24 18:56:38.915486	2015-01-24 18:56:38.915486	alone	20	f	1	\N	\N	\N
1197	Intervention	1195	9	47	2015-01-24 18:56:38.94795	2015-01-24 18:56:38.94795	with verc	20	f	1	\N	\N	\N
1195	Intervention	1188	9	47	2015-01-24 18:56:38.710637	2015-01-24 18:56:49.619886	omep	20	f	1	\N	\N	\N
1199	Intervention	1198	9	47	2015-01-24 18:58:42.983636	2015-01-24 18:58:42.983636	with verc	20	f	1	\N	\N	\N
1200	Intervention	1198	9	47	2015-01-24 18:58:43.023852	2015-01-24 18:58:43.023852	alone	20	f	1	\N	\N	\N
1198	Intervention	1188	9	47	2015-01-24 18:58:42.780389	2015-01-24 18:58:49.911966	rosuva	20	f	1	\N	\N	\N
1201	Intervention	1188	9	47	2015-01-24 19:00:09.458002	2015-01-24 19:00:09.458002	verc	20	f	1	\N	\N	\N
1202	Results	1187	15	47	2015-01-24 19:09:37.41177	2015-01-24 19:09:37.41177	\N	20	f	1	\N	\N	\N
1203	Result	1202	1	47	2015-01-24 19:11:19.298599	2015-01-24 19:11:19.298599	Table 2	20	f	1	\N	\N	\N
1204	Result	1203	1	47	2015-01-24 19:12:29.013709	2015-01-24 19:12:29.013709	Midazolam	20	f	1	\N	\N	\N
1205	Result	1204	1	47	2015-01-24 19:13:36.545977	2015-01-24 19:13:36.545977	Day 1	20	f	1	\N	\N	\N
1206	Result	1205	1	47	2015-01-24 19:14:26.994116	2015-01-24 19:14:26.994116	AUCinf	20	f	1	\N	\N	\N
1207	Result	1205	1	47	2015-01-24 19:15:54.979932	2015-01-24 19:16:01.201028	AUCt	20	f	1	\N	\N	\N
1208	Result	1205	1	47	2015-01-24 19:16:56.528622	2015-01-24 19:17:01.467784	Cmax	20	f	1	\N	\N	\N
1209	Result	1205	1	47	2015-01-24 19:17:41.506789	2015-01-24 19:17:48.150268	t1/2	20	f	1	\N	\N	\N
1210	Result	1205	1	47	2015-01-24 19:18:40.912822	2015-01-24 19:18:40.912822	Tmax	20	f	1	\N	\N	\N
1212	Result	1211	1	47	2015-01-24 19:19:51.406573	2015-01-24 19:19:51.406573	Tmax	20	f	1	\N	\N	\N
1213	Result	1211	1	47	2015-01-24 19:19:51.513528	2015-01-24 19:19:51.513528	t1/2	20	f	1	\N	\N	\N
1214	Result	1211	1	47	2015-01-24 19:19:51.641497	2015-01-24 19:19:51.641497	Cmax	20	f	1	\N	\N	\N
1215	Result	1211	1	47	2015-01-24 19:19:51.770251	2015-01-24 19:19:51.770251	AUCt	20	f	1	\N	\N	\N
1216	Result	1211	1	47	2015-01-24 19:19:51.894338	2015-01-24 19:19:51.894338	AUCinf	20	f	1	\N	\N	\N
1211	Result	1204	1	47	2015-01-24 19:19:51.30404	2015-01-24 19:19:58.979761	Day 11	20	f	1	\N	\N	\N
1219	Result	1218	1	47	2015-01-24 19:23:12.466268	2015-01-24 19:23:12.466268	AUCinf	20	f	1	\N	\N	\N
1220	Result	1218	1	47	2015-01-24 19:23:12.656425	2015-01-24 19:23:12.656425	AUCt	20	f	1	\N	\N	\N
1221	Result	1218	1	47	2015-01-24 19:23:12.784198	2015-01-24 19:23:12.784198	Cmax	20	f	1	\N	\N	\N
1222	Result	1218	1	47	2015-01-24 19:23:12.904346	2015-01-24 19:23:12.904346	t1/2	20	f	1	\N	\N	\N
1223	Result	1218	1	47	2015-01-24 19:23:13.052211	2015-01-24 19:23:13.052211	Tmax	20	f	1	\N	\N	\N
1225	Result	1224	1	47	2015-01-24 19:23:13.269146	2015-01-24 19:23:13.269146	Tmax	20	f	1	\N	\N	\N
1218	Result	1217	1	47	2015-01-24 19:23:12.323452	2015-01-24 19:27:11.403495	Day 12	20	f	1	\N	\N	\N
1224	Result	1217	1	47	2015-01-24 19:23:13.209299	2015-01-24 19:27:17.102805	Day 2	20	f	1	\N	\N	\N
1226	Result	1224	1	47	2015-01-24 19:23:13.386137	2015-01-24 19:23:13.386137	t1/2	20	f	1	\N	\N	\N
1227	Result	1224	1	47	2015-01-24 19:23:13.539465	2015-01-24 19:23:13.539465	Cmax	20	f	1	\N	\N	\N
1228	Result	1224	1	47	2015-01-24 19:23:13.664165	2015-01-24 19:23:13.664165	AUCt	20	f	1	\N	\N	\N
1229	Result	1224	1	47	2015-01-24 19:23:13.784758	2015-01-24 19:23:13.784758	AUCinf	20	f	1	\N	\N	\N
1217	Result	1203	1	47	2015-01-24 19:23:12.178325	2015-01-24 19:23:21.532324	pioglit	20	f	1	\N	\N	\N
1232	Result	1231	1	47	2015-01-24 20:11:32.706175	2015-01-24 20:11:32.706175	AUCinf	20	f	1	\N	\N	\N
1233	Result	1231	1	47	2015-01-24 20:11:32.838667	2015-01-24 20:11:32.838667	AUCt	20	f	1	\N	\N	\N
1234	Result	1231	1	47	2015-01-24 20:11:32.968813	2015-01-24 20:11:32.968813	Cmax	20	f	1	\N	\N	\N
1235	Result	1231	1	47	2015-01-24 20:11:33.163594	2015-01-24 20:11:33.163594	t1/2	20	f	1	\N	\N	\N
1236	Result	1231	1	47	2015-01-24 20:11:33.290567	2015-01-24 20:11:33.290567	Tmax	20	f	1	\N	\N	\N
1238	Result	1237	1	47	2015-01-24 20:11:33.449623	2015-01-24 20:11:33.449623	Tmax	20	f	1	\N	\N	\N
1239	Result	1237	1	47	2015-01-24 20:11:33.561092	2015-01-24 20:11:33.561092	t1/2	20	f	1	\N	\N	\N
1240	Result	1237	1	47	2015-01-24 20:11:33.69439	2015-01-24 20:11:33.69439	Cmax	20	f	1	\N	\N	\N
1241	Result	1237	1	47	2015-01-24 20:11:33.824466	2015-01-24 20:11:33.824466	AUCt	20	f	1	\N	\N	\N
1242	Result	1237	1	47	2015-01-24 20:11:33.95699	2015-01-24 20:11:33.95699	AUCinf	20	f	1	\N	\N	\N
1230	Result	1203	1	47	2015-01-24 20:11:32.554604	2015-01-24 20:11:45.761961	omepra	20	f	1	\N	\N	\N
1237	Result	1230	1	47	2015-01-24 20:11:33.396403	2015-01-24 20:12:24.007845	Day 13	20	f	1	\N	\N	\N
1231	Result	1230	1	47	2015-01-24 20:11:32.653422	2015-01-24 20:12:28.181596	Day 3	20	f	1	\N	\N	\N
1245	Result	1244	1	47	2015-01-24 20:49:20.168282	2015-01-24 20:49:20.168282	Day 13	20	f	1	\N	\N	\N
1246	Result	1245	1	47	2015-01-24 20:49:20.212242	2015-01-24 20:49:20.212242	AUCinf	20	f	1	\N	\N	\N
1247	Result	1245	1	47	2015-01-24 20:49:20.357573	2015-01-24 20:49:20.357573	AUCt	20	f	1	\N	\N	\N
1248	Result	1245	1	47	2015-01-24 20:49:20.510646	2015-01-24 20:49:20.510646	Cmax	20	f	1	\N	\N	\N
1249	Result	1245	1	47	2015-01-24 20:49:20.653621	2015-01-24 20:49:20.653621	t1/2	20	f	1	\N	\N	\N
1250	Result	1245	1	47	2015-01-24 20:49:20.790546	2015-01-24 20:49:20.790546	Tmax	20	f	1	\N	\N	\N
1251	Result	1244	1	47	2015-01-24 20:49:20.913535	2015-01-24 20:49:20.913535	Day 3	20	f	1	\N	\N	\N
1252	Result	1251	1	47	2015-01-24 20:49:20.946519	2015-01-24 20:49:20.946519	Tmax	20	f	1	\N	\N	\N
1253	Result	1251	1	47	2015-01-24 20:49:21.067277	2015-01-24 20:49:21.067277	t1/2	20	f	1	\N	\N	\N
1254	Result	1251	1	47	2015-01-24 20:49:21.200725	2015-01-24 20:49:21.200725	Cmax	20	f	1	\N	\N	\N
1255	Result	1251	1	47	2015-01-24 20:49:21.340661	2015-01-24 20:49:21.340661	AUCt	20	f	1	\N	\N	\N
1256	Result	1251	1	47	2015-01-24 20:49:21.484921	2015-01-24 20:49:21.484921	AUCinf	20	f	1	\N	\N	\N
1244	Result	1203	1	47	2015-01-24 20:49:20.067882	2015-01-24 20:55:53.761712	5-OH-ome	20	f	1	\N	\N	\N
1259	Result	1258	1	47	2015-01-24 21:07:22.401187	2015-01-24 21:07:22.401187	AUCinf	20	f	1	\N	\N	\N
1260	Result	1258	1	47	2015-01-24 21:07:22.55587	2015-01-24 21:07:22.55587	AUCt	20	f	1	\N	\N	\N
1261	Result	1258	1	47	2015-01-24 21:07:22.677801	2015-01-24 21:07:22.677801	Cmax	20	f	1	\N	\N	\N
1262	Result	1258	1	47	2015-01-24 21:07:22.803014	2015-01-24 21:07:22.803014	t1/2	20	f	1	\N	\N	\N
1263	Result	1258	1	47	2015-01-24 21:07:22.948142	2015-01-24 21:07:22.948142	Tmax	20	f	1	\N	\N	\N
1265	Result	1264	1	47	2015-01-24 21:07:23.182882	2015-01-24 21:07:23.182882	Tmax	20	f	1	\N	\N	\N
1266	Result	1264	1	47	2015-01-24 21:07:23.286956	2015-01-24 21:07:23.286956	t1/2	20	f	1	\N	\N	\N
1267	Result	1264	1	47	2015-01-24 21:07:23.407514	2015-01-24 21:07:23.407514	Cmax	20	f	1	\N	\N	\N
1268	Result	1264	1	47	2015-01-24 21:07:23.532071	2015-01-24 21:07:23.532071	AUCt	20	f	1	\N	\N	\N
1269	Result	1264	1	47	2015-01-24 21:07:23.654874	2015-01-24 21:07:23.654874	AUCinf	20	f	1	\N	\N	\N
1257	Result	1203	1	47	2015-01-24 21:07:22.130956	2015-01-24 21:07:30.652315	rosuva	20	f	1	\N	\N	\N
1264	Result	1257	1	47	2015-01-24 21:07:23.129362	2015-01-24 21:07:53.004321	Day 4	20	f	1	\N	\N	\N
1258	Result	1257	1	47	2015-01-24 21:07:22.255137	2015-01-24 21:07:58.560747	Day 14	20	f	1	\N	\N	\N
1270	Result	1202	1	47	2015-01-25 18:05:33.672645	2015-01-25 18:05:33.672645	Table 3	20	f	1	\N	\N	\N
1271	Result	1270	1	47	2015-01-25 18:15:31.064204	2015-01-25 18:15:31.064204	Midazolam	20	f	1	\N	\N	\N
1272	Result	1270	1	47	2015-01-25 18:17:12.352182	2015-01-25 18:17:21.278386	Pioglit	20	f	1	\N	\N	\N
1273	Result	1270	1	47	2015-01-25 18:18:16.537268	2015-01-25 18:19:06.962962	ome	20	f	1	\N	\N	\N
1274	Result	1270	1	47	2015-01-25 18:22:06.112485	2015-01-25 18:22:18.452714	5-OH	20	f	1	\N	\N	\N
1275	Result	1270	1	47	2015-01-25 18:23:11.954492	2015-01-25 18:23:21.486708	5-OH/ome r	20	f	1	\N	\N	\N
1276	Result	1270	1	47	2015-01-25 18:24:16.293217	2015-01-25 18:24:22.020567	rosuva	20	f	1	\N	\N	\N
1277	Result	1202	1	47	2015-01-25 18:27:42.434959	2015-01-25 18:27:42.434959	Table 4	20	f	1	\N	\N	\N
1278	Result	1277	1	47	2015-01-25 18:28:18.519532	2015-01-25 18:28:18.519532	verc d5	20	f	1	\N	\N	\N
1279	Result	1278	1	47	2015-01-25 18:29:48.845492	2015-01-25 18:29:48.845492	AUCt	20	f	1	\N	\N	\N
1280	Result	1278	1	47	2015-01-25 18:45:56.42577	2015-01-25 18:46:01.651665	Cmax	20	f	1	\N	\N	\N
1281	Result	1278	1	47	2015-01-25 18:46:46.320297	2015-01-25 18:46:55.359468	Tmax	20	f	1	\N	\N	\N
1283	Result	1282	1	47	2015-01-25 18:48:06.870306	2015-01-25 18:48:06.870306	Tmax	20	f	1	\N	\N	\N
1284	Result	1282	1	47	2015-01-25 18:48:06.974701	2015-01-25 18:48:06.974701	Cmax	20	f	1	\N	\N	\N
1285	Result	1282	1	47	2015-01-25 18:48:07.12082	2015-01-25 18:48:07.12082	AUCt	20	f	1	\N	\N	\N
1282	Result	1277	1	47	2015-01-25 18:48:06.754895	2015-01-25 18:48:19.554756	622 D5	20	f	1	\N	\N	\N
1287	Result	1286	1	47	2015-01-25 18:50:39.751895	2015-01-25 18:50:39.751895	AUCt	20	f	1	\N	\N	\N
1288	Result	1286	1	47	2015-01-25 18:50:39.882468	2015-01-25 18:50:39.882468	Cmax	20	f	1	\N	\N	\N
1289	Result	1286	1	47	2015-01-25 18:50:40.048889	2015-01-25 18:50:40.048889	Tmax	20	f	1	\N	\N	\N
1286	Result	1277	1	47	2015-01-25 18:50:39.587317	2015-01-25 18:50:48.676755	694 d5	20	f	1	\N	\N	\N
1291	Result	1290	1	47	2015-01-25 18:55:17.66596	2015-01-25 18:55:17.66596	Tmax	20	f	1	\N	\N	\N
1292	Result	1290	1	47	2015-01-25 18:55:17.795225	2015-01-25 18:55:17.795225	Cmax	20	f	1	\N	\N	\N
1293	Result	1290	1	47	2015-01-25 18:55:17.94234	2015-01-25 18:55:17.94234	AUCt	20	f	1	\N	\N	\N
1290	Result	1277	1	47	2015-01-25 18:55:17.53299	2015-01-25 18:55:26.462006	verc d10	20	f	1	\N	\N	\N
1294	Result	1290	1	47	2015-01-25 18:57:38.469964	2015-01-25 18:57:50.158008	Ro AUCt	20	f	1	\N	\N	\N
1295	Result	1290	1	47	2015-01-25 18:59:00.022886	2015-01-25 18:59:06.583481	Ro Cmax	20	f	1	\N	\N	\N
1297	Result	1296	1	47	2015-01-25 18:59:58.340807	2015-01-25 18:59:58.340807	AUCt	20	f	1	\N	\N	\N
1298	Result	1296	1	47	2015-01-25 18:59:58.481993	2015-01-25 18:59:58.481993	Cmax	20	f	1	\N	\N	\N
1299	Result	1296	1	47	2015-01-25 18:59:58.611341	2015-01-25 18:59:58.611341	Tmax	20	f	1	\N	\N	\N
1296	Result	1277	1	47	2015-01-25 18:59:58.139748	2015-01-25 19:00:06.352208	622 d10	20	f	1	\N	\N	\N
1301	Result	1300	1	47	2015-01-25 19:02:53.70728	2015-01-25 19:02:53.70728	Tmax	20	f	1	\N	\N	\N
1302	Result	1300	1	47	2015-01-25 19:02:53.835081	2015-01-25 19:02:53.835081	Cmax	20	f	1	\N	\N	\N
1303	Result	1300	1	47	2015-01-25 19:02:53.991186	2015-01-25 19:02:53.991186	AUCt	20	f	1	\N	\N	\N
1300	Result	1277	1	47	2015-01-25 19:02:53.567328	2015-01-25 19:03:01.097987	694 d10	20	f	1	\N	\N	\N
1304	Adverse Events	1187	\N	47	2015-01-25 19:06:43.475613	2015-01-25 19:06:43.475613	\N	20	f	1	\N	\N	\N
1305	Adverse Event	1304	16	47	2015-01-25 20:50:23.864465	2015-01-25 20:50:23.864465	somn	20	f	1	\N	\N	\N
1306	Adverse Event	1304	16	47	2015-01-25 20:53:08.510121	2015-01-25 20:53:08.510121	GI	20	f	1	\N	\N	\N
1307	Adverse Event	1306	16	47	2015-01-25 22:09:09.027477	2015-01-25 22:09:09.027477	abd pain	20	f	1	\N	\N	\N
1308	Adverse Event	1306	16	47	2015-01-25 22:09:53.367354	2015-01-25 22:09:58.87552	dysp	20	f	1	\N	\N	\N
1309	Adverse Event	1306	16	47	2015-01-25 22:10:24.779199	2015-01-25 22:10:29.743182	naus	20	f	1	\N	\N	\N
1310	Adverse Event	1306	16	47	2015-01-25 22:10:56.617886	2015-01-25 22:11:04.247798	diar	20	f	1	\N	\N	\N
1311	Adverse Event	1306	16	47	2015-01-25 22:11:27.055681	2015-01-25 22:11:39.7786	reflux	20	f	1	\N	\N	\N
1312	Adverse Event	1304	16	47	2015-01-25 22:12:28.48126	2015-01-25 22:12:36.019461	headache	20	f	1	\N	\N	\N
1313	Adverse Event	1304	16	47	2015-01-25 22:13:14.332644	2015-01-25 22:13:45.489808	dizzy	20	f	1	\N	\N	\N
1314	Adverse Event	1304	16	47	2015-01-25 22:13:47.153053	2015-01-25 22:13:52.999868	dreams	20	f	1	\N	\N	\N
1315	Adverse Event	1304	16	47	2015-01-25 22:14:38.606282	2015-01-25 22:14:38.606282	labs	20	f	1	\N	\N	\N
1316	Adverse Event	1315	16	47	2015-01-25 22:16:11.451657	2015-01-25 22:17:51.517292	ALT	20	f	1	\N	\N	\N
1317	Adverse Event	1315	16	47	2015-01-25 22:17:14.455004	2015-01-25 22:17:55.092258	AST	20	f	1	\N	\N	\N
1318	Home	\N	\N	47	2015-01-25 22:26:08.292657	2015-01-25 22:26:08.292657	\N	14	t	1	\N	\N	\N
1319	Home	\N	\N	47	2015-01-25 22:28:16.335562	2015-01-25 22:28:16.335562	\N	17	t	1	\N	\N	\N
1322	Publication Date	1320	10	47	2015-01-25 22:28:30.856437	2015-01-26 22:16:02.059167	\N	17	f	1	21	\N	\N
1320	Document Reference	1319	6	47	2015-01-25 22:28:23.146184	2015-01-26 22:16:10.903311	\N	17	f	1	21	\N	\N
1325	Age	1324	1	47	2015-01-25 22:28:39.79548	2015-01-26 22:16:18.42352	\N	17	f	1	21	\N	\N
1326	BMI	1324	1	47	2015-01-25 22:28:43.051545	2015-01-26 22:16:31.044429	\N	17	f	1	21	\N	\N
1328	African	1327	1	47	2015-01-25 22:28:56.828987	2015-01-26 22:16:34.61501	\N	17	f	1	21	\N	\N
1329	Caucasian	1327	1	47	2015-01-25 22:29:00.151845	2015-01-26 22:16:36.240159	\N	17	f	1	21	\N	\N
1327	Race	1324	\N	47	2015-01-25 22:28:54.897102	2015-01-26 22:16:43.693578	\N	17	f	1	21	\N	\N
1330	Weight	1324	1	47	2015-01-25 22:29:12.075525	2015-01-26 22:16:46.337148	\N	17	f	1	21	\N	\N
1324	Demographics	1323	8	47	2015-01-25 22:28:38.791026	2015-01-26 22:16:49.772844	\N	17	f	1	21	\N	\N
1333	Age	1332	1	47	2015-01-25 22:29:24.399851	2015-01-26 22:16:58.607745	\N	17	f	1	21	\N	\N
1334	BMI	1332	1	47	2015-01-25 22:29:27.08348	2015-01-26 22:17:03.283029	\N	17	f	1	21	\N	\N
1335	Body Weight	1332	1	47	2015-01-25 22:29:29.536962	2015-01-26 22:17:05.31872	\N	17	f	1	21	\N	\N
1336	Sex	1332	1	47	2015-01-25 22:29:32.062189	2015-01-26 22:17:07.178961	\N	17	f	1	21	\N	\N
1332	Inclusion	1331	\N	47	2015-01-25 22:29:22.632939	2015-01-26 22:17:08.588609	\N	17	f	1	21	\N	\N
1337	Study Design	1323	11	47	2015-01-25 22:29:46.144583	2015-01-26 22:17:16.10304	\N	17	f	1	21	\N	\N
1352	Adverse Event	1339	16	47	2015-01-25 22:30:24.61793	2015-01-26 22:17:26.321118	somn	17	f	1	21	\N	\N
1351	Adverse Event	1346	16	47	2015-01-25 22:30:19.460526	2015-01-26 22:17:30.254721	abd pain	17	f	1	21	\N	\N
1350	Adverse Event	1346	16	47	2015-01-25 22:30:17.484095	2015-01-26 22:17:36.002983	dysp	17	f	1	21	\N	\N
1349	Adverse Event	1346	16	47	2015-01-25 22:30:15.093353	2015-01-26 22:17:38.84323	naus	17	f	1	21	\N	\N
1348	Adverse Event	1346	16	47	2015-01-25 22:30:12.687976	2015-01-26 22:17:41.140505	diar	17	f	1	21	\N	\N
1347	Adverse Event	1346	16	47	2015-01-25 22:30:10.112946	2015-01-26 22:17:45.389338	reflux	17	f	1	21	\N	\N
1346	Adverse Event	1339	16	47	2015-01-25 22:30:08.333213	2015-01-26 22:17:47.619118	GI	17	f	1	21	\N	\N
1345	Adverse Event	1339	16	47	2015-01-25 22:30:05.992265	2015-01-26 22:17:50.502698	headache	17	f	1	21	\N	\N
1344	Adverse Event	1339	16	47	2015-01-25 22:30:03.910532	2015-01-26 22:17:55.38769	dizzy	17	f	1	21	\N	\N
1343	Adverse Event	1339	16	47	2015-01-25 22:30:01.32809	2015-01-26 22:17:57.621412	dreams	17	f	1	21	\N	\N
1342	Adverse Event	1340	16	47	2015-01-25 22:29:56.698218	2015-01-26 22:18:01.852724	ALT	17	f	1	21	\N	\N
1341	Adverse Event	1340	16	47	2015-01-25 22:29:53.699932	2015-01-26 22:18:04.231625	AST	17	f	1	21	\N	\N
1340	Adverse Event	1339	16	47	2015-01-25 22:29:52.627343	2015-01-26 22:18:05.907075	labs	17	f	1	21	\N	\N
1339	Adverse Events	1338	\N	47	2015-01-25 22:29:51.875575	2015-01-26 22:18:10.544192	\N	17	f	1	21	\N	\N
1369	Intervention	1367	9	47	2015-01-26 21:37:34.837048	2015-01-26 22:18:15.654288	alone	17	f	1	21	\N	\N
1368	Intervention	1367	9	47	2015-01-26 21:37:29.389038	2015-01-26 22:18:18.350076	with verc	17	f	1	21	\N	\N
1367	Intervention	1353	9	47	2015-01-26 21:37:27.535708	2015-01-26 22:18:25.296733	midazolam	17	f	1	21	\N	\N
1366	Intervention	1364	9	47	2015-01-26 21:37:05.364777	2015-01-26 22:18:28.652767	with verc	17	f	1	21	\N	\N
1365	Intervention	1364	9	47	2015-01-26 21:36:58.493359	2015-01-26 22:18:30.532402	alone	17	f	1	21	\N	\N
1364	Intervention	1353	9	47	2015-01-26 21:36:57.146298	2015-01-26 22:18:32.3487	pio	17	f	1	21	\N	\N
1363	Intervention	1361	9	47	2015-01-26 21:36:48.803796	2015-01-26 22:18:46.949163	alone	17	f	1	21	\N	\N
1362	Intervention	1361	9	47	2015-01-25 22:32:16.535169	2015-01-26 22:18:49.164708	with verc	17	f	1	21	\N	\N
1361	Intervention	1353	9	47	2015-01-25 22:32:14.400457	2015-01-26 22:18:50.644766	omep	17	f	1	21	\N	\N
1360	Intervention	1358	9	47	2015-01-25 22:31:44.408748	2015-01-26 22:18:57.943461	with verc	17	f	1	21	\N	\N
1359	Intervention	1358	9	47	2015-01-25 22:31:37.478137	2015-01-26 22:18:59.81056	alone	17	f	1	21	\N	\N
1358	Intervention	1353	9	47	2015-01-25 22:31:35.992616	2015-01-26 22:19:01.241302	rosuva	17	f	1	21	\N	\N
1354	Intervention	1353	9	47	2015-01-25 22:30:34.573121	2015-01-26 22:19:05.587066	verc	17	f	1	21	\N	\N
1353	Interventions	1338	\N	47	2015-01-25 22:30:33.438098	2015-01-26 22:19:08.821519	\N	17	f	1	21	\N	\N
1373	Result	1372	1	47	2015-01-26 21:38:08.024676	2015-01-26 22:23:30.586407	AUCt	17	f	1	21	\N	\N
1374	Result	1372	1	47	2015-01-26 21:38:11.678362	2015-01-26 22:23:34.535872	Cmax	17	f	1	21	\N	\N
1375	Result	1372	1	47	2015-01-26 21:38:14.03435	2015-01-26 22:23:36.611085	Tmax	17	f	1	21	\N	\N
1372	Result	1371	1	47	2015-01-26 21:38:06.528495	2015-01-26 22:23:38.453997	694 d10	17	f	1	21	\N	\N
1387	Result	1386	1	47	2015-01-26 21:39:16.123374	2015-01-26 22:26:58.585689	Tmax	17	f	1	21	\N	\N
1386	Result	1371	1	47	2015-01-26 21:39:13.741552	2015-01-26 22:27:33.466802	694 d5	17	f	1	21	\N	\N
1385	Result	1380	1	47	2015-01-26 21:39:08.659662	2015-01-26 22:27:37.407566	Tmax	17	f	1	21	\N	\N
1384	Result	1380	1	47	2015-01-26 21:39:06.158054	2015-01-26 22:27:39.611315	Cmax	17	f	1	21	\N	\N
1383	Result	1380	1	47	2015-01-26 21:39:03.437454	2015-01-26 22:27:41.610633	AUCt	17	f	1	21	\N	\N
1382	Result	1380	1	47	2015-01-26 21:38:57.710691	2015-01-26 22:27:43.582287	Ro AUCt	17	f	1	21	\N	\N
1381	Result	1380	1	47	2015-01-26 21:38:51.782104	2015-01-26 22:27:47.107064	Ro Cmax	17	f	1	21	\N	\N
1380	Result	1371	1	47	2015-01-26 21:38:49.817601	2015-01-26 22:27:48.952592	verc d10	17	f	1	21	\N	\N
1379	Result	1376	1	47	2015-01-26 21:38:40.623049	2015-01-26 22:27:53.389318	AUCt	17	f	1	21	\N	\N
1378	Result	1376	1	47	2015-01-26 21:38:36.166423	2015-01-26 22:27:55.28891	Cmax	17	f	1	21	\N	\N
1377	Result	1376	1	47	2015-01-26 21:38:32.643709	2015-01-26 22:27:57.267754	Tmax	17	f	1	21	\N	\N
1376	Result	1371	1	47	2015-01-26 21:38:31.284844	2015-01-26 22:27:58.453538	622 d10	17	f	1	21	\N	\N
1371	Result	1370	1	47	2015-01-26 21:38:05.541668	2015-01-26 22:28:02.284141	Table 4	17	f	1	21	\N	\N
1370	Results	1338	15	47	2015-01-26 21:38:04.057349	2015-01-26 22:28:04.808455	\N	17	f	1	21	\N	\N
1338	Treatment	1323	13	47	2015-01-25 22:29:50.521571	2015-01-26 22:28:19.92653	\N	17	f	1	21	\N	\N
1323	Study	1319	12	47	2015-01-25 22:28:37.625707	2015-01-26 22:28:20.822925	\N	17	f	1	21	\N	\N
1468	Result	1465	1	47	2015-01-26 22:13:52.079637	2015-01-26 22:19:21.841313	Cmax	17	f	1	21	\N	\N
1467	Result	1465	1	47	2015-01-26 22:13:48.164939	2015-01-26 22:19:24.06024	t1/2	17	f	1	21	\N	\N
1464	Result	1459	1	47	2015-01-26 22:13:36.14933	2015-01-26 22:19:34.245809	Tmax	17	f	1	21	\N	\N
1463	Result	1459	1	47	2015-01-26 22:13:33.173895	2015-01-26 22:19:36.619962	t1/2	17	f	1	21	\N	\N
1462	Result	1459	1	47	2015-01-26 22:13:30.352232	2015-01-26 22:19:39.097146	Cmax	17	f	1	21	\N	\N
1461	Result	1459	1	47	2015-01-26 22:13:27.825563	2015-01-26 22:19:41.071766	AUCt	17	f	1	21	\N	\N
1457	Result	1452	1	47	2015-01-26 22:13:08.58116	2015-01-26 22:19:52.565353	AUCinf	17	f	1	21	\N	\N
1455	Result	1452	1	47	2015-01-26 22:13:02.476206	2015-01-26 22:19:58.008057	Cmax	17	f	1	21	\N	\N
1453	Result	1452	1	47	2015-01-26 22:12:54.595735	2015-01-26 22:20:02.359521	Tmax	17	f	1	21	\N	\N
1452	Result	1445	1	47	2015-01-26 22:12:52.618429	2015-01-26 22:20:03.695102	Day 12	17	f	1	21	\N	\N
1451	Result	1446	1	47	2015-01-26 22:12:44.896273	2015-01-26 22:20:07.932979	Tmax	17	f	1	21	\N	\N
1449	Result	1446	1	47	2015-01-26 22:12:39.459066	2015-01-26 22:20:12.005727	Cmax	17	f	1	21	\N	\N
1447	Result	1446	1	47	2015-01-26 22:12:32.634931	2015-01-26 22:20:17.221764	AUCinf	17	f	1	21	\N	\N
1446	Result	1445	1	47	2015-01-26 22:12:31.656091	2015-01-26 22:20:18.412917	Day 2	17	f	1	21	\N	\N
1444	Result	1439	1	47	2015-01-26 21:44:01.854144	2015-01-26 22:20:25.561017	AUCinf	17	f	1	21	\N	\N
1443	Result	1439	1	47	2015-01-26 21:43:58.585053	2015-01-26 22:20:28.185167	AUCt	17	f	1	21	\N	\N
1441	Result	1439	1	47	2015-01-26 21:43:51.662567	2015-01-26 22:20:33.176473	t1/2	17	f	1	21	\N	\N
1440	Result	1439	1	47	2015-01-26 21:43:48.361334	2015-01-26 22:20:35.42195	Tmax	17	f	1	21	\N	\N
1438	Result	1433	1	47	2015-01-26 21:43:28.990154	2015-01-26 22:20:41.764849	Tmax	17	f	1	21	\N	\N
1434	Result	1433	1	47	2015-01-26 21:43:12.981068	2015-01-26 22:20:50.63119	AUCinf	17	f	1	21	\N	\N
1432	Result	1405	1	47	2015-01-26 21:43:07.778797	2015-01-26 22:20:53.606828	omepra	17	f	1	21	\N	\N
1431	Result	1426	1	47	2015-01-26 21:42:55.604288	2015-01-26 22:20:58.72364	AUCinf	17	f	1	21	\N	\N
1430	Result	1426	1	47	2015-01-26 21:42:53.191822	2015-01-26 22:21:01.461424	AUCt	17	f	1	21	\N	\N
1427	Result	1426	1	47	2015-01-26 21:42:40.445474	2015-01-26 22:21:10.252886	Tmax	17	f	1	21	\N	\N
1426	Result	1419	1	47	2015-01-26 21:42:39.218201	2015-01-26 22:21:12.013704	Day 13	17	f	1	21	\N	\N
1422	Result	1420	1	47	2015-01-26 21:42:05.860459	2015-01-26 22:21:22.913514	AUCt	17	f	1	21	\N	\N
1421	Result	1420	1	47	2015-01-26 21:42:00.215059	2015-01-26 22:21:24.773321	AUCinf	17	f	1	21	\N	\N
1419	Result	1405	1	47	2015-01-26 21:41:56.92655	2015-01-26 22:21:27.671266	5-OH-ome	17	f	1	21	\N	\N
1418	Result	1413	1	47	2015-01-26 21:41:47.890468	2015-01-26 22:21:32.09175	AUCinf	17	f	1	21	\N	\N
1416	Result	1413	1	47	2015-01-26 21:41:41.676515	2015-01-26 22:21:35.599841	Cmax	17	f	1	21	\N	\N
1413	Result	1406	1	47	2015-01-26 21:41:33.476132	2015-01-26 22:21:43.318041	Day 14	17	f	1	21	\N	\N
1412	Result	1407	1	47	2015-01-26 21:41:14.846384	2015-01-26 22:22:13.092229	Tmax	17	f	1	21	\N	\N
1409	Result	1407	1	47	2015-01-26 21:41:05.15575	2015-01-26 22:22:21.137974	AUCt	17	f	1	21	\N	\N
1407	Result	1406	1	47	2015-01-26 21:40:49.120422	2015-01-26 22:22:24.154323	Day 4	17	f	1	21	\N	\N
1406	Result	1405	1	47	2015-01-26 21:40:42.878999	2015-01-26 22:22:25.477485	rosuva	17	f	1	21	\N	\N
1404	Result	1398	1	47	2015-01-26 21:40:34.358319	2015-01-26 22:23:08.213289	Midazolam	17	f	1	21	\N	\N
1403	Result	1398	1	47	2015-01-26 21:40:31.070537	2015-01-26 22:23:10.409189	Pioglit	17	f	1	21	\N	\N
1400	Result	1398	1	47	2015-01-26 21:40:17.449522	2015-01-26 22:23:18.693476	5-OH/ome r	17	f	1	21	\N	\N
1399	Result	1398	1	47	2015-01-26 21:40:12.527842	2015-01-26 22:23:20.68318	rosuva	17	f	1	21	\N	\N
1398	Result	1370	1	47	2015-01-26 21:40:10.792299	2015-01-26 22:23:22.305341	Table 3	17	f	1	21	\N	\N
1397	Result	1394	1	47	2015-01-26 21:39:56.120474	2015-01-26 22:23:42.523379	AUCt	17	f	1	21	\N	\N
1395	Result	1394	1	47	2015-01-26 21:39:50.291461	2015-01-26 22:26:30.833179	Tmax	17	f	1	21	\N	\N
1394	Result	1371	1	47	2015-01-26 21:39:48.271684	2015-01-26 22:26:32.454306	verc d5	17	f	1	21	\N	\N
1393	Result	1390	1	47	2015-01-26 21:39:41.733968	2015-01-26 22:26:35.799009	Tmax	17	f	1	21	\N	\N
1392	Result	1390	1	47	2015-01-26 21:39:38.774309	2015-01-26 22:26:38.227894	Cmax	17	f	1	21	\N	\N
1391	Result	1390	1	47	2015-01-26 21:39:35.060163	2015-01-26 22:26:40.478852	AUCt	17	f	1	21	\N	\N
1390	Result	1371	1	47	2015-01-26 21:39:32.889893	2015-01-26 22:26:47.864428	622 D5	17	f	1	21	\N	\N
1389	Result	1386	1	47	2015-01-26 21:39:27.213393	2015-01-26 22:26:53.274528	AUCt	17	f	1	21	\N	\N
1388	Result	1386	1	47	2015-01-26 21:39:22.852917	2015-01-26 22:26:56.143772	Cmax	17	f	1	21	\N	\N
1321	First Author	1320	7	47	2015-01-25 22:28:26.028133	2015-01-26 22:15:59.079584	\N	17	f	1	21	\N	\N
1331	Inclusion and Exclusion Criteria	1323	\N	47	2015-01-25 22:29:20.70767	2015-01-26 22:17:10.125178	\N	17	f	1	21	\N	\N
1470	Result	1465	1	47	2015-01-26 22:13:58.884658	2015-01-26 22:19:16.947001	AUCinf	17	f	1	21	\N	\N
1469	Result	1465	1	47	2015-01-26 22:13:55.250149	2015-01-26 22:19:19.427612	AUCt	17	f	1	21	\N	\N
1466	Result	1465	1	47	2015-01-26 22:13:44.775732	2015-01-26 22:19:26.002881	Tmax	17	f	1	21	\N	\N
1465	Result	1458	1	47	2015-01-26 22:13:42.96221	2015-01-26 22:19:29.017713	Day 1	17	f	1	21	\N	\N
1460	Result	1459	1	47	2015-01-26 22:13:23.935757	2015-01-26 22:19:43.562294	AUCinf	17	f	1	21	\N	\N
1459	Result	1458	1	47	2015-01-26 22:13:22.770774	2015-01-26 22:19:45.095064	Day 11	17	f	1	21	\N	\N
1458	Result	1405	1	47	2015-01-26 22:13:20.394026	2015-01-26 22:19:46.957349	Midazolam	17	f	1	21	\N	\N
1456	Result	1452	1	47	2015-01-26 22:13:05.2322	2015-01-26 22:19:55.803345	AUCt	17	f	1	21	\N	\N
1454	Result	1452	1	47	2015-01-26 22:12:59.320015	2015-01-26 22:19:59.946855	t1/2	17	f	1	21	\N	\N
1450	Result	1446	1	47	2015-01-26 22:12:42.367919	2015-01-26 22:20:09.647062	t1/2	17	f	1	21	\N	\N
1448	Result	1446	1	47	2015-01-26 22:12:36.481346	2015-01-26 22:20:14.868334	AUCt	17	f	1	21	\N	\N
1445	Result	1405	1	47	2015-01-26 22:12:30.016202	2015-01-26 22:20:20.911547	pioglit	17	f	1	21	\N	\N
1442	Result	1439	1	47	2015-01-26 21:43:55.449533	2015-01-26 22:20:30.523432	Cmax	17	f	1	21	\N	\N
1439	Result	1432	1	47	2015-01-26 21:43:44.221399	2015-01-26 22:20:36.716413	Day 3	17	f	1	21	\N	\N
1437	Result	1433	1	47	2015-01-26 21:43:26.070839	2015-01-26 22:20:44.35782	t1/2	17	f	1	21	\N	\N
1436	Result	1433	1	47	2015-01-26 21:43:22.946617	2015-01-26 22:20:46.989645	Cmax	17	f	1	21	\N	\N
1435	Result	1433	1	47	2015-01-26 21:43:16.767699	2015-01-26 22:20:48.707605	AUCt	17	f	1	21	\N	\N
1433	Result	1432	1	47	2015-01-26 21:43:09.279963	2015-01-26 22:20:51.833984	Day 13	17	f	1	21	\N	\N
1429	Result	1426	1	47	2015-01-26 21:42:49.842129	2015-01-26 22:21:06.108358	Cmax	17	f	1	21	\N	\N
1428	Result	1426	1	47	2015-01-26 21:42:46.261643	2015-01-26 22:21:08.002027	t1/2	17	f	1	21	\N	\N
1425	Result	1420	1	47	2015-01-26 21:42:21.807693	2015-01-26 22:21:16.146338	Tmax	17	f	1	21	\N	\N
1424	Result	1420	1	47	2015-01-26 21:42:18.38998	2015-01-26 22:21:18.999748	t1/2	17	f	1	21	\N	\N
1423	Result	1420	1	47	2015-01-26 21:42:10.340177	2015-01-26 22:21:20.955057	Cmax	17	f	1	21	\N	\N
1420	Result	1419	1	47	2015-01-26 21:41:58.786239	2015-01-26 22:21:26.382263	Day 3	17	f	1	21	\N	\N
1417	Result	1413	1	47	2015-01-26 21:41:45.147022	2015-01-26 22:21:33.836209	AUCt	17	f	1	21	\N	\N
1415	Result	1413	1	47	2015-01-26 21:41:38.449449	2015-01-26 22:21:37.323064	t1/2	17	f	1	21	\N	\N
1414	Result	1413	1	47	2015-01-26 21:41:34.89936	2015-01-26 22:21:40.050737	Tmax	17	f	1	21	\N	\N
1411	Result	1407	1	47	2015-01-26 21:41:11.711748	2015-01-26 22:22:15.615082	t1/2	17	f	1	21	\N	\N
1410	Result	1407	1	47	2015-01-26 21:41:08.560488	2015-01-26 22:22:18.214694	Cmax	17	f	1	21	\N	\N
1408	Result	1407	1	47	2015-01-26 21:40:50.468921	2015-01-26 22:22:22.95353	AUCinf	17	f	1	21	\N	\N
1405	Result	1370	1	47	2015-01-26 21:40:41.430387	2015-01-26 22:22:32.819698	Table 2	17	f	1	21	\N	\N
1402	Result	1398	1	47	2015-01-26 21:40:27.238605	2015-01-26 22:23:12.675559	ome	17	f	1	21	\N	\N
1401	Result	1398	1	47	2015-01-26 21:40:22.910077	2015-01-26 22:23:16.789054	5-OH	17	f	1	21	\N	\N
1396	Result	1394	1	47	2015-01-26 21:39:53.17001	2015-01-26 22:26:28.058951	Cmax	17	f	1	21	\N	\N
1474	Home	\N	\N	46	2015-03-24 19:00:02.576081	2015-03-24 19:00:02.576081	\N	1	t	1	\N	\N	\N
1475	stu	1474	12	46	2015-03-24 19:00:12.459512	2015-03-24 19:00:12.459512	\N	1	f	1	\N	\N	\N
1476	incu	1475	18	46	2015-03-24 19:00:26.96095	2015-03-24 19:00:26.96095	\N	1	f	1	\N	\N	\N
1511	Home	\N	\N	46	2015-05-01 21:42:25.73248	2015-05-01 21:42:25.73248	\N	14	t	1	\N	\N	\N
1512	aa	1511	\N	46	2015-05-01 21:42:30.259445	2015-05-01 21:42:30.259445	\N	14	f	1	\N	\N	\N
1515	Home	\N	\N	46	2015-05-06 20:23:19.928826	2015-05-06 20:23:19.928826	\N	17	t	1	\N	\N	\N
1516	test	1515	\N	46	2015-05-07 17:39:33.914303	2015-05-07 17:39:33.914303	\N	17	f	1	\N	\N	\N
2156	Home	\N	\N	93	2015-06-09 18:03:22.069229	2015-06-09 18:03:22.069229	\N	1	t	1	\N	f	\N
\.


--
-- Name: groups_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('groups_id_seq', 2277, true);


--
-- Data for Name: memberships; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY memberships (id, organization_id, account_id, role, "default", concealed) FROM stdin;
1	1	1	1	t	f
2	1	2	2	t	f
3	1	3	2	t	f
4	1	4	1	t	f
5	1	5	7	t	f
6	1	6	6	t	f
7	1	7	5	t	f
8	1	8	8	t	f
9	1	9	9	t	f
10	1	10	5	t	f
11	1	11	5	t	f
12	1	12	1	t	f
13	1	13	1	t	f
14	1	14	5	t	f
15	1	15	5	t	f
16	1	16	5	t	f
17	1	17	6	t	f
18	1	18	6	t	f
19	1	19	6	t	f
20	1	20	7	t	f
21	1	21	1	t	f
22	1	22	8	t	f
23	1	23	10	t	f
\.


--
-- Name: memberships_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('memberships_id_seq', 23, true);


--
-- Data for Name: organizations; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY organizations (id, name, slug, created_at, updated_at, demo, language, document_language) FROM stdin;
1	DACTYL	dactyl	2014-04-25 15:37:52.554067	2014-04-25 15:37:52.554067	f	eng	eng
\.


--
-- Name: organizations_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('organizations_id_seq', 1, false);


--
-- Data for Name: pages; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY pages (id, organization_id, account_id, document_id, access, page_number, text, start_offset, end_offset) FROM stdin;
9	1	1	9	1	1	/usr/bin/ruby /var/lib/gems/1.8/gems/passenger-4.0.29/bin/passenger start -a127.0.0.1 -p 1234 --max-pool-size 1 --spawn-method conservative -e development=============== Phusion Passenger Standalone web server started ===============PID file: /home/rwilliams/documentcloud/tmp/pids/passenger.1234.pidLog file: /home/rwilliams/documentcloud/log/passenger.1234.logEnvironment: developmentAccessible via: http://127.0.0.1:1234/You can stop Phusion Passenger Standalone by pressing Ctrl-C.Problems? Check http://www.modrails.com/documentation/Users%20guide%20Standalone.html#troubleshooting===============================================================================App 2406 stdout:App 2406 stderr: NOTE: Gem.source_index is deprecated, use Specification. It willbe removed on or after 2011-11-01.App 2406 stderr: Gem.source_index called from /var/lib/gems/1.8/gems/rails2.3.18/lib/rails/gem_dependency.rb:21.App 2406 stderr:App 2406 stderr: Faraday: you may want to install system_timer for reliabletimeoutsApp 2406 stderr:fix_rack_110_quote_parsing.rb not loadedApp 2406 stderr: OmniAuth secrets are not available. Not performing initializationApp 2406 stderr:App 2406 stdout: Preparing to launch debugger for 2406[ 2014-01-31 11:44:51.8375 2371/b62bcb40 Pool2/Implementation.cpp:869 ]: Could notspawn process for group /home/rwilliams/documentcloud#default: An error occuredwhile starting the web application.in 'voidPassenger::ApplicationPool2::Spawner::handleSpawnErrorResponse(Passenger::ApplicationPool2::Spawner::NegotiationDetails&)' (Spawner.h:1227)in 'Passenger::ApplicationPool2::ProcessPtrPassenger::ApplicationPool2::Spawner::negotiateSpawn(Passenger::ApplicationPool2::Spawner::NegotiationDetails&)' (Spawner.h:1190)in 'virtual Passenger::ApplicationPool2::ProcessPtrPassenger::ApplicationPool2::DirectSpawner::spawn(constPassenger::ApplicationPool2::Options&)' (DirectSpawner.h:213)in 'void Passenger::ApplicationPool2::Group::spawnThreadRealMain(constPassenger::ApplicationPool2::SpawnerPtr&, constPassenger::ApplicationPool2::Options&, unsigned int)' (Implementation.cpp:802)[ 2014-01-31 11:44:51.8380 2371/b60ffb40agents/HelperAgent/RequestHandler.h:2060 ]: [Client 20] Cannot checkout session.Error page:no such file to load -- linecache (MissingSourceFile)/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:547:in `new_constants_in'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/home/rwilliams/.gem/ruby/1.8/gems/ruby-debug-base-0.10.5.rc9/lib/ruby-debugbase.rb:3/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'	0	2933
10	1	1	9	1	2	/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:547:in `new_constants_in'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/ruby-debug-ide-0.4.22/lib/ruby-debug-ide.rb:6/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:547:in `new_constants_in'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/home/rwilliams/documentcloud/config/initializers/rubymine_passenger_debug.rb:7/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:171:in`load_without_new_constant_marking'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:171:in `load'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:547:in `new_constants_in'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:171:in `load'/var/lib/gems/1.8/gems/rails-2.3.18/lib/initializer.rb:622:in`load_application_initializers'/var/lib/gems/1.8/gems/rails-2.3.18/lib/initializer.rb:621:in `each'/var/lib/gems/1.8/gems/rails-2.3.18/lib/initializer.rb:621:in`load_application_initializers'/var/lib/gems/1.8/gems/rails-2.3.18/lib/initializer.rb:176:in `process'/var/lib/gems/1.8/gems/rails-2.3.18/lib/initializer.rb:113:in `send'/var/lib/gems/1.8/gems/rails-2.3.18/lib/initializer.rb:113:in `run'/home/rwilliams/documentcloud/config/environment.rb:38/usr/lib/ruby/vendor_ruby/1.8/rubygems/custom_require.rb:36:in`gem_original_require'/usr/lib/ruby/vendor_ruby/1.8/rubygems/custom_require.rb:36:in `require'/var/lib/gems/1.8/gems/passenger-4.0.29/helper-scripts/classic-railsloader.rb:87:in `load_app'/var/lib/gems/1.8/gems/passenger-4.0.29/helper-scripts/classic-railsloader.rb:152[ 2014-01-31 11:44:51.8474 2371/b60ffb40agents/HelperAgent/RequestHandler.h:2060 ]: [Client 21] Cannot checkout session.Error page:no such file to load -- linecache (MissingSourceFile)/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:547:in `new_constants_in'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/home/rwilliams/.gem/ruby/1.8/gems/ruby-debug-base-0.10.5.rc9/lib/ruby-debugbase.rb:3/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/activesupport-	2934	5788
1	1	1	4	2	1	ABCDEDFGHIDJKELDCDICHIEMJEFKDBIGJDLABCDE DFGH IDJKEL DCD I CH IEMJEFKDBIGJDLI think it is nice to have a visitor for once	0	120
21	1	1	15	2	4	PK Interaction between PA-824 and MidazolamFIG 2 Mean plasma 1-hydroxy midazolam concentrations ( the SD) overtime after a 2-mg oral dose of midazolam.require dose adjustment of drugs predominantly metabolized by CYP3A4when coadministered with PA-824. If the GMRs were within the 50 to200% limit, then sequentially narrower criteria would be tested, i.e., 70 to143%. If these narrower criteria were met, then the standard no-effector bioequivalence criteria, 80 to 125%, were to be assessed. The intendedsample size was based on the known variability in the AUC and Cmaxassociated with midazolam. Sample size calculations were based on astudy by Stoch et al. (11), who reported 90% CIs for GMRs of midazolamAUCs based on within-subject AUC variability and midazolam 2-mg oraldoses in the presence of ketoconazole. The natural log-scale standarddeviations (SD) computed from these CIs were 0.22 for AUC and 0.31 forCmax. Twelve subjects provided 96% power of yielding a 90% CI forAUC or Cmax within 0.5 to 2.0 bounds if the true underlying GMR was1.00. Midazolam and 1-hydroxy midazolam t1/2 and Tmax were comparedbetween midazolam alone versus midazolam with PA-824 using the Student t test and Wilcoxon signed-rank test. If the t1/2 and Tmax data failedtests for normality, only the Wilcoxon signed-rank test results were reported.RESULTSA total of 14 healthy male (n  10) and female (n  4) subjectsparticipated in this clinical study to assess the safety, tolerability,and PK parameters of midazolam when coadministered with PA824. All subjects were 19 to 46 years old (mean, 27.2 years), had abody mass index of 18 to 29 (mean, 25.4 kg/m2), and were medically healthy as determined by the principal investigator based ontheir medical history, clinical laboratory results, 12-lead electrocardiograms (ECGs), and physical examination. At both screening and check-in, subjects had negative urine test results foralcohol and other drugs of abuse, such as amphetamines, cannabinoids, and cocaine metabolites. Study participants represented aracially diverse group consisting of one Asian, one black, two Hispanic, and 10 white subjects. All 14 subjects who were enrolled inthe study completed all of the study procedures, and there were nodropouts.Pharmacokinetics. The mean plasma concentrations formidazolam and 1-hydroxy midazolam are shown in Fig. 1 and 2,respectively. PK parameters for midazolam and 1-hydroxy midazolam are provided in Table 1. The signicant presence of BLQplasma concentrations resulted in the loss of AUC0  and t1/2 datafor the midazolam data of one subject and the loss of 1-hydroxyAugust 2013 Volume 57 Number 8midazolam data for four subjects. The predose mean PA-824plasma concentrations  the SD on days 12, 13, and 14 for theonce-daily administration of 400 mg of PA-824 were 1,637  610,1,581  539, and 1,607  556 ng/ml, respectively. PA-824 plasmaconcentrations showed no sign of additional accumulation, indicating that steady-state had been achieved for PA-824 prior to thedosing of midazolam. These PA-824 plasma concentrations aresimilar to those found in earlier multiple-dose studies using similar doses.The GMRs (90% CI) when midazolam was coadministeredwith PA-824 compared to when midazolam was administeredalone were as follows: Cmax  83.63% (75.11 to 93.11%),AUC0 t  84.61% (74.21 to 96.47%), and AUC0   84.45%(73.79 to 96.64%). The 90% CIs for the GMRs of AUCs and CmaxTABLE 1 Midazolam and 1-hydroxy midazolam pharmacokineticparametersaMean  SD (n)PharmacokineticparametersTreatment A (reference):midazolam aloneTreatment B (test):midazolam  PA-824MidazolamCmax (ng/ml)AUC0t (ng  h/ml)AUC0 (ng  h/ml)CL/F (liters/h)Tmax (h)t1/2 (h)11.9  5.46 (14)30.7  15.3 (14)32.1  15.7 (14)75.8  32.0 (14)0.505 (0.4991.00) (14)5.69  2.14 (14)9.64  3.43 (14)25.3  10.50 (14)25.0  9.56 (13)91.5  36.21.00 (0.4991.00) (14)5.44  2.4400 (13)1-Hydroxy midazolamCmax (ng/ml)AUC0t (ng  h/ml)AUC0 (ng  h/ml)Tmax (h)t1/2 (h)5.32  2.48 (14)12.0  5.23 (14)12.9  5.82 (13)0.505 (0.4991.00) (14)4.09  2.16 (13)5.42  2.17 (14)13.7  6.24 (14)14.6  7.73 (10)1.00 (0.4991.00) (14)4.45  2.87 (10)Tmax results are presented as the median (range). Other values are arithmetic means the standard deviations. n, number of subjects contributing data; Cmax, maximum observedconcentration; Tmax, time at which Cmax occurs; t1/2, elimination half-life; AUC0 t, areaunder the concentration-time curve during the dosing interval; AUC0 , area under theconcentration-time curve extrapolated to innity.aaac.asm.org 3701Downloaded from http://aac.asm.org/ on May 14, 2014 by guestFIG 1 Mean plasma midazolam concentrations over time ( the SD) after a2-mg oral dose of midazolam.	15650	20383
22	1	1	15	2	5	Winter et al.TABLE 2 Statistical comparisons of midazolam and 1-hydroxy midazolam pharmacokinetic parametersaGeometric LS mean (n)PharmacokineticparametersTreatment A (reference):midazolam aloneTreatment B (test):midazolam PA-824% GMR90% CIMidazolamCmax (ng/ml)AUC0t (ng  h/ml)AUC0 (ng  h/ml)10.82 (14)27.63 (14)28.97 (13)9.05 (14)23.38 (14)24.47 (13)83.6384.6184.4575.1193.1174.2196.4773.7996.641-Hydroxy midazolamCmax (ng/ml)AUC0t (ng  h/ml)AUC0 (ng  h/ml)4.76 (14)10.86 (14)11.57 (10)5.00 (14)12.38 (14)13.04 (10)105.23113.98112.6893.13118.9105.53123.09103.07123.18values were all within the predened 50 to 200 and 70 to 143%no-effect limits; however, the upper limit of the CIs was100%. The 90% CIs for the GMRs of the AUCs and Cmax valueswere not within the no-effect limit of 80 to 125%. The totalextent (AUC) and peak (Cmax) exposure of midazolam decreasedby ca. 15 to 16% when midazolam was coadministered with PA824 compared to when midazolam was administered alone. Basedon the nonparametric Wilcoxon signed-rank test, the midazolamTmax (P  0.891) and t1/2 (P  0.893) were not different betweenboth treatments.As seen in Table 2, a statistical analysis of 1-hydroxy midazolam PK parameters demonstrated that the GMRs (90% CI) whenmidazolam was coadministered with PA-824 compared to whenmidazolam was administered alone were as follows: Cmax 105.23% (93.13 to 118.9%), AUC0 t  113.98% (105.53 to123.09%), and AUC0   112.68% (103.07 to 123.18%). Thelower bound of the 90% CIs for the GMRs of the AUCs was100% but all were within the no-effect limit of 80 to 125%.Based on the nonparametric Wilcoxon signed-rank test, the 1-hydroxy midazolam Tmax (P  0.988) and t1/2 (P  1.00) values werenot different between both treatments.Safety and tolerability. PA-824 was well tolerated throughoutthe study and when coadministered with midazolam. No seriousadverse events occurred. The only adverse events reported bymore than one subject during any treatment period were headache, nausea, abdominal discomfort, and diarrhea. These eventswere reported more commonly by subjects during the periodswhen PA-824 was administered alone or in combination withmidazolam. There was a trend toward increased serum creatinineconcentrations during dosing with PA-824, a nding consistentwith an earlier study that determined that higher doses of PA-824do not affect renal function but may increase serum creatinine byinhibiting renal tubular secretion of creatinine, a clinically benigneffect that has been seen with several marketed drugs (12). Mean(SD) serum creatinine concentrations were 0.785 (0.173) atcheck-in, 0.811 (0.184) when midazolam was dosed alone, 0.916(0.175) after 7 days of once-daily dosing of PA-824, and 0.955(0.189) after 14 days of once-daily dosing of PA-824 with coadministration of midazolam on day 14. All other mean laboratoryparameters for serum chemistry, hematology, and urinalysis remained within reference range. There were no remarkable ndings in the vital signs, ECGs, physical examinations, visual acuitytests, and slit-lamp examinations in this study.3702 aac.asm.orgDISCUSSIONWhen this study was designed, the clinical dose range in patientswith TB had not been determined. The 400-mg PA-824 dose usedhere was chosen as the highest dose that might be used in futureclinical studies. The 400-mg PA-824 dose was expected to producethe maximum change in midazolam exposure relevant to theclinic. Any effects observed at the 400-mg PA-824 dose level couldbe extrapolated to lower doses of PA-824, potentially requiringadditional studies to appropriately characterize the drug interaction at lower clinical doses. The 50 to 200% limit for the 90% CI ofthe GMR was chosen as a no-effect criterion based on a clinicalassessment that if dose adjustment of important drugs metabolized by CYP3A4 were required during coadministration of PA824, then continued development of PA-824 as a therapy for TBwould not be warranted. The 2-mg oral midazolam dose is at thelower range of that typically used in drug-drug interaction studies,but it was chosen due to concerns over the possible magnitude ofCYP3A4 time-dependent inhibition after a 14-day dosing of PA824.The total extent (AUC) and peak (Cmax) exposure of midazolam decreased by ca. 16 and 15%, respectively, with the concomitant coadministration of midazolam and PA-824 400 mg compared to the administration of midazolam alone. The total extent(AUC) and peak (Cmax) exposure of 1-hydroxy midazolam increased 14 and 5%, respectively, with the concomitant coadministration of midazolam and PA-824 compared to the administration of midazolam alone. The 90% CI values for the GMRs ofAUC0 t, AUC0, and Cmax for midazolam and 1-hydroxy midazolam were all within the prespecied no-effect 50 to 200% limitand within the narrower prespecied 70 to 143% limit, whereasonly the 1-hydroxy midazolam GMRs also fell within the defaultbioequivalence 80 to 125% limit. The relatively small decrease inmidazolam exposure, together with the small increase in 1-hydroxy midazolam exposure observed when midazolam is coadministered, appears to be consistent with a small inductive effectby PA-824 on CYP3A4. This result appears inconsistent with invitro data indicating that PA-824 is a weak inhibitor of CYP3A4and exhibits metabolism-dependent inhibition. However, our invitro metabolism data are too limited to indicate the likely mechanism. It has been reported that some metabolism-dependent inhibiters can form relatively stable PA-824 metabolite enzymecomplexes resulting in decreased degradation of the enzyme itselfAntimicrobial Agents and ChemotherapyDownloaded from http://aac.asm.org/ on May 14, 2014 by guestan, number of subjects contributing data; Cmax, maximum observed concentration; AUC0 t, area under the concentration-time curve during the dosing interval; AUC0 , areaunder the concentration-time curve extrapolated to innity; LS mean, least-squares mean; GMR, geometric mean ratio; CI, condence interval.	20384	26407
23	1	1	15	2	6	PK Interaction between PA-824 and MidazolamACKNOWLEDGMENTSThis study was supported by grants from the Rockefeller Foundation, theDevelopment Cooperation Ireland, the Bill & Melinda Gates Foundation,the U.S. Agency for International Development, and the Dutch Ministryof Foreign Affairs.We thank the staff of Celerion, Inc., and the study participants.REFERENCES1. Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P,Ledwidge R, Dowd CS, Lee IY, Kim P, Zhang L, Kang S, Keller TH,Jiricek J, Barry CE. 2008. PA-824 kills nonreplicating Mycobacteriumtuberculosis by intracellular NO release. Science 322:13921395.August 2013 Volume 57 Number 82. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM,Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DNBN,Kreiswirth Barry CE, Baker WR. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962966.3. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H,Sasaki H, Shimokawa Y, Komatsu M. 2006. OPC-67683, a nitrodihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3:e466. doi:10.1371/journal.pmed.0030466.4. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D,Rosenthal I, Grosset JH. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxioxacin, and pyrazinamide ina murine model of tuberculosis. Antimicrob. Agents Chemother. 52:15221524.5. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A,Donald PR, van Niekerk C, Whitney K, Rouse DJ, Laurenzi MW,Ginsberg AM, Spigelman MK. 2010. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother. 54:34023407.6. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald P, vanNiekerk C, Erondu N, Ginsberg A, Becker P, Spigelman M. 2012. Aphase II dose-ranging trial of the early bactericidal activity of PA-824.Antimicrob. Agents Chemother. 56:30273031.7. Diacon AH, Dawson R, von Groote-Bidlinqmaier F, Symons G, VenterA, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, MendelCM, Spigelman M. 2012. 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxioxacin combinations: a randomised trial.Lancet 380:986 993.8. CDC. 2012. Grand rounds: the TB/HIV syndemic. MMWR Morb. Mortal. Wkly. Rep. 61:484  489.9. Dooley KE, Kim PS, Williams SD, Hafner R. 2012. TB and HIV therapeutics: pharmacology research priorities. AIDS Res. Treat. 2012:19.10. Food and Drug Administration. 2006. Guidance for industry: druginteraction studiesstudy design, data analysis, and implications fordosing and labeling. Ofce of Training and Communications Divisionof Drug Information, document HFD-240. U.S. Department of Healthand Human Services, FDA Center for Drug Evaluation and Research,Bethesda, MD.11. Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P, Fitzgerald M,Chodakewitz J, Wagner JA. 2009. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam:shortening the paradigm. J. Clin. Pharmacol. 49:398  406.12. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK.2009. Assessment of the effects of the nitroimidazo-oxazine PA-824 onrenal function in healthy subjects. Antimicrob. Agents Chemother. 53:3726 3733.aac.asm.org 3703Downloaded from http://aac.asm.org/ on May 14, 2014 by guestand ultimately higher steady-state levels of active enzyme. Midazolam is known to exhibit allosteric activation of CYP3A4-mediated metabolism with some drugs. Allosteric activation involvesthe binding of an activator to the enzyme, resulting in an increased rate of metabolism. 1-Hydroxy midazolam forms a glucuronide metabolite. Glucuronide metabolites can be excreted bytransporters in the kidney and other tissues. Increased serum creatinine concentrations were detected. It is possible that PA-824inhibition of a common transporter for creatinine and 1-hydroxymidazolam might have led to the increased 1-hydroxy midazolamexposure that we observed. However, the decrease in midazolamexposure that we detected is not consistent with the inhibition of arenal transporter.We demonstrated that PA-824 at the 400-mg dose does notproduce changes in midazolam exposure that would require doseadjustment. Any changes in midazolam exposure that occur forthe 100- and 200-mg PA-824 doses are likely to be even less thanthat observed for the 400-mg dose. Therefore, our ndings indicate that PA-824 is not likely to affect the PK of CYP3A4-metabolized drugs to a clinically meaningful extent. Most importantly,concomitant use of PA-824 is not expected to produce signicantdrug interactions with antiretroviral drugs that are substrates ofCYP3A4, such as the protease inhibitors. Overall, single doses oforal midazolam (2 mg) administered alone and then after multiple doses of PA-824 (400 mg daily for 14 days) with a single oraldose of midazolam (2 mg on day 14 of PA-824 dosing) were welltolerated by the subjects in our study.	26408	31462
11	1	1	9	1	3	2.3.18/lib/active_support/dependencies.rb:547:in `new_constants_in'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/ruby-debug-ide-0.4.22/lib/ruby-debug-ide.rb:6/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:547:in `new_constants_in'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:182:in `require'/home/rwilliams/documentcloud/config/initializers/rubymine_passenger_debug.rb:7/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:171:in`load_without_new_constant_marking'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:171:in `load'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:547:in `new_constants_in'/var/lib/gems/1.8/gems/activesupport2.3.18/lib/active_support/dependencies.rb:171:in `load'/var/lib/gems/1.8/gems/rails-2.3.18/lib/initializer.rb:622:in`load_application_initializers'/var/lib/gems/1.8/gems/rails-2.3.18/lib/initializer.rb:621:in `each'/var/lib/gems/1.8/gems/rails-2.3.18/lib/initializer.rb:621:in`load_application_initializers'/var/lib/gems/1.8/gems/rails-2.3.18/lib/initializer.rb:176:in `process'/var/lib/gems/1.8/gems/rails-2.3.18/lib/initializer.rb:113:in `send'/var/lib/gems/1.8/gems/rails-2.3.18/lib/initializer.rb:113:in `run'/home/rwilliams/documentcloud/config/environment.rb:38/usr/lib/ruby/vendor_ruby/1.8/rubygems/custom_require.rb:36:in`gem_original_require'/usr/lib/ruby/vendor_ruby/1.8/rubygems/custom_require.rb:36:in `require'/var/lib/gems/1.8/gems/passenger-4.0.29/helper-scripts/classic-railsloader.rb:87:in `load_app'/var/lib/gems/1.8/gems/passenger-4.0.29/helper-scripts/classic-railsloader.rb:152	5789	7728
18	1	1	15	2	1	Evaluation of Pharmacokinetic Interactionbetween PA-824 and Midazolam in HealthyAdult SubjectsHelen Winter, Erica Egizi, Ngozi Erondu, Ann Ginsberg,Doris J. Rouse, Diana Severynse-Stevens, Elliott Pauli andDaniel EverittAntimicrob. Agents Chemother. 2013, 57(8):3699. DOI:10.1128/AAC.02632-12.Published Ahead of Print 20 May 2013.These include:REFERENCESCONTENT ALERTSThis article cites 11 articles, 5 of which can be accessed free at:http://aac.asm.org/content/57/8/3699#ref-list-1Receive: RSS Feeds, eTOCs, free email alerts (when newarticles cite this article), moreInformation about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtmlTo subscribe to to another ASM Journal go to: http://journals.asm.org/site/subscriptions/Downloaded from http://aac.asm.org/ on May 14, 2014 by guestDownloaded from http://aac.asm.org/ on May 14, 2014 by guestUpdated information and services can be found at:http://aac.asm.org/content/57/8/3699	0	956
19	1	1	15	2	2	Evaluation of Pharmacokinetic Interaction between PA-824 andMidazolam in Healthy Adult SubjectsHelen Winter,a Erica Egizi,b Ngozi Erondu,b Ann Ginsberg,b Doris J. Rouse,c Diana Severynse-Stevens,c Elliott Pauli,c Daniel EverittbSchool of Pharmacy, University of Otago, Dunedin, New Zealanda; Global Alliance for TB Drug Development, New York, New York, USAb; RTI International, ResearchTriangle Park, North Carolina, USAcPA-824 is an antitubercular nitroimidazo-oxazine that possesses signicant activity against replicating and nonreplicating/persistent Mycobacterium tuberculosis via a complex mechanism of action distinct from that of any currently marketed drugsfor the treatment of tuberculosis (1, 2). Its mechanism of action isbelieved similar to that of Delamanid, a drug currently under review for market approval by the regulatory authorities (3). PA-824interferes with M. tuberculosis cell wall biosynthesis by inhibitingthe oxidation of hydroxymycolate to ketomycolate. A deazaavin(F420)-dependent nitroreductase has also been identied whoseactivity in M. tuberculosis cells is involved in PA-824 activationand activity (2). Reduction of PA-824 to its des-nitroimidazolemetabolite by this nitroreductase is associated with generation ofreactive nitrogen species, including nitric oxide. PA-824 is activeagainst M. tuberculosis isolates resistant to single or multiple antituberculous drugs and has proven effective in shortening treatment time of drug-sensitive M. tuberculosis in a murine model oftuberculosis (TB) as part of novel drug regimens (4). Moreover,PA-824 was highly active as monotherapy in a 14-day dose rangingearly bactericidal activity (EBA) study in humans where similarefcacy proles were observed across all doses assessed (200 to1,200 mg/day) (5). In EBA studies, the rate of change over time inthe number of M. tuberculosis CFU per ml of sputum in an overnight sputum collection is used to compare different dosing andtreatment regimens. In a follow up study exploring a lower doserange (50 to 200 mg/day), a dose-response trend was detected withdoses 100 mg/day and above showing similar efcacy proles (6).In addition, in a 14-day EBA study of novel antituberculosis drugcombinations, the combination of PA-824 (200 mg/day), moxioxacin (400 mg/day), and pyrazinamide (25 mg/kg [bodyweight]/day) demonstrated EBA activity comparable to the current World Health Organization-recommended gold standardtherapy of rifampin, isoniazid, pyrazinamide, and ethambutol (7).Based on the results of these EBA studies, the expected therapeuticAugust 2013 Volume 57 Number 8doses of 100 and 200 mg/day are being evaluated in longer termtrials in patients with pulmonary TB.The current treatment of TB is greatly complicated by the human immunodeciency virus (HIV) co-epidemic. In 2011, 13%of the estimated 8.7 million new cases of TB were coinfected withHIV and, of the 1.4 million deaths from TB, 430,000 deaths wereamong patients who were also HIV positive (8). The treatment ofTB alone requires the use of multiple antibiotics to prevent thedevelopment of drug resistance. The use of multiple antiretroviralagents to treat HIV infection greatly increases the likelihood ofdrug-drug interactions for patients with both infections. Manyimportant drugs used to treat HIV infection, such as the proteaseinhibitors nevirapine, lopinavir, and ritonavir, are substrates ofCYP3A4 and/or p-glycoprotein and have interactions with drugsfor the treatment of TB, such as rifampin, that are inducers ofhepatic enzymes (9). In vitro data indicate that PA-824 is not aninducer but is a weak substrate and potential weak inhibitor ofCYP3A4 (data not shown). An assessment of PA824s drug-druginteraction potential is critical to determine its place in future TBtherapy.The present study was designed to ascertain whether PA-824affected the pharmacokinetics (PK) of midazolam, a sensitiveprobe substrate and representative compound for drugs metabolized by CYP3A4. Midazolam is one of the most commonly used invivo and in vitro CYP3A4 probe substrates for drug-drug interaction studies.Received 17 January 2013 Returned for modication 1 March 2013Accepted 15 May 2013Published ahead of print 20 May 2013Address correspondence to Daniel Everitt, dan.everitt@tballiance.org.Copyright  2013, American Society for Microbiology. All Rights Reserved.doi:10.1128/AAC.02632-12Antimicrobial Agents and Chemotherapyp. 3699 3703aac.asm.org3699Downloaded from http://aac.asm.org/ on May 14, 2014 by guestThis study assessed the safety, tolerability, and pharmacokinetic interaction between PA-824, a novel antitubercular nitroimidazo-oxazine, and midazolam, a CYP3A4 substrate, in 14 healthy adult male and female subjects. The study followed up on observations in vitro that PA-824 caused weak and time-dependent inhibition of CYP3A4. Subjects received a single oral dose ofmidazolam (2 mg), followed by a 2-day washout. After the washout, all subjects received PA-824 (400 mg) once daily for 14 consecutive days. On day 14, all subjects received the nal PA-824 dose coadministered with a 2-mg oral dose of midazolam. Thepharmacokinetic endpoints AUC0 t, AUC0 , and Cmax for midazolam and 1-hydroxy midazolam were compared betweenmidazolam administered alone versus midazolam coadministered with PA-824. Statistical analysis demonstrated that the meanmidazolam values of Cmax, AUC0 t, and AUC0  parameters were reduced by ca. 16, 15, and 15%, respectively, when PA-824 wascoadministered with midazolam. The total exposure (AUC) of 1-hydroxy midazolam was 13 to 14% greater when coadministered with PA-824 compared to midazolam administered alone. The Cmax of 1-hydroxy midazolam was similar between treatments. Based on these results, PA-824 does not inhibit or induce CYP3A4 to a clinically meaningful extent and is not likely tomarkedly affect the pharmacokinetics of CYP3A4 metabolized drugs.	957	6864
20	1	1	15	2	3	Winter et al.MATERIALS AND METHODS3700aac.asm.orgconstituted and analyzed using liquid chromatography with tandem massspectrometric detection. The PA-824 calibration range for quantitationwas 10 to 10,000 ng/ml. Accuracy ranged from 96.3 to 100%, and precision (RSD) ranged from 1.7 to 4.4%.Midazolam, 1-hydroxy midazolam, and the internal standard -hydroxytriazolam (added during sample processing) were extracted fromhuman plasma samples using liquid-liquid extraction. After evaporationunder nitrogen, the residue was reconstituted and analyzed using liquidchromatography with tandem mass spectrometric detection according toa validated method proprietary to Covance Laboratories, Inc. The midazolam and 1-hydroxy midazolam calibration range for quantitation was0.1 to 100 ng/ml. Accuracy ranged from 102.0 to 102.7% and from 102 to103.3% for midazolam and 1-hydroxy midazolam, respectively. Precision(RSD) ranged from 4.5 to 6.3% and from 3.3 to 4.7% for midazolam and1-hydroxy midazolam, respectively.PK analysis. Midazolam and 1-hydroxy midazolam plasma PK parameters were calculated for each subject when midazolam was dosedalone and in combination with PA-824 by applying a noncompartmentalapproach using WinNonlin professional version 5.0.1 (Pharsight Corp.,Mountain View, CA). The key PK parameters calculated for midazolamand 1-hydroxy midazolam included Cmax (the maximum observed concentration), Tmax (the time at which Cmax occurs), kel (the terminal elimination rate constant), t1/2 (the elimination half-life), AUC0 t (the areaunder the concentration-time curve during the dosing interval), andAUC0  (the area under concentration-time curve extrapolated toinnity).Plasma concentrations below the limit of quantitation (BLQ) werehandled in the following manner. The lower limit of quantitation formidazolam and 1-hydroxy midazolam bioanalysis was 0.1 ng/ml. PK parameters were not calculated for subjects for whom there were insufcientdata. For the calculation of the PK parameters, plasma concentrations thatwere BLQ prior to the rst quantiable concentration were set to zero, andplasma concentrations BLQ after the rst quantiable concentration weretreated as missing. For each subject, the elimination rate constant (kel) wasestimated by unweighted log-linear regression using at least three datapoints from the last portion of the plasma concentration prole accordingto the least-squares approach ending with the last concentration prior tothe rst assay that was below the limit of quantication. The eliminationhalf-life (t1/2) was calculated from the kel, using the formula ln(2)/kel. Thekel was not assigned if the terminal elimination phase was not apparent, ifCmax was one of the three last data points, or if the R2 value was 80%. Incases where the kel interval was not assigned, the values of kel, AUC0 ,and t1/2 were considered not calculable and were not reported. When theresulting t1/2 was more than half as long as the sampling interval, the kelvalues and associated parameters (t1/2 and AUC0 ) were not presented.AUCs were calculated by using linear trapezoidal summation from timezero to the specied time point (either the last available time point or byextrapolation to innity).Statistical analysis. All descriptive and inferential statistics were calculated in SAS version 9.1.3. Plasma concentration values for midazolam,1-hydroxy midazolam, and PA-824 were listed and summarized usingdescriptive statistics. Descriptive statistics were calculated for PK parameters. The PK endpoints AUC0 t, AUC0 , and Cmax for midazolam and1-hydroxy midazolam were compared between midazolam alone versusmidazolam with PA-824 using an analysis of variance (ANOVA) model.The ANOVA model using SAS PROC mixed procedure included treatment, period, and sequence as xed effects and subject within sequence asa random effect. For the present study, a potentially clinically importanteffect of PA-824 on midazolam pharmacokinetics, as specied in the protocol, would be concluded if the 90% condence interval (CI) for thegeometric mean ratios (GMRs) of AUC0 t, AUC0 , and Cmax were notcontained within the prespecied no-effect 50 to 200% CI limit. If theGMRs were below 50% or above 200%, then a clinically important effectwould be concluded. For the purposes of this study, a clinically importanteffect was considered to be a drug interaction of sufcient magnitude toAntimicrobial Agents and ChemotherapyDownloaded from http://aac.asm.org/ on May 14, 2014 by guestStudy design. A phase I study was conducted to evaluate the effects of themultiple-dose administration of PA-824 on the PK of orally administeredmidazolam and to evaluate the safety and tolerability of PA-824 whencoadministered with midazolam. The study was an open-label, multidose,xed-sequence design performed in keeping with the U.S. Food and DrugAdministrations industry guidance (10). The clinical study was conducted by Celerion, Inc. (formerly MDS Pharma Services, Inc.), in Lincoln, NE, under the sponsorship of the Global Alliance for TB Drug Development.Subjects were enrolled into the study and housed in the clinical facilityfrom the evening of day 1 (at least 15 h before dosing) through the morning of day 18. The total study duration for each subject from check-inthrough study termination (including a 2-day washout) spanned 18nights and 19 days, with follow-up evaluation over 3 months.All subjects received an initial single oral dose of 2 mg of midazolamCIV hydrochloride syrup (Boehringer Ingelheim/Roxane Laboratories)administered with 240 ml of water, followed by a 2-day washout. After thewashout, all subjects received 400 mg of PA-824 (two 200-mg tablets)administered with 240 ml of water once daily for 14 consecutive days. Onthe day 14 of PA-824 dosing, a single oral dose of 2 mg of midazolam wascoadministered with 400 mg of PA-824 with 240 ml of water. Subjectsfasted for a minimum of 8 h prior to and 4 h after dosing. Water waspermitted ad libitum 1 h prior to and then again 1 h after dosing. Subjectsremained in an upright position (seated or standing) for 4 h after dosing.Dietary restrictions included caffeine, alcohol, poppy seeds, and grapefruit products prior to and throughout the study. No medication waspermitted without sponsor approval except acetaminophen.Subject inclusion and exclusion criteria. Subjects were included ifthey were healthy nonsmokers aged 19 to 50, with a body mass index of 18to 29, inclusive, with negative tests for alcohol and drugs of abuse. Subjectswere excluded if they had any clinically signicant history or presence of acardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal,endocrine, immunologic, dermatologic, or neurologic disease/disorder.Subjects also were excluded if they had a psychological, psychiatric, ormetabolic disorder (including eating disorders) or if they had experiencedany acute illness within 4 weeks. Female subjects were excluded if theywere pregnant (positive test for serum human chorionic gonadotropin atscreening or check-in), breast feeding, or planning to conceive a childwithin 30 days of cessation of treatment. Male subjects were excluded ifthey were planning to father a child within 12 weeks of cessation of treatment. Finally, subjects were excluded if they had a lens opacity or evidenceof lens opacity on slit-lamp ophthalmologic examination to follow up onndings that some rats developed cataracts in toxicology studies at highdoses over 3 to 6 months of dosing.All subjects provided written informed consent prior to participationin the study. Study protocols and consent forms were reviewed and approved by Celerions Institutional Review Board, and the study was conducted in accordance with U.S. Code of Federal Regulations (21 CFR Parts50, 56, and 312) principles and requirements and International Conference on Harmonization guidelines (ICH E6).Sampling. PK blood samples for midazolam (obtained once, 6 ml)were collected prior to dosing and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, and24 h after each 2-mg oral dose of midazolam. PK blood samples for PA824 (obtained once, 6 ml) were collected predose on days 12 and 13 ofconsecutive PA-824 dosing and predose on the day 14 prior to coadministration.Bioanalytical methods. Blood samples were collected and centrifuged, and plasma was separated and stored at 20C. Plasma sampleswere analyzed for PA-824, midazolam, and the midazolam metabolite1-hydroxy midazolam using separately validated liquid chromatographymass spectrometry methods developed at Covance Laboratories, Inc.PA-824 and the internal standard, triazolam (added during sampleprocessing), were extracted from human plasma samples using liquidliquid extraction. After evaporation under nitrogen, the residue was re-	6865	15649
24	1	2	16	1	1	CENTER FOR DRUG EVALUATION AND  RESEARCHAPPLICA TION NUMBER:22-34 1MEDICAL S)	0	76
25	1	2	16	1	2	Addendum to Clinical Safety ReviewNDA 22341 (Victoza?, liraglutide injection)Submission Received from Applicant 26 Oct 2009Additional Calcitonin Shift TablesKaren Murry Mahoney, MD, Clinical ReviewerDivision of Metabolism and Endocrinology Products27 Oct 2009On 26 Oct 2009, Novo Nordisk, the applicant for NDA 22341, submitted additionalcalcitonin analyses in response to a request from Dr. Hylton offe, Team Leader forDiabetes Products Team I in the Division of Metabolism and Endocrinology Products.These analyses include the ?ve major Phase 3 diabetes trials which were included in theoriginal NDA submission, and add data from two Phase 2 Japanese diabetes trials,preliminary data from a diabetes treatment trial versus exenatide, and preliminary datafrom a Phase 2 obesity treatment trial. Similarly to previous data presentations, thesubmitted shift tables show that the highest percentage of upward shifters occurs in the1.8 mg liraglutide dose group, which is the highest proposed dose for marketing.The following table summarizes the submitted data.Summary of Speci?ed Upward Shifts in Calcitonin Phase 3 DiabetesTrials, Two Phase 2 Japanese Diabetes Trials, Preliminary Data from DiabetesTreatment Trial vs Exenatide, and Preliminary Data from Phase 2 Obesity TrialLGT0Percentage of patients with shift from below theupper limit of normal to persistently? above theupper limit of normal, from baseline to Weeks20/24/26/2821.11.01.90.81.1Rate per 1000 patient-years of patients with shiftfrom below the upper limit of normal topersistently? above the upper limit of normal,from baseline to Weeks 20/24/26/28?23.222.941.820.723.722.7Percentage of patients with shift from below theupper limit of normal to persistently? above theupper limit of normal, from baseline to Week 523(voluntary unblinded extension data included)0.61.31.00.7Rate per 1000 patient-years of patients with shiftfrom below the upper limit of normal topersistently? above the upper limit of normal,from baseline to Week 523 (voluntary unblindedextension data included)6.914.110.98.1Percentage of patients with shift from below theupper limit of normal to persistently? above theupper limit of normal, from baseline to Week 1044(all voluntary unblinded extension data)0.30.60.60.5	77	2335
35	1	2	16	1	12	. . . .Linked Applications Sponsor Name Drug Name/SubjectNDA 22341 ORIG 1 VICTOZA (LIRAGLUTIDE)This is a representation of an electronic record that was signeda electronically and this page is the manifestation of the electronicsignature.IslKAREN MAHONEY08/14/2009HYLTON JOFFE	22753	23028
36	1	2	16	1	13	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)CLINICAL REVIEWApplication Type NDASubmission Number 022341Submission Code N000Letter Date 23 May 08Stamp Date 23 May 08PDUFA Goal Date 23 Mar 09ReViewer~Name Lisa B. Yanoff, M.D.Review Completion Date 22 Jul 09Established Name Liraglutide(Proposed) Trade Name VietozaTherapeutic Class GLP-1 analogueApplicant Novo NordiskPriority Designation Formulation Subcutaneous injectionDosing Regimen 0.6, 1.2, and 1.8 mg dailyIndication Treatment of type 2 diabetesIntended Population Adults	23029	23595
27	1	2	16	1	4	Summary of Speci?ed Upward Shifts in Calcitonin Phase 3 DiabetesTrials, Two Phase 2 Japanese Diabetes Trials, Preliminary Data from DiabetesTreatment Trial vs Exenatide, and Preliminary Data from Phase 2 Obesity TrialLGT LGT LGT PBO AC TC0.6 1.2 1.8Source: Applicant?s Table 2-3, NDA 22341 submission stamp date 26 Oct 2009, serial'pg 9; and Table 2-4, serial pg 10.1 ?Persistently? is de?ned as having elevation in all calcitonin values obtained after baseline, up to the speci?ed week2 Includes measurements at Weeks 20/24/26/28 for the Phase 3 diabetes trials, two Phase 2 Japanese diabetes trials,preliminary data from a Phase 2 obesity trial and preliminary data from a diabetes trial vs exenatide3 Includes data from a Phase 3 monotherapy diabetes trial; and voluntary unblinded extension data from a Phase 3 diabetestrial as add-on to metformin, two Phase 2 Japanese diabetes trials and preliminary data from a Phase 2 obesity trial. Thesedata should be interpreted with caution, because the drop-out rate in extensions was high and differed between treatmentgroups.4 Voluntary unblinded extension data from a Phase 3 monotherapy diabetes trial and a Phase 3 diabetes trial as add-on tometformin. These data should be interpreted with caution, because the drop-out rate in extensions was high and differedbetween treatment groups.In a previous submission (25 Jun 2009), the applicant had stated that there were twoliraglutide-treated patients (both treated with 1.8 mg/day) who began with a serumcalcitonin <50 ng/L and shifted to >50 ng/L during study, and one comparator-treatedpatient. In the 26 Oct 2009, submission, the applicant states that there was only oneliraglutide-treated patient (1.8 mg group) who exhibited this shift, and no comparator-treated patients. The 26 Oct 2009 submission did not discuss this discrepancy. Inresponse (1 1 Nov 2009) to an inquiry regarding the difference, the applicant stated thatthe 25 Jun 2009 submission ?contained an error?.Data provided for Weeks 52 and 104 should be interpreted with caution; most data at 52weeks, and all data at 104 weeks, are from voluntary unblinded extensions. The drop-outrate in extensions was high, and differed between treatment groups, as discussed in theoriginal clinical safety review (DARRTS 8 Aug 2009). The applicant has not submittedstudy reports for the diabetes trial versus exenatide and for the Phase 2 obesity trial, and-therefore these data_are preliminary. As in previous submissions, the mean and medianchanges in serum calcitonin are not large. Also as in previous submissions, the highestpercentage of upward shifters occurs in the 1.8 mg liraglutide dose group, which is thehighest proposed dose for marketing.As discussed in the original clinical safety review, the clinical safety reviewer remainsconcerned about the strong animal carcinogenicity signal for liraglutide, and feels that theduration of blinded controlled human study has been inadequate to recommend marketingat this time. The clinical reviewer continues to recommend a long-term year) double-blinded controlled study, which would include multiple biomarkers to furthercharacterize liraglutide?s effect on C-cells, prior to marketing.	4127	7326
28	1	2	16	1	5	Application SubmissionType/Number Type/Number Submitter Name Product NameNDA-22341 ORIG-1 NOVO VICTOZA (LIRAGLUTIDE)INCThis is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.KAREN MAHONEY7/2009HYLTON JOFFE11/17/2009See CDTL memorandum and addendum	7327	7659
30	1	2	16	1	7	 22341: [ting/z//1?a7e, /Vow /Vomiirl; development program, resulting in an incomplete dataset, which may be biased toward falsenegative misclassi?cation, potentially resulting in regression of group values toward the mean inboth efficacy and safety analyses.Thus, we recommend further evaluation of immunogenicity in the postmarketing stage.Potentially, the Sponsor could add ADA sampling to the already planned 9000 subjectpostmarketing trial for long-term cardiovascular outcomes. Alternatively, the Sponsor canconduct a designated clinical trial to assess adverse events associated with immunogenicity.While antibody levels may be obtained on a subset of patients from the proposed large Phase IVtrial, we recommend sampling subjects following a liraglutide-free period of uniform andsuf?cient duration. This may necessitate periodic drug-withholding periods within the trialdesign in order to screen for ADA with maximal sensitivity. In addition, outcome measures inthis trial should also include assessments relevant to the potential immunopathogenicmechanisms of ADA, not only in tenns of reduced drug efficacy, but also in terms of organ-speci?c adverse events common to drug hypersensitivity reactions. BackgroundDrug Product. Liragltitide is an analogue of human glucagon-like-peptide-I (GLP-I), which iscurrently under review (NDA 22341; Sponsor: Novo Nordisk) for approval as a subcutaneouslyinjected, once daily treatment for diabetes mellitus type 2. Native GLP-1 is a gut incretinhormone that induces glucose-dependent insulin secretion but has an extremely short half?life,due to rapid degradation by endogenous dipeptidy1?peptidase-4. As an analogue to GLP-1,liraglutide has an altered structure, which makes it more resistant to degradation, resulting in alonger half-life. As the insulin?secreting activity of liraglutide is glucose-dependent, the drug isdesigned to facilitate glycemic control with a decreasedrisk of hypoglycemia due to insulinover?secretion, as compared to other insulin secretagogues, such as sulfonylurea drugs.Anti?drug Antibody Formation. A review of the information submitted by the Sponsor for NDA 22341 reveals that anti?drug antibodies (ADA) to liraglutide developed in nearly 10% ofstudy drug recipients in four major Phase clinical trials (Trials 1572, 1436, 1574, and 1697).Of these, approximately half displayed cross-reactivity with native GLP-1 of?liraglutide recipients tested), while roughly 10% (or 1-2% of the total sample) developedantibodies with neutralizing activity against liraglutide. In contrast to these liraglutide-speci?cADA, antibodies formed against another GLP-1 analogue, exenatide (the only FDA-approveddrug product in this class: NDA 21773), demonstrated no signi?cant treatment-emergent cross-reactivity with either or glucagon. Liraglutide-speci?c ADA were detected using aradioimmune assay in which patient serum was adsorbed with radiolabeled liraglutide and thenprotein-extracted with polyethylene glycol. In turn, the amount of precipitated radioactivity liraglutide bound?antibody) was expressed as a percentage of the total amount of radioactivityapplied to the sample and could be used to quantify the level of ADA present in the sample.Assessment of cross-reactivity was done by taking patient serum bound with radiolabeledliraglutide and subsequently incubating it with excess unlabeled native protein todetermine the extent to which GLP-1 competed off bound, radiolabeled liraglutide. Neutralizingactivity of ADA was assessed using a cell-based assay in which a luciferase reporter geneconstruct was created using the human receptor andtransfected into a rodent cell line.This construct allowed for the quanti?cation of cyclic adenosine monophosphate in	9891	13629
31	1	2	16	1	8	 2234./, /l/om response to binding by or an agonist, such as liraglutide. Thus, by incubating patientserum with a known amount of liraglutide prior to application to the cell line, the neutralizingactivity of ADA could be measured as a function of their inhibitory activity against liraglutide-induced production.-Antibody Detection Assays and Efficacy Assessment. A primary concem with the assaysdescribed above is that the ADA detection assay is directly inhibited by the presence of drugproduct in patient serum. In other words, sensitivity of the detection assay is markedlydiminished if sampling is done while levels of liraglutide are still detectable in the circulation,potentially resulting in false negative results. To address this concern, immunogenicity samplestested in the four Phase trials were drawn :5 days following the last liraglutide dose. Of note,however, nonclinical animal studies in cynomolgus monkeys suggested ADA may interfere withliraglutide clearance and result in prolonged drug exposure. Thus, it is unclear whether a 5-daydrug-free window is adequate to minimize misclassi?cation bias in terms of ADA detection.With regard to drug efficacy, the treatment effects of ADA formation, GLP-1 cross-reactivity,and neutralizing antibody formation on glycosylated hemoglobin (HgbAlc, long?termglycemic control) were evaluated in separate AN COVA models and found to have no statisticalimpact. Interestingly, mean HgbAlc levels were actually lower in the small group of patientswith detectable neutralizing ADA However, properly timed samples were not universallyavailable for all subjects in these studies. Moreover, the number of liraglutide-recipientsevaluated in the HgbA1 efficacy analysis (n=1174; ADA?positive=101) was lower than the totalnumber of liraglutide-recipients included in ADA detection studies (n=250l; ADA-positive=160). Thus, the immunogenicity dataset gleaned from the Phase trials appearsincomplete. Moreover, a propensity for false negative misclassi?cation in this dataset withregard to ADA detection would result in regression toward the mean in group values, potentiallymasking the impact of ADA on long-term drug effectiveness.Safety Assessment. Although no serious adverse events emerged in relation to ADA formation,a comparison of adverse event pro?les between subjects who developed anti?liraglutide antibodies versus seronegative patients revealed trends toward an increased incidence in severalcategories of adverse events in the ADA-positive group, including infections (especially of theupper and lower respiratory tract), injection site reactions, and musculoskeletal disorders (eg,arthralgias). Again, false negative misclassi?cations would tend to regress these group valuestoward the mean and obscure actual underlying differences in adverse event rates associated withADA formation. Thus, although there does not appear to be a significant safety signal amongsubjects who developed ADA, it remains concerning that over half of them displayed cross-reactivity to native . and that the assays used for ADA detection have questionableaccuracy, particularly at only 5 days following last study drug administration.RecommendationsDMEP requests input from our Division regarding the potential impact of ADA on the approvalof liraglutide and whether any additional studies should be required of the Sponsor to furtherexplore safety and/or clinical efficacy issues of this drug, with respect to imrnunogenicity.	13630	17097
32	1	2	16	1	9	 _/I/0/r/257% Given concerns over the accuracy of the ADA detection assay used, particularly as it relates todecreased sensitivity in the presence of circulating study drug, as well as the incomplete natureof the Phase clinical trial immunogenicity dataset as re?ected in both partial testing and apropensity for false negative misclassification, we recommend conducting a postmarketing trialof liraglutide recipients to more reliably delineate the incidence and implications of liraglutide-speci?c ADA fonnation. At present, the Sponsor plans to conduct a randomized, blinded,placebo-controlled postmarketing trial of 9000 type 2 diabetic patients at risk for cardiovascularcomplications, in order to discern the impact of study drug on cardiovascular related mortalityand morbidity. Clinical immunogenicity could be evaluated in a subset of liraglutide recipients inthis large Phase IV trial. Altematively, potential adverse events associated with immunogenicitycould be assessed in a separate postmarketing trial.We note that antibody sampling in the Phase trials after a 5-day drug-free period was onlydone after 6 months on study drug, while ADA formation against a similar drug product,exenatide, peaked at 6 weeks following drug initiation. Thus, assessing for antibody formationat more than one time point in the proposed study, including timepoints earlier than 6 months,would provide information on the kinetics of ADA formation. However, immunogenicitysampling must be suf?ciently separated in time from last study drug receipt, as supported by theSponsor?s pharmacokinetic data. Given that liraglutide is administered as a once daily injection,this may necessitate recurrent periods of drug withholding at pre-planned points in the study, inorder to draw immunogenicity samples only after a suf?cient drug-free period, after which, studydrug may be re?started for the purposes of completing the long-term cardiovascular outcomesstudy. A planned and uniformly executed immunogenicity evaluation would allow the Sponsorto robustly determine the effects of ADA formation on both the ef?cacy and safety pro?le ofliraglutide, as such a study would capture immunogenicity data on the full dataset.As mentioned in the Clinical Safety Review of NDA 22341, the DMEP Clinical Review Teamalready recommended that an assessment of immune-related adverse events also be done for theentire sample of the proposed cardiovascular outcomes postmarketing study, with which weconcur. To facilitate correlation of observed immune-related adverse events to seroconversion,antibody levels could be obtained from a subset of patients in this trial. The number of patientssampled should take into account the overall rate of seroconversion as well as the ratesof seroconversion for neutralizing antibodies and cross-reactive antibodies observed in the Phase clinical development program..Although no major safety signals emerged in this dataset related to IgE-mediated immediatehypersensitivity events other than urticaria, -ADA formation with documented cross-reactivity toan endogenous protein carries a potential risk not only of inactivation of the native protein, butalso of antigen?antibody complex mediated disease, including immune complex deposition,serum sickness, or other systemic hypersensitivity Thus, outcome measures in thispostmarketing immunogenicity study should also address these immune mechanisms, includingappropriate historical and physical assessments of target body systems cutaneous andmusculoskeletal manifestations), measuring complement levels as an index of immune complexmediated disease, and screening hepatic transaminases and renal function tests in the setting ofsystemic in?ammatory ?ndings.	17098	20813
33	1	2	16	1	10	Application SubmissionTypemumber Type/Number Submitter Name Product NameNDA-22341 ORIG-1 NORDISK VICTOZA (LIRAGLUTIDE)This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature.IslBRIAN PORTER1 1/03/2009SUSAN LIMB1 1/03/2009SALLY SEYMOURfor Badrul Chowdhury	20814	21152
34	1	2	16	1	11	ADDENDUM TO CLINICAL SAFETY REVIEWNDA 22341 (Victoza?, liraglutide injection)14 Aug 2009Karen Murry Mahoney, MD, FACEAt the time of the original clinical safety review of liraglutide (DARRTS 7 Aug 2009),information from the applicant was pending regarding a patient who was treated withliraglutide and who had an event of ?jaundice?. On 12 Aug 2009, the applicant submittedthe requested information. Patient 212002 was a 45 year old woman who had a nonserious event of ?jaundice?reported after 98 days of treatment with liraglutide. No further clinical history wasavailable. However, the applicant provided laboratory data which suggests that this eventwas not clinically significant and may not have represented actual jaundice. Prior to theevent, the patient had three separate sets of normal laboratory for serum alanineaminotransferase, aspartate aminotransferase and bilirubin, including normal values 4days prior to the reported date of the event. At that time, her bilirubin was 0.16 mg/dL(upper limit of normal 1.28). Subsequent to the date of the event of ?jaundice?, allbilirubin levels and transaminase levels were normal on all seven subsequent collectionsover an additional 20 months. The closest post?event values were from samples collected3 months after the event; there is a small possibility that the patient had an event ofjaundice that rapidly resolved. However, liraglutide had not been discontinued, anddespite its continued use for 20 months, multiple subsequent measures of liver functionwere normal, suggesting that liraglutide was not causative in a signi?cant liver injury.	21153	22752
38	1	2	16	1	15	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,34] (Submission 000)Victoza? (Iiraglutide)7.1.1 Deaths .. Error! Bookmark not de?ned.7.1.2 Other Serious Adverse Events .. Error! Bookmark not de?ned.7.1.3 Dropouts and Other Signi?cant Adverse Events .. Error! Bookmark not de?ned.7.1.4 Other Search Strategies .. Error! Bookmark not de?ned.7.1.5 Common Adverse Events .. Error! Bookmark not de?ned.7.1.6 Less Common Adverse Events .. Error! Bookmark not de?ned.7.1.7 Laboratory Findings .. Error! Bookmark not de?ned.7.1.8 Vital Signs .. Error! Bookmark not de?ned.7.1.9 Electrocardiograms (ECGS) .. Error! Bookmark not de?ned.7.1.10 Immunogenicity .. Error! Bookmark not de?ned.7.1.11 Human Carcinogenicity .. Error! Bookmark not de?ned.7.1.12 Special Safety Studies .. Error! Bookmark not defined.7.1.13 Withdrawal Phenomena and/or Abuse Potential .. Error! Bookmark not defined."7.1.14 Human Reproduction and Pregnancy Data .. Error! Bookmark not de?ned.7.1.15 Assessment of Effect on Growth .. Error! Bookmark not de?ned.7.1.16 Overdose Experience .. Error! Bookmark not de?ned.7.1.17 Postmarketing Experience .. Error! Bookmark not de?ned.7.2 ADEQUACY OF PATIENT EXPOSURE AND SAFETY ASSESSMENTS BOOKMARK NOT DEFINED.7.2.1 Description of Primary Clinical Data Sources (Populations Exposed and Extent of Exposure) Used toEvaluate Safety .. Error! Bookmark not de?ned.7.2.2 9 Description of Secondary Clinical Data Sources Used to Evaluate Safety ..Error! Bookmark notde?ned.7.2.3 Adequacy of Overall Clinical Experience .. Error! Bookmark not de?ned.7.2.4 Adequacy of Special Animal and/or In Vitro Testing .. Error! Bookmark not de?ned.7.2.5 Adequacy of Routine Clinical Testing .. Error! Bookmark not de?ned.7.2.6 Adequacy of Metabolic, Clearance, and Interaction Workup .. Error! Bookmark not de?ned.7.2.7 Adequacy of Evaluation for Potential Adverse Events for Any New Drug and Particularly for Drugsin the Class Represented by the New Drug; Recommendations for Further Study ..Error! Bookmark notde?ned. .7.2.8 Assessment of Quality and Completeness of Data .. Error! Bookmark not de?ned.7.2.9 Additional Submissions, Including Safety Update .. Error! Bookmark not de?ned.7 .3 SUMMARY OF SELECTED DRUG-RELATED ADVERSE EVENTS, IMPORTANT LIMITATIONS OF DATA, ANDCONCLUSIONS BOOKMARK NOT DEFINED.7.4 -GENERAL METHODOLOGY BOOKMARK NOT DEFINED.7.4.1 Pooling Data Across Studies to Estimate and Compare Incidence .. Error! Bookmark not de?ned.7.4.2 Explorations for Predictive Factors .. Error! Bookmark not de?ned.7.4.3 Causality Determination .. Error! Bookmark not de?ned.8 ADDITIONAL CLINICAL ISSUES  1218.1 DOSING REGIMEN AND ADMINISTRATION ..1218.2_ DRUG-DRUG INTERACTIONS .. 228.3 SPECIAL POPULATIONS ..1228.4 PEDIATRICS "1238.5 ADVISORY COMMITTEE MEETING ..1248.6 LITERATURE REVIEW .. 1248.7 POSTMARKETING RISK MANAGEMENT PLAN .. 1248 .3 OTHER RELEVANT MATERIALS .. 1249 OVERALL ASSESSMENT 1249.1 CONCLUSIONS ..1249.2 RECOMMENDATION ON REGULATORY ACTION ..1259.3 ON POSTMARKETING ACTIONS .. 125Risk Management Activity ..1259.3.2 Required Phase 4 Commitments ..125	25280	28346
39	1	2	16	1	16	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,34] (Submission O00)Victoza? (liraglutide)9.3.3 Other Phase 4 Requests ..1259.4 LABELING REVIEW .. 1259.5 COMMENTS TO APPLICANT .. 12510 APPENDICES 12610.1 REVIEW OF INDIVIDUAL STUDY REPORTS .. 12610.2 LINE-BY-LINE LABELING REVIEW ..128REFERENCES 129	28347	28638
40	1	2	16	1	17	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Vict0za? (liraglutide)1 EXECUTIVE SUMMARYThis document contains the clinical ef?cacy review for liraglutide, a human glucagon-likepeptide (GLP-1) analogue that has been developed as an adjunct to diet and exercise to improveglycemic control in patients with type 2 diabetes mellitus. The clinical safety review forliraglutide is contained in a separate document prepared by Dr. Karen Mahoney.1.1 Recommendation on Regulatory ActionThe recommendation for regulatory action in this review is based on a clinical review of efficacyonly. Safety is addressed by Dr. Mahoney in her Clinical Review of Safety. For acomprehensive risk/bene?t analysis that incorporates all known efficacy and safety informationthe reader is referred to the cross discipline team leader memo written by Dr. Joffe.Based on my review of clinical efficacy, 1 recommend approval of liraglutide from a clinicalefficacy perspective for the Sponsor?s proposed indication and at the doses proposed by theSponsor. There is substantial evidence of effectiveness from ?ve pivotal phase 3 trials(randomized, double?blind, and controlled (some placebo?controlled and some active-controlled)) that are considered by this reviewer to be ?adequate and well-controlled? and permitselection of an appropriate dosing regimen for the claimed indication in the general type 2diabetic population as well as in special populations including various demographic subgroups,and those with renal or hepatic impairment.1.2 Recommendation on Postmarketing ActionsFrom an efficacy standpoint there are no recommendations on postmarketing actions. Theefficacy of liraglutide has been well-established in the premarketing development program.1.2.1 Risk Management ActivityPlease see Dr. Mahoney?s clinical safety review1.2.2 Required Phase 4 CommitmentsRequired phase 4 commitments, if any, are discussed in Dr. Mahoney?s clinical safety review.5	28639	30588
41	1	2	16	1	18	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)1.2.3 Other Phase 4 RequestsNone1.3 Summary of Clinical Findings1.3.1 Brief Overview of Clinical ProgramLiraglutide (proposed trade name Victo2:a?) is a new molecular entity in the class of drugsknown as glucagon-like peptide (GLP-1) analogues that has been developed as an adjunct to dietand exercise to improve glycemic control in patients with type 2 diabetes mellitus. Liraglutide isadministered by subcutaneous injection. The clinical ef?cacy of liraglutide was studied in adult(age 2 18 years) type 2 diabetic patients in ?ve pivotal phase 3 trials. A total of 3978 patientswere exposed to treatment in the phase 3 efficacy trials (2501 to liraglutide, 524 to placebo, and953 to an active comparator). The overall number of patients in the safety database and extent ofexposure are discussed in Dr. Mahoney?s clinical safety review.1.3.2 Efficacy -The five major efficacy trials investigated the bene?ts of liraglutide as:Monotherapy liraglutide alone) (52 week trial)Add-on to one oral anti-diabetic drug (two 26 week trials)0 combination with metformin0 combination with a sulfonylurea (glimepiride)Add-on to two oral anti-diabetic drugs (two 26 week trials)0 combination with a thiazolidinedione (TZD) (rosiglitazone) and metformin0 combination with an sulfonylurea (glimepiride) and metforminThe three above-listed scenarios, monotherapy liraglutide alone), ?add-on? to one oral anti-diabetic drug combined with one other commonly used anti-diabetic drug), and ?add-on? totwo oral anti-diabetic drugs combined with two other commonly used anti-diabetic drugs)represent the manner in which liraglutide will be used in the diabetic population because diabetesis a progressive disease that typically requires the stepwise addition of anti-diabetic agents (andultimately insulin) to maintain adequate glycemic control. Therefore, this development programhas adequately studied liraglutide in a large proportion of the potential conditions of its use bydiabetic patients.	30589	32648
42	1	2	16	1	19	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)The ?ve pivotal studies were ?adequate and well-controlled.? This reviewer identi?ed no majorproblems with the ef?cacy studies including choice of endpoint, choice of control, adequacy ofblinding, conduct of the studies, and appropriateness of statistical analyses.The primary endpoint primary ef?cacy variable) for all pivotal studies was change frombaseline in hemoglobin Alc (HbAlc) at the end of the double?blind treatment period. HbAlcis an appropriate endpoint for reasons discussed in section The FDA draft guidanceentitled Guidance for Industry, Diabetes Mellitus: Developing Drugs and Therapeutic Biologicsfor Treatment and Preventioncm071624.pdf) states, ?For purposes of drug approval and labeling, ?nal demonstration ofef?cacy should be based on reduction in HbAlc HbAlc is the primary endpoint of choice,albeit a surrogate), which will support an indication of glycemic control.? .Important secondary endpoints included other glycemic control parameters such as change infasting plasma glucose at the end of the double?blind treatment period, as well as body weightchange at the end of the double?blind treatment period.The development program used both placebo and active comparators (meaning another anti-diabetic drug) for control groups in the phase 3 clinical trials. The monotherapy trial did nothave a placebo group, but rather compared liraglutide with glimepiride, a commonly usedsulfonylurea drug for the treatment of type 2 diabetes. The add-on trials used various activecomparators" that consisted of commonly used anti-diabetic therapies, mostly oral, but alsoinsulin glargine in one trial. The active comparators dosages generally were adequate forsupporting approval of liraglutide for the proposed indication. The full discussion of theadequacy of active comparator dosages is located in section 6 of this review.Blinding was accomplished in all of the phase 3 trials (note exception below) by incorporating aplacebo and/or a double-dummy technique in which active comparators were also blinded by theuse of indistinguishable ?dummy? comparators. (exception: the trial that compared liraglutide toinsulin glargine included open-label insulin glargine because of the need for titration of insulin).Conduct of the studies was appropriate with adherence to good clinical practices and fullfinancial disclosures reported. Statistical analyses were appropriately performed; these arediscussed more fully in the statistical review written by the Division of Biometrics.This reviewer concludes that liraglutide is effective for the proposed indication: as an adjunct todiet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Thisconclusion is based both on the quality of the phase 3 clinical trials conducted, as discussed inthe previous paragraphs in this section, as well as the clinical importance of the ?ndings of thosetrials. Based on the results of the trials, it can be concluded that liraglutide results in a clinicallyimportant placebo-corrected reduction in HbAlc of approximately 1% when used asmonotherapy, as add-on to one other oral anti-diabetic agent, or as add-on to two other oral anti-diabetic agents. This reviewer did not identify any major limitations of the available clinical data	32649	35993
44	1	2	16	1	21	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)1.3 .5 Drug-Drug InteractionsDrug-drug interactions are discussed in Dr. Mahoney?s review.1.3.6 Special PopulationsSubject DemographicsComparison of the ef?cacy of liraglutide in sub-populations including various demographic sub-groups as well as various diabetes disease characteristics was assessed based on data from the?ve phase 3 trials. These analyses did not suggest that there were any subsets of the populationthat demonstrated differences with respect to the effectiveness, as measured by HbA1c, amongtreatments. Therefore, from an ef?cacy standpoint, there were no meaningful differences inef?cacy across these demographic variables that would affect this product?s use.Renal and Hepatic ImpairmentBased on clinical pharmacology data (including one pharmacokinetic study in patients with renalimpairment and one pharmacokinetic study in patients with hepatic impairment) no doseadjustment is proposed for renal and hepatic impairment subjects (see section 5.1). The clinicalpharmacology reviewer concluded the same. The clinical ef?cacy review of the phase 3program also did not find evidence that dose adjustment should be recommended for patientswith mild renal and hepatic impairment. However, the phase 3 trials did not enroll many subjectswith moderate or severely impaired renal and hepatic function so there is limited ef?cacy data inthese populations.Pregnancy and LactationThe use of liraglutide during pregnancy and lactation is primarily a safety issue. Please see Dr.Mahoney?s review.	38685	40275
45	1	2	16	1	22	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)2 INTRODUCTION AND BACKGROUND2.1 Product InformationProduct descriptionLiraglutide is a once-dailyhuman GLP-1 analogue in which lysine at position 34 has been replaced with arginine, andpalmitic acid has been attached via a glutamoyl spacer to lysine at position 26.Established name and proposed trade nameThe established name of this product is liraglutide. The proposed trade name is Victoza?. Thistrade name has been approved by the Division of Medication Error Prevention and Analysis(DMEPA).Chemical classLiraglutide is a new molecular entity.Pharmacologic classLiraglutide belongs to the class of anti-diabetic agents known as glucagon-like peptide-l (GLP-l) analogues. Liraglutide is the second GLP-1 analogue to undergo FDA review as a New DrugApplication (NDA). The other GLP-1 analogue, exenatide (trade name Byetta?) was approvedas a treatment for type 2 diabetes mellitus in April, 2005 and is dosed subcutaneously twicedaily. A once weekly formulation of exenatide (exenatide LAR) is currently under review by theDivision of Metabolism and Endocrinologic Products (DMEP).Discussion of the pharmacologic class (source: sponsor?s clinical overview)Oral glucose leads to greater insulin secretion than intravenous glucose despite equivalentincreases in plasma glucose levels. This phenomenon, known as the incretin effect, is caused bygastrointestinal hormones released from the small intestine during a meal that stimulate insulinrelease from the pancreatic beta?cell in a glucose-dependent manner. GLP-1 and glucose-dependent insulinotropic polypeptide formerly known as gastric inhibitory peptide) are thetwo most important incretin hormones.Studies with native GLP-1 have shown ?that the primary mechanisms of action are to:- stimulate insulin secretion and decrease glucagon secretion in a physiological and glucosedependent manner- delay gastric emptying- reduce appetite10	40276	42248
46	1	2	16	1	23	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)An important and possibly primary defect in type 2 diabetes may be an impaired incretinfunction. Patients with type 2 diabetes have reduced levels and a well-preserved insulinresponse to GLP-1. In contrast, patients with type 2 diabetes have normal or increasedGIP levels, but an impaired insulin response to GIP. These properties make GLP-1 a suitablecandidate for the treatment of type 2 diabetes. However, due to the very short half-life of nativeGLP-I <1.5 minutes after i.v. administration) and short duration of action, the nativehormone is not a useful therapeutic agent. The short half-life is due to rapid degradation bydipeptidyl peptidase-IV (DPP-IV). Therefore, GLP-I analogues with a longer half-life are thetarget of drug development for the treatment of type 2 diabetes.Applicant?s proposed indication, dosing regimen, age groupThe sponsor proposes liraglutide as an adjunct to diet and exercise to improve glycemic controin adult patients with type 2 diabetes mellitus. The reader should be aware that DMEP is no longer issuing separate indications for speci?ccombinations of drugs and biologics for the? treatment of type 2 diabetes. The indication sectionin labeling is instead has been replaced by a single, simpli?ed indication (Drug is indicated asan adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetesmellitus). If the risk/bene?t pro?le is favorable when the drug is used in combination with otherdrugs, the study ?ndings and conclusions will be described in the Clinical Studies section of thelabel, effectively providing support for the combination use in clinical practice. If the drug is notstudied in combination with medications that are likely to be commonly co-administered with it in clinical practice, DMEP will require that the label contain a statementreflecting this limitation under ?Important Limitations of Use?.The applicant?s proposed dosing regimen is as follows:For all patients liraglutide treatment should be initiated with a dose of 0.6 mg injectedsubcutaneously for at least one week, after which the dose should be increased to 1.2 mg. Basedon clinical response and after at least one week at 1.2 mg, the dose can be increased to 1.8 mg toachieve maximum efficacy.2.2 Currently Available Treatment for IndicationT2DM can be treated with a combination of proper diet, exercise, and the following classes ofdrugs, alone or in combination:0 Insulin and insulin analogues0 Sulfonylureas0 Biguanides0 MeglitinidesThiazolidinediones (TZDS)Inhibitors of alpha-glucosidaseAnalogues of Glucagon-like Peptide analogues of human amylinll	42249	44942
47	1	2	16	1	24	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)0 Inhibitors of the enzyme dipeptidyl peptidase 40 Bile acid sequestrants 0 Dopamine agonistsDespite the number of drugs available for the treatment of T2DM, a substantial proportion ofpatients either remain under poor glycemic control or experience deterioration of glycemiccontrol after an initial period of successful treatment with an antidiabetic drug. Further, many ofthesedrug classes have limited usefulness in certain populations. For example, metfonnin is notfor use in patients with renal insuf?ciency and TZDs are not for use in many patients withcongestive heart failure. Insulin and insulin analogues as well as sulfonylureas are oftenassociated with hypoglycemia and weight gain. For these reasons, there is an unmet need fornew antidiabetic therapies.	44943	45793
550	1	4	42	1	1	A Randomized Comparison of TranscervicalFoley Catheter to Intravaginal Misoprostol forPreinduction Cervical RipeningANTHONY C. SCISCIONE, DO, LISA NGUYEN, MD, JAMES MANLEY, MD,MARJORIE POLLOCK, MSN, CRNP, BRIDGET MAAS, BSN, RNC, ANDGARRETT COLMORGEN, MDObjective: To compare the efcacy of intravaginal misoprostol tablets with transcervical Foley catheter for preinductioncervical ripening.Methods: Pregnant women who presented for induction oflabor with unfavorable cervices (Bishop score less than 6)were assigned randomly to intravaginal misoprostol (50 gtablet every 4 hours for a maximum of six doses) or 30-mLFoley catheter placed transcervically with maintenance oftraction.Results: Among 111 women, 53 were allocated to misoprostol and 58 to Foley bulb. Contractile abnormalities weremore frequent in the misoprostol group (20.4%) than theFoley group (0%) (P < .001). No statistically signicantdifferences were noted between groups in change in Bishopscore, preinduction cervical ripening times, and total induction times. There were no statistically signicant differencesin mode of delivery or adverse neonatal outcomes. Uterinerupture occurred in one woman with two previous cesareandeliveries in the misoprostol group.Conclusion: Intravaginal misoprostol and transcervicalFoley catheter are equivalent for cervical ripening. Uterinecontractile abnormalities and meconium passage are morecommon with misoprostol. (Obstet Gynecol 2001;97:6037. 2001 by The American College of Obstetricians andGynecologists.)Women who require labor induction often present withunfavorable cervices, which can lead to a prolongedand difcult induction. Preinduction cervical ripening isoften done to increase the likelihood of successful laborinduction.13 More than 15% of pregnant women havepreinduction cervical ripening and labor induction,4 sothere is keen interest in developing safer, more cost-From the Department of Obstetrics and Gynecology, Christiana CareHealth Services, Maternal-Fetal Medicine Division, Newark, Delaware.VOL. 97, NO. 4, APRIL 2001effective, and more efcient means of preinductionripening.Embrey and Mollison5 rst described using a transcervical Foley catheter for cervical ripening. Obed andAdewole6 documented its effectiveness by increasingBishop scores in women with unripe cervices. Sincethen, two studies found transcervical Foley catheters aseffective as various prostaglandin (PG) preparations forripening.7,8 In a larger, randomized trial, we found thatthe Foley catheter was more effective and more economical than PGE2 gel (Prepidil; Upjohn, Kalamazoo, MI)for providing preinduction ripening.9Misoprostol (Cytotec, Searle Pharmaceuticals, Chicago, IL) is a PGE1 analog, which is indicated forprevention of gastric ulcers in patients taking nonsteroidal anti-inammatory drugs. Margulies et al10 suggested that the drug might be effective for induction oflabor, so there has been great interest in the safety andefcacy of misoprostol, especially compared with PGE2agents for preinduction ripening. Multiple studies documented clinical advantages and cost benets of intravaginal misoprostol compared with PGE2 preparationsfor cervical ripening and induction of labor.4 However,some reports found a high rate of uterine contractileabnormalities.11,12We report the ndings of a trial in which we compared efcacy of misoprostol to transcervical Foleycatheter for preinduction cervical ripening.Materials and MethodsAfter approval from the institutional review board atChristiana Care Health Services, the study was conducted from July 1, 1997, to July 1, 1999. All deliverieswere at the Christiana Hospital, which serves as the0029-7844/01/$20.00PII S0029-7844(00)01186-8603	0	3711
551	1	4	42	1	2	tertiary referral center for the State of Delaware.Women who were admitted to the Labor and DeliverySuite for labor induction and met criteria for entrance inthe trial were invited to participate. Women referredfrom outside hospitals who met entrance criteria andwere being delivered at Christiana hospital also wereoffered entry. Inclusion criteria included singleton gestations in vertex presentation at greater than 28 weeksgestation. Women were monitored for at least 1 hourand had reactive nonstress tests without decelerations,and fewer than six contractions per hour. Each womanhad a Bishop score assigned by her attending physicianor an obstetrics and gynecology resident. Most of thetime the person who assigned Bishop scores was theperson doing preinduction cervical ripening and subsequent cervical examinations. Bishop score less than 6was necessary for entry.Exclusion criteria included rupture of membranes,antepartum bleeding, active genital herpes infection,fetal death, placenta previa, previous induction or preinduction agent during the pregnancy, and knownallergy to misoprostol. Women with histories of cesarean deliveries were not excluded.During computer-generated random allocation,methods of preinduction cervical ripening were placedconsecutively in opaque envelopes by a research nurseand sealed. After written consent was obtained, eachwoman was assigned to receive cervical ripening with atranscervical Foley catheter or misoprostol, by selectionof the next consecutive envelope.All women who presented for induction had routineadmission laboratory studies, (complete blood countand a type and screen) an intravenous (IV) infusionstarted, and continuous fetal heart rate monitoring andcontraction monitoring before randomization. Only IVoxytocin could be used for labor induction after completion of the protocol for preinduction cervical ripening. No uniform guidelines for oxytocin were enforced,but almost all physicians used our hospitals policy forit; beginning at 1 mIU and increasing 1 mIU every 15minutes. Women who had spontaneous labor during orafter preinduction ripening did not receive oxytocinunless a labor abnormality was diagnosed. Articialrupture of membranes was done as soon as clinicallyfeasible in both groups.After meeting entrance criteria, a 16F Foley catheterwith a 30-mL balloon was inserted into the endocervicalcanal under direct visualization during a sterile speculum examination for women assigned to transcervicalFoley catheters. Cleansing or sterilization of the vaginaor cervix was not done; however, every effort was madeto avoid contact with the vagina or ectocervix with thecatheter. The catheter was advanced into the endocervical canal. Once past the internal os, 30 mL of sterile604 Sciscione et alPreinduction Cervical Ripeningwater was injected into the balloon. Traction was applied by taping the end of the catheter to the medial sideof the womans knee or thigh. The catheter was checkedfor extrusion of the balloon from the cervix every 6hours by cervical examination. If the balloon had notbeen extruded, the catheter was adjusted to continuegentle traction. Each subject had external fetal monitoring for reactive nonstress tests after Foley catheterplacement. Then she was allowed to ambulate withintermittent fetal heart rate (FHR) assessment every 30minutes. Continuous external fetal monitoring wasdone every 2 hours for a reactive nonstress test or untilregular, strong contractions ensued. There was no predicted time limit for the Foley catheter to be extruded.Once the catheter was extruded from the cervix, IVoxytocin was begun.The group assigned misoprostol had 50 g of misoprostol (Cytotec, Searle Pharmaceuticals, Chicago, IL)placed intravaginally. Because 50-g tablets were notavailable, a 100-g tablet was cut in half by the pharmacist, using a pill cutter. A 50-g half tablet wasplaced in the posterior fornix of the vagina every 4hours for a maximum of six doses. Women in thatgroup had continuous external fetal monitoring. Subsequent doses were held if labor ensued or if uterinetachysystole, nonreassuring FHR, or rupture of membranes occurred. Oxytocin was begun 4 hours after thelast dose of misoprostol in women who did not havespontaneous labor (regular contractions with continuedcervical change), but had Bishop scores over 5, or ifwomen had received six doses of misoprostol.Our intent was to evaluate the success of preinduction cervical ripening, so the primary outcome measurewas change in Bishop score. For women in the Foleycatheter group, that was dened as the difference between initial cervical examination and examination atthe time of extrusion. In the misoprostol group, it wasthe difference between initial examination and Bishopscore assigned with the last dose of misoprostol. Todetect a change of at least 1 in the Bishop score andmaintain 80% power, with an alpha error of 0.05, usinga variance of 3.96 from our previous trial,9 50 womenwere needed in each group. Despite needing fewerwomen to nd a larger difference in Bishop scorechange, we felt that a difference of 1 was the least thatwould be clinically important.Secondary outcome measures included length of timefor preinduction cervical ripening (time from placementof preinduction method until extrusion of Foley catheter, or 1 hour after the last dose of misoprostol), totaltime for induction (time of placement of ripening agentuntil delivery), delivery route, uterine tachysystole (dened as six contractions in 10 minutes, in two consecutive 10-minute periods), side effects, subject comfort,Obstetrics & Gynecology	3712	9318
552	1	4	42	1	3	Table 1. Indication for InductionTable 3. Preinduction and Induction DataIndicationnPreeclampsiaOligohydramniosPost datesGrowth restrictionElectiveChronic hypertensionDiabetesMacrosomiaOtherTotal352816953339111and FHR disturbances. Uterine tachysystole or uterinehypertonus (contraction lasting longer than 3 minutes)with a nonreassuring FHR pattern was described ashyperstimulation syndrome. Also, women were askedto evaluate their discomfort on a scale from 0 to 10 onthe rst postpartum day, with zero being no discomfortand 10 as the most pain the woman had ever felt.Student t test, Mann Whitney U Test, Fisher exact test,and 2 were used when appropriate to compare groups.Values are stated as means with standard deviation(SD) unless otherwise noted. P  .05 was consideredstatistically signicant.ResultsOne hundred fourteen women were entered. Threewere excluded because of deviations from entry criteria:one received a Foley catheter and misoprostol, onereceived 100 g intravaginal misoprostol, and one hada transverse lie when oxytocin was begun. That left 111eligible subjects, 58 of whom were assigned to cathetersand 53 to misoprostol. Indications for induction of laborare presented in Table 1. Groups were similar in maternal age, gestational age at inclusion, gravidity, nulliparity, and Bishop score at entry (Table 2).Initially, women with histories of cesarean deliverieswere included in the trial. Three women were enrolledin the Foley group and two in the misoprostol group.After uterine rupture in a woman who had two previ-Foley group(n  58)Change in Bishop score(median)Preinduction cervicalripening time (h)(mean  SD)Total time for induction(h) (mean  SD)Misoprostol group(n  53)P3.02.0.488.1  6.69.0  4.9.1019.1  10.116.3  7.2.25ous cesarean deliveries who received misoprostol,women with previous uterine surgeries were excluded.13Women assigned to misoprostol received a mean of2  1.2 doses before beginning oxytocin or spontaneouslabor. Twenty-one subjects (39.6%) in the misoprostolgroup did not require oxytocin because of spontaneouslabor after misoprostol administration. No Foley catheter needed to be replaced after initial insertion and nopatients had spontaneous labor in that group. Maternalside effects were infrequent. The most frequent complaint in the Foley group was mild discomfort atinsertion. However, the amount of discomfort was mildto moderate in both groups, with the misoprostol groupat a median discomfort level of 5.0 and the Foley groupat a mean discomfort level of 4.0 (P  .87). There was nodifference in epidural analgesia between groups, with84% of the Foley group and 93% of the misoprostolgroup receiving epidural analgesia.There was no statistically signicant difference inmedian Bishop score at the end of preinduction cervicalripening or change in Bishop score between groups(Table 3). There was no difference in preinductioncervical ripening time or total time from the beginningof preinduction cervical ripening to delivery (Table 3).Also there was no difference in number of vaginaldeliveries or total deliveries within 24 hours in eachgroup (Table 4). The mode of delivery and infantweights were not statistically different between theTable 4. Labor and Delivery DataFoley group(n  58)Table 2. Demographic CharacteristicsFoley group(n  58)Maternal age (y)(mean  SD)Gravidity(mean  SD)Nulliparous (%)Baseline Bishopscore (median)Misoprostol group(n  53)P25.1  6.925.9  6.9.582.1  1.3.592.16  1.270.63.0VOL. 97, NO. 4, APRIL 200171.72.0.74.14Infant weight (g)2979.5  619.9Cesarean delivery (%)31.8Contractile0abnormalities (%)Meconium (%)5.2Delivery within 2454.5hours (%)Vaginal delivery within7324 hours (%)Sciscione et alMisoprostol group(n  53)P2969.8  743.737.820.4.94.46.00121.567.9.01.3184.23Preinduction Cervical Ripening605	9319	13140
553	1	4	42	1	4	groups (Table 4). The number of cesarean deliveries fornonreassuring fetal testing was higher in the misoprostol group, but the difference was not statistically significant (12% versus 24%; P  .09). However, there was astatistically signicant increase in meconium passage inthe misoprostol group. Mode of delivery and Bishopscore change, were not signicantly different betweennulliparous women and multiparous women betweengroups.Misoprostol-treated women were statistically morelikely to have uterine contractile abnormalities andmeconium passage (Table 4). Two women in the misoprostol group had nonreassuring FHR patterns associated with uterine contractile abnormalities (hyperstimulation syndrome) that necessitated cesareandeliveries. Both were treated with IV terbutaline todiminish uterine hypertonus without clinical effect.Both infants did well, despite one being depressed atdelivery.DiscussionWe found that a pharmacologic method of cervicalripening, misoprostol, and a mechanical method, theFoley catheter, were similarly effective and timely.However, signicantly higher rates of uterine tachysystole and meconium passage were found in the misoprostol group. There were two cases of uterine hyperstimulation syndrome in the misoprostol group, both ofwhich required immediate cesarean delivery.All pharmacologic methods of cervical ripening havebeen associated with uterine contractile abnormalities.Misoprostol is no exception.11 The rate of uterine contractile abnormalities has varied between 7.1 and36.7%.4 The Foley catheter has been associated with rareuterine contraction abnormalities.7 In our previous trial,we reported a rate of 11.8%,9 partially caused by ourliberal denition of hyperstimulation (six contractionsin 10 minutes), and the technique for placement of theFoley bulb in that trial. All cases of hyperstimulation inour previous report were transient and shortly afterplacement of the catheter, and did not produce FHRabnormalities. In the current study we used a smallerFoley catheter, abandoned the obturator to help placethe catheter, and no longer permitted a tenaculum tohold the cervix. No cases of hyperstimulation (using amore strict denition) or FHR abnormalities were notedin the Foley catheter arm in this trial. We were able toplace all Foley catheters without an obturator or atenaculum without difculty.We believe that methods that quantitate frequency ofcontractions are important for documentation and communication, but have little clinical value. Uterine contractile abnormalities are common in laboring women606 Sciscione et alPreinduction Cervical Ripeningand often attract little attention until they begin toadversely affect fetuses. We believe that the most compelling and clinically useful denition is a uterinecontraction abnormality that causes a nonreassuringFHR, which has been called hyperstimulation syndrome.12 In this trial and other reports, hyperstimulation syndrome was not associated with Foley catheteralone for ripening.7 In a recent review of the literature, the relative risk (RR) of hyperstimulation syndrome was 1.45 (95% condence interval [CI] 1.04, 2.04)with misoprostol,14 which might decrease with lowerdosages.4In a report by Perry et al,15 a Foley catheter withdinoprostone gel was compared with 25 g of intravaginal misoprostol every 4 hours, and there was signicant reduction in time to vaginal delivery and signicantly more women delivered within 24 hours in theFoley-dinoprostone group. Although not statisticallysignicant, the Foley-dinoprostone group had a lowerfrequency of hyperstimulation syndrome (3% versus11%; P  .091). There are several signicant differencesbetween our trial and the report by Perry et al. The rstand most obvious is the addition of dinoprostone gel tothe Foley catheter; second is the larger balloon used intheir trial (50 mL versus 30 mL); last is the smaller doseof misoprostol (25 g versus 50 g). Whether timeadvantages in the Perry et al trial were caused byaddition of dinoprostone gel, the larger balloon, thesmaller dose of misoprostol, or all three, is unclear.In a report by Abramovici et al,16 oral misoprostol at50 g every 4 hours to a maximum of 300 g wascompared with Foley catheter placement with concomitant IV oxytocin. In our trial we found no difference inmultiparous or nulliparous delivery within 24 hours,but they found a signicantly higher percentage ofmultiparous women who delivered within 24 hours andshorter induction times in the Foley catheter and oxytocin group. Unfortunately, they also found a very highrate of uterine hyperstimulation syndrome (13%) in theFoley and oxytocin group. However, there were nodifferences in rate of cesarean delivery or neonataloutcomes.Intravaginal misoprostol dosages have ranged from25-, 50-, or 100-g tablets every 4  6 hours to maximumdoses as high as 800 g.4 The 50-g dosing appears tobe associated with a signicantly higher incidence ofvaginal delivery within 24 hours and shorter inductionto delivery times, compared with the 25-g dose.11 The50-g dose was associated with a higher rate of uterinetachysystole (36.8% versus 17.4%; P  .003) comparedwith the 25-g dose. However, there does not appear tobe a difference in uterine hyperstimulation syndrome(7.3% in the 50-g group versus 5.8% in the 25-ggroup).11 In the same analysis, there was no greaterObstetrics & Gynecology	13141	18525
554	1	4	42	1	5	incidence of adverse neonatal outcomes, thus, the onlyadvantage to using 25 g appears to be a lower rate ofuterine tachysystole. We chose to use a 50-g dosingschedule because we believed it would provide the bestefcacy and safety.Based on our experience,13 we agreed with Wing4that caution should be exercised when using misoprostol in women with previous uterine surgeries. Untilmore experience with misoprostol in these women isaccrued, we have abandoned its use at our institution.Despite the randomized design of this trial, therewere limitations. It was not possible to mask physiciansto type of ripening method. A strict protocol for ripening should have minimized potential bias. The intent ofthe trial was to determine the efcacy of preinductioncervical ripening between methods, so no standardizedprotocol was devised or required for oxytocin administration or intrapartum management. Women withprevious cesarean deliveries were not admitted afterour adverse event, so the Foley in women with previouscesarean deliveries was not adequately studied. Wehave not had adverse events in women with previoussurgeries using the catheter. We currently offer cervicalripening with Foley catheter to women with previouscesarean deliveries.This report highlights the ability of the transcervicalFoley catheter to serve purely as a preinduction ripening agent, with women in this report requiring addedoxytocin to begin induction. Misoprostol, however, actsas a ripening agent and an induction agent, with closeto 40% of women entering labor without added oxytocin. Misoprostols dual role in induction offers the smalladvantage of less nursing time in preparation anddelivery of oxytocin. However, the associated increasein meconium passage and contractile abnormalities,combined with lack of signicant time benet or decrease in the cesarean delivery rate, minimize thatadvantage.References1. Bishop EH. Pelvic scoring for elective induction. Obstet Gynecol1964;24:266  8.2. Garret WJ. Prognostic signs of surgical induction of labor. Med JAust 1960;47:929 31.3. Brindley BA, Sokol RJ. Induction and augmentation of labor: Basisand methods for current practice. Obstet Gynecol Surv 1988;43:730 3.4. Wing DA. Labor induction with misoprostol. Am J Obstet Gynecol1999;181:339  45.5. Embrey MP, Mollison BC. The unfavorable cervix and the induction of labor using a cervical balloon. J Obstet Gynaecol BrCommonw 1967;74:44  8.VOL. 97, NO. 4, APRIL 20016. Obed JY, Adewole IF. The unfavorable cervix: Improving thebishop score with the Foleys catheter. West Afr J Med 1994;13:209 12.7. Sherman DJ, Frenkel E, Tovbin J, Arieli S, Caspi E, Bukovsky I.Ripening of the unfavorable cervix with extra-amniotic catheterballoon: Clinical experience and review. Obstet Gynecol Surv1996;51:6217.8. Thomas IL, Chenoweth JN, Tronc GN, Johnson IR. Preparation forinduction of labor of the unfavorable cervix with foley cathetercompared with vaginal prostaglandin. Aust N Z J Obstet Gynaecol1986;26:30 5.9. Sciscione A, McCullough H, Shlossman P, Manley J, Pollock M,Colmorgen G. A prospective, randomized comparison of Foleycatheter insertion versus intracervical prostaglandin E2 gel forpreinduction cervical ripening. Am J Obstet Gynecol 1999;180:559.10. Margulies M, Perez GC, Voto LS. Misoprostol to induce labor.Lancet 1992;339:64.11. Sanchez-Ramos L, Kaunitz AM, Wears RL, Delke I, Gaudier FL.Misoprostol for cervical ripening and labor induction: A metaanalysis. Obstet Gynecol 1997;89:633 42.12. Wing DA, Paul RH. A comparison of differing dosing regimens ofvaginally administered misoprostol for preinduction cervical ripening and labor induction. Am J Obstet Gynecol 1996;175:158  64.13. Sciscione A, Nguyen L, Manley J, Shlossman P, Colmorgen G.Uterine rupture during preinduction cervical ripening with misoprostol in a patient with a previous cesarean delivery. Aust NZ JObstet Gynaecol 1998;38:12.14. Hofmeyr GJ, Gulmezoglu AM, Alrevic Z. Misoprostol for induction of labour: A systematic review. Br J Obstet Gynaecol 1999;106:798  803.15. Perry KG, Larmon JE, May WL, Robinette LG, Martin RW. Cervicalripening: A randomized comparison between intravaginal misoprostol and an intracervical balloon catheter combined with intravaginal dinoprostone. Am J Obstet Gynecol 1998;178:1333 40.16. Abramovici D, Goldwasser S, Mabie BC, Mercer BM, GoldwasserR, Sibai BM. A randomized comparison of oral misoprostol versusFoley catheter and oxytocin for induction of labor at term. Am JObstet Gynecol 1999;181:1108 12.Address reprint requests to:Anthony C. Sciscione, DODepartment of Obstetrics and GynecologyMaternal Fetal Medicine DivisionChristiana Care Health Services4755 Ogletown-Stanton RoadNewark, DE 19718E-mail: asciscione@christianacare.orgReceived September 6, 2000.Received in revised form November 9, 2000.Accepted November 29, 2000.Copyright  2001 by The American College of Obstetricians andGynecologists. Published by Elsevier Science Inc.Sciscione et alPreinduction Cervical Ripening607	18526	23537
48	1	2	16	1	25	3m=5E3a _o;UHu>> new wc?tomoa Bmo_o>O Amoomv cm?wz Amoomv :o>EEm Eat nuEmu< ?venomoEaonEon_ E2Eun_u_u-umou2w ED 6 umm??oa >759 7.50 5Bo e35: rm.? I 255% 2: co muzoauu concave. .8 Eats 2: he :3 H302 8: 3 ummu?un ueuunxm - Esau: Em_o>> Ecomw oEEmn_oD?ooho 2.6 5 Eoohco 2% oEEo>mm Eon ozmm=o:om2 E?oobmoga msocomo 5 mo am: B3oq w.o-m.o $0 cc :50 EE__m?_m oocoaoaxo REES Ema? cotom 2: m?mco?oa >H-mn5 mst??Euobmo9E.B ESE woowmooscom85:25 FEES ma ..oBo no. Boo . . sou?oom ._om8=_m osmo mam.V. . m8. zmap 5. m??ao oc?m esem oa?sxm F30Bantu 25 HO E0235 3; . 3 umm22 85:25 3:85 mommouoom$2 390% o.Tm.o boumm m8oEoE oc::__EEm mosmo?cm Bantu ova 5 . comosom sommoam . . .wciow >mEmoE: M5380 m>>o_mozmsomxm sos?sv team mg; usmom?mzoom mE::wBmZ w?mou 338:5 82.5. . . . . .mcao om_oEm32m omon.ao< oEo._n_ Em: wo>oE:: . . musmms 32:? can o_om:E 83% 382w mBm_:E:m 5:65. mcosoom? omou wow_.o3ou~H* Tm b_>Emcom mommob? o::oNNmg:_m_monm ao?coxz uimcomxo? mg oswow??oum 2:35 . 02: 2:20235 .55: m_moEom oso? Bum o. Ewzm? wommos? ova 5 . EUSUOH omoo? own on mommououm3 9:25250 8.5 omnohoou :28: .3 mo??mxm mm?o MP5u?uomxm .m=:=oE m?oamz. 093 moEa.::= co>o.Eam oEa.H	45794	46938
50	1	2	16	1	27	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)Safety exposures and monitoringThe Division agreed upon the proposed number of patient exposures. Please see Dr. Mahoney?s reviewfor a discussion of safety exposures included in the NDA submission. Agreements were made on theproposal for antibody assessment and collection of adverse events. The plan for c-cell relatedmonitoring in the phase 3 trials that are at least 6 months in duration was deemed acceptable by theDivision.2.5.2 Type guidance (teleconference, 20 Sep?O5)The purpose of this meeting was to discuss initiation of the Phase 3 program for liraglutide in thecontext of concerns stemming from a 26 Feb 04 teleconference between the sponsor and the Divisionreporting the preliminary ?ndings from the 2-year rat carcinogenicity studies. The sponsor stated that 2-year rat toxicity studies indicated an increased frequency of C-cell tumors of the thyroid. The discussionpoints included questions related to proceeding with phase 3 studies in light of these ?ndings. Basedupon the limited clinical information that was available at that time, the following agreements werereached0 The Division agreed it was acceptable to proceed cautiously into Phase 3a studies without calcitoninmonitoring at 12 week intervals after unblinding of the data from the 14-week, European, Phase 2Study NN221 1-1571, provided that it yielded additional evidence of a lack of liraglutide effect oncalcitonin release.0 The Division stated that the available information was not yet sufficient to rule out the potentialhuman relevance of the rodent C-cell ?ndings. The sponsor was advised that unstimulated calcitoninmeasurement is not particularly sensitive to detect C-cell hyperplasia in humans. The Division urgedthe sponsor to perform a pentagastrin stimulated calcitonin test on a subset of subjects in Phase 3a atbaseline and at the end of the study. A0 The Division concurred that the exclusion of patients with elevated calcitonin or family history ofthyroid disease is not warranted.A ?nal discussion point was that the Division agreed upon the general design of an additional Phase 3study trial 1697 (see section 6.2.3.8.4_for a description of this trial).2.5.3 meeting (face to face, 5 Feb 08)Non-clinicalA major discussion point was the rodent thyroid C-cell ?nding. The Sponsor stated that it washypothesized that a non~genotoxic induction of the C-cell tumors occurs in rodents via a mechanism notrelevant for humans and asked if the Agency agreed that this hypothesis had been substantiated. TheDivision stated that the proposed mechanism of action of rodent C-cell thyroid tumors and their clinicalrelevance was a review issue and agreement could not be given at that time. A similar discussionoccurred with respect to calcitonin measurements, i.e. the Division stated that calcitonin measurementswould be a review issue and did not agree that it could be de?nitively concluded at that time thattreatment with liraglutide does not result in a clinically meaningful change in calcitonin secretion inhumans.15	49210	52305
73	1	2	16	1	50	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Total cholesterol (TC)Very low-density lipoprotein?cholesterol (VLDL-C)Triglycerides (TG)High-density lipoprotein-cholesterol (HDL-C)Apolipoprotein (ApoB)Liraglutide antibodies: measured at several time points in study 1573.6.1.2.3 Overview of Statistical MethodsSee Dr. Derr?s statistical review for more discussion.Randomization: At the time of randomization subjects were strati?ed with respect to their previousOAD (monotherapy or combination therapy) or diet/exercise therapy.Efficacy Assessments:The efficacy assessments for all key phase 3 trials were mostly based on the Intent?to-Treat (ITT)population, which consisted of allpatients who were randomized and exposed to at least one dose oftrial productFor these trials, the Sponsor also de?ned a per-protocol population (PP) consisting of patients in theprimary ITT population who completed the trial and had no major protocol deviations. The PPpopulation was used for supportive analyses.For all five therapeutic con?rmatory trials, the HbAlc change from baseline was analyzed using ananalysis of covariance (ANCOVA) model with treatment, country and previous anti-diabetic treatmentas ?xed effects and baseline HbAlc value as covariate. The primary endpoint was analyzed for both theITT analysis set and the PP analysis set. For tests of superiority, the ITT analysis set was considered theprimary test and the PP supportive, whereas for tests of noninferiority (noninferiority margin of the two analysis sets were considered of equal importance. In analyses based on the ITT analysis set,post-baseline missing values were replaced using last observation carried forward (LOCF). Furthermore,a sensitivity analysis without imputation was also done.All five therapeutic con?rmatory trials employed a hierarchical testing procedure in order to protect theoverall type I error rate (Figure 6.1 below).Figure 6.1 Hierarchical Testing Procedure for Phase 3 Studies38	101262	103266
53	1	2	16	1	30	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)oral anti-diabetic drug placebo) trials, providing long-term efficacy and safety data. Trial 1697 includedan open-label comparator arm (insulin glargine glimepiride metformin). The double-blind periodwas 26 weeks in the combination trials and 52 weeks in the monotherapy trial (Trial 1573). Two of thetherapeutic confirmatory trials have ongoing open-label extension periods (Trial 1573: 48 monthsextension and Trial 1572: 18 months extension), which provide additional long-term safety data.There were also 6 ongoing trials at the time of NDA submission for which no full study reports weresubmitted. These include trials 1796, 1797, 1799, 1700 and 1701 (Japanese phase 3a trials) andNN8022-1807 (obesity extension trial). These trials are not listed in the tables below. However, safetyinformation for some of these trials was submitted at the 120-day safety update per Dr. Mahoney, thesafety reviewer.4.2 Tables of Clinical StudiesTables of Biopharmaceutics and Clinical Pharmacology StudiesTable 4.1. Biopharmaceutic StudiesStudy . . . Study Treatment, Route, Duration ofNumber Objectives Study Deslgn Population Regimen, Dosage Therapy RelevanceRandomized, Healthy Single Sic" dosias 0? . Shciwed. . . . mg liraglutide . bloequlvalence1331 bloequivalence volunteers . Single dosecI_OSS_0ver formulation 2 and between phase 2formulation 3 and 3 formulationRandomized, Healthy Smgle doses0.75 mg liraglutide . Bioequivalence at1636 bloequlvalence volunteers . Single dose . .formulat1on 3 at pH7.7, differing pH valuescross-over 7.9, and 8.15Single s.c. doses of0.72 mg liraglutideRandomized, Healthy formulation 4 and 1692 bioequivalence double-blind, volunteers formulation 4 with Single dose betwec?n hase 3across?over ?nal manufacturing and 3b fognula?onprocess for drugsubstanceRandomized, Healthy Single doses. of . . . . 0.71 mg llraglutlde . btoequwalence1693 bloequlvalence double-blind, volunteers . Single doseformulation 3 and betweencross-over . .formulation 4 formulations18	56746	58820
54	1	2	16	1	31	ClinicalReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Table 4.2. Pharmacokinetic (PK) and Pharmacodynamic (PD) StudiesStudy . . . . Treatment, Route, Duration ofNumber Objectives Study Design Study Population Regimen, Dosage Therapy RelevanceRandomized, Healthy volunteers Three do.SeS of Showlxi1745 PK and Opemlabel N221 0.6 mg liraglutide in the Single dose comparability atbioavailability over? differegtuisigjectionRandomized,double-blind, Healthy volunteers Eight single s.c. doses of Bioavailability ofH49 PK, PD, and placebo- N272 1.25, 2.5, 5, 10, 12.5, 15, sin 16 dose s.c. administrationbioavailability controlled, 17.5 or 20 pg/kg vs. i.v. in healthyparallel-group, liraglutide subj ectsdose-escalationHealthy volunteers Single s.c. dose of 0.75 .1699 PK Open-label mg radio-labeled Single dose liraglutideRandomlz?d? Initial single s.c. dose andsubse uent once dail placebo- Healthy volunteers goses with dosey Single dose1189 PK and PD controlled, and type 2 . followed by 7 Dose ?nding. . escalation of 1.25, 5, 7.5,parallel-group, diabetics 10 and 12 5 daysdose-escalation pg/kg liraglu?detrial. Healthy volunteers . Pharmacokinetics1327 PK Young (N215) and Smgla mg Single dose in young vs.elderly elderlyHealthy volunteers- and type 2 diabetics1329 PK Open-label, with normal renal Single  dose ?of 0.75 Single dose _Pharinacokirieticsparallel-group function or renal mg liraglutide in renal impairmentimpairmentHealthy volunteersand type 2 diabetics . .Open-label, with normal hepatic Single s.c. dose of 0.75 . 1328 PK . . . . Single dose in hepaticparallel-group function or hepatic mg liraglutide im airmemimpairment Randomized,double?b1ind,placebo- Liraglutide: Once dailyThorough controlled, cross- Healthy volunteers s.c. doses of 1.8 mg .1644 study over trial followed Moxifloxacin: Single p.o. 7 weeks Cardiac Safetyby open-label dose of 400 mgmoxi?oxacin(positive control)Table continued on next page19	58821	60779
55	1	2	16	1	32	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)Randomized,double-blind,Liraglutide: Once dailys.c. doses of 1.8 mgEvaluate the effectsbalanced Glime Hide Once dail on appetite in patients,incomplete Latin Type 2 diabetics with type 2 diabetes1589 PD . . p.o. dose of 1-4 mg 4 weeks . .square design trial 1 . of l1rag1ut1de vs.with placebo and aracie aglg. giils glimepiride oractive control fnleg p'O? placebo(glimepiride) 053 0 Randomized, Effect of liraglutide- double-blind, 2 diabetics Once daily s.c. doses of on hormonal1332 PK and PD placebo? yp N313 liraglutide 6 pg/kg of 9-10 days pro?les, gastriccontrolled, cross- liraglutide emptying, andover gluconeogenesisRandomized, . .double-blind1219 PK and PD placebo? yeeN=ie1 ?ee e"f"1. Single dose e? Put?a me? controlled, cross? ?g 0 ?rag 1 Secre (11.03 typeOver 1a 1csRandomized, PK informationdouble-blind, Healthy volunteers Single 0 dose Of? 5 plus early PD2063 PK and PD placebo? and type 2 . . Single dose evidence usingpg/kg of liraglutidecontrolled, cross- diabetics over clamp procedureEffect of liraglutideRandomized, on hypoglycemicdouble-blind, . . . counter-regulation1224 PK and PD placebo? Type Zihabetlcs Smgle 5'0? ciose 0t.e7'5 Single dose during stepwisepg/kg of l1raglut1decontrolled, cross- hypoglycemicover clamp in type 2diabeticsRandomized,double-blind, .Within greep? 1th 1 011] s?e2?$a?e2Ss?' doses ref PK 1694 PK and PD placebo? ga V0 I. I  5 weeks ancontrolled, dose apanese) Wig] 1 6? 1 15:6. gl/Ir: escalation, wee 5 eps 0 multiple s.c. doseRandomized, .e??bIe'e??e= Health 1 i13SeSf?f5? PK 1551 PK and PD placebo? V0 unfers . or. ?g 0 . 3 weeks apanese an(Japanese) liraglutide, titrated in PD studycontrolled, dose kl 5 /kescalation trial wee 3 eps 0 ?g Randomized,double-blind, Single s.c. dose of 2.5, 5,1326 PK and PD placebo? Healthy Veleefeere 10dose PK (Japanese) PD studcontrolled, dose liraglutide escalation trialRandomized,double?-blind . . .1 Type 2 diabetics Once daily s.c. doses of 5 Japanese PK and1591 PK and PD cgiifz?gd (Japanese) or 10 pg/kg of liraglutide 14 days PD studyparallel-groupTable continued on next page20	60780	62942
620	1	4	50	1	10	DMD#60558occurrences for 10s. The EPI scan was run in positive mode at a scan range forproduct ions from m/z 50 to 650. The EPI scanning parameters are listed as follows:scan mode = profile; step size = 0.08 Da; and scan rate = 1000 Da/s, 5 ms pausebetween mass ranges.Synthesis of IMP-GSH Conjugates. IMP (2.5 mg) was dissolved in acetone(200 L) and mixed with saturated sodium bicarbonate solution (40 L) and oxone(6.5 mg). The mixture was stirred for 30 min at room temperature, followed byaddition of GSH (35mg). The mixture was further stirred for 1 h at room temperatureand was centrifuged. The supernatant was divided into two equal portions. One wasdirectly submitted to LC-MS/MS analysis. The other portion of the supernatant wasmixed with sodium borohydride (10 mg, NaBH4). The resulting mixture was gentlyvotexed for 5 min, followed by LC-MS/MS analysis.10	12526	13394
57	1	2	16	1	34	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Tables of Ef?cacy and Safety StudiesTable 4.4. Phase 2 studiesStudy Treatment Route DurationObjectives Study Design Study Population . of RelevanceNumber Regimen, Dosage TherapyRandomized Type 2 diabetics double-blind, (N42) d?Sed) Once dail d?. . s.c. oses ose in mgEf?cacy and Liraglutide 0.65 mg 1571 placebo- . . of 0.65, 1.25 or 1.9 mg 14 weeks study placebo-Safety Liraglutide 1 25 mg (N-42)controlled, . . liraglutide controlledparauebgmup Liraglutide 1.90 mg Placebo Type 2 diabetics Randomized, Liraglutide 0.045 (open-label Liraglutide 0.225 mg - Dose finding. . . 0.045, 0.225, 0.45,Efficacy and glimepiride), study placebo1310 . . 0.60, or 0.75 mg. 12 weeks .Safety parallel-group. Liraglutide 0.45 mg . . . and active. . . Glimepiride: OncePlacebo and active Liraglutide 0.60 mg . controlledcontrol Liraglutide 0 70 mg daily p'0' dose Of1'4(glimepiride) Glimepiride mgPlacebo Randomized, Liraglutide: Oncedouble-blind Type 2 diabetics daily s.c. doses of 2.0(metformin and Liraglutide mg (titrated in weeklyEf?cac and glimepiride open- Liraglutide+metformin steps of 0.5 mg) Early evidence1499 Safey label), parallel- Metformin: bid, p.o. 5 weeks of efficacy asty group. Metformin doses of 1 add-on therapyActive control Metformin+glimepiride Glimepiride: Once(metforinin and daily p.o. doses of 2-4glimepiride) mgRandomized? Obese type 2 diabeticsEfficacy and double?bl1nd, (N233) lnraglutidez Once E?icacy in1333 placebo- . . daily s.c. doses of 0.6 8 weeks .afety Liraglutide obese subjectscontrolled, mgPlacebo parallel groupObese, type 2 diabeticsRandomized . Liraglutide: OncedOuble_b]ind? Liraglutide 0.045 mg daily s.c. doses of Dose ?nding2072 Ef?cacy and ara?el_ mu? Liraglutide 0.225 mg 0.045, 0.225, 0.45, 12 weeks trial in obeseSafety wifh ac?vegconfml Liraglutide_0.45 mg 0.60, or 0.75 mg type 2(metformin) Liraglutide 0.60 mg Metformin: bid, diabeticsLiraglutige 0.75(mg 1 g/dayMet ormin d, . . .Type 2 diabetics (Japanese) Lh_aglutide_ Once Dose ?ndingEfficacy and =226 . trial in1334 placebo- . . daily s.c. doses of 0.1 14 weeksSafety Controlled Liraglutide Japanese typePlacebo 2 diabeticsparallel-groupTable continued on next page22	64560	66808
58	1	2	16	1	35	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Randomized, Healthy obese subjectsdOub]e_b1ind Liraglutide: Once Evaluation ofEf?cacy and (orlistat open_ Liraglutide 1.2 mg daily s.c. doses of 1.2, . safety of1807 Safe label) trial with Liraglutide 1.8 mg 1.8, 2.4, or 3.0 mg 20 weeks liraglutide atty placebo and active Liraglutide 2.4 mg Orlistat: tid, p.0. doses higher dosescon to} (or?statTHIS ON ORIGWN.23	66809	67255
60	1	2	16	1	37	Clinical ReviewLisa B. Yanoff, NDA 22,341 (Submission 000)Victoza? (liraglutide)Table 4.6. Extension studies- Treatment, .Study Objectives Stud): Route, Regimen, Duration of RelevanceNumber Design Population TherapyDosageRandomized, Type 2_d1abet1cs?. . open label, Liraglutide 1-2 mg Liraglutide. Onceexlinlion Ef?cacyand l?b Longtemsafewsafety . . Liraglutide 1.8 mg . . data1 with active Ghrnepiride. Once monthscontrol 1. . .d daily p.o. 8 mg/day(glimepiride) 337)Type 2 diabeticsLiraglutide 0.6 mgmetforrnin Liraglutide: Once-Randomized, daily s.c. doses ofopen?1abel, Liraglutide 1.2 mg 0.6, 1.2, or 1.8 mg inegfeilion Ef?cacv and ?Eb Long safety1 Safety with active Liraglutide 1.8 mg Metformin: p.o. bid, months datacontrol metfonnin 2 g/day(glimepiride) (N=l74) Glimepiride: p.o.Metformin (N=6l) daily 4 mg/dailyMetformin glimepiride83)4.3 Review StrategyFor the clinical efficacy review, the five phase 3 pivotal studies were emphasized. The phase 2 studieswere evaluated as supportive data in the clinical efficacy review. The long term extension studies werenot complete at the time of NDA submission, and therefore, were not reviewed to support efficacy.Literature was not relied on to support efficacy since liraglutide is a new molecular entity.Review strategy for the safety review is described in Dr. Mahoney?s review.4.4 Data Quality and IntegrityThe Division of Scienti?c Investigations (DSI) inspected two sites for this NDA.Andrew Lewin, M.D. was selected because he enrolled a relatively large number of subjects. At this site,for Protocol 1-1574, 34 subjects were screened, 26 subjects were enrolled, and eleven subjectscompleted the study. There were no deaths or serious adverse events reported. An audit of all 34subjects? records, including informed consent documents was conducted. No regulatory violations were25	69535	71375
611	1	4	50	1	1	DMD#60558Imperatorin is a mechanism-based inactivator of CYP2B6Liwei Zheng, Jiaojiao Cao, Dan Lu, Lin Ji, Ying Peng, and Jiang ZhengSchool of Pharmacy (L.Z., J.C., D.L., L.J., Y.P), Key Laboratory of Structure-BasedDrug Design & Discovery of Ministry of Education (J.Z.), Shenyang PharmaceuticalUniversity, Shenyang, Liaoning, 110016, P. R. China. Center for DevelopmentalTherapeutics (J.Z.), Seattle Childrens Research Institute, Division ofGastroenterology and Hepatology, Department of Pediatrics, University ofWashington School of Medicine, Seattle, WA 981011	0	563
613	1	4	50	1	3	DMD#60558AbstractImperatorin (IMP) is the major active ingredient in many common medicinalherbs. We examined the irreversible inhibitory effect of IMP on cytochrome P4502B6 (CYP2B6). IMP produced a time- and concentration-dependent inactivation ofCYP2B6. About 70% of activity of CYP2B6 was suppressed after its incubation with1.5 M IMP for 9 min. KI and kinact were found to be 0.498 M and 0.079 min-1,respectively.The loss of CYP2B6 activity required the presence of NADPH.Glutathione (GSH) and catalase/superoxide dismutase showed little protection againstthe IMP-induced enzyme inactivation. Ticlopidine, a substrate of CYP2B6, showedprotection of the enzyme against the inactivation induced by IMP. The estimatedpartition ratio of the inactivation was approximately 4. Additionally, a -ketoenalintermediate was identified in microsomal incubations with IMP. CYPs 1A2, 2A6,2B6, 2D6, 2E1, 3A4, and 3A5 were found to be involved in bioactivation of IMP. Inconclusion, IMP is a mechanism-based inactivator of CYP2B6. The formation of ketoenal intermediate may account for the enzyme inactivation.3	1891	2992
63	1	2	16	1	40	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Absorption, Distribution, Metabolism. and ExcretionLiraglutide has a pharmacokinetic and pharmacodynamic pro?le in humans suitable for once dailyadministration. Following subcutaneous administration, absorption is slow, reaching maximumconcentration 8-12 hours post dosing. Mean maximum concentration was 9.4 nmol/L for a singlesubcutaneous dose of 0.6 mg of liraglutide. At 1.8 mg, the average steady state concentrations reached33.7 nmol/L. Exposure was lower following s.c. administration of liraglutide in the thigh compared toabdomen, however, the observed difference in bioavailability between injection sites was minor and notconsidered by the sponsor to be of clinical relevance and therefore all injection sites (including the upperarm) could be used interchangeably in the pivotal clinical trials. The clinical pharmacology reviewerDr. Khurana agreed with this conclusion. The mean liraglutide apparent clearance was 0.7 L/hour andapparent volume of distribution was 12.5 after a single subcutaneous dose of 0.7 mg. Liraglutide waseliminated with an average half-life of 13 hours suggesting that liraglutide follows a flip-?oppharmacokinetics after subcutaneous administration - a situation where the half-life is observed to belonger after subcutaneous administration than that observed with the intravenous route. This suggeststhat the absorption process is slower than the elimination process. The dose-proportionality assessmentrevealed that liraglutide exposure increased in proportion to the increase in dose up to 20 ug/kg(equivalent to 1.8 mg dose based on 90 kg medianiweight in Phase 3 trials). There was slightaccumulation (RA of 1.4- 1.5) after multiple once daily subcutaneous administrations. The absolutebioavailability of liraglutide following subcutaneous administration is approximately 55% at 5 ug/kg. InTrial 1745, the relative bioavailability of liraglutide after s.c. administration in the thigh, upper arm andabdomen was estimated as relative ratios of for liraglutide after administration at the varioussites. The relative bioavailability of liraglutide after s.c. administration was estimated to 0.81 in thighversus abdomen, 0.90 in upper arm versus abdomen and 1.11 in upper arm versus thigh. Liraglutide isextensively bound to plasma protein 8In vitro and in vivo metabolism and excretion studies demonstrated that liraglutide is fully metabolizedin the body by sequential cleavage of the peptide with no excretion of liraglutide, i.e. neither renal norbiliary excretion are major routes of clearance, and only very limited excretion of closely relatedmetabolites in the feces or urine occurred in all tested animal species and humans. No unique humanmetabolite was found. Liraglutide was metabolized by dipeptidyl peptidase 4 (DPP-IV) and neutralendopeptidase (NEP) in similar positions in the peptide as observed for native .The potential inhibitory effect of liraglutide on the important human drug metabolizing cytochromeP4503 was examined in vitro using human liver microsomes. Data suggested that liraglutide atconcentrations up to 100 uM did not inhibit or only very inhibited all the human cytochromeP4505 studied (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4).Thus, liraglutide is not expected to cause any drug?drug interactions related to inhibition of cytochromeP4503. Dr. Khurana concurred with this assessment in his review.Pharmacokinetic effects of dru2~demographic and drug-disease interactionsBody weight and BMI28	77183	80749
64	1	2	16	1	41	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Several studies including the population pharmacokinetic analysis investigated the effect of body weightand BMI on the pharmacokinetics of liraglutide. Most of the evidence suggested that the effect of bodyweight on exposure was statistically signi?cant with higher body weight associated with lower exposure(inverse relationship). See ?gure 5.1 below. However, the effect of BMI was not signi?cant. Weightbut not BMI was found to be a signi?cant predictor of clearance of liraglutide. According to the clinicalpharmacology reviewer Dr. Khurana, although weight was found to affect clearance, the effect does notappear to be clinically relevant. Considering that steady state exposures, resulting from 1.2 and 1.8 mgdoses, were in the maximal response region of the exposure-relationship for the primary ef?cacyvariable (HbAlc) (see section 5.3), these differences are not clinically meaningful to warrant a dose-adjustment.Figure 5.1. Scatter plot of dose adjusted vs. body weight following single dose liraglutide inhealthy subjects (trials 1331, 1636, 1692, 1693, and 1745) 600?i} U13 3cs- 1.. i'raglnitide E363Weiglit (kg)Gender Females  MalesSex -The effect of sex on the pharmacokinetics of liraglutide was investigated in several trials. In a single-dose trial (1327) the mean liraglutide plasma pro?les indicated that female subjects had higher plasmaconcentrations than male subjects. The difference appeared to be primarily explained by difference inbody weight between females and males, i.e. no statistically signi?cant difference between males andfemales was demonstrated for for liraglutide when corrected for body weight. In addition, nostatistically signi?cant differences between females and males were observed for other pharmacokineticendpoints.29	80750	82599
66	1	2	16	1	43	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)5.2 PharmacodynamicsPlease refer to section 4.2 for tables of pharmacodynamic studies submitted with this NDA and to Dr.Khurana?s Clinical Pharmacology Review for details of the pharmacodynamic investigations. Results ofpharmacodynamic studies were consistent with the proposed mechanism of action of liraglutide. Thepharmacodynamic effects of liraglutide on glucodynamics were demonstrated. Liraglutideadministration resulted in increased insulin secretion in response to glucose. There was a signi?cantreduction in post?prandial glucose over a 24 hour period, slight increase in post-prandial insulin andsigni?cant post-prandial glucagon suppression. There was also a substantial increase in the first phaseinsulin secretion as assessed during a clamp. Please see Dr. Mahoney?s review (section 7.1.12) for a discussion of the thorough study.5.3 Exposure?Response RelationshipsAccording to the end-of?phase 2 meeting minutes, there was no specific determination of dose selectionfor the phase 3 program, although the Division did state that it found the phase 2 clinical pharmacologyprogram including doses tested during phase 2 acceptable. Therefore, the selection of the three dosestested in the phase 3 program, 0.6, 1.2 and 1.8 mg was determined by the sponsor based on results ofphase 2 studies, speci?cally trial 1571 (source: sponsor?s summary of clinical ef?cacy, section 1.3.6).Monotherapy studies were used to evaluate the exposure-response relationship of liraglutide. Becausethe maximal mean reduction in HbAlc from baseline with liraglutide is achieved by week 12, the 12week data for the phase 2 (study 1310 and 1571) and phase 3 (trial 1573) monotherapy studies could becompared. A graphic examination of these data (?gure 5.1 below) showed that the response with 0.6 mgwas in reasonable proximity to half the maximal response. Graphical analysis of pooled dose?responsedata from phase 2 and 3 studies showed that liraglutide treatment is associated with a dose dependentreduction in HbAlc from baseline. The maximal effect is achieved at 1.2 mg dose with a numericaladvantage of 1.8 mg over 1.2 mg with regards to maximal HbAlc reduction. The consistent ?ndings ofmultiple studies and the identi?cation of what appears to be the maximal effective dose for HbAlclowering ?attening of the curve) provide evidence for adequacy of the clinical assessment and thisreviewer agrees these three doses were a reasonable choice for the phase 3 clinical trials.According to Dr. Khurana?s review, in the phase 2 program, there was a considerable overlap in theexposures for 1.2 mg and 1.8 mg doses so the two doses could not be differentiated using a doseresponse analysis. In patients with body weight 160 kg the expected mean average concentration (Cavg)is 9 nmol/L and 13 nmol/L using 1.2 mg and 1.8 mg dose, respectively. However, the liraglutideconcentration response change from baseline HbAlc) suggests that maximum effect is achieved at orabove 7 nmol/L liraglutide concentration (see Dr. Khurana?s review Fig. 15a). This was consistent forthe Phase 3 data where the liraglutide concentrations ranged from 5 nmol/L to 45 nmol/L (see Dr.Khurana?s review Fig. 15b). Hence, Dr. Khurana inferred that the proposed doses provide adequateliraglutide exposures over the body weight range of 40-1 60 kg and the sponsor?s proposed ?xed dosetitration is acceptable from clinical pharmacology perspective.31	85257	88749
67	1	2	16	1	44	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)The clinical ef?cacy_ implications of these ?ndings are discussed further in section 8.1 Dosing Regimenand Administration.Figure 5.1: Dose dependent increase in effectiveness of liraglutide based on Mean(iSE) changefrom baseline in HbAlc from 12-week Phase 2 trial (1310), 14-week Phase 2 trial (1571) and 12-weekdata from the 52-week Phase 3 trial (1573).{la} a1 8' -0 Phase 2 A112-weselk (Data 319)Phase- 2 (e14-wreak "Data 571,)It Piiase 13 1 2-week Data 573)    Cihzange from Baseline in 3 :31w?m-3.2 19.? 0.6 13.3 '1 1.2" 1.3% 1.6 3.3 2Liragizstide; Dose (mgSource: Dr. Khurana?s Clinical Pharmacology Review, page 296 INTEGRATED REVIEW OF EFFICACY6.1 Indication 132	88750	89504
69	1	2	16	1	46	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Source: Summary of Clinical Ef?cacyTable 6.2Overview of Treatment Regimens in the Therapeutic Con?rmatory TrialsStudy Liraglutide Doses regimensTrial Weeks Lira 0.6 Lira 1.2 Lira 1.8 Placebo Comparator1573 52 Glimepiride 8 mgplacebo placebo placebo (lira)(glimepiride) (glimepiride)1572 26 Glimepiride 4 mg placebo placebo placebo placebo placebo (lira)(glimepiride) (glimepiride) (glimepiride) (glimepiride) metformin 2 metformin 2 metformin 2 metformin 2 metformin 2 1436 26 Rosi 4 mgplacebo (rosi) placebo (rosi) placebo (rosi) placebo (rosi) placebo (lira)glimepiride 4mg glimepiride 4 glimepiride 4 mg glimepiride 4 mg glimepiride 4 mgmg1574 26 - -metformin 2 metformin 2 metformin 2 rosi 8 mg rosi 8 mg rosi 8 mg1697 26 - - Insulin glargineglimepiride 4 mg glimepiride 4 mg glimepiride 4 mgmetformin 2 metformin 2 metformin 2 Doses of metformin and glimepiride could be adjusted in trial 1572 (metformin 1.5 2 trial 1436 (glimepiride 2 - 4 mg) and trial1697 (glimepiride 2 4 mg) Rosi rosiglitazone; Lira liraglutideSource: Summary of Clinical Efficacy, Table 1-1, section 2.7.36.1.2 General Discussion of EndpointsThis section provides an overview of the endpoints used in the ?ve phase 3 trials which were mostlysimilar among the trials. Aspects unique to individual trials are discussed in the sections relating tostudy design of each trial (starting with section 6.1.3.7).6.1.2.1 Primary Ef?cacy VariableThe primary efficacy variable for all key studies was change from baseline in HbAlc at the end ofthe double-blind treatment period. HbAlc is an appropriate endpoint becausea) HbAlc is a widely?accepted, objective, surrogate measure of glycemic control that correlateswell with mean blood glucose over the preceding 1-3 months (Nathan DM 1984).b) The National Glycohemoglobin Standardization Program (NGSP) has established andpromulgated standardized assays for HbAlc based on data from the Diabetes Control and34	91873	93881
80	1	2	16	1	57	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000) -Victoza? (liraglutide)   1573 FPG 240 mg/dL after week 8  i     FPG 220 mg/dL a?er week 28 '3  1572 FPG 239 mg/dL after week 8 Iftitratedl     Inmore than 2000 mg metformin.1436 FPG 239 mg/dL after week 8 If dosed with less than 2 mg/day or greaterthan 4 mg/day glimepiride.1574 FPG 240 mg/dL after week 8 Dose adjustment not speci?ed. Protocol statesthat ?subjects needed to be on metformin androsiglitazone throughout the study?1697 FPG 239 mg/dL after week 8 If being dosed with less than 1.8 mg liraglutidedaily (after uptitration), less than 2000 mgmetformin daily, or less than 2 mg or morethan 4 mg glimepiride daily6.1.3.7 Individual Trial Design - Liraglutide as monotherapy(Liraglutide 1.8) vs. (Liraglutide 1.2) vs. (Glimepiride)One monotherapy study was conducted in both patients with drug-naive diabetes (diet/exercise therapyonly) and patients on one oral antidiabetic medication at less than half the maximum dose for at leasttwo months.Trial 1573: Liraglutide Effect and Action in Diabetes (LEAD 3): Effect on Glycemic Control ofLiraglutide versus Glimepiride in Type 2 Diabetes Fifty-Two Week (with Fifty?Two Week Open-Label Extension) Double-Blind, Multicenter, Randomized, Parallel Study to Investigate Safety andEfficacy] Trial 1573Hypothesis: Liraglutide (1.8 mg once daily) will provide glycemic control [as measured by glycosylatedhemoglobin (HbA1c)] as good as that achieved with glimepiride (8 mg once daily) after 52 weeks insubjects with type 2 diabetes previously treated with diet/exercise or a single oral antidiabetic agent atnot more than the half-maximal recommended dose for at least two months.Reviewer?s comments: non-inferiority to glimepiride is a rational study design choice becauseglimepiride is an approved treatment for type 2 diabetes that has a mechanism of action as aninsulin secretagogue. The dose being used in this study is the maximum FDA approvedtherapeutic dose.This was a multicenter (117 centers in the United States and Mexico), randomized, double-blind,double-dummy, parallel, active-controlled study. A total of 746 patients with type 2 diabetes wererandomized in a 1:l:l ratio to:Liraglutide 1.2 mg so qdLiraglutide 1.8 mg sc qd45	118723	120976
71	1	2	16	1	48	Clinical ReviewLisa B. Yanoff, M.D.NDA 000)Victoza? (liraglutide)DXA scan for body composition (sub-study)Frequently sampled intravenous glucose tolerance test (FSIGT) (sub-study) 1573 onlyCalcium stimulation test (sub-study) 1573 only. Liraglutide antibodies 1573 onlyCT scan for visceral and subcutaneous adiposity as well as liver to spleen attenuation ratio forhepatic steatosis assessment 1572 onlyReviewer?s comment: not all of these secondary endpoints are included in this review becausethey are not used to support approval of the primary indication and are not intended to beincluded in the product label.Details of Secondary Endpoints:Key secondary endpoints:Body weight and Beta cell sparing effect:Change in body weight was a key secondary endpoint in all ?ve therapeutic con?rmatory trials, meaningthat the trials were powered to evaluate changes in both HbAlc and body weight. In addition, ?beta-cellsparing? effect (evaluated on the basis of HbAlc trend after nadir) was a key secondary endpoint in the52 week monotherapy Trial 1573. The slope of the HbAlc by time pro?le after nadir was analyzed andcompared between treatment arms in Trial 1573. This endpoint is assumed to re?ect the long-term effectof treatment on beta-cell function.Reviewer?s comment: HbAlc trend after nadir is not a validated method of assessing beta-cellsparing effect. Past practices of the Division have been to not allow information about beta cellsparing into the label.Other reviewed secondary endpoints:Fasting plasma glucose measured at visits with a colorimetric assay kit using the glucose oxidasemethod at the central laboratory.Self-measured 7- and 8-point plasma glucose pro?les and post-prandial glucose. Subjects were asked toperform two consecutive days of 8-point plasma glucose pro?les at the start, middle, and end of t1j_2?ll which consisted of measuring glucose at the time points: before each meal, 90 minutes after thestart of each meal, at bedtime and at 3 am 30 minutes. (note: regular calibration of glucose meterswas left up to study participants). Calculated endpoints were mean prandial increments of glucose andmean post-prandial glucose (PPG). Mean post-prandial glucose was determined by obtaining a patient-measured glucometer reading taken 90 minutes after the start of each meal and then by taking theaverage of the measurement after each meal. -Reviewer?s comment: It is more rigorous to obtain PPG data in a clinic setting after astandardized meal or oral glucose tolerance test. When measured at home there are issues ofcompliance did patients measure at the right times) and also less accuracy with glucometersvs. lab measures in a clinic. Therefore, this reviewer has concerns about including the PPG, as36	96263	98998
76	1	2	16	1	53	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Vict0za? (liraglutide)- 6.1.3.1 Dose SelectionFixed dose levels of liraglutide were used in all ?ve therapeutic con?rmatory trials. Doses could beadministered in the three sites (thigh, abdomen, and upper arm) interchangeably. Based on the phase 2dose range ?nding trial, Trial 1571, three dose levels of liraglutide were chosen for the program oftherapeutic con?rmatory trials: 0.6, 1.2, and 1.8 mg administered as a once-daily s.c. injection, but notall dose levels were evaluated in every trial. In trial 1310, a 12-week, multi-center, multi-national,seven-arm parallel-group trial with ?ve doses of liraglutide (0.045, 0.225, 0.45, 0.60 or 0.75 mg/day,double-blind) versus placebo double-blind) or glimepiride (1 or 2 mg, open?label) insubjects with type 2 diabetes mellitus showed the estimated dose for half-maximal effect on glycemiccontrol parameters (such as fasting plasma glucose and glucose pro?les), ED50, was 0.76 mg. As in the14-week dose range ?nding trial (Trial 1571) involving 163 subjects with type 2 diabetes, significantimprovement in glycemic control at all 3 tested dose levels (0.65, 1.25 and 1.9 mg/day) and a signi?cantreduction in body weight at the highest dose level were observed. These data formed the rationale for theplanned dose levels in the phase 3a program (0.6, 1.2 and 1.8 mg/day). The slight apparent difference indose levels between the NN2211-1571 trial and the phase 3a program was due to a change in the wayliraglutide content is declared, i.e. the dose levels were actually similar.See section 10.1 - Review of Individual Study Reports for details of the phase 2 dose ?nding studies.6.1.3.2 Duration of treatmentThe duration of treatment for all pivotal trials was 26 weeks, except Trial 1573, in which subjects weretreated for 52 weeks.6.1.3.3 Inclusion, and Exclusion Criteria Phase 3 TrialsThe inclusion, exclusion, and randomization criteria were similar across the ?ve trials. Therefore, asummary is presented below. Any important differences are highlighted in the specific study reviews.Inclusion Criteria - Informed consent obtained before any trial-related activities- Diagnosed with type 2 diabetes mellitus- Age 18-80 years (both inclusive)- Body mass index 345.0 kg/m2With respect to previous antidiabetic therapy and baseline HbA]c, the inclusion criteria differed amongtrials, reflecting the different treatment combinations being studied:41	108158	110620
78	1	2	16	1	55	Clinical ReviewLisa B. Yanof? M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or arenot using adequate contraceptive methods (adequate contraceptive measures as required by local law orpractice)- Any contraindications to concomitant OAD and/or insulin treatment a For inclusion criteria related to diabetes therapy and baseline l-lbA1c, see below.Body mass index 5 40.0 kg/m2 in Trial 1572. Aspartate aminotransferase only included in Trials 1573 and 1574.2152 pmol/L (21.7 mg/dL) in Trial 1573 and 2135 umol/L .53 mg/dL) in Trials 1572 and 1697.2152 umol/L (21.7 mg/dL) in Trial 1573.Only Trials 1573 and 1574.Hypoglycemic unawareness was not an exclusion criterion in Trial 1572.Glimepiride and metformin in Trial 1572, glimepiride and rosiglitazone in Trial 1436, metformin and rosiglitazone in Trial1574 and glimepiride, metformin and insulin glargine in Trial 1697.6.1.3.4 Run-in periods and forced dose escalation periodsAll trials utilized standardized and widely accepted treatment regimens during a run-in phase to providea uniform baseline of treatment prior to addition of liraglutide, placebo, or active comparator drug(Table 6.3). The run-in period (before randomization) was used to increase and maintain the dose levelof some of the concomitant OADs. Subjects already treated with the relevant OAD could advancedirectly to the maintenance period. The speci?ed maintenance period was mandatory for all subjects.Table 6.3Run in Period for Phase 3 TrialsTrial 1572 Metformin to 2 (3 weeks titration, 3 weeks maintenance)Trial 1436 Glimepiride to 4 mg (2 weeks titration, 2 weeks maintenance)Trial 1574 Metformin to 2 and rosiglitazone to 8 mg (2 weeks titration, 6 weeksmaintenance)Trial 1697 Metformin to 2 and glimepiride to 4 mg (3 weeks titration, 3 weeksmaintenance) . For all trials, the randomized treatment period included an initial period of forced dose escalation toreach the intended daily dose level. The main reason for dose escalation for liraglutide was becausestarting at the dose of liraglutide resulted in increased gastrointestinal adverse effects.- For subjects randomized to 1.2 or 1.8 mg liraglutide/day, an initial dose of 0.6 mg/day was used duringthe first week, followed by 1 or 2 weeks after which the dose was increased by 0.6 mg per week.- For Trial 1573, four weeks of forced dose escalation with glimepiride to reach 8 mg/day.- For Trial 1572, three weeks of forced dose escalation with glimepiride to reach 4 mg/day.Reviewer?s comments: The run in period for most of these trials was sufficient to reac.h steadystate, but generally too short to be re?ected in the baseline Hbalc values, although by the end ofthe run-in period subjects had some relatively low HbAlc values at the baseline43	113789	116626
89	1	2	16	1	66	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)titration, as only the starting dose of glargine was speci?ed in the protocol and the subsequent titrationwas managed by the subject.Reviewer?s comments: the baseline value for HbAlc was determined at visit 3 at the same time asrandomization. This visit occurred at a minimum of 3 weeks and a maximum of 6 weeks afterdiscontinuation of pre-study OADs and initiation of the study drugs of metformin and glimepirideat visit 2. The baseline HbAlc will re?ect pre-study OAD doses as well as the metformin andglimepiride initiated at study entry.The starting dose of glargine seems very low and would result in inadequate therapy. Howeverthe titration guideline would allow the glargine dose to reach clinically effective levels over time.At the end of 26 weeks this reviewer would expect the glargine dosed in this manner to be a faircomparator to liraglutide.All subjects treated with insulin glargine were instructed to measure their fasting plasma glucosefrequently for the purpose of insulin glargine titration. This behavior might encourage greatercompliance.    Study Design Protocol deviations: The Sponsor lists two study design protocol deviations 1) As the NGSP Level I certi?cationifor testing of HbAlc at expired at the end of August2006, a transfer of HbAlc analyses from. to the laboratory in was done for allsamples from sites in as of 17 September 2006. Samples analyzed at between the endof August and until the transfer to (Level 11 analysis) were reanalyzed at for HbAlcunless there was no sample material left, which was the case for 8 subjects (817003, 817004, 817009,817010, 818015, 819023, 820009 and 820010). There were 52 subjects from sites in ;totalalthough it is not reported how many of these subjects were affected by the protocol deviation hadsamples dating from 17 September 2006).2) There was a discrepancy between the laboratory and the protocol?s conversion factor between umol/Land mg/dL for serum creatinine; the limits in mg/dL for the exclusion criteria regarding impaired renalfunction (exclusion criterion no. 4) were 21.53 mg/dL for males and 21.24 mg/dL for females. Thisinformation was included in the amendment to central laboratory speci?cations   Reviewer?s comment: Potentially 52 subjects out of a total of 581 randomized subjectswould be affected by this protocol deviation. The Sponsor did not report if the samples wereappropriately transferred and handled and did not report if HbAlc values obtained at  were similar to the results obtained from reanalysis at However, this reviewer and thestatistical reviewer believe that the overall assessment of ef?cacy in the liraglutide developmentprogram would not be signi?cantly affected by this deviation (note: this issue is not addressed inthe written Statistical Review which was formalized before this issue came to light, but wasdiscussed in person with Dr. Derr). This deviation could, however, have labeling implications asclinical data are presented separately for each trial in the label. Therefore, the Sponsor was askedon 23 Jul 2009 to provide the following:1. A reanalysis of the primary ef?cacy endpoint (change in HbAlc at the end of 26 weeks) for trial54	140829	144075
568	1	4	46	1	1	Evaluation of Pharmacokinetic Interactionbetween PA-824 and Midazolam in HealthyAdult SubjectsHelen Winter, Erica Egizi, Ngozi Erondu, Ann Ginsberg,Doris J. Rouse, Diana Severynse-Stevens, Elliott Pauli andDaniel EverittAntimicrob. Agents Chemother. 2013, 57(8):3699. DOI:10.1128/AAC.02632-12.Published Ahead of Print 20 May 2013.These include:REFERENCESCONTENT ALERTSThis article cites 11 articles, 5 of which can be accessed free at:http://aac.asm.org/content/57/8/3699#ref-list-1Receive: RSS Feeds, eTOCs, free email alerts (when newarticles cite this article), moreInformation about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtmlTo subscribe to to another ASM Journal go to: http://journals.asm.org/site/subscriptions/Downloaded from http://aac.asm.org/ on October 21, 2014 by guestDownloaded from http://aac.asm.org/ on October 21, 2014 by guestUpdated information and services can be found at:http://aac.asm.org/content/57/8/3699	0	964
569	1	4	46	1	2	Evaluation of Pharmacokinetic Interaction between PA-824 andMidazolam in Healthy Adult SubjectsHelen Winter,a Erica Egizi,b Ngozi Erondu,b Ann Ginsberg,b Doris J. Rouse,c Diana Severynse-Stevens,c Elliott Pauli,c Daniel EverittbSchool of Pharmacy, University of Otago, Dunedin, New Zealanda; Global Alliance for TB Drug Development, New York, New York, USAb; RTI International, ResearchTriangle Park, North Carolina, USAcPA-824 is an antitubercular nitroimidazo-oxazine that possesses signicant activity against replicating and nonreplicating/persistent Mycobacterium tuberculosis via a complex mechanism of action distinct from that of any currently marketed drugsfor the treatment of tuberculosis (1, 2). Its mechanism of action isbelieved similar to that of Delamanid, a drug currently under review for market approval by the regulatory authorities (3). PA-824interferes with M. tuberculosis cell wall biosynthesis by inhibitingthe oxidation of hydroxymycolate to ketomycolate. A deazaavin(F420)-dependent nitroreductase has also been identied whoseactivity in M. tuberculosis cells is involved in PA-824 activationand activity (2). Reduction of PA-824 to its des-nitroimidazolemetabolite by this nitroreductase is associated with generation ofreactive nitrogen species, including nitric oxide. PA-824 is activeagainst M. tuberculosis isolates resistant to single or multiple antituberculous drugs and has proven effective in shortening treatment time of drug-sensitive M. tuberculosis in a murine model oftuberculosis (TB) as part of novel drug regimens (4). Moreover,PA-824 was highly active as monotherapy in a 14-day dose rangingearly bactericidal activity (EBA) study in humans where similarefcacy proles were observed across all doses assessed (200 to1,200 mg/day) (5). In EBA studies, the rate of change over time inthe number of M. tuberculosis CFU per ml of sputum in an overnight sputum collection is used to compare different dosing andtreatment regimens. In a follow up study exploring a lower doserange (50 to 200 mg/day), a dose-response trend was detected withdoses 100 mg/day and above showing similar efcacy proles (6).In addition, in a 14-day EBA study of novel antituberculosis drugcombinations, the combination of PA-824 (200 mg/day), moxioxacin (400 mg/day), and pyrazinamide (25 mg/kg [bodyweight]/day) demonstrated EBA activity comparable to the current World Health Organization-recommended gold standardtherapy of rifampin, isoniazid, pyrazinamide, and ethambutol (7).Based on the results of these EBA studies, the expected therapeuticAugust 2013 Volume 57 Number 8doses of 100 and 200 mg/day are being evaluated in longer termtrials in patients with pulmonary TB.The current treatment of TB is greatly complicated by the human immunodeciency virus (HIV) co-epidemic. In 2011, 13%of the estimated 8.7 million new cases of TB were coinfected withHIV and, of the 1.4 million deaths from TB, 430,000 deaths wereamong patients who were also HIV positive (8). The treatment ofTB alone requires the use of multiple antibiotics to prevent thedevelopment of drug resistance. The use of multiple antiretroviralagents to treat HIV infection greatly increases the likelihood ofdrug-drug interactions for patients with both infections. Manyimportant drugs used to treat HIV infection, such as the proteaseinhibitors nevirapine, lopinavir, and ritonavir, are substrates ofCYP3A4 and/or p-glycoprotein and have interactions with drugsfor the treatment of TB, such as rifampin, that are inducers ofhepatic enzymes (9). In vitro data indicate that PA-824 is not aninducer but is a weak substrate and potential weak inhibitor ofCYP3A4 (data not shown). An assessment of PA824s drug-druginteraction potential is critical to determine its place in future TBtherapy.The present study was designed to ascertain whether PA-824affected the pharmacokinetics (PK) of midazolam, a sensitiveprobe substrate and representative compound for drugs metabolized by CYP3A4. Midazolam is one of the most commonly used invivo and in vitro CYP3A4 probe substrates for drug-drug interaction studies.Received 17 January 2013 Returned for modication 1 March 2013Accepted 15 May 2013Published ahead of print 20 May 2013Address correspondence to Daniel Everitt, dan.everitt@tballiance.org.Copyright  2013, American Society for Microbiology. All Rights Reserved.doi:10.1128/AAC.02632-12Antimicrobial Agents and Chemotherapyp. 3699 3703aac.asm.org3699Downloaded from http://aac.asm.org/ on October 21, 2014 by guestThis study assessed the safety, tolerability, and pharmacokinetic interaction between PA-824, a novel antitubercular nitroimidazo-oxazine, and midazolam, a CYP3A4 substrate, in 14 healthy adult male and female subjects. The study followed up on observations in vitro that PA-824 caused weak and time-dependent inhibition of CYP3A4. Subjects received a single oral dose ofmidazolam (2 mg), followed by a 2-day washout. After the washout, all subjects received PA-824 (400 mg) once daily for 14 consecutive days. On day 14, all subjects received the nal PA-824 dose coadministered with a 2-mg oral dose of midazolam. Thepharmacokinetic endpoints AUC0 t, AUC0 , and Cmax for midazolam and 1-hydroxy midazolam were compared betweenmidazolam administered alone versus midazolam coadministered with PA-824. Statistical analysis demonstrated that the meanmidazolam values of Cmax, AUC0 t, and AUC0  parameters were reduced by ca. 16, 15, and 15%, respectively, when PA-824 wascoadministered with midazolam. The total exposure (AUC) of 1-hydroxy midazolam was 13 to 14% greater when coadministered with PA-824 compared to midazolam administered alone. The Cmax of 1-hydroxy midazolam was similar between treatments. Based on these results, PA-824 does not inhibit or induce CYP3A4 to a clinically meaningful extent and is not likely tomarkedly affect the pharmacokinetics of CYP3A4 metabolized drugs.	965	6876
570	1	4	46	1	3	Winter et al.MATERIALS AND METHODS3700aac.asm.orgconstituted and analyzed using liquid chromatography with tandem massspectrometric detection. The PA-824 calibration range for quantitationwas 10 to 10,000 ng/ml. Accuracy ranged from 96.3 to 100%, and precision (RSD) ranged from 1.7 to 4.4%.Midazolam, 1-hydroxy midazolam, and the internal standard -hydroxytriazolam (added during sample processing) were extracted fromhuman plasma samples using liquid-liquid extraction. After evaporationunder nitrogen, the residue was reconstituted and analyzed using liquidchromatography with tandem mass spectrometric detection according toa validated method proprietary to Covance Laboratories, Inc. The midazolam and 1-hydroxy midazolam calibration range for quantitation was0.1 to 100 ng/ml. Accuracy ranged from 102.0 to 102.7% and from 102 to103.3% for midazolam and 1-hydroxy midazolam, respectively. Precision(RSD) ranged from 4.5 to 6.3% and from 3.3 to 4.7% for midazolam and1-hydroxy midazolam, respectively.PK analysis. Midazolam and 1-hydroxy midazolam plasma PK parameters were calculated for each subject when midazolam was dosedalone and in combination with PA-824 by applying a noncompartmentalapproach using WinNonlin professional version 5.0.1 (Pharsight Corp.,Mountain View, CA). The key PK parameters calculated for midazolamand 1-hydroxy midazolam included Cmax (the maximum observed concentration), Tmax (the time at which Cmax occurs), kel (the terminal elimination rate constant), t1/2 (the elimination half-life), AUC0 t (the areaunder the concentration-time curve during the dosing interval), andAUC0  (the area under concentration-time curve extrapolated toinnity).Plasma concentrations below the limit of quantitation (BLQ) werehandled in the following manner. The lower limit of quantitation formidazolam and 1-hydroxy midazolam bioanalysis was 0.1 ng/ml. PK parameters were not calculated for subjects for whom there were insufcientdata. For the calculation of the PK parameters, plasma concentrations thatwere BLQ prior to the rst quantiable concentration were set to zero, andplasma concentrations BLQ after the rst quantiable concentration weretreated as missing. For each subject, the elimination rate constant (kel) wasestimated by unweighted log-linear regression using at least three datapoints from the last portion of the plasma concentration prole accordingto the least-squares approach ending with the last concentration prior tothe rst assay that was below the limit of quantication. The eliminationhalf-life (t1/2) was calculated from the kel, using the formula ln(2)/kel. Thekel was not assigned if the terminal elimination phase was not apparent, ifCmax was one of the three last data points, or if the R2 value was 80%. Incases where the kel interval was not assigned, the values of kel, AUC0 ,and t1/2 were considered not calculable and were not reported. When theresulting t1/2 was more than half as long as the sampling interval, the kelvalues and associated parameters (t1/2 and AUC0 ) were not presented.AUCs were calculated by using linear trapezoidal summation from timezero to the specied time point (either the last available time point or byextrapolation to innity).Statistical analysis. All descriptive and inferential statistics were calculated in SAS version 9.1.3. Plasma concentration values for midazolam,1-hydroxy midazolam, and PA-824 were listed and summarized usingdescriptive statistics. Descriptive statistics were calculated for PK parameters. The PK endpoints AUC0 t, AUC0 , and Cmax for midazolam and1-hydroxy midazolam were compared between midazolam alone versusmidazolam with PA-824 using an analysis of variance (ANOVA) model.The ANOVA model using SAS PROC mixed procedure included treatment, period, and sequence as xed effects and subject within sequence asa random effect. For the present study, a potentially clinically importanteffect of PA-824 on midazolam pharmacokinetics, as specied in the protocol, would be concluded if the 90% condence interval (CI) for thegeometric mean ratios (GMRs) of AUC0 t, AUC0 , and Cmax were notcontained within the prespecied no-effect 50 to 200% CI limit. If theGMRs were below 50% or above 200%, then a clinically important effectwould be concluded. For the purposes of this study, a clinically importanteffect was considered to be a drug interaction of sufcient magnitude toAntimicrobial Agents and ChemotherapyDownloaded from http://aac.asm.org/ on October 21, 2014 by guestStudy design. A phase I study was conducted to evaluate the effects of themultiple-dose administration of PA-824 on the PK of orally administeredmidazolam and to evaluate the safety and tolerability of PA-824 whencoadministered with midazolam. The study was an open-label, multidose,xed-sequence design performed in keeping with the U.S. Food and DrugAdministrations industry guidance (10). The clinical study was conducted by Celerion, Inc. (formerly MDS Pharma Services, Inc.), in Lincoln, NE, under the sponsorship of the Global Alliance for TB Drug Development.Subjects were enrolled into the study and housed in the clinical facilityfrom the evening of day 1 (at least 15 h before dosing) through the morning of day 18. The total study duration for each subject from check-inthrough study termination (including a 2-day washout) spanned 18nights and 19 days, with follow-up evaluation over 3 months.All subjects received an initial single oral dose of 2 mg of midazolamCIV hydrochloride syrup (Boehringer Ingelheim/Roxane Laboratories)administered with 240 ml of water, followed by a 2-day washout. After thewashout, all subjects received 400 mg of PA-824 (two 200-mg tablets)administered with 240 ml of water once daily for 14 consecutive days. Onthe day 14 of PA-824 dosing, a single oral dose of 2 mg of midazolam wascoadministered with 400 mg of PA-824 with 240 ml of water. Subjectsfasted for a minimum of 8 h prior to and 4 h after dosing. Water waspermitted ad libitum 1 h prior to and then again 1 h after dosing. Subjectsremained in an upright position (seated or standing) for 4 h after dosing.Dietary restrictions included caffeine, alcohol, poppy seeds, and grapefruit products prior to and throughout the study. No medication waspermitted without sponsor approval except acetaminophen.Subject inclusion and exclusion criteria. Subjects were included ifthey were healthy nonsmokers aged 19 to 50, with a body mass index of 18to 29, inclusive, with negative tests for alcohol and drugs of abuse. Subjectswere excluded if they had any clinically signicant history or presence of acardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal,endocrine, immunologic, dermatologic, or neurologic disease/disorder.Subjects also were excluded if they had a psychological, psychiatric, ormetabolic disorder (including eating disorders) or if they had experiencedany acute illness within 4 weeks. Female subjects were excluded if theywere pregnant (positive test for serum human chorionic gonadotropin atscreening or check-in), breast feeding, or planning to conceive a childwithin 30 days of cessation of treatment. Male subjects were excluded ifthey were planning to father a child within 12 weeks of cessation of treatment. Finally, subjects were excluded if they had a lens opacity or evidenceof lens opacity on slit-lamp ophthalmologic examination to follow up onndings that some rats developed cataracts in toxicology studies at highdoses over 3 to 6 months of dosing.All subjects provided written informed consent prior to participationin the study. Study protocols and consent forms were reviewed and approved by Celerions Institutional Review Board, and the study was conducted in accordance with U.S. Code of Federal Regulations (21 CFR Parts50, 56, and 312) principles and requirements and International Conference on Harmonization guidelines (ICH E6).Sampling. PK blood samples for midazolam (obtained once, 6 ml)were collected prior to dosing and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, and24 h after each 2-mg oral dose of midazolam. PK blood samples for PA824 (obtained once, 6 ml) were collected predose on days 12 and 13 ofconsecutive PA-824 dosing and predose on the day 14 prior to coadministration.Bioanalytical methods. Blood samples were collected and centrifuged, and plasma was separated and stored at 20C. Plasma sampleswere analyzed for PA-824, midazolam, and the midazolam metabolite1-hydroxy midazolam using separately validated liquid chromatographymass spectrometry methods developed at Covance Laboratories, Inc.PA-824 and the internal standard, triazolam (added during sampleprocessing), were extracted from human plasma samples using liquidliquid extraction. After evaporation under nitrogen, the residue was re-	6877	15665
571	1	4	46	1	4	PK Interaction between PA-824 and MidazolamFIG 2 Mean plasma 1-hydroxy midazolam concentrations ( the SD) overtime after a 2-mg oral dose of midazolam.require dose adjustment of drugs predominantly metabolized by CYP3A4when coadministered with PA-824. If the GMRs were within the 50 to200% limit, then sequentially narrower criteria would be tested, i.e., 70 to143%. If these narrower criteria were met, then the standard no-effector bioequivalence criteria, 80 to 125%, were to be assessed. The intendedsample size was based on the known variability in the AUC and Cmaxassociated with midazolam. Sample size calculations were based on astudy by Stoch et al. (11), who reported 90% CIs for GMRs of midazolamAUCs based on within-subject AUC variability and midazolam 2-mg oraldoses in the presence of ketoconazole. The natural log-scale standarddeviations (SD) computed from these CIs were 0.22 for AUC and 0.31 forCmax. Twelve subjects provided 96% power of yielding a 90% CI forAUC or Cmax within 0.5 to 2.0 bounds if the true underlying GMR was1.00. Midazolam and 1-hydroxy midazolam t1/2 and Tmax were comparedbetween midazolam alone versus midazolam with PA-824 using the Student t test and Wilcoxon signed-rank test. If the t1/2 and Tmax data failedtests for normality, only the Wilcoxon signed-rank test results were reported.RESULTSA total of 14 healthy male (n  10) and female (n  4) subjectsparticipated in this clinical study to assess the safety, tolerability,and PK parameters of midazolam when coadministered with PA824. All subjects were 19 to 46 years old (mean, 27.2 years), had abody mass index of 18 to 29 (mean, 25.4 kg/m2), and were medically healthy as determined by the principal investigator based ontheir medical history, clinical laboratory results, 12-lead electrocardiograms (ECGs), and physical examination. At both screening and check-in, subjects had negative urine test results foralcohol and other drugs of abuse, such as amphetamines, cannabinoids, and cocaine metabolites. Study participants represented aracially diverse group consisting of one Asian, one black, two Hispanic, and 10 white subjects. All 14 subjects who were enrolled inthe study completed all of the study procedures, and there were nodropouts.Pharmacokinetics. The mean plasma concentrations formidazolam and 1-hydroxy midazolam are shown in Fig. 1 and 2,respectively. PK parameters for midazolam and 1-hydroxy midazolam are provided in Table 1. The signicant presence of BLQplasma concentrations resulted in the loss of AUC0  and t1/2 datafor the midazolam data of one subject and the loss of 1-hydroxyAugust 2013 Volume 57 Number 8midazolam data for four subjects. The predose mean PA-824plasma concentrations  the SD on days 12, 13, and 14 for theonce-daily administration of 400 mg of PA-824 were 1,637  610,1,581  539, and 1,607  556 ng/ml, respectively. PA-824 plasmaconcentrations showed no sign of additional accumulation, indicating that steady-state had been achieved for PA-824 prior to thedosing of midazolam. These PA-824 plasma concentrations aresimilar to those found in earlier multiple-dose studies using similar doses.The GMRs (90% CI) when midazolam was coadministeredwith PA-824 compared to when midazolam was administeredalone were as follows: Cmax  83.63% (75.11 to 93.11%),AUC0 t  84.61% (74.21 to 96.47%), and AUC0   84.45%(73.79 to 96.64%). The 90% CIs for the GMRs of AUCs and CmaxTABLE 1 Midazolam and 1-hydroxy midazolam pharmacokineticparametersaMean  SD (n)PharmacokineticparametersTreatment A (reference):midazolam aloneTreatment B (test):midazolam  PA-824MidazolamCmax (ng/ml)AUC0t (ng  h/ml)AUC0 (ng  h/ml)CL/F (liters/h)Tmax (h)t1/2 (h)11.9  5.46 (14)30.7  15.3 (14)32.1  15.7 (14)75.8  32.0 (14)0.505 (0.4991.00) (14)5.69  2.14 (14)9.64  3.43 (14)25.3  10.50 (14)25.0  9.56 (13)91.5  36.21.00 (0.4991.00) (14)5.44  2.4400 (13)1-Hydroxy midazolamCmax (ng/ml)AUC0t (ng  h/ml)AUC0 (ng  h/ml)Tmax (h)t1/2 (h)5.32  2.48 (14)12.0  5.23 (14)12.9  5.82 (13)0.505 (0.4991.00) (14)4.09  2.16 (13)5.42  2.17 (14)13.7  6.24 (14)14.6  7.73 (10)1.00 (0.4991.00) (14)4.45  2.87 (10)Tmax results are presented as the median (range). Other values are arithmetic means the standard deviations. n, number of subjects contributing data; Cmax, maximum observedconcentration; Tmax, time at which Cmax occurs; t1/2, elimination half-life; AUC0 t, areaunder the concentration-time curve during the dosing interval; AUC0 , area under theconcentration-time curve extrapolated to innity.aaac.asm.org 3701Downloaded from http://aac.asm.org/ on October 21, 2014 by guestFIG 1 Mean plasma midazolam concentrations over time ( the SD) after a2-mg oral dose of midazolam.	15666	20403
572	1	4	46	1	5	Winter et al.TABLE 2 Statistical comparisons of midazolam and 1-hydroxy midazolam pharmacokinetic parametersaGeometric LS mean (n)PharmacokineticparametersTreatment A (reference):midazolam aloneTreatment B (test):midazolam PA-824% GMR90% CIMidazolamCmax (ng/ml)AUC0t (ng  h/ml)AUC0 (ng  h/ml)10.82 (14)27.63 (14)28.97 (13)9.05 (14)23.38 (14)24.47 (13)83.6384.6184.4575.1193.1174.2196.4773.7996.641-Hydroxy midazolamCmax (ng/ml)AUC0t (ng  h/ml)AUC0 (ng  h/ml)4.76 (14)10.86 (14)11.57 (10)5.00 (14)12.38 (14)13.04 (10)105.23113.98112.6893.13118.9105.53123.09103.07123.18values were all within the predened 50 to 200 and 70 to 143%no-effect limits; however, the upper limit of the CIs was100%. The 90% CIs for the GMRs of the AUCs and Cmax valueswere not within the no-effect limit of 80 to 125%. The totalextent (AUC) and peak (Cmax) exposure of midazolam decreasedby ca. 15 to 16% when midazolam was coadministered with PA824 compared to when midazolam was administered alone. Basedon the nonparametric Wilcoxon signed-rank test, the midazolamTmax (P  0.891) and t1/2 (P  0.893) were not different betweenboth treatments.As seen in Table 2, a statistical analysis of 1-hydroxy midazolam PK parameters demonstrated that the GMRs (90% CI) whenmidazolam was coadministered with PA-824 compared to whenmidazolam was administered alone were as follows: Cmax 105.23% (93.13 to 118.9%), AUC0 t  113.98% (105.53 to123.09%), and AUC0   112.68% (103.07 to 123.18%). Thelower bound of the 90% CIs for the GMRs of the AUCs was100% but all were within the no-effect limit of 80 to 125%.Based on the nonparametric Wilcoxon signed-rank test, the 1-hydroxy midazolam Tmax (P  0.988) and t1/2 (P  1.00) values werenot different between both treatments.Safety and tolerability. PA-824 was well tolerated throughoutthe study and when coadministered with midazolam. No seriousadverse events occurred. The only adverse events reported bymore than one subject during any treatment period were headache, nausea, abdominal discomfort, and diarrhea. These eventswere reported more commonly by subjects during the periodswhen PA-824 was administered alone or in combination withmidazolam. There was a trend toward increased serum creatinineconcentrations during dosing with PA-824, a nding consistentwith an earlier study that determined that higher doses of PA-824do not affect renal function but may increase serum creatinine byinhibiting renal tubular secretion of creatinine, a clinically benigneffect that has been seen with several marketed drugs (12). Mean(SD) serum creatinine concentrations were 0.785 (0.173) atcheck-in, 0.811 (0.184) when midazolam was dosed alone, 0.916(0.175) after 7 days of once-daily dosing of PA-824, and 0.955(0.189) after 14 days of once-daily dosing of PA-824 with coadministration of midazolam on day 14. All other mean laboratoryparameters for serum chemistry, hematology, and urinalysis remained within reference range. There were no remarkable ndings in the vital signs, ECGs, physical examinations, visual acuitytests, and slit-lamp examinations in this study.3702 aac.asm.orgDISCUSSIONWhen this study was designed, the clinical dose range in patientswith TB had not been determined. The 400-mg PA-824 dose usedhere was chosen as the highest dose that might be used in futureclinical studies. The 400-mg PA-824 dose was expected to producethe maximum change in midazolam exposure relevant to theclinic. Any effects observed at the 400-mg PA-824 dose level couldbe extrapolated to lower doses of PA-824, potentially requiringadditional studies to appropriately characterize the drug interaction at lower clinical doses. The 50 to 200% limit for the 90% CI ofthe GMR was chosen as a no-effect criterion based on a clinicalassessment that if dose adjustment of important drugs metabolized by CYP3A4 were required during coadministration of PA824, then continued development of PA-824 as a therapy for TBwould not be warranted. The 2-mg oral midazolam dose is at thelower range of that typically used in drug-drug interaction studies,but it was chosen due to concerns over the possible magnitude ofCYP3A4 time-dependent inhibition after a 14-day dosing of PA824.The total extent (AUC) and peak (Cmax) exposure of midazolam decreased by ca. 16 and 15%, respectively, with the concomitant coadministration of midazolam and PA-824 400 mg compared to the administration of midazolam alone. The total extent(AUC) and peak (Cmax) exposure of 1-hydroxy midazolam increased 14 and 5%, respectively, with the concomitant coadministration of midazolam and PA-824 compared to the administration of midazolam alone. The 90% CI values for the GMRs ofAUC0 t, AUC0, and Cmax for midazolam and 1-hydroxy midazolam were all within the prespecied no-effect 50 to 200% limitand within the narrower prespecied 70 to 143% limit, whereasonly the 1-hydroxy midazolam GMRs also fell within the defaultbioequivalence 80 to 125% limit. The relatively small decrease inmidazolam exposure, together with the small increase in 1-hydroxy midazolam exposure observed when midazolam is coadministered, appears to be consistent with a small inductive effectby PA-824 on CYP3A4. This result appears inconsistent with invitro data indicating that PA-824 is a weak inhibitor of CYP3A4and exhibits metabolism-dependent inhibition. However, our invitro metabolism data are too limited to indicate the likely mechanism. It has been reported that some metabolism-dependent inhibiters can form relatively stable PA-824 metabolite enzymecomplexes resulting in decreased degradation of the enzyme itselfAntimicrobial Agents and ChemotherapyDownloaded from http://aac.asm.org/ on October 21, 2014 by guestan, number of subjects contributing data; Cmax, maximum observed concentration; AUC0 t, area under the concentration-time curve during the dosing interval; AUC0 , areaunder the concentration-time curve extrapolated to innity; LS mean, least-squares mean; GMR, geometric mean ratio; CI, condence interval.	20404	26431
573	1	4	46	1	6	PK Interaction between PA-824 and MidazolamACKNOWLEDGMENTSThis study was supported by grants from the Rockefeller Foundation, theDevelopment Cooperation Ireland, the Bill & Melinda Gates Foundation,the U.S. Agency for International Development, and the Dutch Ministryof Foreign Affairs.We thank the staff of Celerion, Inc., and the study participants.REFERENCES1. Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P,Ledwidge R, Dowd CS, Lee IY, Kim P, Zhang L, Kang S, Keller TH,Jiricek J, Barry CE. 2008. PA-824 kills nonreplicating Mycobacteriumtuberculosis by intracellular NO release. Science 322:13921395.August 2013 Volume 57 Number 82. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM,Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DNBN,Kreiswirth Barry CE, Baker WR. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962966.3. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H,Sasaki H, Shimokawa Y, Komatsu M. 2006. OPC-67683, a nitrodihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3:e466. doi:10.1371/journal.pmed.0030466.4. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D,Rosenthal I, Grosset JH. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxioxacin, and pyrazinamide ina murine model of tuberculosis. Antimicrob. Agents Chemother. 52:15221524.5. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A,Donald PR, van Niekerk C, Whitney K, Rouse DJ, Laurenzi MW,Ginsberg AM, Spigelman MK. 2010. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother. 54:34023407.6. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald P, vanNiekerk C, Erondu N, Ginsberg A, Becker P, Spigelman M. 2012. Aphase II dose-ranging trial of the early bactericidal activity of PA-824.Antimicrob. Agents Chemother. 56:30273031.7. Diacon AH, Dawson R, von Groote-Bidlinqmaier F, Symons G, VenterA, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, MendelCM, Spigelman M. 2012. 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxioxacin combinations: a randomised trial.Lancet 380:986 993.8. CDC. 2012. Grand rounds: the TB/HIV syndemic. MMWR Morb. Mortal. Wkly. Rep. 61:484  489.9. Dooley KE, Kim PS, Williams SD, Hafner R. 2012. TB and HIV therapeutics: pharmacology research priorities. AIDS Res. Treat. 2012:19.10. Food and Drug Administration. 2006. Guidance for industry: druginteraction studiesstudy design, data analysis, and implications fordosing and labeling. Ofce of Training and Communications Divisionof Drug Information, document HFD-240. U.S. Department of Healthand Human Services, FDA Center for Drug Evaluation and Research,Bethesda, MD.11. Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P, Fitzgerald M,Chodakewitz J, Wagner JA. 2009. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam:shortening the paradigm. J. Clin. Pharmacol. 49:398  406.12. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK.2009. Assessment of the effects of the nitroimidazo-oxazine PA-824 onrenal function in healthy subjects. Antimicrob. Agents Chemother. 53:3726 3733.aac.asm.org 3703Downloaded from http://aac.asm.org/ on October 21, 2014 by guestand ultimately higher steady-state levels of active enzyme. Midazolam is known to exhibit allosteric activation of CYP3A4-mediated metabolism with some drugs. Allosteric activation involvesthe binding of an activator to the enzyme, resulting in an increased rate of metabolism. 1-Hydroxy midazolam forms a glucuronide metabolite. Glucuronide metabolites can be excreted bytransporters in the kidney and other tissues. Increased serum creatinine concentrations were detected. It is possible that PA-824inhibition of a common transporter for creatinine and 1-hydroxymidazolam might have led to the increased 1-hydroxy midazolamexposure that we observed. However, the decrease in midazolamexposure that we detected is not consistent with the inhibition of arenal transporter.We demonstrated that PA-824 at the 400-mg dose does notproduce changes in midazolam exposure that would require doseadjustment. Any changes in midazolam exposure that occur forthe 100- and 200-mg PA-824 doses are likely to be even less thanthat observed for the 400-mg dose. Therefore, our ndings indicate that PA-824 is not likely to affect the PK of CYP3A4-metabolized drugs to a clinically meaningful extent. Most importantly,concomitant use of PA-824 is not expected to produce signicantdrug interactions with antiretroviral drugs that are substrates ofCYP3A4, such as the protease inhibitors. Overall, single doses oforal midazolam (2 mg) administered alone and then after multiple doses of PA-824 (400 mg daily for 14 days) with a single oraldose of midazolam (2 mg on day 14 of PA-824 dosing) were welltolerated by the subjects in our study.	26432	31490
116	1	2	16	1	93	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,34] (Submission 000)Victoza? (liraglutide)Figure 6.11 - Trial 1436 Plot of Mean HbA1c by Treatment and Week (LOCF, ITT)10.Gf9.5?9.135:8-See. we 3 - . -at 8'0.   . 7.0- A6.56.0-].i6'1'8'2.'0'2'2.2j4'2'6Time (Week)Glam Ros:-I-GiimSource: Figure 11-1, Trial 1436 reportReviewer?s comment: The HbA1c lowering effect liraglutide dosesappear to be maintained until the end of the 26 week trial although somewhat less so in trial 1436.These ?ndings suggest sustainability of the liraglutide effect when added to one OAD.6. .4. 2.5 Supplementary Analyses of the Primary Endpoint Hb/1106.1.4.2.5.l Percentage of subjects achieving HbA1c targetsThe percentages of subjects reaching the pre-de?ned HbA1c targets (ADA target 7% and AACE target5 at Week 26 are summarized in Table 6.24 and Table 6.25, respectively. In Trial 1572,signi?cantly more subj ects reached both the ADA and the AACE targets with liraglutide (0.6, 1.2 or 1.8mg) combined with metformin than with metformin alone. Similarly, in Trial 1436, signi?cantly moresubjects reached both the ADA and the AACE targets with liraglutide glimepiride than withglimepiride alone.81	198532	199700
81	1	2	16	1	58	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Glimepiride 8 mg po qdIn addition to the 746 subjects, one of the sites (site 507), with 11 randomized subjects ofrandomized subjects), was excluded from ITT and safety analyses due to GCP compliance issues.Procedures: . -At week 0 (visit 2) subjects were asked to discontinue use of current OADS after screening, uponrandomization, and before initiation of study drugs.Figure 6.2 Procedures for Trial 1573 0Liragiutide 1.2 mg, qd Liragiutide 1.8 mg, qd Glimepirid-e 8 mg, qd (Nw234,Randornisation Telephone Contact-Screening Dose?trationWeek -Visit?! 2313aReviewer?s comments: There appears to have been no washout period of OADS prior torandomization and the baseline measurement of HbA1c. This may bias results in that it couldlead to underestimation of the within group primary efficacy variable (change in HbA1c frombaseline to endpoint) in the patients taking OADs prior to randomization in a direct comparisonto diet/exercise patients because of the expectation of the HbA1c to ?drift back to baseline? amongthe subjects who were enrolled in the trial on OADs and then taken off those OADS atrandomization. Note: This lack of washout period may also have affected the secondary endpointof change in body weight. The change in HbA1c relative to comparator should be unaffected bythe lack of washout.6.1.3. 7.2 z?y-two week open label extension periodThe open label portion of the study started a?er the last subject had completed the 52-week double-blindportion of the study. The primary ef?cacyvariable was change in HbAlc from baseline to week 76.Four hundred forty (440) patients continued into the open-label portion of this trial and 53.9%completed 18 months of the voluntary study by the cutoff date of February 21, 2008.Reviewer?s comment: The extension period was unblinded and its data were not used to supportef?cacy claims, although these data may provide supportive information on durability of effect.46	120977	122982
82	1	2	16	1	59	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)6.1.3.8 Individual Trial Designs - Liraglutide as Combination Therapy(Liraglutide Mezformin) vs. (Placebo Metformin) vs. (Glimepiride Metformin)Trial 1572: Liraglutide Effect and Action in Diabetes (LEAD-2) Effect on glycemic control after oncedaily administration of liraglutide in combination with metformin versus metformin rnonotherapy versusmetformin and glimepiride combination therapy in subjects with type 2 diabetes. A six-month double-blind, double-dummy, randomized, active control, para1lel?group, multicenter, multinational trial with an18 months extension period.Hypothesis: Combination therapy of liraglutide and metformin will provide glycemic control (asmeasured by glycosylated hemoglobin [HbAlc]) signi?cantly better than metformin monotherapy, andat least as good as or better than that achieved by metformin and glimepiride combination therapy insubjects with type 2 diabetes.This was a multicenter (170 centers in 21 countries), double-blind, double-dummy, randomized, study.Subjects with type 2 diabetes inadequately controlled on OADs (HbA1c 7.5-11% inclusive) wererandomized in a 212:2: 1 :2 ratio to:Liraglutide active (0.6 mg/day) glimepiride placebo metformin (1 .5-2.0 g/day)Liraglutide active (1.2 mg/day) glimepiride placebo metformin (1.5-2.0 g/day)Liraglutide active (1.8 mg/day) glimepiride placebo metformin (1 .5?2.0 g/day)Liraglutide placebo glimepiride placebo metformin (1 .5-2.0 g/day)Liraglutide placebo glimepiride (4 mg/day) metformin (1 .5-2.0 g/day)Dose Adjustments:After randomization the dose level of metformin could, at the discretion of the investigator, be decreasedto a minimum of 1500 mg /day in case of unacceptable hypoglycemia or other adverse events. Likewise,the metformin dose could be increased again to 2000 mg/day. If a dose level less than 1500 mg/day ormore than 2000 mg/day was required, the subject had to be withdrawn from the trial (see also section6.1.3.6 Withdrawal and rescue).Reviewer's comment: Although the maximum recommended dose of metformin is 3,000 mg daily,the 2000 mg dose used in this trial is considered the maximally/near?maximally efficacious dose(Garber 1997) and is commonly used in trials of antidiabetic medications.The doses of liraglutide and glimepiride were to be maintained throughout the trial.Inclusion criteria differed from those presented in section 6.1.3.3 in that:1. Body mass index (BMI) 5 40.0 kg/m247	122983	125470
574	1	4	47	1	1	Eur J Clin Pharmacol (2014) 70:3745DOI 10.1007/s00228-013-1592-7CLINICAL TRIALEffects of vercirnon on the activity of CYP3A4, CYP2C19and CYP2C8 enzymes and BCRP and OATP1B1 transportersusing probe substratesLynda J. Haberer & Iain McSherry & Anna Cargill &Linda McCarthyReceived: 10 May 2013 / Accepted: 20 September 2013 / Published online: 8 October 2013# The Author(s) 2013. This article is published with open access at Springerlink.comAbstractPurpose Vercirnon is a CCR9 chemokine receptor antagonistbeing developed for the treatment of Crohns disease. As avariety of concomitant medications are often required for thetreatment of Crohns disease, it is important to characterise thedrug interaction profile of vercirnon. To confirm the results ofprevious in vitro inhibition studies, this study assessed thein vivo effect of vercirnon on the activity of cytochrome P450enzymes (CYP3A4, CYP2C19 and CYP2C8) and drug transport proteins (BCRP and OATP1B1) using probe substrates.Methods This was an open-label, single-sequence, repeatdose study conducted in 24 healthy adult subjects. On days14, subjects received probe substrates (midazolam, pioglitazone, omeprazole and rosuvastatin; in that order), followed byadministration of vercirnon 500 mg twice daily (BID) on days514. On days 1114, in addition to vercirnon 500 mg BID,subjects also received probe substrates as on days 14. Bloodsamples were collected for pharmacokinetic analysis of probesubstrates, vercirnon and two of its metabolites.Electronic supplementary material The online version of this article(doi:10.1007/s00228-013-1592-7) contains supplementary material,which is available to authorized users.L. J. Haberer (*)Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline,5 Moore Drive, Research Triangle Park, NC 27709, USAe-mail: Lynda.J.Haberer@gsk.comI. McSherryClinical Pharmacology Sciences and Study Operations,GlaxoSmithKline, Stockley Park, UKA. CargillStatistics and Programming, PHASTAR, Chiswick, UKL. McCarthyGenetics, GlaxoSmithKline, Stevenage, UKResults Geometric least-squares mean ratios (90 % confidence interval) of area under the concentration-time curvefrom time zero to infinity for probe administered withvercirnon (test) compared with probe alone (reference) formidazolam, pioglitazone, omeprazole and rosuvastatin were0.92 (0.85, 0.99), 1.01 (0.95, 1.07), 0.99 (0.76,1.31) and0.98 (0.88, 1.09), respectively.Conclusions Co-administration of probe substrates midazolam, pioglitazone, omeprazole, and rosuvastatin followingrepeat dosing of vercirnon 500 mg BID demonstratedvercirnon had no clinically significant effect on CYP3A4,CYP2C8, CYP2C19 enzyme activity or BCRP or OATP1B1transporter activity.Keywords Drug interaction . Vercirnon . CYP3A4 .CYP2C19 . CYP2C8 . BCRP . OATP1B1IntroductionVercirnon (formerly CCX282-B or GSK1605786) is a highlypotent, orally active, chemokine receptor antagonist whosesingle target is the G-proteincoupled receptor CCR9,which has been implicated in the aetiology of inflammatorybowel diseases such as Crohns disease [14]. Crohnsdisease is a chronic, idiopathic, relapsing inflammatory disorder of the gastrointestinal (GI) tract associated with adysregulated activation of immune cell function. It canaffect any portion of the GI tract but most commonly affectsthe terminal small intestine and colon [5]. Current treatments for subjects with Crohns disease consist of corticosteroids, immunosuppressives (e.g., methotrexate, cyclosporine, mercaptopurine and azathioprine), and tumour necrosisfactor inhibitors (e.g., infliximab, adalimumab and certolizumab).Although there have been recent advances in the treatment of	0	3669
575	1	4	47	1	2	38patients with Crohns disease [6], there is still an unmetmedical need for new therapies [5, 7]. Currently, patients withCrohns disease use multiple prescription and non-prescriptionmedications to treat their inflammatory bowel disease (IBD)symptoms and other systemic and non-IBD disease-relatedconditions (e.g., diabetes, hypertension, heart disease). Consequently, patients with Crohns disease have a potentiallyhigher risk for drugdrug interactions compared with thegeneral population [8].Following oral administration (250 to 1,000 mg), vercirnonis readily absorbed with a time to maximum concentration(tmax) of 34 h and an estimated half-life between 12 and17 h [9]. Once absorbed, vercirnon is extensively metabolisedby multiple oxidative and reductive pathways, including cytochrome P450 (CYP) enzymes such as CYP3A4, CYP2C19and CYP2B6 (ChemoCentryx, data on file). Vercirnon ispassively permeable and unlikely to be a substrate for humanp-glycoprotein transporter protein or other transport proteins,and its metabolites are highly protein bound (>90 %) with lowuptake of drug-related material into tissues (ChemoCentryx,data on file). Based on these observations, the potential forother drugs to have a clinically-significant effect on vercirnonwas predicted to be low.No clinical studies have been performed to evaluate thepotential for vercirnon to affect the pharmacokinetics (PK) ofother drugs. Due to the high plasma protein binding forvercirnon and its metabolites, and the relatively low anticipated liver concentrations estimated from likely therapeutic plasma concentrations (maximum observed concentration [Cmax]range 35 M for vercirnon and <0.5 M for metabolites;ChemoCentryx, data on file), the potential for vercirnon tosignificantly affect the clearance of other drugs utilising CYPenzymes as a primary clearance pathway was considered to below. However, the estimated [I]/Ki ratio, where [I] representsthe mean steady-state Cmax value for total drug (bound plusunbound) following administration of the highest proposedclinical dose of vercirnon, was between 0.1 and 1.0 for cytochrome P450 enzymes CYP3A4, CYP2C19, and CYP2C8activity. This indicated a possible interaction requiring afollow-up clinical evaluation [10]. In addition, in vitro studiesshowed that vercirnon can inhibit breast cancer resistant protein (BCRP) and organic anion transporter (OAT) proteins,specifically OAT1B1, OAT1 and OAT3 (ChemoCentryx andGlaxoSmithKline, data on file).It is important to confirm these in vitro findings and characterise the drug interaction profile of vercirnon in humans tosupport late-phase clinical trials, as patients with Crohnsdisease are often prescribed multiple medications, such asimmunosuppressants, GI anti-inflammatory agents, antibiotics and pain relievers. This study investigated the potentialeffect of steady-state vercirnon on CYP3A4, CYP2C19 andCYP2C8 activity, plus BCRP and OATP1B1 transporter activity, by evaluating the effect of vercirnon co-administrationEur J Clin Pharmacol (2014) 70:3745on the PK of well-established probe substrates for eachenzyme/transporter [11]. As a secondary objective, the systemic exposure of two metabolites: GSK2635622 andGSK2656694, relative to the parent drug, vercirnon, wereassessed following single and repeat dosing of vercirnon. Inaddition, exploratory pharmacogenetic (PGx) evaluationswere conducted to investigate the relationship between genetic variants in drug metabolism and transporter genes, andinter-individual variability in PK parameters.MethodsSubjectsA total of 24 subjects were enrolled to ensure that at least 16subjects would complete the study. Subjects were eligible toparticipate if they were a healthy adult male or female,of non-childbearing potential, 1855 years of age withbody weight 60 kg and body mass index (BMI) within the1930 kg/m2 range. Subjects were excluded from the study ifthey were pregnant, smoked, or had liver disease, active orlatent tuberculosis, coeliac disease or a positive serologic testfor tissue transglutaminase (tTG), hepatitis B, hepatitis C, orhuman immunodeficiency virus (HIV). Subjects were alsoexcluded if they had drug or alcohol problems, blood pressureabnormalities, mental/legal incapacities, sensitivities, medicalconditions judged by the principal investigator to be unsuitable for the study, or if they had consumed red wine, citrusfruits, fruit juices, vegetables from the mustard green family orcharbroiled meats within 7 days prior to the first dose of studymedication. No alcohol, caffeine, or concomitant medicationswere allowed while in the clinic. All subjects provided writteninformed consent before any study-specific procedures wereperformed.The study was conducted in accordance with good clinicalpractice and all applicable regulatory requirements under theDeclaration of Helsinki at a single site: Buffalo Clinical Research Center, Buffalo, NY, USA. A local Institutional Review Board reviewed and approved the study.Study design and treatmentsThis was an open-label, single-sequence, repeat-dose study(CCX114671; ClinicalTrials.gov identifier NCT01489943)designed to evaluate the effect of repeat doses of vercirnonon the PK of probe substrates of three CYP enzymes and twotransporter proteins in healthy subjects. The probes used toinvestigate the enzyme and transporter activity were: midazolam for CYP3A4, pioglitazone for CYP2C8, omeprazole forCYP2C19, and rosuvastatin for BCRP and OATP1B1. Allprobe substrates were administered orally and at doses thatwould provide adequate concentrations of parent and/or	3670	9257
576	1	4	47	1	3	Eur J Clin Pharmacol (2014) 70:3745metabolite for the assessment of potential interactions withvercirnon. The probe compounds were administered in themorning on the study days outlined in Table 1. Vercirnon500 mg was administered twice a day (BID), after a meal,on days 514. Eligible subjects were admitted to the clinicalunit on day -1 (day before first dose) and remained in-houseuntil day 15. On days 1, 2, 3 and 4 they received single dosesof the probe compounds: midazolam 3 mg oral syrup, pioglitazone 15 mg tablet, omeprazole 40 mg capsule androsuvastatin 10 mg tablet, respectively. This was followedby vercirnon 2 x 250-mg capsules BID on days 510. Ondays 11, 12, 13 and 14, in addition to vercirnon 500 mg BID,subjects also received the probe compound in the same orderas days 14.For each morning dose, subjects were required to fastovernight. Subjects were served a moderate fat breakfast(i.e., fed state) consisting of approximately 28 % fat and700 cal. Thirty minutes after breakfast was served, studymedication was administered with 240 mL of water. For eachevening dose of vercirnon, subjects were also served a standard meal 30 min prior to dosing. Serial blood samples werecollected over a 24-h period following the administration ofall probe substrates; except for rosuvastatin, where sampleswere collected over 48 h. Full details of sample collection andprobe substrate analysis (including validation, precision andaccuracy ranges) are provided in Online Resource 1. Systemiclevels of the probe substrates when co-administered withvercirnon were compared with systemic levels when theprobes were administered alone. On study days 510, singletrough concentrations were collected immediately prior todosing. Additionally, a subset of subjects volunteered to haveserial blood samples collected over 24 h on study days 5 and10 for analysis of vercirnon and its metabolites, GSK2635622and GSK2656694. All subjects returned to the unit for afollow-up visit within 710 days after the last dose of studymedication before being discharged from the study. The totalduration of a subjects participation in the study, includingscreening (30 days), treatment and the follow-up visit wasapproximately 54 days.Table 1 Summary of treatment administrationsStudy dayProbe and/or study drugDay 1Pioglitazone 15 mgOmeprazole 40 mgRosuvastatin 10 mgVercirnon [500 mg BID]Vercirnon [500 mg BID] + midazolam 3 mgVercirnon [500 mg BID] + pioglitazone 15 mgVercirnon [500 mg BID] + omeprazole 40 mgVercirnon [500 mg BID] + rosuvastatin 10 mgSample size considerationsThe potential effect of vercirnon on the probe substratesevaluated in this study was assessed by comparing the ratioof area under the concentration curve from zero to infinity(AUC 0) of the probe substrate in combination withvercirnon (test) to the AUC0 of the probe substrate alone(reference). The precision for the comparison of interest wasestimated, using a sample size of 16 subjects and based on thelargest average estimate of within-subject variability (%CVw)for the CYP450 substrates to be studied (28.0 % forrosuvastatin AUC0; GlaxoSmithKline, data on file). Pointestimates and corresponding 90 % confidence intervals (CIs)were constructed for the differences between the mean of thetest and reference treatments (the comparison of interest). Theestimated precision is no more than 19 % of the observedpoint estimate, where precision is expressed as the half-widthof the 90 % CI. For a point estimate of one, the corresponding90 % CI for the ratio of geometric means would be 0.841.19.This calculation was based on the loge-scale and a two-tailedprocedure with a type I error rate of 10 %. A total of 24subjects were enrolled to ensure 16 patients would completethe study.A sensitivity analysis was to be conducted in the event thatthe %CVw estimates were greater than expected. For the%CVw in the upper range of 35 %, it was estimated that theprecision for the comparisons of interest would be no morethan 23 % of the observed point estimate (i.e., the 90 % CI forthe ratio of geometric means would be 0.811.23, with a pointestimate of one). This calculation was based on the loge-scaleand a two-tailed procedure with a Type I error rate of 10 %.Study populationThe safety population consisted of all subjects who receivedat least one dose of study medication. The PK populationincluded subjects in the safety population with PK samplesadequate for calculation of PK parameters. The day 5 and day10 population excluded subjects from the PK population whohad multiple PK samples collected on day 5 and day 10. ThePGx population excluded subjects who were predicted to bepoor metabolisers or have potentially reduced transporteractivity based on genotyping.Midazolam 3 mgDay 2Day 3Day 4Day 5 through day 10Day 11Day 12Day 13Day 1439Pharmacokinetic analysisPlasma concentration time data for all probe substrates, vercirnonand metabolites were analysed by non-compartmental methodsusing WinNonlin v5.3 (PharSight, a Certara Company, StLouis, MO). From the concentration time data for eachprobe compound, the AUC0, the AUC time curvefrom time zero (pre-dose) to last time of quantifiableconcentration (AUC0t), Cmax, time of occurrence of	9258	14491
577	1	4	47	1	4	40Cmax (tmax), and apparent terminal phase half-life (t1/2)(where data were available) were determined followingadministration with and without vercirnon.For vercirnon and its two metabolites, the AUC time curveover the dosing interval (AUC0), Cmax and tmax were determined in the subset of six subjects who had serial PK sampling on days 5 and 10. Vercirnon accumulation followingrepeat dosing was determined by calculating the accumulationratio (Ro) for AUC0 and comparing the Cmax for day 10 withday 5. The ratio of metabolite AUC0 to vercirnon AUC0on day 5 and day 10 was calculated after converting theAUC0 values to appropriate molar units.Eur J Clin Pharmacol (2014) 70:3745needed to be close to zero or the 90 % CI for the slope estimateneeded to include zero.SafetySafety and tolerability parameters were assessed by the measurement of vital signs, cardiac monitoring, adverse event(AE) assessments and clinical laboratory tests. The twovercirnon metabolites (GSK2635622 and GSK2656694) wereassayed and the molar ratio of each metabolite to vercirnon(parent) concentrations were determined.Pharmacogenetic analysesStatistical analysisProbe assessmentThe potential effect of vercirnon on the probe substratesevaluated in this study was assessed by comparing the ratioof AUC0 of the probe substrate with and without concomitant vercirnon. The primary endpoint for all probe substrates(except omeprazole) was the ratio of AUC0 for each of theprobe substrates when administered with and without concomitant vercirnon. Due to the high inter- and intra-subjectvariability associated with omeprazole PK [12], its metabolite(5-OH-omeprazole) was also quantified in plasma and theratio of omeprazole metabolite to parent was calculated tonormalise for the variability associated with the absorptionand metabolism of omeprazole. The statistical endpoint foromeprazole was calculated from the AUC 0 ratio ofmetabolite:parent, both with and without concomitantvercirnon. Following loge-transformation, the primary endpoints were separately analysed using a mixed-effects model.Treatment was fitted as a fixed effect and subject as a randomeffect. Point estimates and their associated 90 % CI wereconstructed for the ratios, by back transforming the respectivedifference between the treatment least squares (LS) means andthe associated 90 % CI.Vercirnon steady-state analysisTrough concentration (C) samples collected from all 24subjects on study days 611 were used to assess attainmentof steady-state. Individual plasma vercirnon pre-dose concentrations were obtained and the mean (+ standard deviation [SD]) and median (range) were plotted andsummarised by day. A mixed-effects model with subjectas a random effect and day as a fixed effect was performedon the loge-transformed C data. Day was treated as acontinuous variable in the model. Achievement of plasmavercirnon steady state was assessed by calculating the 90 %CI of the slope of the linear regression of pre-dose C versusday. To claim steady state was reached, the slope estimateTo account for potential inter-patient variability as a result ofgenetic polymorphisms, exploratory PGx evaluations werealso conducted. Exploratory analyses included PK parametersin a sub-population of subjects who had no common geneticvariations in the CYP enzymes or BCRP/OATP1B1 transporters that could negatively impact their activity (the PGxpopulation). The Affymetrix DMET-Plus genotyping array[13] was used to genotype common genetic variants inCYP3A4/3A5, CYP2C8, CYP2C19, SLCO1B1 (OATP1B1)and ABCG2 (BCRP). Subjects carrying genetic variantswhich predicted poor metabolism or reduced activity for therespective CYP enzymes or transporters were excluded fromthe relevant exploratory PGx analysis, thereby creating subpopulations with fewer confounding factors.ResultsSubjectsA total of 24 subjects (23 males: 1 female) enrolled andcompleted the study. Subjects had a mean (SD) age of3310.6 years (range 1954 years), weighed 78.712.8 kg(range 61.0109.9 kg) and had a mean (SD) BMI of25.682.77 kg/m2 (range 20.130.2 kg/m2). Sixteen subjects (67 %) were Caucasian or of European heritage and8 (33 %) were African-American or of African heritage.All 24 (100 %) subjects enrolled were included in thesafety population and the PK population. The day 5 andday 10 population consisted of six subjects whilst the BCRPPGx and OATP1B1 PGx populations consisted of 19 and22 subjects, respectively.PharmacokineticsProbe and treatment comparisonsThe plasma PK parameters for probe substrates midazolam,pioglitazone, omeprazole, 5-OH-omeprazole and rosuvastatin	14492	19124
578	1	4	47	1	5	Eur J Clin Pharmacol (2014) 70:374541administered with and without concomitant vercirnon aresummarised in Table 2. PK parameters for each of the probesubstrates were similar irrespective of whether they were administered alone or in combination with vercirnon. AUC0variability for each of the probe substrates are presented inTable 3. In the case of omeprazole, the % CVw for the AUC0treatment comparison was 54.3 % (Table 3). The %CVw wasgreater than the 28 % used to estimate sample size and theprecision of the comparison of interest. However, using theplanned ratio of the 5-OH-omeprazole metabolite AUC0 toomeprazole AUC0, the %CVw was reduced to 13.7 %.The %CVw for AUC0 for midazolam, pioglitazone,rosuvastatin and 5-OH-omeprazole:omeprazole, (with and without vercirnon) ranged from 11.6 % to 21.7 %. The 90 % CI ofthe geometric LS mean ratios for midazolam, pioglitazone,rosuvastatin, and 5-OH-omeprazole:omeprazole all fell withinthe 0.801.25 range of standard bioequivalence (Table 3).Vercirnon and metabolitesaccumulation and steady-stateassessmentA summary of the derived vercirnon PK parameters on studyday 5 (day 1 of vercirnon dosing) and study day 10 (day 6 ofvercirnon repeat dosing) for the 6 subjects who participated inthe serial PK sampling are presented in Table 4. The averageaccumulation for vercirnon in terms of AUC0 and Cmax onday 10, compared with day 5, was 14 % and 3 %, respectively.Concentration-time profiles for the metabolites GSK2656694and GSK2635622 paralleled that of vercirnon (Fig. 1) andappear (by visual inspection) to accumulate and reach steadystate after 2 days of dosing (48 h). The statistical assessmentof vercirnon steady-state, following daily dosing of vercirnon500 mg twice daily for 6 days, confirmed that plasma concentrations of vercirnon achieved steady-state (90 % CI of theslope estimates included zero) by the end of the second day ofTable 2 Summary of plasma probe pharmacokinetic parameters after administration of probe with and without vercirnonTreatmentNAUC0-a(ng*hr/mL)AUC0-t(ng*hr/mL)Cmax(ng/mL)t1/2(hr)tmaxb(hr)Midazolam aloneDay 1Midazolam + vercirnonDay 11Pioglitazone aloneDay 2Pioglitazone + vercirnonDay 12Omeprazole aloneDay 3Omeprazole + vercirnonDay 135-OH-omeprazole aloneDay 35-OH-omeprazole + vercirnonDay 13Rosuvastatin alone2435.9(31.0, 41.7)33.0(29.5, 36.8)5248.9(4685, 5881)5284.5(4835, 5775)634.9c(453.0, 889.9)626.8e(466.9, 841.3)692.8d(547.3, 877.0)653.0c(576.4, 739.8)28.634.1(29.5, 39.5)31.4(28.1, 35.2)4595.9(4068, 5193)4715.8(4230, 5257)616.4e(452.9, 839.1)617.4(465.3, 819.3)671.8e(535.0, 843.6)660.9(587.3, 743.8)25.39.56(8.33, 10.99)8.60(7.52, 9.83)528.3(471.7, 591.7)569.4(522.9, 619.9)256.5(179.6, 366.5)275.4(208.9, 363.0)210.2(151.5, 291.5)238.7(194.9, 292.4)2.383.50(2.97, 4.12)3.54(2.99, 4.18)6.6(5.8, 7.4)5.3(4.9, 5.8)1.08c(0.94, 1.25)1.18e(0.99, 1.40)1.60d(1.36, 1.88)1.79c(1.43, 2.25)13.150.5(0.52.0)0.5(0.52.0)3.0(1.54.0)3.0(1.54.0)4.0(1.524.0)4.0(1.06.0)4.0(1.524.0)4.0(1.06.0)4.0(22.9, 35.7)28.4(23.0, 35.0)(20.1, 31.8)25.1(19.9, 31.7)(1.95, 2.90)2.50(1.97, 3.18)(10.96, 15.79)11.99(10.27, 13.99)(1.06.0)3.0(1.06.0)Day 4Rosuvastatin + vercirnonDay 142424242424242424e23Numbers of subjects are different because AUC values could not be calculated in a few instancesAUC 0- area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time, AUC 0-t area under the concentration-time curvefrom time zero (pre-dose) to last time of quantifiable concentration, C max maximum observed concentration, t 1/2 apparent terminal phase half-life, t maxtime of occurrence of CmaxaData presented as geometric mean (95 % confidence intervals) except for tmaxbtmax presented as median (min-max)cn =21dn =22en =23	19125	22882
579	1	4	47	1	6	42Eur J Clin Pharmacol (2014) 70:3745Table 3 Statistical summary of plasma AUC0 treatment comparisons for probe interaction assessments (PK population)TreatmentParameternTest Geom.LS MeannRef Geom.LS MeanGeom.LSMean Ratio90 % CITest : ReferenceCVw(%)Midazolam + VercirnonPioglitazone + VercirnonOmeprazole + VercirnonOmeprazole + VercirnonOmeprazole + VercirnonMidazolamPioglitazoneOmeprazoleOmeprazoleOmeprazoleRosuvastatin + VercirnonRosuvastatinMidazolam AUC0-Pioglitazone AUC0-Omeprazole AUC0-5-hydroxyomeprazole AUC0-5-hydroxyomeprazole AUC0-/omeprazole AUC0-Rosuvastatin AUC0-242423212133.05284.5634.8655.31.015242421222135.95248.9638.0692.21.0040.921.010.990.951.01(0.85, 0.99)(0.95, 1.07)(0.76, 1.31)(0.76, 1.18)(0.93, 1.09)16.011.654.342.913.72328.12428.60.98(0.88, 1.09)21.7PK pharmacokinetic, Ref reference, Geom geometric, LS least squares, CI confidence interval, CVw coefficient of variation within subjectdosing. When vercirnon was at steady-state (day 10), themean AUC 0 for the metabolites GSK2635622 andGSK2656694 averaged 1.1 % and 2.6 % of parent AUC0,respectively. Based on the data from the six subjects in thisstudy, neither metabolite would be predicted to exceed 10 %of parent exposure.SafetyVercirnon, along with the four probe substrates, was welltolerated in the 24 subjects who completed all treatments overthe course of 14 days. There were no deaths, non-fatal seriousAEs, early withdrawals due to AEs or pregnancies. A total of43 post-treatment AEs were reported during the study. Themost frequent AE was somnolence, which was reported by 13subjects on 19 occasions. In all cases, subjects were beingtreated with either midazolam alone or a combination of midazolam and vercirnon. Eight gastrointestinal AEs (dyspepsia[n =3], nausea [n =2], and one each of abdominal pain, diarrhoea and gastro-oesophageal reflux) were reported by sevensubjects. Three of these AEs were classified as potentiallydrug-related by the investigator, though only two (abdominalpain, dyspepsia) were reported during treatment with vercirnonalone. Other non-gastrointestinal AEs that occurred in morethan one subject were headache (n =4), dizziness (n =2), andabnormal dreams (n =2). All AEs were classified as mild inintensity with the exception of two clinical chemistry laboratory AEs in one subject, which were judged by the investigatorto be of severe intensity, but unrelated to study treatment. Onesubject who had normal aspartate aminotransferase (AST) andalanine aminotransferase (ALT) levels throughout the studyand at discharge was also recorded as having elevated ALT andTable 4 Summary of plasma vercirnon and metabolite PK parameters after administration of a single dose of vercirnon 500 mg (study day 5) and aftervercirnon 500 mg BID for 6 days (study day 10)Analyte/dayNAUC0 a (ng*hr/mL)Cmax (ng/mL)tmaxb(hr)VercirnonDay 5VercirnonDay 1067227(5554, 9404)8231(6657, 10,177)931(711, 1219)959(783, 1174)4.0(46)2.5(04)6.25(1.57, 24.9)65.8(28.5, 152.5)4.72(1.73, 12.88)185.0(112.1, 305.2)2.64(1.11, 6.28)7.35(3.36, 16.06)2.85(1.46, 5.54)21.15(13.63, 32.82)11.92(10.0 11.9)3.50(0.011.9)11.92(10.011.9)0.50(0.010.0)GSK2635622Day 5GSK2635622Day 10GSK2656694Day 5GSK2656694Day 1065666RoAUC0day 10/day 5RoCmaxday 10/day 51.14(0.96, 1.35)1.03(0.89, 1.19)NCNCNCNCAUC 0 area under the concentration-time curve over the dosing interval, C max maximum observed concentration, t max time of occurrence of Cmax,Ro accumulation ratio, NC not calculatedaData presented as geometric mean (95 % confidence intervals) except for tmaxbtmax presented as median (min-max)	22883	26478
580	1	4	47	1	7	Eur J Clin Pharmacol (2014) 70:374510000.0Mean plasma concentration (ng/mL)Fig. 1 Mean (95 % CI) plasmaconcentrations of vercirnon andmetabolites GSK2635622 andGSK2656694 followingvercirnon 500 mg BID for6 days (n =6)431000.0100.010.0Vercirnon1.0GSK2656694GSK26356220.101224364860728496108120132144Time (hr)AST values at an unscheduled visit (when the subject returnedto the clinic to screen for another clinical study). This was16 days after the last dose of vercirnon and rosuvastatin, whendrug concentrations would be negligible. Additional information provided by the investigator confirmed that the subjectremained well and that the transaminase levels had returned tonormal over a few weeks.All AEs resolved by the end of the study and no otherclinically significant laboratory findings, haematology, vitalsigns, or electrocardiogram (ECG) changes were observed.PharmacogeneticsPK analyses were performed for the BCRP andOATP1B1 transporter PGx sub-populations only, as nosubjects were predicted to be poor metabolisers basedon their CYP3A4/3A5, CYP2C8 or CYP2C19 genotype.An evaluation of PK endpoints in the BCRP (n =19)and OATP1B1 (n =22) PGx populations revealed no significant difference in PK outcomes compared with the overallstudy population. All geometric mean ratios were between0.98 and 1.01 and the 90 % CI were between 0.86 and 1.13.DiscussionAssessing potential drugdrug interactions is a key aspect inthe development of any pharmaceutical treatment, especiallyin the assessment of safety and effectiveness. The objective ofdrugdrug interaction studies is to determine the potential forinteractions and whether these may require dosage adjustments or additional therapeutic monitoring to maintain treatment efficacy and/or mitigate risk. Preclinical studies identified a potential interaction between vercirnon and CYP3A4,CYP2C19, and CYP2C8 activity with [I]/Ki ratios between0.1 and 1.0, which would require a follow-up clinical evaluation in line with the recommendations in the US Food andDrug Administration Guidance for Industry: Drug InteractionStudies [10], as well a potential interaction with the transporterproteins BCRP, OAT1B1, OAT1 and OAT3 (ChemoCentryxand GlaxoSmithKline, data on file). Since the in vitro resultswere similar, these studies did not help to prioritise the evaluation of clinical drug interactions. Given the number ofpotential interactions, this study was designed to utilise probesubstrates to evaluate the effect of vercirnon on the activity ofall the CYP enzymes and transporter proteins of interest inhealthy adult subjects.Ideally, selected probe substrates should be the most sensitive and specific substrates for the CYP enzymes or transportproteins under investigation. Midazolam and omeprazole arerecognised as sensitive probe substrates for CYP3A4 andCYP2C19, respectively: their AUC0 values would beexpected to increase by 5-fold when co-administered with aknown CYP3A4 or CYP2C19 inhibitor. Pioglitazone wasused as the probe substrate for CYP2C8 instead of the moresensitive probe substrate repaglinide, because it has a lowerpotential for hypoglycaemia in healthy non-diabetic subjects,and because it is also a substrate for OATP1B1; in vitro studieshave shown that vercirnon has the potential to inhibitOATP1B1 transport proteins. CYP2C8 and CYP3A4 are themain enzymes catalysing the transformation of pioglitazone. Co-administration of pioglitazone with gemfibrozil(Ki = 6975 M), a strong inhibitor of CYP2C8, significantly increases pioglitazone AUC by 3.4-fold [14]. Coadministration with rifampin, a potent inducer of CYP2C8,decreases the exposure (AUC) of pioglitazone by 54 % [15].However, co-administration of pioglitazone with ketoconazole, a strong inhibitor of CYP3A4, only increases pioglitazone by 34 %. For these reasons, pioglitazone was considereda suitable probe substrate for CYP2C8.	26479	30352
581	1	4	47	1	8	44Drug transport proteins affect the concentration of drugsand metabolites in various tissues and can have a significant effect on the safety profile of a drug. Rosuvastatin, anHMG-CoA reductase inhibitor indicated for the treatmentof hypercholesterolaemia, is recognised as a probe substratefor multiple transporters: OATP1B1, OATP1B3, OAT3 andBCRP [11]. Rosuvastatin is actively transported into hepatocytes by OATP1B1, resulting in a high first-pass effect and alow bioavailability (20 %). Co-administration of cyclosporin, an inhibitor of OATP1B1, increased rosuvastatin AUC by7-fold [16]. A recent in vitro study suggested that the BCRPefflux transporter may also play a role in rosuvastatin disposition [17]. While rosuvastatin may not be able to identifywhich transporter protein vercirnon may affect, a negativeresult would rule out drug interaction due to several transporters and confirm rosuvastatin as an anti-cholesterol agentthat may be co-administered with vercirnon.Overall, administration of midazolam, pioglitazone, omeprazole, or rosuvastatin following repeat dosing of vercirnonhad no significant effect on the systemic exposure (AUC0)of each probe. This indicates that vercirnon exerted no substantial clinical effect on the activity of CYP enzymesCYP3A4, CYP2C8, CYP2C19 or on BCRP and OAT1B1transporter activity.In the case of omeprazole, the %CVw for the AUC0treatment comparison was particularly high (54.3 %). Thiscould be an outlier effect, as one subject recorded the lowestexposure when receiving omeprazole alone, followed by oneof the highest exposures when he received omeprazole incombination with vercirnon. Additional statistical analysis,excluding this subject from the omeprazole analysis, reducedthe %CVw for omeprazole to 27.8 %. However, excludingthis subject did not have a substantial impact on the overallfindings. While safety and tolerability data were collected inthis study, it must be noted that the study was not powered toassess these outcomes, and any interpretation should be madewith caution. Nevertheless, the results of this study suggestthat short-term exposure to vercirnon appears to have afavourable safety and tolerability profile. This requires confirmation in future studies. In addition, although there is a lowpredicted potential for vercirnon to interact with other drugs,or vice versa, this study did not directly assess the interactionof vercirnon with current treatments for Crohns disease, suchas corticosteroids, immunosuppressives, and tumour necrosisfactor inhibitors. Vercirnon is a distinct class of compound tothese treatments, and so the potential for combination therapywarrants investigation in future studies.In conclusion, the results of this study confirm and extendthose from in vitro studies, demonstrating that vercirnon isunlikely to affect the clearance of other drugs metabolised byCYP3A4, CYP2C8 and CYP2C19 enzymes, or affect thetransport activity of BCRP or OATP1B1. This indicates thatEur J Clin Pharmacol (2014) 70:3745there is a low risk of drugdrug interactions with repeat dosesof vercirnon, supporting its use in Phase III clinical trials.Acknowledgments The authors wish to thank Robert Blum and thestaff at Buffalo Clinical Research Center (BCRC), Buffalo, NY, US fortheir support with the study; Beth Harris and Louise Drewett for assistancein analysing genetic outcomes; and Gary Bowers, Grant Generaux, and JoePolli for scientific consultation. Editorial support was provided by KarenYee and Stuart Wakelin at Fishawack Scientific Communications Ltd.Funding disclosure This study was funded by GlaxoSmithKline. Statistical analysis, provided by PHASTAR, Chiswick, UK, and editorialsupport, provided by Fishawack Scientific Communications Ltd., werefunded by GlaxoSmithKline.Declaration of conflict of interest Lynda J Haberer, Iain McSherry,and Linda McCarthy are GlaxoSmithKline employees and holdGlaxoSmithKline stock and stock options. Anna Cargill is an employeeof PHASTAR, Chiswick, UK (funded by GlaxoSmithKline to providestatistical analysis).Open Access This article is distributed under the terms of the CreativeCommons Attribution License which permits any use, distribution, andreproduction in any medium, provided the original author(s) and thesource are credited.References1. Wurbel MA, Philippe JM, Nguyen C, Victorero G, Freeman T,Wooding P et al (2000) The chemokine TECK is expressed bythymic and intestinal epithelial cells and attracts double- and singlepositive thymocytes expressing the TECK receptor CCR9. Eur JImmunol 30:2622712. Papadakis KA, Prehn J, Nelson V, Cheng L, Binder SW, Ponath PD,Andrew DP, Targan SR (2000) The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regionalspecialization of the mucosal immune system. J Immunol 165:506950763. Zabel BA, Agace WW, Campbell JJ, Heath HM, Parent D, RobertsAI et al (1999) Human G protein-coupled receptor GPR-9-6/CCchemokine receptor 9 is selectively expressed on intestinal homingT lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J ExpMed 190:124112564. Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ et al(2010) Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatorybowel disease. J Pharmacol Exp Ther 335:61695. Abraham C, Cho JH (2009) Inflammatory bowel disease. N Engl JMed 361:206620786. Keshav S, Vanasek T, Niv Y, Petryka R, Howaldt S, Bafutto M et al(2013) A randomized controlled trial of the efficacy and safety ofCCX282-B, an orally-administered blocker of chemokine receptorCCR9, for patients with Crohns disease. PLoS One 8:e600947. Marsal J, Agace WW (2012) Targeting T-cell migration in inflammatory bowel disease. J Intern Med 272:4114298. Buckley JP, Kappelman M, Allen JK, Van Meter SA, Cook S (2013)The burden of comedication among inflammatory bowel diseasepatients. Gastroenterology 144(Supp 1):S-3889. Haberer LJ, Hacquoil K, Ino H, Sakamoto T, Kanemoto N, McSherryI et al (2013) Single-dose pharmacokinetics of the CCR9 receptor	30353	36483
582	1	4	47	1	9	Eur J Clin Pharmacol (2014) 70:3745antagonist vercirnon in healthy US and Japanese subjects. ClinPharmacol Drug Dev. doi:10.1002/cpdd.4110. US Department of Health and Human Services Food and DrugAdministration Center for Drug Evaluation and Research (CDER)(2006) Guidance for Industry: Drug Interaction StudiesDraft Guidance. Study Design, Data Analysis, and Implications for Dosing andLabeling11. US Department of Health and Human Services Food and DrugAdministration Center for Drug Evaluation and Research (CDER)(2012) Guidance for Industry: Drug Interaction StudiesDraft Guidance. Study Design, Data Analysis, and Implications for Dosing andLabeling. Accessed September 2013 at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf.12. Lawson EB, Wu JC, Baldwin RM, Ingelman-Sundberg M,Rosenborg S, Yim DS et al (2012) Omeprazole limited samplingstrategies to predict area under the concentration-time curve ratios:implications for cytochrome P450 2C19 and 3A phenotyping. Eur JClin Pharmacol 68:40741313. Deeken J (2009) The Affymetrix DMET platform and pharmacogeneticsin drug development. Curr Opin Mol Ther 11:2602684514. Deng LJ, Wang F, Li HD (2005) Effect of gemfibrozil on thepharmacokinetics of pioglitazone. Eur J Clin Pharmacol 61:83183615. Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ(2005) Effect of rifampicin on the pharmacokinetics of pioglitazone.Br J Clin Pharmacol 61:707816. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, BrownCD et al (2004) Rosuvastatin pharmacokinetics in heart transplantrecipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:16717717. Huang L, Wang Y, Grimm S (2006) ATP-dependent transport ofrosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738742Contributions of authors statementAll authors were involved in the conception and design of the study aswell as in the analysis and interpretation of data. Linda McCarthy wasalso involved in acquisition of data. All authors contributed to drafting themanuscript, revised it critically for important intellectual content andprovided final approval for the final version to be published.	36484	38733
85	1	2	16	1	62	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,34] (Submission 000)Victoza? (liraglutide)Study procedures included a screening visit followed by a 2 4 week forced glimepiride titration up to 4mg/day prior to randomization. Subjects that were evaluated as being eligible at the screening visit wereto discontinue their usual and commence an open 2-week run-in period with forced titration ofglimepiride therapy increasing to 4 mg/day followed by a 2-week maintenance period. Subjects oncurrent glimepiride therapy could go through a modified titration period or advance directly to the 2-week maintenance period at the discretion of the investigator. The doses of glimepiride (open-label)could be reduced from 4 mg/day to 3 or 2 mg/day (minimum) after randomization in the event ofunacceptable hypoglycemia or other adverse events. Subjects who required less than 2 mg glimepiridewere discontinued from the trial (see Table 6.5).Figure 6.4 Procedures for Trial 1436forced titration of (louhle~biind follow-u glimepiride trial product? 'n1ainIcna'ncc periodtitration treatmentscreening rand nmisationiI 2 weeks 2 to 4 weeks? 2 weeks 24 weeks 1 weeklimglutide (0.6 y)  glimepiride (2-4 rngday) rosiglitazone placeboiiragiutide (1.2 glimepiride (2-4 rnsiglilazone placeboIiraglulide (1.8 midday)  zziinaepirideil-41:1gfday) rosiglitzxzone piacebeN=l 14: liraglulide placebo glimepiride (2-4 mgfday)  resiglitazoiie. placebolimglulide placebo giiniepiride (2-4 rnsiglitazonc Reviewer's comments: Th_e usual maintenance dose of glimepiride is 2-4 mg daily. Therefore, thisstudy?s 4 mg background glimepiride dose is appropriate. Because sulfonylureas have similarefficacy, results from this trial should also apply to patients using maintenance doses of othersulfonylureas.The protocol permitted an increase in glimepiride dosage within 3-6 weeks prior to the baselineHbA1c measurement. Improved glycemic control resulting from this regimen change would not befully reflected in the baseline HbA1c measurement (HbA1c represents glycemic control over theprior three months). This could lead to over-estimation of the within group primary ef?cacyvariable (change in HbA1c from baseline to endpoint) in these patients because some of theimprovement in HbA1c during the double-blind treatment period would be attributable to therecent increase in glimepiride dosage. Therefore, the change in HbA1c should be reported relativeto placebo. The baseline value of HbA1c is really a reflection of the decreasing effects of OADSused prior to study entry and the increasing effects of glimepiride.50	131020	133595
583	1	4	48	1	1	1521-009X/41/5/987993$25.00DRUG METABOLISM AND DISPOSITIONCopyright  2013 by The American Society for Pharmacology and Experimental Therapeuticshttp://dx.doi.org/10.1124/dmd.112.050203Drug Metab Dispos 41:987993, May 2013Drug Cocktail Interaction Study on the Effect of the OrallyAdministered Lavender Oil Preparation Silexan on CytochromeP450 Enzymes in Healthy VolunteersOxana Doroshyenko, Dennis Rokitta, Gregor Zadoyan, Stephan Klement, Sandra Schlfke,Angelika Dienel, Thomas Gramatt, Hendrik Lck, and Uwe FuhrITECRA GmbH & Co. KG, Cologne, Germany (O.D., G.Z., H.L., U.F.); Department of Pharmacology, Clinical Pharmacology Unit;University Hospital, University of Cologne, Cologne, Germany (D.R., G.Z., U.F.); Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe,Germany (S.K., S.S., A.D.); and Drug Development Consulting, Dresden, Germany (T.G.)Received November 19, 2012; accepted February 7, 2013This cocktail study evaluated the interaction potential of the orallavender oil preparation silexan with major P450 (cytochrome P450)enzymes. Subjects and Methods: Sixteen healthy male or femaleCaucasians completed this double-blind, randomized, 2-fold crossover study. Silexan (160 mg) or placebo were administered once dailyfor 11 days. Additionally, on day 11 of both study periods, 150 mgcaffeine (CYP1A2), 125 mg tolbutamide (CYP2C9), 20 mg omeprazole(CYP2C19), 30 mg dextromethorphan-HBr (CYP2D6), and 2 mgmidazolam (CYP3A4) were administered orally. Formal interactionwas excluded if the 90% confidence interval (CI) for the silexan overplacebo ratios for phenotyping metrics (primary: AUC0t) was withina 0.701.43 range. Results: According to the AUC0t comparisons,silexan had no relevant effect on CYP1A2, 2C9, 2D6, and 3A4 activity.Secondary phenotyping metrics confirmed this result. Mean ratiosfor all omeprazole-derived metrics were close to unity. The 90% CIfor the AUC0t ratio of omeprazole but not for omeprazole/5OH-omeprazole plasma ratio 3 hours post-dose or omeprazole/5OH-omeprazole AUC0t ratio (secondary CYP2C19 metrics) wasabove the predefined threshold of 1.43, probably caused by theinherent high variability of omeprazole pharmacokinetics. Silexanand the phenotyping drugs were well tolerated. Repeated silexan(160 mg/day) administration has no clinically relevant inhibitory orinducing effects on the CYP1A2, 2C9, 2C19, 2D6, and 3A4 enzymes invivo.Introduction(Frye et al., 1997; Tucker et al., 2001; Christensen et al., 2003; Sharmaet al., 2004; Fuhr et al., 2007; Wohlfarth et al., 2012).The oral lavender oil preparation silexan (the active substance ofLASEA, W. Spitzner Arzneimittelfabrik GmbH, Ettlingen, Germany)80 mg/day showed its efficacy as compared with placebo or to low-doselorazepam 0.5 mg/day in patients with subthreshold and syndromalanxiety disorders (Kasper et al., 2010a,b; Woelk and Schlfke, 2010).Silexan has been approved in Germany for the treatment of restlessnesswith anxious mood [Summary of Product Characteristics (SmPC) forLASEA (NN, 2010)]. Pharmacokinetic studies performed with silexandemonstrate a rapid absorption and elimination of linalool with anapparent elimination half-life (t1/2) of about 4 hours after a single doseand about 9 hours after 14 days of once daily administration (Kasperet al., 2010b).Information from traditional use of Lavandula angustifolia (e.g.,EMA community herbal monographs on L. angustifolia Miller, flos(European Medicines Agency, 2012a) and aetheroleum (EuropeanMedicines Agency, 2012b) and from limited in vitro tests conductedusing human hepatocytes does not suggest that silexan would interactwith cytochrome P450 enzymes (Dr. Willmar Schwabe GmbH & Co.KG, data on file). Because it is, however, questionable whether invitro drug-drug interaction studies with herbal drugs are predictive forin vivo interactions, the present clinical study was conducted toAssessing the potential of new drugs to change the activity ofenzymes and/or transporters involved in pharmacokinetic processesand thus to cause respective drug-drug interactions is an integral partof clinical development also for herbal medicines. To this end, actualactivity of many important drug-metabolizing enzymes in an individual may be quantified by phenotyping, i.e., by administrationof an appropriate substrate for a given enzyme and subsequent determination of pharmacokinetic parameters reflecting activity of thisenzyme (Fuhr et al., 2007). Phenotyping methods are extensively usedfor the qualitative and quantitative determination of factors influencingenzyme activity, including drug-drug interactions (Schellens et al.,1989; Adedoyin et al., 1998; Gorski et al., 2004; Zadoyan et al.,2012). Several selective substrates of important P450s may beadministered concomitantly (cocktail) to simultaneously investigateeffects of particular drugs toward the major drug-metabolizing enzymesIn adherence to the guidelines of the International Committee of MedicalJournal Editors, it is declared that this study is work for hire supported byDr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany (sponsor). S.K., S.S.,and A.D. are employees of Dr. Willmar Schwabe GmbH & Co. K.G. and T.G.received honoraria from Schwabe. No further conflict of interest is to be declared.dx.doi.org/ 10.1124/dmd.112.050203.ABBREVIATIONS: AE, adverse event; AUC0t, area under the plasma concentration-time curve between 0 and time of last quantifiableconcentration; AUC0, area under the plasma concentration-time curve extrapolated to infinity; Cmax, maximal plasma concentration; CI,confidence interval; DMSO, dimethylsulfoxide; EI, electron ionization; linalool, 3,7-dimethylocta-1,6-dien-3-ol; linalyl acetate, 3,7-dimethylocta-1,6dien-3-yl acetate; LLOQ, lower limit of quantification; P450, cytochrome P450.987Downloaded from dmd.aspetjournals.org at ASPET Journals on October 21, 2014ABSTRACT	0	5852
584	1	4	48	1	2	988AUC0t, area under the plasma concentration-time curve between 0 and time of last quantifiable concentration; AUC0, area under the plasma concentration-time curve extrapolated to infinity; Cmax, maximal plasma.aAUC0t, AUC0, Cmax, t1/2: geometric mean (95% CI), tmax: median (range).bUnits for Cmax of omeprazole, dextromethorphan, and midazolam are nM, those for caffeine and tolbutamide are mM; units for AUC0 of omeprazole, midazolam, and dextromethorphan are h*nM, those for caffeine and tolbutamide are h*mM.cThe primary phenotyping metrics are printed in bold.dN = 15.eOne subject excluded because identified as genetically poor metabolizer.fN = 10.gN = 12.hN = 13.(27.243.5)(0.332.50)(71.3110.0)(74.3121.1)(2.395.21)(31.5-43.5)(0.501.00)(72.3104.6)(75.0120.0)(2.846.62)(1.94-6.72)(1.005.00)(9.4043.3)(16.566.6)(5.138.53)(2.045.75)(0.504.00)(9.837.7)(13.758.0)(4.808.81)(352895)(0.506.00)(7521800)(7211791)(0.7030.938)(50.869.3)(0.756.00)(477648)(539794)(6.719.68)(50.868.5)(1.505.00)(458631)(492703)(6.258.37)(18.324.5)(0.173.02)(114198)(120213)(3.635.09)21.200.761501604.30(20.525.4)(0.181.50)(135221)(147250)(3.945.72)tmax (h)AUC0tb,cAUC0bt1/2 (h)CmaxbTreatment22.810.55173192d4.75dPlaceboN =16ParametersaSilexan59.03.03537589d7.23dPlaceboN = 1659.33.005566548.06Silexan5242.25101810360.834Placebo(314877)(0.504.00)(6331636)(6461661)(0.7120.976)5612.0011641137d0.812dSilexan3.422.5019.228.2f6.50fPlacebo3.612.5020.233.1g6.61gSilexan37.00.7587.095.0h4.33hPlacebo34.40.7588.694.9d3.53dN = 16N = 15eN = 16Omeprazole (2C19)Tolbutamide (2C9)Caffeine (1A2)Phenotypingdrug (P450)TABLE 1Plasma pharmacokinetic parameters of the phenotyping drugs including primary phenotyping metricsStudy Population and Study Design. The study protocol was approved bythe Ethics Committee of the North Rhine Medical Association, Germany, andthe study carried out in accordance with German laws, the Declaration ofHelsinki, and other international guidelines. All study subjects provided writteninformed consent. Healthy male and female caucasians aged between 18 and 55years were included in a single center, double-blind, randomized, placebocontrolled, two-period crossover design.In the test period, 160 mg silexan (one soft gelatin capsule) was administeredorally once daily on days 111. This preparation contains 160 mg of anessential oil produced from L. angustifolia flowers by steam distillation. Itcomplies with the monograph Lavender oil (Lavandulae aetheroleum) of theEuropean Pharmacopeia (Council of Europe, 2008) with respect to all qualityparameters. According to these specifications, required contents are 2045%and 2546% for linalool and linalyl acetate, respectively. In the referenceperiod, placebo capsules were administered instead. For each drug intake, thevolunteers reported to the study ward.In both study periods, administrations on day 11 were performed togetherwith the five-probe phenotyping cocktail. The volunteers were hospitalized 12hours before cocktail administration until 24 hours thereafter. Solid oralpreparations of four cocktail drugs [150 mg caffeine (three tablets ofPercoffedrinol N; Lindopharm GmbH, Germany), 125 mg tolbutamide (onequarter of a tablet, to be weighed; Actavis UK Limited, UK), 20 mg omeprazole(one tablet Omeprazol-ratiopharm NT 20 mg; ratiopharm GmbH, Germany),and 30 mg dextromethorphan-HBr (one capsule Hustenstiller ratiopharm;ratiopharm GmbH, Germany)] were administered orally together with silexanor placebo to evaluate the in vivo CYP1A2, 2C9, 2C19, and 2D6 activities,respectively. For the assessment of the total (liver and intestine) CYP3A4activity, 2 mg midazolam [2 ml taken orally with 120 ml of water (Dormicum Vinjection solution 5 mg/5ml; Roche Pharma AG, Grenzach-Wyhlen, Germany)]were administered 1 minute thereafter.Intake of food and beverages was standardized for the in-house phase. Onday 11, the fasting period lasted from at least 9 hours before until 6 hours afterdosing, and fluid intake regularization was applied from 1 hour before until 6hours after dosing. During the ambulant periods (days 110 in both studyperiods and the washout phase of 21 days between cocktail administrations),nonalcoholic and noncaffeinated food and beverages without quinine or grapefruitcould be consumed ad libitum. Alcohol and grapefruit juice were prohibitedfrom 1 week prior to the study until the follow up examination performed 410days after last dosing.From 1 hour before administration of phenotyping cocktail until 4 hourspost-dose, subjects remained in a recumbent position, which was continuouslysupervised by study personnel.The study subjects were closely surveyed throughout the study for evidenceof clinical or laboratory adverse events (AEs).Blood Sampling. In both study periods, blood (10 ml per sample) for thedetermination of constituents of silexan was sampled approximately 10 minutesprior to the 5th, 10th, and 11th dosing to quantify exposure. The blood sampleswere collected into Sarstedt Monovette citrate tubes (Sarstedt AG and Co.,Nmbrecht, Germany) and then centrifuged (2000g, room temperature, 10minutes). The resulting plasma was transferred into two polypropylene tubes,immediately frozen, and stored in a freezer at 20 or below until assayed.For determination of the phenotyping substances and calculation of theprimary phenotyping metrics (Table 1), 9-ml blood samples were drawn approximately 10 minutes prior to dosing and 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5,3, 4, 5, 6, 8, 12, 16, and 24 hours post-dose. For determination of secondaryphenotyping metrics (Table 2) with the purpose of further validation of thephenotyping results, additional blood sampling was carried out approximately 10minutes prior to dosing and 3 and 6 hours post-dose. The blood samples werecollected into Sarstedt Monovette lithium heparin tubes, immediately cooledin ice water, and then centrifuged (2000g, +4C, 10 minutes). The supernatantDownloaded from dmd.aspetjournals.org at ASPET Journals on October 21, 2014Midazolam (3A4)Materials and MethodsDextromethorphan (2D6)provide conclusive data on any potential effects of silexan on theactivity of major P450s in humans. A cocktail approach was used toassess the interaction potential of silexan 160 mg toward CYP1A2,2C9, 2C19, 2D6, and 3A4 enzymes.SilexanDoroshyenko et al.	5853	12218
585	1	4	48	1	3	989Cocktail Interaction Study on Silexan in Healthy SubjectsTABLE 2Secondary phenotyping metricsGeometric Mean (95% CI)Secondary Phenotyping MetricaCYPSample SizeUnitsPlaceboSilexanMolar paraxanthine/caffeine plasma concentrationratio 6 h post-doseTolbutamide plasma concentration 24 h post-doseMolar omeprazole/5-OH-omepazole plasmaconcentration ratio 3 h post-doseMolar omeprazole/5-OH-omepazole AUC0t ratio CYP2C19Molar dextromethorphan/dextrorphan plasmaconcentration ratio 3 h post-doseMidazolam plasma concentration 6 h post-dose1A216None1.09 (0.761.56)1.27 (0.931.73)2C92C191616bmMNone6.16 (4.408.63)0.800 (0.5831.10)6.81 (4.989.31)0.820 (0.5611.20)2D61615cNoneNone0.795 (0.6151.03)0.263 (0.1370.504)0.884 (0.6941.13)0.297 (0.1490.592)3A416nM4.07 (3.195.20)4.23 (3.255.52)AUC0t, area under the plasma concentration-time curve between 0 and time of last quantifiable concentration.aUnits for concentrations of midazolam are nM, those for tolbutamide are mM.bConcentration in one subject in the silexan period was below limit of quantification.cOne subject excluded because identified as genetically poor metabolizer.assessments were considered as separate tests for the respective enzyme. Linearcorrelation was used to assess the relationship between primary and secondaryphenotyping parameters.Sample Size Determination. Intraindividual CVs were assumed not toexceed 25% for any phenotyping metric (Fuhr et al., 2007). Lack of interactionwas assumed if the 90% CI for estimated ratio mtest/mreference did not exceeda tolerance zone of 0.701.43 for phenotyping metrics. For 0.95 # true ratiomtest/mreference # 1.05, N = 14 would allow rejection of each null hypothesisinteraction present with a = 0.05 (two-sided) and a power of at least 90%.Two additional subjects were included to account for eventual drop-outs asa safety margin, resulting in a sample size of N = 16.ResultsDemographic Data. In total, 17 white Caucasian subjects (8 males,9 females) participated in this study. The respective means and rangesfor age and body mass index were 37 (2152) years and 23.5(19.726.9) kg/m2. All subjects were nonsmokers at the time of thestudy, three subjects (17.6%) had smoked in the past. Six of the femalesubjects used oral contraceptives prior to and during the study. Allsubjects were healthy as confirmed by an extensive prestudy examination. After completion of the first study period, one subjectwithdrew due to AEs. Sixteen subjects completed the study and wereincluded in the analysis.Concentrations of Linalool and Linalyl Acetate in Plasma.Following administration of silexan, concentrations of linalyl acetatewere unquantifiably low (,2 ng/ml) in all samples, whereas thepresence of linalool (concentrations ranged from 2.2 to 9.0 ng/ml,LLOQ 2 ng/ml) confirmed compliance in all cases. Mean values forthe linalool concentrations were 2.02 ng/ml, 3.30 ng/ml, and 2.95 ng/mlprior to the 5th, 10th, and 11th dose of silexan, respectively, indicatingthat steady state has been reached on the phenotyping day.Identification of Genotypes Coding for Absent ProteinExpression. One study subject was identified as a poor metabolizerfor CYP2D6 and was excluded from the analysis of interaction for thisenzyme. With respect to the CYP2C19 genotype, no carriers of twoalleles coding for nonfunctional enzyme were identified in the studypopulation.Pharmacokinetic Parameters for Phenotyping Substrates.Concentration-time profiles of phenotyping drugs are shown in Fig. 1.Phenotyping metrics of the P450 substrates calculated followingadministration of the test and reference treatments are presented inTables 1 and 2. A summary of the statistical analysis, i.e., pointestimates and 90% CIs, on the effect of silexan on phenotypingmetrics is provided in Table 3.Downloaded from dmd.aspetjournals.org at ASPET Journals on October 21, 2014plasma was transferred into four polypropylene tubes, immediately frozen, andstored deep-frozen at a temperature below 65C.At the eligibility assessment, blood was drawn for genotyping into SarstedtMonovette EDTA tubes. Genotyping was performed to identify individualswith two important nonfunctional alleles of CYP2C19 (*2, *3) and/or CYP2D6(*3, *4, *5, *6) (see http://www.cypalleles.ki.se/) with an approximategenotype frequency of 1 and 7%, respectively, in the Caucasian population.Such subjects were excluded from analyses for the respective metric becauseany interaction with regard to a specific enzyme cannot occur in its absence.Analytical Methods. The quantification of phenotyping substrates (caffeine,tolbutamide, omeprazole, dextromethorphan, and midazolam) in plasma wasperformed using specific and sensitive liquid chromatography/tandem massspectrometry methods as described earlier (Kasel et al., 2002; Jetter et al., 2004;Tomalik-Scharte et al., 2005; Frank et al., 2007; for specific details, seeZadoyan et al., 2012).For the silexan constituents linalool (3,7-dimethylocta-1,6-dien-3-ol) andlinalyl acetate (3,7-dimethylocta-1,6-dien-3-yl acetate), samples were analyzed by headspace gas chromatography-mass spectrometry with electronionization mode using a headspace autosampler G1888 (Agilent Technologies, Santa Clara, CA), gas chromatograph 7890A (Agilent Technologies;from 80C to 230C with 10C/min, helium, flow 1.5 ml/min), mass selectivedetector 5975C (Agilent Technologies), software MSDCHEM Station(Agilent Technologies), and a capillary column (J&W) DB WAXetr (60 m 0.32 mm, 0.5 mm; Agilent Technologies). Dimethylsulfoxide (DMSO) was usedas solvent for test and calibration solutions. Extraction and purification ofreference substances was done in-house by Dr. Willmar Schwabe GmbH & Co.KG, Karlsruhe, Germany, achieving 97.6% purity of linalool and 97.7% purityfor linalyl acetate. Quantification of both substances was performed by linearregression with the primary reference standard linalool (ion 93.1 m/z) andinternal standard. Lower limit of quantification (LLOQ) for linalool and linalylacetate was 2 ng/ml, working range was 22000 ng/ml. Interday precision forlinalool was between 0.1 and 7.0% and for linalyl acetate between 0.4 and12.0%, with interday accuracy between 6.0 and 1.6%, and 7.2 and 5.6%,respectively.Data Analysis. Pharmacokinetic parameters of phenotyping drugs weredetermined from actual blood sampling times (relative to drug administration)for post-dose samples, and assayed drug plasma concentrations at these timesusing standard noncompartmental methods (WinNonlin Professional, version5.2; Pharsight Corporation, Palo Alto, CA).Plasma concentrations and all phenotyping metrics were assumed to arisefrom a log-normal distribution (multiplicative model).For all probe substances of the cocktail, the main phenotyping metric wasthe area under the plasma concentration-time curve between administration andtime of last quantifiable concentration (AUC0t) of the parent compound(Tables 1 and 2). The treatments were compared using standard averagebioequivalence procedures (Steinijans et al., 1996) for the respective phenotypingmetrics (Tables 1 and 2) obtained following silexan (test) and placebo (reference)treatments. There was no adjustment for multiple comparisons because all	12219	19425
586	1	4	48	1	4	990Doroshyenko et al.Mean Cmax, AUC0t, and and area under the plasma concentrationtime curve extrapolated to infinity (AUC0) (reflecting the extent ofdrug absorption and exposure) as well as median tmax (indicating therate of drug absorption) and mean t1/2 (reflecting drug elimination)values of the probe substances were in most cases very similar afterboth treatments (Tables 1 and 2), with a few apparent exceptions.Downloaded from dmd.aspetjournals.org at ASPET Journals on October 21, 2014Fig. 1. Median plasma concentration-time profiles of the phenotyping drugs insilexan and placebo periods. Values below respective LLOQ are not shown.Median tmax of a CYP1A2 probe drug caffeine occurred later aftersilexan (0.76 hour) than after placebo (0.55 hour) administration.Mean AUC0t of the CYP2C19 probe substrate omeprazole wasslightly increased after treatment with silexan (1164 hours*nM)compared with the value observed after placebo treatment (1018hours*nM). For the CYP3A4 probe substrate midazolam, mean t1/2was shorter after silexan administration (3.53 hours) compared withplacebo administration (4.33 hours).Phenotyping Metrics and Effect of Silexan on the Activity ofP450 Enzymes. For CYP1A2, 2C9, 2D6, and 3A4 metrics, the 90%CIs for the ratios (silexan/placebo) of the primary and secondaryphenotyping metrics were well within the predefined acceptance rangeof 0.701.43 (Table 3). Thus, a pharmacokinetic interaction betweensilexan and drugs which are substrates of these enzymes could beexcluded.The upper bound of the 90% CI for the AUC0t ratio of theCYP2C19 probe substrate omeprazole was above the threshold of1.43, while the respective values for secondary phenotyping metrics(molar omeprazole/5-OH-omepazole plasma concentration ratio 3 hourspost-dose and molar omeprazole/5-OH-omepazole AUC0t ratio) werewithin the acceptance range. Point estimates for the ratios silexan/placebo of all CYP2C19 metrics used were close to unity (Table 3).Marked heterogeneity of measurements with respect to the AUC0t,AUC0, and Cmax values for all omeprazole metrics used was observed.The exceeding of the acceptance range for the main phenotyping metricof omeprazole thus is probably caused by the inherent high variability ofomeprazole pharmacokinetics. Therefore, a clinically relevant pharmacokinetic interaction between silexan and CYP2C19 substrates is notexpected.In general, secondary phenotyping metrics provided similar resultsas the primary ones with regard to a potential interaction. Intraindividual variability of secondary phenotyping metrics depended on thetype of metric and on phenotyping drug and could be lower or higherthan for the primary metric (Table 3). Correlations between the mainand the secondary phenotyping metrics, calculated to provide furtherinformation for the use of simplified phenotyping strategies, weresignificant (P , 0.05) in all cases (Table 4).Safety and Tolerability. Eleven AEs were observed in 5/16(31.3%) subjects and 30 AEs in 15/17 (88.2%) subjects during anduntil 7 days after last placebo or silexan administration.Mild eructation occurred shortly after drug intake and was the mostfrequently reported AE, which was experienced by 10 (58.8%)subjects (in five subjects as a single event) after treatment with silexanand by no subject after placebo.With respect to the double-blind treatment, the causal relationshipwith silexan was considered as probable for five AEs (five cases ofeructation, silexan), as possible for eight AEs [eructation (five cases,silexan), diarrhea (one case, silexan), nausea (one case each, silexanand placebo)], and as unlikely for 27 AEs.With respect to the phenotyping cocktail, the causal relationship wasconsidered as possible for three AEs (nausea, dizziness, and vomiting)in two subjects and as unlikely for three AEs (cold, increased hematocrit, and increased erythrocytes count) in two subjects.No severe or serious AEs occurred during the study. One subjectdropped out due to moderate AEs (nausea before intake of study drugand vomiting after administration of the phenotyping cocktail) in thestudy period with silexan treatment.Mean vital signs, ECG, and laboratory parameters showed noclinically relevant changes during the study.Thus, repeated administration of silexan (160 mg/day) alone ortogether with the probe substrates were well tolerated by healthysubjects in this study.	19426	23808
587	1	4	48	1	5	991Cocktail Interaction Study on Silexan in Healthy SubjectsTABLE 3Assessment of the effect of silexan on phenotyping metrics given as ratios for silexan over placebo periodsCYPParameteraSample SizeRatio90% CICVintra%1A2AUC0t of caffeine in plasmaMolar paraxanthine / caffeine plasma concentration ratio 6 h post-doseAUC0t of tolbutamide in plasmaTolbutamide plasma concentration 24 h post-doseAUC0t of omeprazole in plasmaMolar omeprazole / 5-OH-omepazole plasma concentration ratio 3 h post-doseMolar omeprazole / 5-OH-omepazole AUC0t ratioAUC0t of dextromethorphan in plasmaMolar dextromethorphan / dextrorphan plasma concentration ratio 3 h post-doseAUC0t of midazolam in plasmaMidazolam plasma concentration 6 h post-dose161616161615b1615c15c16160.8691.161.0351.1061.1431.0441.1111.0461.1311.0181.0400.7860.9610.9561.4140.9731.1010.9701.2610.8101.6140.8421.2940.9981.2370.8381.3050.9621.3280.8941.1590.8471.27716.232.210.021.359.934.317.436.725.221.133.82C92C192D63A4AUC0t, area under the plasma concentration-time curve between 0 and time of last quantifiable concentration; CI, confidence interval; CVintra, intrasubjectcoefficient of variation.aThe main phenotyping metrics are printed in bold.bConcentration in one subject in the silexan period was below limit of quantification.cOne subject excluded because identified as genetically poor metabolizer.The objective of the study was to assess the in vivo interactionpotential of silexan with respect to the activities of five major P450enzymes using the cocktail approach. The study using state-of-the-artmethodology showed that repeated administration of silexan has noclinically relevant inhibitory or inducing effects toward the CYP1A2,2C9, 2C19, 2D6 and 3A4 enzymes.A higher silexan dose (160 mg/day) as compared with the standarddose of 80 mg/day was chosen in the study to maximize exposure inthe present drug interaction study (European Medicines Agency,2012c; Food and Drug Administration, 2012).Plasma concentration measurements of the silexan constituents(linalool and linalyl acetate) confirm the compliance of study subjects.Based on linalool concentration data, it could be concluded that theinteraction potential of silexan was assessed under steady-state conditions. Plasma concentrations of linalyl acetate below LLOQ can beexplained by the pharmacokinetic properties of the compound (rapidelimination) and the time point of sampling.The current pharmacokinetic approach allowed the effects ofsilexan toward major P450 enzymes to be examined systematically,simultaneously, and under standardized conditions. For scientificreasons and in line with existing guidelines on drug interactions(European Medicines Agency, 2012c; Food and Drug Administration,2012), a crossover design of the study was chosen as the within-subjectvariability was expected to be smaller than the between-subjectvariability. Based on the a priori estimation of the sample sizerequired, the number of study participants turned out to be sufficientfor all enzymes except CYP2C19, although intraindividual variability for several phenotyping metrics was higher than expected(Table 3).The probe drugs were selected in accordance with existingguidelines (Food and Drug Administration, 2012; European MedicinesAgency, 2012c) and scientific literature (Gorski et al., 2004; Franket al., 2007; Fuhr et al., 2007; Wohlfarth et al., 2012). All of thesedrugs are established probe substrates meeting the important criteriafor cocktail drugs: selectivity toward the respective P450s (i.e., theprobe drug is cleared predominantly by a single P450 enzyme),absence of interference with the metabolism and clearance of otherdrugs in the cocktail, safety and good tolerability, availability andvalidity of bioanalytical assays, and appropriateness of phenotypingmetrics. Selectivity of these substrates for respective P450s is supported by a number of investigations; following single doses, they donot affect the in vivo activity of any other of the enzymes to a relevantextent and no mutual interactions by their coadministration has beenreported (Endres et al., 1996; Frye et al., 1997; Streetman et al., 2000;Wang et al., 2001; Zhu et al., 2001; Fuhr et al., 2007; Turpault et al.,2009). There is, however, a caveat for CYP2C19 phenotyping. TheEMA Guideline on the Investigation of Drug Interactions (EuropeanMedicines Agency, 2012c) considers omeprazole as not sufficientlyvalidated as a phenotyping drug, but accepts its use as a standard ofTABLE 4Correlation of secondary phenotyping metrics to the primary metric AUC0t of the parent substanceSilexan TreatmentCYPnrd0.531*160.698**1615b0.842**0.697**16160.928**0.539*1615c0.905**0.971**1615c0.771**0.983**160.933**160.855**n1A22C92C192D63A4aMolar paraxanthine / caffeine plasma concentration ratio6 h post-doseaTolbutamide plasma concentration 24 h post-doseMolar omeprazole/5-OH-omepazole plasma concentration ratio3 h post-doseMolar omeprazole/5-OH-omepazole AUC0t ratioMolar dextromethorphan/dextrorphan plasma concentrationratio 3 h post-doseMidazolam plasma concentration 6 h post-doser16For calculation of this correlation, the inverse value (i.e., caffeine/paraxanthine ratio) was used.Concentration in one subject in the silexan period was below LLOQ.One subject excluded because identified as genetically poor metabolizer.dPearsons correlation coefficient.*P = 0.05; **P = 0.01.bcPlacebo TreatmentSecondary MetricdDownloaded from dmd.aspetjournals.org at ASPET Journals on October 21, 2014Discussion	23809	29326
588	1	4	48	1	6	992Doroshyenko et al.gastric emptying is expected to contribute to variability in pharmacokinetic parameters. An intraindividual comparison of the ratio foromeprazole revealed that in 6 of 16 volunteers the ratio AUC-silexanto AUC-placebo was $1.25, but in five volunteers it was below one.The group of the six volunteers with ratios $1.25 showed the lowestmedian of their AUC values after placebo treatment and individualratios $1.25 were observed only for low omeprazole AUCs underplacebo. Ratios $1.25 are primarily caused by particularly low AUCsafter placebo and not by high AUCs after silexan. The terminalelimination half-life of omeprazole was not affected by silexan. Forthese reasons, most probably the high variability and not an inhibitoryeffect of silexan on CYP2C19 is the explanation for the observations.Repeated administration of silexan 160 mg/day was well toleratedwhen given alone and together with the phenotyping cocktail. MostAEs observed in this trial (eructation, nausea) were expected (SmPCfor LASEA; NN, 2010), their nature and intensity were in line withpreviously reported data to silexan safety and tolerability profile(Kasper et al., 2010a; Kasper et al., 2010b; Woelk and Schlfke,2010). Also, the phenotyping cocktail used in the study is consideredto be safe and well-tolerated taking into account that the phenotypingsubstances have been widely used for various therapeutic applicationsin patients, their doses in the present study were reduced as far aspossible compared with the therapeutic doses by the application ofhighly sensitive analytical methods, only two single doses of eachdrug were administered for phenotyping, and available reports ofcocktail interactions studies confirm their appropriate safety and goodtolerability (Frye et al., 1997; Streetman et al., 2000; Wang et al.,2001; Zhu et al., 2001; Tomalik-Scharte et al., 2005; Turpault et al.,2009; Zadoyan et al., 2012).The use of a crossover design with well controlled conditions,including supervised intake of study drug, the clinically relevant doseof the drug to be tested, proof of exposure, and standardized food andfluid intake for assessment of enzyme activity may be considered asstate of the art and is stipulated by the respective guidelines (Food andDrug Administration, 2012; European Medicines Agency, 2012c).The data also suggest that the use of simplified phenotyping metricsshould take absorption properties of the phenotyping drugs intoaccount.In conclusion, the study reported here provides information to the invivo interaction potential of silexan at therapeutic doses toward majorP450s as well as further data to respective phenotyping metrics.Repeated oral administration of the standardized lavender oil preparation silexan at the dose 160 mg/day does not cause clinicallyrelevant inhibitory or inducing effects on the CYP1A2, 2C9, 2C19,2D6, and 3A4 enzymes.AcknowledgmentsThe authors thank Gnther Pabst for conducting the pharmacokineticanalyses, and Julia Stingl for conducting the genotyping analyses.Authorship ContributionsParticipated in research design: Klement, Dienel, Fuhr.Conducted experiments: Lck, Fuhr.Performed data analysis: Doroshyenko, Rokitta, Zadoyan, Schlfke, Lck.Wrote or contributed to the writing of the manuscript: Doroshyenko,Rokitta, Zadoyan, Klement, Gramatt, Lck, Fuhr.ReferencesAdedoyin A, Frye RF, Mauro K, and Branch RA (1998) Chloroquine modulation of specificmetabolizing enzymes activities: investigation with selective five drug cocktail. Br J ClinPharmacol 46:215219.Andersson T, Bergstrand R, and Cederberg C (1991) Influence of acid secretory status on absorption of omeprazole from enteric coated granules. Br J Clin Pharmacol 31:275278.Downloaded from dmd.aspetjournals.org at ASPET Journals on October 21, 2014convenience in the absence of better choices, because mephenytoin isno longer available (Klaassen et al., 2008).The main phenotyping metric for respective enzyme was theAUC0t of the parent drug, a reliable metric reflecting the activity ofthe particular enzyme, although it requires multiple blood collectionsand is time-consuming. Irrespective of the phenotyping drug, assessment of full concentration-time profile is also recommendedby the EMA Guideline on the Investigation of Drug Interactions(European Medicines Agency, 2012c), most probably because pharmacokinetic interactions other than those caused by modificationof enzyme activity could occur, such as delayed absorption, whichmay erroneously be attributed to changes in enzyme activity, if onlya sample would be available. Still, phenotyping metrics based onsingle-point plasma concentration and molar metabolic ratios(Tables 1 and 2) are appealing, and suitability of such (secondary)phenotyping metrics had been previously assessed in cocktailinteraction studies (Jetter et al., 2004; Frank et al., 2007; Fuhr et al.,2007; Zadoyan et al., 2012) and were also assessed in the presentstudy. Intraindividual variability of secondary phenotyping metrics(Table 3) obviously depended on the type of metric and on gastrointestinal absorption of the phenotyping drug. For single pointmeasurements of the parent drug only (tolbutamide, midazolam), itwas higher than that for AUC0t. For single-point metabolic ratios,variability was lower for drugs with poor and irregular bioavailability(omeprazole, dextromethorphan), but higher for caffeine, which israpidly and completely absorbed and does not undergo first-passmetabolism. The molar AUC ratio, combining an assessment based onmany samples (thus leveling out inaccuracies) and on standardizationwith regard to absorption differences, had the lowest variability ofthe CYP2C19 metrics tested. Both similar results with regard to theinteraction tested and the close correlations between most of thephenotyping metrics (Table 4) support the use of such phenotypingmetrics, with preference on metrics with lower variability, explainedby avoiding confounders.A clinically relevant effect of a perpetrator drug on the activity ofa given enzyme is difficult to define and depends on the victim drug.For the purpose of this study, formally interaction was excluded ifthe 90% CI for the ratios active treatment over placebo was within a0.71.43 range. These boundaries have often been used to assess drugdrug interactions (Steinijans et al., 1996; Rani and Pargal, 2004;Tomalik-Scharte et al., 2005; Fuhr et al., 2007).The upper bound of the 90% CI for the AUC0t ratio of omeprazole(a CYP2C19 probe substrate) was above the threshold of 1.43 withthe mean AUC0t ratio close to unity. Assuming this to reflect a realeffect of silexan on CYP2C19 activity, an inhibitory action of silexanon CYP2C19 cannot be excluded formally. For the assessment ofrelevance, however, it has to be considered that: 1) as shown previously by genotype/phenotype relationships, omeprazole clearanceis primarily mediated by the CYP2C19 activity, and the enzymeactivity itself is highly variable (ndersson et al., 1993; Chang et al.,1995; Roh et al., 1996); 2) the inability to formally exclude aninteraction toward CYP2C19 was observed only for the most variable(albeit primary) of the three phenotyping metrics applied; 3) asdescribed above, the main phenotyping metric (AUC of parentcompound) is not fully validated (Fuhr et al., 2007; EuropeanMedicines Agency, 2012c); 4) other factors may contribute for a highinter- and intraindividual variability of the omeprazole-derivedCYP2C19 metrics. Specifically, omeprazole is acid labile and, therefore, is administered as acid-fast preparations dissolving in the smallintestine [Howden et al., 1984; Andersson et al., 1991; SmPC foromeprazol-ratiopharm NT, 20 mg hard capsule (NN, 2008); SmPC foromeprazole, 20 mg capsules (NN, 2012)], and the highly variable	29327	37101
589	1	4	48	1	7	Cocktail Interaction Study on Silexan in Healthy SubjectsNN (2008) Summary of product characteristics for Omeprazol-Ratiopharm NT 20 mg hardcapsule as of June 2008, Ratiopharm GmbH, Neu-Ulm, Germany.NN (2010) Summary of product characteristics for LASEA 80 mg soft capsule as of September2010, W. Spitzner Arzneimittelfabrik GmbH, Ettlingen, Germany.NN (2012) Summary of product characteristics for omeprazole 20 mg capsules as of August 29,2012, Actavis UK Ltd, Whiddon Valley, Barnstaple, Devon, UK.Rani S and Pargal S (2004) Bioequivalence: An overview of statistical concepts. Indian JPharmacol 36:209216.Roh H-K, Dahl M-L, Tybring G, Yamada H, Cha Y-N, and Bertilsson L (1996) CYP2C19genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics6:547551.Sharma A, Pilote S, Blanger PM, Arsenault M, and Hamelin BA (2004) A convenient five-drugcocktail for the assessment of major drug metabolizing enzymes: a pilot study. Br J ClinPharmacol 58:288297.Schellens JH, van der Wart JH, Brugman M, and Breimer DD (1989) Influence of enzymeinduction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrinein humans as assessed by a cocktail study design. J Pharmacol Exp Ther 249:638645.Steinijans VW, Hartmann M, Huber R, and Radtke HW (1996) Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther 34(1, Suppl)S25S30.Streetman DS, Bertino JS, Jr, and Nafziger AN (2000) Phenotyping of drug-metabolizingenzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187216.Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, Skott A, Srgel F, Klaassen T, Kasel D,Harlfinger S, Doroshyenko O, and Frank D, et al. (2005) Effect of propiverine on cytochromeP450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 33:18591866.Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies toassess drug metabolism/transporter interaction potentialtowards a consensus. Br J ClinPharmacol 52:107117.Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, and Boulenc X (2009)Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.Br J Clin Pharmacol 68:928935.Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, and Hall SD (2001) The effects of StJohns wort (Hypericum perforatum) on human cytochrome P450 activity. Clin PharmacolTher 70:317326.Woelk H and Schlfke S (2010) A multi-center, double-blind, randomised study of the Lavenderoil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine 17:9499.Wohlfarth A, Naue J, Lutz-Bonengel S, Dresen S, and Auwrter V (2012) Cocktail approach forin vivo phenotyping of 5 major CYP450 isoenzymes: development of an effective sampling,extraction, and analytical procedure and pilot study with comparative genotyping. J ClinPharmacol 52:12001214.Zadoyan G, Rokitta D, Klement S, Dienel A, Hoerr R, Gramatt T, and Fuhr U (2012) Effect ofGinkgo biloba special extract EGb 761 on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol 68:553560.Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, and Zhou HH (2001) Assessment ofcytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 70:455461.Address correspondence to: Dr. Uwe Fuhr, Institut fr Pharmakologie, KlinischePharmakologie, Universitt zu Kln, Gleueler Strae 24, 50931 Kln, Germany.E-mail: uwe.fuhr@uk-koeln.deDownloaded from dmd.aspetjournals.org at ASPET Journals on October 21, 2014Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA,and Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediatingomeprazole metabolism. Br J Clin Pharmacol 36:521530.Chang M, Dahl M-L, Tybring G, Gtharson E, and Bertilsson L (1995) Use of omeprazole asa probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoinhydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358363.Christensen M, Andersson K, Daln P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G,Wahlberg A, Yasar U, and Bertilsson L (2003) The Karolinska cocktail for phenotyping of fivehuman cytochrome P450 enzymes. Clin Pharmacol Ther 73:517528.Council of Europe (2008) European pharmacopoeia 6.0, Lavender oil (Lavandulae aetheroleum)monograph 01/2008:1338, European directorate for the quality of medicines and health care, p.22442245European Medicines Agency (2012a) Community herbal monograph on Lavandula angustifoliaMiller, flos, EMA/HMPC/734125/2010, March 27, 2012, Committee on Herbal MedicinalProducts.European Medicines Agency (2012b) Community herbal monograph on Lavandula angustifoliaMiller, aetheroleum EMA/HMPC/143181/2010, March 27, 2012, Committee on Herbal Medicinal Products.European Medicines Agency (2012c): Guideline on the Investigation of Drug Interactions CPMP/EWP/560/95/Rev. 1, June 21, 2012, Committee for Human Medicinal Products.Endres HG, Henschel L, Merkel U, Hippius M, and Hoffmann A (1996) Lack of pharmacokineticinteraction between dextromethorphan, coumarin and mephenytoin in man after simultaneousadministration. Pharmazie 51:4651.Food and Drug Administration (2012) Guidance for Industry. Drug Interaction StudiesStudyDesign, Data Analysis, Implications for Dosing, and Labeling Recommendations. DraftGuidance, February 2012, Center for Drug Evaluation and Research.Frank D, Jaehde U, and Fuhr U (2007) Evaluation of probe drugs and pharmacokinetic metrics forCYP2D6 phenotyping. Eur J Clin Pharmacol 63:321333.Frye RF, Matzke GR, Adedoyin A, Porter JA, and Branch RA (1997) Validation of the five-drugPittsburgh cocktail approach for assessment of selective regulation of drug-metabolizingenzymes. Clin Pharmacol Ther 62:365376.Fuhr U, Jetter A, and Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the cocktailapproach. Clin Pharmacol Ther 81:270283.Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M,and Hall SD (2004) The effect of echinacea (Echinacea purpurea root) on cytochrome P450activity in vivo. Clin Pharmacol Ther 75:89100.Howden CW, Meredith PA, Forrest JA, and Reid JL (1984) Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol 26:641643.Jetter A, Kinzig-Schippers M, Skott A, Lazar A, Tomalik-Scharte D, Kirchheiner J, WalchnerBonjean M, Hering U, Jakob V, and Rodamer M, et al. (2004) Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 60:165171.Kasel D, Harlfinger S, Kinzig-Schippers M, Soergel F, Gebhardt W, and Fuhr U (2002) Determination of midazolam in human plasma using LC-MS/MS devices from two differentmanufacturers. Eur J Clin Pharmacol 58:87.Kasper S, Gastpar M, Mller WE, Volz HP, Mller HJ, Dienel A, and Schlfke S (2010b)Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials. Wien Med Wochenschr 160:547556.Kasper S, Gastpar M, Mller WE, Volz HP, Mller HJ, Dienel A, and Schlfke S (2010a)Silexan, an orally administered Lavandula oil preparation, is effective in the treatment ofsubsyndromal anxiety disorder: a randomized, double-blind, placebo controlled trial. Int ClinPsychopharmacol 25:277287.Klaassen T, Jetter A, Tomalik-Scharte D, Kasel D, Kirchheiner J, Jaehde U, and Fuhr U (2008)Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity.Eur J Clin Pharmacol 64:387398.993	37102	44767
86	1	2	16	1	63	Clinical Review .Lisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)61.3.8.3 (Liraglutide Rosiglitazone Mezformin) vs. (Placebo Rosiglitazone Mezformin)Trial 1574: Liraglutide Effect and Action in Diabetes (LEAD-4): Effect on Glycemic Control ofLiraglutide in Combination with Rosiglitazone plus Metformin versus Rosiglitazone plus Metformin inType 2 Diabetes (A Twenty-Six Week Double-Blind Parallel Trial to Investigate Safety and Efficacy)The primary ef?cacy objective was to assess and compare the additive effect (as assessed by change inHbAlc) of two doses of liraglutide (liraglutide 1.2 mg and liraglutide 1.8 mg) in combination withrosiglitazone and metformin versus the combination of rosiglitazone and metformin, on glycemic .control after 26 weeks in subjects with type 2 diabetes.Hypothesis: Liraglutide (1.8 mg once daily) in combination with rosiglitazone (4 mg twice daily) plusmetformin (1000 mg twice daily) will provide glycemic control (as measured HbAlc) better than thatachieved with the combination of rosiglitazone (4 mg twice daily) and metformin (1000 mg twice daily)in subjects with type 2 diabetes.This was a multicenter (96 centers in the United States and Canada), randomized, double-blind, placebo-controlled study. A total of 533 patients with type 2 diabetes inadequately controlled on (HbAlc 7.0-1 were randomized in a 1:111 ratio to:Liraglutide 1.2 mg qd rosiglitazone 4 mg bid metformin 1000 mg bidLiraglutide 1.8 mg qd rosiglitazone 4 mg bid metformin 1000 mg bidLiraglutide placebo rosiglitazone 4 mg bid metformin 1000 mg bidStudy procedures (Figure 6.5):Subjects who satis?ed inclusion and exclusion criteria underwent a 9-week forced titration period (3week dose escalation with 6 week dose maintenance) with rosiglitazone (starting at 4 mg once daily andincreasing to 4 mg twice daily within 2 weeks) and metformin (starting at 500 mg with increasingweekly increments of 500 mg to a ?nal dose of 1000 mg twice daily). Subjects who tolerated the ?naldose of rosiglitazone (8 mg/day) and metformin (2000 mg/day) were eligible for randomization after a6-week run-in period. Subjects who did not tolerate the ?nal dose were not randomized into the trial.Once randomized, all groups underwent a double-blinded forced titration period with liraglutide (activeor placebo) in order to achieve their ?nal doses. All subjects started on 0.6 mg liraglutide (active orplacebo). The dose was increased to 1.2 mg after one week. Subjects randomized to receive the highestdose had their dose of liraglutide (or placebo) increased to 1.8 mg/day one week later.Reviewer?s comment: The mandatory maintenance period with rosiglitazone 8 mg and metformin2000 mg prior to randomization was 6 weeks. Improved glycemic control resulting from this 6Week period would not be fully re?ected in the baseline HbA1c measurement (HbAlc representsglycemic control over the prior three months).- Figure 6.5 Procedures for Trial 157451	133596	136557
87	1	2	16	1	64	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)26Inclusion criteria:Type 2 Diabetes and treated withfor 3 months- ?1.0 mauorherapy10.0 VnifmC??lhm?fm iherapr Liragluticie 1.2 mg once daily ?N=178?l- No Insulin treamient within the last 3 months?Week 0 Liraglutide 1.8 mg once daily {N=l78}If       Week -12 Placebo once daiiy              Rnudomizatiuu criteria:-  6 weeks on 2000 mguietfennin and 8 mgrosiglitazme- F955 13.8 m.?vt(235 mg.?clLg FPGE 230- All subjects needed to be on metformin and rasiglitazouethrougjiour the study61.3.8.4 (Liraglutide glimepiride metformin) vs. (placebo glimepiride metformin)vs. (insulin glargine glimepiride metformin): Trial 1697: Liraglutide Effect and Action in Diabetes (LEAD-5): Effects on glycemic control afteronce daily administration of liraglutide in combination with glimepiride and metformin versusglimepiride and metforrnin combination therapy, and versus insulin glargine added to glimepiride andmetformin combination therapy in subjects with type 2 diabetes. A six-month randomized, double-blind, parallel-group, multicenter, multinational trial with an open-label treat?to-target insulin glarginecontrol arm.Study rationale: The purpose of this trial was to demonstrate that the addition of liraglutide to existingmetformin and SU therapy (glimepiride) provided additional improvements in glycemic control, andfurthermore to compare the addition of liraglutide with that of insulin glargine to subjects treated withmetformin and SU therapy (glimepiride).This was a multicenter (107 centers in 17 countries), randomized, double?blind, placebo-controlledstudy. A total of 581 patients with type 2 diabetes were randomized in a 211:2 ratio to:Liraglutide 1.8 mg so qd OAD .Liraglutide placebo OAD Open label glargine OADStudy procedures (Figure 6.6)Randomization took place after a run-in period including a 3-week forced metformin and glimepiridetitration period followed by a maintenance period of 3 weeks. During the titration period, doses ofmetformin and glimepiride were to be increased up to 2000 mg/day and 4 mg/day, respectively. Afterrandomization, the subjects underwent a 2-week period of titration with liraglutide for reaching a daily52	136558	138795
88	1	2	16	1	65	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 "(Submission 000)Victoza? (liraglutide)dose of 1.8 mg liraglutide in the last week. After this 2-week titration period, a 24-week maintenanceperiod commenced, during which doses of liraglutide/liraglutide placebo and metformin were ?xed,although glimepiride and insulin glargine doses could be adjusted. The dose of insulin glargine was tobe adjusted by the subject 2 times weekly, based on self-measured fasting plasma glucose using aglucose meter on the day of titration, and following a titration guideline (Table 6.6).Figure 6.6 Procedures for Trial 1697 Forcetl Mt-tforrninand Titm?on amym. ofTitration of Trial T1121 Pl oductsPro{h1cts3Follow-upScreening Sam)? Visitweeks 3-6 weeks? 2 weeks 24 weeks 1 weekLiraglutide (1.8 glimepiride 2-4 mgfday) 1netfom1in(20O0 Limglutide placebo glimepiride (2-4 4- :uetfo1min(2O00  7Insniin glargine _Ei.in1?Piric1c (3-4 metfozmilz (3000 n1g? The starting dose of insulin glargine was to be numerically equivalent to the mean FPG value in mmol/Lmeasured for the purpose of randomization at the clinic using a glucose meter. For example, if the meanFPG was 12 mmol/L, the initial dose of insulin glargine was 12 IU. However, as the brand ofglucometer used in the trial (Optiset) worked in increments of 2 IU it was necessary to round off to thenearest unit, e.g. if 10.9 then 10 IU and if 1 1.1 then 12 IU.Table 6.6Guideline for Titration of Insulin GlargineSelf-measured FPG Increase in insulin glargine dose (IU)5.5 100 mg/dL) Target No adjustment5.5 and 6.7 mmol/L -100 and 120 mg/dL) 0-2 lUa2 6.7 mmol/L (2 120 mg/dL) 2 IUaAccording to the individualized recommendation by the investigator at the previous visit for exampledepending on whether the subject has experienced hypoglycemiaSource: Trial 1697 report, Table 9-3, page 48For this particular trial, with regard to the titration of insulin glargine done according to the titrationguideline, it was decided that no subjects could be excluded from the PP analysis set due to inadequate53	138796	140828
92	1	2	16	1	69	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)BMI (kg/m2)Mean (SD) 32.8 (6.3) 33.2 (5.6) 33.2 (5.6)Duration of diabetes (years)Mean (SD) 5.3 (5.1) 5.2 (5.5) 5.6 (5.1)Previous anti-diabetictreatment, Diet/exercise 87 (35.22) 91 (36.25) 94 (37.90)Monotherapy 160 (64.78) 160 (63.75) 154 (62.10)HbA1c at screening Mean (SD) 8.3 (1.1) 8.3 (1.0) 8.4 (1.2)Source: Table 11-1, Trial 1573 reportAt randomization the subjects were similar with regards to HbAl c, fasting plasma glucose, and bloodpressure.Table 6.8 Trial 1573 - Key Ef?cacy Parameters of All Randomized SubjectsAll randomized patients (N) 233 228 234Liraglutide 1.8 Liraglutide 1.2 GlimepirideHbA1c 247 251 248Mean (SD) 8.19 (1.08) 8.18 (1.05) 8.23 (1.06)Fasting plasma glucose (mmol/L)236 239 242Mean (SD) 9.5 (2.6) 9.3 (2.6) 9.5 (2.6)Diastolic BP (mmHg) 247 251 248Mean (SD) 78.8 (8.4) 78.5 (8.3) 79.5 (8.6)Systolic BP (mmHg)247 5 251 248Mean (SD) 128.1 (13.9) 127.6 (14.3) 130.0 (16.1)Source: Table 11-2, Trial 1573 report6. 1.4.1.2 Participation and withdrawals in the monotherapy population (disposition ofpatients)Participation and withdrawals in the monotherapy trial are summarized in table 6.9. Although 746subjects were randomized, one did not receive any treatment. In addition to the 746 subjects, one sitewith 11 subjects was not included in the ITT analysis set due to GCP compliance issues. As a result,there are 745 subjects in the analysis and tables.57	148783	150247
93	1	2	16	1	70	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Table 6.9Trial 1573 - Subject DispositionLiraglutide 1.8 Liraglutide 1.2 GlimepirideSubjects Randomized . 247 (100.0) 251 100.0) 248 100.0)Exposed (ITT Analysis Set) 246 (99.6) 251 (100.0) 248 (100.0)Withdrawals 74 (30.0) 89 (35.5) 96 (38.7)Adverse Events 18 (7.3) 25 (10.0) 15 (6.0)Ineffective therapy 9 (3.6) 15 (6.0) 25 (10.1)Non-compliance with 11 (4.5) 11 (4.4) 5 (2.0)protocol Other 36 (14.6) 38 (15.1) 51 (20.6)Completers 173 (70.0) 162 (64.5) 152 (61.3)PP Analysis Set 154 (62.3) 142 (56.6) 130 (52.4)Source: Table 10-1, trial 1573 report. Reviewer?s comment: 11 subjects removed from a sample size of 746 would not be expected toalter ef?cacy results.Overall, 65.3% of subjects completed the trial (64.5% in the liraglutide 1.2 mg arm, theliraglutide 1.8 mg arm, and 61.3% in the glimepiride arm. The difference in completion rates seemed tobe based on a higher rate of therapeutic failure in the glimepiride arm. Early in the study, however,there was a higher withdrawal rate in the liraglutide groups compared with _glimepiride. For example,during month 1 the dropout rate was 24.7% in the lira 1.8 group, 25.8% in the lira 1.2 group, and 14.6%in the glimepiride group. The majority of the subjects in the liraglutide treatment groups that withdrewfrom the study early due to an adverse event, withdrew due to a gastrointestinal system related adverseevent. Details of withdrawals due to adverse events are discussed in detail in Dr. Mahoney?s ClinicalSafety Review. At 52 weeks, the discontinuation rate due to unsatisfactory therapeutic effect was lowestfor the liraglutide 1.8 mg group intermediate for the liraglutide 1.2 mg group andhighest for the glimepiride group Reviewer?s comment: Handling of dropouts was addressed in Dr. Derr?s statistical review. PerDr. Derr there was no compromise of the efficacy assessment due to the somewhat high dropoutrate. It was also concluded that the lower and dose-dependent discontinuation due tounsatisfactory therapeutic effect in the liraglutide 1.8 mg groups was evidence for efficacy ofliraglutide.6.1.4. 1.3 Adequacy of comparator drug dosages used58	150248	152442
96	1	2	16	1	73	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Lira 1.2 - Glimepiride-0.3 87-0.6l7? (-0.157)0.0010Lira 1.8 ?Lira 1.2-0.262-0.432 (-0.042)0.0196 .Source: BOT Table 14.2-5-8, trial 1573 reportTable 6.13Trial 1573 - ANCOVA of Primary Endpoint Change in HbAlc (noimputation) IT populationTreatment/comparison EstimatesLeast Square Means LS SEMeanLira 1.8 170 -1.289 (0.087)Lira 1.2 159 -1.044 (0.089)Glimepiride 150 -0.662 (0.088)Estimated Treatment LS 95% CI p-valueDifferences MeanLira 1.8 Glimepiride -0.627 -0.853 (-0.402) <.0001Lira 1.2 Glimepiride -0.383 -0.612 (-0.154) 0.0011Lira 1.8 Lira 1.2 -0.245 -0.466 (-0.023) 0.0304Source: EOT Table trial 1573 reportReviewer's comments: Both of the liraglutide doses resulted in clinically meaningful reductions inHbAlc.For the HbAlc endpoint, the ITT with LOCF, ITT without imputation, and PP results weresimilar, supporting robustness of the ef?cacy results. As expected the PP analysis set shows thegreatest ef?cacy for all groups.The -0.513% mean HbAlc reduction with glimepiride is lower than expected. For comparison, intwo 14-week placebo controlled studies in 720 subjects, the average net reduction in HbAlc forpatients treated with 8 mg Amaryl once daily was 2.0% compared with placebo-treated patients.(Amaryl label, 2005). Several possible explanations for the lower-than-expected response toglimepiride are differing trial populations, starting HbAlc levels, duration of diabetes, etc. Also,trial 1573 was not a placebo controlled trial, whereas the trial cited in the Amaryl label wasplacebo controlled.A plot of the mean HbAlc values over time by treatment for the ITT analysis set with LOCF ispresented in Figure 6.7.Figure 6.7 Trial 1573 Mean HbAlc Over Time by Treatment, ITT with LOCF61	155814	157600
97	1	2	16	1	74	Cl_inical ReviewLisa B. Yanoff, M.D.NDA 22,34] (Submission 000)Victoza? (liraglutide)9.0-8.5?8.0-7.5?Mam HbA1c 7.0-65' ?IJra1.8mg :Llra1.2nng Source: Figure 11-1, Trial 1573 report Reviewer's comments: The ?gures show that the greatest impact on lHbA1c occurred between 8. and 12 weeks with a leveling off of HbAlc that remains stable up to 52 weeks, suggestingpersistence of effect of liraglutide. Also, according to these data, the persistence of effect is dose-dependent with the error bars for the 1.2 mg and 1.8 mg not overlapping throughout the trial andpossibly appearing more separated at 52 weeks than at 28 weeks. As this was the only 52 weektrial these ?ndings may be important in determining which dose(s) should be approved since theother four pivotal studies (all 26 weeks in length) show equivalence in efficacy between the 1.2 and1.8 mg doses. 61.4.1.5 Supplementary Analyses of the Primary E?icacy Variable HbA1c6.l.4.1.5.l Percentage of subjects achieving HbA1c targetsThe percentage of subjects achieving HbA1c targets (ADA target and AACE target 56.5%) werecompared between the treatments (Table 6.14).Table 6.14Trial 1573 - Summary of subjects reaching HbA1c target of good glycemic control atweek 52Liraglutide Liraglutide Glimepiride1.8 1.2. Week 52 HbAlc 7% (completers) 99 (58.2) 85 (53.5) 50 (33.3) Week 52 l-lbAlc (LOCF) 19 (50.9) 101 (42.8) 67 (27.8)62	157601	158980
147	1	2	16	1	124	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Lira1.8+OADs 227 85.8 -1.39 0.000] -3.43 (19.3) 0.69 2.86Placebo+OADs 113 85.4 -0.42 (0.39)(16.3)Glargine+OADs 227 85.2 1.62 (0.33)(17.9)"In Trial 1574 the OADS were metformin rosiglitazone, in Trial 1697 glimepiride metformin.The p~values correspond to a two-sided test for superiority on a 5% signi?cant level (statistical signi?cance for *The change in body weight was estimated using an ANCOVA model with treatment, country and previous anti-diabetic treatmentas ?xed effects and baseline value as covariateThere was no comparator in Trial 1574; the comparator in Trial 1697 was glargine+OADsSource: [Tables 11-8, 11-9, trial 1574 report] [Tables 11-16, 11-17, trial 1697 report]Plots of mean body weight over time by treatment in the ITT population with LOCF are presented in?gure 6.20 for trial 1574 and in ?gure 6.21 for trial 1697.Figure 6.20 Trial 1574 Plot of Mean Body Weight (kg) Over Time by Treatment 8 102-5 190? 3 986  96- --Week-?oAosSource: Table 14.2-6-20, trial 1574 report112	258382	259461
99	1	2	16	1	76	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Odds Ratio 95% CI p-valueLira 1.8 - Glimepiride 3.32 2.11 5.22 <.000lLira 1.2 - Glimepiride 2.04 1.29 3.25 0.0025Lira 1.8 Lira 1.2 1.62 1.08 2.45 0.0208Odds ratio is from logistic regression with treatment as ?xed effect and baseline HbAlc value as a covariateSource: Table 11-7 trial 1573 reportReviewer?s comments: The difference between liraglutide 1.2 mg and 1.8 mg was statisticallysigni?cant for the AACE goal comparison (which is more stringent) but not the ADA goalcomparison (although no corrections were made to avoid type 1 error in this analysis); Further,the difference between liraglutide 1.2 mg and 1.8 mg was not signi?cant in an ANCOVA done withno imputation for the AACE target. Clinically, this suggests there may not be an importantdifference between 1.2 mg and 1.8 mg as monotherapy in the percent of patients reaching goals ofHbA1c lowering.The logistic regression did not exclude subjects who had HbA1c below target at baseline.However, the mean and range of HbA1c were similar among groups at baseline making theprobability that the groups were imbalanced at baseline for the percentage with HbA1c alreadybelow goal very small. 6.1.4.1.5.2 Change in HbA1c by Previous TreatmentThe Sponsor reports that previous treatment (diet/exercise versus monotherapy) indicated a greaterdecrease in HbA1c for subjects previously treated with diet and exercise in all treatment groups (Table6.16). Table 6.16Trial 1573 Summary of Change in HbAlc by Previous Treatment, ITT Population Treatment by Previous Treatment Interaction Lira 1.8 Lira 1.2 Glime irideBaseline Change Baseline Change Baseline ChangeDiet/exercise -Mean (SD) 8.59 -1.60 8.43 -1.19 8.59 -0.88 .(1.29) (1.29) (1.29) (1.40) (1.25) (1.23) Range I Monotherapy159 155 160 152 154 15064	160760	162603
100	1	2	16	1	77	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (Iiraglutide)Mean (SD) 7.97 -0.71 8.04 -0.47 8.01 -0. 17 (0.89) (1.16) (0.86) (1.23) (0.87) (1.04)Range . Treatment by Previous Treatment Interaction p?0'6747'Source: Table 14.2-5-3, Trial 1573 reportReviewer?s comment: Although the subjects with previous treatment of diet/exercise appear tohave a greater decrease in HbA1c, the treatment by previous treatment interaction term p-value isnon-signi?cant. Therefore, this reviewer has concerns about a claim of greater efficacy inprevious diet/exercise treated patients being included in the product label. Also, the previouslytreated with monotherapy group had an insufficient washout period (see section 6.1.3.7 methodstrial 1573) so the lesser effect in the monotherapy group is possibly due to loss of effect from theprior agent. Another possible explanation for this ?nding is regression to the mean sinceglimepiride may also more effective among patients with previous diet/exercise therapy.6.1.4.1.5.3 Treatment effect on selected subgroupsFurther supplementary analyses of HbA1c were performed to investigate the treatment effect on selectedsubgroups. There was no reported notable effect on change in HbA1c due to country, gender, race,ethnicity, age (as a continuous variable), and BMI (as a continuous variable) (data not shown).Reviewer?s comment: Statistical power is too low to answer the questions regardingdemographics from individual trials. These questions are better answered by pooling data fromthe add-on indication trials, or by newly designed trials.6.1.4. 1.6 Additional Exploratory Analyses Related to HbA]eThe Sponsor conducted the following additional exploratory analyses for HbA1c reduction0 Age categories Disease severity (quartiles of HbA1c, and HbA1c 5 9.5% and Baseline body weight and BMI categoriesBaseline hypertension and hyperlipidemia (presence or absence)The Sponsor did not perform formal statistical comparisons between subgroups because patients werenot allocated to these subgroups by randomization.Liraglutide at both 1.8 mg and 1.2 mg doses appeared to reduce HbA1c to a similar extent regardless ofage group, although the sample size for the 2 75 age group was small 65	162604	164840
101	1	2	16	1	78	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)A summary of change in HbA1c by baseline quartiles suggested a greater decrease in HbA1c with higherbaseline HbA1c in all three treatment groups. This was similar to the result of change in HbA1c bybaseline HbA1c categories (HbA1c 5 9.5% and HbA1c Reviewer?s comment: This ?nding may re?ect regression to the mean and is commonly seen withother anti-diabetic medications.The inclusion of baseline body weight as covariate in the ANCOVA model used for analysis of HbA1cwas similar with respect to superiority of liraglutide to glimepiride for change in HbA1c as_ compared tothe analyses performed without baseline body weight as covariate. This result was similar when BMIwas used as a covariate in the ANCOVA model. A summary of change in HbA1c at the end of the studyby BMI subgroups indicates less change in HbA1c in the higher BMI subgroup for subjectstreated with liraglutide. .A summary of change in HbA1c at the end of the study by whether or not a subject had hypertension orhyperlipidemia indicates that these conditions had no impact on change in HbAlc during the study.61.4.1.7 Secondary e?icacy variables for the monotherapy populationFasting Plasma Glucose (FPG)All groups had a mean decrease in FPG from baseline to 52 weeks, with the greatest mean decreaseoccurring in the liraglutide 1.8 mg group (1.42 mmol/L); the liraglutide 1.2 mg group had a decrease of0.84 mmol/L, and the glimepiride group had the smallest decrease (0.29 mmol/L) (Table 6.17). Themean decreases in FPG values in the liraglutide groups were signi?cantly greater than in the glimepiridegroup, and the decrease in FPG was signi?cantly greater in the liraglutide 1.8 mg group compared withthe 1.2 mg group, as shown by ANCOVA analysis using the ITT population with both LOCF and noimputation. In conventional units, the mean decreases were 25.6 mg/dL for liraglutide 1.8 mg, 15.2 forliraglutide 1.2 mg, and 5.3 for glimepiride. As expected, for completers the decreases were greater at32.6, 17.2, and 7.2 mg/dL respectively for liraglutide 1.8 mg, liraglutide 1.2 mg, and glimepiride.Table 6.17Trial 1573 - ANCOVA of Change in FPG (mg/dL), (LOCF) ITT populationTreatment/comparison EstimatesLeast Square Means LS Mean SELira 1.8 230 -25.6 3.5Lira 1.2 234 -15.2 3.5Glimepiride 242 -5.3 3.3Estimated Treatment LS Mean 95% CI p?valueDifferences66	164841	167252
148	1	2	16	1	125	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Figure 6.21 Trial 1697 Plot of Mean Body Weight (kg) Over Time by Treatment.3 0 1'  I  6 I Time (Week)9-9-9 GAD -we ?333-rgine GAB GADSource: Figure 11-2, trial 1697 reportHowever, it should be noted that the duration of the studies was relatively short (only 6 months induration). The ?gures above show that placebo+OADs groups show either mean weight maintenance or weightgain over time, and the liraglutide+OADs groups show mean body weight reduction early on in the trialswith most of the weight lost by week 8 to week 12 and with weight maintenance to a slight increase inthe latter part of the trial. The plots for completers (not shown) were similar.Reviewer?s comment: This reviewer agrees with the proposed wording in the label I0(4)6.1.4.3.6.3 Blood PressureThe mean changes a?er 26 weeks and results of analyses of systolic blood pressure (SBP) for trials 1574and 1697 are summarized in Table 6.37.113	259462	260457
623	1	4	50	1	13	DMD#60558The MS/MS spectrum of the conjugate was obtained by MRM-EPI scanning (iontransition m/z 594/465). The spectrum showed the indicative characteristic fragmentions associated with the cleavage of the GSH moiety (Fig. 4B). The product ions atm/z 465 and 519 were derived from the neutral loss of -glutamyl portion (-129 Da)and glycine portion (-75 Da) from parent ion m/z 594, respectively.To verify the characterization, IMP was chemically oxidized by oxone in acetone,followed by reaction with GSH. As expected, the product responsible for the IMPderived GSH conjugate showed the same chromatographic behaviors and identicalmass spectrum (Fig. 4C) as that of the conjugate generated in the microsomalreactions (Fig. 4B). Unfortunately, we were unable to have enough amount of theproduct for NMR characterization, due to poor reaction yield. Furthermore, the otherportion of the reaction solution was mixed with sodium borohydride for reduction andthen analyzed by LC-MS/MS. A new peak at retention time of 6.7 min was observed(Fig. 5A), and the M+H]+ was m/z 596.2, 2 Da higher than that of the conjugate[observed before the reduction by sodium borohydride (Fig. 5B).P450 Enzymes Responsible for IMP Bioactivation. To determine which P450enzymes preferentially catalyze the oxidation of IMP, IMP was incubated withindividual recombinant human P450 enzymes, including CYPs 1A2, 2A6, 2B6, 2C9,2C19, 2D6, 2E1, 3A4, or 3A5 (0.1 M for each) in the presence of GSH as thetrapping agent. The IMP-GSH conjugate was assessed in the incubation with CYPs1A2, 2A6, 2B6, 2D6, 2E1, 3A4, or 3A5. Apparently, little IMP-GSH adduct wasfound in the incubations with CYPs 2C9 or 2C19 (Fig. 6).13The experiments	16639	18338
624	1	4	50	1	14	DMD#60558demonstrated that multiple P450 enzymes are involved in bioactivation of IMP,especially for CYP1A2.14	18339	18448
103	1	2	16	1	80	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Reviewer?s comment: These results are consistent with the analyses of subjects reaching HbAlctargets.6_.1.4.1.7.3 8-Point Self-Measured Glucose Pro?lesThis endpoint is discussed here because this variable is mentioned in the proposed product label. Atbaseline the three groups had similar glucose pro?les.  Figure 6.8Trial 1573 - 8?Point Profiles of Self-Measured Plasma Glucose Pro?les at Week 52 (ITT withLOCF analysis population)210'190-1so- 270-460-:50-mo130-120- Se|f?Measured Plasma Glucose 9eelJra1.2mg --eIImapmde|Source: Figure 11-5, Trial 1573 reportReviewer?s comment: The glucose pro?les do suggest a glucose decrease at all 8 time points forthe liraglutide group, but the ?gures do not show error bars, and no statistical analysis wasreported. Data from glucose pro?les have not been included in labeling for other anti-diabeticdrugs to date.6.1.4.1.7.4 Post-prandial glucose68	169212	170185
104	1	2	16	1	81	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)Post?prandial glucose was patient-measured by glucometer 90 minutes after the start of each meal. Theadjusted mean reduction in postprandial glucose due to liraglutide 1.8 mg across all three daily mealswas 37.4 mg/dL using the ITT population with LOCF. The reduction was 40.7 mg/dL for completers.ANCOVA showed that liraglutide 1.8 mg was signi?cantly better at lowering mean post-prandialglucose than glimepiride (adjusted mean change -12.9 mg/dL, There were no othersigni?cantly different comparisons liraglutide 1.2 mg was not better than glimepiride and liraglutide1.8 mg was not better than liraglutide 1.2 mg). Similar results were obtained when analyzingcompleters. When analyzed by meal, there were similar results: the mean decrease in the liraglutide 1.8mg group was signi?cantly greater than the reduction seen in the glimepiride group, except at lunch. Inaddition, the decrease for the liraglutide 1.2 mg group was signi?cantly greater than the glimepiridegroup at breakfast Reviewer?s comment: These analyses of each meal are not adjusted for multiple comparisons, noris the study powered for these analyses. The subsequent analyses in this section suffer from asimilar problem. In the product label it states 1 These reported values were generated from other trials (the value 31 mg/dL may come from the liraglutide 0.6 mg arm in trial 1572. The 49 mg/dL valueseems to come from the liraglutide 1.8 mg+glimepiride arm in trial 1436) and are discussed insection 6.1.4.2.6.2.6.1.4.1.7.5 Body weightANCOVA analysis was performed with the ITT analysis set using both the LOCF method (Table 6.19)and 52 week completer values. The LOCF method showed that both liraglutide groups resulted in asigni?cantly greater negative weight change (?2.454 kg for liraglutide 1.8 mg and -2.048 kg forliraglutide 1.2 mg) than the glimepiride group which showed a mean increase in weight of 1.123 kg.The difference between the liraglutide groups was not signi?cant. The 52 week completer analysisshowed similar results. 1Table 6.19Trial 1573 - ANCOVA of Change in Body Weight ITT population with LOCFTreatment/comparison EstimatesLeast Square Means LS SEMeanLira 1.8 240 -2.454 - 0.282Lira 1.2 - 245 -2.048 0.281Glimepiride 248 1.123 0.269Estimated Treatment LS 95% CI p?valueDifferences Mean69	170186	172557
105	1	2	16	1	82	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Lira 1.8 - Glimepiride -3.577 -4.281 (-2.873) <0.0001Lira 1.2 - Glimepiride -3.171 -3.872 - (-2.471) <0.0001Lira 1.8 Lira 1.2 -0.406 -1.111 0.299 0.2584The estimates are from ANCOVA model with treatment, country and previous OAD treatment as ?xedeffects and baseline value as a covariateSource: Table 11-9, trial 1573Plots of the LOCF values of mean body weight over time are presented in Figure 6.9. Weight loss in theliraglutide treatment groups primarily occurred in the ?rst 12 weeks, with a slight increase in the laterpart of the trial. Body weight in the glimepiride group increased during the first 20 weeks, andthen remained steady throughout the trial.Figure 6.9 Trial 1573 - Mean Body Weight over Time by Treatment, ITT (LOCF) Mean) Body Weigla (kg)1?Week . I ?Ura1.2mg Source: Figure 11-2, Trial 1573 reportPercentage change in body weight was -2.5 for the liraglutide 1.8 mg group, -2.2 for the liraglutide1.2 mg group and +1.3 for the glimepiride group. In the liraglutide group, 24.4 of subjects gainedweight, 47.2% lost 0?5% of their body weight, 20.7% lost 5-10% of their body weight, and 5.3% lostmore than 10% of their body weight. The percentages were similar in the liraglutide 1.2 mg group49.8%, 16.7%, and 4.8% in each of the four categories of weight change, respectively). Agreater percentage of subjects achieved a weight loss of 5% or more in the liraglutide 1.8 mg group vs.the glimepiride group (OR 6.6, CI 3.5 12.3). A greater percentage of subjects achieved a weight lossof 5% or more in the liraglutide 1.2 mg group vs. the glimepiride group as well (OR 5.1, CI 2.7 9.6).A greater percentage of subjects achieved a weight loss of 10% or more in the liraglutide 1.8" mg groupvs. the glimepiride group (OR 7.1, CI 1.6 31.6), and a greater percentage of subjects achieved a weightloss of 10% or more in the liraglutide 1.2 mg group vs. the glimepiride group (OR 6.4, CI 1.4 29.0).There was no difference in the percentage of subjects who lost 5% or more or 10% or more of bodyweight between the two liraglutide treatment groups.70	172558	174700
626	1	4	50	1	16	DMD#60558down the generation of the reactive metabolites of IMP. This critical finding providesthe evidence that bioactivation of IMP took place in the active site of CYP2B6.The P is defined as the number of product molecules produced per inactivationevent and reflects the efficiency of the inactivator. The values of Ps reported inliteratures for mechanism-based inactivators of P450 enzymes vary from 2 (veryhighly efficient inactivators) to >1000 (inefficient) (Kent et al., 2001). Bergamottin, afuranocoumarin compound, was an efficient mechanism-based inactivator of CYPs2B6 and 3A5 with partition ratio of approximately 2 for CYP2B6 and 20 for CYP3A5, respectively (Lin et al., 2005). Therefore, IMP (P = 4) may be ranked as anefficient inactivator of CYP2B6.At time 0 min, decrease in enzyme activity was observed with the increasing ofthe concentrations of IMP applied. The observed enzyme inhibition may result fromreversible inhibition at the beginning of the incubation.Generation of reactive metabolites is a key step for mechanism-based enzymeinactivation. We hypothesized that IMP is metabolized to furanoepoxide intermediate2 (Scheme 1) or/and -ketoenal intermediate 3, and the -ketoenal is also suggested tobe generated by rearrangement of the furanoepoxide. To probe the hypothesis, wesearched for the electrophilic intermediates using GSH as a trapping agent. An IMPderived GSH conjugate in microsomal incubations with IMP was detected by LCMS/MS (Fig. 4D). The detected protonated molecular ion [M+H]+ matched themolecular weight of GSH conjugates 4-6 (Scheme 1). The MS/MS spectrum of themetabolite showed the indicative characteristic fragments of GSH and some other16	19971	21662
108	1	2	16	1	85	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)proposed indication of liraglutide and changes in lipid pro?le are not discussed in labeling, thisvariable will not be discussed in the next sections (the sections presenting the ef?cacy data for theother phase 3 trials.)6.1.4.1.7.9 Metabolic PrevalenceThe proportion of subjects having metabolic at the end of the trial were compared between theliraglutide groups and glimepiride group using a chi-square test. At baseline, 72.0% of the subjects inthe liraglutide 1.8 mg group, 79.6%% in the liraglutide 1.2 mg group, and 76.4% in the glimepiridegroup were classi?ed as having metabolic At the end of trial, 66.5% of the subjects in theliraglutide 1.8 mg group, 73.4% in the liraglutide 1.2 mg group, and 78.4% in the glimepiride groupwere classified as having metabolic The Sponsor did not report which component(s) of themetabolic drove these differences. The ?nal proportion of subjects with metabolic in the liraglutide 1.8 mg group was significantly lower than the glimepiride group but theliraglutide 1.2 mg group did not reach a statistically signi?cant difference from the glimepiride group(0.2) Also there was no difference between the two liraglutide doses Reviewer?s comment: The label states that liraglutide reduces the occurrence of metabolicNote that this ?nding is not dose dependent and that this analysis for this secondaryendpoint was not corrected for type _1 error. Also, this ?nding was not consistently found acrossthe Phase 3 program as will be discussed in later sections.6.1.4.2 Combination therapy trials with one OAD (Trials 1572 and 1436)Trials 1572 and 1436 evaluated 26 weeks of treatment with liraglutide in combination with one OAD(metformin in Trial 1572 and glimepiride in Trial 1436). Both trials assessed three liraglutide dose levels(0.6, 1.2 and 1.8 mg), compared with placebo (the OAD alone) and compared with another OAD (activecomparator). In Trial 1572 the active comparator was glimepiride (+metformin), and in Trial 1436 it wasrosiglitazone (+glimepiride).Demographic features of the combination therapy with one OAD populationThe screening demographic and diabetes-related characteristics of the randomized subjects in the pivotaladd-on with one OAD studies are summarized in table 6.20.The treatment arms within each trial were generally well matched with regard to baseline demographics.The two trials also had mostly similar baseline characteristics between them. Trial 1572 studied a totalof 1091 subjects (58% male and 42 female) subjects, and trial 1436 studied a total of 1041 subjects(49.4% male and 50.6% female); the percentage of men was higher in trial 1542. The mean age of73	180542	183260
110	1	2	16	1	87	Clinical ReviewLisa B. Yanof? M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)(4.8) (5.9) (5.6) (5.3) (5.6)Previousanti-diabetictreatment, Monotherapy 81 91 (37.8) 83 (34.3) 41 89 (36.5) 71 71 (31.1) 63 37 I 73(33.5) (33.6) (30.5) (26.9) (32.5) (31.5)Combination 161 150 159 81 156 (63.5) 162 157 (68.9) 171 77 159therapy (66.5) (62.2) (65.7) (66.4) (69.5) (73.1) (67.5) (68.5)HbAlc atscreeningMean (SD) 8.4 8.3 (0.9) 8.3 (0.9) 8.4 8.4 (0.9) 8.4 (0.9) 8.4 (0.9) 8.5 8.4 8.3(0.9) (1.0) (0.9) (0.9) (0.9)Source: [Study 1572 Table 11-1], [Study 1436 Table 11-2]The mean baseline values of selected efficacy parameters (HbA1c, FPG, and blood pressure) of therandomized population in the add-on with one OAD studies are summarized in table 6.21. These valueswere comparable between all treatment arms.Table 6.21Selected Baseline Ef?cacy Parameters Subjects in the add-on therapy with one OAD populationTrial 1572 26 weeks Trial 1436 26 weeksLira 0.6 Lira 1.2 Lira 1.8 Pbo Met'+ Lira 0.6 Lira1.2 Lira1.8 Pbo RosiMet Met Met Met Glim +Glim +Glim +Glim +Glim +GlimAll 242 241 242 122 244 233 228 . 234 114 232randomizedsubjects (N)HbA1c .240 238 240 I22 239 227 228 229 I 1 1 229Mean (SD) 8.4 (0.9) 8.3 (1.0) 8.4 (1.0) 8.4 (1.1) 8.4 (1.0) 8.4 (1.0) 8.5 (1.1) 8.5 (0.9) 8.4 8.4 (1.0)(1.0)Fastingplasmaglucose(mg/dL)239 237 236 1 17 237 231 224 229 111 229Mean (SD) 10.2 9.9 (2.3) 10.1 10.0 10.0 (2.6) 10.0 9.8 (2.7) 9.7 (2.4) 9.5 9.9 (2.5)(2.4) . (2.3) (2.3) (2.4) (2.0)Diastolic BP(mmHg)242 240 242 122 243 233 228 233 114 232Mean (SD) 79.9 79.9 (9.5) 79.4 80.7 79.5 (8.3) 80.1? 80.1 (8.8) 80.6 80.7 80.1(8.2) (7.7) (9.0) (8.3) (8.6) (8.9) (8.4)Systolic BP(mm?232Mean (SD) 131 132 131 135 132(l5.9) 130.9 133.1 132.4 131.3 132.575	185965	187691
628	1	4	50	1	18	DMD#60558was the primary GSH conjugate resulting from metabolic activation of IMP.However, we are unable to tell whether conjugate 6 came from intermediate 2 or 3,since conjugate 5 may be spontaneously converted to conjugate 6, and vice versa. Inother words, whether intermediate 2 or 3 was the primary metabolic intermediateremains unknown. We speculate that IMP was oxidized to the corresponding ketoenal/epoxide (on the furan rings), which chemically attacked the host enzyme toform covalent binding and the enzyme modification initiated the process of theenzyme inactivation.The bioactivation studies with individual recombinant enzymes demonstratedthat multiple P450 enzymes catalyzed the metabolism of IMP to the reactiveintermediate (Fig. 6). CYP1A2 was found to be the major enzyme responsible for thebioactivation of IMP. Whether IMP is a mechanism-based inactivator of CYP 1A2 isunder investigation.In summary, we have shown that IMP is characterized as a mechanism-basedinactivator of CYP2B6. A GSH conjugate derived from a -ketoenal intermediatewas identified in microsomal incubations with IMP trapped with GSH.18	23426	24553
629	1	4	50	1	19	DMD#60558Authorship contributionsParticipated in research design: Zheng J, Peng.Conducted experiments: Zheng L, Cao, Lu, and Ji.Performed data analysis: Zheng L.Wrote or contributed to the writing of the manuscript: Zheng J, Zheng L.19	24554	24788
112	1	2	16	1	89	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)6.1.4.2.3.1 Trial 1572The comparator in this study was glimepiride 4 mg qd. Additionally subjects were on backgroundtherapy of 1.5 2 metformin daily.Reviewer?s comment: Although the maximal allowed dose of glimepiride close to the maximally effective dose. Therefore, the dose of 4 mg qd is adequate. Thebackground metformin exposure was also adequate.6.1.4.2.3.2 Trial 1436The comparator in this study was rosiglitazone 4 mg qd. Additionally, subjects were on backgroundtherapy of 2-4 mg glimepiride qd. AReviewer?s comment: Rosiglitazone 8 mg qd is the maximal FDA approved dose. Therefore, inthis trial the highest proposed doses of liraglutide are being compared to the half maximal dose ofrosiglitazone calling into question the adequacy of the active comparator dosage in this trial. Thechoice of active comparator dose was based on manufacturer?s recommendations and theapproved doses at the time in the regions where the trial was conducted (21 non-U.S. sites). Thisexplains the difference in rosiglitazone doses between Trial 1436 (4 mg/day) and Trial 1574 (8mg/day) (The design of Trial 1574 is discussed in section 6.1.3.83) However, use of the full 8 mgper day dose of rosiglitazone is often limited in clinical practice by side effects such as edema andweight gain limiting the usefulness of the highest dose. Therefore, rosiglitazone 4 mg daily as acomparator may have real world signi?cance.Background glimepiride exposure was adequate.6.1.4. 2.4 Primary efficacy variable for the add-on with one OAD populationAnalyses of the changes in HbAlc from baseline to the end of the trials for liraglutide groups comparedwith placebo and active comparator groups (ITT with LOCF) for the add-on with one OAD populations are summarized in table 6.23. For the HbAl endpoint, analyses using the ITT population with LOCFand the PP population were consistent across studies, supporting robustness of results. Unless otherwisenoted, this section presents efficacy data using the ITT population with the LOCF method.77	189954	192055
114	1	2	16	1	91	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000) Victoza? (liraglutide)1.8 mg+rnetformin lowered HbAlc In study 1436, relative to placebo+glimepiride, liraglutide0.6 mg+glimepiride lowered HbA1c by liraglutide 1.2 mg+glimepiride lowered HbA1c by -1.31%, and liraglutide 1.8 mg+glirnepiride lowered HbA1c ANCOVA showed that in both trials, liraglutide in combination with one OAD was superior totreatment with the same OAD alone the placebo-controlled arms of the study) (all Theresults for the active comparator arms were as follows: In trial 1572, liraglutide at doses of 1.2 and 1.8mg in combination with metformin was non-inferior to treatment with metformin+glimepiride. In trial1436, liraglutide at doses of 1.2 and 1.8 mg in combination with.glimepiride was superior to treatmentwith glimepiride rosiglitazone, and liraglutide 0.6 mg in combination with glimepiride was non-inferior to glimepiride rosiglitazone.Reviewer?s comments: These trials support efficacy of liraglutide 1.2 mg and 1.8 mg over placebowhen added to one OAD.Concerning clinical importance: The HbA1c reductions for the 1.2 and 1.8 mg doses were greaterthan 1% over placebo in both trials. Therefore, when added to one OAD liraglutide can beexpected to have an important clinical impact.Concerning dose selection: Both trials show liraglutide at the higher two doses outperforming the0.6 mg dose. However, the higher two doses seem roughly equally effective based on the HbA1c reduction relative to placebo in both trials. Note: among the 5 major efficacy trials reviewed inthis document, only the monotherapy trial showed liraglutide 1.8 mg to be superior to 1.2 mg.Concerning the active comparator arms: Liraglutide added to metformin was non-inferior toglimepiride added to metformin, and at the 0.6 mg dose liraglutide was worse thanglimepiride added to metformin. Liraglutide at both the 1.2 and 1.8 mg doses added toglimepiride was better than rosiglitazone added to glimepiride. However, the rosiglitazone dose inthis trial was only 4 mg qd. Therefore, one should be cautious in concluding that liraglutide issuperior to rosiglitazone given at the maximal FDA approved dose of 8 mg. Based on these twotrials, taking into account the dose selection of the active comparator rosiglitazone, this reviewerconcludes that liraglutide is at least non-inferior to both of the active comparators at an HbA1cmargin of 0.4% when added to one OAD.A plot of mean HbAl by treatment and week for the treatment groups for trial 1572 is shown in 6.10and for trial 1436 in figure 6.11. Overall, in the liraglutide and active comparator groups, the decrease inHbA1c was evident after 8-12 weeks of treatment in both trials.In trial ?1572 there was a decrease in mean HbA1c from baseline to 12 weeks of treatment in all 3liraglutide groups and in the glimepiride+metformin group. In the metformin group, HbA1c increasedfrom baseline to 8 weeks of treatment and then decreased to close to the baseline level at 12 weeks oftreatment. In the period from 12 weeks of treatment to end of treatment, mean HbAlc remainedessentially unchanged in all 5 treatment groups.79	194361	197501
115	1	2	16	1	92	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)In trial 1436 there was a decrease in mean HbA1c from baseline to 12 weeks of treatment in all 3liraglutide treatment groups and in the rosig1itazone+glimepiride treatment group, with the greatestdecrease seen for liraglutide 1.2 mg+glimepiride and liraglutide 1.8 mg+glimepiride treatment. In theperiod from 12 weeks of treatment to end of treatment, mean HbA1c remained relatively unchanged toincreased in the 3 liraglutide treatment groups. In the rosig1itazone+glimepiride treatment group HbA1c appeared to continue to improve past 12 weeks, although a slight increase inmean HbA1c wasseen at the end of the trial. No change in mean HbA1c during the trial was apparent in the glimepiridetreatment group.Figure 6.10 Trial 1572 Plot of Mean HbA1c by Treatment and Week (LOCF, ITT)10.0I7' . 5 7.1'0 1'2 1'4 1'6 1'3 2'0 2'2 2'4 2'6Time (Week)HHS Lira 0.6 Mei "4 Lira 1.2 Met Lira 1.8 Met Met Hr-'3 Glim MetSource: Figure 11-1, Trial 1572 report80	197502	198531
631	1	4	50	1	21	DMD#60558release. Eur J Pharmacol 573: 170175.Huang Z, Roy P, and Waxman DJ (2000) Role of human liver microsomal CYP3A4 andCYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.Biochem Pharmacol 59: 961972.Kent UM, Jushchhyshyn MI, and Hollenberg PF (2001) Mechanism-based inactivators asprobes of cytochrome P450 structure and function. Curr Drug Metab 2: 215243.Kim YK, Kim YS, and Ryu SY (2007) Antiproliferative effect of furanocoumarins from theroot of Angelica dahurica on cultured human tumor cell lines. Phytother Res 21: 288290.Klaassen CD, Amdur MO, and Doull J (1986) Biotransformation of xenobiotics, in Casarettand Doulls Toxicology, the Basic Science of Poisons (Klaassen CD ed) pp113186,McGraw-Hill, New York.Koenigs LL and Trager WF (1998) Mechanism-based inactivation of cytochrome 2B1 by 8methoxypsoralen and several other furanocoumarins. Biochemistry 37: 1318413193.Li HB and Chen F (2004) Preparative isolation and purification of bergapten and imperatorinfrom the medicinal plant Cnidium monnieri using high speed counter-currentchromatography by stepwise increasing the flow-rate of the mobile phase. J ChromatogrA 1061: 5154.Lin G, Tang J, Liu X, Jiang Y, and Zheng J (2007) Deacetylclivorine: A gender-selectivemetabolite of clivorine formed in female SD rat liver microsome. Drug Metab Dispos35: 607613.Lin HL, Kent UM, and Hollenberg PF (2005) The Grapefruit juice effect is not limited to21	26246	27696
119	1	2	16	1	96	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)All analyses were performed using the ITT population with LOCP to test for signi?cant interactions.Treatment by Pre-Treatment InteractionIn both trials the decrease in HbAlc from baseline to end of treatment in all groups was greater in thosesubjects having received previous OAD monotherapy, representing an add-on scenario, compared withthose subjects having received previous OAD combination therapy, representing a switch scenario.Note: in the metformin group, there was a lowering in HbAlc in subjects having received OADmonotherapy, while there was an increase in HbAlc in subjects having received OAD combinationtherapy. -Reviewer?s comment: This ?nding may be due to inadequate washout of previous OAD. Further,in both trials, the differences between treatment groups with respect to change in HbAlc did notdepend on previous OAD therapy (non?signi?cant treatment by previous treatment interaction).Treatment by Country Interaction .For trial 1572, from the statistical analysis, differences between treatment groups with respect to changein HbAlc did not significantly depend on country (non-signi?cant treatment by country interaction).For trial 143 6, the difference between treatment groups with respect to change in HbAlc diddemonstrate a statistically significant country interaction, meaning that the differences betweentreatment groups with respect to change in HbAlc differed between the countries Reviewer?s comment: The primary analysis for the primary ef?cacy variable included country asa ?xed?effect in the model the effect of country was accounted for in the primary ef?cacyanalyses).Treatment by Gender Interaction There was no statistically signi?cant treatment by gender interaction on HbAlc in either trial.Treatment by Race InteractionFor trial 1572, differences between treatment groups with respect to change in HbAlc did notsigni?cantly depend on race (non-significant treatment by race interaction).For trial 1436, there was no apparent difference in change in HbAl from baseline to end of treatmentfor liraglutide among the different racial subgroups. The statistical analysis did, however, show asignificant HbAlctreatment by race interaction (p value was 0.0026), meaning that the differencesbetween treatment groups with respect to change in HbAlc differed between races.Reviewer?s comment: The statistical reviewer concluded that across the ?ve Phase 3 studies, theaverage HbAlc response to liraglutide was not consistently affected by race or ethnicity. Most ofthe p-values of the interactions of race/ethnicity with treatment group were greater than 0.1. Inthe opinion of the statistical reviewer, the few p-values that were less than 0.1 (such as in this case)84	203801	206586
120	1	2	16	1	97	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)were not consistent across studies and do not indicate an important effect of race on the ef?cacy ofliraglutide.Treatment by Age Group InteractionThis analysis investigated if the differences between treatment arms in change in HbAlc were dependenton age group 65 years and 2 65 years). From the statistical analysis, the differences betweentreatment groups with respect to change in HbAlc did not significantly depend on age group (non-significant treatment by age group interaction).Treatment by BMI Group InteractionThis analysis investigated whether there was an interaction between the effect of treatment group andthe effect of BMI group (BMI 25 25 kg/m2 2 BMI 30 kg/m2, 30 kg/m2 3 BMI 35 kg/m2 andBMI 2 35 kg/m2) on change in HbAlc. There was no statistically significant treatment by BMI groupinteraction on change in HbAlc in either trial.6.1.4.2.5.3 Selected Exploratory AnalysesRelationship between Renal and Hepatic Impairment and Change in HbAlc_To investigate whether renal or hepatic impairment had any in?uence on the treatment effects seen onchange in HbAl c, change in HbAlc was summarized by baseline creatinine level (re?ecting renalimpairment), by baseline alanine aminotransferase (ALT) level and by baseline aspartateaminotransferase (AST) level (the latter two re?ecting hepatic impairment). The Sponsor noted that thedegree of impairment was limited as exclusion criteria restricted the entry of subj eets with significantimpairment. The differences between the treatment groups for change in HbAlc did not appear todepend on baseline creatinine, baseline ALT, or baseline AST status in either trial.Reviewer?s comment: This reviewer agrees with the Sponsor that these analyses are limitedbecause of the exclusion criteria. In addition the chosen measures of renal and hepaticimpairment are not optimal. Estimated glomular ?ltration rate (GFR) or creatinine clearance forassessment of renal impairment may have been a better choice. In terms of hepatic impairment,tests of function bilirubin, INR, etc.) may be more re?ective of hepatic impairment.patients with cirrhosis may have very little elevation in transaminases because little tissue isleft. However, in this trial which excluded patients with medical comorbidities such as cirrhosis,tests of function may not have been helpful.6. 1.4. 2.6 Secondary efficacy variables for the add-on with one OAD populationSecondary glycemic control parameters were changes in fasting plasma glucose and post-prandialplasma glucose.85	206587	209171
121	1	2	16	1	98	Clinical Review -Lisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)6.1.4.2.6.1 Fasting plasma glucose (FPG)Table 6.26 summarizes the changes in FPG for the add-on to one OAD studies. The greatest decreaseswere seen for the two higher dose liraglutide groups which were quite similar to each other.Liraglutide vs. placebo: In both trials, changes in FPG in the three liraglutide groups were signi?cantlydifferent from the placebo groups in favor of liraglutide.Liraglutide vs. comparator: In triawere comparable to not statistically di1 1572, changes in FPG in the three liraglutide groups+metforminfferent from) the glimepiride+metformin group. When theanalyses were performed on the data set where no imputation had been perfonned differences betweenthe liraglutide 1.2 mg+metformin and liraglutide 1.8 mg+metformin groups and theglimepiride+metformin group were statistically significant in favor of liraglutide. In tria] 1436, the twohigher doses of liraglutide performed better than the comparator rosiglitazone, both when added toglimepiride.Table 6.26ANCOVA of Change in Mean Fasting Plasma Glucose (FPG) (mg/dL) (add-on therapy with one OADtrials)Placebo #Comparat0rBaselineFPG .un- Mean Meanadjusted *Adjusted difference differencemean mean change from com? from com? (SD) in FPG (SE) parator 95% Cl value parator 95% CI valueTrial 1572Metformin add-onLira 0.6 238 183.1 -20.3 (2.789) -27.59 <.0001 3.16 12.1 0.8079(43.6) 16.9 .. Lira 1.2 234 178.8 -29.4 (2.864) -36.67 -47.3; - <.0001 ?5.92 -14.8; 3.0 0.3047(42.0) 26.0Lira 1.8 235 181.2 -30.3 (2.787) -37.58 -48.2; - I <.0001 -6.83 -15.7; 2.0 0.1845(41.5) 26.9Placebo 116 181.0 7.24 (3.814)(41.4)Comparator 234 180.4 -23.5 (2.823)(46.2)Trial 1436Glimepirideadd-onLira 0.6 230 179.9 -13.0 (2.855) -31.13 -42.6; <.0001 2.85 12.2 0.8786(43.2) 19.7Lira 1.2 218 177.1 -28.3 (2.946) -46.41 -58.0; - <.0001 -12.44 -22.0; -2.9 0.005686	209172	211077
123	1	2	16	1	100	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)Figure 6.12 Trial 1572 Plot of Mean Fasting Plasma Glucose by Treatment and Week (mg/dLTime (Week)9-9-9 Lira 0.6 Met Lira 1.2 Met Lira 1.8 4? Met Met v-M~ Giim 4* MetSource: EOT Figure 14.2.67, Trial 1572 reportFigure 6.13 - Trial 1436 Plot of Mean Fasting Plasma Glucose by Treatment and Week (mg/dL)22.0j2l0'_200?. 9?31.90? g3150~ i ?m?jaz?-150?1403 2 gg 130, 120li? ilk ilk lis izb lz? lz? '23Time (Week) =3-Mk Ros:-I-GlamSource: EOT Figure 14.2.64	212879	213413
124	1	2	16	1	101	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)Revieweris comment: The proposed label states that .The lower value of mg/dL appears to have come from trial 1436 at theliraglutide 0.6 mg dose. The upper value of .--mg/dL derives from trial 1574. The plots over timefor these two trials support the claim that the reduction in FPG occurs within 2 Weeks of startingtreatment. However, the type 1 error rate was not controlled and this was not prespecified as akey endpoint. Therefore, this information may not be appropriate for the product label. 6.l.4.2.6.2 Post-Prandial Plasma GlucoseANCOVA analyses for the change in mean postprandial glucose are presented in table 6.27.Post-prandial glucose was patient-measured by glucometer 90 minutes after the start of each meal. Thevalues measured at each of the three daily meals were averaged to obtain the mean post-prandial glucosevalue. In both trials, there was a dose-dependent reduction in estimated mean post-prandial plasmaglucose across all 3 dose levels of liraglutide.Liraglutide vs. placebo: In both trials, liraglutide at all doses was better than placebo when added to oneOAD at reducing mean post-prandial glucose, although the decrease was smaller in the liraglutide 0.6mg groups.Liraglutide vs. comparator: For liraglutide in combination with metformin compared with glimepiridemetformin (trial 1572), the reduction in mean post-prandial plasma glucose did not differ from theactive comparator for the higher doses of liraglutide. Liraglutide at 0.6 mg was worse than the activecomparator arm. In trial 1436, the mean reduction in post-prandial plasma glucose values wassigni?cantly greater in the liraglutide 1.8 mg+g1imepiride and liraglutide 1.2 mg+glimepiride treatmentgroups compared to those in the rosiglitazone+g1imepiride treatment group. The liraglutide 0.6mg+glimepiride group was comparable to the rosiglitazone+g1imepiride group.Table 6.27ANCOVA of Change in Mean Postprandial (PostP) Glucose (mg/dL) (add?on therapy with one OADtrials)Placebo #ComparatorBaselinePostPglucose *Adjusted Mean Meanun- mean change difference difference .adjusted in PostP from com- from com- mean glucose (SE) parator 95% CI value parator 95% CI value89are	213414	215660
125	1	2	16	1	102	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)I (SD) I Trial 1572 Metformin add-onLira 0.6 214 223.2 -30.24 (2.91) -19.15 -30.77; 0.0003 14.06 4.81; 23.31 0.0008(54.9) 1 -7.54Lira 1.2 207 214.2 -42.00 (3.02) -30.91 -42.53; <.0001 2.30 -6.97; 0.9368(49.6) -19.29 11.58Lira 1.8 205 220.3 -46.21 (2.97) -35.12 -46.75; <.0001 -1.91 -11.17; 0.9670(47.8) -23.49 7.36Placebo 90 220.9 -11.09 (4.26)(53.9)Comparator 214 220.2 -44.30 (2.95)(52.9)Trial 1436Glimepirideadd-onLira 0.6 220 228.5 -33.35 (3.32) -26.87 -40.57; <.0001 -0.18 -11.28; 1.0000(57.6) -13.17 10.91Lira 1.2 208 231.9 -44.70 (3.43) -38.21 -52.07; <.0001 -11.53 -22.81; 0.0434(60.6) -24.36 -0.25Lira 1.8 221 233.2 -48.89 (3.40) -42.41 -56.15; <_0001 -15.72 46.89; 0.0022(60.0) -28.66 -4.55Placebo 96 228.2 -6.49 (4.91)(56.0)Comparator 209 234.2. -33.17 (3.41)(61.6)#Comparator in trial 1572 is glimepiride and in trial 1436 is rosiglitazoneThe 95% CI for_the estimated differences are based on Dunnett?s method*The change in mean PostP glucose was estimated using an ANCOVA model with treatment, country and previous anti-diabetictreatment as ?xed effects and baseline value as covariateSource: Table 14.2.94, Trial report 1572], Table 14.2.98, Trial report 1436]Reviewer?s comment: It is reported in the labeling that The number mg/dL appears to come from trial 1572 at the 0.6 mg dose. The number.-? mg/d'L comes from trial 1436 at the 1.8mg dose. The label does not indicate that this reduction is on top of background therapy.Overall conclusions regarding ?other? glvcemic control parameters: Lira lutide at the two8higher doses appears to reduce both FPG and post-prandial glucose signi?cantly over placebo?when added to one OAD.6.1.4.2.6.3 Body weightEstimated change in body weight and analyses of change in body weight after 26 weeks for trials 1572.-and 1436 are shown in Table 6.28. Changes in body weight for all three liraglutide groups (favoring90	215661	217615
126	1	2	16	1	103	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)weight loss) were shown to be superior to the active comparator in both trials. Liraglutide 1.2 mg metformin and liraglutide 1.8 mg metformin were shown to be superior to placebo metformin in trial1572. The liraglutide glimepiride groups were not better than placebo glimepiride in trial 1436.Reviewer?s comment: It appears that for both trials the possible reason the change in body weightfor all three liraglutide groups were shown to be superior to the active comparator was becausethe active comparator groups experienced weight gain, although in trial 1572, the weight loss withliraglutide was greater than the weight gain with the comparator glimepiride. The weightdifference between the liraglutide groups compared to the placebo groups in both trials wasclinically trivial (although statistically signi?cant for the two higher liraglutide doses in trial 1572).These results suggest that although liraglutide per se may not result in a clinically importantweight loss, the relative weight decrease compared with the active comparators in these trials(glimepiride and rosiglitazone both known to be associated with weight gain) may be clinicallymeaningful when choosing a particular drug therapy for an individual patient.Table 6.28ANCOVA of Change in Body Weight after 26 weeks (kg) (add-on therapy with one OAD trials)Placebo #ComparatorBaselineBodyWeightun- *Adjusted Mean Meanadjusted mean change difference differencemean in body from com- from com- (SD) weight (SE) parator 95% CI value parator 95% CI valueTrial 1572Metformin add-onLira 0.6 242 87.8 -1.78 (0.23) -0.28 -1.15; 0.60 0.8198 -2.73 -3.47; 2.00 <.0001(17.1)Lira 1.2 236 88.5 -2.58 (0.24) -1.07 -1.94; - 0.0117 -3.53 -4.27; 2.79 (19.1) 0.19Lira 1.8 241 88.0 -2.79 (0.23) -1.29 -2.16; 0.41 0.0016 -3.75 -4.48; 3.01 <.0001(16.3) -Placebo 121 91.0 -1.51 (0.31)(17.0) .Comparator 237 89.0 0.95? (0.23)(16.8)Trial 1436Glimepirideadd-onLira 0.6 231 82.6 0.72 (0.20) 0.82 0.04; 1.60 0.0355 -1.38 -2.03; - (17.7) 0.74Lira 1.2 224 80.0 0.32 (0.20) 0.42 -0.37; 1.20 0.4546 -1.79 -2.44; - (17.1) 1.13Lira 1.8 232 83.0 -0.23 (0.20) -0.14 -0.92; 0.64 0.9702 -2.34 -2.99; <.000191	217616	219838
128	1	2	16	1	105	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Figure 6.14 Trial 1572 - Mean Change in Body Weight (kg) by Treatment and Week2.01.5?1.00.5?0.0??2.0Change in E3c>cly tight (kgTime (Week)B-E-B Lira 0.6 Met Lira 1.2 Met Lira 1.8 Met MW Met 9% Giim 4- MetSource: Figure 11-3, trial 1572 report93	221718	222045
129	1	2	16	1	106	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)Figure 6.15 Trial 1436 - Mean Change in Body Weight (kg) by Treatment and Week Change in Body? We'igl1t (kg1:"Flme(Week) A ?We? ?sews Bears? i.ira1.8+Glim (Slim were Source: Figure 11-2, trial 1436 reportReviewer?s comment: The early reductions in weight in the liraglutide groups were notmaintained and at the end of 26 weeks. Even though there was a slight decrease in weight in theliraglutide 1.8 mg group, these weight changes are probably not clinically meaningful.Further statistical analyses showed that-differences between treatment groups with respect to change inbody weight did not signi?cantly depend on BMI group (non-signi?cant treatment by BMI groupinteraction) for trial 1572, while the effect of baseline BMI on change in body weight was dependent ontreatment group (p=0.023 3) in trial 1436 with the greater BMI groups bene?ting from the greatestweight loss. Also, because nausea was a common side effect of liraglutide, the change in body weightwas evaluated for 6 different nausea subgroups; there was no consistent pattern with respect to therelation between nausea and change in body weight for either trial.6.1.4.2.6.4 Measures of beta-cell function and insulin resistance94	222046	223326
131	1	2	16	1	108	Clinical ReviewLisa B. Yanof? M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Table 6.29AN COVA of Change in Systolic Blood Pressure (SBP) in after 26 weeks (add-on therapy withone OAD trials)Placebo #ComparatorBaselineSBPun- Mean Meanadjusted *Adjusted difference differencemean mean change from com- from com- (SD) in SBP (SE) parator 95% CI value parator 95% C1 valueTrial 1572Metformin add-onLira 0.6 242 131.2 -0.58 (0.84) 1.18 -2.01;4.38 0.7286 -0.98 -3.66;1.70 0.7885Lira1.2 236 132.1 -2.81 (0.86) -1.05 -4.25;2.15 0.7987 -3.21 0.0128. 0.52Lira 1.8 241 131.3 -2.29 (0.83) -0.53 -3.72; 2.66 0.9765 -2.69 0.04670.03Placebo 121 134.9 ?-1.76 (1.14)Comparator 239 131.7 0.41 (0.85)Trial 1436Glimepirideadd-on Lira 0.6 232 130.9 -0.94 (0.84) 1.38 -l.93;4.70 0.6453 -0.01 -2.76;2.74 1.0000Lira1.2 224 133.1 -2.56 (0.85) -0.24 -3.58;3.11 0.9990 -1.63 -4.41; 1.15 0.4186Lira1.8 231 132.4 -2.81 (0.86) -0.49 -3.82; 2.84 0.9841 -1.88 -4.65; 0.89 0.2842Placebo 112 131.3 -2.32 (1.17)Comparator 229 1132.5 -0.93 (0.84)#Comparator in trial 1572 is glimepiride and in trial 1436 is rosiglitazoneThe 95% CI for_the estimated differences are based on Dunnett?s method*The change in SBP was estimated using an ANCOVA model with treatment, country and previous anti-diabetic treatment as fixedeffects and baseline value as covariateSource: [Table 11-33 trial 1572 report]; [Table 11-33 trial 1436 report]Reviewer?s comment: Neither trial showed a reduction in SBP compared with placebo at the endof 26 weeks. The statistically signi?cant difference found between the active comparator andliraglutide in trial 1572 has as much to do with a SBP increase in the comparator group. While areduction in blood pressure was seen, it was seen among placebo groups as well, suggesting thatthe blood pressure reduction was not related to liraglutide use per se. Alternative explanation arethat subjects enrolled in clinical trials may have better monitoring and treatment of comorbiditiessuch as blood pressure, or that subjects enrolled in clinical trials are more health conscious diet and exercise) that may promote lower blood pressure. These studies do not support the claimin the label that 196- bat	226531	228717
634	1	4	50	1	24	DMD#60558Footnotes. This work was supported in part by the National Natural ScienceFoundation of China [Grant 81373471].24	30164	30285
636	1	4	50	1	26	DMD#60558Figure 3. Partition ratio determination for CYP2B6 inactivation by IMP. CYP2B6was incubated with IMP at various concentrations. The extrapolated P+1 wasdetermined from the point of intersection to the abscissa. Data are meanSD (n=3).Figure 4. A, The MS/MS spectrum, chemical structure and origins of thecharacteristic fragment ions for IMP. B, MS/MS spectrum of IMP-GSH conjugategenerated in microsomal incubation. C, MS/MS spectrum of synthetic IMP-GSHconjugate. D, Extracted ion (m/z 594 465) chromatograms obtained from LC-QTrap mass spectrometry analysis of microsomal incubations containing IMP (solidline) and chemical oxidation of IMP trapped by GSH (dashed line).Figure 5. A, Extracted ion (m/z 596 467) chromatogram obtained from LC-Q-TrapMS analysis of the chemical oxidation reaction followed by reaction with NaBH4. B,MS/MS spectrum of the reduced product.Figure 6. Human P450 enzymes involved in the formation of IMP-conjugate. IMPwas incubated with individual recombinant human P450 enzymes in the presence ofNADPH and GSH. Data are meanSD (n=3).26	31598	32672
637	1	4	50	1	27	Scheme 1OOOO1P450OOOOOHOO2O3OGSHGSHOOOOOOHOGSOOOH54HOOGSHOOOO6OSGNaBH 4HHOOO7HOSG	32673	32753
638	1	4	50	1	28	Figure 1Log % remaining activityA21.71.40369Time (min)501/Kobs (min)By = 6.2806x + 12.621R= 0.954640302010-3-11351/[IMP]CLog % remaining activity1.91.61.3036Time (min)9	32754	32922
639	1	4	50	1	29	Figure 2511m:_:_mE2 oxo mo._1.3Time (min)	32923	32963
640	1	4	50	1	30	m:_:_mE2 ?0Figure 31008040 6020	32964	32994
641	1	4	50	1	31	Figure 4379--glutamyl portion-H2OO2.2e64.5e63.5e6230AA203.569203-coOO0.060594.2- H2O501COOHO447.0 465.1-H O465 2245.0 269.0447203.06.0e5215.5175.4185.5229.6 271.4177NHCOOHO69.35.0e5519HNH2N1.0e61.5e6319SO1.4e6-C 2OOO175OO162- HO22692871.8e62162.5e6 185245B221HO177.0 199.02.0e5519.2501.1327.0379.0162.0576.2430.080 100 120 140 160 180 200 220 240 260 280 300501001502002503003504004505005506006506.806.5e4D1.4e65.5e41.2e64.5e41.0e63.5e48.0e52.5e46.0e51.5e44.0e55000.00.0594.1C2.0e5465.2519.3203.01.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.011.012.013.014.00.0Time (min)50150447.1319.0379.0501.3576.3287.0430.2250 300 350 400 450 500 550 600245.0162.0100269.0200650	32995	33655
642	1	4	50	1	32	Figure 56.693.8e43.5e4AA3.0e42.5e42.0e41.5e41.0e45000.00.01.02.03.04.05.06.07.08.09.010.011.012.013.014.0596.26.0e5BO223-CO21795.0e5HOOO1624.0e52 71- H2O28 9-H2O144HOS- H2OO3.0e5521HNH2NCO HO503467.2NH2.0e5CO HOO162.0203.01.0e5179.1144.1467-H2O449521.2235.0271.0217.0332.0 364.2 381.0449.1100150200250300350400578.2503.2189.10.050450500550600	33656	33997
133	1	2	16	1	110	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)6.1.4.3 Combination therapy population with two OADS (Trials 1574 and 1697)Both Trials 1574 and 1697 evaluated 26 weeks of treatment with liraglutide in combination with twoOADS. In Trial 1574 the OADS were metformin rosiglitazone, in Trial 1697 glimepiride metformin.Trial 1574 assessed two liraglutide dose levels; 1.2 and 1.8 mg and compared these with placebo (thetwo OADs alone). Trial 1697 assessed the 1.8 mg liraglutide dose and compared this with placebo (thetwo OADS alone) and with insulin glargine the two OADS).6.1.4. Demographic features of the add-on with two OADS populationA summary of screening characteristics and demographics for trials 1574 and 1697 is presented in Table6.30. In trial 1574, thebaseline demographic parameters were similar between treatment groups exceptin the sex category where the three groups appeared imbalanced. For trial 1697, the trialpopulation in all 3 groups was well matched with only small differences in baseline characteristics,again most notably in the category of sex where the trial population had a somewhat higherrepresentation of male subjects in the liraglutide 1.8 mg+OADs and glargine+OADs groups compared tothe OADS alone group. -Reviewer?s comment: There was not a signi?cant sex by HbA1c interaction in analyses of theprimary efficacy variable. See section 6.1.4.3.5.2There were some notable differences between the two trials. Subjects in trial 1697 appear to be older, have a mean duration of diabetes longer, and a mean HbAl higher than trialsubjects in trial 1574. Mean BMI was higher in trial 1574. Also a higher percentage of subjectshad been using OAD combination therapy prior to participation in the trial than usedcombination therapy in trial 1574. Racial distribution was also somewhat different between the trialswith Black subjects representing a smaller proportion in trial 1697 with 15.7% of subjects categorized asAsian or Paci?c Islanders.Reviewer?s comment: Within each trial randomization seems successful for the most part.Comparing between trials, overall, trial 1697 enrolled older and more advanced diabetics.In trial 1697, there were a small number of African Americans which is unlike the U.S. diabeticpopulation. 98	230990	233279
134	1	2	16	1	111	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Table 6.30Subject Baseline and Demographic Features of all Randomized SubjectsAdd-On therapy with Two StudiesTrial 1574 26 weeksTrial 1697 26 weeksLira 1.8 Lira 1.2 OADs Lira 1.8 OADs GlargineOADs OADS OADS OADSAll randomized 178 178 177 232 115 234subjects (N)Sex Male 87 (48.88) 102 (57.30) 109 (61.58) 132 (56.9) 56 (48.7) 140 (59.8)Female 91 (51.12) 76 (42.70) 68 (38.42) 100 (43.1) 59 (51.3) 94 (40.2)Age (years)Mean (SD) 55.1 (10.7) 55.2 (10.2) 54.9 (9.8) 57.6 (9.5) 57.5 (9.6) 57.5 (10.5)*Race White 148 (83.15) 144 (80.90) 149 (84.18) 176 (75.9) 89 (77.4) 171 (73.1)Black 18 (10.11) 27 (15.17) 18 (10.17) 9 (3.9) 5 (4.3) 7 (3.0)Asian/Paci?c 34 (14.7) 15 (13.0) 42 (17.9)IslanderAsian 5 (2.81) . 2 (1.12) 3 (1.69)Native 0 (0.0) 0 (0.0) 0 (0.0)Hawaiian/Paci?cIslanderAmerican Indian 1 (0.56) 1 (0.56) 2 (1.13) 0 (0.0) 0 (0.0) 0 (0.0)Alaska NativeOther 6 (3.37) 4 (2.25) 5 (2.82) 2 (0.9) 1 (0.9) 2 (0.9)Unknown 11 (4.7) 5 (4.3) 12 (5.1)BMI (kg/m2) Mean (SD) 33.5 (5.0) 33.2 (5.4) 33.9 (5.2) 30.4 (5.3) 31.3 (5.0) 30.3 (5.3)Duration ofdiabetes (years)Mean (SD) 9.1 (5.6) 8.9 (5.5) 8.9 (5.9) 9.2 (5.8) 9.4 (6.2) 9.7 (6.4)Previous anti-diabetictreatment, Monotherapy 29 (16.29) 29 (16.29) 32 (18.08) 15 (6.5) 6 (5.2) 12 (5.1)Combination 149 (83.71) 149 (83.71) 145 (81.92) 217 (93.5) 109 (94.8) 222 (94.9)therapy .HbA1c atscreening Mean (SD) 8.3 (0.9) 8.3 (0.9) 8.3 (1.1) 8.6 (0.8) 8.5 (0.8) 8.5 (0.8)*Racial categorization differed between the trials"In Trial 1574 the OADs were metformin rosiglitazone, in Trial 1697 glimepiride metformin.Source: [Table 11-1, Trial 1574 report]; [Table 11-2, Trial 1697 report]The mean baseline values of selected ef?cacy parameters (HbA1c, FPG, and blood pressure) of therandomized population in the add-on with two OADs studies are summarized in Table 6.31. Thesevalues were comparable between all treatment arms within each study. Between the studies, it appearsthat in Trial 1697, HbA]c decreased from screening, while in trial 1574 HbA1c increased99	233280	235355
135	1	2	16	1	112	Clinical ReviewLisa B. Yanof? M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)from screening resulting in a higher HbA1c at baseline for trial 1574. Blood pressurewas overall higher among 1697 trial participants.Table 6.31Selected Baseline Efficacy Parameters Subjects Add?0n therapy with Two StudiesTrial 1574 26 weeksTrial 1697 - 26 weeksLira 1.8 Lira 1.2 Pbo Lira 1.8 Pbo GlargineOADS 0ADs OADs OADS OADs OADSAll randomized 178 178 177 232 115 234subjects (N)178 178 177 232 113 234Mean (SD) 8.56 (1.22) 8.48 (1.23) 8.43 (1.16) 8.3 (0.9) 8.3 (0.9) 8.2 (0.9)Fasting plasma glucose (mg/dL)174 177 169 231 112 232Mean (SD) 184.9 (43.3) 181.1 (42.5) 179.6 (47.1) 163.8 169.2 163.8 Diastolic BP(mmHg)178 178 177 232 115 234Mean (SD) 75.2 (8.4) 0 75.8 (9.0) 76.2 (9.2) 80.8 (9.1) 80.4 (9.3) 80.5 (8.0)Systolic BP(m'mHg)178 178 177 232 115 234Mean (SD) 126.0 (14.2) 128.7 (14.8) 128.2 (14.5) 135 (15.0) 133 (14.0) 133 (14.7)"In Trial 1574 the OADs were metforrnin rosiglitazone, in Trial 1697 glimepiride metformin.Mean and SD converted from mmol/L using formula rng/dL mmol/L 18Source: [Table 11-2, Trial 1574 report]; [Table 11-3 Trial 1697 report]6.1.4. 3.2. Participation and withdrawals in the add-on therapy to two OADS population(disposition of subjects)In trial 1574, 821 subjects were screened and 533 subjects were randomized. Three subjects (2 in theliraglutide 1.2 mg+0ADs group and 1 in the OADS alone group) were randomized but did not receivetrial drug (liraglutide or placebo). In trial 1697, 973 subjects were screened, 581 subjects wererandomized to treatment, and 576 subjects were exposed to trial products after randomization; 5 subjectswere randomized but not exposed to liraglutide active/placebo or insulin glargine.Participation and withdrawals in the pivotal add-on with two OADS treatment groups are summarized inTable 6.32. For trial 1574 in both liraglutide treatment groups, most subjects that withdrew did so dueto adverse events (AE5), and, in the OADS alone group, most subjects withdrew due to ineffective100	235356	237398
136	1	2	16	1	113	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)therapy or ?other? reasons. The number of withdrawals was highest during the first month, with a steadydecrease throughout the trial for the liraglutide groups. Most of the withdrawals due to AEs in theliraglutide groups occurred in the first two months.In trial 1697, the largest percentage of withdrawals occurred in the OADs alone group primarily due toineffective therapy. The liraglutide 1.8 mg+OADs group had a withdrawal rate of 10.8% with the mainreasons being adverse events and ?other reasons?. In the glargine+OADs group, the main reasons forwithdrawal were adverse events and non-compliance with the protocol. Overall, 30.5% of thewithdrawals occurred within the ?rst month. There was an imbalance in the timing of the withdrawals,i.e. earlier withdrawals in the liraglutide group (44% of total withdrawals in the ?rst month) and theglargine group (40% of total withdrawals in the ?rst month) compared with only 5% of the totalwithdrawals in the OAD group.Table 6.32 Subject Disposition of All Randomized Subjects Add-on Therapy toTwo TrialsTrial 1574 26 weeks Trial 1697 - 26 weeksLira 1.3 Lira 1.2 OADs Lira 1.3 OADs GlargineOADS OADS OADS OADSSubjects Randomized 173(100) 178(100) 177(100) 232(100) 115(100) 234(100)Exposed (ITT 178 (100) 177 (99.4) 175 (98.9) 230 (99.1) 114 (99.1) 232 (99.1)analysis set)Withdrawals 45 (25.3) 25 (14.0) 56 (31.6) 25 (10.8) 19 (16.5) 15 (6.4)Adverse 27 (15.2) 11 (6.2) 6 (3.4) 11 (4.7) 1 (0.9) 5 (2.1)Events Ineffective 3 (1.7) 3 (1.7) 29 (16.4) 2 (0.9) 13 (11.3) 1 (0.4)therapyNon- 4 (2.2) 4 (2.2) 5 (2.8) 1 (0.4) 1 (0.9) 5 (2.1)compliancewith protocolOther 11 (6.2) 7 (3.9) 16 (9.0) 11 (4.7) 4 (3.5) 4 (1.7)Completers 133 (74.7) 153 (86.0) 121 (68.4) 207 (89.2) 96 (83.5) 219(93.6)PP analysis 123 (69.1) 133 (74.7) 106 (59.9) 195 (84.1) 90 (78.3) 205 (87.6)set"In Trial 1574 the OADs were metformin rosiglitazone, in Trial 1697 glimepiride rnetformin.Source: [Table xx Trial 1574 14.2.1 Trial 1697 report]Reviewer?s comment: According to Dr. Derr?s statistical review, support for the ef?cacy ofliraglutide compared to a placebo control and compared to an active control comes from aconsistent pattern of early withdrawals due to ineffective therapy in comparator arms, whenobserved across the studies. The completer rate is adequate.101	237399	239770
643	1	4	50	1	33	Figure 6% Formation of GSH-conjugate1201008060402001A22A62B62C92C192D62E13A43A5	33998	34076
612	1	4	50	1	2	DMD#60558RUNNING TITLE PAGERunning Title: Inhibition of CYP2B6 by imperatorinCorresponding Authors:Jiang Zheng, PhDCenter for Developmental Therapeutics, Seattle Children's Research Institute,Division of Gastroenterology and Hepatology, Department of Pediatrics, University ofWashington, Seattle, WA 98101Key Laboratory of Structure-Based Drug Design & Discovery of Ministry ofEducation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, P. R.ChinaEmail: jiang.zheng@seattlechildrens.orgTel: 206-884-7651; Fax: 206-987-7660.Ying Peng, PhDSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning,110016, P. R. ChinaEmail: yingpeng1999@163.comTel: +86-24-23986361; Fax: +86-24-23986510.The number of text pages: 26The number of figures: 6The number of references: 28The number of words in the Abstract: 169The number of words in the Introduction: 444The number of words in the Discussion: 947Abbreviations: EPI, enhanced product ion; GSH, glutathione; IDA, informationdependent acquisition; IMP, imperatorin; LC, liquid chromatography; LC-MS/MS,liquid chromatography coupled to tandem mass spectrometry; MRM, multiplereaction monitoring; MS, mass spectrometry; NADPH, -nicotinamide adeninedinucleotide 2 -phosphate reduced tetrasodium salt; RLMs, rat liver microsomes;SOD, superoxide dismutase.2	564	1890
614	1	4	50	1	4	DMD#60558IntroductionImperatorin (IMP), a linear furanocoumarin compound, is the major activeingredient in many common umbelliferous herbs used as traditional Chinesemedicines, such as Cnidium monniericuss and Angelica dahurica (Li and Chen, 2004;Baek et al., 2000). The IMP-containing herbs are widely used in China for thetreatment of osteoporosis and relief of swelling and pain (Zhang et al., 2003). Thereported pharmacological activities of IMP included anti-inflammatory property(Garcia-Argaez et al., 2000), anti-osteoporosis (Tang et al., 2008), antibacterialeffects (Rosselli et al., 2007), antitumor (Kim et al., 2007), -secretase inhibition(Marumoto and Miyazawa, 2010), and inhibition of myocardial hypertrophy (Zhanget al., 2010). Recent studies demonstrated that IMP participated in hypertensiontreatment by inhibiting voltage-dependent calcium channels and receptor-mediatedCa2+ influx and release (He et al., 2007). The observed multiple pharmacologicalactivities of IMP, along with its natural abundance, have shown a great potential to beused as a pharmaceutical agent.A number of furanocoumarin compounds have been found to be inhibitors ofcytochromeP450enzymes.6,7-Dihydroxybergamottinwasthefirstfuranocoumarin compound reported as an inhibitor of rat CYP3A subfamily (Edwardset al., 1996). Angelicin, isopimpinellin, 8-methoxypsoralen, psoralen, isopsoralen,bergamottin, and other related compounds in this family showed inhibitory effects onCYPs 1A1, 1A2, 2B6, 3A4, and 3A5 (Baumgart et al., 2005; Zhuang et al., 2013; Linet al., 2005).In addition, several furanocoumarin compounds in umbelliferous4	2993	4616
138	1	2	16	1	115	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)liraglutide was superior to treatment with glargine (upper CI limit below The analysis performedwithout using LOCF supported these results as did the analysis performed on the PP analysis set.Finally, therapy with glargine was demonstrated to be superior to the placebo treatment (the 0ADs alone group).Table 6.34Analysis of HbA1c Change from Baseline at 26 weeks (add-on therapy with two OADS trials)Placebo #ComparatorBaselineHbA1cun- *Adjusted Mean Meanadjusted mean change difference differencemean in HbA1c from com- from com- (SD) (SEM) parator 95% CI value parator 95% CI valueTrial 1574Lira 174 8.5 (1.2) -1.482 (0.078) -0.94 -1.12; - <.00010.76Lira 177 8.6 (1.2) -1.487 (0.075) -0.94 -1.12; - <.00010.75Placebo+OADs 167 8.4 (1.2) -0.541 (0.080)Trial 1697 -Lira 224 8.3 (0.9) -1.33 -1.09 -1.28; - <.0001 -0.24 -0.39; - 0.00290.90 0.08Placebo+OADs 110 8.3 (0.9) -0.24Glargine+OADs 225 (0.9) -1.09"in Trial 1574 the OADS were metformin rosiglitazone, in Trial 1697 glimepiride metformin.The p?values correspond to a two-sided test for superiority on a 5% signi?cant level (statistical signi?cance for *The change in HbA1c was estimated using an ANCOVA model with treatment, country and previous anti-diabetic treatment as?xed effects and baseline HbA1c as covariateTest for non-inferiority with switch to superiority if non-inferiority is shown.Non-inferiority is concluded if the upper limit of the 95% con?dence interval for the treatment difference is below 0.4% i.e. non-inferiority to comparator is shown for all liraglutide groups.There was no comparator in Trial 1574; the comparator in Trial 1697 was g1argine+OADsA hierarchical testing procedure is used.Source: Tables 3-2, 3-3 Summary of Clinical Ef?cacyReviewer?s comments: In trial 1574 liraglutide 1.2 mg and 1.8 mg show almost identical ef?cacy.It is not clear that comparing the efficacy of liraglutide to glargine in this particular trial is auseful comparison because the ef?cacy of glargine is dependent on the dose which was notoptimized in all subjects, and subjects who failed to meet titration criteria were not excluded fromthe PP analysis set (making the PP analysis set not useful for sensitivity analysis). However, thiscomparison may be useful for predicting ?real world? efficaciousness.103	242350	244707
139	1	2	16	1	116	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)A plot of the mean HbAlc values over time by treatment in trial 1574 is presented in Figure 6.16 and fortrial 1697 in Figure 6.17. The PP and completer populations showed similar results (data not shown).Figure 6.16 Trial 1574 Mean HbA1c Over Time by Treatment 9.0-5? 8.5-0 ?a-?nnv 8.0 7.57_g  6.5243. s?1b1?1'413s1a2a2'2242'aWeak?uraz2+oA.t3s ~?oAns Source: Figure 11-1, Trial 1574 reportFigure 6.17 Trial 1697 - Mean HbA1c Over Time by Treatment10.0?9.5?8.5 8 0 7.5- 7.0? 6.5" 5.0-Haa. I Glargine+C>A9 OADSource: Figure 11-1, Trial 1697 reportBoth trials show that the majority of the response to therapy was seen in the ?rst 12 weeks which wasthen followed by a leveling off of HbAlc or a slight increase as was seen in trial 1697.104	244708	245528
141	1	2	16	1	118	Clinical ReviewLisa B. Yanoff, MD.NDA 22,34] (Submission 000)Victoza? (liraglutide)Table 6.36Percentage of Subjects Reaching AACE Target (HbA1c at 26 weeks (add?on therapy with twotrials) Logistic Regression Placebo Comparatorof Subjects Odds Odds Reaching Target Ratio 95% CI value Ratio 95% CI valueTrial 1574Lira 174 37.3 4.84 2.64 8.86Lira 177 36.2 5.62 3.08 10.26Placebo+OADs 167 14.4Trial 1697Lira 230 37.1 5.83 2.88 2.52 1.59 4.00 11.78Placebo+OADs 1 14 10.8Glargine+OADs 232 23.6"In Trial 1574 the OADs were metformin rosiglitazone, in Trial 1697 glimepiride metformin.There was no comparator in Trial 1574; the comparator in Trial 1697 was glargine+OADs=number of subjects in ITT analysis setThe estimates are obtained from a logistic regression with treatment as ?xed effect and baseline HbA1c value as a eovariate.Source: [Table 11-7, Trial 1574 report] [Table 11-15, Trial ,1 697 report]Reviewer?s comments: Both doses of liraglutide when combined with these two OADS weresuperior to the two OADS alone for the efficacy endpoint of dichotomous HbA1c treatment goals.Similar to the primary ef?cacy variable of percent HbAlc reduction, there does not seem to be adose dependent effect in trial 1574 for the efficacy endpoint of HbA1c dichotomous treatmentgoals (only one dose of liraglutide was tested in trial 1697).6.1.4.3.5.2 Treatment effect on selected subgroupsAll analyses were performed using the ITT population with LOCF to test for signi?cant interactions.For both trials, previous antidiabetic treatment, country, gender, BMI, and age did not have a signi?canteffect on efficacy analyses for interaction between these variables and treatment group were notsigni?cant). For trial 1574, there was no effect of race/ethnicity on ef?cacy. For trial 1697, an analysisof race by treatment interaction effect showed a value of 0.0407. A summary of the changes in HbA1cshowed that both liraglutide and glargine reduced HbAlc in all racial groups as follows [mean HbA1cchange from baseline Caucasian (n=176): -1.4 (0.9), Black -1.5 (0.9), Asian/Paci?cIslander -1.0 (1.0), and Other -0.3 (0.0). The Sponsor states that while, there was a106	247416	249566
615	1	4	50	1	5	DMD#60558vegetables, such as 8-methoxypsoralen, bergapten, and isopimpinellin, were found tobe the mechanism-based inactivators of CYP2B1 (Cai et al., 1993; Koenigs andTrager, 1998). We speculated that IMP may show similar irreversible inhibitoryeffect on CYP2B subfamily.CYP2B6 has been found in liver, brain, kidney, and heart in humans (Thum andBorlak, 2000; Miksys and Tyndale, 2004). Hepatic CYP2B6 content ranges from 2 to10% of total P450 content (Stresser and Kupfer, 1999). Human CYP2B6 has beenproven to be a very important metabolizing enzyme, and the enzyme is responsible forthe preferential metabolism of approximately 3 to 8% of widely used pharmaceuticals,such as buprokpion, methadone, ifosfamide, efavirenz, and cyclophosphamide(Faucette et al., 2000; Gerber et al., 2004; Huang et al., 2000; Ward et al., 2003). Todetermine the role of specific P450s in the clearance of various drugs and to preventdrug-drug interactions induced by the inhibition of P450s, prediction andidentification of compounds that act as mechanism-based inactivators of P450s havebecome an important issue in the drug discovery process.The objectives of the work were to investigate the mechanism-based inactivationof CYP2B6 by IMP, to characterize the reactive metabolites responsible for theenzyme inactivation, and to identify the P450 enzymes responsible for the metabolicactivation of IMP.5	4617	6004
616	1	4	50	1	6	DMD#60558Materials and MethodsChemicals and Materials. Imperatorin (IMP) with purity of 98% was purchasedfrom Shanghai Yuanye Biological Technology Co., Ltd. Glutathione (GSH), hexylglutathione, bupropion, propranolol, ticlopidine, and NADPH were purchased fromSigma-Aldrich (St. Louis, MO). Liver microsomes (RLMs) were prepared from maleSD rat, by following our published method (Lin et al., 2007). Recombinant humanP450 enzymes were acquired from BD Gentest (Woburn, MA). All organic solventswere from Fisher Scientific (Springfield, NJ). Distilled water was purchased fromWahaha Co. Ltd (Hangzhou, China). All solvents and reagents were either analyticalor HPLC grade.Time-, Concentration-, and NADPH-dependent Inactivation of CYP2B6 byIMP. The primary incubation mixtures contained CYP2B6 (0.1 M) and IMP atconcentrations of 0, 0.2, 0.5, 1, 1.5, and 2.5 M in potassium phosphate buffer (pH7.4). To determine the NADPH-dependence in enzyme inactivation, IMP (1.5 M)and CYP2B6 were incubated in the absence of NADPH as negative control. Exceptfor the negative control, the primary reactions were initiated by addition of NADPH,and aliquots of the primary mixtures (40 L) were transferred at 0, 3, 6, and 9 min tothe secondary incubation mixtures containing 100 M bupropion and 0.45 mMNADPH in potassium phosphate buffer (pH 7.4) with a total reaction volume of 0.12mL. After 30 min of incubation at 30 C, the reaction was stopped by adding equalvolume ice-cold acetonitrile containing propranolol as internal standard, followed by6	6005	7544
143	1	2	16	1	120	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)liraglutide 1.8 mg group was signi?cantly better than theplacebo+OADs group (-27.9 vs. 9.6 mg/dL,Analysis of the number of subjects achieving target FPG values (90-130 mg/dL) demonstrated thatsubjects treated with liraglutide+OADs were signi?cantly more likely to achieve these FPG goals thanthe subjects treated with placebo+OADs. In trial 1574, approximately 47% of subjects in theliraglutide+OADs treatment groups reached the FPG target compared to 24% in the p1acebo+OADstreatment group, and in trial 1697 43% of su 'ects reached the FPG goal in the liraglutide+OADs group,while only 14% reached the goal in the placebo+OADs group (data not shown).Liraglutide vs. active comparator: In trial 1697 reduction in PG in the liraglutide 1.8 mg+OADs group(was not statistically signi?cantly different ?om the reduction seen in theglargine+OADs group (Table. 6.35). -Table 6.35Analysis of FPG (mg/dL) Change from Baseline at 26 weeks (add-on thera with two OADs trials)Placebo #ComparatorBaselineFPGun- *Adjusted Mean Meanadjusted mean change difference differencemean in FPG from com- - from com- (SD) (SEM) parator 95% CI value parator 95% CI valueTrial 1574Lira 175 181.3 -39.96 (3.74) -35.56 -44.40; <0.0001(42.49) 26.71Lira 174 184.9 -43.58 (3.62) -31.94 -40.70; <0.0001(43.35) 23.19Placebo+OADs 164 179.2 -8.02 (3.86)(47.25)Trial 1697Lira 225 164.6 -27.92 (3.70) -37.48 -45.47; 4.24 -2.25; 0.2002(37.6) -29.48 10.73Placebo+OADs 111 169.6 -32.16 (3.75)- (36.4)Glargine+OADs 226 164.1 9.56 (4.43)1 (35.4)"In Trial 1574 the OADS were metformin rosiglitazone, in Trial 1697 glimepiride metformin.The p?values correspond to a two-sided test for superiority on a 5% signi?cant level (statistical signi?cance for *The change in FPG was estimated using an ANCOVA model with treatment, country and previous anti-diabetic treatment as ?xedeffects and baseline value as covariateThere was no comparator in Trial 1574; the comparator in Trial 1697 was glargine+OADsSource: [Tables 11-14, 11-15, trial 1574 report] [Tables 11-23, 11-24, trial 1697 report]108	251750	253881
144	1	2	16	1	121	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)Plots of FPG Values by treatment and week are shown for trial 1574 in ?gure 6.18 and for trial 1697 in?gure 6.19. In trial 1574, mean PG appeared to decrease in the liraglutide+OADs groups within thefirst 2 weeks after randomization. The placebo+OADs group had a modest downward trend in PGstarting at Week 4. The liraglutide 1.8 mg+OADs and placebo+OADs groups showed sustained FPGreduction through the trial while the liraglutide 1.2 mg+OADs group?s mean FPG seemed to increase6 by the end of the trial. In trial 1697, mean FPG Values decreased within the first 2 weeks afterrandomization for all 3 groups and in the last period of the trial, a slight increase in mean FPG wasobserved for all 3 treatment groups. Figure 6.18 Trial 1574 Plots of Mean FPG over Time by Treatment ITT Population11.0 290195- 190. - :r10.9  . ,5 we 9.5- 1 x. 170 9.9-  19?? -180935-  - 150 3.0- ?lit 14:} -. - .7.5? 4- - -- - -5 7.o? 129c24?a1o12i41s1a2o2242aWeakISource: Figure 11-2, trial 1574 report109	253882	254950
145	1	2	16	1	122	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Figure 6.19 Trial 1697 Plots of Mean FPG over Time by Treatment ITT Population13.012.512.0?lI.5?11.0?10.510.7.5? -7-0 6.5PG 612 Time (Week)ww Glargine+OAD OADSource: Figure 11-3, trial 1697 reportan Reviewer?s comment: The proposed label states that ?i- 1.7 A. The upper value of mmol/L appears to have come from trial 1574 (the lowervalue came from trial 1436). Similar to the add?on to one OAD trials, here the FPG also appearsto drop within two weeks of starting treatment as the proposed label states. However, the type 1error rate was not controlled and this was not prespecified as a key endpoint. Therefore, thisinformation may not be appropriate for the product label. Post-prandial Plasma GlucosePost-prandial glucose was patient?measured by glucometer 90 minutes after the start of each meal. Thevalues measured at each of the three daily meals were averaged to obtain the mean post-prandial glucosevalue.Trial 1574-The decreases in mean post-prandial glucose in the liraglutide+OADs groups weresigni?cantly greater than the decrease seen in the placebo+OADs group (both Thereductions were -47.97 mg/dL and -46.35 mg/dL for the liraglutide 1.8 mg+OADs and 1.2 mg+OADsgroups, respectively. The mean difference between the liraglutide 1.8 mg+OADs group and theplacebo+OADs group was -33.47 mg/dL and between the liraglutide 1.2 mg+OADs group and theplacebo+OADs group was -31.85 mg/dL. 110	254951	256431
617	1	4	50	1	7	DMD#60558centrifugation at 16,000 rpm for 10 min. The supernatants were then collected andanalyzed by LC-MS/MS as described below.Substrate Protection. Substrate protection from IMP-induced inactivation ofCYP2B6 was determined by incorporating ticlopidine (50, 100, and 200 M) withIMP (1.5 M) in the primary reaction mixture. The reaction was initiated withNADPH, and aliquots (40 L) of the mixtures containing 0.1 M CYP2B6 weretransferred at 0, 3, and 9 min to the secondary incubation mixture for thedetermination of bupropion hydroxylase activities of CYP2B6. Control incubationswere performed in the absence of IMP or ticlopidine in parallel.Effects of GSH and Catalase/Superoxide Dismutase on the EnzymeInactivation. GSH (2.0 mM) was included in the primary reaction mixture containingCYP2B6 (0.1 M), IMP (1.5 M), and NADPH (1.0 mM). Aliquots (40 L) weretransferred to the secondary incubation mixture to determine the remaining enzymeactivities at various time points. Equal volume of phosphate buffer was added insteadof GSH solution as a control sample. In a separate study, CYP2B6 was incubatedwith IMP and NADPH in the presence or absence of a mixture of catalase andsuperoxide dismutase (SOD) (800 unit/mL for each). After incubation for 0, 3, and 9min, the residual activities were then detected as described below.Partition Ratio. CYP2B6 (0.1 M) was mixed with IMP at concentrations of 0(control), 0.2, 0.5, 1.0, 1.5, 2.5, 5.0, 7.5, and 10 M. The primary reactions wereinitiated by adding NADPH at a final concentration of 1.0 mM. Negative controlincubations were performed at the absence of NADPH. After incubation for 9 min in7	7545	9195
618	1	4	50	1	8	DMD#60558a water bath shaker at 30 C, aliquots (40 L) were transferred from the primaryreaction mixtures to the secondary reaction mixtures for measurement of CYP2B6.activities as followsIrreversibility of inactivation. Primary incubations containing 2.5 M IMP and0.1 M CYP2B6 were performed in the presence of NADPH at 30 C. The controlincubations lacked IMP. Aliquots of the mixtures were withdrawn partly at 0 min forenzymatic activity determination (non-dialyzed sample).At 9 min incubation,aliquots of the control and inactivated samples were dialyzed at 4 C against 1 Lpotassium phosphate buffer (pH 7.4, 3  2 h). The dialyzed samples were brought toroom temperature, and the enzyme activities of the resulting samples were assessed asdescribed below.CYP2B6 Assay. CYP2B6 activity was assessed by measuring the formation ofhydroxybupropion analyzed by LC-MS/MS. The LC-MS/MS system consists of ABSciex Instruments 4000 Q-Trap mass spectrometry (Applied Biosystems, Foster City,CA) interfaced online with an ekspert ultra LC 100 system (Applied Biosystems,Foster City, CA). The chromatographic separations were performed on an AccuoreC18 column (2.1  50 mm, 2.6 m, ThermoFisher, Pittsburgh, PA). The mobile phaseconsisted of 0.1% formic acid in acetonitrile (mobile phase A) and 0.1% formic acidin water (mobile phase B). The flow rate was maintained at 0.3 mL/min and thecolumn temperature was operated at 30 C. The gradient elution was set as follows:0-1.0 min, 10% A; 1.0-1.5 min, 10-30% A; 4.0-5.5 min, 30-10% A; 5.5-8.0 min,10%A. Quantification was performed by multiple reaction monitoring (MRM), and8	9196	10817
150	1	2	16	1	127	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)not between the reduction in the liraglutide 1.8 mg+OADs and the reduction in the p1acebo+OADsgroup. This was also the result when the analysis was performed without LOCF (data not shown).Reviewer?s comment: There seems to be clinically relevant systolic blood pressure reduction inthe liraglutide two OADS groups. Unlike the add-on to one OAD trials, which showed nodecrease in SBP compared with the placebo groups, here trial 1574 does show a reduction in SBPcompared to placebo. However, these reductions are not dose dependent in trial 1574, and therewas only one dose of liraglutide tested in trial 1697 making an assessment of dose-dependencyimpossible. It is unclear why there is an inconsistency in the blood pressure results across thePhase 3 trials. Also, as mentioned in previous sections, it is unclear if there is confounding byblood pressure medications that may have been given in the trials.A plot of SBP by treatment and week in the ITT population with LOCF was not presented for trial 1574.For trial 1697, a plot of mean SBP during the trial is presented in Figure 6.22.Figure 6.22 Trial 1697 Plot of SBP (mmHg) by Treatment and Week ITT with LOCF 340?$55Ia?  3T. :30325-0 4 6 810121416182.0'222426Time (Week)6-8-9 Lira1.8 OAD H-0 Glargine OAD OADSource: Figure 11-5, trial 1697 reportReviewer?s comment: This plot illustrates I   Proportion of Subjects Having Metabolic 115	262615	264090
151	1	2	16	1	128	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)In trial 1574 the proportion of subjects with metabolic at the end of treatment in the liraglutide1.2 mg+OADs group was signi?cantly lower than the placebo+OADs grou but the liraglutide 1.8mg+OADs group did not reach a statistically signi?cant difference from the p1acebo+OADs group.Reviewer?s comment: The ?ndings in the add-on to two OADs trials related to metabolicdo not support the labeling claim ..J. Note that the add-on to one OAD trials also did not show a consistent effect. Further, as mentioned previously the concept of?metabolic is problematic because of the several different definitions employed byresearchers and clinicians. Therefore, this information has not been previously allowed intolabeling by the Division.6.1.4.4 Efficacy Results Regarding Liraglutide Dose116	264091	264959
152	1	2	16	1	129	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,34] (Submission 000)Victoza? (liraglutide)Liraglutide vs. Active Comparator Treatment Liraglutide vs. Placebo Treatment1573112 mg) NIA1573 (1-8 mg) MA1572 (0.6 mg) 1572 mg) 1572 (3 .8 mg) 1-4-1 i?o?I1436 (as mg) mg) 1436 (1 .8 mg) 1 i-?o?11574 (1.2 mg) NIA 1574 (1-8 mg) NIA - 189? (1.8 mg) -2 -1.5 -1 -0.5 0 0.5 -2 -1.5 -1 -0.5 0.5points) points)Source: Figure 3-2, Summary of Clinical Ef?cacyThis ?nding (ie. that only in trial 1573 was there a notable difference in ef?cacy between the 1.2 mgand 1.8 mg) was also shown by ANCOVA analysis as shown in the following table (6.38):Table 6.38 - Com utide Dose Levels"son after 26 weeks of treatmentTreatment/comparison LS Means/Estimated Treatment 95% ClDifference'del.8 .1 -1.111.2 -0.81de 1.8 vs. 1.2 -0.29 -0.50? -0.09utide 1.8 -1.01utide 1.2 -0.97'de 0.6 -0.701.8 vs. . -0.04 -0.21? 0.13  rjr-?rt-fr       1 de 1.2 Vs. . -0.27 -0.44? -0.10utide1.8 -1.111.2 -1.070.6 -0.631.8 vs. 1.2 -0.04 -0.23? 0.15 0.6785Liraglutide 1.2 vs. 0.6 -0.44 -0.63; -0.25 <0.000]117	264960	266013
619	1	4	50	1	9	DMD#60558ion pairs of 256 238 for hydroxybupropion (product) and 260.7 116.3 forpropranolol (internal standard) were acquired in positive mode.Reactive Intermediate Trapping by GSH. IMP (100 M) and GSH (1.0 mM)were incubated with RLMs (1.0 mg protein/mL) or individual human recombinantP450 enzymes, including CYPs 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, 3A4, or 3A5(0.1 M for each) in the presence or absence of NADPH (1.0 mM) at 37 C. Tomaximize the quantity of the reactive intermediate to be formed, the enzymeincubations were conducted for 60 min. The resulting reactions were quenched bymixing with equal volume ice-cold acetonitrile containing hexyl glutathione asinternal standard, followed by vortexing and centrifuging. The supernatants wereharvested and evaporated to dryness. The residue was reconstituted with 50 L of 50%acetonitrile in water and analyzed by LC-MS/MS. The separation of GSH conjugateswas achieved on an Accuore C18 column (4.6  150 mm, 5 m, ThermoFisher,Pittsburgh, PA). The solvent system consisted of mobile phase A (acetonitrile with0.1% formic acid) and mobile phase B (water with 0.1% formic acid), and the flowrate was set at 0.8 mL/min. The gradient elution was set as follow: 0-2.0 min, 10% A;2.0-8.0 min, 10-90% A; 8.0-10 min, 90% A; 10-13 min, 90-10% A; 13-15 min, 10%A. GSH conjugates were monitored in positive MRM mode (594.0 465.0 for IMPGSH conjugates; and 392.2 246.3 for hexyl glutathione as internal standard). Theinformation-dependent acquisition (IDA) standard was followed by triggering theenhanced product ion (EPI) scans. IDA was used to initiate acquisition of EPI spectrafor ions exceeding 500 cps with exclusion of former target ions after three9	10818	12525
621	1	4	50	1	11	DMD#60558ResultsTime-, Concentration-, and NADPH-dependent Inactivation of CYP2B6 byIMP. The remaining CYP2B6 activity was monitored by measuring the amount ofhydroxybupropion produced.As shown in Fig. 1A, IMP produced a time- andconcentration-dependent inhibition on CYP2B6. The residual enzymatic activities at0 min were normalized to 100% at each concentration. The inactivation of CYP2B6increased progressively with increasing time and concentrations of IMP applied.About 70% of activity of CYP2B6 was suppressed after its incubation with 1.5 MIMP for 9 min at 30 C. Nevertheless, no loss of enzyme activity was observed in theabsence of IMP or NADPH (Fig. 1C).A double-reciprocal plot (Wilsons plot) of the observed rates of inactivation(Kobs) and IMP concentrations was used to calculate the kinetic constants KI and kinact(Fig. 1B). KI was found to be 0.498 M, and kinact was 0.079 min-1.Substrate Protection. Substrate protection from IMP-dependent inactivation ofCYP2B6 was evaluated by including ticlopidine, a substrate of CYP2B6 (Talakad etal., 2011), in the primary incubations that contain CYP2B6 and IMP. The presence ofticlopidine was found to slow down the CYP2B6 inactivation induced by IMP (Fig. 2).In addition, the protective effect of ticlopidine increased with the increase in theconcentrations of ticlopidine applied.Effects of GSH and Catalase/Superoxide Dismutase on the EnzymeInactivation. To evaluate the protective effect of GSH against the enzymaticinactivation induced by IMP, CYP2B6 inactivation incubation was conducted in the11	13395	14958
155	1	2	16	1	132	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Liraglutide?s maior ef?cacv ?ndings 6-month add-on therapy with one OAD)o_ Liraglutide add-on to metformin 2000 mg/day lowered HbA1c by -0.78% (0.6 mg qd) and -1.06%(1.2 mg qd) to -1.09% (1.8 mg qd) relative to placebo add-on to metformin; liraglutide add-on tometformin was superior to placebo add-on to metformin 0 Liraglutide add-on to metformin 2000 mg/day was non?inferior to glimepiride add-on to metformin0 Liraglutide add-on to glimepiride 2 - 4 mg a day reduced HbA1c by -0.83% (0.6 mg qd) and -1.31%(1.2 mg qd) to ?1.36% (1.8 mg qd) relative to placebo add-on to glimepiride- Liraglutide add-on to glimepiride 2 - 4 mg a day was superior to rosiglitazone 4 mg add-on toglimepiride0 Liraglutide 1.2 mg and 1.8 mg qd showed similar ef?cacy when added to one other OAD0 Liraglutide add-on therapy with one OAD resulted in near?maximal HbA1c reduction by week 120 Liraglutide add-on to one OAD maintained HbA1c reduction through week 26, although with aslight increase at the end of the trials .Liraglutide?s maior efficacy findings 6-month add-on therapy with two OADs)0 Liraglutide add-on to metformin and rosiglitazone lowered HbA1c by ?0.94% at both doses ofliraglutide relative to placebo add-on to those same liraglutide was superior to placebo plusOADs -0 Liraglutide 1.8 mg add-on-to glimepiride and metformin lowered HbA1c by -1.09% relative toplacebo plus glimepiride and metformin0 Liraglutide 1.8 mg add-on to glimepiride and metformin lowered HbA1c by -0.24% relative toglargine plus glimepiride and metformin 0 Liraglutide 1.8 mg add-on to glimepiride and metformin was superior to placebo add-on to the twoOADS and glargine add-on to the two OADS0 Liraglutide add-on therapy with two OADS resulted in near-maximal HbA1c reduction by week 120 Liraglutide add-on to two OADS maintained HbA1c reduction through week 26, although? with aslight increase at the end of one trialOther efficacy ?ndingsA summary report submitted by the Sponsor and data presented at the Type A meeting between theDivision and the Sponsor on June 1, 2009, suggests that liraglutide may have greater efficacy thanexenatide, the only other approved member of the GLP-1 analogue class (section 6.1.1.5). These datahave not yet been fully reviewed by the Division and therefore, these data were not used by thisreviewer in the decision to recommend approval. However, these data may be considered by signatoryauthorities for regulatory action because they provide some information about the potential role ofliraglutide in the anti-diabetes drug armamentarium.Important considerations and limitationsOne limitation of some of the phase 3 pivotal studies is the low enrollment of non-Caucasians,particularly blacks and Asians. These minority populations will likely make up a sizable segment of thereal world population treated with liraglutide because they are at higher risk for diabetes than120	270726	273696
157	1	2	16	1	134	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)This reviewer has ?ill con?dence that the doses and regimen have been studied adequately. Please seesection 5.3 for a discussion of exposure response relationships. The ?ndings discussed in that sectionsuggest that the 1.2 mg and 1.8 mg doses will have similar ef?cacy in long-term trials and in fact, theefficacy review identi?ed very little difference between the 1.2 mg and 1.8 mg dose in terms of theprimary ef?cacy endpoint HbA1c (see section 6). The question is then raised whether 1.2 mg wouldbe the appropriate maximal dose if liraglutide were to be approved. One consideration is the dose-toxicity relationship and the differential rate of adverse events between the 1.2 mg and 1.8 mg dose (ifone exists); if the rate of adverse events were signi?cantly higher with the 1.8 mg dose one mightconsider only approving up -to 1.2 mg daily. (See section 7.4.2.1 in Dr. Mahoney?s safety review forexplorations for dose dependency of adverse reactions). From an ef?cacy standpoint, this reviewer agrees with the sponsor?s dosing recommendations becausein three of the four of the phase 3 ef?cacy trials that evaluated both the 1.2 mg and 1.8 mg doses (trials1573, 1572, 1436) there was a greater proportion of subjects reaching glycemic targets of 7% and/or 56.5% with 1.8 mg. (In trial 1574 the proportions meeting targets were similarbetween the doses).However, if the Clinical Safety Review reveals signi?cant adverse events with the 1.8 mg dosecompared with the 1.2 mg dose, this reviewer believes that the 1.2 mg dose would be suf?cient.8.2 Drug-Drug InteractionsSee Dr. Mahoney?s safety review.8.3 Special PopulationsSpecial dosing considerations based on demographicsThere are no special dosing considerations based on demographics and diabetes disease characteristicsexcept that liraglutide has not been tested in the pediatric population and therefore, cannot berecommended for use in children at this time. See section 5.1 for a discussion of the pharmacokineticinvestigations in demographic subgroups which suggest that special dosing considerations are notwarranted. Comparison of the clinical ef?cacy of liraglutide in sub-populations was assessed throughstatistical testing of interaction between treatment effect and demographic and other intrinsic factors,based on data from the ?ve phase 3 trials 1573, 1572, 1436, 1574 and 1697. These analyses wereperformed in order to evaluate whether there were any subsets of the population that demonstrateddifferences with respect to the effectiveness, as measured by HbA1c, among treatments. Both data fromthe individual trials as well as pooled data from the four 26-weeks combination trials (Trials 1572, 1436,1574 and 1697) were assessed. Pooled analyses using all of the phase 3 studies took into account factorsof demographic differences between groups of subjects (gender, age, race, ethnicity, BMI and bodyweight), and disease (baseline HbA1c, duration of diabetes, previous anti-diabetic treatment (diet, oralantidiabetic drug monotherapy, or oral antidiabetic drug combination therapy). From an ef?cacystandpoint, there were no meaningful differences in ef?cacy across these variables that would affect thisproduct?s use. 1122	275504	278782
158	1	2	16	1	135	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Vict0za? (liraglutide)Special dosing considerations based on renal and hepatic impairmentBased on clinical pharmacology data no dose adjustment is proposed for renal and hepatic impairmentsubjects (see section 5.1). The clinical ef?cacy review of the phase 3 program supports this conclusionto some extent (see caveat below). In order to assess whether disease-related factors in?uence theclinical ef?cacy of treatment with liraglutide, statistical tests were performed for interactions amongtreatment and disease factors either related to diabetes or resulting from comorbidities. Results from thetest for interaction among treatment and disease-related factors on glycemic control as measured byHbAlc by the end of 26 weeks of treatment (Trials 1572, 1436, 1574, 1697) and 52 weeks of treatment(Trial 1573) on the individual data and on the pooled data from the four 26-weeks combination therapytrials displayed no clinically relevant effect on any of the selected disease factors: serum albumin,creatinine or ALT. One caveat, however, is that although the clinical pharmacology program evaluatedsevere renal and hepatic impairment, the phase 3 clinical program excluded those patients. Exclusioncriteria for the phase 3 studies included impaired renal ?lnction, de?ned as serum creatinine 2125umol/L (21.4 mg/dL) for males and 2110 umol/L (21.24 mg/dL) for females (although renal functionbased on or Cockcroft-Gault or MDRD) often reveals that there are some patients withmild renal impairment in the studies) and impaired liver function, de?ned as alanine aminotransferase oraspartate aminotransferase 22.5 times upper limit of normal. The only therapeutic experience in patientswith moderate renal impairment (creatinine clearance of 30-59 ml/min) and severe renal impairment(creatinine clearance below 30 ml/min) comes from one clinical pharmacology study. In addition, thetherapeutic experience in patients with all degrees of hepatic impairment is currently limited againstemming from one clinical pharmacology study.Special dosing considerations in pregnancyThere are insufficient data for the use of liraglutide in pregnant and nursing women, and therefore,efficacy in pregnant and nursing women is unknown. However, there is no known reason why theefficacy in pregnancy would be different. The use of liraglutide in pregnancy is primarily a safety issue.8.4 PediatricsThe Sponsor has studied liraglutide in patients aged 18 years and older. In the United States, theprevalence of type 2 diabetes has been increasing substantially over the past decade in parallel with theobesity epidemic. Although originally considered a disease of middle- and older-aged people, type 2diabetes is being increasingly diagnosed in obese children. Therefore, liraglutide needs to undergotesting in children to comply with the Pediatric Research Equity Act (PREA). With the original NDAthe sponsor submitted a partial pediatric waiver for children below 10 years of age because pediatricstudies in this age group are impossible or highly impractical, and requested a deferral for older children.At the May 4, 2004 end?of-phase 2 meeting conducted under IND 61,040 between the sponsor and theAgency, the Division agreed that the sponsor?s plan to seek a waiver for subjects below years of ageand a deferral for older children was acceptable, provided regulations did not change by the time the initial NDA was submitted. At the pre-NDA meeting on February 5, 2008, the sponsor proposed to (4)123	278783	282331
159	1	2	16	1	136	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)revise the age range for the pediatric development plan to include a deferral for children of age 10 andolder, effectively changing the age cut-off for the proposed waiver population.The proposed pediatric development plan includes a study(NN221 1-1800) and an ef?cacy and safety study (NN221 1-3659). These studies have not yet beenformally reviewed by DMEP clinical reviewers or by (Pediatric Review Committee) at the time ofthis review. Please see Dr. Mahoney?s review for more information regarding pediatric studies.8.5 Advisory Committee MeetingSee Dr. Mahoney?s safety review for discussion of the Advisory Committee Meeting held Apr 2009.Please see also Dr. Mahoney?s review -for a discussion of the CDER Regulatory Brie?ng held June 26,2009.8.6 Literature ReviewPublished literature used in this review is referenced throughout the review (references are listed at theend of the document).8.7 Postmarketing Risk Management PlanSee Dr. Mahoney?s safety review.8.8 Other Relevant MaterialsNone9 OVERALL ASSESSMENT9.1 ConclusionsEfficacy conclusions are discussed in section 6.1.4.5.124	282332	283507
160	1	2	16	1	137	Clinical ReviewLisa B. Yanotf, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)9.2 Recommendation on Regulatory ActionThe recommendation on regulatory action is discussed in section 1.1.9.3 Recommendation on Postmarketing Actions9.3.1 Risk Management ActivitySee Dr. Mahoney?s safety review. 9.3.2 Required Phase 4 CommitmentsSee Dr. Mahoney?s safety review.9.3.3 Other Phase 4 RequestsNone9.4 Labeling ReviewComments regarding labeling related to ef?cacy data are included throughout section 6.9.5 Comments to ApplicantNone125	283508	284039
622	1	4	50	1	12	DMD#60558presence or absence of GSH (2 mM), an electrophile trapping agent. After incubationfor 9 min, the remaining CYP2B6 activities were 27.42.0% (with GSH) and29.92.4% (without GSH), respectively. This agent produced little protective effecton the enzyme from inactivation. Additionally, a mixture of catalase and superoxidedismutase (SOD), scavengers of reactive oxygen species, showed little protectionagainst the inactivation of CYP2B6 by IMP, and the remaining enzyme activitieswere 29.71.0% (with catalase/SOD) and 29.92.4% (without catalase/SOD) at 9 min.Partition Ratio. The partition ratio (P), a measure of the efficiency of anenzyme inactivator, was estimated by a plot of the percentage remaining activity vsthe IMP/CYP2B6 molar ratio (Fig. 3), according to previously published method(Silverman, 1996). The turnover number (P+1) was about 5, and the extrapolatedpartition ratio of IMP was approximately 4 (Fig. 3).Irreversibility of inactivation. CYP2B6 was incubated with IMP (2.5 M) inthe presence of NADPH, followed by 6 h dialysis (3  2 h). The remaining activitiesof control samples and those treated with IMP were determined before and afterdialysis. Only 10% of CYP2B6 activity was recovered after dialysis.Reactive Metabolite Trapping by GSH. GSH was included in the IMPincubation systems containing RLMs or recombinant P450 enzymes to trap thereactive metabolites.The samples of incubation in the presence or absence ofNADPH were all conducted and then analyzed by LC-MS/MS.A peak withprotonated molecule ion [M+H]+ at m/z 594 at retention time of 6.8 min was observed(Fig. 4D), but no such peak was found in the control sample (absence of NADPH).12	14959	16638
162	1	2	16	1	139	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Trial 1333Primary Objectives: To evaluate the effect of liraglutide in obese subjects with type 2 diabetes mellituson weight. Design: An 8-week, single?centre, double-blind, parallel-group mechanism of action trialwith one dose of liraglutide (0.60 mg/day, versus placebo in subjects with type 2 diabetes mellitus.Glycemic control was not the primary endpoint of this study, however treatment with liraglutideimproved glycemic control as measured by a reduction in HbA1c(liraglutide: placebo: 0.47%,p=0.028) as compared with placebo. The placebo subtracted change in HbAlc was Reviewer?s comment: The HbAlc reduction in this trial is consistent with the results of trial 1310for the 0.6 mg dose.Trial 2072Primary Objectives: to determine the dose-response relationship between body weight and fiveescalating doses of liraglutide in subjects with type 2 diabetes mellitus.Design: A 12-week multi?center, double-blind, parallel?group, double-dummy trial with 5 doses ofliraglutide (0.045, 0.225, 0.45, 0.60 or 0.75 mg/day, s.c. versus metformin (1000 mg, p.o. inobese subjects with type 2 diabetes mellitus. HbAlc was a secondary endpoint in this trial. Ej?cacyresults: The primary ef?cacy endpoint in this trial was body weight, but HbAlc was obtained as asecondary ef?cacy endpoint. Results showed that the subjects were well controlled at baseline with amean HbA1cranging from 6.76 to 7.38 Mean HbAlc changes (all increases) from baseline for 0.045,0.225, 0.45, 0.60, 0.75 mg liraglutide and metformin were 1.28, 0.86, 0.22, 0.16, 0.30 and 0.09 respectively. No significant differences in HbAlc were found between liraglutide and metformin groupsat the three highest liraglutide dose levels (0.45, 0.6 and 0.75 mg). The two lowest liraglutide doses(0.045 and 0.225 mg) were not able to maintain HbAlc values comparable to metformin.Trial 1499Primary Objectives: to assess the effect on glycemic control of individual maximum effective dose ofliraglutide as add-on therapy to metformin, and to compare this to the effect of maximum effective doseof metformin given as monotherapy, assessed by serum glucose. Design: A 5-week, multi-centre, multi-national, double-blind, double?dummy, randomized, parallel, individual dose titration trial with 0.5-2.0mg/day liraglutide as add-on to metformin (1000 mg, versus liraglutide placebo, metforminplacebo, or metformin glimepiride (2?4 mg, adjusted according to glycemic control). E?icacyResults: Liraglutide in combination with metformin produced signi?cant improvement in glycemiccontrol, as assessed by fasting serum glucose, compared to metformin monotherapy, by -3.90% (95% CI[-4.95 p<0.0001 and compared to metformin glimepiride treatment, by -1.25% (95% CI 2.25 p=0.0146. Likewise, liraglutide as monotherapy signi?cantly improved glycemic controlcompared to metformin monotherapy, by -1.37% (95% CI p=0.0l09. The dose-responsecurve (and thus the maximum effect) for liraglutide metformin was established within the tested doserange with 0.51 mg and 0.80 mg.Reviewer?s comment: This trial suggests a lower dose might be effective compared to theminimally effective dose shown in the other phase 2 studies. However, the primary efficacyendpoint in this trial was not HbAlc.127	286825	290132
163	1	2	16	1	140	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)Trial 1334 (Exploratory Japanese Trial)Primary Objectives: to evaluate the dose-response relationship on glycemic control as assessed byHbA1c of four doses of liraglutide and placebo in Japanese subjects with type 2 diabetes mellitus.Design: A 14-week multi-centre, double?blind, randomized parallel, placebo-controlledJapanese trial with four dosesof liraglutide (0.1, 0.3, 0.6 and 0.9 mg/day, versus placebo inJapanese subjects with type 2 diabetes mellitus. Efficacy Results: HbA1c decreased dose?dependent1y inall treatment groups compared to placebo from a baseline value of 8.3% by and -respectively HbA1c <7.0 was achieved the subjects in_the liraglutide groups compared to 9% in the placebo group.Reviewer?s comments: In summary the selected doses for the phase 3 studies appear justi?ed bythe phase 2 data.10.2 Line-by-Line Labeling ReviewNot performed128	290133	291080
164	1	2	16	1	141	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)REFERENCESAmaryl Prescribing Information, revised July, 2009Byetta Prescribing Information, revised June, 2008College of American Pathologists. Glycohemoglobin survey. 1999. North?eld, IL: College of AmericanPathologists; 1999 (Set GH-2).Cycloset Prescribing Information, revised April, 2009Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on thedevelopment and progression of long-term complications in insulin-dependent diabetes mellitus. Engl Med.1993; 329: 977-86.Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and ComplicationsStudy Research Group. Intensive diabetes treatment and cardiovascular disease in patients withtype I diabetes. Engl Med. 2005; 353: 2643-53.Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of adouble-blind, placebo-controlled, dose-response trial. Am Med. 1997; 102: 491-7.Goldstein D, Parker K, England J, et al. Clinical application of the glycosylated hemoglobin. Diabetes. 1982; 31:70-8.Nathan DM, Buse JB, Davidson MB, et al. Medical management of ni type 2 diabetes: aconsensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2008; 31: 1-11.Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobinassay. Engl Med. 1984; 310: 341-6.Stumvoll M, Goldstein BJ, van Hae?en TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet.2005; 365: 1333-46.The Facts about HbA1c from UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulincompared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33 .Lancet. 1998; 352: 837-53.UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin oncomplications in overweight patients with type 2 diabetes (UKPDS 34). Lancet; 1998; 352: 854-65.WelcholPrescribing Information, revised January, 2008129	291081	293197
165	1	2	16	1	142	. l. . 3 .Linked Applications Typg?glgger Sponsor Name Drug Name/SubjectNDA 22341 ORIG VICTOZA (LIRAGLUTIDE)This is a representation of an electronic record that was signedelectronically and this page is the manifestation of the electronicsignature. LJSA YANOFF3/2009HYLTON JOFFE08/13/2009Please see CDTL memorandum.	293198	293513
166	1	2	16	1	143	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)CLINICAL REVIEWApplication TypeSubmission NumberSubmission CodeLetter DateStamp DatePDUFA Goal DateReviewer NameReview Completion DateEstablished Name(Proposed) Trade NameTherapeutic ClassApplicantPriority DesignationFormulationDosing RegimenIndicationIntended PopulationNDA2234123 May 200823 May 200823 Mar 2009 (Division Action GoalDate 26 Aug 2009)Karen Murry Mahoney, MD, FACE22 Jul 2009Liraglutide injectionVictoza?Glucagon-like-peptide-1 analogueNovo Nordisk?Subcutaneous injection0.6-1.8 mg SQ dayImprove glycemic control in patientswith type _2 diabetes mellitusAdults with type 2 diabetes mellitusPage 1 of 249	293514	294239
625	1	4	50	1	15	DMD#60558DiscussionOur kinetic study clearly demonstrated that IMP produced a time-dependentinhibition of CYP2B6. The observed enzyme inactivation was also found to beconcentration-dependent, and it reached about 70% inactivation at the concentrationof 2.5 M. CYP2B6 inactivation induced by IMP was not observed unless NADPHwas present in the primary incubation mixtures. This indicates that IMP itself is notan inactivator of CYP2B6 and that the enzyme inactivation by IMP needsbiotransformation with assistance of P450 cofactor NADPH. Taken together, theseresults provided strong evidence that IMP is a mechanism-based inactivator ofCYP2B6.Little protection by catalase and SOD against enzyme inactivation by IMP wasobserved. Catalase and SOD are known as enzymes quenching hydrogen peroxide,superoxide anion, and other reactive oxygen species that are possible agents toinactivate enzymes (Klaassen et al., 1986). The observed lacking of protection effectby catalase and SOD indicates that reactive oxygen species may not play a significantrole in CYP2B6 inactivation induced by IMP. Additionally, GSH, a nucleophilicagent, did not show protective effect on CYP2B6 inactivation by IMP. This impliesin part that CYP2B6 is covalently modified by electrophilic metabolites of IMPbefore escaping from the active site. The protective effect of ticlopidine on CYP2B6inactivation observed in the competition experiment indicates the competitionbetween ticlopidine and IMP to reach the active site of the enzyme, which slows15	18449	19970
168	1	2	16	1	145	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA-22341 Submission 000Victoza? (liraglutide injection}7.1.15 Assessment of Effect on Growth ..1857.1.16 Overdose Experience ..1857.1.17 Postmarketing Experience ..I857.2 ADEQUACY OF PATIENT EXPOSURE AND SAFETY ASSESSMENTS .. I 857.2.1 Description of Primary Clinical Data Sources (Populations Exposed and Extent of Exposure) Used toEvaluate Safety ..1857.2.2 Description of Secondary Clinical Data Sources Used to Evaluate Safety ..1947.2.3 Adequacy of Overall Clinical Experience ..1947.2.4 Adequacy of Special Animal and/or In Vitro Testing .. 1947.2.5 Adequacy of Routine Clinical Testing ..1947.2.6 Adequacy of Metabolic, Clearance, and Interaction Workup ..1947.2.7 Adequacy of Evaluation for Potential Adverse Events for Any New Drug and Particularly for Drugs inthe Class Represented by the New Drug; Recommendations for Further Study ..1957.2.8 Assessment of Quality and Completeness of Data ..1957.2.9 Additional Submissions, Including Safety Update ..1957.3 SUMMARY OF SELECTED DRUG-RELATED ADVERSE EVENTS, IMPORTANT LIMITATIONS OF DATA, ANDCONCLUSIONS ..2137.4 GENERAL METHODOLOGY ..2137.4.1 Pooling Data Across Studies to Estimate and Compare Incidence ..2137.4.2 Explorations for Predictive Factors ..2137.4.3 Causality Determination ..2178 ADDITIONAL CLINICAL ISSUES ..2178.1 DOSING REGIMEN AND ADMINISTRATION ..2 I78.2 DRUG-DRUG INTERACTIONS ..2 I 78.3 SPECIAL POPULATIONS ..2178.4 PEDIATRICS . .2188.5 ADVISORY COMMITTEE IVIEETING ..2 I 88.6 LITERATURE REVIEW ..2238.7 POSTMARKETING RISK MANAGEMENT PLAN ..2248.8 OTHER RELEVANT MATERIALS .2269 OVERALL ASSESSMENT .. 2279.1 CONCLUSIONS .2279.2 RECOMMENDATION ON REGULATORY ACTION .2389.3 RECOMMENDATION ON POSTMARKETING ACTIONS .2389.3.1 Risk Management Activity ..2389.3.2 Required Phase 4 Commitments ..2389.3.3 Other Phase 4 Requests ..2399.4 LABELING REVIEW .2399.5 COMMENTS TO APPLICANT .24410 APPENDICES ..245I0.I REVIEW OF INDIVIDUAL STUDY REPORTS .245I02 LINE-BY-LINE LABELING REVIEW .245REFERENCES ..246Page 3 of 249	296276	298318
169	1	2	16	1	146	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)1 EXECUTIVE SUMMARY1.1 Recommendation on Regulatory ActionThe clinical safety reviewer does not recommend approval of liraglutide at this time, for tworeasons: 0 A strong signal in animals of C?cell tumors of the thyroid gland, with inadequate duration ofcontrolled study in humans to adequately assess the human risk, and0 Inadequate data to assess the risk of major adverse cardiovascular events in humans.In the United States, there are already 11 classes of drugs approved for glycemic control in type2 diabetes, and one other in this class. The need for new therapies for type 2 diabetes is not sourgent that one must tolerate a signi?cant degree of uncertainty regarding serious risk concerns.Other safety concerns exist for liraglutide, but are not part of the basis for this recommendation.It should be noted that this reviewer conducted only the clinical safety review, and that thisrecommendation is made solely on the basis of safety information. The clinical efficacy reviewof liraglutide is ongoing by Dr. Lisa Yanoff. It is possible that signatory authorities, after havingconsidered ef?cacy information and all other available data regarding liraglutide, mayreasonably decide that the drug has an acceptable riskzbene?t ratio.1.2 Recommendation on Postmarketing Actions1.2.1 Risk Management ActivityNot applicable, as approval is not recommended. However, the applicant?s proposed riskmanagement activities are discussed in Section 8.7.1.2.2 Required Phase 4 CommitmentsNot applicable, as approval is not recommended. However, the applicant?s proposed Phase 4activities are discussed in Section 8.7.1.2.3 Other Phase 4 RequestsNot applicable, as approval is not recommended. However, the applicant?s proposed Phase 4activities are discussed in Section 8.7.Page 4 of 249	298319	300209
170	1	2	16	1	147	Clinical Safety ReviewKaren Mu1Ty Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)1.3 Summary of Clinical Findings1.3.1 Brief Overview of Clinical ProgramLiraglutide injection (Victoza?) is an analogue of human glucagon-like-peptide-l, intended forthe treatment of type 2 diabetes mellitus. Native glucagon?like-peptide-1 is a gut incretinhormone which causes glucose-dependent secretion of insulin. The native hormone has a veryshort half-life, due to_ rapid degradation by dipeptidyl-peptidase-4. Liraglutide?s altered structurerenders it less susceptible to degradation, and thus prolongs its half-life. It is intended for oncedaily subcutaneous injection.At the time of NDA submission, there had been 38 completed trials of liraglutide. At the time ofthe 120-day safety update, liraglutide had been administered to 4430 patients for a total of 2434patient-years. Of these patients, 2412 had received liraglutide for 224 weeks, and 840 hadreceived it for 250 weeks.1.3.2 EfficacyPlease see Dr. Yanoffs clinical efficacy review.1.3.3 SafetyUp to the time of the safety update, there were 4 deaths among patients who had receivedliraglutide, and 3 deaths among patients who had received comparator. There was no evidenceof an association between liraglutide and overall mortality or cause?speci?c mortality.Withdrawals due to adverse events were more common among liraglutide-treated patients thanamong comparator-treated patients. This difference was primarily due to withdrawals due togastrointestinal adverse events. These withdrawals were primarily in the two higher dose groups(1.2 and 1.8 mg). The most common reason for withdrawal from the 0.6 mg dose group wasineffectiveness of therapy. All withdrawals due to injection site reactions and allwithdrawals due to hepatobiliary adverse events were among liraglutide-treated patients.For the clinical safety reviewer, there were two major safety concerns that affected approvability;inadequate data to assess the human risk of medullary thyroid carcinoma, and inadequate data toassess the risk of major adverse cardiovascular events.Medullary thyroid carcinoma and C-cell tumors are discussed in Sections 7.1.3.3.2 and 9.1.1. Inlifetime carcinogenicity studies in rats and mice, liraglutide caused C-cell tumors in both species,in both genders, at clinically relevant exposures. In rats, adenomas and carcinomas occurred inboth genders at clinically relevant exposures. In mice, adenomas occurred at clinically relevantexposures, but carcinomas were seen only in females at high exposures. However, in rodents, C-cell adenomas are considered to be a precancerous lesion. There was a long latent periodbetween initial exposure and development of C-cell tumors. A similar signal is being noted ininterim carcinogenicity data for other long-acting glucagon-like-peptide-1 analogues. ln rodents,Page 5 of 249	300210	303094
171	1	2	16	1	148	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)calcitonin may not have been a reliable biomarker for development of these tumors; in humans,serum calcitonin has historically served as a clinical marker for medullary thyroid carcinoma, thehuman form of C-cell carcinoma. Calcitonin physiology differs somewhat between rodents andhumans, and rodent thyroids may be more likely to contain glucagon-like-peptide-l receptors.The applicability of these rodent ?ndings to the risk of human medullary thyroid carcinoma isuncertain. In a meeting of the Endocrine and Metabolic Drugs Advisory Committee, theCommittee voted 12 to I that the applicant had not established that the rodent C-cell tumor riskwas not relevant to humans.Medullary thyroid carcinoma is ordinarily a rare tumor, which occurs in sporadic and familialforms. No drug-induced forms have been described in humans. The described sporadic andfamilial forms are usually, although not always, indolent in terms of rate of growth. Althoughusually indolent in terms of rate of growth, the tumor can be aggressively invasive if notdiscovered in time for complete resection, and medullary thyroid carcinoma is considered to be amore serious form of thyroid cancer than the more common differentiated thyroid cancers. Earlycomplete surgical resection is currently the only curative option. Those who undergo completeresection usually survivesomething other than medullary thyroid cancer.However, the outcome for nonresectable cases is much worse, with a median survival of 3.2years, and with medullary thyroid cancer as the usual cause of death. In these patients, localneck invasion, with or other catastrophic local invasive process, is often the cause ofdeath.In the liraglutide program, there were no treatment?emergent cases of medullary thyroidcarcinoma, but one might not expect to see this relatively indolent tumor over the duration of thetypical drug development program.A total of ?ve liraglutide-treated patients and one comparator-treated patient had C-cellhyperplasia. These represent approximate rates per 1000 patient-years of 1.7 (5 cases/2882 PY)and 0.7 (1 case/1486 PY), respectively. There is controversy in the medical literature regardingwhether C-cell hyperplasia is a preneoplastic lesion in humans, and C-cell hyperplasia has beennoted at autopsy in some people who had no known thyroid disease prior to death.Calcitonin is a peptide hormone which is primarily by the C-cells of the thyroid.There are multiple stimuli for release, including calcium, several gut hormones, proton pumpinhibitors, and several disease states such as renal impairment. Historically, it was used as ascreening test for medullary thyroid cancer in relatives of patients with known medullary thyroidcancer; this use has largely been replaced by assays for speci?c genetic mutations known tooccur in the familial forms. Most patients with medullary thyroid cancer have marked elevationsof calcitonin, to over 50 ng/L, while the upper limit of normal is 5 ng/L for women and 8.4 ng/Lfor men. Serum calcitonin was measured in the major Phase 3 trials o_f liraglutide.In general, liraglutide did not cause marked changes in calcitonin levels. In the blindedcontrolled portions of trials (6 months in 4 trials and 1 year in ltrial), mean calcitonin valuesremained near the lower limit of quantitation. In voluntary unblinded extension studies out totwo years, mean calcitonin levels remained near the lower limit of quantitation, but dropout rateswere high and somewhat different between treatment groups. Patients who began study withPage 6 of 249	303095	306747
172	1	2	16	1	149	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)calcitonin elevations did not tend to develop progressive further increases in calcitonin over time.Among patients who began study with calcitonin values <50 ng/L, two liraglutide-treatedpatients and one comparator-treated patient developed calcitonin levels >50 ng/L (ratio However, liraglutide may have had some effect on calcitonin levels. From baseline to 26 weeks(the end of the blinded controlled portion of the trials), there was a dose-dependent trend forwomen to shift from below the lower limit of quantitation to within the range of quantitation.Also, from baseline to 26 weeks, the percentage of patients who had any upward category shift incalcitonin levels was highest, in both genders, for patients treated with the highest proposedliraglutide dose, 1.8 mg. At Week 12, for comparisons of all doses of liraglutide to activecontrol, and to placebo, mean percent changes in calcitonin values were statistically signi?cantlyhigher for liraglutide. At 26 weeks, this remained true for comparisons of liraglutide to placebo,and a dose dependent trend was noted for comparisons to both active control and placebo.However, mean values in these analyses were near the lower limit of quantitation. The incidenceof new elevations of calcitonin to >20 ng/L was numerically higher for liraglutide thanfor comparator and there appeared to be a dose?related trend. The highest percentage ofpatients who developed a new elevation of calcitonin to >20 ng/L was among patients in theliraglutide 1.8 mg group The clinical signi?cance of small changes in calcitonin in thissetting is uncertain.When asked whether the available data on thyroid C-cell tumors permit marketing of liraglutide,the Advisory Committee vote was 6 6 ?yes?, and ?abstain?.Most trials of liraglutide were 6 months or less in duration. Calcitonin data from voluntaryunblinded extensions of two trials are available for up to two years for approximately 500liraglutide-treated patients. In the clinical safety reviewer?s opinion, this duration of observationis not adequate to assess the human risk of this tumor, which may be relatively indolent in termsof expected rate of growth, but which can have very poor outcomes in unresectable cases. Theapplicant?s proposed labeling does not provide for monitoring with calcitonin, thyroidultrasound, or thyroid physical examination.Besides calcitonin, there are other potential biomarkers for medullary thyroid carcinoma,including procalcitonin and carcinoembryonic antigen.Drugs for the treatment of type 2 diabetes have the potential to be prescribed for millions ofpatients, and inadequately assessed safety problems can have signi?cant public healthconsequences. To address the de?ciency related to inadequate assessment of human medullarythyroid cancer risk for liraglutide, the clinical safety reviewer recommends a longer durationrandomized, controlled, blinded trial, that would include monitoring not only of calcitonin, but ofthese other biomarkers, with measurements at baseline and every three to six months. Theapplicant has already proposed a large cardiovascular outcomes trial which would includeapproximately 9000 patients. The clinical safety reviewer recommends that, in that trial, theapplicant measure these biomarkers as outlined, and perform an interim analysis of calcitonin,procalcitonin and carcinoembryonic antigen levels at three years of study in this trial whenthe last enrolled patient has three years of follow-up). At three years of study, one would notexpect to see actual cases of medullary thyroid carcinoma, but the proposed analyses of multiplePage 7 of 249	306748	310461
173	1	2	16	1	150	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)biomarkers could provide a reasonable assessment of whether any degree of C-cell activation isgoing on. Three years is recommended because currently, there are limited data for calcitonin(and no data for other biomarkers) from voluntary unblinded extensions out to two years. Theseextensions had high dropout rates that differed between treatment groups. At the AdvisoryCommittee meeting, at which the applicant discussed calcitonin data out to two years, Dr.Burman (the Chairman of the Committee, and one of the two thyroid cancer experts on theCommittee) recommended a longer period of observation, and measurement of additionalbiomarkers. If there is no evidence of C-cell activation, even over three years of study, thiscould provide some level of comfort that the likelihood of induction of an aggressive form ofmedullary thyroid cancer by liraglutide would be small. With this information in hand, thepublic health consequences related to medullary thyroid cancer risk for liraglutide couldreasonably be expected to be relatively low.The second safety concern which, in the clinical safety reviewer?s opinion, affects approvabilityof liraglutide, is that of inadequate data to assess the risk of major adverse cardiovascular events.In a recent Guidance, the Agency outlined requirements for sponsors of new diabetes drugs torule out unacceptably increased risk of cardiovascular events. There are multiple elements to theGuidance, but two relevant elements are inclusion in the development program of patients athigh risk for cardiovascular events (which permits accrual of sufficient events for analysis), andpremarket exclusion of a certain level of increased cardiovascular risk. Events of interest includea composite of cardiovascular death, nonfatal myocardial infarction and nonfatal_stroke. Theliraglutide NDA had already been submitted at the time of ?nalization of the Guidance, but theAgency has stated that it and other applications in the same circumstance must also meet therequirements of the Guidance.The liraglutide trials excluded patients with known cardiovascular disease, and event rates werevery low. In a composite of event terms deemed likely to represent true events of cardiovasculardeath, myocardial infarction or stroke, there were only 26 total events (liraglutide andcomparator combined) during the controlled, blinded portions of the trials, and only 23 of theseevents met the de?nition of a serious adverse event. In general, strati?ed analyses of liraglutideversus total comparator (active control plus placebo) did have point estimates which favoredliraglutide, and upper bounds of the 95% confidence interval of <1 .8, which was the prespeci?edupper boundary that could permit approval of a diabetes drug with a requirement for a largepostmarketing cardiovascular outcomes trial. The Guidance does not require applicants to meetspeci?ed con?dence interval boundaries for subgroup analyses. However, subgroups were?analyzed for consistency of the ?ndings. Analyses of liraglutide versus active comparator werequalitatively similar to those versus total comparator. Analyses of liraglutide versus placebo,however, were sensitive to analysis method, and sometimes had point estimates not favoringliraglutide, and upper bounds of 95% con?dence intervals which exceeded 1.8. The ?nding ofupper bounds that sometimes exceeded 1.8 can be attributed in large part, to very low eventrates. The ?nding of point estimates that sometimes exceeded 1 cannot be attributed to lowercardiovascular risk among placebo-treated patients, as these analyses were strati?ed by study,and baseline risk was similar between treatment arms in each of the included studies. Analyses?by baseline duration of diabetes (<10 years or 210 years) also showed point estimates andupper bounds >1 .8, for comparisons of liraglutide versus placebo, particularly when oneconsidered patients who had had diabetes for <l0 years at baseline. This was not an expectedPage 8 of 249	310462	314545
174	1	2	16	1	151	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)?nding, as the risk of cardiovascular events is generally thought to be higher in patients withdiabetes of longer duration, but very low event rates limited interpretability.In the Advisory Committee meeting, data regarding major adverse cardiovascular events werepresented to the panel, which included two cardiologists and a biostatistician, in addition toendocrinologists, an epidemiologist, a patient representative and a consumer representative. Thepanel?s overall vote was 8 ?yes? and 5 ?no? regarding whether the applicant had ruled out anunacceptable increase in cardiovascular risk. However, both cardiologists and the biostatisticianvoted citing concerns about small numbers of events, low cardiovascular risk of the studiedpopulation, and the difference in results for analyses versus placebo. Other panel members,including some who voted ?yes?, also expressed concerns about the adequacy of the data.There are several other safety concerns for liraglutide, but, in the clinical safety reviewer?sopinion, these other issues, while potentially important, can be addressed through labeling and/orfuture studies, and do not rise to the level of approvability issues. They include:0 A numerical imbalance in cases of papillary thyroid cancer, not favoring liraglutide (6 casesversus 1; ratio Almost all of these cancers were <1 cm, and were discovered at surgerythat was prompted by routine protocol-speci?ed calcitonin or ultrasound screening. They arelikely incidental papillary microcarcinomata, which are common in the general population.However, ascertainment issues cannot fully explain the imbalance, because screeningoccurred for both liraglutide and comparator groups, and one would expect a similar rate ofincidental papillary cancers if this observation was entirely related to increased screening.0 Gastrointestinal adverse events, especially nausea, Vomiting and diarrhea. Rates ofwithdrawals due to gastrointestinal adverse events were higher for liraglutide-treated patients.0 Pancreatitis. There were 8 events of pancreatitis among liraglutide-treated patients, and 1among comparator?treated patients (ratio One liraglutide-treated case was fatal,although there were confounding elements to this case. The comparator group patient, andfour of the liraglutide group patients, had risk factors for pancreatitis. Pancreatitis may be aclass effect for glucagon-like-peptide-1 analogues, given recent postmarketing reports forexenatide, for which final labeling discussions are ongoing.0. Serious neoplasm events. In the original New Drug Application, serious neoplasm eventsoccurred at rates of 8.9 versus 5.3 events per 1000 patient-years for liraglutide versus totalcomparator. After the 120-day safety update, these rates were 12.3 versus 8.1. After removalof serious but nonmalignant neoplasms, and papillary thyroid cancers, these rates were 10.3versus 8.1 events per 1000 patient years. No particular cancer cell type predominated. Therehave been recent concerns, based on epidemiologic data (some of which are con?icting), of apossible association between insulin and increased risk of malignancy. Liraglutide causes anincrease in insulin levels. This risk should be further assessed in future trials of liraglutide.0 Serious hypoglycemic events. In the major Phase 3 trials submitted with the NDA, all serioushypoglycemic events (defined as events requiring the assistance of another person) occurredamong liraglutide-treated patients, with none among comparator-treated patients. Six of these9 events occurred among patients concomitantly administered a sulfonylurea. The risk forthis may be similar between liraglutide and exenatide; in recent preliminary results of acomparative trial, two exenatide-treated patients and one liraglutide-treated patient hadserious hypoglycemic events.Page 9 of 249	314546	318479
175	1	2	16	1	152	Clinical Safety Review Karen Murry Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Injection site reactions were more common among liraglutide-treated patients than amongcomparator-treated patients, and liraglutide dose-dependency was noted.Antibodies to liraglutide developed in approximately 10% of liraglutide-treated patients, andantibodies which cross-reacted with native glucagon-like-peptide-1 developed in about 5% ofpatients. About l?2% of liraglutide-treated patients developed antibodies which had aneutralizing effect on liraglutide in an in vitro assay. Ef?cacy as measured by meanhemoglobin Al was not affected by antibody formation. The three liraglutide-treatedpatients with the highest antibody titres had almost no change in hemoglobin Alc over time,suggesting that those patients with the highest anti-liraglutide antibody titres may have somediminution in efficacy, but these three patients are too few upon which to base a conclusion.Antibody-positive patients were more likely to have events related to infections; most of thesewere nonserious nasopharyngeal or upper respiratory infections. Antibody-positive patientsalso had more events of musculoskeletal pain and of certain injection site adverse reactions.Immunogenicity events from standardized queries using the Medical Dictionary forRegulatory Activities were more common among liraglutide-treated patients than amongcomparator-treated patients. About 40% of immunogenicity-related events were urticariaevents.Slowing of gastric emptying, with effects on the pharmacokinetics of other drugs. Theclinical significance of this effect is under discussion with the Clinical Pharmacology team.Overall thyroid neoplasms (19 versus 4 for liraglutide versus comparator; ratio 2.4: 1). Thesewere mostly thyroid nodules discovered after protocol-speci?ed screening.Hepatobiliary adverse events. Overall rates of hepatobiliary adverse events were similar forliraglutide and comparator, but all withdrawals due to hepatobiliary adverse events occurred among liraglutide-treated patients. A higher numerical percentage of liraglutide-treated patients had bilirubin levels above the upper limit of normal. There was no differencebetween liraglutide and comparator for transaminase elevations. No patients met the criteriafor Hy?s law.A small increase in heart rate of 2-3 beats per minute, and a numerical imbalance in adverseevents related to increased heart rate, not favoring liraglutide. A ?thorough QT study? did notshow evidence of a liraglutide-associated risk of QT prolongation.Risk of medication errors due to design and labeling of the pen injector for the 0.6 and 1.2 mgdoses. The applicant is submitting a new pen device to address these concems, and reviewsby the Chemistry, Manufacturing and Controls reviewer and the Devices reviewer areongoing.Potential for off-label use/abuse for weight loss. Liraglutide was associated with a smallamount of weight loss in clinical trials. Potential exists for off-label use in a non-diabeticpopulation that would not bene?t from 1iragIutide?s glucose-lowering effects, but could stillbe at risk for all its adverse effects.Animal fetal anomalies at exposures at or below that expected for the human clinical dose.Pregnancy Category is recommended.Nonserious adverse events of dizziness and fatigue.During the review cycle, there were some issues with data quality regarding laboratory reportingfor serum calcitonin, bilirubin and creatinine. There was a discrepancy regarding missingcalcitonin values, which the applicant attributed to programming errors. Two sets of errata weresubmitted. During the review of bilirubin and creatinine data, the clinical safety reviewer notedPage 10 of249	318480	322213
627	1	4	50	1	17	DMD#60558fragments valuable for metabolite identification (Fig. 4B). A fragment at m/z 162responsible for molecular formula of C9H6O3+ was detected, indicating that the 5member ring fused with the coumarin ring was opened (Scheme 1). This allows us toexclude the formation of GSH conjugate 4, since the ring opening of conjugate 4would produce a thio-ester. Only GSH conjugate 6 has the ring opening structure,and conjugate 5 could be spontaneously converted to conjugate 6.To furthercharacterize conjugate 6, we chemically reduced the conjugate with NaBH4. Thereduction reaction afforded a new product with retention time at 6.7 min and [M+H]+at m/z 596.2 (Fig. 5A), 2.0 Da higher than that of the one detected before thereduction reaction.The MS/MS spectrum of the reduced GSH conjugatedemonstrated that the fragment at m/z 162 was retained, indicating that no reductiontook place in the coumarin ring. In addition, the original IMP-GSH conjugate showeda fragment at m/z 177 that resulted from the elemental composition of C10H9O3+ of theconjugate losing the side chain, GSH, and CO2. In other words, fragment of m/z 177contained the aldehyde group (Fig. 4B). However, no such fragment was observed inthe MS/MS spectrum of the reduced IMP-GSH conjugate (Fig. 5B). Instead, thereduced IMP-GSH conjugate showed a fragment of m/z 179, 2 Da higher than that(m/z 177) observed in the MS/MS spectrum of the original IMP-GSH conjugate (Fig.5B). This provided the evidence that the reduction took place on the aldehyde not onthe lactone group. Additional experiment showed that IMP was resistant to thereduction by NaBH4 (data not shown). We anticipate that the NaBH4based reductionof conjugate 6 gave conjugate 7. The observed conjugate 7 indicates that conjugate 617	21663	23425
630	1	4	50	1	20	DMD#60558ReferencesBaek NI, Ahn EM, Kim HY, and Park YD (2000) Furanocoumarins from the root of Angelicadahurica. Arch Pharm Res 23: 467470.Baumgart A, Schmidt M, Schmitz HJ, and Schrenk D (2005) Natural furocoumarins asinducers and inhibitors of cytochrome P450 1A1 in rat hepatocytes. Biochem Pharmacol69: 657667.Cai Y, Bennett D, Nair RV, Ceska O, Ashwood-Smith M, and DiGiovanni J (1993) Inhibitionand inactivation of murine hepatic ethoxy- and pentoxyresorufin O-dealkylase bynaturally occurring coumarins. Chem Res Toxicol 6: 872 879.Edwards DJ, Bellevue FH 3rd, and Woster PM (1996) Identification of 6,7dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug MetabDispos 24:12871290.Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM(2000) Validation of bupropion hydroxylation as a selective marker of humancytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:12221230.Garcia-Argaez AN, Ramirez-Apan TO, Delgado HP, Velazquez G, and MartinezVazquez M(2000) Anti-inflammatory activity of coumarins from Decatropis bicoloron TPA ear micemodel. Planta Med 66: 279281.Gerber JG, Rhodes RJ, and Gal J (2004) Stereoselective metabolism of methadone Ndemethylation by cytochrome P4502B6 and 2C19. Chirality 16: 3644.He JY, Zhang W, He LC, and Cao YX (2007) Imperatorin induces vasodilatation possibly viainhibiting voltage dependent calcium channel and receptor-mediated Ca2+ influx and20	24789	26245
177	1	2	16	1	154	Clinical Safety Review_Karen Murry Mahoncy, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)2 INTRODUCTION AND BACKGROUND2.1 Product InformationVictoza? (liraglutide injection, hereafter often referred to as LGT) is a human glucagon-like-peptide-l analogue, intended for the treatment of type 2 diabetes mellitus. Native is a gut incretin hormone which causes glucose-dependent secretion of insulin.? Therefore, amedication which mimics would be expected to have the potential to lower blood glucoseonly when glucose is high, and not when it is normal or low. This is in contrast to some otheroral antidiabetic drugs, such as sulfonylureas, which stimulate insulin secretion independently ofblood glucose levels, and are therefore associated with a risk of hypoglycemia. A lower risk forhypoglycemia is a potential advantage of this drug class. However, native has a veryshort half-life, due to almost instantaneous degradation via the enzyme dipeptidyl-peptidase-4(DPP4). Approaches to the development of drugs which act via have focused on eitheraltering the structure of to make it resistant to degradation, or on inhibition of DPP4 activity. Liraglutide is an analogue of GLP-1, with a prolonged pharmacokinetic, (PK) pro?leintended for once daily subcutaneous (SQ) injection. The applicant states that liraglutide has anelimination half-life of 13 hours, and a duration of action of 24 hours.The proposed indication is: ?Liraglutide, a human analogue, is indicated as an adjunct todiet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.?Initiation at a dose of 0.6 mg SQ once daily is proposed, with titration to 1.2 mg SQ once dailyafter at least one week. Uptitration to 1.8 mg SQ once daily is possible after at least one week at1.2 mg/day.2.2 Currently Available Treatment for IndicationsPlease see Dr. Yanoff clinical ef?cacy review.2.3 Availability of Proposed Active Ingredient in the United StatesPlease see Dr. Yanoffs clinical efficacy review.2.4 Important Issues With Pharmacologically Related ProductsThere is one approved analogue, exenatide (Byetta?). Clinical safety issues withexenatide include:0 gastrointestinal adverse events such as nausea, vomiting and diarrhea0 formation of anti-exenatide antibodies, some of which are neutralizing and may result inreduction in glycemic control response0 hypoglycemia, particularly when coadministered with a sulfonylurea0 altered renal function, such as increased serum creatinine and adverse events of renalimpairment Page 12 of 249	323989	326533
178	1	2	16	1	155	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234! Submission 000Victoza? (liraglutide injection)0 a recent concern regarding pancreatitis; some postmarketing cases have been severe2.5 Presubmission Regulatory ActivityPlease see Dr. Yanoff? clinical efficacy review.3 SIGNIFICANT FINDINGS FROM OTHER REVIEW DISCIPLINES I3.1 CMC (and Product Microbiology, if Applicable)There are 2 reviews by the Chemistry, Manufacturing and Controls (CMC) reviewer, Dr.Leginus (Division File System Archive 29 Dec 2008 and 17 Apr 2009). He recommendsapproval and does not have signi?cant concerns regarding CMC issues.The device reviewer, Dr. Syed, had some concerns in his review memorandum, which was 4)attached to Dr. Ri1ey?s second review (DF 17 Apr 2009). Novo had used their own .device, which they have used for insulin products, and modi?ed it to be used with liraglutide.0 The applicant had not provided the 5 10K ?number or an NDA number for their predicatedevice which was modi?ed to produce the liraglutide pen device.0 He felt that the color and marking changes on the device could confuse the user, and that aproper Human Factors study needed to be conducted to support the reasoning behind thesechanges, and their effectiveness.  Dr. Riley, the Microbiology reviewer, did not note Microbiology issues that would preclude approvability. The drug product is sterile and contains an (4)Dr. Riley?s review is in DFS (10 Mar 2009).3.2 Animal Pharmacology/ToxicologyIn his review (DFS 8 Jul 2009), Dr. Parola, the Pharmacology/Toxicology reviewer states thatthe application is not approvable from a Pharmacology/Toxicology standpoint because there isinsuf?cient nonclinical information about liraglutide to determine if it is safe for chronic use.His primary concern is the ?nding in 2-year lifetime exposure carcinogenicity studies in miceand rats that liraglutide caused thyroid C?cell tumors in both species, in both genders, atclinically relevant exposures. In rats, C-cell carcinomas occurred at clinically relevantexposures. In mice, only females developed carcinomas, and only at high multiples of expectedhuman exposure. However, in rodents, C-cell adenomas are considered to be a precarcinomatouslesion. A similar animal signal is being noted in interim carcinogenicity data for some otherlong-acting (q day and longer) analogues in development. In animal studies ofliraglutide, calcitonin (which has been used historically as a biomarker for medullary thyroidcancer in humans) may not have been a reliable biomarker for C-cell tumor risk. Dr. Parolastated that the mechanistic studies performed by the applicant did not mitigate this risk. Dr.Parola recommends that the applicant determine the mode of action for liraglutide-inducedrodent C-cell tumors. Determination of the mode of action could provide important informationto evaluate the potential human relevance of these rodent C-cell adenomas and carcinomas. Dr.Page 13 of 249	326534	329478
179	1	2	16	1	156	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission O00Victoza? (liraglutide injection)Parola suggests some possible animal studies which could provide further mode of actioninformation.Dr. Parola was also concerned that local toxicity after repeat subcutaneous injection had not beenadequately assessed in nonclinical studies. In chronic repeat dose toxicity studies, liraglutidecaused irreversible injection site reactions in monkeys, using drug formulations that were at least3 times more dilute than the clinical formulation. Liraglutide also caused fibrosarcornas in thedorsal skin and subcutis in mice in the high dose group in the 2-year carcinogenicity study. Dr.Parola states that these frbrosarcomas were attributable to local toxicity due to high drugconcentration at or near the injection site. The concentration of liraglutide in the high doseformulation in the mouse study was 0.6 mg/mL, which is 1/ 1 0m the concentration of the clinicalformulation (6 mg/mL).An additional concern was that some liraglutide impurities were not quali?ed in genetic toxicitystudies. Dr. Parola recommends evaluation of the in vitro genetic toxicity of liraglutideimpurities at impurity levels consistent with drug substance and drug product acceptance criteria.Dr. Parola recommends Pregnancy Category C. Liraglutide cause abnormalities in fetal rats atmaternal systemic exposures that were 0.8 times the expected human exposure from the 1.8 mgliraglutide dose. Liraglutide also caused major fetal malformations in rabbits at 0.2x humandose.4 DATA SOURCES, REVIEW STRATEGY, AND DATA INTEGRITY4.1 Sources of Clinical DataAs of the date of submission of the NDA (23 May 2008), the liraglutide development programconsisted of 38 completed clinical trials (data cutoff date 31 Jan 2008) and 2 ongoing controlledopen-label extension trials (data cutoff date 21 Feb 2008).The clinical safety review included review of pooled data from these trials, from a safety updatesubmitted by the applicant on 23 Sep 2008, from multiple other submissions containing liraglutide-related safety information, from the only approved GLP-1 analogue (Byetta?,exenatide injection), and from the medical literature. After submission of the original NDA, the applicant has forwarded 41 additional submissions tothe NDA. These submissions are discussed in Section 7.2.9.Throughout the NDA review period, the applicant continued to submit individual safety reports?to the IND (61040), which were also incorporated into the review.4.2 Tables of Clin_ical StudiesThe following table lists all studies included in the original NDA submission.Page 14 of 249	329479	332119
632	1	4	50	1	22	DMD#60558cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, hemedestruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol ExpTher 313: 154164.Marumoto S and Miyazawa M (2010) -secretase inhibitory effects of furanocoumarins fromthe root of Angelica dahurica. Phytother Res 24: 510513.Miksys S and Tyndale RF (2004) The unique regulation of brain cytochrome P450 2 (CYP2)family enzymes by drug and genetics. Drug Metab Rev 36: 313333.Rosselli S, Maggio A, Bellone G, Formisano F, Basile A, Cicala C, Alfieri A, MascoloN, and Bruno M (2007) Antibacterial and anticoagulant activities of coumarins isolatedfrom the flowers of Magydaris tomentosa. Planta Med 73: 116120.Silverman RB (1996) Mechanism-based enzyme inactivation, in Contemporary EnzymeKinetics and Mechanisms (Purich DL ed) pp 291335, Academic Press, San Diego.Stresser DM and Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P4502B6. Drug Metab Dispos 27: 517525.Tang CH, Yang RS, Chien MY, Chen CC, and Fu WM (2008) Enhancement of bonemorphogenetic protein-2 expression and bone formation by coumarin derivatives via p38and ERK-dependent pathway in osteoblasts. Eur J Pharmacol 579: 4049.Talakad JC, Shah MB, Walker GS, Xiang C, Halpert JR, and Dalvie D (2011) Comparison ofin vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbitcytochrome P450 2B4. Drug Metab Dispos 39: 539550.Thum T and Borlak J (2000) Gene expression in distinct regions of the heart. Lancet 355:979983.22	27697	29225
633	1	4	50	1	23	DMD#60558Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochromeP450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondarymetabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substratemarker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306: 287300.Zhang QY, Qin LP, Huang BK, Zheng HC, Wang Y, Wang H, and Chen L (2003) Study oneffects of total coumarines from the fruits of Cnidium monnieri on osteoporosis inovariectomized rats. Chin Pharm J 38: 101103.Zhang Y, Cao YJ, Zhan YZ, Duan HJ, and He LC (2010) Furanocoumarins-imperatorininhibits myocardial hypertrophy both in vitro and in vivo. Fitoterapia 81: 11881195.Zhuang XM, Zhong YH, Xiao WB, Li H, and Lu C (2013) Identification and characterizationof psoralen and isopsoralen as potent CYP1A2 reversible and time-dependent inhibitorsin human and rat preclinical studies. Drug Metab Dispos 41:19141922.23	29226	30163
635	1	4	50	1	25	DMD#60558Scheme LegendsScheme1. Proposed pathways for the formation of reactive intermediate(s) and GSHadducts during the metabolism of IMP.Figure LegendsFigure 1. A, Time- and concentration-dependent inactivation of CYP2B6 by IMP.Recombinant human CYP2B6 was incubated with IMP at concentrations of 0 ( ), 0.2( ), 0.5 ( ), 1.0 ( ), 1.5 ( ), and 2.5 ( ) M in the presence of NADPH at 30 C for 0,3, 6 and 9 min. Aliquots of incubation mixtures were transferred to the secondaryincubation mixtures for the determination of residual enzymatic activity. The residualenzymatic activities at 0 min were normalized to 100% at each concentration. B,Wilsons plot. The observed inactivation rate constant Kobs was calculated from theslope of the regression lines shown in Figure 1A. C, NADPH-dependent inactivationof CYP2B6 by IMP. CYP2B6 was incubated with vehicle ( ) and IMP (1.5 M) inthe presence ( ) or absence ( ) of NADPH. Data are meanSD (n=3).Figure 2. Substrate protection against inactivation of CYP2B6 by IMP. CYP2B6 wasincubated with vehicle ( ) and IMP (1.5 M) in the absence ( ) or presence ofticlopidine at concentrations of 50 ( ), 100 ( ), and 200 M ( ) of ticlopidine. Theresidual enzymatic activities at 0 min were normalized to 100% at each concentration.Data are meanSD (n=3).25	30286	31597
183	1	2	16	1	160	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 4.2.1: Clinical Studies in Liraglutide Development Program at Time of NDASubmissionTrial Country Type of Design Study Drugs Pop Duration Status]ID2 Study andControlAR, AU, Efficacy, MC, R, DB, LGT QD SQ, 1040 total DM2 26 Complete1436? BG, HR, CZ, safety parallel grpand mg, titrated GLIM: 233IN, IL, IT, PBO from 0.6 mg, in LGT 1.2 KR, MY, combo with GLIM: 228PH, PL, RO, GLIM LGT 1.8 ZA, CH, GLIM 4 mg by GLIM: 234TW, TH, TR mouth QD GLIM PBO PBO: 114RSG 4 mg by RSG mouth QD GLIM: 231GLIMNN221 1- US, CA Efficacy, MC, R, DB, LGT QD SQ, 530 total DM2 26 Complete1574? safety parallel grp, 1.2 or 1.8 mg, LGT 1.2 PBO titrated from 0.6 MET RSG:mg, in combo 177with MET and LGT 1.8 RSG MET RSG:MET 1 gm by 178mouth BID PBO METRSG 4 mg by RSG: 175mouth BID NN221 1- AR, AT, Efficacy, MC, R, DB, LGT QD SQ, 576 total DM2 26 Complete16972 DK, ES, FI, safety parallel grp, 1.8 mg, titrated LGT FR, GB, IN, PBO and from 0.6 mg, in GLIIVI IT, ME, NL, AC combo with MET: 230NO, PH, PL, GLIM and MET PBO RS, RU, SK, GLIM 4 mg by GLIM ZA mouth QD MET: 114MET, 1 gm by Glargine mouth QD GLIM Glargine QD MET: 232SQ, titratedNN221 total Healthy 5 Complete1694 dose 15, 20 or 25 LGT: 18escalation mcg/kg, titrated PBO: 6in weekly stepsof 5 mcg/kg NN221 total Healthy 3 Complete1551 dose 10 0:15 LGT: 18escalation mcg/kg, titrated PBO: 6in weekly stepsof 5 mcg/kgNN221 total Healthy SD Complete1326 parallel 2.5, 5, 10 or 15 LGT: 24mcg/kg PBO: 8NN2211total DM2 14 Complete1591 parallel or 10 meg LGT: 11PBO: 4NN2211- - JP Efficacy, MC, R, DB, LGT SQ QD, 226 total DM2 14 Complete13342 safety PC, parallel 0.1, 0.3, 0.6, or LGT: 1800.9 mg PBO: 46Page 18 of 249	337011	338768
184	1	2	16	1	161	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 2234! Submission 000Vict0za? (liraglutide injection)Table 4.2.1: Clinical Studies in Liraglutide Development Program at Time of NDASubmissionTrial Country Type of Design Study Drugs Pop Duration Status?ID2 Study andControl1- US Efficacy, MC, R, DB, LGT SQ QD, 210 total Obese DM2 12 Complete20722 safety AC, parallel 0.045, 0.225, LGT 0.045:0.45, 0.6 or 0.75 37mg LGT 0.225:MET 1 gm by 35mouth BID LGT 0.4533LGT 0.6: 34LGT 0.75:37MET: 34NN2211- DK Efficacytotal Obese DM2 8 Complete13332 safety parallel 0.6 mg LGT: 21PBO: 12NN221 1- GB BA R, X0 LGT single 32 total Healthy SD Complete1464 (pulmonary) inhalation, 6, I2 LGT: 30or 24 mcg/kg PBO: 2LGT SQ, 6mcg/kgNN8022- DK, SE, Fl, Efficacy564 total Obese healthy 20 Complete1807 GB, NL, BE, safety (orlistat 1.2, 1.8, 2.4 or 3 LGT 1.2: 95ES, CZ OL), PC and mg, titrated LGT 1.8: 90AC from 0.6 LGT 2.4: 93Orlistat: 120 LGT 3.0: 93mg by mouth Orlistat: 95TIDNN9233- US BA R, DB, PC LGT single 12 total Healthy SD Complete1898 (intranasal) intranasal dose, LGT: 92.5, 5 or 10 mg PBO: 3LGT SQ, 0.6 mgSource: Applicant?s Tabular Listing, Module 5.2, pages 4-11 1 Status at time of NDA submission (23 May 2008)2 Denotes Phase 2 and Phase 3 trials which were included in analyses of major adverse cardiovascular events (MACE). The MACEanalyses also included 3 trials for which data were submitted after the original NDA submission (Studies 1700, 1701 and 1797).Abbreviations: 2C two center, abd abdomen, AC active control, approx approximately, AR Argentina, AT Austria, atorva atorvastatin, AU Australia, BA bioavailability, BE Belgium, BG Bulgaria, BID 2 times per day, Bioequiv bioequivalence, CACanada, CH Switzerland, contr controlled, CZ Czech Republic, days, DB double blind, DDI drug-drug interaction, DE Germany, DM2 type 2 diabetes mellitus, ES Spain, FI Finland, FR France, function, GB United Kingdom, GLIM glimepiride, group, HK Hong Kong, HR Croatia, HU Hungary, IE Ireland, IL Israel, IN India, Italy, IV intravenous, JP Japan, KR Korea, LGT liraglutide, MC multicenter, ME Montenegro, MET metformin, moxi moxilloxacin, MX Mexico, MY Malaysia, moxi moxilloxacin, NL The Netherlands, N0 Norway, NZ New Zealand, OCP oral contraceptive pill (Neovletta?, 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel), OL open label, PC placebo-controlled, PD pharmacodynamics, PH Philippines, PK pharmacokinetics, PL Poland, pop population, QD each day, randomized, R0 Romania, RS Serbia, RSG rosiglitazone, RU Russia, SB single-blind, SC single center, SD single dose, SE Sweden, SK Slovakia, SQ subcutaneously, TH Thailand, TID three times per day, TW Taiwan, US United States, wk week, X0 crossover, ZA South AfricaThe applicant submitted data from 38 completed clinical trials. One trial (NN8022-1807) was aPhase 2 dose-?nding trial for the treatment of obesity in nondiabetic subjects. Two Phase 1 trialsexplored altemate routes of administration; intranasal in NN9233-1898 and pulmonary inThe other trials were conducted in healthy volunteers or patients with diabetesfor the diabetes indication. Seven trials were conducted exclusively in Japanese subjects. At thetime of NDA submission, there were also six ongoing trials.The following table, by Dr. Janice Derr of FDA Biometrics, provides additional summaryinformation regarding the designs, rescue criteria, and extensions of the five major Phase 3 trials.Page 19 0f249	338769	342196
185	1	2	16	1	162	oi? ?809334.?Ego.mi .N32 A2: :33. 8695wo??owc?so @235 E8 3%:30878 E995Eocbmoh,woNmEo_u:Eso uommgm ?oo?smgon? 53oz$.2235;mm-?2EC.buam Eocno>oEommv?m Socvu>oEombu?m Eo?co>oEombu?m Eo?_uo>oEoM_?3m Eocno>oEom axme Sm A GAE53 aovmm 3:55030 cowmc?xmdame SN A GAE3%dxme 2% A P:?3 3:562.5 Ezeso 087% .?ma Em A 9:"~98 es?UOC0 co?c?xmgame 98. A PEeww ?3 33-395? Q8 A GAEmv_ou32.N9:wd:mxooa om       w?EANESmSm?saw we M: :5 .3 oEs.?. "ou.=Sm onoo?m ohm E3bug onoo?m .m+.uuE omm g?op. 3.2 .m?we %:2mE: .N"we: 2; ?_Bo.r $2 "?85503 onmomi 4?E_.cEo.toE mgE_E._oosuE onuomi ?gob .  . O8 m_U<m P32 co._mv_35? bamm _auE:U	342197	342799
186	1	2	16	1	163	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Of note from the above table is the fact that patients who met criteria for glycemic control rescuewere removed from study, and therefore were not available to experience further adverse events.Rescue withdrawals were more common among patients treated with add-on placebo than withliraglutide or active control.The following ?gure displays the clinical trials grouped by duration:Figure 4.2: Liraglutide Clinical Trials Grouped by Durationincluded in the of Safety- Singie-dose trialsHeaitlfy sreizjecxsrIL-19, 132?, 1328*, 1329*. 1331,1636, 1692. 1693, ?699, H45, 1464(puim-ozialj, NN9233-1898 ijintmnasal)Sizbjecrs wz"rii- 33:2 2 dim?eres.?interned-iaie-term trinisSubjects wr?:?i2 ape 2 diabe-res:1316, 1333, 2542, 1=t?9Japanese min! in SIIQEECTS with 3323 2diabetes.?1334Other. Supportixre Safety DataOngoing trials:179?: 1799*, extension, and 13.301. (Japanesephase 3:1 iriais) 1219, 1224. 20-63obese 80'? (minus ext}5Long-term trialsJapcme2.'.'e trial in iizsaifiigir su?gcrs:1 326Sl1ort?t'ern1 irialsSu?gfezcrs wit}: 135:2: 2 cffa?eres:15?} (32 (-9- open-label next up to 21 Feb 2903)1189*, 1330, $603. 3651-1 I532 {26 wins} open-label ext up to 31 Fe?) 2908}I435 (26 Siriz?eetrwirii 2 diabetes.? I 374 {35 wks)3.332, 1339, 1693 159:? (36 Japanese in szriyiecrs: 2551and ?694sriqiecfs wit}: rgye 2'diabetes."3. 5%To:-ai: 38 trials I-3 open-iahel extensions, 6 ongoing lri-ais?fincluded 5, 3 and siabjects with  2 diabeies, iespeetixre?ri? did not cmmibute subject exposure in this documentSource: Applicant?s Figure pg 23, ISSThe primary source of data for the safety review was the set of all patients who received at leastone dose of study medication from the set of all completed trials at time of NDA submission.For some safety descriptions, other data were used, such as the set of the ?ve major Phase 3studies (referred to as ?long-term? studies in the above ?gure), or the set of all extension data outto certain time periods. In each section of the review, the safety population under considerationis described. 4.3 Review StrategyThe clinical safety review was conducted by Dr. Karen Murry Mahoney. The clinical ef?eacyreview is being conducted to Dr. Lisa Yanoff, and will be provided in a separate document.Page 21 of 249	342800	345146
189	1	2	16	1	166	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 7.1.1: Postrandomization Deaths ListingClinical- Applicant's SafetyTreatment Trial Pt ID Age Gender Dose Pt- Listed -Reviewer's(Yrs) (mg) Time Cause of Assessment of(Days) Death Cause ofDeathLiraglutide 1697 698 698004 47 1.8 117 Renal cell Samecarcinomastage IVLiraglutide 1572 225 225011 63 1.2 160 Liver cirrhosis Sameand 7hepatocellular. carcinomaLiraglutide 1700 O9 9025 63 0.9 34 Gastroenteritis Cardiorespiratoryarrest, possiblydue to aspirationof vomitusGlimepiride 1697 689 689012 67 n/a 78 Acute Acute myocardialmetformin myocardial infarction duringinfarction hospitalization forpulmonary. embolismGlargine 1697 827 827005 54 n/a 117 Acute Sameglimepiride myocardialmetformin infarctionGlimepiride 1573 504 504036 56 n/a 194 Road traffic SameaccidentSource: Applicant's Table 2-6, pg 79, Summary of Clinical Safety, Narratives beg pg 3930 ISSAbbreviations: center, ID identi?cation, n/a not applicable, pt patientBrief narratives follow for each of these deaths.Patient 698004 was a 48 year old man with a past medical history of hypertension anddyslipidemia. Approximately 4 months alter beginning liraglutide, the patient began to have"left-sided discomfort", but did not report it to a physician. The patient completed 117 days ofliraglutide treatment per protocol; he also received metformin (MET) and glimepiride (GLIM)during the study. Approximately two weeks after routine per-protocol discontinuation ofliraglutide, the patient felt a lump in his left side, and three weeks later saw a physician. At thattime, ultrasound revealed a 15 cm renal mass, and chest computerized tomography (CT) showeda suspicious node in the left mediastinum. One week after initial presentation, the patientunderwent a left radical nephrectomy for a Fuhrman Grade IV renal cell carcinoma. On anunknown date, a CT of the thorax and abdomen showed extensive hepatic, pulmonary andskeletal metastases. The patient's postoperative course is not otherwise mentioned in thenarrative, but he died 7 months postoperatively from his renal cancer. His last liraglutideexposure had been approximately 8.5 months prior to his death.Patient 225011 was a 63 year old man with a prior history of "hypersensitive bronchial tubes".The narrative states that he had not had alcohol for seven years prior to study entry, but does notPage 24 of 249	349780	352217
190	1	2	16	1	167	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)discuss whether he had a signi?cant prior alcohol history. Approximately four months afterbeginning liraglutide, he presented with bronchitis and four days later, he washospitalized. Six days after hospitalization, he was diagnosed with liver cirrhosis andhepatocellular carcinoma. His presenting signs and/or were not mentioned in thenarrative, but during the hospitalization, he was found to have elevated transaminases andferritin. Five days after diagnosis of his liver cancer, liraglutide was discontinued. He had alsobeen taking concomitant metformin. He was discharged from the hospital; treatment for thishepatocellular carcinoma is not mentioned. He died approximately 10 months after diagnosis.Patient 9025 was a 63 year old woman with a prior medical history of hypertension andhyperlipidemia. Approximately 5 weeks after starting liraglutide, the patient experiencedabdominal enlargement, malaise and headache. The next day, vomiting and diarrhea began. Oneday later, the patient was admitted to the hospital with a diagnosis of acute gastroenteritis. Thepatient was febrile and had an elevated white blood cell count, C-reactive protein, blood ureanitrogen, creatinine and creatine phosphokinase. Troponin and ECG were normal. Meropenemtrihydrate was initiated. The next morning, the patient was found in cardiorespiratory arrest.Resuscitation was attempted for two hours, but the patient did not respond. The investigatorstated that "the direct cause of death was airway obstruction as a result of vomiting". An autopsywas not done. In the clinical safety reviewer's opinion, the cause of death was more likely due toaspiration of vomitus with resultant respiratory and cardiac arrest, rather than to gastroenteritisper se. Had the patient not aspirated, recovery would have been likely (as in the vast majority ofcases of acute gastroenteritis), although the clinical course described for this patient was particularly severe (fever, leukocytosis and renal dysfunction at presentation). The possibility ofanother explanation for the patient's presentation exists, also, such as bowel infarction, whichmight have been expected to have a much more severe course, sometimes resulting in sepsisand/or hypotension with cardiovascular collapse and death. However, the paucity of data doesnot permit a determination of whether a different diagnosis was possible.Patient 689012 was a 67 year old woman with a prior medical history of hypertension,hyperlipidemia and nephrolithiasis. Approximately 2.5 months after starting control medications(glimepiride and metformin), the patient was admitted to the intensive care unit (ICU) with apulmonary embolism; presenting were not mentioned in the narrative. Five days afterpresentation, a stent was placed in the left anterior descending coronary artery; the reason forstent placement was not mentioned. The patient was hemodynamically unstable; stent occlusionwas suspected. Thrombolytic was administered and two more stents were placed. The patientnever regained hemodynamic stability, and remained hospitalized. Twelve days later, the patientsuffered an acute myocardial infarction with cardiorespiratory arrest and died. Autopsy was notperformed.Patient 827005 was a 54 year old man with a prior medical history of hypertension anddyslipidemia. After approximately 3.5 months on control medications (glargine, glimepiride andmetformin), the patient awoke at 0245 with chest pain, shortness of breath and sweating. Anambulance arrived within 5 minutes, but the patient died during transport to the hospital.Electrocardiogram during transport showed ?at line. Cause of death was listed as acutemyocardial infarction; autopsy was not performed.Page 25 of 249	352218	356035
191	1	2	16	1	168	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234! Submission 000Victoza? (liraglutide injection)Patient 504036 was a 57 year old woman with no prior medical history mentioned other thandiabetes mellitus. She received control medication (glimepiride) for 194 days. A relativenoti?ed the principal investigator that the patient had died in an automobile accident; thenarrative states that hypoglycemia was not suspected.Overall, deaths occurred at a low rate, and occurred with equal frequency among liraglutide- andcomparator-treated patients. There was no evidence of an association between liraglutide andoverall mortality or cause-speci?c mortality.In the 120-day safety update, an additional death was reported, with the cause of death beingacute pancreatitis. Patient 117006 was a 64 year old woman who received liraglutide 1.8 mg for668 days. She had no known history of alcohol consumption. Approximately 5 weeks prior toher death, she had undergone a colonoscopy which revealed a colonic polyp, whichwas suspicious for adenocarcinoma. Three days prior to her death, she underwent a repeatcolonoscopy, in order to ?re-biopsy the area and to determine the extent and need forinvasivesurgery?. No perforation appeared to occur, and endoscopic retrogradecholangiopancreatography was not performed. After the colonoscopy, the patient reportedabdominal pain, but two days later, she was reported to be active. The next day, she rapidlydeteriorated and died. Autopsy was reportedly consistent with acute and chronic pancreatitis.Macroscopic evaluation revealed mottled white, tan and dark red to black areas, ?with most ofthe lighter areas about the periphery?. Microscopic analysis revealed fatty change and autolysis.Autolysis was seen ?in a range of organs beyond the pancreas?. Gallbladder stones were present;biliary obstruction was not mentioned. The presence of dark red to black areas raised thequestion of whether this patient had necrotizing pancreatitis, and further information wasrequested from the applicant. On 29 Jun 2009, in an email to Dr. Parks (Division of Metabolismand Endocrinology Products Division Director), Dr. Thompson of Novo submitted areport of a pathology cons_ultation that was performed at Dartmouth by Dr. Daniel Longnecker.He had received 3 slides from the original autopsy, which had been performed in Florida. NovoNordisk had requested the consultation from Dr. Longnecker. In his blinded review of the slides,which he performed prior to knowledge of the original autopsy ?ndings, he did not identifypancreatic tissue. Some of the tissues on the slides were unidenti?able, with advanced autolysis.After examining the slides, he received the autopsy report. He concurred with the diagnosis ofacute pancreatitis based on the macroscopic description. He also stated ?The fact that pancreatictissue was not identi?ed in the blinded review of the autopsy slides is not surprising inasmuch asnecrosis is an expected ?nding in acute pancreatitis. In addition, the pancreas is known toundergo autolysis more rapidly than many other tissues because of its high content of hydrolyticdigestive enzymes. One can assume that one or more of the unidenti?ed tissues in the slidescame from the pancreas and was unidenti?able because of the combined effects of antemortemnecrosis and postmortem autolysis.? 07.1.2 Other Serious Adverse EventsIn general, serious adverse events occurred with similar frequency among liraglutide-treated andnon-liraglutide-treated patients across the development program. The following tablesummarizes serious adverse events by Medical Dictionary for Regulatory Activities System Organ Class and Preferred Term.Page 26 of 249	356036	359723
192	1	2	16	1	169	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 7.1.2.1: Serious Adverse Events by System Organ Class and PreferredTerm, All Completed Trials at Time of NDA SubmissionLGT System Organ Class Preferred Term Ratel Rate/1000 PY 1000 PYAny Any 160 3.8 86.6 90 4.0 97.5Cardiac Any 37 0.9 17.4 18 0.8 16.7Angina pectoris 7 0.2 3.1 3 0.1 2.6Acute myocardial infarction 5 0.1 2.2 4 0.2 3.5Myocardial infarction 5 0.1. 2.2 5 0.2 4.4Coronary artery disease 4 0.1 1.8 1 <0.1 0.9Atrial ?brillation 2 <0.1 0.9 1 <0.1 0.9Cardiac failure congestive 2 <0.1 0.9 0 0 0Myocardial ischemia 2 <0.1 0.9 0 0 0Supraventricular 2 <0.1 0.9 0 0 tachycardiaAcute coronary 1 <0.1 0.4 0 0 Angina unstable 1 <0.1 0.4 0 0 0Atrial flutter 1 <0.1 0.4 1 <0.1 0.9Cardiac arrest 1 <0.1 0.4 0 0 0Cardiac failure 1 <0.1 0.4 0 0 0Congestive ca rdiomyopathy 1 <0.1 0.4 0 0 0Coronary artery occlusion 1 <0.1 0.4 0 0 0Right ventricular failure 1 <0.1 0.4 0 0 0Tachycardia 1 <0.1 0.4 1 <0.1 0.9Tachycardia paroxysmal 1 <0.1 0.4 0 0 Coronary artery stenosis 0 0 0 1 <0.1 0 9Ischemic cardiomyopathy 0 0 0 1 <0.1 0 9Ventricular tachycardia 0 0 0 1 <0.1 0.9Gastrointestinal disorders Any 20 0.5 10.7 9 0 4 10.5Appendicitis perforated 2 <0.1 0.9 0 0 0Gastritis 2 <0.1 0.9 0 0 0Inguinal hernia 2 <0.1 0.9 1 <0.1 0.9Pancreatitis 2 <0.1 0.9 0 0 0Vomiting 2 <0.1 0.9 1 <0.1 0.9Abdominal distension 1 <0.1 0.4 1 <0.1 0.9Abdominal pain upper 1 <0.1 0.4 0 0Crohn?s disease 1 <0.1 0.4 0 0 0Diarrhea 1 <0.1 0.4 1 <0.1 0.9Duodenal ulcer 1 <0.1 0.4 0 0Femoral hernia, obstructive 1 <0.1 0.4 0 0 0Gastrointestinal 1 <0.1 0.4 0 0 0hemorrhageGastroesophageal re?ux 1 <0.1 0.4 0 0 0diseaseHemorrhoids 1 <0.1 0.4 0 0 0Hiatus hernia 1 <0.1 0.4 0 0 0Mallory-Weiss 1 <0.1 0.4 0 0Page 27 of 249	359724	361512
193	1	2	16	1	170	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Table 7.1.2.1: Serious Adverse Events by System Organ Class and PreferredTerm, All Completed Trials at Time of NDA SubmissionLGT System Organ Class Preferred Term Ratel Rate/1000 PY 1000 PYEdematous pancreatitis 1 <0.1 0.4 0 0 0Pancreatitis chronic 1 <0.l 0.4 0 0 Umbilical hernia 1 <0.1 0.4 0 0 0Abdominal pain 0 0 0 1 <0.l 0.9Constipation 0 0 0 1 <0.1 0.9Diverticulum 0 0 0 1 <0.1 0.9Diverticulum esophageal 0 0 0 1 <0.1 0.9Gastrointestinal pain 0 0 0 1 <0.1 0.9Ileus 0 0 0 1 <0.1 0.9Intestinal obstruction 0 0 1 <0.1 0.9Pancreatitis acute 0 0 1 <0.1 0.9Infections and infestations Any 20 0.5 9.8 10 0.4 10.5Upper respiratory tract 3 0.1 1.3 0 '0 0infectionAppendicitis 2 <0.l 0.9 <0.1 0.9Bronchitis 2 <0.1 0.9 0 0 0Gastroenteritis 2 <0.1 0.9 1 0.9Osteomyelitis Abscess sweat gland 1 <0.1 0.4 0 0 0Clostridial infection 1 <0.1 0.4 0 0 0Diabetic foot infection 1 <0.1 0.4 0 0 0Erysipelas 1 <0.l 0.4 0 0 0Herpes zoster 1 <0.1 0.4 0 0 0Infected skin ulcer 1 <0.1 0.4 1 <0.1 0.9In?uenza 1 <0.1 0.4 0 0 0Pyelonephritis 1 <0.1 0.4 I 0 0 0Sinusitis 1 <0.1 0.4 0 0Spermatic cord funiculitis 1 <0.l 0.4 0 . 0 0Abscess limb 0 0 0 1 <0.1 0.9Breast abscess 0 0 0 1 <0.1 0.9Cellulitis 0 0 0 1 <0.1 0.9Ear infection 0 0 0 1 <0.1 0.9Localized infection 0 0 0 1 <0.1 0.9Parapharyngeal abscess 0 0 0 1 <0.l 0.9Viral infection 0 0 0 1 <0.1 0.9Wound sepsis 0 0 0 1 <0.1 0.9Neoplasms benign, Any 19 0.5 8.9 6 0.3 5.3malignant and unspeci?edPapillary thyroid cancer 4 0.1 1 8 1 <0.l -0.9Prostate cancer 4 0.1 1.8 1 <0.1 0.9Breast cancer 2 <0.1 0.9 1 <0.1 0.9B-cell 1 <0.1 0.4 0 0 0Benign neoplasm of thyroid 1 <0.l 0.4 0 0 0glandPage 28 of 249	361513	363243
195	1	2	16	1	172	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 7.1.2.1: Serious Adverse Events by System Organ Class and PreferredTerm, All Completed Trials at Time of NDA SubmissionLGT System Organ Class Preferred Term 139Ratel Rate/1000 PY 1000 PYMyositis 1 <0.l 0.4 0 0 0Osteolysis 1 <0.1 0.4 0 0 0Patellofemoral pain 1 <0.1 0.4 0 0 0Rheumatoid arthritis 1 <0.l 0.4 0 0 Tendon disorder 1 <0.1 0.4 0 0 Arthralgia 0 0 0 1 <0.l 0.9Back pain 0 0 0 1 <0.l 0.9Spinal column stenosis 0 0 0 1 <0.l 0.9Injury, poisoning and Any 11 0.3 6.2 12 0.5 11.4procedural complicationsFall 4 0._1 1.8 3 0.1 2.6Brain contusion 1 <0.l 0.4 0 0Concussion 1 <0.1 0.4 0 0Hip fracture 1 <0.l 0.4 1 <0.l 0.9Humerus fracture 1 <0.1 0.4 1 <0.l 0.9Joint injury 1 <0.1 0.4 0 0 0Limb injury 1 0.4 0 0Lower limb fracture 1 0.4 0 0 0Road traffic accident 1 <0.l 0.4 1 <0.l 0.9Sympathetic nerve injury 1 <0.1 0.4 0 0 0Wound 1 <0.l 0.4 0 0Ankle fracture 0 0 1 <0.l 0.9Femur fracture 0 0 0 1 <0.l I 0.9Joint dislocation 0 0 0 1 <0.1 - 0.9Open fracture 0 0 0 1 <0.1 0.9Patella fracture 0 0 0 1 <0.l 0.9Pelvic fracture 0 0 0 1 <0.l 0.9Tibia fracture 0 0 . 0 1 <0.l 0.9General disorders and Any 8 0.2 3 6 6 0.3 5.3administration siteconditionsChest pain 5 0.1 2.2 4 0.2 3.5Hernia 1 <0.1 0.4 0 0Noncardiac chest pain 1 <0.l 0.4 1 <0.1 0.9Pyrexia 1 <0.1 0.4 0 0Malaise 0 0 0 1 <0.l 0.9Endocrine disorders Any 6 0.1 2.7 0 0Goitre Adrenocortical insuf?ciency 2 <0.l 0.9 0 0 0acuteThyroid disorder 1 <0.1 0.4 0 0Metabolism and nutrition Any 5 0.1 2.2 5 0.2 4.4disordersPage 30 of 249	364897	366485
196	1	2	16	1	173	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234! Submission 000Victoza? (liraglutide injection)Table 7.1.2.1: Serious Adverse Events by System Organ Class and PreferredTerm, All Completed Trials at Time of NDA SubmissionLGT System Organ Class Preferred Term 139Ratel Rate/1000 PY 1000 PYHypoglycemia <0.1 0.4 3 0.1 2.6Hypokalemia 1 <0.1 0.4 0 0 0Dehydration 0 0 0 1 <0.1 0.9Hyponatremia 0 0 0 1 <0.1 0.9Respiratory, thoracic and Any 5 0.1 2.2 4 0.2 3.5mediastinal disordersPulmonary embolism 2 <0.1 0.9 1 <0.1 0.9Asthma 1 1 <0.1 0.4 0 0 0organizing 1 <0.1 0.4 0 0 0pneumoniaSnoring 1 <0.1 0.4 0 0 0Bronchitis chronic 0 0 0 1 <0.1 0.9Pulmonary edema 0 0 0 1 <0.1 0.9Sleep apnea 0 0 0 1 <0.1 0.9Hepatobiliary disorders Any 4 0.1 1.8 2 0.1 1.8Cholecystitis 1 <0.1 0.4 1 <0.1 0.9Cholecystitis acute 1 <0.1 0.4 0 0Cholelithiasis 1 <0.1 0.4 0 0 0Hepatic cirrhosis 1 <0.1 0.4 0 0 0Biliary colic 0 0 1 <0.1 0.9Reproductive system and Any 3 0.1 1.3 1 <0.1 0.9breast disordersMenorrhagia 1 <0.1 0.4 0 0 0Ovarian 1 <0.1 0.4 0 0 0Testicular pain 1 <0.1 0.4 0 0 0Benign prostatic 0 0 0 1 <0.1 0.9hypertrophyVascular disorders Any 3 0.1 1.3 4 0.2 3.5Arteriosclerosis 1 <0.1 0.4 0 0 0Orthostatic hypotension 1 <0.1 0.4 0 0Peripheral vascular 1 0.4 0 0 0disorderAortic aneurysm 0 0 0 1 <0.1 0.9Arterial stenosis limb 0 0 0 1 <0.1 0.9Arteriosclerosis obliterans 0 0 0 1 <0.1 0.9Hypertension 0 1 <0.1 0.9disorders Any 2 <0.1 0.9 2 0.1 1.8Retinal detachment 1 <0.1 0.4 1 <0.1 0.9Uveitis 1 <0.1 0.4 0 0 0Glaucoma 0 0 1 <0.1 0.9Investigations Any 2 <0.1 0.9 1 <0.1 0.9Blood calcitonin increased 1 <0.1 0.4 0 0Heart rate increased 1 <0.1 0.4 0 0Page 31 of 249	366486	368134
197	1	2	16	1	174	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 7.1.2.1: Serious Adverse Events by System Organ Class and PreferredTerm, All Completed Trials at Time of NDA SubmissionLGT System Organ Class Preferred Term 139Ratel Ratel. 1000 PY 1000 PYElectrocardiogram 0 0 0 1 <0.1 0.9abnormalRenal and urinary Any 2 <0.1 0.9 5 0.2 4.4disordersHematuria 1 <0.1 0 4 0 0 0Renal pain 1 <0.1 0.4 0 0 0Nephrolithiasis 0 0 0 1 <0.1 0.9Renal colic 0 0 0 1 <0.1 0.9Renal failure acute 0 0 0 1 <0.1 0.9Renal tubular acidosis 0 0 0 1 <0.1 0.9Urethral stenosis 0 0 0 1 <0.1 0.9Skin and subcutaneous Any 2 <0.1 0.9 2 0.1 1.8tissue disordersAngioedema 1 <0.1 0 4 0 0 0Penile ulceration 1 <0.1 0 4 0 0 0Skin ulcer 0 0 0 2 0 1 1.8disorders . Any 1 <0.1 0.4 0 0 0Suicidal ideation 1 <0.1 0.4 0 0 0Blood and system Any 0 0 0 I <0.1 0.9disorders Anemia 0 0 0 1 <0.1 0.9Congenital, familial and Any 0 0 0 1 <0.1 0.9genetic disordersUrachal abnormality 0 0 0 1 <0.1 0.9Ear and labyrinth disorders Any 0 0 0 1 <0.1 0.9Vertigo 0 0 0 1 <0.1 0.9Source: Applicant's Table 72, beg pg 1123 ISSAbbreviations: LGT liraglutide; PY patient-yearsMost serious adverse events occurred with approximately equal frequency among LGT-treatedand non?LGT-treated patients. Types of events which occurred with somewhat greater numericfrequency among LGT-treated patients than among non?LGT-treated patients includedpancreatitis, thyroid cancer, thyroid disorders in general, events of immune etiology, stroke orcerebral hemorrhage events, angina events, and malignancies overall. Serious adverse events offractures, which have been events of particular recent interest for diabetes drugs, did not appearto have occurred more frequently among liraglutide-treated patients. Thyroid disorders, pancreatitis and cardiovascular adverse events are discussed further in Section7.1.3.3. The observed imbalance in the incidence of serious adverse events (SAES) ofmalignancies is discussed in Section Serious events of immune etiology are furtherdiscussed below. The following table summarizes events which may have been immune in nature.Page 32 of 249	368135	370285
213	1	2	16	1	190	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 7.1.3.3.1.2: Preferred Terms Included in Endpoints] Presented forEvaluation of Myocardial Infarction and Stroke for Liraglutide (All Terms Included inDatabase Queries, but Actual Events Did Not Occur for Every Term)?BroadMACE Custom?NarrowMACE Prior NovoMACE2Cerebellar ischemiaCerebral aneurysm rupturedsyphiliticCerebral arteriosclerosisCerebral arteriovenousmalformation hemorrhagicCerebral artery embolismCerebral artery occlusionCerebral artery stenosisCerebral artery thrombosisCerebral hematomaCerebral hemorrhageCerebral hemorrhage fetalCerebral hemorrhage neonatalCerebral infarctionCerebral infarction fetalCerebral ischemiaCerebral thrombosisCerebral vasoconstrictionCerebral venous thrombosisCerebrovascular accidentCerebrovascular accidentprophylaxisCerebrovascular disorderCerebrovascular insufficiencyCerebrovascular spasmCerebrovascular stenosisCharcot-BouchardCranial nerve palsies multipleDiplegiaDysarthriaEmbolic cerebral infarctionEmbolic strokeFacial palsyHematomyeliaHemiparesisHemiplegiaHemorrhage intracranialHemorrhagic cerebralinfarctionHemorrhagic strokeHemorrhagic transformationstrokelntracerebral aneurysmoperationPage 48 of 249	402439	403710
199	1	2	16	1	176	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Patient 375005 had an event of angioedema. This was a 60 year old Russian woman whopresented with dif?culty swallowing, facial and eyelid swelling, and a ?suffocation attack? afteradministration of Bioparox (fusafungine) for acute laryngopharyngitis. Fusafungine appears tobe an agent with local antibacterial action that is used for treatment of upper respiratoryinfections in some countries outside the United States. She had been taking liraglutide 1.2 mgfor 211 days prior to onset of the angioedema. She was hospitalized and treated with intravenousglucocorticoids and recovered. She was discharged from the hospital 9 days later; LGT wasnever discontinued. Patient 471040 was a 51 year old Finnish man who had an event of organizingpneumonia (COP). He presented with prolonged ?u-like and fatigue after 48 days ofLGT 0.6 mg/day. About two months prior to starting LGT, he had had a pneumonia. At thetime of presentation (Study Day 48), he had a left lung in?ltrate on chest X-ray, and wasadmitted to hospital. Computerized tomography and bronchoscopy con?rmed an organizingpneumonia of unknown etiology. He was discharged the next day. It appears that two weekslater, he had a high-resolution CT which showed a 4 cm diameter left lung in?ltrate;bronchoscopy showed ?a mild in?ammation?. One month later, LGT was discontinued due to?ineffective therapy?, and the patient was withdrawn from study. About two months later,prednisone was initiated. Two months later, he underwent mediastinoscopy which revealed onlymildly enlarged nodes. At that time, he was considered to be ?recovering?.Patient 504010 had an event of acute adrenocortical insufficiency. This was a 48 year oldMexican woman with a prior history of Cushing?s and bilateral adrenalectomy. Shepresented with malaise, fever, abdominal pain, nausea and vomiting after 2l3 days of liraglutide1.2 mg/day. She was hypotensive on presentation, and was treated with intravenoushydrocortisone, followed by oral prednisone. She also received cipro?oxacin. She wasdischarged two days later. Liraglutide was discontinued during the hospitalization, but wasresumed on discharge.Patient 516007 had an event of rheumatoid arthritis. This was a 62 year old Australian womanwith a prior diagnosis of rheumatoid arthritis, who presented with worsening knee pain after 103days of liraglutide 0.6 mg/day. She was admitted, underwent knee arthroscopy to determine ifknee replacement was warranted, and was discharged 1 day later. Four days after thearthroscopy, she developed a knee infection, which was treated with cephalexin, and resolvedafter 7 days of treatment. The narrative states that knee replacement will be required at somepoint in the future.Patient 526011 had an event of myositis. This was a 45 year old South African woman whopresented with severe left thigh pain after 229 days of liraglutide 1.8 mg/day. Eighteen days afterpresentation with thigh pain, she was admitted to the hospital. Magnetic resonance imagingrevealed ?increased signaling? of muscles in the anterior upper thigh. The narrative does notmention whether she had measurements of creatine phosphokinase (CPK) or in?ammatorymarkers. She was treated with antibiotics, vitamin B12, iron supplements, amitriptyline,cipro?oxacin, diclofenac and ?anti-in?ammatory medication?. She had a history of chronic irondeficiency anemia. The narrative states that doctors felt that the? pain might be due to diabeticPage 34 of 249	373205	376757
201	1	2	16	1	178	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table Disposition in the Five Major Phase 3 TrialsSource: Applicant?s Table 14, pg 542, ISSAbbreviations: comp comparator, LGT liraglutide, PBO placeboLGT LGT LGT LGT PBO Active Total0.6 1.2 1.8 Total Comp Compmg mg mgRandomized (N) 475 898 1133 2506 528 958 1486Exposed (N) 475 896 1130 2501 524 953 1477Withdrawals Anyreason 59 188 213 460 150 178 328during controlled [n (12.4) (21.0) (18.9) (18.4) (28.6) . (18.7) (22.2)portion of trial (3.4) (7.7) (8.2) (7.1) (2.9) (3.7) (3.4)Noncompliance with protocol (1.1) (2.7) (2.0) (2.0) (2.1) (2.0) (2.0)in Ineffective 31 34 34 99 91 50 141therapy In (6.5) (3.8) (3.0) (4.0) (17.4) (5.3) (10.0)Other [107(1.5) (6.8) (5.7) (5.3) (6.3) (7.8) (7.2)Com pleters of 416 708 917 2041 374 775 1149controlled portion (87.6) (79.0) (81.2) (81.6) (71.4) (81.3) (77.8)of trial [n Entered extension 184 327 328 839 61 320 381[n of original (38.7) (36.5) (29.0) (33.6) (11.6) (33.6) (25.8)randomized)]Withdrawals Any reason during open-label [n (21.7) (14.1) (16.5) (16.7) (41.0) (21.9) (24.9)extension portionof trial(2.7) (2.1) (1.8) (2.2) (1.6) (1.6) (1.6)Noncompliance with protocol (2.7) (1.8) (1.2) (1.8) (1.6) (1.3)In Ineffective therapy [n (12.0) (7.7) (7.6) (8.6) (31.2) (13.4) (16.3)Other [(4.4) (2.5) (5.8) (4.2) (8.2) (5.3) (5.8)Total 12 month 171 330 337 838 48 318 366completers In (92.9) (76.9) (80.2) (81.1) (78.7) (73.8) (74.4). Total 18 month 110 200 187 497 29 168 197completers [n (59.8) (61.2) (57.0) (59.2) (47.5) (52.5) (51.7)The following table summarizes disposition by trial, for the ?ve ?major Phase 3 trials.Page 36 of 249	379711	381400
202	1	2	16	1	179	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 7.l.3.1.2: Disposition by Trial, Five Major Phase 3 TrialsTrial Pt Reason for if LGT LGT LGT PBO AC ?TotalStatus Applicable 0.6 1.2 1.8Rand 233 228 234 114 232 10411436 Expos 233 228 234 114 231 1040(RSG)Compl 89.3 86.0 91.0 72.8 83.6 85.910.7 14.0 9.0 27.2 16.4 14.1Ineff therapy 5.2 3.5 3.0 17.5 6.9 6.1AE 2.1 4.8 3.8 5.3 3.0 3.7Non?compliance 1.3 2.2 1.3 1.8 2.6 1.8Other 2.1 3.5 0.9 2.6 3.9 2.6Rand 242 241 242 122 244 10911572 Expos 242 240 242 121 242 1087(GLIM)Compl 86.0 81.7 78.9 60.7 86.1 80.714.0 18.3 21.1 39.3 13.9 19.3Ineff therapy 7.9 3.3 5.4 23.8 3.7 7.1AE - 4.5 9.5 12.0 1.6 3.3 6.7Non?compliance 0.8 1.7 1.7 3.3 2.0 1.7Other 0.8 3.7 2.1 10.7 4.9 3.8Rand 247 251 248 7461573 Expos 246 251 248 745(GLIM)Compl 70.0 64.5 61.3 65.3WID 30.0 35.5 38.7 34.7Ineff therapy 3.6 6.0 10.1 6.6AE 7.3 10.0 6.0 7.8Non?compliance 4.5 4.4 2.0 3.6Other 14.6 15.1 20.6 16.8Rand 178 178 177 5331574 Expos 178 177 175 530Compl 74.7 86.0 68.4 76.425.3 14.0 31.6 23.6Ineff therapy 1.7 1.7 16.4 6.6AE 15.2 6.2 3.4 8.3Non?compliance 2.2 2.2 2.8 2.4Other 6.2 3.9 9.0 6.4Rand 232 115 234 5811697 Expos 230 114 232 576(GLAR) 1Comp] 89.2 83.5 93.6 89.810.8 16.5 6.4 10.2Ineff therapy 0.9 11.3 0.4 2.8AE 4.7 0.9 2.1 2.9Non?compliance 0.4 0.9 2.1 1.2Other 4.7 3.5 1.7 3.3Page 37 of 249	381401	382784
239	1	2	16	1	216	955 <D.m F59 an "8u=om  ?313-1W3-?awW35315I$523r..m  magwmm Mgmamo=_s> .m aoz?saom coiom 2:5. :35.oa8uE E825 4% ..8 BE ?munch ?o:uo.E_ o_u:EwE_: aoi??m HER mU<m .92 iosozmi ESE 	440616	440792
240	1	2	16	1	217	$96 3 ow?<Q.m an nu?som Etmm??Ego,3 $.mm.mw 1 mm mama mam H. mm E53 mam? A - Em ENE a mmiw0a   Emma Hmwma $Emma . - mm; m_mmo=_m>  ccium  m_mz_a:< Emmcon?coutnbm @334 ?.=Ouw=Q  uO?n# ?munch So SE mU<m .92 >532 =8mMEsom _8E__u	440793	441017
241	1	2	16	1	218	$20 3 ems.an m.m?5 mam mamM_?mam- 3 wow? gm $.39 mam3.3% mm?m wm.% y. mag Saw. mm?w3 Q9 32* Emz. Bm_,_w3 Q3 ewxe 3% Nb? 3% NE mmmu=_a> .m cctom BEE :23 m_mbn:<13o E330 Sm BE umogcm 2&3O8 ae?a?m Sam <02mU<m .92 .>u:oamS_ ESE =o.aM>S_>um 	441018	441253
204	1	2	16	1	181	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 7.1.3.2: Adverse Events Associated with Dropouts, All Completed Trials at Time ofNDA SubmissionLGT Non-SOC Preferred Term LGTN=421l Intestinal obstruction 0 1 Pancreatitis acute 0 1 Metabolism and nutrition disorders Any 41 (1.0) 9 (0.4)Anorexia 20 (0.5) 2 (0.1)Decreased appetite 10 (0.2) 7 (0.2) 7 (0.3)Hypoglycemia 2 0Polydipsia 2 0Fluid retention 1 0Hypertriglyceridemia I 0Nervous system disorders Any 35 (0.8) 6 (0.3)Headache 13 (0.3) 1 Dizziness 9 (0.2) 2 (0.1)Lethargy 4 (0.1) 1 Burning sensation 2 0Paresthesia 2 0Ageusia 1 Cerebrovascular accident 1 0Cerebrovascular disorder 1 1 Dysgeusia 1 0Facial palsy 1 0Hemorrhage intracranial 1 0Hypoaesthesia 1 0Somnolence 1 0Tunnel vision 1 0Ischemic stroke 0 1 General disorders and administration site Any 34 (0.8) 6 (0.3)conditionsFatigue 9 (0.2) 0Aesthenia 6 (0.1) 2 (0.1)Malaise 4 (0.1) Pyrexia 3 (0.1) 0Chest discomfort 2 0Injection site bruising 2 0Injection site rash 2 0Edema peripheral 2 1 Chest pain 1 1 Injection site discomfort 1 0Injection site erythema 1 0Injection site irritation 1 0Injection site nodule 1 0Gait disturbance 0 1 Pain 0 1 Investigations Any 22 (0.5) 13 (0.6)4 Weight decreased 6 (0.1) 0Page 39 of 249	384356	385653
205	1	2	16	1	182	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Table 7.1.3.2: Adverse Events Associated with Dropouts, All Completed Trials at Time ofNDA SubmissionLGT Non?_SOC Preferred Term LGTN=421l Weight increased 3 (0.1) 4 (0.2)Blood calcitonin increased 2 1 Blood creatine phosphokinase 2 0increasedBlood creatinine increased 2 2 (0.1)Heart rate increased 2 0Aspartate aminotransferase increased 1 0Blood glucose increased 1 3 (0.1)Blood pressure increased 1 0Electrocardiogram abnormal 1 0Hepatic enzyme increased 1 1 Liver function test abnormal 0 1 Transaminases increased 0 1 Infections and infestations Any 13 (0.3) 4 (0.2)Gastroenteritis 2 0Tonsillitis 2 0Diabetic foot infection 1 0Ear infection 1 0Erysipelas 1 Gastroenteritis viral 1 0Herpes Zoster 1 0Oral fungal infection 1 0Pharyngitis 1 0Sinusitis 1 0Spermatic cord funiculitis 1 0Upper respiratory tract infection 1 0Vulvovaginal mycotic infection 1 0Infected skin ulcer 0 1 Nasopharyngitis _0 1 Viral infection 0 1 Cardiac disorders Any 12 (0.3) 7 (0.3)Myocardial infarction 3 (0.1) 3 (0.1)Acute myocardial infarction 2 3 (0.1)Angina pectoris 1 Atrioventricular block first degree 1 0Cardiac arrest 1 0Cardiac failure congestive 1 0Coronary artery disease 1 0Myocardial ischemia 1 0Palpitations 1 0Atrial ?brillation 1 Tachycardia 1 Skin and subcutaneous tissue disorders Any 12 (0.3) 6 (0.3)Rash 3 (0.1) 3 (0.1)Erythema 2 0Page 40 of 249 A	385654	387109
206	1	2	16	1	183	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 7.1.3.2: Adverse Events Associated with Dropouts, All Completed Trials at Time ofNDA SubmissionLGT Non-SOC Preferred Term LGT1 11 II Hyperhidrosis 2 0Pruritus 2 0Hyperkeratosis 1 0Rash papular 1 0Urticaria 1 0Skin ulcer '0 3 (0.1)disorders Any 10 (0.2) 3 (0.1)Food aversion 2 0Insomnia 2 1 Aggression 1 0Alcohol abuse 1 0Depressed mood 1 0Depression 1 0Mood swings 1 0Sleep disorder 1 0Anxiety 0 2 (0.1)Musculoskeletal and connective tissue Any 9 (0.2) 1 disordersMyalgia 2 1 Pain in extremity 2 0Back pain 1 1 Collagen disorder 1 0Intervertebral disc protrusion 1 0Muscle spasms 1 1 Musculoskeletal chest pain 1 0Neoplasms Any 8 (0.2) 3 (0.1)Breast cancer 2 1 Prostate cancer 2 0iGastrointestinal carcinoma 1 0Hepatic neoplasm malignant 1 0Lung carcinoma cell type unspecified 1 0recurrentMalignant unclassi?able 1 0high gradePapillary thyroid cancer 0 1 Renal cell carcinoma stage unspecified 0 1 Hepatobiliary disorders Any 5 (0.1) 0Cholelithiasis 2 Cholecystitis 1 0Hepatic cirrhosis 1 0Hepatic function abnormal 1 0Vascular disorders Any 5 (0.1) 2 (0.1)Hypertension 2 1 Aneurysm 1 0Flushing 1 0Page 41 of 249	387110	388335
207	1	2	16	1	184	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 22341 Submission G00Victoza? (liraglutide injection)Table 7.1.3.2: Adverse Events Associated with Dropouts, All Completed Trials at Time ofNDA SubmissionLGT Non-SOC Preferred Term LGTHypotension 1 0Arterial stenosis limb 0 1 disorders Any 4 (0.1) 1 pain 1 0 Macular edema 1 0Vision blurred 1 0Visual acuity reduced 1 0Diplopia 0 1 Renal and urinary disorders Any 4 (0.1) 2 (0.1)Polyuria 2 0Nephrolithiasis 1 0Nocturia 1 0Renal colic 1 0Urinary retention 1 0Renal failure acute 0 1 Renal tubular necrosis 0 1 Respiratory, thoracic and mediastinal Any 4 (0.1) 1 disorders2 0Hiccups 1 0Pleural effusion 1 01 0Pulmonary edema 1 Ear and labyrinth disorders Any 3 (0.1) Vertigo 3 (0.1) 0Immune system disorders Any 3 (0.1) 0Allergy to metals 1 0Drug hypersensitivity 1 0Hypersensitivity 1 0Injury, poisoning and procedural Any 4 3 (0.1) 4 (0.2)complications -Arthropod bite 1 0Carbon monoxide poisoning 1 A 0Fall 1 0Femur fracture 0 1 Pelvic fracture 1 Road traffic accident 0 1 Wrist fracture 0 1 Blood and system disorders Any 1 4 (0.2)Thrombocytopenia 1 1 Anemia 0 2 (0.1)Granulocytopenia 0 1 Endocrine disorders Any 1 0Goitre 1 0Reproductive system and breast Any 1 Page 42 of 2491 	388336	389570
242	1	2	16	1	219	9% go OWEAS was muusmrc 35>? m_o<E 53> ma?a Em m.o.8 cououtoo b:E_Eoo ._uuE>oE Boa SEE .50 .5 nu?svcoo .BmE=mo cm oE>o.a 8: En 23.835 Smxo of. ombouo uo?aa?ou E8. aozuam mmosm 5% use .5 mo. _u2osucoo ox siomxu?m no u2E3_mo 8: 2:8 8:33 mmobm bE5woEo: So 2: use .5 w?osvcoo EB. E2 .962 u?osucoo 38. F..238 25 8:03. Ba Ba 3_:mE .9: .m x:EonE$ an BREE 8:932: E8 2E:o>u 8522: mm uu?om muoc?otzu uoE>o:_ o>oZ vm Bank .25 mm .m doom: :3 hm 2 omsonmmz n2:En:m .o>oZ_HBESEOU 03:33:.x.o ?98 mw.o 30 oES_mm._5$0 83 ans m_ .8 on_oomE %:2mS:a Sr:. E: nmxk.mmBREE ESSEOU .33 032.o?aa .9 033.92:EsouwEizm 2: Sank.8:253mE? 2: ?:96 ammo.as :22: m?banmof :23wu:.E& MSG:    . T. mo=:=m .3    828      T. onoo.x.Eaton? uEE_mm:: @mn2u_>.32 <02mU<m .n:2 s2_9_?2 =o._mM_su_>um _woE:U	441254	442013
210	1	2	16	1	187	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Application for liraglutide, and thus would not have been able to prospectively design itsdevelopment program in the fashion described in the Guidance. However, evaluation of thecardiovascular risk of liraglutide is still necessary prior to approval, and the Agency has statedthat drugs with pending applications would still be expected to meet the standards of theguidance for reassurance regarding a lack of an overall increase in cardiovascular risk. To theextent possible, the clinical review of cardiovascular safety attempts to present data consistentwith the requirements of the Guidance. However, for liraglutide, it was not possible to followthe Guidance entirely for several reasons, including:0 Cardiovascular events were not prospectively adjudicated in the development program,and there were inadequate data to perform post hoc adjudication.0 A speci?c effort had not been made in the liraglutide development program to includepatients at high risk of cardiovascular events; in fact, patients with signi?cantcardiovascular disease were generally excluded.0 The overall Phase 2/3 development program was not designed to be combined into ameta-analysis. Trials were of varying durations, and the blinded and open-labelextension periods differed among major Phase 3 trials.0 Few major adverse cardiovascular events occurred.Therefore, the approach to evaluation of the cardiovascular risk of liraglutide had to be adaptedto the available data, which presented challenges.7 .1 .3.3.1 .2 Description of Types of Analyses and Summaries for Major Adverse CardiovascularEventsInitially, the Agency requested that Novo Nordisk, and the applicants for two other recent NewDrug Applications, submit analyses of an endpoint of myocardial infarction, stroke andcardiovascular death. The applicants were allowed discretion in which (MedicalDictionary for Regulatory Activities) Preferred Terms were included in their endpoints. Theanalyses for liraglutide are presented in Section 3.3.1.4 below. However, upon comparison,it was noted that the component terms chosen by the applicants were quite different for the threeproducts. The types of data presentations also differed considerably. While realizing that thedevelopment programs were quite different from one another, and that cross?comparisons shouldnot be made between drugs, the Division felt that it would be useful for the Advisory Committeeand signatory authorities to see a similar type of information for each of the three drugs.Therefore, the Division made a ?uniform? information request of each of the applicants. Aprecisely identical format for data presentation is not possible for the three products, because thedevelopment programs differed in several ways, and cross-developrnent-program comparisonswould not be appropriate. However, the endpoints are uniform, and to the extent possible,similar analyses were presented for each product. The intention for each of the endpoints wasstill to provide an assessment of the incidence of the composite of cardiovascular death,myocardial infarction or stroke. Results of the ?uniform? analyses are presented in Section7.1 .3.3.l.3 below, and are likely the most useful for evaluation of the cardiovascular risk ofliraglutide. In the interest of completeness, Section 7.l.3.3.l.5 also presents data on allcardiovascular adverse events by System Organ Class and Preferred Term. Thisprovides the reader with information on cardiovascular events other than myocardial infarction,stroke and cardiovascular death. Total mortality data are also presented in Section 7.1.1.Page 45 of 249	395704	399400
211	1	2	16	1	188	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)For clarity, the following table presents the terms included in the endpoints which were analyzed,and the sections in which each endpoint?s analyses may be found. For ?Broad Custom and ?Narrow MACE all possible terms for the endpoint areincluded. That is, the listed terms are not limited to events which actually occurred, but ratherare all the Preferred Terms for which the applicant was asked to query their database. Theendpoint ?Prior Novo is from an earlier analysis submitted by the applicant, and iscomposed entirely, of event terms for events which actually occurred in the database.Table 7.l.3.3.1.2: Preferred Terms Included in Endpoints] Presented forEvaluation of Myocardial Infarction and Stroke for Liraglutide (All Terms Included inDatabase Queries, but Actual Events Did Not Occur for Every Term) ?Broad Custom ?Narrow Prior ovoMACE MACE MACE2Location of Analyses in 7.1.3.3.1.3 7.1.3.3.1.3 7.1.3.3.l.3 7.1.3.3.l.4ReviewMyocardial Infarction TermsAcute coronary Acute myocardial infarctionBlood creatine phosphokinase abnormalBlood creatine phosphokinase increasedBlood creatine phosphokinase MB abnormalBlood creatine phosphokinase MB increasedCardiac arrest Cardiac enzymes increased Circulatory collapse Coronary artery embolismCoronary artery occlusionCoronary artery reocclusionCoronary artery thrombosisCoronary bypass thrombosisElectrocardiogram waveabnormalElectrocardiogram ST segment abnormalElectrocardiogram ST segment elevationElectrocardiogram ST-T segment elevationInfarctionMyocardial infarctionMyocardial reperfusioninjuryPapillary muscle infarctionPostinfarction anginaPage 46 of 249	399401	401125
59	1	2	16	1	36	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Table 4.5. Phase 3 key efficacy studiesStudy . . . . Treatment, Route, DurationNumber Objectives Study Design Study Population Regimen, Dosage of Therapy Relevance. Type 2 diabetics . . .Ef?cacy and Liraglutide 1.2 mg Ef?cacy andsafety and safety of1573 . parallel-group . . 1.8 mg 52 weeks . .populatlon with active control Llraglutlde 1'8 mg Glime iride' Once daily hraghmde asPK (gums hide) ppo 8 g/ day monotherapyGlimepiride Type 2 diabetics. . .Liraggu?de 0 6) mg Liraglutidez Once-dailyd, . .. fO.6,1.2,SICS Ef??a?y andEf?cacy and parallel-group Liraglutide 1'2 mg with metformin Safety of1572 safety with placebo and nietfomiin Metformin: p.o. bid, 26 weeks liraglu?de asactive Control Liraglutide 1.8_mg 2 g/day add-on therapy(glime iride) Glime iride: .0. daily Metformin (N?l2l) am Mr;Metformin glimepiride Type 2 diabetics. . .Liraggutide 0 6)mg . .. .. 0.6,l.2,S108  ccombinatiogir Ef?m? andEf?cacy and parallel-group Liraglutide 1'2 mg 1 with glimepiride safety of1436 Safety with placebo and g1imepiride(N=228) Glimepiride 0 daily 26 weeks liraglutide asactive control Liraglutide 1.8 mg 4 mda'y' add-on therapy. . gliinepiride . . . to glimepiride(rosiglitazone) Glimepiride Rosiglitazone. p.o. daily,I Glimepiride 4 mg/dayrosiglitazone Ty 2 diabetics Liraglutide: Once-dailyLiraglutide 1.2 mg s.c. doses of 0.6, 1.2, or Ef?cacy andRandomized metformin rosiglitazone 1.8 mg in combination safety ofEf?cacy and d0ub1e_blind? with metformin and liraglutide as1574 Safety para?e1_grOuI; Liraglutide 1.8 mg +6 rosiglitazone 26 weeks add-on therapymetformin rosiglitazone Metformin: p.o. bid, to metformin2g/day andMetformin rosiglitazorie Rosiglitazone: p.o. bid, rosiglitazone8 mg/dayLiraglutide: Once dailyType 2 diabetics S'c' doseis of 1'8 n.]g inRandomized Liraghitide 1'8 mg Ef?cacy andd0ubIe_b1in d? glimepiride metformin metformin safety ofEfficacy and parallel-group . . Glimepiride? 0 daily liraglu?de as1697 . Glimepiride metformin 26 weeks add-on therapysafety with placebo and 4 4 mg/day .active control Metformin 0 bid to metformm(ins lar me) Insulin glargine 2 g/da andI glimepiride metformin Insulin lat (100 glimepirideg_ .- lU/mL). s.c. daily,individual titration24	67256	69534
212	1	2	16	1	189	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Table 7.1.3.3.I.2: Preferred Terms Included in Endpoints] Presented forEvaluation of Myocardial Infarction and Stroke for Liraglutide (All Terms Included inDatabase Queries, but Actual Events Did Not Occur for Every Term)?BroadMACE Custom?NarrowMACE Prior NovoMACE2Postprocedural myocardialinfarctionScan myocardial perfusionabnormalSilent myocardial infarctionTroponin I increasedTroponin increasedTroponin increasedVascular graft occlusionStroke TermsAgnosiaAmaurosis fugaxAngiogram cerebral abnormalAphasiaBalint?s Basal ganglia hemorrhageBasilar artery occlusionBasilar artery stenosisBasilar artery thrombosisBrain stem hemorrhageBrain stem infarctionBrain stem ischemiaBrain stem strokeBrain stem thrombosisCapsular warning Carotid aneurysm ruptureCarotid arterial embolusCarotid arteriosclerosisCarotid artery aneurysmCarotid artery bypassCarotid artery diseaseCarotid artery dissectionCarotid artery insufficiencyCarotid artery occlusionCarotid artery stenosisCarotid artery stent insertionCarotid artery thrombosisCarotid endarterectomyCentral pain Cerebellar artery occlusionCerebellar artery thrombosisCerebellar embolismCerebellar hematomaCerebellar hemorrhageCerebellar infarctionPage 47 of 249	401126	402438
243	1	2	16	1	220	$58 MK 99$4am SEE. an a?somEEmww3 .3.  3  mmim  mo=_a> .m =o:2=mom scram ?tsm_mbn:< .oa_oom_m m=m.5> Guam cmohm .5. BE ?wagon Eonoobz So =oEE5=m <02mU<.m .92 =2mv_buo?m. .H.I	442014	442187
244	1	2	16	1	221	$30 3 om?an 5u.=am  mMEm5% .    mama 3mm. mama   3.3% mmw?, mam Ja .3 Ewmm 2 m?a mm? _m NE 3   Ewmw-  Ja 3 Em? Emkw-  wmmo=_n> .m catch BEE :23 m_mbn=< _o~m:oaE-_3=sZ 2:34 m=m.3> Guam unchm BE ?munch ?o:ou.nE ?mno.u_>ooc <02mU<m .92 :uEv_325.0 	442188	442431
245	1	2	16	1	222	ax We 3 Omanhm?mm? Erma Em mm 1%  2 Emwmmmam mmam Em gag mwma $mm-%mw 33? ?mm- 3 Amgm  gmmmw?Awmmg?uam .A.. llC331-..-?Ln?:4 mo ?3 2: 3 mo=_n> .m soc?saom carom ?rs ,._eE.aaoo EBB m=m.5> Guam csogm BE .mo.S,m coo <22mU<m b.E_2 :uEv_	442432	442663
246	1	2	16	1	223	mamHm 202.: x.u.:.cma .5. on he22.: am HER ?amA :o_mm_En_ V..oo_2 moi 23%	442664	442736
215	1	2	16	1	192	Clinical Safety ReviewKaren Murry Mal-ioney, MD, FACENDA 22341 Submission 000Victoza? (liragiutide injection)Table 7.1.3.3.1.2: Preferred Terms Included in Endpointsl Presented forEvaluation of Myocardial Infarction and Stroke for Liraglutide (All Terms Included inDatabase Queries, but Actual Events Did Not Occur for Every Term)?Broad Custom ?Narrow Prior NovoMACE MACE MACE2Transient ischemic attack Vascular encephalopathy Vertebral artery occlusion Vertebral artery stenosis Vertebral artery thrombosis Vertebrobasilar insuf?ciency Visual midline shift Wallenberg 1 All endpoints also included cardiovascular death2 Source: NDA 22341-000, EDR 7 Oct 2008, pg 6. Terms in this endpoint were selected from events which actually occurred, ratherthan from a SMQ7.1 .3.3.1.3: ?Uniform MACE Analyses?Please refer to the Information Request (DF 11 Jan 2009) which was sent to each of theapplicants for the three products which had pending applications at the time of the diabetescardiovascular evaluation Guidance. The information request details what was requested forthese ?uniform? analyses.As mentioned earlier, when comparing MACE analyses initially submitted by differentapplicants, it was noted that the component Preferred Terms chosen by the applicants differedconsiderably, as did the analysis methods. Therefore, a group of three FDA Clinical Reviewerscollaborated to attempt to devise uniform endpoints for evaluation. This was not a simple task;there are many possible Preferred Terms which might be assigned when a patient has had amyocardial infarction or stroke. Post hoc adjudication of all events was not possible due toinadequate information. Therefore, a collection of Preferred Terms for myocardialinfarction and stroke, as originally coded, with the addition of cardiovascular deaths, seemed thebest approach. Two endpoints were chosen, one intended to broadly capture all possible strokesand myocardial infarctions; and one intended to include those terms which seemed likely to bechosen as the term to describe an event that truly was a myocardial infarction or a stroke. Thebroad endpoint used was the combination of the Broad Standard Queries formyocardial infarction and central nervous system hemorrhages and cerebrovascular accidents;and cardiovascular deaths (see Section 7.1.1). This is referred to as the ?Broad MACE The more speci?c endpoint, referred to as the Custom is a subset of the ?BroadMACE Without considering which events had actually occurred for a given product,each clinical reviewer independently reviewed the list of all possible terms included in the?Broad MACE The clinical reviewer then considered each term, with this question inmind: ?If I had a patient who actually had a myocardial infarction or a stroke, is this a PreferredTerm that I might actually have chosen for such an event??, with the goal of selecting only thosePreferred Terms that seemed highly likely to represent events that would truly be a myocardialinfarction or a stroke. The interest was also that these events likely represent acute events with amechanism of atherosclerotic plaque development followed by plaque rupture/thrombosis (asPage 50 of249	404944	408113
216	1	2	16	1	193	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)opposed to events with nonatherosclerotic mechanisms, e.g. rupture of congenital aneurysma).The three reviewers? lists were compared, and any terms for which there was not unanimousagreement to include or exclude were open for discussion. Consensus was reached on whichterms were included. The clinical safety reviewer acknowledges that this is an imperfectprocess; other reasonable physicians may have chosen a different set of terms. Also, althoughthe SMQS are broad, they may not be all-inclusive. For example, the BroadMyocardial Infarction SMQ does not contain the terms ?cardiac arrest? or ?circulatory collapse?;?cardiac arrest? was a Preferred Term assigned for one patient exposed to LGT, and ?circulatorycollapse? was assigned for one patient each in the placebo and active comparator groups.However, the overall goal was to have a uniform, fairly speci?c endpoint for use with each of theagents, in order that the Advisory Committee and signatory authorities could see data that wereas similar as possible for each product. It should be noted that this endpoint is not a standardFDA endpoint and should not be presumed to be the Agency?s choice for future evaluations ofcardiovascular events. Please see Table 7.l.3.3.l .2 for an exact list of terms included in the?Broad MACE and the Custom endpoints.In addition to the above two endpoints requested by the FDA, the applicant also included anendpoint composed of cardiovascular death and the Narrow Standard Queries for?Myocardial Infarction? and ?Central Nervous System Haemorrhages and CerebrovascularAccidents?. This is a subset of the aforementioned ?Broad MACE This endpoint isreferred to as ?Narrow MACE and the included Preferred Terms are also listed in Table7.1.3.3.1.2.These analyses include all data from all Phase 2 and Phase 3 trials, up to the 120-day safetyupdate submitted during the review cycle. The applicant included data both from their diabetesdevelopment program, and from their obesity development program. For pooled analyses, theapplicant obtained estimates and 95% con?dence intervals using a Cochran Mantel-Haenszelestimation with stratification by trial. Only the first MACE for each patient was counted in theanalyses.Summary tables follow which display these estimates, and the numbers of events which actuallyoccurred, for liraglutide versus comparator. In these tables, there are two time periodpopulations. Population A includes the randomized, controlled periods for all completed Phase 2and Phase 3 trials of LGT, up to collection of the primary efficacy endpoint. The Divisionconsiders Population A the primary population of interest. Population adds the controlled, butunblinded, voluntary extension periods (after collection of the primary endpoint) of Trials 1572and 1573. Exposure for these populations is as follows:Page 51 of 249	408114	411054
217	1	2	16	1	194	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Table 7.1.3.3.1.3.l: Exposure in Trials Included in Time Period Populations A and in the?Broad MACE Custom and ?Narrow MACE AnalysesPop A1 Pop B2Total number of patients included 6638 6638Total patient-years of exposure a 2926 4368Total number of patients exposed to LGT 4257 4257Total patient-years of liraglutide exposure 1880 2882Source: Applicant?s Table 1, pg 10, NDA 22341 subm 21 Jan 20091 Population A includes the randomized, controlled portions of all Phase 2 and Phase 3 trials, up to collection of the primary endpoint2 Population includes all of Population A, plus the controlled, but unblinded, voluntary extension periods (after collection of theprimary endpoint) 0l'Trials 1572 and 1573.Abbreviations: MACE major adverse cardiovascular events, Pop time period population, SMQ Standard QueryThe majority of the patients and the patient-year exposure came from the Phase 3 diabetes trials.These trials included 3978 patients, or 60% of all patients included in the analyses, and 2501LGT-exposed patients (5 9% of all LGT-exposed patients in the analyses). Patient?year exposurein the randomized, controlled portions of the Phase 3 DM trials (up to collection of the primaryendpoint) was 2024 total patient-years, with 1291 patient-years of LGT exposure, representing69% of total patient exposure, and 69% of LGT exposure, for time period ?Population Serious adverse events were de?ned using a commonly used regulatory de?nition. Speci?cally,a serious adverse event was de?ned as an experience that at any dose results in any of thefollowing:0 Death0 A life-threatening experience (refers to an event in which the subject was at risk of deathat the time of the event; does not refer to an event which hypothetically might havecaused death if it was more severe) 0 Inpatient hospitalization or prolongation of existing hospitalization0 A persistent or signi?cant disability/incapacity0 A congenital anomaly or birth defectAdditionally, the applicant stated the following: ?Important medical events that may not resultin death, be life-threatening or require hospitalization may be considered serious adverse events(SAES) when, based upon appropriate medical judgment, they may jeopardise the subject andmay require medical or surgical intervention to prevent one of the outcomes listed in thisde?nition.? (Source: NDA 22341-000, received 23 May 2008, Module 2.7.4, pg 45)Statistical Methods for the Analysis of Major Adverse Cardiovascular Events (Point Estimates and 95% Con?dence Intervals)The focus in this document is on the incidence ratio, calculated ?'om the proportion of patients inthe liraglutide dose arms with a MACE event (alldose levels combined) divided by theproportion of patients in the comparator arms with a MACE event. The point estimate and 95%con?dence interval (CI) were calculated using several statistical methods. The intention in usingseveral methods was to explore the sensitivity of the results, in particular the upper 95% CIbound, to the estimation method. Each method has advantages and disadvantages with respect toestimating this upper bound in the context of the MACE analysis for the liraglutide studies. Theprimary source of dif?culty is the relative rarity of the MACE events, such that, depending onPage 52 of 249	411055	414426
167	1	2	16	1	144	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table of Contents1 EXECUTIVE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..41.1 RECOMMENDATION ON REGULATORY ACTION ..41.2 RECOMMENDATION ON POSTMARKETING ACTIONS ..4Risk Management Activity ..41.2.2 Required Phase 4 Commitments ..41.2.3 Other Phase 4 Requests ..41.3 SUMMARY OF CLINICAL FINDINGS ..51.3.1 Brief Overview of Clinical Program ..51.3.2 Efficacy ..51.3.3 Safety ..51.3.4 Dosing Regimen and Administration ..111.3.5 Drug-Drug Interactions ..111.3.6 Special Populations ..112 INTRODUCTION AND BACKGROUND . . . . . . . . . . . . .. 2.1 PRODUCT INFORMATION ..122.2 CURRENTLY AVAILABLE TREATMENT FOR INDICATIONS ..122.3 AVAILABILITY OF PROPOSED ACTIVE INGREDIENT IN THE UNITED STATES ..122.4 IMPORTANT ISSUES WITH PHARMACOLOGICALLY RELATED PRODUCTS .. I2 .2.5 PRESUBMISSION REGULATORY ACTIVITY ..13 3 SIGNIFICANT FINDINGS FROM OTHER REVIEW DISCIPLINES .. ..133.1 CMC (AND PRODUCT MICROBIOLOGY, IF APPLICABLE) ..I33.2 ANIMAL ..134 DATA SOURCES, REVIEW STRATEGY, AND DATA INTEGRITY ..144.1 SOURCES OF CLINICAL DATA .. 144.2 TABLES OF CLINICAL STUDIES ..144.3 REVIEW STRATEGY ..144.4 DATA QUALITY AND INTEGRITY ..224.5 COMPLIANCE WITH GOOD CLINICAL PRACTICES ..224.6 FINANCIAL DISCLOSURES ..225 CLINICAL PHARMACOLOGY ..226 INTEGRATED REVIEW OF EFFICACY ..237 INTEGRATED REVIEW OF SAFETY ..237.1 METHODS AND FINDINGS "237.1.1 Deaths ..237.1.2 Other Serious Adverse Events ..267.1.3 Dropouts and Other Signi?cant Adverse Events ..357.1.4 Other Search Strategies ..1457.1.5 Common Adverse Events ..1457.1.6 Less Common Adverse Events .. 1607.1.7 Laboratory Findings ..1617.1.8 Vital Signs ..1667.1.9 Electrocardiograms (ECGS) ..1697.1.10 Immunogenicity ..1717.1.1] Human Carcinogenicity ..1807.1.12 Special Safety Studies ..l847.1.13 Withdrawal Phenomena and/or Abuse Potential ..1847.1.14 Human Reproduction and Pregnancy Data ..184Page 2 of 249	294240	296275
219	1	2	16	1	196	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission O00 Victoza? (liraglutide injection)Results From the Statistical Analysis of Major Adverse Cardiovascular EventsThe analyses that Novo conducted produced 12 point estimates with associated 95% con?denceintervals (CI). These 12 point estimates were obtained from the combination of three MACEendpoints (FDA Custom, SMQ Broad and SMQ Narrow), two types of events (all treatment-emergent adverse events and serious TEAE), both analysis populations A and B, andone estimation method. The analyses that Dr. Derr conducted produced 8 point estimates with95% Cls. These 8 point estimates were obtained from a combination of two MACE endpoints(FDA Custom and SMQ Broad), one type of event (TEAE), both analysis populations A and B,and two estimation methods.As these are presented, there are three important values to keep in mind. The point estimate ofthe risk for liraglutide versus comparator will be considered. Also presented is how the upperbound of the 95% con?dence interval for that point estimate falls with respect to theaforementioned boundary of 1.8, which is the boundary above which the cardiovascular risk evaluation guidance states that further study of cardiovascular events would be needed prior toapproval. Also considered is how the upper bound of the 95% con?dence interval falls withrespect to 1.3. In the guidance, products that have values >1.3 and <1.8 could be considered forapproval, but would require postmarketing study to provide further reassurance of cardiovascularsafety.Liraglutide versus Total Comparator (Placebo and Active Controls)The stratified analyses that Dr. Derr and Novo conducted were based on 15 studies, because all15 studies had either a placebo arm,? an active comparator arm or both arms. Based on Novo?sanalyses, all 12 point estimates for the incidence ratio of LGT versus total comparator were <the estimated upper 95% Cl bounds were with 1 being This?ndingis consistent with the estimates calculated by FDA using two other estimation procedures(Tables 7.1.3.3.1.3.9, 7.1.3.3.1.3.10, 7.1.3.3.1.3.11 and 7.1.3.3.1.3.12 for FDA Custom Mace andSMQ broad MACE, all TEAE and analysis populations A and B). All 8 of the FDA pointestimates were 1.0 and all 8 estimated upper 95% CI bounds were 1.8, with 3 being 1.3.Results were similar for different endpoints, time period populations, event seriousnessgroupings, and statistical analysis methods. For this reason Dr. Derr concluded that the estimatesfor liraglutide versus total comparator were not very sensitive to the choice of estimationmethodology.The number of actual events for the liraglutide and pooled comparator groups is summarized inTable 7.1 .3.3.1.3.3. Of note is the small number of relevant events that occurred in the overalldevelopment program. For the FDA Custom MACE endpoint (all treatment-emergent events,Pop A), there were only 26 events, only 23 of which met the regulatory de?nition of a seriousadverse event. For the analysis with the most events (Broad SMQ MACE, all TEAE, Pop B),there were 114 events, of which 44 were serious adverse events (SAES).Page 54 of249	417835	420989
220	1	2	16	1	197	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission O00Victoza? (liraglutide injection)Liraglutide versus Placebo ControlThe cardiovascular risk guidance does not require that applicants meet the speci?ed boundariesfor subgroups. However, subgroups were examined, as an assessment of consistency of theresults for the overall comparison. When considering comparator subgroups (active control orplacebo), results for comparisons of liraglutide to placebo differed somewhat from those that hadbeen seen with comparisons of liraglutide to total comparator.The strati?ed analyses that Dr. Derr and Novo conducted were based on the 12 studies whichhad a placebo comparator group. Based on Novo?s analyses, 7 of the 12 point estimates for theincidence ratio of LGT versus placebo control were >1 .0. The upper 95% CI bound of all of the95% was >1.8 for all 12 estimates. Two of the 6 point estimates from time periodPopulation A exceeded 1.0; the Division considers time period Population A to be the primarytime period population of interest. Based on the FDA analysis, the upper 95% CI boundestimates were sensitive to the choice of estimation methodology, displaying a range from 1.25to 4.76, on both sides ofthe critical boundary of 1.8 (Tables 7.1.3.3.l.3.9, 7.l.3.3.l.3.l0,7.1 .3.3.1.3.l1 and 7.1 One estimate of the upper 95% CI bound was 3 werebetween 1.3 and 1.8, and 4 were >1 .8. Six of the 8 point estimates were The Agencybelieves that the sensitivity and the wide con?dence intervals are due in part to the low eventrates in the placebo arms (Tables 7.1 3.3.1 The number of actual events for the liraglutide and placebo control groups is summarized inTable 7.1.3.3.1.3.5. This summary illustrates that the event rates in placebo arms were low. Forexample, in analyses for the FDA Custom MACE endpoint, all TEAE, Pop A, there were only 3events in the combined placebo arms. In the analysis with the most placebo arm events (BroadSMQ, all TEAE, Pop B), there were only 13 events, of which only 3 were SAES.The reason why some point estimates were greater than 1 for subgroup analyses of liraglutideversus placebo is not clear. Because Dr. Derr and Novo conducted strati?ed analyses on the 12studies that had placebo groups, the clinical safety reviewer expects the distribution of baselinecardiovascular risk factors to be relatively similar among the randomized arms within each study.For this reason, the clinical safety reviewer does not expect an imbalance in baselinecardiovascular risk factors to contribute appreciably to an imbalance in the incidence of MACEevents between the liraglutide and placebo groups. As stated earlier, more placebo-treatedpatients were withdrawn from study for inadequate glycemic control and therefore, fewer ofthem may have been available to experience adverse cardiovascular events. The applicantconducted some analyses which took patient-year exposure into account, and these analyses hadsomewhat lower point estimated for liraglutide versus placebo (Tables 7.1.3.3.l.3.9-7.1.3.3.1.3.l2). Low event rates may have contributed to unstable point estimates.Liraglutide versus Active ControlThe strati?ed analyses that Dr. Derr and Novo conducted were based on the nine studies that hadan active control comparator. Based on Novo?s analyses, all 12 point estimates for the incidenceratio of LGT versus active control were <1 .0. All of the upper 95% CI bounds were <1 .8, withone being <1 .3. (Table 7.1 .3.3.l .3.6). The ?ndings from the FDA using two other estimationPage 55 of 249	420990	424532
222	1	2	16	1	199	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 2234] Submission 000Vietoza? (liraglutide injection)Table 7.1.3.3.1.3.3: Number of Major Adverse Cardiovascular Events for Liraglutideversus Pooled Comparator (Placebo Active Comparator)MACE Endpoint Type of Events Time PeriodPopulation1 LGT 4257Comp N=238lAgent FDA Broad Narrow All Serious Pop A Pop 0/0Custom SMQ i SMQ TEAE Only LGT LGTComp CompLGT 13 0.31Pooled 13 0.55Comp LGT 51 1.20Pooled 35 1.47CompLGT - 22 0.52Pooled 17 0.71CompLGT 11 0.26Pooled 12 0.50CompLGT 16 0.38Pooled 16 0.67CompLGT 15 0.35Pooled 16 0.67CompLGT 21 0.49Pooled 17 0.71Comp LGT 69 1.62Pooled 45 1.89CompLGT 35 0.82Pooled 24 1.01Comp 6LGT 17 0.40Pooled 15 0.63CompLGT 25 0.59Pooled 19 0.80CompLGT 24 0.56Pooled 19 0.80CompSource: Applicant?s Tables 16and 108, NDA 2234] subm stamp date 21 Jan 2009. Also, Applicant?sTables 29, 33, 37 and 111, 125, 139, and 153, subm stamp date 13 Feb 2009 (updated from 2] Jan 2009 submission with additionof one event to active control for Custom FDA endpoint)Abbreviations: CI con?dence interval, Pop time period population, SMQ Medical Dictionary for Regulatory Activities Standard Query, TEAE treatment-emergent adverse eventsPage 57 of249	426891	428101
223	1	2	16	1	200	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Table 7.1.3.3.1.3.4: Incidence Ratio, Liraglutide versus Placebo, Novo Strati?edCMH AnalysisMACE Endpoint Type of Events PopPoint EstimateFDA Broad Narrow All Serious A (95% CI)Custom 9 SMQ SMQ TEAE Only0.80 (0.23, 2.83)1.04 (0.50, 2.16)1.06 (0.37, 3.02)- 0.94 (0.19, 4.58)0.90 (0.25, 3.22)0.90 (0.25, 3.22)0.92 (0.30, 2.83)1.02 (0.54, 1.92)1.11 (0.45, 2.74)1.32 (0.28, 6.20)1.33 (0.38, 4.60)1.33 (0.38, 4.60)Source: Applicant?s Tables 16and 108, NDA 22341 subm stamp date 21 Jan 2009Abbreviations: CI con?dence interval, Pop time period population, SMQ Medical Dictionary for Regulatory Activities Standard Query, TEAE treatment-emergent adverse events; CMH Cochran Mantel-HaenszelPage 58 of 249	428102	428904
224	1	2	16	1	201	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 7.1.3.3.l.3.5: Number of Major Adverse Cardiovascular Events for Liraglutideversus PlaceboMACE Endpoint Type of Events Time PeriodPopulationLGT PBO Agent FDA Broad Narrow All? Serious Pop A Pop Custom SMQ SMQ TEAE Only LGT LGTPBO PBOLGT 13 0.31PBO 3 0.33LGT 51 1.20PBO 9 0.99LGT 22 0.52PBO 4 0.44LGT 11 0.26PBO 2 . 0.22LGT 16 0.38PBO 3 0.33LGT 15 0.35PBO 3 0.33LGT 21 0.49PBO 4 0.44LGT 69 1.62PBO 13 1.43LGT 35 0.82PBO 6 0.66LGT 17 0.40PBO 2 0.22LGT 25 0.593 0.33LGT 24 0.56PBO 3 0.33Source: Applicant?s Tables 16and 108, NDA 22341 subm stamp date 21 Jan 2009Abbreviations: CI con?dence interval, Pop time period population, SMQ Medical Dictionary for Regulatory Activities Standard Query, TEAE treatment-emergent adverse eventsPage 59 of249	428905	429758
225	1	2	16	1	202	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 7.1.3.3.l.3.6: Incidence Ratio, Liraglutide versus Active Comparator, NovoStrati?ed CMH AnalysisMACE Endpoint Type of Events PopPoint EstimateFDA Broad Narrow All Serious A (95% CI)Custom SMQ SMQ TEAE Only 0.68 (0.28, 1.66)0.82 (0.51, 1.32)0.79 (0.37; 1.69)0.63 (0.26, 1.57)0.61 (0.27, 1.38)0.57 (0.25, 1.30)0.76 (0.36, 1.61)0.35 (0.55, 1.29)0.32 (0.44, 1.52)0.68 (0.32, 1.47)0.74 (0.37, 1.47)0.70 (0.35, 1.41)Source: Applicant?s Tables 16and 108, NDA 22341 subm stamp date 21 Jan 2009. Also, Applicant?sTables 29, 33, 37 and 41; 111, 125, 139, and 153, subm stamp date 13 Feb 2009 (updated from 21 Jan 2009 submission with additionof one event to active control for Custom FDA endpoint)Abbreviations: CI con?dence interval, Pop time period population, SMQ Medical Dictionary for Regulatory Activities Standard Query, TEAE treatment-emergent adverse events; CMH Cochran Mantel-HaenszelPage 60 of 249	429759	430770
226	1	2	16	1	203	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Table 7.1.3.3.1.3.7: Number of Events for Liraglutide versus Active ComparatorMACE Endpoint Type of Events Time PeriodPopulationLGT 4257AC Agent FDA Broad Narrow All Serious Pop A Pop Custom SMQ SMQ TEAE Only LGT LGTAC ACLGT 13 0.31AC 10 0.68LGT 51 1.20AC 26 1.76LGT 22 0.52AC 13 0.88LGT 11 0.26AC 10 0.68LGT 16 0.38AC 13 0.88LGT 15 0.35AC 13 0.88LGT 21 0.49AC 13 0.88LGT 69 1.62AC 32 2.17LGT 35 0.82AC 18 1.22LGT 17 0.40AC 13 0.88- LGT 25 0.59AC 16 1.09LGT 24 0.56AC 16 - 1.09Source: Applicant?s Tables 16and 108, NDA 22341 subm stamp date 21 Jan 2009. Also, Applicant?sTables 29, 33, 37 and 41; 111, 125, 139, and 153, subm stamp date 13 Feb 2009 (updated from 21 Jan 2009 submission with additionof one event to active control for Custom FDA endpoint)Abbreviations: CI con?dence interval, Pop time period population, SMQ Medical Dictionary for Regulatory Activities Standard Query, TEAE treatment-emergent adverse eventsAs evidenced by the above tables of event numbers, the number of events included in an analysiscould be quite different, depending on the analysis scenario. The following table displays a fewexamples of analysis scenarios and the numbers of events included in those analyses, with anexplanation for the decrease in number of events from scenario to scenario. This table helps toillustrate the major factors which resulted in very few events for certain analysis scenarios, andin more (but less speci?c) events, in other scenarios.Page 61 of 249	430771	432344
228	1	2	16	1	205	Clinicai Safety ReviewKaren Murry Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)nonserious events didn?t change the numbers for liraglutide group events much for the FDACustom endpoint, going from 13 to 11. This is because the FDA Custom endpoint didn?t includeCPK events, as well as some other mostly nonserious event terms. The primary message of thistable is that event numbers were low, especially when one tried to include the most clinicallyrelevant events, and the most interpretable time period. Low event rates presented a challenge tothe review of major cardiovascular events for liraglutide.APPEARS nus amON omssamPage 63 of 249	435073	435738
229	1	2	16	1	206	$85 3 om?Qwm. 3. was man. E. on 859": mEu>m Ema 5:5 .8 mobs cozoutou b_=EEou 53> .umE>oE Eo? Hmmzoo Ema .5 .3 uu?sncoo ?moo;_2mE:mm cm oE>oE 8: En SS3 ..2Emn_EoU un::_mE? nm?u?m mmobm b_ucumoEo_._ Sm :30 .5 .3 B?sucoo ummhmF.o nu mvu?m?? BREE uE?_mE5 ?mania mmohom bB:umoEo~_ Em Fan .5 .3 u?osucou E2 .952 .3 cuwusucoo .255 E. .8285: Ho: 03 3.23.. A2 u_n_mr_. .m H.523 ou:oEuE can mm vu?om m8:2ot_n ouE>oE 952 u_n_m,w van m_ .m doom: 5 :o:mE.o.HE So H3232 <nE 9 om:on_mE uo:_En:m .952.$0 93 . 2 2 85858 .8085 .2, =c.:um.Eek uE..2wE5:3 53 .88 mod is 5 ?.mN GEN .23 who 2 .8 on_8mE uos?m??muuaxm ?Beam ?mm.@uh.m.:2 name :5 :3 .39 who 2 .8 oES_wm.9eo< .2, %:2me3QQN name who ?.mN 32 .33 om.o 3 .8 885 2: 3:95 2: :83 2.3.:23 5.3 an 5:5 mabazwmo:.3& E9: airman EPC 2: coE:3B m.:n.E .3 6065-33 mumso .3 mozu_x.mm.o .x.wo.o .8m._3EoO . onuomi_.nmv .<02mU<m .92 E33. beam 	435739	436602
230	1	2	16	1	207	3&0 8 OMS33$ 2: @353 8: mm?, _onE?m2: can :o_m_oo.E B2 :23 m?m?umo can m?w?m o?om .?o:mtm> om5>E. 23 Ems? 2: 8 Bmco?omoa m_ _onE?m 2: 05 3.5REL mcwo 2: mo uou?sa?oo 2.: 29: 5% 953 3:52 um_oo.a 89: 5:5 momu?m .mE._m Eon 5563:05 O.5N 5:5 mumzdm 8 33% m.o+ mo sosoutoo b?cucoo 53> _oNm:owE-EEmE Boob?. comm ?ocunbmof Eob Bw?umo _uu:EEoo 2: how. was Exam some Em oocowmcoo $3 was mwwo of SE2. 303 BELSo .32 mU<m .n=2 .mu=o__m_2 >6_>oM _mu_E_U	436603	437040
231	1	2	16	1	208	e& 8 ow?45m u?zsn. an 5u.:mama Lm.  3% 2.,  mama. Em   3  giw $w2.W mam ms 3 Amma $mwmmzmm%a.mll31.-of Ga mo=_n>   m_mbn:< E330  wO_n~ ?munch  ncocuub: @mNEu_>O8 coaua?m .n:2 Begum botwm 	437041	437227
232	1	2	16	1	209	9A om?mo_.5oEo_.m <nE stun "uu.:Sw mmE? ._m_mm$3-9 S?w.x ma ?m.3 $.39 mam: E?ma 1 3 $9.3 Ewwmmm Egdg _.mma 3 $.39 mm?m1. 3 mwma  EmJIM.I3 Em: - we wmagg mg 3% mag ?m_vwmm %u?wT.3  2: OH nos?smom cotom  Eumnom?E330  Sm wO?n# amoaom  o..=wEAmazon? 80 =o_wm_s5=m _vmNm <02.m_U<m E52 =u:wv_boumm _muE:U	437228	437525
233	1	2	16	1	210	380 mm<Q.m _ou.=Sw$2 $5 ?9 mm 3 ?39 mama Q8 54. no $2 mmam gag E_tw.. we . A 35% Em: E?wmwma wm?wma ?gwa 3.5mo:_n> aos?smom Each m:m.5> E330 $mmomm3% mam Sm mm?w?3 mma ?g 55"Es. ?3 Em rm:23 m_mba:<35 coo _a_a_aa_m _vm~.N <02mU<n_ ?020.32 >5_>om 	437526	437770
234	1	2	16	1	211	oi uw?Gm. H.m.m. 2. was E. H.m.m. mE:m_n: 3:03 55> mE._m Sm m.o..E cocootoo b:.:E:oo 5:5 .8255 Eo? SE3 3 nuwusvcoo .2mEnmo cm uE>oE Hoe Eu 22.8%. Emxo ..mmndua ..BEmaEoo =38. 25:32: $28 b$:omoEo; Eu. Eco .5 3 n?osuzoo mm?oua .?EmaEoU E8. uEE_mE_u_ mm um ..wnm.oua oaoom? o_u::_mE3 Hmeu?m mmobm b6comoEo.._ .8 Son .5 cowosncoo ..E2 .962 u?onucoo Ema. 933 25 uutome 8: Eu 2.32 $4 235. .m x_E_2a$ i E322 8:022: can z\\mEm>u 8522: mm 838 moucubet? 962 En?. E3 .m x:EunE< doom: 5 .8 Susan? <nE omsoamo. .o>oZ_?e&Eoo E8. .3 253.808.: uz?me??aeuumteu a ~33muumxkm weak                 E: .38 2.: .38 .8 ._oE._mmEoU ?Bob .33 $2 .38 is $9.2 92.. $3.8 E: 2 mo on_oomE un::_wESmuck.?EmaEoU EBB .23882m ?533.35EuouwEsoaw 3: 2: ?:95 um?:3:95 5? ?ns .35 23.253:253 m_mm_::m Eat EPG m?gt 2: _3u=_8B woman Smwxauhw Sam $.21 mm m._oE.amEoU 2083@520. . . ya?   .  2.5??S9u_>So m_U<m .92 =o._mM333. boxy, _moE=U	437771	438661
235	1	2	16	1	212	$Qwaw A . m-_m giw E. ?m.mW .Em:.mmmam E?wmy 3 :m mmgwas Mmm_mE{wma mamm- - 3 3% EE 35 . .. QMma$$.mW _Em_.m. I no $.33 can 3% Em an ?Sam:4 mo to. 2: 3 mo:_n> :23 2:5. m=m.8> 9% 33.5 3.. SE .8.5.m 4.3.m.m.E 2:5.uo__nEm b_::_Eoo ?rs no?o? m?mzss Prom gm .8 Qh?umo :Eo>o. 2: Sm was 5.5: m_m>SE_ oocovmsoo Qomm was m?m?umo Eon Ow/Mm wmohm 2: Eu 303 22.?mn9o_>So ._oE_Ee_m <02.92 E32 :uEv___5um>oM b?mm 	438662	439060
236	1	2	16	1	213	3.80 om?mu_hoEo_m 45h ou_=E. an ?uu.:Sm mm  . - mm,  mm awa?w%mm@.m Qm-  mama Em a  935 Re a  _?m?mL mm? 3  mwm_Tma?a Qua mm.:.?Li?Gin .3  2: Ce me=_a> m_mba:< ?Aw cotum  ..~otw.EmEoU 9:54 cnoum umouom  So S_m_E_=m GEN mU<n_ b::2 2033. bwam 	439061	439301
237	1	2	16	1	214	 Q. emfan  .mmw_mmm; mag war; A mm $3 mama -  3&3 [mama mm? wwa S. 33mg ?m.m am?m Emwmma ?gm. 3 E. _m.m?m Em  mwma mm? ?m-wv mmam 3g?..mhLm ?n 3% mam 3% mm; mmimNd 3.4, 3.3.3 m_.mE'35!=4 .3 :2 of 3 mo:_a> :23 m_mbm=< socmzaom cotom .35. Guam cmoum SE Bogom ?2.85 ?S9u_>O8 3mm <02mU<.m .92 beam 	439302	439595
238	1	2	16	1	215	$20 OWERem. can H.m.m. 5.. Km. m?zmrc 3:03 mU<? 5:5 2:3 Em m.o%o couootoo 5:5 .woE>o.a 32? :28 Eon u?unucou mum? .BmEmmo ca ov_>oE DLSUDUOMQ SS8 oomdnq ..oE._muEoU Hmau?m mmobm b_u:uwoEo: SM mo3m>-n_ PEG .5 uu?sucoo cs zbumv??m co cuE_:o__8 on 8: 2:8 muzu?m mmosm b_u5moEo; 8.. 38.. 2: can .5 nu?sucoo ..E2 .962 nebsncoo .038 votoamz Ea 0.3 3.53.? .m x:u:2ES hm 8.325 uucou?? can z\\mEo>o oo:oE..E_ ma Baum B255 962 93.3? new mm v32. .m x_u:ona< doom: 5 .8 $0392 <Qm 8 umcoamu. nB:En:m .962.EEG GNU V: .um_u.aa NOV: 32: M20 36% 2.: mama.8EmmEoU Eorw $8085 .2, \\E.=umhao 2 Sr: .E3 u..Gm;.Q.m umpwx 3? Sn.? .228 .3 $3 8.0 3 Q8 ._8EmmEoU ,x.mTo 35 T38 end So N. .x.w885 .2, mucus K938 .38 Sue $.32 $2 and 2 we a .889Eo< :3 3mm 6N8 8.0 gm: aw.? 6&8 mac 9 ,3 0 8353 Ezouw 2: 3:95 2: :55 3.3.E53 9 a 5? m__a__2amuzw?mv m_mb::s Eoh mo?kt airman M95: of cuu=_3B .3 uu_::8B $23 no wozzam me 31 id 2 mm m._o..S.mmEoU mw? 5? 2 ME: 3.3 S?.aqEoU . .3 2% Bo oguomiom.? _m mam SQ oEamm.?ouuo_.E So .32 <02mU<m .92 ESE =uEv_Barron buanm 	439596	440615
26	1	2	16	1	3	Summary of Specified Upward Shifts in Calcitonin Phase 3 DiabetesTrials, Two Phase 2 Japanese Diabetes Trials, Preliminary Data from DiabetesTreatment Trial vs Exenatide, and Preliminary Data from Phase 2 Obesity TrialLGT1Rate per 1000 PY of patients with shift from below 0 1.7 3.4 3.5the upper limit of normal to persistently? abovethe upper limit of normal, from baseline to Week1044 (all voluntary unblinded extension data)3.0Percentage of patients who shifted from below the0.7 A 0.6 1.7 0.8 0.8upper limit of normal to persistently above theupper limit of normal, all post?baselineobservations 0.8Percentage of patients who began with serum 0.2 0.1 0.5 0.1 0.4calcitonin <20 ng/L and who shifted to a serumcalcitonin 2 20 ng/L at Week 20/24/26/280.3Rate per 1000 PY of patients who began with 3.9 2.3serum calcitonin <20 ng/L and who shifted to aserum calcitonin 20 ng/L at Week 20/24/26/2812.4 3.4 4.74.3Percentage of patients who began with serum 0.4 0.6 0.3calcitonin <20 ng/L and who shifted to a serumcalcitonin 2 20 ng/L at Week 52 (voluntaryunblinded extension data included)0.2Rate per 1000 PY of patients who began with 3.8 7.1 3.6serum calcitonin <20 ng/L and who shifted to aserum calcitonin 2 20 ng/L at Week 52 (voluntaryunblinded extension data included)2.7Percentage of patients who began with serum 0.5 0.3calcitonin <20 ng/L and who shifted to a serumcalcitonin 2 20 ng/L at Week 104 (all voluntaryunblinded extension data)0.3Rate per 1000 PY of patients who began with 3.1 1.8serum calcitonin <20 ng/L and who shifted to aserum calcitonin 2 20 ng/L at Week 104 (all1.5voluntary unblinded extension data)Percentage of patients who began with serum 0.5 0.6 1.1 0.3 0.5calcitonin <20 ng/L and who shifted to a serumcalcitonin 2 20 ng/L, all post?baseline observations0.4	2336	4126
29	1	2	16	1	6	H/3/orConsult, NDA 22341, Liraglutide, Novo Nordisk, 11/3/09DIVISION OF PULMONARY AND ALLERGY PRODUCTSMEDICAL OFFICER CONSULTATIONDate: November 3, 2009To: 0 John Bishai, Regulatory Project Manager, Division of Metabolic andEndocrine Products (DMEP)From: Brian Oscar Porter, M.D., M.P.H., Medical ReviewerThrough: Susan Limb, M.D., Medical Team LeaderThrough: Badrul Chowdhury, M.D., Division DirectorSubject: Anti-drug antibody formation to liraglutideGeneral InformationNDA 22341Sponsor: Novo NordiskDrug Product: Liraglutide (Victoza?)Request From: John Bishai, Regulatory Project Manager, DMEPDate of Request: October 28, 2009Date Received: October 29, 2009Date Due: ASAPMaterials Primary review of NDA 22341 by Clinical Review team; sections ofReviewed: NDA 22341 related to immunogenicity of drug productExecutive SummagThis is a Medical Officer Consultation Review requested by the Division of Metabolic andEndocrine Products (DMEP) from the Division of Pulmonary and Allergy Products (DPAP) forthe drug liraglutide (N DA 22341). Liraglutide is an analogue of the glucose-dependent insulinsecretagogue human glucagon-like-peptide-1 (GLP-1), which is engineered to resist degradationby endogenous peptidases and thus contribute to long-term glycemic control with a decreased risk of hypoglycemia. The NDA was submitted on May 23, 2008. The proposed indication is asan adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetesmellitus. The target age group is adults aged 18 years and older.In pooled Phase clinical trials, nearly 10% of liraglutide recipients formed anti-drugantibodies (ADA), of which ~50% cross-reacted with native and ~10% demonstratedneutralizing activity in a cell-based assay. Although an ef?cacy analysis of the treatment effectof ADA formation, . cross?reactivity, and the presence of neutralizing ADA onglycosylated hemoglobin levels demonstrated no statistical impact of these factors on long-termglycemiccontrol, the assay used to detect liraglutide-speci?c ADA is directly inhibited by thedrug product itself. Although immunogenicity samples were drawn 25 days following last studydrug administration, sampling was not done uniformly for all subjects in the Phase 	7660	9890
37	1	2	16	1	14	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Table of Contents -1 EXECUTIVE SUMMARY 51.1 RECOMMENDATION ON REGULATORY ACTION ..51.2 RECOMMENDATION ON POSTMARKETING ACTIONS ..51.2.1 Risk Management Activity ..51.2.2 Required Phase 4 Commitments ..51.2.3 Other Phase 4 Requests ..61.3 SUMMARY OF CLINICAL FINDINGS ..61.3.1 Brief Overview of Clinical Program ..61.3.2 Ef?cacy ..61.3.3 Safety ..81.3.4 Dosing Regimen and Administration ..81.3.5 Drug-Drug Interactions ..91.3.6 Special Populations ..92 INTRODUCTION AND BACKGROUND PRODUCT INFORMATION ..102.2 CURRENTLY AVAILABLE TREATMENT FOR INDICATIONS ..1 12.3 AVAILABILITY OF PROPOSED ACTIVE INGREDIENT IN THE UNITED STATES .. I42.4 IMPORTANT ISSUES WITH PHARMACOLOGICALLY RELATED PRODUCTS .. 142.5 PRESUBMISSION REGULATORY ACTIVITY ..142.6 OTHER RELEVANT BACKGROUND INFORMATION .. 163 SIGNIFICANT FINDINGS FROM OTHER REVIEW DISCIPLINES 173.1 CMC (AND PRODUCT MICROBIOLOGY, IF APPLICABLE) ..173.2 ANIMAL ..174 DATA SOURCES, REVIEW STRATEGY, AND DATA INTEGRITY 174.1 SOURCES OF CLINICAL DATA .. 174.2 TABLES OF CLINICAL STUDIES ..184.3 REVIEW STRATEGY ..254.4 DATA QUALITY AND INTEGRITY ..254.5 COMPLIANCE WITH GOOD CLINICAL PRACTICES ..264.6 FINANCIAL DISCLOSURES ..265 CLINICAL PHARMACOLOGY  275.1 PHARMACOKINETICS .. ..275.2 PHARMACODYNAMICS ..315.3 EXPOSURE-RESPONSE RELATIONSHIPS ..316 INTEGRATED REVIEW OF EFFICACY 326.1 INDICATION ..326.1.1 Methods ..336.1.2 General Discussion of Endpoints ..346.1.3 Study Design ..4O6.1.4 Ef?cacy Findings ..566.1.5 Clinical Microbiology ..1216.1.6 Efficacy Conclusions ..1217 INTEGRATED REVIEW OF SAFETY 1217 .1 METHODS AND FINDINGS BOOKMARK NOT DEFINED.	23596	25279
43	1	2	16	1	20	Clinical ReviewLisa Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)that would in?uence ef?cacy conclusions. Limitations of the development program arediscussed in section 6.1.4.5.There is a need for new antidiabetic drugs. There are now over 23 million patients diagnosed inthe U.S. alone and over 170 million worldwide with more than 1.5 million new cases per year.~Diabetes has a devastating impact on patients from diabetic microvascular complicationsincluding blindness, amputation, and the need for dialysis, as well as from cardiovasculardisease. A vast number of diabetic patients do not reach glycemic targets due to limitations ofcurrent therapies. Furthermore, since diabetes is a chronic, progressive disease, there is usuallythe need for additional treatments to be added to the patients? regimens over time. The results of the major clinical ef?cacy trials show that liraglutide has a clinically importanteffect on HbA1c compared to placebo and should be considered a useful addition to the diabeticdrug armamentarium. Comparison studies with liraglutide and other anti-diabetic drugs thatwere conducted as part of the liraglutide development program suggest that liraglutide is at leastas effective and in some cases, superior to, some other commonly used anti-diabetic drugs.1.3.3 SafetySee Dr. Mahoney?s safety review1.3.4 Dosing Regimen and AdministrationThe applicant?s proposed dosing regimen is as follows: For all patients liraglutide treatmentshould be initiated with a dose of 0.6 mg for at least one week, after which the dose should beincreased to 1.2 mg. Based on tolerability and/or clinical response and after at least one week at1.2 mg, the dose can be increased to 1.8 mg to achieve maximum ef?cacy. This reviewer agreeswith the Sponsor?s proposal on the basis of evidence of ef?cacy provided in the phase 3program. However, an alternative dosing regimen may be acceptable as described in the nextparagraph.The recommendation for approval for the Sponsor?s proposed dosing regimen is based on reviewof efficacy only. However, if the overall risk bene?t analysis shows a signi?cant safety concernfor the highest tested dose of liraglutide (1.8 mg daily), this reviewer concludes that the nexthighest tested dose of liraglutide (1.2 mg daily) has also shown substantial evidence ofeffectiveness from four phase 3 trials (four of the ?ve trials mentioned above tested the 1.2 mgdose) that, as stated above, are considered by this reviewer to be ?adequate and well-controlled?and would, in the situation of a safety concern for the 1.8 mg dose, recommend approval of amodi?ed dosing regimen with a maximal approved dose of liraglutide of 1.2 mg daily.	35994	38684
49	1	2	16	1	26	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)2.3 Availability of Proposed Active Ingredient in the United StatesLiraglutide is not currently marketed in the UnitedeStates.2.4 - Important Issues with Pharmacologically Related ProductsLiraglutide is a member of the analogue class of antidiabetic therapies. Exenatide (marketed asByetta?) is the only FDA approved member of this class. Effectiveness concerns regarding Byetta havestemmed from immunogenicity patients who develop high titer antibodies to Byetta) with evidenceof reduced effectiveness in about half of patients with high titer antibodies. However, the developmentof high titer antibodies is relatively rare (Byetta prescribing information). With liraglutide, antibodygeneration has been 15% in completed trials over 26 weeks, with no apparent attenuation of glycemiccontrol in patients with high antibody titers. For a discussion of safety concerns that have arisen in thisclass see Dr. Mahoney?s safety review.2.5 Presubmission Regulatory ActivityThis section summarizes important presubmission activities including major milestone interactions withthe applicant and agreements made at each one focusing on clinical topics. 2.5.1 End-of?phase 2 meeting (face to face," 4 May 04)Proposed Phase 3 Study Design and Indication discussion:Discussion of DesignThe Division agreed that the proposed trials and trial designs are adequate to support the indication ofadjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus, andthat the" comparator doses and the potential adjustment downwards are acceptable to support the abovementioned indication. The Division considered the statistical plan acceptable.EndpointsPrimary endpoints were agreed upon and were adhered to by the sponsor. The sponsor asked if theAgency agreed that the described approach of assessing the improvement in beta cell function supportsthe indication. The Division stated that response to this question is deferred until review of the NDAsubmission. The sponsor was informed that considerationwould be given based on submitted data,strength of the evidence, and the appropriateness of the endpoints as surrogates for delayed progressionof type 2 diabetes. (l7	46939	49209
51	1	2	16	1	28	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)EfficacyThe statistical analysis plan for efficacy was discussed and agreed upon at this meeting. The sponsorcomplied with the recommendations/plans in this NDA submission. SafetyDiscussion also focused on the strategy of safety evaluation for liraglutide. The sponsor generallycomplied with all FDA requests and, per Dr. Mahoney, any information requested by the safety reviewerwas provided in a timely fashion. -Risk management planThe topic of a risk management plan was raised. No formal agreements were reached at this pre-NDAmeeting. It was deemed too early to determine whether the proposed program was acceptable. TheSponsor was encouraged to engage in further discussions with FDA about the nature of the risks and thepotential need for a Risk Minimization Action Plan if they believed that there were productrisks that merit more than conventional professional product labeling package insert (P1) or patientpackage insert and postmarketin surveillance to manage risks.DeviceThe Sponsor was encouraged to submit the proposed device (a working model of the same pre?f1lled penwhich was used in the clinical trials) and all associated packaging, any usability studies performed onthe pre-filled pen, the proprietary name and all associated labels and labeling for review as soon asavailable.Pediatric studies -The status of pediatric investigation was discussed. At the End of Phase 2 Meeting, May 4, 2004, the Division agreed to the sponsor?s plan to seek a waiver for subjects below -ryears and a deferral forolder children. The sponsor reported plans to conduct a trial inpediatric patients with type 2 diabetes including children of age 10 years and older. The Agency did notimmediately agree with this plan but rather asked the sponsor to submit the proposal and all referencesto support the proposal and it would be reviewed. The sponsor outlined the proposed pediatric trial and were informed that the study design as proposed, wouldnot satisfy the requirement for pediatric assessment under the Pediatric Research Equity Act (PREA)because it would not adequately address the ef?cacy and safety of liraglutide in pediatric subjects, norwould this proposal be sufficient to obtain pediatric exclusivity under the Best Pharmaceuticalsfor Children Act (BPCA).2.6 Other Relevant Background InformationRegulatory actions in other countriesLiraglutide was approved by the European Medicines Agency (EMEA) on 30 Jun 09.16	52306	54818
52	1	2	16	1	29	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Per the EMEA website Victoza is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycemic control:In combination with:- Metformin or a sulfonylurea, in patients with insuf?cient glycemic control despite maximal tolerateddose of monotherapy with metformin or sulfonylurea.In combination with:- Metformin and a sulfonylurea or metformin and a thiazolidinedione in patients with insufficientglycemic control despite dual therapy.3 SIGNIFICANT FINDINGS FROM OTHER REVIEW DISCIPLINES3.1 CMC (and Product Microbiology, if Applicable)See Dr. Mahoney?s safety review.3.2 Animal Pharmacology/ToxicologySee Dr. Mahoney?s safety review.4 DATA SOURCES, REVIEW STRATEGY, AND DATA INTEGRITY4.1 Sources of Clinical DataClinical data used in this review are derived solely from studies performed by the Sponsor or designatedcontract organizations.Clinical studies that were completed (total of 38) and for which reports were submitted at the time ofNDA submission are summarized in tables in section 4.2. These include the extension phases of two ofthe phase 3 trials since data as of a cutoff date of 21 Feb 2008 were submitted to support long termsafety of liraglutide. However, these trials were still ongoing at the time of NDA submission and are notused to support efficacy claims. In sum, there are a total of 40 trials listed in the tables. Of the 40 trials,two trials investigated liraglutide delivered by alternative routes of administration; NN2211-1464(pulmonary administration) and NN9233-1898 (intranasal administration).The clinical pharmacology development program was designed to evaluate the pharmacokinetic andpharmacodynamic properties of liraglutide and included 26 clinical pharmacology trials. The five long-term pivotal phase 3 trials were randomized, double-blind, double-dummy (including liraglutide and/or17	54819	56745
56	1	2	16	1	33	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Single inhalation dose of Safety (counts1464 Bioavailability Randomized, Healthy volunteers 6, 12, and 24 pg/kg Single dose towards total(pulmonary) cross?over Single s.c. dose of 6 exposures)Hg/kg. Single intranasal dose of. . . . Randomized, Safety (counts1898 double-blind, Healthy :25? 5= am? 10 Single dose towards total(intranasal) 151-12 Single s.c. dose of 6pl acebo~controlled pg/kg exposures)Table 4.3. Drug Interaction Studies in Healthy Volunteers"Study . . . Study Treatment, Route, Duration ofNumber Oblectwes Study Design Population Regimen, Dosage Therapy RelevanceEthiny]- Randomized, Healthy post- Once daily s.c. doses of 1.8estradiol and double-blind, menopausal mg liraglutide. Single p.o. 3 week and Drug 1330 levonorgestrel placebo? women dose of 0.03 mg Sin '6 dose interaction Safetyinteraction controlled, ethinylestradiol plus 0.15 study cross?over mg levonorgestrel. Liraglutidez Once daily s.c.Atorvastatin doses of 1.8 mglisinopril ]aCebO_ Healthy Part A: Single p.o. doses ofriseofulvin volunteers 40 mg atorvastatin and 20 4 weeks and Drug drug81608 . . controlled, twoand digoxin way in Part A and mg lisinopril single dose interaction sa etyinteraction trial in two parts in Part Part B: Single p.o. doses ofstudy 500 mg griseofulvin and I(A and . . .digoxind, . . .Paracetamol Liraglutide: Once daily s.c.1698 interaction ]aceb0_ Type 2 diabetics doses of 1.8 mg 3 weeks Drug drugN=l8 Paracetamol: Single p.o. interaction safetystudy controlled, -cross-over dose 1 APPEARS ?#118 Will?Oil ORIGINAL21	62943	64559
61	1	2	16	1	38	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)noted. No under?reporting of adverse events was detected. The DSI inspector concluded that the studyappears to have been conducted adequately, and the data generated by this site appear acceptable insupport of the respective indication.?v wasselected because reported disclosable ?nancial information (see section 4.6 Financial Disclosures). At this site, subjects were screened, subjects were enrolled, and subjects completed the study. There were rr subjects on placebodiscontinued due to lack of efficacy. An audit of 10 subjects? records was conducted. No regulatoryviolations were noted. No under-reporting of adverse events was detected. The DSI inspector concludedthat the study appears to have been conducted adequately, and the data generated by this site appearacceptable in support of the respective indication. 4.5 Compliance with Good Clinical PracticesThe clinical studies were conducted in accordance with ethical standards including informed consentfrom all subjects.All attempts were made to adhere to protocol guidelines. Furthermore, an individual subject?scompliance to the protocol was scrutinized prior to database release and subjects with violations to theprotocol that were considered to affect the efficacy assessments were excluded from the ?per protocol?analysis sets (see section 6). Analyses using per protocol sets were used to support the primary intentionto treat analyses. Reasons for being excluded from the per protocol analysis set included not having anevaluable HbA1c at the ?nal study visit, not meeting all inclusion criteria, or meeting exclusion criteria,not meeting randomization criteria, or subjects with HbA1c values taken at baseline more than threedays apart from the date of the first dose of study medication, among others. For the primary efficacyendpoint in all 5 pivotal phase 3 studies, the per protocol analyses supported the primary intention totreat analyses. Speci?c protocol violations and study design procedural deviations are discussed withinthe context of each trial design (section 6).4.6 Financial DisclosuresMost, but not all investigators who enrolled subjects in phase 2/3 studies submitted ?nancial disclosureforms. None of the clinical investigators were direct employees of NovoNordisk. Any de?ciencies ordisclosable information are discussed in the following paragraphs.Several investigators for the phase 2 study from . didnot submit ?nancial disclosure forms and these investigators enrolled a total of subjects. investigators from this study had some ?nancial disclosure to report. (enrolled bi?lsubjects) reported that NovoNordisk had recently given a grant of ?50,000 to the (enrolled subjects) disclosed that the with which af?liatedis supported by grants from NovoNordisk. Since the year 2000, -?-Mreports 2 million pounds in grantmoney given to this facility. (enrolled -subjects) disclosed two grants from 26	71376	74349
62	1	2	16	1	39	Clinical ReviewLisa B. Yanoff, M.D. NDA 22,341 (Submission 000)Victoza? (liraglutide)  NovoNordisk in the amount of ?25,000 each to i involved but that are unrelated to the current -application. Therefore, a total of out of a total of -- subjects in study were enrolled by investigators with a possible ?nancial con?ict ofinterest. Several investigators enrolling a total of subjects for the phase 2 study whichconsisted of -- randomized subjects in total, did not submit ?nancial disclosure informationappears that ?nancial disclosure information was often not obtained for this trial. Of the investigatorsthat did submit ?nancial information of them (enrolling subjects total) reported disclosableinformation, of which received grants and/or honoraria totaling over $100,000.These two phase 2 studies (o 2 - studies) were not pivotal in the evaluation of ef?cacy and safetyof liraglutide and therefore, have little impact on the overall conclusions of this review. investigators participating in phase 3 pivotal studies disclosed potential conflicts of interest:was a for two of the pivotal trials. He disclosed receivingover $25,000 in payments for 1 and over $50,000 for     He enrolled ?subjects in trial and/subjects in trial  (disclosed owning over 7,000 shares of Novo Nordisk stock valued at over$50,000) was a" ?.for two of the ?ve pivotal trials. He enrolled subjects intrial and /subjects in trial Any potential bias from these -- investigators will have minimal, if any, affect on liraglutide?s ef?cacyand safety conclusions, because the number of affected patients is a very small fraction of the totalnumber of patients in the phase 2/3 clinical development program, the studies were double-blinded and controlled, and the primary endpoint (HbA1c) was objective. Further, was inspected by theDivi_sion of Scienti?c Investigations and no irregularities were found (see section 4.4 Data Quality andIntegrity). 5 CLINICAL PHARMACOLOGYFor a full review of clinical pharmacology information relevant to this NDA the reader is referred toClinical Pharmacology Review by Dr. Manoj Khurana, Per the executive summary of Dr.Khurana?s review, the Of?ce of Clinical Pharmacology/Division of Clinical Pharmacology 2has reviewed the clinical pharmacology data submitted in support of NDA 22-341 forliraglutide and found it acceptable, pending an acceptable resolution of the de?ciencies found in theDivision of Scienti?c Investigation with regards to the bio-analytical method. According to Dr.Khurana these de?ciencies have been resolved at the time of this review and a memo documenting theresolution is forthcoming. Key ?ndings from Dr. Khurana?s review are summarized in sections 5.1, 5.2and 5.3 below.5.1 PharmacokineticsLiraglutide was studied in healthy subjects and T2DM patients to determine pharrnacokinetic properties.27	74350	77182
65	1	2	16	1	42	Clinical ReviewLisa B. Yanof? M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)AssThe effect of age on the pharmacokinetics of liraglutide was investigated in the single dose trial, Trial1327 and based on the population pharmacokinetics from Trial 1573. Liraglutide was declaredequivalent in young and elderly subjects after a single 1 mg dose. There was no effect of age on otherpharmacokinetic endpoints.Race/EthnicityThe impact of race and ethnicity on pharmacokinetics of liraglutide was investigated using thepopulation pharmacokinetic data from Trial 1573. Five racial groups (White, Asian, Black, Hawaiian,and ?Other?) and two ethnic categories (Hispanic and non-Hispanic) were investigated. In an analysis ofcovariance including body weight and gender, race and ethnicity were not significantly associated withpharmacokinetic variables.Renal and Hepatic Impairment The pharmacokinetics of a single s.c. dose of 0.75 mg liraglutide administered in the abdomen insubjects with renal impairment was evaluated in Trial 1329. Subjects with four different grades of renalimpairment (based on creatinine clearance estimated by the Cockcroft-Gault formula) were comparedagainst subjects with normal renal function. Overall on average, the of liraglutide was around19 - 35% 1 in the renally impaired subjects than the normal subjects. However, equivalence wasdemonstrated for maximum concentration (Crnax) a subjects with moderate renal impairment (creatinine .?clearance greater than 30 but less than or equal to 50 mL/minute). Total apparent clearance variedacross the renal groups; however, no trend with respect to renal function was seen.The pharmacokinetics of a single s.c. dose of 0.75 mg liraglutide injected in the thigh was evaluated insubjects with hepatic impairment in Trial 1328. Subjects with three different grades of hepaticimpairment (classi?ed according to the Child-Pugh scores) were compared against subjects with normalhepatic function. Severe hepatic impairment was found to have an impact on the liraglutidepharmacokinetics in terms of around a two?fold increase in clearance and 42% lower mean ofliraglutide. The reason for this ?nding is unknown, but could possibly be attributed to lower albuminlevels found in hepatic impairment, as a statistically significant positive relationship between albuminconcentration and liraglutide exposure was observed.No dose adjustment is proposed by either the sponsor or by Dr. Khurana, the clinical pharmacologyreviewer, for renal and hepatic impairment subjects.Pharmacokinetic effects of drug-drug interactionsPlease see Dr. Mahoney?s review for a discussion of drug-drug interactions.30	82600	85256
68	1	2	16	1	45	Clinical ReviewLisa B. Yanoff, M.D. .NDA 22,341 (Submission 000)Victoza? (liraglutide)The Sponsor is seeking approval for liraglutide as an adjunct to diet and exercise to achieve glycemiccontrol in patients with type 2 diabetes mellitus.The pivotal phase 3 studies in support of these indications are reviewed in sections 6.1.3.7(monotherapy), 6.1.3.8 (combination therapy with one oral antidiabetic drug and combinationtherapy with two OADS).6.1.1 MethodsThe primary clinical data used in the review of ef?cacy came from ?ve therapeutic con?rmatory trials which investigated the bene?ts of liraglutide as:0 monotherapy (Trial 1573)I combination with metformin (Trial 1572)0 combination with an SU (glimepiride) (Trial 1436)0 combination with a TZD (rosiglitazone) and metformin (Trial 1574)0 combination with an SU (glimepiride) and metformin (Trial 1697)Tables 6.1 and 6.2 summarize lirag1utide?s ef?cacy trials. Please also refer to section 4.2 Tables ofClinical Studies for details of the ef?cacy trials including study designs, dosages, and treatmentdurations. A total of 3978 patients were exposed to treatment in the therapeutic con?rmatory trials (2501to liraglutide, 524 to placebo, and 953 to an active comparator). In addition to the therapeuticcon?rmatory trials, six therapeutic exploratory trials (Trials 1571, 1310, 1333, 2072, 1499 and 1334(Japan)) provide some additional relevant ef?cacy data. These trials enrolled a total of 966 patients.Open-label extension studies (1572 extended to 18 months to a total of 2 years and 1573 extended to48 months for a total of 5 years) are not usedto support ef?cacy claims and therefore, not reviewed inthis section, but are used to support long-term safety and are discussed by Dr. Mahoney in her ClinicalSafety Review.Table 6.1Overview of Ef?cacy Data for LiraglutideSource of dataDetailsPhase 2 dose or regimenselection6 studies2 placebo-controlled dose ?nding trials (dose selection) (1571, 1310)Liraglutide vs. placebo for body weight reduction (1333)Active control (metformin) dose ?nding trial (2072)Individual dose titration W/add on to metformin (1499) 9Placebo-controlled dose ?nding Japanese trial (1334)Phase 3 con?rmatory trials5 studies1 monotherapy phase 3 trial (1573)2 add-on combination therapy with one OAD studies (1572, 1436)2 add-on combination therapy with two OADS studies (1574, 1697)33	89505	91872
214	1	2	16	1	191	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglulide injection)Table 7.l.3.3.1.2: Preferred Terms Included in Endpoints] Presented forEvaluation of Myocardial Infarction and Stroke for Liraglutide (All Terms Included inDatabase Queries, but Actual Events Did Not Occur for Every Term)?Broad Custom ?Narrow Prior ovoMACE MACE MACE2lntracerebral hematoma evacuationIntracranial aneurysmIntracranial hematomaIntraventricular hemorrhageIntraventricular hemorrhageneonatalIschemic cerebral infarctionIschemic strokeLacunar infarctionLateral medullary Meningorrhagia -Monoparesis -MonoplegiaMoyamoya diseaseParalysisParalysis ?accidParaparesisParaplegiaParesisPostprocedural strokePrecerebral artery occlusionPutamen hemorrhageQuadriparesisQuadriplegiaRed blood cells cerebrospinal?uid positiveReversible ischemic neurologicde?citRuptured cerebral aneurysmSpastic paralysisSpastic paraplegiaSpinal artery embolismSpinal cord hemorrhageSpinal epidural hemorrhageSpinal hematomaStroke in evolutionSubarachnoid hemorrhageSubarachnoid hemorrhageneonatalSubdural hemorrhageSubdural hemorrhage neonatalThalamic infarctionThalamus hemorrhageThrombotic cerebral infarctionThrombotic strokePage 49 of 249	403711	404943
70	1	2	16	1	47	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)Complications Trial (DCCT). Use of standardized methodology has reduced inter-laboratorycoefficients of variation to (College of American Pathologists 1999; Goldstein 1982).c) HbAlc has excellent reliability, predicts several diabetes-speci?c complications, and providesthe current basis for treatment decisions (American Diabetes Association 2008).d) Lowering HbAlc reduces microvascular complications in patients with type 1 and type 2diabetes (Diabetes Control and Complications Trial Research Group 1993, UK ProspectiveDiabetes Study (UKPDS) Group 1998) and possibly macrovascular complications in patientswith type 1 diabetes (Diabetes Control and Complications Trial/Epidemiology of DiabetesInterventions and Complications Study Research Group 2005).For these reasons, the FDA draft guidance entitled Guidance for Industry, Diabetes MellituszDeveloping Drugs and Therapeutic Biologics for Treatment and Preventionformation/Guidances/ucm071624.pdt) states, ?For purposes of drug approval and labeling, ?nal demonstration of ef?cacy should bebased on reduction in HbAlc HbAlc is the primary endpoint of choice, albeit a surrogate), whichwill support an indication of glycemic control.?The percentage of subjects who .reached the pre-de?ned target for HbAlc of and HbAlc of 6.5%was also examined. These are clinically appropriate endpoints becausee) The American Diabetes Association (ADA) currently recommends a target of roughly7% for non-pregnant adults in general with diabetes. Lowering HbAlc to an average of 7% hasbeen shown to reduce microvascular and possibly macrovascular complications of diabetes.Since pregnant subjects are excluded from these clinical trials, is an appropriate endpointfor these trials (ADA 2008).t) The AACE (American Association of Clinical Endocrinologists) recommended target for HbAlcis 6.5% HgA1c was measured by a National Glycohemoglobin Standardization Program certi?ed high-performance liquid chromatography assay at a central laboratory.6.1.2.2 Secondary Efficacy EndpointsSecondary ef?cacv endpoints includedBody weightOther measures of glycemic control (fasting plasma glucose, plasma glucose pro?les)Biomarkers of beta-cell functionFasting glucagonBlood pressureLipid pro?leCardiovascular effectsWaist and hip circumferencePatient-reported outcome35	93882	96262
72	1	2	16	1	49	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)obtained by the applicant, in. the label. The Division is in the process of considering whether PPGdata (even those obtained appropriately) should be included in labeling for diabetes productsbecause of concerns about inappropriate promotion about potential reduction in diabetescomplications, and because the relevance to physicians is unclear for medications that cannot betitrated based on PPG.Beta?cell function, insulin sensitivity, and fasting glucagon: measured by the central laboratory usingfasting insulin, fasting C-peptide, proinsulin to insulin ratio, HOMA-B and HOMA-IR with formulas asfollows:HOMA-B 20><fasting serum insulin plasma glucose (mmol/L) 3.5)HOMA-IR fasting serum insulin plasma glucose In trial 1573, an insulin-modi?ed frequently-sampled intravenous glucose tolerance test (FSIGT) wasdone for a subset of subjects at randomization and after 52 weeks of treatment.Reviewer?s comment: these are useful but non-validated measures of beta cell function and shouldnot be included in labeling.Blood pressure - As effects on blood pressure were observed in the Phase 2 exploratory trials, theevaluation methods used in the con?rmatory trials followed guidelines for evaluating effects of agentsused to treat blood pressure.Body composition was assessed in ?a subset of subjects (Trials 1573 and 1572) at randomization and endof trial using dual-energy x-ray absorptiometry (DXA). The DXA scans were analyzed centrally by aspecialist who was blinded with regard to treatments and the change in body composition from baselineto end of trial was calculated.Metabolic prevalence (NCEP criteria) meeting at least three of the following:Abdominal obesity (Waist Circumference)Men >102 cm (>40 in)Women >88 cm (>35 in)Triglycerides 2150 mg/dLHigh?density lipoprotein cholesterolMen <40 mg/dLWomen <50 mg/dLBlood pressure 2130/85 Fasting glucose 2110 mg/dLCardiovascular disease markers: (plasminogen activator inhibitor-l (PAl?l), N-terminal B-typenatriuretic peptide and highly sensitive C?reactive protein Reviewer?s comment: most of these are non-validated markers of CVD.Lipid pro?le (fasting)Free fatty acids (FFA)Low-density lipoprotein-cholesterol (LDL-C)37	98999	101261
74	1	2	16	1	51	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)                1.3 mg Iiragiutide(1) Superiority vs. placebo(2) Non-inferiority vs.active comparator                1.2 mg iiragtutide(1) Superiority vs. placebo(2) Non-inferiority vs.active comparator1.8 mg tiragiuticie(3) Superiority vs.active comparator                      0.6 mg iiragiuiide(1) Superiority vs. piacebo(2) Non-inferiority vs.active comparator1.2 mg iiragtutideSuperiority vs.active comparator       0.6 mg liraglutide .(3) Superiority vs.active comparator       An ANCOVA model similar to that described above was used for analyses of the key secondary ef?cacyvariable - body weight. The model included treatment, country, and previous antidiabetic treatment as?xed effects and baseline body weight as the covariate. The other secondary endpoints were analyzedfor the ITT analysis set using the same ANCOVA model as described above. For change in bodyweight, no claim was made unless the noninferiority claim could be made for change in HbA1c relativeto the placebo in each trial (or if no placebo the active comparator). Multiplicity correction was notapplied to the secondary endpoint analyses.Analysis of Treatment Effect-by-Factor InteractionBased on the primary analysis, a number of exploratory analyses were done to evaluate if observedtreatment effect was consistent across selected sub-populations. The analyses were done using thestandard ANCOVA, but with the addition of the respective baseline characteristic sex) and baselinecharacteristic by treatment interaction as ?xed effects. The following baseline characteristics wereevaluated: - Demographic differences between groups of subjectssex (female, male)age (<65 years, 65-75 years, 275 years)ethnicity (Hispanic/Latino, not Hispanic/Latino)race (American Indian/Alaska Native, Asian/Native Hawaiian/Paci?c Islander, Black/AfricanAmerican, White)BMI (<25 kg/m2, 25?29.9 kg/m2, 30-349 kg/m2, 235 kg/m2)- body weight (<90 kg, 290 kg)- Diseasebaseline HbA1c duration of diabetes (<10 years, 0 years)- serum albumin (<75m percentile, 275th percentile)serum creatinine (<75th percentile, 275th percentile)39	103267	105439
75	1	2	16	1	52	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)serum alanine aminotransferase (ALT), (<75m percentile, 275th percentile)- serum aspartate aminotransferase (AST), (<75th percentile, 275m percentile)- Previous anti-diabetic treatment (diet, OAD monotherapy, OAD combination therapy)- Concomitant drug interaction (albumin? and protein-bound drugs)The analyses were based on individual data from the ?ve therapeutic con?rmatory trials and on pooleddata from the four 26-week combination therapy trials (Trial 1572, 1436, 1574 and 1697).6.1.3 Study DesignThe ?ve pivotal phase 3 efficacy study protocols are reviewed in sections 6.1.3.7 and 6.1.3.8 [section6.1.3.7: monotherapy (one trial), section 6.1.3.8: combination therapy with one OAD (two trials) andcombination therapy with two OADS (two trials)]. Six phase 2 studies relevant for ef?cacy arediscussed in section 10. The ?ve therapeutic con?rmatory trials were similar in design. All trials wererandomized, parallel group, multi-center trials in which the therapeutic response to liraglutide wascompared with that of placebo and/or a speci?c active comparator drug.The designs of the ?ve major studies supporting effectiveness for the proposed indication are adequateand well controlled in that: (1) There is a clear statement of the objectives of the investigation and a summary of the proposed oractual methods of analysis in the protocols for thestudy and in the report of their results. In addition, theprotocols contain a description of the proposed methods of analysis, and the study reports contain adescription of the methods of analysis ultimately used.(2) The studies use designs that permit a valid comparison with a control to provide a quantitativeassessment of drug effect. The protocols for the study and report of results describe the study designsprecisely.(3) The method of selection of subjects provides adequate assurance that they have the disease orcondition being studied.(4) The method of assigning patients to treatment and control groups minimizes bias and is intended toassure comparability of the groups with respect to pertinent variables. In the case of the ?ve pivotalstudies, assignment is by randomization, with strati?cation.(5) Adequate measures are taken to minimize bias on the part of the subjects, observers, and ofthe data since the majority of the studies are double-blind.(6) The methods of assessment of subjects? response are well-de?ned and reliable. HbA1c is anobjective, surrogate measure of glycemic control (see section 6.1.2).(7) There is an analysis of the results of the study adequate to assess the effects of the drug (see sectionand also Dr. Derr?s Statistical Review). 40	105440	108157
149	1	2	16	1	126	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Table 6.37Analysis of Systolic Blood Pressure (SBP) in - Change from Baseline at 26 weeks (add-ontherapy with two OADs trials) Placebo #ComparatorBaselineSBPun- Mean Meanadjusted *Adjusted difference differencemean mean change from com- from com- (SD) in SBP (SEM) parator 95% CI. value parator 95% Cl valueTrial 1574Lira 176 128.8 -6.7 (1.1) -5.6 -2.9(14.8)Lira 178 126.0 -5.6 (1.1) -4.5 -1.9(14.2)Placebo+OADs 173 128.2 -1.1 (1.2)(14.5)Trial 1697Lira 227 134.9 -4.0 1.3) -2.5 0.3 0.0791 -4.5 -2.2 0.0001(14.9)Placebo+0ADs 114 133.4 -1.4 (1.6)(14.1)Glargine+0ADs 228 133.0 0.5 (1.3)(14.7)"In Trial 1574 the OADs were metformin rosiglitazone, in Trial 1697 glimepiride metformin.The p-values correspond to a two-sided test for superiority on a 5% signi?cant level (statistical signi?cance for *The change in SBP was estimated using an ANCOVA model with treatment, couneffects and baseline value as covariateThere was no comparator in Trial 1574; the comparator in Trial 1697 was glargine+OADstry and previous anti-diabetic treatment as ?xedSource: [Table 11-28, trial 1574 report] Table l4.2.123, trial 1697 report]In trial 1574 systolic blood pressure decreased in the liraglutide treatment groups (-6.7 in theliraglutide 1.2 mg+OADs group and -5.6 in the liraglutide 1.8 mg+OADs group) from baselineto end of treatment, and decreased only in the placebo+OADs group (-1.1 mmHg). ANCOVAanalysis of the estimated mean changes demonstrated that the difference between the liraglutide+OADsgroups and the placebo+OADs group was statistically signi?cant. However, there was no differencebetween the two liraglutide groups; Similar results were obtained when analyzing only completers (datanot shown).In trial 1697, The liraglutide 1.8 mg+OADs group had an estimated mean reduction in systolic bloodpressure of -4.0 mmHg, the placebo+OADs group a mean reduction of -1 .4 and theglargine+OADs group a mean increase of +0.5 mmHg. There was a statistically significant differencebetween the reduction in the liraglutide 1.8 mg+OADs and the increase in the glargine+OADs group but114	260458	262614
77	1	2	16	1	54	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)- Trial 1573 included subjects treated with diet/exercise or one OAD for at least two months. If treatedwith an OAD the dose was to be no more than half maximal dose, except subjects previously treatedwith metformin 1500 mg or pioglitazone 30 mg were also eligible.HbAlc at screening: 7.0-1 1.0% for subjects on diet/exercise treatment and 7.0?10.0% forsubjects on OAD therapy.- Trials 1572 and 1436 included subjects treated with for at least 3 months.HbAl at screening: 7.0-1 1.0% for subjects on OAD monotherapy and 0.0% for subjectson OAD combination therapy.- Trial 1574 included subjects treated with and/or exenatide for at least 3 months.HbAlc at screening: 7.041 1.0% for subjects on OAD monotherapy or exenatide therapy aloneand 0.0% for subjects on combination therapy including OADS and/or exenatide.- Trial 1697 included subjects treated with for at least 3 months.HbAlc at screening: 7.5?10.0% for subjects on OAD monotherapy and 7.0?l0.0% for subjectson OAD combination therapy.Exclusion Criteria- Previous participation in the randomized phase of the trial- Treatment with insulin within the last 3 months prior to trial (except for short-term treatment withinsulin in connection with intercurrent illness at the discretion of the investigator) Note: this criterion didapply to trial 1697 the trial comparing liraglutide to insulin glargine.- Impaired liver function, de?ned as alanine aminotransferase or aspartate aminotransferase times upper limit of normal based on analysis from central laboratory- Impaired renal function, de?ned as serum creatinine 2125 umol/L (21.4 mg/dL) for males id) and 2110umol/L (21.24 mg/dL) for females (6) based on analysis from central laboratory- Clinically signi?cant, active (over the past 12 months) disease of the gastrointestinal, pulmonary,neurological, genitourinary or hematological system that might confound the results of the study or poseadditional risk in administering the study drug (9Clinically signi?cant active cardiovascular disease including history of myocardial infarction withinthe past 6 months and/or heart failure (New York Heart Association class and IV)- Proliferative retinopathy or maculopathy requiring acute treatment- Uncontrolled treated/untreated hypertension (systolic blood pressure 2180 and/or diastolicblood pressure Z100 mmHg)- Subjects known to be Hepatitis surface antigen or Hepatitis antibody positive- Cancer (except basal cell skin cancer or squamous cell skin cancer) or any clinically signi?cant diseaseor disorder, except for conditions associated to type 2 diabetes, which could interfere with the results ofthe trial0 - Recurrent major hypoglycemia or hypoglycemic unawareness (E)- Known or suspected allergy to trial product(s) or related products- Use of any drug (except for OADS), which could interfere with glucose levels systemiccorticosteroids)- Receipt of any investigational drug within the 4 weeks prior to this trial- Known or suspected abuse of alcohol or narcotics- Mental incapacity, unwillingness or language barrier precluding adequate understanding orcooperation42	110621	113788
79	1	2	16	1	56	Clinical ReviewLisa B. Yanof? M.D.NDA 22,341 (Submission 000)Vict0za? (liraglutide)measurement. Nonetheless, as a result of the short run-in period, the within group changes frombaseline in HbA1c may overestimate the true effect but between group changes from baseline inHbA1c should be unaffected, assuming that patients were well balanced? between treatment groupsas a result of randomization.6.1.3.5 Randomization Criteria Therapeutic Con?rmatory TrialsRandomization occurred after the run-in period of background therapy as indicated in Table 6.4 for eachtrial. Subjects also were required to meet FPG criteria in order to be randomized.Table 6.4Randomization Criteria for Phase 3 TrialsFPGTrial II1573 gigs;   0. i FPG 7.0?13.9 mmol/L (126?250 mg/dL) ifondiet/exercise therapy or FPG 512.2 mmol/L (220mg/dL) if on single OAD    1572 use of2000 mg rail 0 FPG in the range 7.0?l2.8 mmol/L (12a230 mg/dLat least three weeks1436 Daily use of 4 mg glimepiride for at FPG in the range 7.0?l2.8 mmol/L 126-230 least two weeks1574 Daily use of 2000 mg metformin and FPG in the range 7.5?l2.8 mmol/L (1 35?230 mg/dL).8 mg rosiglitazone for at least 3 weeks1697 Daily use of 4 mg glimepiride and FPG in the range 7.5?l2.8 mmol/L (l35?230 mg/dL).2000 mg metformin for at least 3 weeks6.1.3.6 Withdrawal and rescueNo glycemic rescue medication other diabetes drugs) was permitted during the studies subjectswith an unsatisfactory therapeutic effect (see withdrawal criteria) were discontinued from the trial.Subjects were expected to be withdrawn from the study if FPG became above a pre-determined value forthree consecutive days and con?rmed by a central laboratory (See Table 6.5 FPG Criteria). Subjectscould also be withdrawn if background therapy needed to be adjusted beyond the approved range. Forexample for trial 1572, if a subject required down-titration to below 1500 mg per day then he or shewould be discontinued from the trial (See Table 6.5 Background Therapy Criteria).Table 6.5Criteria for Withdrawal for Therapeutic Con?rmatory TrialsTrial FPG Criteria I Background Therapy Criteria44_	116627	118722
83	1	2	16	1	60	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Procedures: Each subject underwent a screening visit at week 0 and then an open forced metformintitration period of 3-6 weeks. Depending on randomization criteria being met, subjects were thenrandomized to a 2 week double-blind up-titration of liraglutide and glimepiride (active and/or placebo)(Figure 6.3).Figure 6.3 Procedures for Trial 1572 Forced Double-blindsvletformin Titration of MaintenanceTrial P1?oduct-? tment?ScreeningVisit .Randon1isatio 113ff  2 weeks 3-6 weeks? 2 weeks 24 weeks1 II I I ILirngiulidc {(16 placebo Mctformin .5-2.0 ydny)Liraglutide (1.2 nugfduy) Glimepiridc placebo Metfonnin (1 .5?2.0 giday)L-iraglntide (1.8 mgidav) Glimcpiride placebo Metformin (1.5-2.0 giday)1~E=l 14: Limgiutide placebo Glimepiride placebo Metfoi-min (1 .5?2.0 gjdayj}Li.mg?utide placebo -9- Glimepiride mg~'day') Metformin 0.5-2.0 ay)Reviewer?s comment: The protocol permitted an increase in metformin dosage within 3-6 weeksprior to the baseline HbA1c measurement. Improved glycemic control resulting from this regimen 3change would not be fully re?ected in the baseline HbA1c measurement (HbA1c representsglycemic control over the prior three months). This could lead to over-estimation of the withingroup primary efficacy variable (change in HbA1c from baseline to endpoint) in these patientsbecause some of the improvement in HbAlc during the double-blind treatment period would beattributable to the recent increase in metformin dosage. Therefore, the change in HbA1c should bereported relative to placebo.Study Design Procedural Deviations . The NGSP Level I certi?cation for testing of HbA1c at expired 1 September 2006. Thereafter, had a Level II certification. The majority of samples analyzed atafter 1 September 2006 were reanalyzed at (NGSP Level I certi?ed)at a later time point. However, for a number of samples there was no material left and it was thereforenot possible to perform -the reanalysis at 1 (subjects 401009, 401012, 401013, 401014,401015, 401016, 401017, 401018, 402015, 402016, 402018, 402019, 403008, 403010, 403011, 403012,403014, 403016, 403018, 403019 and 403020 at Visit 3, subjects 401002, 401003, 401004, 401005,402001, 402004, 402005, 403001, 403002, 403003, 403005, 403006, 404001, 404002, 404003, 404005,404006, 404008, 404010, 404011, 404013, 404014, 404019 and 404020 at Visit 7, subject 404002 atVisit 8 and subjects 402004, 402019, 403016 and 403019 at Visit 10 which was the visit during whichthe ?nal HbA1c measurement used for efficacy analyses was obtained) and for another few samples the .48	125471	128099
84	1	2	16	1	61	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)analysis at not performed because the samples were hemolyzed (subjects 401002 and 401005 at Visit 10). For all these samples, the results from the analysis at (NGSPLevel II certi?ed) were used. The Sponsor concluded that this approach would not in?uence the resultsof the study. Reviewer?s comment: This reviewer agrees that this protocol deviation is not likely to haveaffected study results because the number of affected samples from visit 3, (the visit at which thebaseline HbA1c measurement was obtained) was only 21, and the number of affected samplesfrom visit 10, the study endpoint visit (the visit at which the ?nal HbA1c measurement for analysisof the primary ef?cacy endpoint was obtained) was only 6. This small number of affected samplesis unlikely to have resulted in altered -study results.18 month extension period of trial 1572This report aimed to ful?ll the FDA request to present data following longer exposure time for a largenumber of subjects. At Visit 10 at 26 weeks after randomization, all subjects were asked to confirm theircontinued participation in an 18-month, voluntary, open-label treatment extension period. Subjects whocontinued into the extension period were unblinded to treatment assignment at their first visit at the siteafter database release and continued the treatment regimen they had been randomized to in the blindedpart of the trial. Data from the extension trial are used to support safety (see Dr. Mahoney?s ClinicalSafety Review).6.1.3.82 (Liraglutide glimepiride) vs. (placebo glimepiride) vs. (rosiglitazone glimepiride)Trial 1436: Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on glycemic control after oncedaily administration of liraglutide in combination with glimepiride versus glimepiride monotherapyversus glimepiride and rosiglitazone combination therapy in subjects with type 2 diabetesThe rationale for this trial was to demonstrate that the addition of liraglutide to existing sulfonylurea(SU) therapy, glimepiride, provides additional improvements in glycemic control. Furthermore, therationale was to compare liraglutide in combination with glimepiride to glimepiride monotherapy and torosiglitazone, a thiazolidinedione (TZD), in combination with glimepiride.This was a 6 month, multicenter (116 centers in 21 countries), randomized, double?blind, double-dummy, active control, ?ve armed parallel group study. 1041 subjects were randomized in a 2:2:2:l:2ratio to:Liraglutide active (0.6 mg/day) glimepiride (2-4 mg/day) rosiglitazone placeboLiraglutide active (1.2 mg/day) glimepiride (2-4 mg/day) rosiglitazone placeboLiraglutide active (1.8 mg/day) glimepiride (2-4 mg/day) rosiglitazone placeboLiraglutide placebo glimepiride (2-4 mg/day) rosiglitazone placeboLiraglutide placebo glimepiride (2-4 mg/day) rosiglitazone (4mg/day)Procedures (Figure 6.4):49	128100	131019
90	1	2	16	1	67	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)1697.excluding the subjects whose samples had to be reanalyzed due to the protocol deviation andexcluding the 8 subjects who did not have enough sample material left to perform the reanalysis atToronto.2. An assessment of the inter-laboratory differences in HbA1c levels of samples that were assayed byboth laboratories.The responses submitted on 29 Jul 2009 were as follows:1. We looked into the 52 subjects randomized in trial 1697 described above. These were all randomizedin . .. In comparison to the original ITT population we excluded 51 subjects (1 subject did nothave any samples reanalyzed in and 50 subjects had at least one post?baseline sample  reanalyzed in The remaining subject (820005) did not have any post baseline values and wastherefore not included in the original analysis (and was also not included in the revised analysis).We analyzed the primary endpoint change in HbA1c at the end of 26 weeks using the same model asdescribed originally excluding the 51 subjects. To facilitate comparison to the original results weperformed the same three analyses ITT with LOCF, ITT without imputation, and the PP population.  The ANCOVA results for the ITT with LOCF population showed that lirag1utide+OADs loweredby -1.29% (vs. -1.33% in the original analysis), glargine+OADs by -1.10% (vs. -1.09% in theoriginal analysis), and placebo+OADs by -0.25% (vs. -0.24% in the original analysis). The tests ofsuperiority were similar to the original analysis, i.e. liraglutide+OADs was superior to both theglargine+OADs group and the placebo+OADs group.2. We looked into the inter-laboratory differences by plotting the average vs. the difference (so calledBland?Altrnan plot), and also performed a statistical analysis. We found a difference between the meanof HbA1c values from the two analysis of -0.56 p<0.000l) with results at  being lower than at  Reviewer?s comment: Although there appears to be lower mean HbA1c values at compared to the mean changes from baseline were not sensitive to excluding the subjects  4;whose samples had to be reanalyzed due to the protocol deviation. Therefore, the overall efficacyconclusions are not affected by the protocol deviation.6.1.3.9 Study design conclusions:Based on review of the study designs, this reviewer concludes that the designs are adequate to provideassessment of bene?t in patients with type 2 diabetes mellitus, are of adequate duration to allow for suchconclusions, allow for generalizability of results (excepting severely ill diabetics with high HbA1c levelsas well as advanced cardiovascular disease and other excluded populations, i.e. renal and hepaticfailure), and that the doses studied in the pivotal Phase 3 trials were adequate based on the ?ndings inPhase 2.55	144076	146897
91	1	2	16	1	68	Clinical ReviewLisa B. Yanoff, MD.NDA 22,341 (Submission 000)Victoza? (liraglutide)6.1.4 Efficacy FindingsSee Dr. Derr?s statistical review for additional information.6.1.4.1 Monotherapy TrialTrial 1573 - (liraglutide 1.2 placebo) vs. (liraglutide 1.8 placebo) vs. (glimepiride placebo)Demographic and baseline features of the monotherapy populationThere was one monotherapy trial. The tri(glimepiride in this case). The screerandomized subjects are summarizeThe study population was roughly half male and half female, hawas 77% White and 12% Black or African and 10% other races, anmean duration of diabetes was 5.4of the subjects were treated previously with monotherapy while the other one-third was previouslyal compared two doses of liraglutide to an active comparatorning characteristics and the key ef?cacy parameters at baseline ofin Table 6.7 and Table 6.8, respectively.a mean age of 53 years (range 19-79),had a mean BMI of 33 kg/m2. Theyears with a mean HbA1c of 8.3% at screening. Roughly two-thirdstreated with diet_and exercise and hence were drug naive. There were no reported differences betweenrandomization groups with respect to baseline parameters.Table 6.7Trial 1573 - Screening Characteristics and Demographic Features of all Randomized SubjectsAll randomized subjects (N) 247 251 248Lira 1.8 Lira 1.2 GlimepirideSex Male 121 (48.99) 117 (46.61) 133 (53.63)Female 126 (51.01) 134 (53.39) 115 (46.37)Age (years)Mean (SD) 52.0 (10.8) 53.7 (11.0) 53.4 (10.9)Ethnicity Hispanic or Latino 87 (35.22) 81 (32.27) 93 (37.50)Not Hispanic or Latino 160 (64.78) 170 (67.73) 155 (62.50)Race White 186 (75.30) 200 (79.68) 192 (77.42)Black or African American 30 (12.15) 34 (13.55) 30 (12.10)Native Hawaiian/Paci?c Islander 2 (0.81) 0 (0.00) 0 (0.00)American Indian Alaska Native 0 (0.00) 0 (0.00) 0 (0.00)Asian 12 (4.86) 5 (1.99) 9 (3.63)Other 17 (6.88) 12 (4.78) 17 (6.85)56	146898	148782
94	1	2	16	1	71	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)In this study (1573) the active comparator was glimepiride 8 mg once daily in the morning. This is themaximal recommended dose of glimepiride. .Reviewer's comments: The glimepiride group was adequately exposed to an effective glimepiridedosage.61.4.1.4 Primary ej?cacy variable for the monotherapy populationTable 6.10 summarizes the changes in HbA1c from baseline using the ITT analysis set.Table 6.10Trial 1573 - Summary of Change in HbA1c ITT PopulationLira 1.8 Lira 1.2 GlimepirideITT Analysis SetBaseline246 251 -248Mean (SD) 8.19 (1.085) 8.18 (1.054) 8.23 (1.062)Week 52 completers170 159 150Mean (SD) 6.97 (1.091) 7.16 (1.225) 7.54 (1.111)Change from Baselineto Week 52 completers170 159 150Mean (SD) -1.22 (1.134) -0.93 (1.261) -0.55 (1.130)End of Treatment LOCF234 236 241Mean (SD) 7.17 (1.229) 7.46 (1.345) 7.80 (1.242)Change from Baselineto End of TreatmentLOCF234 236 241Mean (SD) -1.01 (1.277) -0.73 (1.333) -0.44 (1.165)Source: Table 11-3, trial 1573 reportThis trial used a non-inferiority design with the pre-defined non-inferiority margin of 0.4% change inHbA1c. A hierarchical testing procedure was used to test for non-inferiority and then superiority (seesection 6.1.2.3 statistical methods).Reviewer?s comment: The non?inferiority margin of 0.4% change in HbA1c is standard fordiabetes trials. The hierarchical testing procedure was used to reduce the type 1 error rate. Dr.Derr?s statistical review identi?ed no concerns with this procedure.59	152443	153991
95	1	2	16	1	72	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Mean change in HbAlc from baseline to end of treatment was analyzed in the ITT analysis set withLOCF using an ANCOVA model (Table 6.11). -The adjusted mean decrease in HbA1c value frombaseline to end of treatment was 1.14% in the liraglutide 1.8 mg group, 0.84% in the liraglutide 1.2 mggroup, and 0.51% in the glimepiride group (note: these are not placebo aajusted percentages as therewas no placebo group in this trial). Treatment with liraglutide at both the 1.8 and 1.2 mg dose wassuperior to treatment with glimepiride, and there was also a significantly greater decrease in HbA1cvalues for liraglutide 1.8 mg compared to liraglutide 1.2 mg. The ANCOVA model was also performedon the PP analysis set (Table 6.12) and for the ITT analysis set without imputation (Table 6.13) withsimilar results.Table 6.11 Trial 1573 - ANCOVA of Primary Endpoint Change in HbA1c (LOCF) ITTpopulation Treatment/comparison EstimatesLeast Square Means LS SEMean Lira 1.8 234 -1.136 (0.081)Lira 1.2 236 -0.843 (0.080)Glimepiride 241 -0.513 (0.077)Estimated Treatment LS 95% CI p-valueDifferences MeanLira 1.8 - Glimepiride -0.623 -0.826 (-0.421) <.000lLira 1.2 - Glimepiride -0.329 -0.531 (-0.127) 0.0014Lira 1.8 Lira 1.2 -0.294 -0.497 (-0.091) 0.0046The estimates are from an ANCOVA model with treatment, country, and previous OAD treatment as ?xedeffects and baseline value as a covariate. Source: Table 11-4, trial 1573 reportTable 6.12Trial 1573 ANCOVA of Primary Endpoint Change in HbA1c PPpopulationTreatment/comparison EstimatesLeast Square Means LS SEMeanLira 1.8 154 -1.311 (0.087)Lira 1.2 142 -1.049 (0.088)Glimepiride 130 -0.662 (0.089)Estimated Treatment LS 95% CI p-valueDifferences MeanLira 1.8 - Glimepiride -0.649 -0.875 (-0.423) <.000l60	153992	155813
98	1	2	16	1	75	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Week 52 HbA1c 56.5% (completers). 76 (44.7)60 (37.7)30 (20.0)Week 52 HbA1c 56.5% (LOCF)88 (37.6)66 (28.0)39 (16.2)Source: Table 11-5 Trial 1573 reportStatistical analysis by logistic regression using the ITT with LOCF population showed that thepercentage of subjects achieving ADA and AACE targets was signi?cantly greater in the liraglutidegroups as compared to the glimepiride group (Table 6.14 and Table 6.15, respectively). Also,signi?cantly more subjects in the liraglutide 1.8 mg group achieved the 5 6.5% target than liraglutide1.2 mg. Logistic regression analyses using the ITT population with no imputation were similar to the?ndings for the 7% target and for the 5 6.5% target except that there was no signi?cant differencebetween the liraglutide 1.8 mg and the liraglutide 1.2 mg treatment groups for the percentage of subjectsachieving the 5 6.5% target Table 6.14Trial 1573 - Logistic Regression of Subjects Reaching HbA1c ITT (LOCF)Comparison after 52 weeks oftreatmentTreatment/comparison Estimates 95% CIProportionsLira 1.8 234 119 (50.9) 44.3 57.4Lira 1.2 236 101 (42.8) 36.4 49.4Glimepiride 241 67 (27.8) 22.2 33.9Odds Ratio 95% CI p?valueLira 1.8 - Glimepiride 2.92 1.94 4.39 <.000lLira 1.2 4 Glimepiride 2.01 1.34 3.02 0.0007Lira 1.8 Lira 1.2 1.45 0.98 2.14 0.0629Odds ratio is from logistic regression with treatment as ?xed effect and baseline HbA1c value as a covariateSource: Table 11-6 trial 1573 reportTable 6.15Trial 1573 - Logistic Regression of Subjects Reaching HbA1c ITT (LOCF)Comparison after 52 weeks oftreatmentTreatment/comparison Estimates 95% CIProportions 234 88 (37.6) 31.4 44.2Lira 1.8 236 66 (287.0) 22.3 34.2Lira 1.2 241 39 (16.2) 11.8-21.5Glimepiride63	158981	160759
102	1	2	16	1	79	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Lira 1.8 - Glimepiride -20.3 -29.1 (-11.5) <0.000lLira 1.2 - Glimepiride - 9.9 -18.7 (-1.1) 0.0270Lira 1.8 Lira 1.2 -10.4 -19.2 (-1.5) 0.0223The estimates are from an ANCOVA model with treatment, country, and previous OAD treatment as ?xedeffects and baseline value as a covariate.Source: Table 11-15 and EOT Table 14.2-7-7, trial 1573 reportReviewer?s comment: These data support the primary ef?cacy indication. One caveat is thatthese values are not adjusted for multiple comparisons and no method has been implemented toreduce the type 1 error rate.The proposed label states that - 1 . -F.. 0 These values do not ?seem to have come from this trial and do not appear to be placebo-corrected.6.1.4.1.7.2 Proportion of subjects achieving FPG targetsLogistic regression was performed to determine if there was a difference in the number of subjectsachieving target FPG values of 90 130 mg/dL in the LOCF-ITT population at 52 weeks of treatment.Subjects treated with liraglutide were signi?cantly more likely to achieve these FPG targets than thesubjects treated with glimepiride (Table 6.18). Approximately 41% of subjects in the liraglutide 1.8 mggroup and 38% in the liraglutide 1.2 mg group reached the FPG target as compared to 22% in theglimepiride treatment group. There was no signi?cant difference between the two liraglutide doses.Table 6.18Trial 1573 - Logistic Regression of Subjects Achieving FPG Target Values, ITT(LOCF)Treatment/comparison Estimates 95% CIProportionsLira 1.8 239 99 (41.4) 35.1 48.0Lira 1.2 245 92 (37.6) 31.5 43.9Glimepiride 248 55 (22.2) 17.2 27.9Odds Ratio 95% CI p-valueLira 1.8 - Glimepiride 3.28 2.12 5.07 <.000lLira 1.2 - Glimepiride 2.33 1.51 3.60 0.0001Lira 1.8 Lira 1.2 1.40 0.94 2.10 0.0991Odds ratio is from logistic regression with treatment as ?xed effect and baseline PG value as a covariateSource: Table 11-16 trial 1573 report67	167253	169211
106	1	2	16	1	83	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)Reviewer?s comment: While the weight change in the liraglutide groups was statisticallysigni?cantly different from the comparator (mostly because the comparator induced weight gain),the absolute percentage weight loss in the liraglutide groups is less than that seen with alreadyFDA approved drugs for obesity. The summary of distribution of body weight change percentageshowed that about a quarter of subjects actually gained weight while on liraglutide therapy andabout half lost less than 5% of body weight.Further analyses were performed to determine if nausea contributed to the greater weight loss seen in theliraglutide groups. Subjects were categorized based upon the number of days nausea was reported in theearly phase of the trial (up to 8 weeks of treatment) and in the late phase (after 8 weeks of treatment).The Sponsor reports that greater weight loss was observed in the subjects who experiencednausea, but all liraglutide-treated groups demonstrated a mean weight loss.6.1.4.1.7.6 Measures of beta-cell function and insulin resistanceFive endpoints were related to [3-cell function and insulin secretion (fasting insulin, fasting C-peptide,pro-insulin to insulin ratio, HOMA index of B-cell function, and HOMA index of insulin resistance).Fasting insulin values from baseline? to end of treatment showed a decrease in the liraglutide groupcompared with the glimepiride group (adjusted mean difference -22.7 pmol/L, There were nodifferences in C-peptide values among treatment groups (all were decreased). The pro-insulin to insulinratio (calculated from fasting insulin and fasting pro-insulin) decreased in both liraglutide treatmentgroups, and increased in the glimepiride group. However, ANCOVA analysis of the estimatedmean changes in the ratios demonstrated that the differences between the liraglutide groups and theglimepiride group were not statistically significant.B-cell function was assessed by HOMA. ANCOVA analysis demonstrated no difference between thetreatment groups. Insulin resistance as measured by HOMA-IR was reduced in the liraglutide treatmentgroups compared with the glimepiride group in an ANCOVA model using the LOCF population(lira 1.8 vs. glimepiride adjusted mean difference 95% CI -3.5 p=0.001 1, lira 1.2 vs.glimepiride adjusted mean difference 95% CI -2.8 p=0.0249, lira 1.8 vs. lira 1.2 adjustedmeandifference not significant). Similar results were observed in an analysis performed with Week 52values, although the differences were not signi?cant.Reviewer?s comment: Using the completer?ITT no imputation) analysis set the results werenot statistically signi?cant calling into question the robustness of these efficacy results. Measuresof beta-cell function and insulin resistance, including HOMA, have not yet risen to the level ofinclusion in labeling primarily because they are not fully validated surrogates.Blood Pressure7]	174701	177664
107	1	2	16	1	84	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Observed mean systolic blood pressure (SBP) values decreased from baseline to end of treatment in allthree treatment groups. The decreases occurred after 2-4 weeks of treatment and were maintained to theend of the treatment period. ANCOVA, including baseline value as a covariate, of change in SBP withthe LOCF-ITT analysis set showed that liraglutide lowered SBP signi?cantly more than glimepiride.The liraglutide 1.8 mg group had an adjusted mean reduction in SBP of 3.64 (from a meanbaseline of 128 mmHg), the liraglutide 1.2 mg group a mean reduction of 2.12 (baseline: 128mmHg) and the glimepiride group a mean reduction of 0.69 (baseline: 130 mmHg). Thedifference between the reduction in SBP from liraglutide 1.8 mg and glimepiride was statisticallysigni?cant (2.95 mmHg, 0.0117). Using the completer-ITT no imputation) analysis set theresults were not statistically signi?cant (mean adjusted difference between liraglutide 1.8 andglimepiride -2.72, 95% CI -5.5 0.03, For diastolic BP there were no differences betweentreatment groups.The proportions of subjects reaching targets of a diastolic blood pressure below 80 and a SBPbelow 130 was compared between the liraglutide groups and the glimepiride group using a chi-square test. Using LOCF, 42.1% of subjects in the liraglutide 1.8 mg group, 41.2% of subjects in theliraglutide 1.2 mg group, and 34.7% of subjects in the glimepiride group reached this target. Thesedifferences were not statistically signi?cant and the results were similar when performing the analysison Week 52 values. 1Reviewer?s comment: Using the completer-ITT no imputation) analysis set the results werenot statistically significant calling into question the robustness of these blood pressure efficacyresults. However, in this case there appears to be a trend comparing liraglutide 1.8 mg toglimepiride On the other hand, using a dichotomous variable (subjects reaching targetsof "diastolic BP below 80 and a systolic BP below 130 mmHg) and chi-square test, therewere still no differences among treatment groups.The data listings of concomitant medication that may have an effect on blood pressure,medications known as anti-diuretics, and medications for edema were not presented. Therefore,possible confounding by anti-hypertensive medications added or adjusted during the trial cannotbe ruled out.6.1.4.1.7.8 Fasting lipid pro?leThere were no clinically important changes in total cholesterol over the 52 week study period and nosignificant differences among treatment groups. -Reviewer?s comment: Similar data were seen in the other trials that are discussed in the nextsections with some trials showing improvements in one or two lipid related variables but nooverall consistent picture of lipid improvements. Since a change in lipid profile is not the72	177665	180541
109	1	2	16	1	86	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)subjects was similar in trials 1572 and 1436 (mean age 57 and 56.1 years, respectively), the mean BMIin trial 1572 was 31 kg/m2 and in trial 1436 the mean BMI was 29.9 kg/m2, also similar.In trial 1572 the mean HbA1cwas 8.4% with a mean duration of diabetes of 7.4 years. Similarly, in trial1436 the mean HbA1c was 8.4% with a mean duration of diabetes of 7.9 years. The racial distributionwas somewhat different between the two trials. In trial 1572, the majority of subjects were whitewith 9% of subjects being Asian or Paci?c Islanders. In trial 1436 the majority of subjects werewhite, albeit a smaller percentage of white subjects than in trial 1572, while 32.4% of subjects wereAsian/Paci?c Islanders and 2.8% of subjects were black. In both trials approximately one-third of therandomized subjects had been using OAD monotherapy prior to participation in the trial, while the othertwo-thirds had been using OAD combination therapy. [notez prior OAD (monotherapy vs. combinationtherapy) was a randomization stratum in both trials]. At screening BMI appeared similar across groupsand between the two trials.Table 6.20 Screening Characteristics and Demographic Features of all Randomized Subjects in the add-ontherapy with one OAD populationTrial 1572 26 WeeksTrial 1436 26 weeksLira0.6 Lira 1.2 Lira 1.8 Pbo Met Lira0.6 Lira1.2 A Lira1.8 Pbo RosiMet Met Met Met Glim +Glim +Glim +Glim Glim +GlimAll 242 241 242 122 244 233 228 234 114 232randomizedsubjects W)Sex Male 151 129 142 73 140 (57.4) 126 102 (44.7) 124 53 109. (62.4) (53.5) (58.7) (59.8) (54.1) (53.0) (46.5) (47.0)Female 91 112 100 49 104 (42.6) 107 126 (55.3) 110 61 123(37.6) (46.5) (41.3) (40.2) (45.9) (47.0) (53.5) (53.0)Age (years) .Mean (SD) 56.0 57.2 (9.3) 56.8 (9.4) 56.2 57.4 (8.8) 55.7 57.7 (9.0) 55.6 54.7 56.0(10.5) (9.4) (9.9) (10.0) (10.0) (9.8)Race White 202 211 214 107 216 (88.5) 154 143 (62.7) 145 77 151(83.5) (87.6) (88.4) (87.7) (66.1) (62.0) (67.5) (65.1)Black 4 (1.7) I 9 (3.7) 5 (2.1) 3 (2.5) 5 (2.0) 7 (3.0) 7 (3.1) 9 (3.8) 1 (0.9) 5 (2.2)Asian/Paci?c 31 19 (7.9) 18 (7.4) 9 (7.4) 21 (8.6) 72 78 (34.2) 79 35 73Islander (12.8) (30.9) (33.8) (30.7) (31.5)American 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)Indian Alaska NativeOther 5 (2.1) 2 (0.8) 5 (2.1) 3 (2.5) 2 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)0 (0.0) 0 (0.0) 1 (0.4) 1 (0.9) 3 (1.3)BMI (kg/m2) .Mean (SD) 30.5 31.1 (4.8) 30.9 (4.6) 31.6 31.2 (4.6) 30.0 29.8 (5.1) 30.0 30.3 29.4(4.8) (4.4) (5.0) (5.1) (5.4) (4.8)Duration of Idiabetes(years)Mean (SD) 7.0 6.8 (4.9) 7.8 (5.2) 7.9 7.8 (5.3) 8.1 (5.5) 7.8 7.8 8.074- 7.7 (5.0)	183261	185964
111	1	2	16	1	88	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission O00)Victoza? (liraglutide)(13.8)(14.4)I (14.1)1 (15.3)(16.1)(15.3) 1 (14.6)Source: [Study 1572 Table 11-1], [Study 1436 Table 11-2](15.9) (15.2)61.4.2.2 Participation and withdrawals in the combination therapy population (dispositionof subjects)Participation and withdrawals in the pivotal add-on with onetable 6.22. At 26 weeks, the completion rates for the liraglutide groups (78.9?91the control groups and similar to the active comparator groups (83.6-86.1withdrawal rates foWithdrawals due to ineffective therapy were higher in the controgroups and to the active comparator groups.Approximately 25-3 0% of the withdrawand the overall withdrawal rate decreasetrend for all treatment groups.Reviewer?s comment: See Dr. Derr?s statistical review for more comment on the effect ofwithdrawals on the efficacy evaluation.OAD treatment groups are summarized inwere higher thanAs expected,these 26-week trials arelower than withdrawal rates for the 52-week monotherapytrial. Withdrawals due to adverse events are discussed in Dr. Mahoney?s Clinical Safety Review.1 groups compared to the liraglutidesubjects were withdrawn from the trial during the first monthovertime. The withdrawal rate over time showed a similarSource: [Trial 1572 Table 10-1], [Trial 1436 Table 10-1]Table 6.22 Subject Disposition (add-on therapy with one OAD trials) (randomized subjects)Trial 1572 Trial 143626 weeks 26 weeksLira0.6 Lira1.2 Lira1.8 Met Met Lira0.6 Lira1.2 Lira1.8-1-glim Glim Rosi+met . +met +met +glim +glim +glim +g1imTotal randomized (N) 242 241 242 122 244 233 228 234 114 232Exposed 100% 99.6% 100% 99.2% 99.2% 100% 100% 100% 100% 99.6%Withdrawals 14.0% 18.3% 21.1% 39.3% 13.9% 10.7% 14.0% 9.0% 27.2% 16.4%Adverse Events 4.5% 9.5% 12.0% 1.6% 3.3% 2.1% 4.8% 3.8% 5.3% 3.0%Ineffective therapy 7.9% 3.3% 5.4% 23.8% 3.7% 5.2% 3.5% 3.0% 17.5% 6.9%Non-compliance with 0.8% 1.7% 1.7% 3.3% 2.0% 1.3% 2.2% 1.3% 1.8% 2.6%protocol Other 0.8% 3.7% 2.1% 10.7% 4.9% 2.1% 3.5% 0.9% 2.6% 3.9%Completers 86.0% 81.7% 78.9% 60.7% 86.1% 89.3% 86.0% 91.0% 72.8% 83.6%PP analysis set 80.2% 77.6% 74.8% 58.2% 82.8% 81.1% 82.0% 86.3% 64.9% 78.4%6.1.4. 2.3 Adequacy of comparator drug dosages used in the key add?on with one OADstudies76	187692	189953
113	1	2	16	1	90	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Table 6.23 -Analysis of HbAlc Change from Baseline at 26 weeks (add-on therapy with one OAD trials)Placebo #Comparator*AdjustedBaseline mean Mean MeanHbAlc change in difference differenceunadjusted HbAlc from com- from com- mean (SD) (SEM) parator 95% CI value parator 95% CI valueTrial 1572 Metformin add-onLira 0.6 239 8.4 (0.9) -0.70 -0.78 -0.99 - <.0001 0.29 0.12 0.46 0.0009(0.067) 0.57Lira 1.2 232 8.3 (1.0) -0.97 -1.06 -1.27 - <.0001 0.01 -0.16 0.8775(0.069) 0.85 0.19Lira 1.8 236 8.4 (1.0) -1.00 -1.09 -1.30 - <.0001 -0.02 -0.19 0.8592(0.066) 1 0.88 0.15Placebo 120 8.4 (1.0) 0.08(0.090)Comparator 234 8.4 (1.0) -0.99(0.068)Trial 1436Glimepirideadd-on Lira 0.6 224 8.4 (1.0) -0.60 -0.83 -1.07 - <.0001 -0.16 -0.35 0.0857(0.071) 0.60 0.02Lira 1.2 223 8.5 (1.1) -1.08 -1.31 -1.54 - <.0001 -0.64 -0.82 <.0001(0.072) 1.08 0.45Lira 1.8 226 8.5 (0.9) -1.13 -1.36 -1.60 <.0001 -0.69 -0.88 - <.0001(0.072) 1.13 0.51Placebo 107 8.4 (1.2) 0.23(0.100)Comparator 224 8.4 (1.0) -0.44(0.071)Comparator in trial 1572 is glimepiride and in trial 1436 is rosiglitazoneThe p-values correspond to a two-sided test for superiority on a 5% signi?cant level (statistical signi?cance for *The change in HbAlc was estimated using an ANCOVA model with treatment, country and previous anti-diabetic treatment as?xed effects and baseline HbAlc as covariateTest for non-inferiority with switch to superiority if non-inferiority is shown.Non-inferiority is concluded if the upper limit of the 95% confidence interval for the treatment difference is below 0.4% i.e. non-inferiority to comparator is shown for all liraglutide groups, except for the 0.6rng liraglutide group in trial 1572.A hierarchical testing procedure is used.Source: Tables 3-2, 3-3 Summary of Clinical Ef?cacyIn summary, subjects treated with liraglutide at doses of 0.6, 1.2 or 1.8 mg plus one additional OADimproved glycemic control as indicated by a signi?cant decrease in their HbAlc. The placebo groupshad small increases in HbAlc (0.08% to 0.23%) over the 26 week treatment periods despite thebackground therapy. In study 1572, relative to placebo+metformin, liraglutide 0.6 mg+metforminlowered HbAlc by liraglutide 1.2 mg+metformin lowered HbAlc by and liraglutide78	192056	194360
117	1	2	16	1	94	Clinical ReviewLisa B. Yanoff, MD.NDA 22,341 (Submission 000)Victoza? (liraglutide)For Trial 1572, the percentage of subjects reaching the ADA target with liraglutide 1.2 and 1.8 mg metformin) did not differ signi?cantly from the glimepiride metformin group. With liraglutide 0.6 mgmetformin signi?cantly fewer subjects reached the target compared with the glimepiride metformingroup. The same pattern was observed with respect to the percentage of subjects reaching the AACEtarget. For Trial 143 6, the percentage of subjects achieving the ADA target with liraglutide 1.2 and 1.8mg glimepiride) was signi?cantly higher than with rosiglitazone glimepiride. With liraglutide at the0.6 mg dose there was no difference. The same pattern was observed with respect to the percentage ofsubjects reaching the AACE target.Reviewer?s comment: These results appear similar to the primary ef?cacy variable in thatliraglutide OAD was better than placebo OAD for both trials, but with the active comparators,liraglutide added to metformin was not better than glimepiride added to metformin, and at the 0.6mg dose was actually Worse than metformin glimepiride, while liraglutide at both the 1.2and 1.8 mg doses added to glimepiride was better than rosiglitazone added to glimepiride. Thesame caveat that was mentioned in section 6.l.4.2.3.2 applies regarding the comparison with halfmaximal rosiglitazone dose.Although no statistical comparison of liraglutide 1.2 mg vs. liraglutide 1.8 mg was reported, thepercentage of subjects reaching the ADA target in both trials was higher in the liraglutide 1.8 mggroup compared with the 1.2 mg group lending support to the conclusion of greater efficacy forthe 1.8 mg dose over the 1.2 mg dose when added on to one OAD. For the AACE target thisdistinction was less clear since in trial 1436 the percentages reaching target for the 1.8 mg groupand the 1.2 mg group were similar.Table 6.24Percentage of Subjects Reaching ADA Target (HbA1c at 26 weeks ("add-on therapy with oneOAD trials)Logistic RegressionPlacebo ComparatorofSubjectsReaching Odds Odds Target (SEM) Ratio 95% CI value Ratio 95% CI valueTrial 1572Metformin add-on Lira 0.6 67 28.03 0.144 4.13 2.05 8.30 <.000l 0.63 0.41 0.97 0.0357Lira 1.2 82 35.34 0.137 5.86 2.92 <.000l 0.89 0.58 1.36 0.594711.72Lira 1.8 100 42.37 0.132 8.97 4.48 <.000l 1.36 0.90 2.07 0.146717.94Placebo 13 10.83 0.294Comparator 85 36.32 0.136Trial 1436Glimepiride82	199701	202128
118	1	2	16	1	95	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)add-onLira 0.6 54 24.11 0.156 5.17 2.26; <.0001 1.21 0.75 1.96 0.435011.81Lira 1.2 77 34.53 0.141 10.10 4.44; <.0001 2.37 1.48 3.79 0.000322.99Lira 1.8 94 41.59 0.135 15.96 7.01 <.0001 3.74? 2.35 5.97 <.000136.36Placebo 8 7.48 0.368Comparator 49 21.88 0.162Comparator in trial 1572 is glimepiride and in trial 1436 is rosiglitazoneThe estimates are obtained from a logistic regression with treatment as ?xed effect and baseline HbA1c value as a covariate.Source: Table 3-6, Summary of Clinical EfficacyTable 6.25Percentage of Subjects Reaching AACE Target (HbA1c at 26 weeks (add-on therapy with oneOAD trials)Logistic RegressionPlacebo ComparatorOfSubjectsReaching Odds Odds Target (SEM) Ratio 95% CI value? Ratio 95% CI valueTrial 1572Metformin add-onLira 0.6 27 11.30 0.204 3.62 1.28; 10.30 0.0157 0.40 0.23; 0.69 0.0009Lira 1.2 46 19.83 0.165 7.19 2.60; 19.93 0.0001 0.80 0.49; 1.29 0.3566Lira 1.8 58 24.58 0.151 10.5 3.82; 28.97 <.0001 1.16 0.73; 1.86 0.5223Placebo 5 4.17 0.457Comparator 52 22.22 0.157Trial 1436Glimepirideadd-onLira 0.6 28 12.50 0.202 4.67 1.53; 14.28 0.0068 1.43 0.76; 2.69 0.2680Lira 1.2 48 21.52 0.163 10.5 3.50; 31.36 <.0001 3.20 1.77; 5.80 0.0001Lira 1.8 48 21.24 0.163 11.7 3.90; 35.21 <.0001 3.59 1.98; 6.50 <.0001Placebo 4 3.74 . 0.510Comparator 22 9.82 0.225Comparator in trial 1572 is glimepiride and in trial 1436 is rosiglitazoneThe estimates are obtained from a logistic regression with treatment as ?xed effect and baseline HbA1c value as a covariate.Source: Table 3-7, Summary of Clinical Efficacy6.1.4.2.5.2 Treatment effect on selected subgroups83	202129	203800
122	1	2	16	1	99	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)(48.0) 34.9Lira 1.8 227 173.9 -28.7 (2.953) -46.81 -12.84 0.0036(43.7) 35.3Placebo 109 171.2 18.1 (4.042)(36.9)Comparator 226 179.2 -15.8 (2.880)(44.9)#Comparator in trial 1572 is glimepiride and in trial 1436 is rosiglitazoneThe 95% C1 for_the estimated differences are based on Dunnett?s method*The change in mean FPG was estimated using an ANCOVA model with treatment, country and previous anti-diabetic treatment as?xed effects and baseline value as covariateSource: Tables 14.2.68 and 14.2.72 trial 1572 report; Tables 14.2.65 and 14.2.65 trial 1436 reportReviewer?s comment: the reduction in FPG for liraglutide one OAD compared to one OAD placebo appears consistent across the two trials in favor of liraglutide. The two highest doses ofliraglutide appear virtually identical in their FPG lowering effect. Liraglutide at all doses wassimilar to glimepiride when added to metforinin. Liraglutide at the two highest doses was betterthan rosiglitazone when added to glimepiride. The previously discussed caveat applies regardingthe half maximal rosiglitazone comparator dose.Plots of FPG values by treatment and week are shown for trial 1572 in Figure 6.12 and for trial 1436 inFigure 6.13. In summary, for trials 1572 and 1436, in the 3 liraglutide groups and in the activecomparator treatment groups, FPG decreased within the ?rst 2 weeks after randomization while anincrease in FPG was seen in the placebo treatment groups. During the remaining 24 weeks of the trial,no change to a slight increase in FPG was demonstrated for all 3 liraglutide treatment groups and theactive comparator treatment groups, although the end of treatment FPG values for these treatmentgroups were still below the baseline values.87	211078	212878
127	1	2	16	1	104	Clinical ReviewLisa B. Yanof? MD. .NDA 22,341 (Submission 000)Victoza? (liraglutide)(18.1) I 1.69 IPlacebo 112 81.9 ?0.10(0.27)(17.1)Comparator 229 80.6 2.11 (0.20)(17.0)#Comparator in trial 1572 is glimepiride and in trial 1436 is rosiglitazoneThe 95% CI for_the estimated differences are based on Dunnett?s method*The change in body weight was estimated using an ANCOVA model with treatment, country and previous anti?diabetic treatmentas ?xed effects and baseline value as covariateSource: Tables 11-4, 11-15 trial 1572 report; Tables 11-5 and 11-16 trial 1436 reportReviewer?s comment: The reason for the differing ?ndings in terms of body weight change vs.placebo in these two trials is unclear but likely has to do with the differing background therapy(metformin in trial 1574 and glimepiride in trial 1436). It may first appear to be due to the higherbaseline weights in trial 1572. However, there was a higher proportion of men in trial 1572, andthe baseline BMIs were similar between the two trials.Figure 6.14 shows that for trial 1572, during the period from treatment start to Weeks 8-12, the 3liraglutide+metformin groups and the placebo+metformin group appeared to show reductions in meanbody weight, whereas the glimepiride+metformin group showed an increase in mean body weight.Figure 6.15 shows that for trial 1436 during the period from treatment start to Week 8, the two highestdose liraglutide+glimepiride groups and the glimepiride group appeared to show reductions in meanbody weight, whereas the rosiglitazone+ glimepiride treatment group showed an increase in mean bodyweight. From Week 8 until end of treatment, the mean body weight appeared to increase in thethree liraglutide treatment groups and the glimepiride treatment group. Mean body weight in therosiglitazone+ glimepiride treatment group increased steadily throughout the entire trial period.92	219839	221717
130	1	2	16	1	107	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)In the two trials some measures of beta?cell function signi?cantly improved in the liraglutide groupsrelative to the comparators and placebo groups as follows:In trial 1572 increases (by 20-26 percentage points) in HOMA-B from baseline to end of treatment wereseen in the 3 liraglutide groups and in the glimepiride+metformin group, while no relevant change wasseen in the metformin group. There were slight decreases in the pro-insulin to insulin ratio in the 3liraglutide groups and in the glimepiride+metformin group, while no relevant change was seen in themetformin group. There were no significant differences between the 3 liraglutide groups and theg1imepiride+metformin group with respect to change in HOMA-B or pro-insulin to insulin ratio. Therewas no difference in fasting insulin, fasting C-peptide or HOMA-IR between the liraglutide groups andthe comparator or placebo group.In trial 1436, measures of beta-cell function including fasting insulin, C-peptide, pro-insulin to insulinratio, and HOMA-B showed signi?cant improvement favoring liraglutide in some analyses althoughthese changes were not always dose dependent. For HOMA-IR, no statistically signi?cant differenceswere seen between liraglutide at any dose, in addition to glimepiride, and glimepiride alone or .rosiglitazone+glimepiride treatments. Comparable results were obtained when the same analysis wasperformed without data imputation, except for a signi?cantly reduced insulin resistance observed in therosiglitazone+glimepiride treatment group versus the liraglutide 1.8 mg+glimepiride treatment group.Reviewer?s comment: The proposed label reports that liraglutide. . Ibut these data suggest this effect may not be consistent across trials as these two 26-week trials showed different results regarding HOMA-IR. However, it may not be appropriate tocompare monotherapy to add-on therapy.6.l.4.2.6.5 Blood PressureThe results of analyses of systolic blood pressure (SBP) for trials 1572 and 1436 are summarized inTable 6.29. Reductions in SBP from baseline to week 26 were seen in all treatment groups except theactive comparator group in trial 1572 which had a small mean increase.In an ANCOVA model, there were no signi?cant differences between the 3 liraglutide groups and theplacebo groups with respect to change in SBP in either trial. When compared to the active comparatorarms, there were no differences between the 3 liraglutide groups and the rosiglitazone+glimepiridegroup in trial 1436, but in trial 1574 the change in SBP was signi?cantly different between theliraglutide 1.2 mg+metformin and liraglutide 1.8 mg+metformin groups which showed lowering frombaseline and the glimepiride+metformin group which experienced a small increase from baseline. Whensensitivity analyses were performed on the data set with no imputation, the same conclusions werereached except for the difference between the liraglutide 1.8 mg+metformin group and theglimepiride+metformin group in trial 1574, which was not statistically signi?cant (data not shown).There were no significant ?ndings related to diastolic blood pressure for either trial.95	223327	226530
132	1	2	16	1	109	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,34] (Submission 000)Victoza? (liraglutide)11(4)6.1.4.2.6.6 Metabolic prevalenceIn trial 1572, the proportion of subjects without metabolic at end of treatment wassignificantly higher in all 3 liraglutide groups compared with the metformin group (p=0.009 forliraglutide 1.8 mg). However, when the analysis was performed without data imputation, none of thecomparisons were signi?cant. In trial 1436, there were no signi?cant differences between groups in theproportion of subjects without metabolic at the end of the trial.Reviewer?s comment: These data as a whole do not support the proposed labeling claim thatm? Although some analyses from trial 1572 did suggest that liraglutide overall dataacross the liraglutide development program do not consistently support this labeling claim.Further, the concept of is problematic because of the several differentde?nitions employed by researchers and clinicians. Therefore, this information has not beenpreviously allowed into labeling by the Division. This reviewer does not see the data presentedhere (because of lack of consistent effect) as strong enough to change this position.6.1.4.2.6.7 Liver to Spleen Attenuation Ratio Trial 1572 onlyVisceral and subcutaneous adipose tissue areas in the central region of the body as well as theliver/spleen attenuation ratio were measured using CT performed at baseline and at 26 weeks. Baseline levels of liver to spleen attenuation ratio were comparable in all 5 treatment groups. In the liraglutide -1.8mg+metformin group, an increase in the liver to spleen attenuation ratio was observed (indicating arelief in hepatic steatosis) while no relevant changes were observed in the other 4 treatment group. TheSponsor concluded that hepatic steatosis was reduced following treatment with liraglutide 1.8 mg metformin. -Reviewer?s comment: The proposed label states that liraglutide . This reviewer has concerns about including this information in the product label because it was only shown with this technique with one liraglutide dose in one of thephase 3 studies. It is also unclear if this technique is validated for measuring . TheDivision of Metabolism and Endocrinologic Products has never put such language in diabetesdrug labels.  97	228718	230989
137	1	2	16	1	114	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)6.1.4.313 Adequacy of comparator drug dosages used in the key add-on with two OADSstudiesIn Trial 1574 the background therapy OADs were metformin 1000 mg bid rosiglitazone 4 mg bid, inTrial 1697 the OADS were glimepiride 2-4 mg/day metformin 2000 mg/day.Trial 1574 did not have an active comparator arm. In trial 1697 the active comparator was glargine.(Please see section 6.1 .3.8.4 (Table 6.6) for details of the titration guidelines). Glargine was expected tobe titrated to a FPG target. Therefore, adequacy of titration is important in determining adequacy ofcomparator dose. The percent of subjects reaching glargine targets is presented in Table 6.33.Table 6.33Percent of Subjects Reaching Glargine Targets in Trial 1697Glargine OADITT Analysis Set 232Week 26 FPG 100 mg/dL 47 (20.26)Week 26 FPG 120 mg/dL 93 (40.09)100 mg/dL 5.5 mmol/L; 120 mg/dL 6.7 mmol/LSource: Table 11-5 Trial 1697 reportRevieWer?s comment: The background therapy for both trials was adequate. As described insection 6.1.3.8.4 the glargine titration guidelines were adequate although they were entirely patienteffort-dependent. The percentage of subjects reaching glargine titration targets was notably low.However, the Sponsor claims that this re?ects real-world experience with insulin glargine.6. 1.4. 3.4 Primary efficacy endpoint for the add-on with two populationAnalysis of the changes in HbA1c from baseline to the end of the trials for the ITT with LOCFpopulations is summarized in table 6.34. In trial 1574, the mean decrease in HbA1c from baseline to endof treatment was 1.48% in both liraglutide groups and 0.54% in the OADs alone group. Treatment withliraglutide at both the 1.8 and 1.2 mg dose was superior to treatment with OADs alone (both Analyses of the PP population and the ITT population without imputation showed similar results.In trial 1697, the estimated mean reduction in HbAlc from baseline to end of treatment was -1.33% forthe liraglutide 1.8 mg+OADs group, -0.24% for the OADs alone group, and -1.09% for theglargine+OADs group. The results were similar for the PP population for the liraglutide 1.8mg+OADs group, -0.35% for the OADS alone group, and -1.10% for the glargine+OADs group). TheANCOVA analysis demonstrated that treatment with liraglutide was superior to treatment with placebowhen added to metformin and glimepiride (upper Cl limit below Subsequently it was demonstratedthat treatment with liraglutide was non-inferior to treatment with glargine and that treatment with102	239771	242349
140	1	2	16	1	117	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Reviewer?s comment: These ?gures generally support the sustainability of liraglutide?s effect onHbA1c upto 26 weeks although there may be a slight loss of ef?cacy after 18 weeks when added toglimepiride and metformin in (data from trial 1697).6.1.4.3.5 Supplementary Analyses of the Primary Endpoint Hb/1] 6.1.4.3.5.1 Percentage of Subjects Achieving HbA1c targetsThe percentages of subjects reaching the pre-de?ned HbA1c targets (ADA target 7% and AACE targetat Week 26 are summarized in Table 6.35 and Table 6.36, respectively.For trial 1574, statistical analysis by logistic regression showed that the percentages of subjectsachieving ADA and AACE targets were signi?cantly greater in the liraglutide+OADs groups ascompared to the OADS alone group. Similarly, for trial 1697, the likelihood of achieving ADA andAACE targets was statistically signi?cantly higher in the liraglutide 1.8 mg+OADs group as comparedto the glargine+OADs and the OADS alone groups.Table 6.35Percentage of Subjects Reaching ADA Target (HbA1c at 26 weeks (add-on therapy with twotrials)Logistic Regression Placebo Comparatorof Subjects Odds Odds Reaching Target Ratio 95% CI value Ratio 95% CI valueTrial 1574 1Lira 174 57.5 5.91 3.41 . 57-?. 10.24Lira 177 53.7 4.78 2.81 8.12 Placebo-l~OADs 167 28.1Trial 1697Lira 230 53.1 9.03 4.73 1.71 1.12 2.64 0.013917.23Placebo+OADs 1 14 15.3Glargine+OADs 232 45.8?In Trial 1574 the OADS were metformin rosiglitazone, in? Trial 1697 glimepiride -5- metformin.There was no comparator in Trial 1574; the comparator in Trial 1697 was glargine+OADsN=.number of subjects in ITT analysis set The estimates are obtained from a logistic regression with treatment as fixed effect and baseline HbA1c value as a covariate.Source: [Table 11?6, Trial 1574 report] [Table 11-14, Trial 1697 report]105	245529	247415
142	1	2	16	1	119	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000_)Victoza? (liraglutide)statistically signi?cant treatment by race interaction effect across all therapies, the number of subjects inparticular in the ?Black? and the ?Other? group are too small to draw any conclusions.Reviewer?s comments: The statistical reviewer concluded that across the ?ve Phase 3 studies, theaverage HbA1c response to liraglutide was not consistently affected by race or ethnicity. Most ofthe p-values of the interactions of race/ethnicity with treatment group were greater than 0.1. Inthe opinion of the statistical reviewer, the few.p-values that were less than 0.1 (such as in this case)were not consistent across studies and do not indicate an important effect of race on the ef?cacy ofliraglutide.6.l.4.3.5.3 Selected Exploratory AnalysesRenal and hepatic impairment: For trial 1574 the relationship between change in HbAlc and renal andhepatic impairment (baseline creatinine, ALT and AST by baseline quartiles) was stated as a pre-speci?ed analysis but data were not presented. For trial 1697, summaries of changes in HbA1c by renalimpairment (by baseline quartiles of creatinine values) and hepatic impairment (by baseline quartiles ofAST and A-LT values) did not indicate an effect of renal or hepatic impairment by creatinine, AST, orALT on the changes in HbAlc.Reviewer?s comment: See section 6.1.4.2.5.3 for a discussion of renal and hepatic impairmentmarkers. .6. 1.4. 3.6 Secondary e?icacy variablesfor the add-on with two OADS population6.1.4.3.6.l Glycemic control parametersSecondary glycemic control parameters were changes in fasting plasma glucose and post-prandialplasma glucose.asting Plasma Glucose (FPG)Table 6.35 summarizes the mean changes in FPG for the add?on to two OADS studies.Liraglutide vs. placebo: In trial 1574 all groups had a mean decrease in FPG, with the greatest meandecrease occurring in the liraglutide 1.8 mg+OADs group (44 mg/dL). The liraglutide 1.2 mg+OADsgroup had a decrease of 40 mg/dL, and the placebo+OADs group had the smallest decrease (8 mg/dL).The liraglutide groups were significantly better than the placebo+OADs group. In trial 1697, the107	249567	251749
146	1	2	16	1	123	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Trial 1697-The estimated mean reduction in post-prandial plasma glucose in the liraglutide 1.8mg+OADs group (-32.67 mg/dL) was not statistically signi?cantly different from the reduction seen inthe glargine+OADs group (-29.00 mg/dL) (p=0.3364, 95% Cl -11.15 3.82 mg/dL) but statisticallysigni?cantly greater than the very slight increase in the p1acebo+OADs group (0.57 mg/dL, p<0.0001,95% CI -42.47 (-24.00) mg/dL).Reviewer?s comment: the label states . 7 . The number mg/dL appears to comefrom trial 1572 at the 0.6 mg dose. These values were generated from the add-on with one OADtrials but are generally consistent with the add-on to two OADs trials reviewed in this section. Thenumber-- mg/dL comes from trial 1436 at the 1.8 mg dose (See section 6.1.4.2.6.2). The labeldoes not indicate that this reduction is on top of background therapy.6.1.4.3.6.2 Body WeightEstimated change in body weight from baseline to end of treatment and analyses of change in bodyweight after 26 weeks for trials 1574 and 1697 are shown in Table 6.36. In both trials, change in weightfor the liraglutide+OADs treatment groups was signi?cantly different from the placebo+OADs groupsin favor of liraglutide. Treatment with liraglutide 1.8mg+OADs was signi?cantly better than treatmentwith glargine+OADs for weight reduction (although the glargine+OADs group experienced a meanweight gain). Table 6.36Analysis of Body Weight (kg) Change from Baseline at 26 weeks (add-on therapy with two OADS trials)Placebo #ComparatorBaselinebodyweightun- *Adjusted Mean Meanadjusted mean change difference differencemean in body from com- from com? (SD) weight (SEM) parator 95% CI value parator 95% Cl valueTrial 1574Lira 1.2+oADs 176 95.3 -1.02 (0.33) -1.62 -2.39; - <.0001  (18.3) 0.85Lira 178 94.9 -2.02 (0.32) -2.62 -3.39; - <.0001(19.2) 1.89P1acebo+OADs 173 98.5 0.60 (0.34)(18.2)Trial 1697111	256432	258381
153	1	2	16	1	130	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)   Victoza? (liraglutide)         . . .     Liraglutide 1.8 mg -1.52Liraglutide 1.2 mg -1.54Liraglutide 1.3 vs. 1.2 0.02 -0.16; 0.20 0.8106Explanatory variables are Previous Treatment (Monotherapy/Combination), Randomized Treatment and baseline HbAlc value as a covariate.Source: Sponso?r?s Table 3-4When analyzing liraglutide treatment with regard to the number of subjects reaching HbAlc targets, thesmall difference between liraglutide 1distinguished. The table below (6.39) ofpercent reaching targets shows better why 1.8 should be considered for the maximal approved dosedepending on the riskzbene?t pro?le determined based on the safety review. Table 6.39 - Comparing Liraglutide Treatment Arms with Regard to Number of SubjectsReachin HbAlc after 26 weeks of treatmentTreatment/comparison n/N Odds/Odds 95% CI valueRatio1.3 '4 4 in 0.51 it 1.221.2 0.43 0.321.3 vs. 1.2 1.50 1.00 2.25utide 1.8 0.79utide 1.2 0.480.6 0.341.8 vs. . 1.64 1.06-2.53'de 1.2 vs. . 1.44 0.92 2.27utide 1.8 0.911.2 0.530.6 0.27e1.8vs.1.2 1.71 1.10-2.68de 1.2 vs. 0.6 2.00 1.24 3.2233 1.3 it 177 95 0.54 in 1.511.2 174 100 0.57 1.861.8 vs. 1.2 0.81 0.49 1.35 0.4160Explanatory variables arelPrevious Treatment (monotherapy/combination), Randomized Treatment and baseline HbAlc value as a covariateSource: ?s Table 3-86.1.4.5 Data presented at the June 1, 2009 Type A meeting between the Division and the SponsorCurrently, exenatide is the only approved GLP-1 agonist and is marketed as Byetta?. For the Type Ameeting between the Division and the Sponsor held on June 1, 2009, the Sponsor submitted a summaryof the results of trial 1797 which compared liraglutide to exenatide In this randomized, open-label,parallel group study, subjects who were on metformin, sulfonylurea, or both were randomized in a 1:1118'	266014	267866
154	1	2	16	1	131	Clinical ReviewLisa B. Yano??, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)ratio to either liraglutide or exenatide. From week 0 to 26 weeks (ITT with LOCF) the reduction in HbAlc was -1.12% for liraglutide and -0.79% for exenatide, which resulted in a statistically signi?canttreatment difference of -0.33% in favor of liraglutide (95% CI, -0.47 <0.000l). A 14 weekextension was also conducted for this trial in which subjects in the exenatide group were switched toliraglutide at week 26 and continued on therapy until week 40. From week 26 to week 40 (LOCF), themean decreases in HbAlc were -0.32% for the exenatide?>liraglutide group (p <0.000l) and -0.06% forthe group (p From week 0 to week 40 (LOCF), the mean decreases inHbAlc were 1.17% for the exenatide??>liraglutide group and 1.29% for the liraglutide?>liraglutide group(p <0.0001 for both groups). 86% of subjects treated with liraglutide and 81% of subjectstreated with exenatide completed the 26-week, head-to-head phase of the trial. 99% ofrandomized subjects (N=l99/202) who entered the extension in the liraglutide?>liraglutide group and95% of subjects who entered the extension in the group completedthe 14-week extension. The sponsor also noted that antibody development and nausea were less frequentwith liraglutide than with exenatide. In this head-to~head trial, 58% of patients treated with exenatidewere positive for antibodies while only 1.5% of patients treated with liraglutide had antibodies.6.1 ..4.6 Efficacy ConclusionsThe key phase 3 studies ful?ll the criteria for ?adequate and well?controlled? because0 the study objectives and statistical plans were stated a priori0 the study designs used valid control groups given adequate doses of comparator drugs in most cases(see important considerations and limitations)- the inclusion and exclusion criteria assured selection of patients with type 2 diabetes (HbAlcinclusion criteria)0 bias was limited by randomization, blinding, and objective, standardized endpointsLiraglutide?s maior efficacy ?ndings (1?year monotherapv)0 Liraglutide lowered HbAlc from baseline by to on average (not placebo-adjusted)0 Liraglutide lowered HbAlc by -0.34% to -0.62% relative to glimepiride0 Maximal HbAlc reduction occured by 12 weeks and was maintained through week 520 Liraglutide 1.8 mg and liraglutide 1.2 mg were both superior to glimepiride for HbAlc lowering0 Liraglutide 1.8 mg was superior to liraglutide 1.2 mg for HbAlc lowering0 The percentage of subjects achieving ADA and AACE targets was significantly greater in theliraglutide groups as compared to the glimepiride group0 There was no reported notable effect on change in HbAlc due to country, gender, race, ethnicity,age, and BMI. 0 Liraglutide (and glimepiride) was more effective among patients with higher baseline HbAlc, whichmay re?ect regression to the mean119	267867	270725
156	1	2	16	1	133	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)Caucasians. The Sponsor should increase enrollment of minorities in ongoing liraglutide studies toobtain a better assessment of efficacy in these populations.Given the similar efficacy between liraglutide 1remains to be seen whether thesmall bene?t of 1.8 mg over 1.2 mg is worth any extra risk incurred by the higher dose. This decisionwill be made taking the safety review into account.Rosiglitazone 8 mg qd is the maximal FDA approved dose. In trial 1436, the highest proposed doses ofliraglutide are being compared to the half maximal dose of rosiglitazone (4 mg qd). Therefore, caution iswarranted in concluding that liraglutide is superior to rosiglitazone given at the maximal FDA approveddose of 8 mg.In trial 1697, the rate of attainment of fasting plasma glucose goals for the glargine comparator groupwas notably low. Therefore, caution is also warranted in making conclusions regarding the ef?cacy ofliraglutide added to two OADS to the efficacy of glargine added to those same OADs.6.1.5 Clinical MicrobiologyNot applicable to this NDA6.1.6 Efficacy ConclusionsSee section 6.1.4.67 INTEGRATED REVIEW OF SAFETYThe entirety of section 7 was completed by Dr. Mahoney in her Clinical Safety Review.8 ADDITIONAL CLINICAL ISSUES8.1 Dosing Regimen and AdministrationThe sponsor?s proposed dosing regimen is as follows: 1 For all patients liraglutide treatment should be initiated with a dose of 0.6 mg for at least one week, afterwhich the dose should be increased to 1.2 mg. Based on tolerability and/or clinical response and after atleast one week at 1.2 mg, the dose can be increased to 1.8 mg to achieve maximum efficacy. The dosecan be given any time of day and does not need to be given in relation to meals.121	273697	275503
161	1	2	16	1	138	Clinical ReviewLisa B. Yanoff, M.D.NDA 22,341 (Submission 000)Victoza? (liraglutide)10 APPENDICES10.1 Review of Individual Study ReportsDetails of phase 2 studiesDose Selection/Dose Regimen Trials (Phase 2 trials relevant for efficacy)Trial 1571This is the phase 2 study cited by the Sponsor as the study that determined the doses for the phase 3study.Design: 14 week, multicenter, four-arm, double-blind, randomized parallel group, placebo-controlled trial with three doses of liraglutide (?xed doses of 0.65 1.25 (n=42) or 1.90 (n=41)mg/day liraglutide, once daily with forced titration during 1-2 weeks for the two higher doses) vs.placebo (n=40) in patients with type 2 diabetes either on diet/exercise therapy or drug monotherapy(baseline HbAlc 6.4 E?icacy Results: Liraglutide dose-dependently reduced HbAlc levels inall active groups compared with placebo The estimated difference of change in HbAlc frombaseline to end of treatment between the 1.90 mg dose and placebo was and between the 1.25mg dose and placebo was with 46% of subjects from both groups achieving an HbAlc level(placebo group: The estimated difference of change in HbAlc from baseline to end oftreatment between the 0.65 mg dose and placebo was -1.27%Reviewer?s comment: The 1.25 and 1.90 mg doses appear equally effective in this trial with the0.65 mg dose effective compared with placebo as well. The minimally effective dose was notestablished by this phase 2 study. The maximally effective dose seems to be close to 1.90 mg.Trial 1310Primary Objectives: to establish the dose-response relationship on glycemic control of ?ve dose levelsof liraglutide and placebo. Design: A 12-week, multi-center, multi-national, seven-arm parallel-grouptrial with ?ve doses of liraglutide (0.045, 0.225, 0.45, 0.60 or 0.75 mg/day, double-blind) versusplacebo double-blind) or glimepiride (1 or 2 mg, open-label) in subjects with type 2 diabetesmellitus. E?icacy Results: The effect of liraglutide on HbAlc increased with increasing dose; theestimated maximal effect, Emax, was a 1.74 percent unit decrease, while the estimated dose for half-maximal effect, ED50, was 0.76 mg. As the estimated ED50 was similar to the highest doseinvestigated, this indicates that only the lower part of the dose-response curve has been established inthis trial. A dose-response relationship was found for glycemic control. After 12 weeks of treatment,HbAlchad decreased in all but the lowest liraglutide dose group. Mean HbAlc decreasedby -0.70 at 0.60 mg and -0.75 at 0.75 mg and the difference was signi?cant ascompared to placebo (p=0.0002 and p<0.000l, respectively).RevieWer?s comment: This trial establishes that the ED50 is 0.76 mg. Therefore, the selection of0.6 mg as the starting dose in the phase 3 program "is appropriate. 126	284040	286824
176	1	2	16	1	153	Clinical Safety ReviewKaren Murry Malioney, MD, FACENDA 2234! Submission 000Victoza? (liraglutide injection)that the applicant?s analyses had omitted some patients who had elevated values. The applicantattributed the bilirubin data omissions to a programming error, and submitted errata. A responsefrom the applicant regarding the creatinine elevation reporting discrepancy is pending.1.3.4 Dosing Regimen and AdministrationPlease see Dr. Yanoff? clinical efficacy review.1.3.5 Drug-Drug InteractionsLiraglutide had little effect on the metabolism of other drugs by multiple cytochrome P450isoforms. It is metabolized by dipeptidyl-peptidase-4, and by other peptidases..Liraglutide slows gastric emptying, and thus may prolong Tmax, and lower Cmax of orallyadministered drugs. Liraglutide delayed Tmax and lowered Cmax for atorvastatin, lisinopril,paracetamol and digoxin. For griseo?ilvin, however, Cmax was 37% higher at liraglutide steadystate conditions when compared to placebo. The clinical signi?cance of these effects is underdiscussion with the Clinical Pharmacology team.No drug-drug interaction study with warfarin was performed. There have been postmarketingreports of possible warfarin interactions with exenatide. The Clinical Pharmacology team isdiscussing whether a warfarin interaction study would be advisable for liraglutide.1.3.6 Special PopulationsDosage adjustment does not appear necessary for patients with hepatic or renal impairment.There were too few patients age 75 years or older to make conclusions regarding dosing in thispopulation; the 1.8 mg dose may be associated with more gastrointestinal and nervous systemadverse events in this age group than in younger patients. No dosage adjustment appearsnecessary by race or ethnicity.Page 11 of249	322214	323988
180	1	2	16	1	157	Clinical Safety Review -Karen Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutidc injection)Table 4.2.1: Clinical Studies in Liraglutide Development Program at Time of NDASubmissionTrial Country Type of Design Study Drugs Pop Duration Status]ID2 Study andControlNN2211- DE Bioequiv SCHealthy SD Complete1331 X0 LGTformulations 2and 3NN2211- AU Bioequiv SC, R, DB, SD SQ, 0.75 mg 24 Healthy SD Complete1636 X0 LGTformulation 3 at7.7, 7,9 and8.15NN2211- SE Bioequiv SC, R, DB, SD SQ, 0.72 mg 21 Healthy SD Complete1692 X0 LGTformulation 4and fonnulation4 with ?nalmanufacturingprocess for /drugsubstanceSE Bioequiv SC, R, DB, SD SQ, 0.71 mg 22 Healthy SD Complete1693 X0 LGTformulations 3and 4NN2211Healthy SD Complete1745 X0 LGT, in abd,thigh and upperarmNN2211DB, Eight single SQ 72 Healthy SD Complete1 149 BA PC, parallel- doses (1.25, 2.5, (54 LGT,grp, dose 5, 10, 12.5, 15, 18 PBO)escalation 17.5 or 20meg/kg) or onesingle IV dose 5meg/kgNN22110.75 mg 7 Healthy SD Complete1699 radiolabeledLGTGB PK and PD SC, R, DB, Initial SD SQ, Healthy: Healthy and SD Complete1189 PC, parallel followed by QD 20 LGT, DM2 followed bygrp, dose escalating doses 10 PBO 7 days 1escalation of1.25, 5, 7.5,10 and 12.5 DM2:2 LGT,2 PBONN2211elderly, Healthy elderly SD Complete1327 parallel 16 non- and non?elderlyelderlyNN22110.75 mg Nondiabetic: Nondiabetic and SD Complete1329 parallel 27 DM2 withDM2: 3 normal or(All divided impaired renalinto?5 by renal fxn)NN22110.75 mg Nondiabetic: Nondiabetic and SD Complete1328 parallel 24 DM2 withDM2: 5 normal or(All divided impaired hepaticinto 4 by hepaticfxn)Page 15 01249	332120	333741
181	1	2	16	1	158	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 4.2.1: Clinical Studies in Liraglutide Development Program at Time of NDA 1SubmissionTrial Country Type of Design Study Drugs Pop Duration Status?1132 Study andControlNN221 SQ, titrated 21 Healthy 3 LGT Complete1330 PC, X0 from 0.6-1.8 mg postmenopausal and SDand SD by women OCPmouth OCP1- SE DDI 2C, R, DB, LGT SQ, Part A: 42 Healthy 4 LGT Complete1608 PC, 2-way titrated from Part B: 28 and SD drugX0 trial in 2 0.6-1.8 mg. for DDIparts Part A: SD bymouth 40 mgatorva and 20mg lisinoprilPart B: SD bymouth 500 mggriseofulvin and1 mg digoxinNN2211-. US QT SC, R, DB, LGT, titrated 58 Healthy 7 Complete1644 PC X0 from 0.6-1.8 mgfollowed by SQ, then moxiOL moxi SD 400 mg bymouthDE PD and DDI SC, R, DB, LGT, titrated 18 DM2 3 Complete1698 . PC, X0 from 0.6-1.8 mgSQ, andparacetamol SD1 gm by mouthNN2211- AU, DE PD 2C, R, DB, LGT: titrated 46 DM2 4 Complete1589 balanced from 0.6-1.8incomplete mg.Latin square. Glimepiride: 1-4PBO and mg by mouthglimepiride QD controls Paracetamol: SD1 gm by mouthNN2211DM2 9-10 days Complete1332 PC, X0 QD 9-10 daysNN221 Complete1219 PC, SD, X0 mcg/kg SQNN2211LGT 7.5 Healthy: 10 Healthy and SD Complete2063 PC, X0 meg/kg SQ DM2Complete1224 PC, X0 mcg/kg SQDK, FR, NL, EfficacyHealthy: 12 DM2 14 Complete15712 SK safety PC, parallel (0.65, 1.25 or (not dosed)1.9 mg) 14 DM2: I63(LGT 0.65mg: 40LGT 1.PBO: 40)Page 16 of249	333742	335210
182	1	2	16	1	159	Clinical Safety ReviewKaren Murry Mahoncy, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Table 4.2.1: Clinical Studies in Liraglutide Development Program at Time of NDASu bmissionTrial Country Type of Design Study Drugs Pop Duration Status]ID2 Study andControlNN221 1- DK, NO, SE, Efficacy190 total DM2 12 Complete13102 GB safety (LGT vs. (0.045, 0.225, LGT 0.045PBO) 0.45, 0.6 or 0.75 mg: 26parallel grp, mg) LGT 0.225with AC OL Glimepiride 1-4 mg: 24glimepiride mg by mouth LGT 0.LGT 0.75mg: 28GLIM: 26PBO: 29AT, AU, CZ, Efficacy, MC, R, DB LGT QD SQ, 144 total DM2 5 Complete14992 DK, FR, DE, safety (LGT vs. titrated from LGT: 36PL, GB PBO), 0.5-2 mg. LGT MET:parallel grp, MET 1 gm by 36with AC OL mouth BID . MET: 36MET and GLIM, 2-4 mg MET GLIM by mouth QD GLIM: 361- US, MX Efficacy, MC, R, DB, LGT QD SQ, 745 total DM2 52 Complete15732 safety, pop AC, parallel titrated from 0.6 LGT 1.2;PK group to 1.2 or 1.8 mg 251GLIM, 8 mg by LGT 1.8:mouth QD 246GLIM: 2481- US, MX Efficacy, MC, R, OL, LGT QD SQ, 440 total DM2 approx I8 Ongoing1573 safety parallel grp, 1.2 or 1.8 mg LGT 1.2: moEXT 12 AC, GLIM, 3 mg by 149extension mouth QD LGT 1.8:154GLIM: 1371- AR, AU, Efficacy, MC, R, DB, LGT QD SQ, 1087 total DM2 26 Complete15722 BE, BG, DE, safety parallel grp, 0.6 or 1.2 or 1.8 LGT 0.6 DK, ES, GB, PBO and mg, titrated MET: 242HR, HU, IE, AC from 0.6 mg, in LGT 1.2 IN, IT, NL, combo with METMET: 242SK, ZA mouth BID MET PBO:PBO 121GLIM 4 mg by GLIM mouth QD MET: 242METNN2211- AR, AU, Efficacy, MC, R, OL, LGT QD SQ, 780 total DM2 approx 18 Ongoing1572 BE, BG, DE, safety parallel grpand mg, titrated MET: 184HU, IE, IN, PBO, from 0.6 mg, in LGT 1.2 IT, NL, NO. extension combo with METMET: 174ZA mouth BID MET PBO:PBO 61GLIM 4 mg by GLIM mouth QD MET: 183MET Page 17 of 249	335211	337010
187	1	2	16	1	164	Clinical Safety ReviewKaren Muiry Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Within this clinical safety review document, those sections which ordinarily would include onlyef?cacy data are marked, and the reader is referred to Dr. Yanoff? review.4.4 Data Quality and IntegrityIn general, the data were of suf?cient quality to permit safety review. A full listing of adverseevents had not been provided in the original NDA, but the applicant complied with a request tosubmit a complete list. An inquiry from the Agency regarding missing calcitonin data led theapplicant to submit corrected calcitonin analyses on 25 Jun 2009 and 8 Jul 2009; the applicantreported that there had been a programming error in the calcitonin analyses. Two inquiries fromthe Agency regarding bilirubin data led the applicant to submit corrected analyses on 17 Jul2009; the applicant reported that there ?had been a programming error in the bilirubin analyses.An inquiry from the Agency regarding serum creatinine values raised a question regardingwhether the applicant had appropriately captured elevated values. The Agency is awaitingclari?cation of this discrepancy from the applicant.The Division of Scienti?c Investigations performed multiple inspections of Novo facilities andinvestigative sites related to this application. Inspections were performed of clinical and analytic -facilities in Plainsboro, New Jersey; Copenhagen, Denmark; and Lund, Sweden. The PlainsboroNew Jersey site inspection revealed some minor procedural de?ciencies; the applicant submitteda corrective plan which the inspector concluded was adequate. The applicant also submittedresponses to de?ciencies noted at the Copenhagen and Lund sites; as of 21 Jul 2009, evaluationof the adequacy of the applicant?s responses by the Division of Scienti?c Investigations ispending. In addition, individual study sites were inspected in Des Moines, Iowa; Las Lomas,Puerto Rico; and Los Angeles, Califomia. Inspection of the site in Puerto Rico revealed someminor regulatory violations which the investigator at the site agreed to correct. At all sites, theconclusion was that the data generated from the sites could be used in support of the application.34.5 Compliance with Good Clinical PracticesPlease see Dr. Yanoff? clinical ef?cacy review.4.6 Financial DisclosuresPlease see Dr. Yanoff? clinical ef?cacy review.5 CLINICAL PHARMACOLOGYPlease see Dr. Khurana?s Clinical Pharmacology review and Dr. Yanoff? clinical ef?cacyreview. Drug?drug interactions are discussed in Section 8.2. Dr. Khurana found the clinicalpharmacology evaluation acceptable, and does not have recommendations for postmarketingcommitments related to clinical pharmacology issues.No dose adjustment is proposed for renal or hepatic impairment. In a renal study, AUC 0-infwas 19-35% lower in renally impaired patients than in patients with normal renal function.Page 22 of249	345147	348072
188	1	2	16	1	165	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection) 7Severe hepatic impairment was associated with a Zefold increase in clearance and a 42% meanlower AUC 0?inf for liraglutide.Liraglutide?s effect on metabolism by multiple cytochrome P450 isoforms was investigated, andliraglutide had little effect. It is metabolized by DPP4, and by other peptidases.Liraglutide slows gastric emptying, and thus may prolong Tmax, and lower Cmax of orallyadministered drugs. Liraglutide delayed Tmax and lowered Cmax for atorvastatin, lisinopril,paracetamol and digoxin. For griseo?ilvin, however, Cmax was 37% higher at liraglutide steadystate conditions when compared to placebo. The clinical significance of this effect is underdiscussion with the Clinical Pharmacology team. Liraglutide lowered the Cmax ofethinylestradiol and levonorgestrel by 12 and 13%, respectively, and delayed Tmax by 1.5 hrs;these effects are unlikely to affect the contraceptive efficacy of these drugs.6 INTEGRATED REVIEW OF EFFICACYPlease see Dr. Yanoffs clinical ef?cacy review.7 INTEGRATED REVIEW OF SAFETY7.1 Methods and Findings7.1.1 DeathsAt the time of submission of the NDA, the applicant reported a total of 8 deaths in the liraglutidedevelopment program. Three deaths occurred among liraglutide-treated patients, three occurredamong active-comparator-treated patients, and two occurred in patients who had not yet beenrandomized to a study drug. The applicant states that they have reported all deaths of which theyhave knowledge, even those which occurred after study drug discontinuation. Deaths whichoccurred post-randomization are listed in the following table.Page 23 of 249	348073	349779
194	1	2	16	1	171	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 2234! Submission 000Victoza? (liraglutide injection)Table 7.1.2.1: Serious Adverse Events by System Organ Class and PreferredTerm, All Completed Trials at Time of NDA SubmissionLGT System Organ Class Preferred Term 139Ratel Rate/1000 PY 1000 PYColon adenoma 1 0.4 0 0 '0Gastrointestinal carcinoma 1 0.4 0 0 0Hepatic neoplasm malignant 1 0.4 0 0 0Lung carcinoma cell type 1 0.4 0 1 0 0unspeci?ed recurrentMalignant 1 0.4 0 0 unclassifiabie high gradeasopharyngeal cancer 1 0.4 0 0 0Renal cell carcinoma stage 1 0.4 1 0.9unspeci?edUterine leiomyoma 1 0.4 0 0 0Colon cancer 0 0 0 1 0.9Glioblastoma multiforme 0 0 1 0.9Nervous system disorders Any 18 0.4 8.0 7 0.3 6.1Cerebrovascular accident 3 0.1 1.3 0 0 0Syncope 2 0.9 0 0 0Cerebral hemorrhage 1 0.4 0 0 0Cerebrovascular disorder 1 <0.1 0.4 1 0.9Diabetic neuropathy 1 <0.1 0.4 0 0 0Dizziness 1 0.4 0 0 0Hemorrhage intracranial 1 <0.1 0.4 0 0 0Headache 1 <0.1 0.4 0 0 Hypoaesthesia 1 <0.1 0.4 0 0 0Loss of consciousness 1 <0.1 0.4 0 0 0Nerve compression 1 0.4 0 0 0Radial nerve palsy 1 0.4 0 0Sciatica 1 <0.1 0.4 0 0 0Subarachnoid hemorrhage 1 <0.1 0.4 0 0Transient ischemia attack 1 <0.1 0.4 1 <0.1 0.9Carotid artery stenosis 0 0 0 2 0.1 1.8Grand mal convulsion 0 0 0 1 <0.1 0.9Ischemic stroke 0 0 0 1 0.9Presyncope 0 0 0 1 0.9Musculoskeletal and Any 14 0.3 6.2 7 0.3 6.1connective tissue disordersIntervertebral disc 2 0.9 0 0 0protrusionOsteoarthritis 2 0.9 3 0.1 2.6Collagen disorder 1 0.4 0 0Intervertebral disc 1 0.4 0 0degenerationIntervertebral disc disorder I 0.4 1 0.9Lumbar spinal stenosis 1 0.4 0 0 0Muscle spasms 1 0.4 0 0 0Page 29 of 249	363244	364896
198	1	2	16	1	175	Clinical Safety ReviewKaren Murry Malioney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)Table 7.1.2.2: Serious Adverse Events of Possible Immune EtiologyLGT Non-System Organ Class Preferred Term LGT1 1 Gastrointestinal disorders Crohn?s disease 1 <0.1 0.4 0 0 0Musculoskeletal and connective tissue Collagen disorder 1 <0.1 0.4 0 0 0disordersMyositis 1 <0.1 0.4 0 0Rheumatoid arthritis 1 <0.1 0.4 0 0 0Endocrine disorders Adrenocortical insuf?ciency 2 <0.1 0.9 0 0 0acuteRespiratory, thoracic and mediastinal organizing 1 <0.1 0.4 0 0 0disorders pneumoniadisorders Uveitis 1 <0.1 0.4 0 0 0Skin and subcutaneous tissue disorders Angioedema 1 <0.1 0.4 0 0 0Source: Applicant?s Table 72, beg pg 1123 ISSA total of nine serious potential immune-related events occurred among 4211 liraglutide-treatedpatients. Narratives for these cases follow:Patient 175012 had an event of uveitis. This was a 71 year old Spanish woman who presentedwith blurred vision and ?vision of black dots? after 297 days of LGT 1.8 mg/day. She had aprior history of glaucoma and hypertension. She was admitted. Ophthalmoscopy showed paleoptic papillae and atrophic retinal lesions. Intraocular pressure was 45 mmHg. ?Hypertensiveuveitis? was diagnosed. She was treated with dexamethasone, atropine, and cusimolol. Angiography was not performed. Serology (not specified) showed ?nothing abnormal?. Shewas discharged one day later, and one month later was considered recovered.Patient 180014 had an event of Crohn?s disease. This was a 52 year old American woman whopresented with ?regional enteritis? after 462 days of liraglutide 1.8 mg/day. The narrative statesonly that the patient was admitted to the hospital and discharged two days later. No details ofhow the diagnosis of Crohn?s disease was made, or what treatment was administered, wereprovided.Patient 188004 had an event of acute adrenocortical insuf?ciency. This was a 47 year oldAmerican woman with a prior history of adrenogenital hirsutism, ovaries,vitamin de?ciency, dyslipidemia and depression. She presented with ?adrenal crisis? after 226days of liraglutide 1.2 mg/day. At presentation, her potassium was 6.6 mEq/L. The narrativestates that the patient was discontinued from study at this time, but discontinuation was due toalcohol abuse. The narrative does not speci?cally state that the patient was admitted to thehospital at that time. It does state that she was admitted seven days later due to hyperkalemia,with a serum potassium of 7.0 mEq/L. She also had bronchitis. Aldactone was discontinued,and she received intravenous ?uids and Kayexalate. Intravenous hydrocortisone and anintravenous insulin drip were administered. was also administered. She wasdischarged three days later. She did not resume study, and began subcutaneous insulin fortreatment of her diabetes. The narrative states that she resumed physiologic steroid replacement.Page 33. of 249	370286	373204
200	1	2	16	1	177	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234! Submission 000Victoza? (liraglutide injection)microvascular disease. After three days in hospital, the patient was discharged. After about onemore month, the pain resolved.Patient 762012 had an event of collagen disorder. This was a 59 year old Polish man whopresented with fever, weakness, abdominal pain and after 123 days of liraglutide1.8 mg/day. He was diagnosed with ?collagenosis? and ?sperrnatitis?. He was treated withNovomix? (mixed insulin aspart and insulin aspart) and cipro?oxacin.Study medication was discontinued. He was discharged after 17 days in the hospital. Thenarrative does not include details of how the diagnosis of collagen disorder was assigned.?Collagenosis? is an alternative term for collagen-vascular disease, and is defined as ?any of agroup of diseases affecting connective tissue and often characterized by tibrinoid necrosis orvasculitis and including such diseases as lupus erythematosus, progressive systemic sclerosis,rheumatoid arthritis, rheumatic fever, polyarteritis nodosa and dermatomyositis?.Although there was an apparent imbalance in serious immune system events based on eventterms, review of narratives revealed that several of the events were exacerbations of pre-existingconditions, and others had inadequate information to assign causality. Patients 188004 and504010 had pre-existing chronic adrenal insuf?ciency, and presented with acute adrenalinsufficiency at the time of infections, a common scenario in patients with chronic adrenalinsuf?ciency. Patient 516007 presented with an exacerbation of pre-existing rheumatoidarthritis. Patient 175012?s uveitis, Patient 52601l?s myositis, and Patient 471040?s COP werenot clearly immune in etiology. Patient 375005?s angioedema appeared temporally related toantibiotic therapy rather than LGT therapy. There were too few details of Patient 1800l4?sCrohn?s disease and Patient 7620l2?s collagen disorder to assign causality. Overall, it appearsunlikely that LGT was associated with causality for new immune disorders. If another largestudy of LGT is initiated, e.g. for cardiovascular (CV) outcomes, systematic collection ofimmune system event datawould be useful.7.1.3 Dropouts and Other Signi?cant Adverse Events7.1.3.1 Overall pro?le of dropoutsAcross the development program, the highest rate of withdrawal occurred among placebo-treatedpatients, for whom the most common reason for withdrawal was ineffectiveness of therapy.Withdrawals due to adverse events were more common among LGT-treated patients than amongcomparator-treated patients, with gastrointestinal events contributing to the excess withdrawalrate. This excess withdrawal rate was seen primarily for the 1.2 and 1.8 mg/day dose groups; themost common reason for withdrawal from the 0.6 mg/day dose group was ineffectiveness oftherapy.The following table summarizes disposition for the five major Phase 3 trials.Page 35 of249	376758	379710
203	1	2	16	1	180	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 7.l.3.1.2: Disposition by Trial, Five Major Phase 3 TrialsTrial Pt Reason for if LGT LGT LGT PBO AC TotalStatus Applicable 0.6 1.2 1.8Source: Table 5, beg pg 23, Statistical Review by Dr. DerrIn studies which had a placebo arm, patients in the placebo arm were more likely to withdrawearly due to ineffective therapy. In the studies which had- an active comparator arm, patients inthe liraglutide and active control arms were approximately equally likely to withdraw early dueto ineffective therapy.7.1.3.2 Adverse events associated with dropoutsThe following adverse events were associated with dropouts.Table 7.1.3.2: Adverse Events Associated with Dropouts, All Completed Trials at Time ofNDA Submission .LGT Non-SOC Preferred Term LGTN=421l Any Any 250 (5.9) 69 (3.0)Gastrointestinal disorders Any 155 (3.7) 16 (0.7)Nausea 81 (1.9) 2 (0.1)Vomiting 46 (1.1) 1 Diarrhea 31 (0.7) 4 (0.2)Dyspepsia 14 (0.3) 0Constipation 12 (0.3) 2 (0.1)Abdominal distension '9 (0.2) 2 (0.1)Abdominal pain upper 7 (0.2) 0Abdominal pain 6 (0.1) 3 (0.1)Gastritis 5 (0.1) 0Abdominal discomfort 4 (0.1) 2 (0.1)Dry mouth 4 (0.1) 0Eructation 4 (0.1) 0Gastrointestinal discomfort 4 (0.1) 0Gastroesophageal re?ux disease 4 (0.1) 1 Flatulence 3 (0.1) . 0Abdominal tenderness 2 0Diverticulum 1 1 1 0Hemorrhoids 1 0Infrequent bowel movements 1 0Lip swelling 1 0Edematous pancreatitis 1 0Pancreatitis 1 0Stomach discomfort 1 0Umbilical hernia 1 0Diverticulum esophagus 0 1 Page 38 of 249	382785	384355
208	1	2	16	1	185	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Table 7.1.3.2: Adverse Events Associated with Dropouts, All Completed Trials at Time ofNDA SubmissionLGT Non-SOC Preferred Term LGT11 11 disordersVulvovaginal pruritus 1 0Erectile dysfunction 0 1 Source: Applicant?s Table 108, beginning pg 1262, ISSAcross all completed trials of liraglutide at the time of NDA submission, withdrawals due toadverse events occurred in 5.9% of liraglutide-treated patients and in 3.0% of non-liraglutide-treated patients. This difference was largely accounted for by more withdrawals forgastrointestinal (GI) events among liraglutide-treated patients, especially events of nausea,vomiting and diarrhea.All withdrawals due to injection site events (8 versus 0), and all withdrawals due to hepatobiliarydisorders (5 versus 0), occurred among liraglutide?treated patients.The event of ?hepatic enzyme increased? in a liraglutide-treated patient occurred in a 42 year oldman (ID 267005) who had a maximum elevation of alanine aminotransferase of 85 (ULN 43but who was withdrawn from study due to the event.The event of ?aspartate aminotransferase (AST) increased? occurred in a 57 year old man (ID499003), who had a baseline elevation of AST to 129 (ULN 43 After 3 months ofliraglutide treatment, he had an AST of 174 and LGT was discontinued. After 42 days offliraglutide, he was considered ?recovered?, but follow-up AST values were not reported.Two liraglutide-treated patients were withdrawn from study due to events of elevated creatinephosphokinase (CPK). Patient 124003 was a 39 year old man who had a CPK of 361 (ULN179 after 6 months of liraglutide therapy. Liraglutide was withdrawn; a brief narrativestates that 6 days after withdrawal, the patient was recovering, but follow-up CPK was notreported. Patient 273015 was a 57 year old man who had a CPK of 207 after 9 months ofliraglutide. He also had a mild elevation of aspartate aminotransferase of 58 (ULN 43 He was withdrawn from study; follow-up CPK values are not mentioned. These elevations ofCPK are relatively mild, and do not represent rhabdomyolysis.The events of hypersensitivity were both reported as nonserious events, but resulted inwithdrawal from study. Patient 185006 was a 65 year old woman who developed ?delayedhypersensitivity reaction? after 28 days of LGT treatment. The event was not furthercharacterized. Liraglutide was discontinued and she was reported as recovered 6 days after theevent. Patient 502007 was a 42 year old woman who had an event of ?drug hypersensitivity?that was not further characterized. She had been on liraglutide for 28 days. She recovered 3days after discontinuation of liraglutide. .Page 43 of 249	389571	392313
209	1	2	16	1	186	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 22341 Submission 000Victoza? (Eiraglutide injection)7.1.3.3 Other significant adverse eventsMajor Adverse Cardiovascular Events7.l.3.3.1.l Introduction to the Review of Major Adverse Cardiovascular EventsThere has been a great deal of interest in the cardiovascular safety of drugs for the treatment ofdiabetes. This interest has resulted in two recent Advisory Committee meetings in July 2007 andJuly 2008. In the 2008 Advisory Committee meeting, the panel (populated by members of theEndocrine and Metabolic Drugs Advisory Committee, members of the Drug Safety and RiskManagement Advisory Committee, and other diabetologists, cardiologists and statisticians) wasasked to discuss whether cardiovascular outcomes trials (or equivalent evidence ofcardiovascular safety) were needed for new drugs for the treatment of type 2 diabetes mellitus.This panel recommended, by a vote of 14:2, that more extensive cardiovascular safetyassessment should be required. After that meeting, the Division of Metabolism andEndocrinology Products issued a Guidance for Industry regarding the evaluation ofcardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Please refer to thatGuidance for ?irther details. In the Guidance, prospective planning of an overall developmentprogram is recommended, in order that the eventual marketing application will contain adequateinformation for evaluation of cardiovascular risk. Some important elements of the guidanceinclude:0 All Phase 2 and Phase 3 trials should have prospective independent blinded adjudicationof major adverse cardiovascular events. The events should include cardiovascularmortality, myocardial infarction, and stroke, but could possibly include other majoradverse cardiovascular events.0 All Phase 2 and Phase 3 trials should be designed so that a meta-analysis can beperformed on the overall Phase 2/3 trial population.0 Patients at higher risk of cardiovascular events should be included in clinical trials.0 Prior to submission of a New Drug Application, the applicant must demonstrate that thedrug is unlikely to carry a signi?cantly increased risk of cardiovascular events. This maybe done by a meta-analysis of the overall Phase 2/3 development program, or by theaddition of a large single cardiovascular outcomes trial to the Phase 2/3 developmentprogram. In either instance, when the overall study drug is compared to the overallcontrol population, the upper bound of the 95% confidence interval for the risk ratio ofthe chosen composite of major adverse cardiovascular events should be less than 1.8,prior to submission of the New Drug Application.- If the upper bound of the 95% confidence interval is between 1.3 and 1.8, and theremainder of the overall risk-bene?t analysis supports -approval, a postmarketingcardiovascular outcomes trial will generally be required, this time with an upper bound ofthe 95% con?dence interval of less than 1.3. 0 If the premarketing upper bound of the 95% confidence interval is less than 1.3, and theremainder of the overall risk?bene?t analysis supports approval, a postmarketingcardiovascular outcomes trial might not be needed.This Guidance is important, but it is intended for drugs that are currently in development. At thetime that the Guidance was issued, Novo Nordisk had already submitted its New DrugPage 44 of 249	392314	395703
218	1	2	16	1	195	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)the speci?c MACE endpoint, some studies had 0 MACE events in one or both groups that werebeing compared. In this context, Dr. Derr, the FDA Biostatistician, did not identify one specificmethod of estimation that was preferable to others. For this reason, she evaluated the sensitivityof the upper 95% CI bound estimate across a selection of methods. An estimated upper 95% CIbound that varied greatly from method to method would suggest that there is an insuf?cientnumber of MACE events, or other inconsistencies among studies, to provide a stable estimate ofthe upper 95% CI bound.The methods that Novo and Dr. Derr used are the following, presented with a brief description ofthe advantages and. disadvantages of each method in the context of the MACE analysis in theliraglutide studies:0 Novo used an stratified, Cochran Mantel-Haenszel analysis (CMH). While thismethod is well-established for the analysis of incidence ratios, a limitation is that studies withMACE events in the comparator group are omitted from the estimate. The method relies on the assumption that the variance of the estimated ratio is approximatelynormally distributed. This assumption may not apply well in circumstances where the eventsare rare.0 Dr. Derr conducted an exact, stratified analysis, and obtained the estimates from StatXact7TMsoftware. This method uses a different approach to estimation than the approachused in the CMH analysis. -The exact method tends to be conservative, resulting in upper 95%.CI bounds that may be wider than they need to be. Another limitation is that studies with MACE events in the comparator group are omitted from the estimate.0 Dr. Derr also conducted a stratified fixed-effects Mantel-Haenszel meta-analysis with acontinuity correction of 0.5 applied to studies with 0 events in one or both groups. Thisapproach permits studies with 0 events to be included in the estimate. However, incircumstances where the events are rare, the continuity correction can be quite in?uential inestimating the 95% CI bounds. In addition, Dr. Derr constructed forest plots to depict thestudy-by-study estimates as well as the overall estimate.Dr. Derr notes that all three methods are stratified, re?ecting her preference for this approach inthe context of the analysis of MACE events from the liraglutide studies. The primary reason forthis preference is the variety of designs in the Phase 2 and 3 studies, with different allocationratios of liraglutide to comparator and somewhat different study populations. Dr. Derr believesthat use of a stratified analysis in this context results in a more accurate point estimate for theincidence ratio than does use of an unstrati?ed analysis.Dr. Derr notes further that other estimation methods are available, and that this is not intended as. a comprehensive list of all available methods. In addition, Dr. Derr notes that other forms of thesummary statistic are available, such as the incidence difference and the incidence rate ratio (theincidence divided by the patient-years of exposure, expressed as a ratio between liraglutide andthe comparator). Novo also provided estimates for these summary statistics. However, thefocus in this document is on the incidence ratio and the three methods Dr. Derr selected forevaluating sensitivity. -Page 53 of 249	414427	417834
221	1	2	16	1	198	Clinical Safety ReviewKaren Muny Mahoney, MD, FACENDA 22341 Submission 000Victoza? (liraglutide injection)procedures were somewhat more variable, with a wider range in the estimated 95% CI bounds.All 8 point estimates were Seven of the 8 upper 95% C1 bounds were with 2 being<1.3 (Tables 7.1.3.3.l .3.9-7.1 .3.3.1.3.12). For this reason Dr. Derr concluded that the estimatesfor the liraglutide versus active control were somewhat sensitive to the choice of estimationmethodology.The number of actual events for the liraglutide and active control groups is summarized in Table7.1.3.3.1.3.7. The number of events was small in most analyses. 1As mentioned earlier, time period Population A (in the Tables 7.l.3.3.1.3.2 through 7.1 includes all data from the randomized, controlled portions of the trials, out to measurement of theprimary endpoint. The ?Uniform? MACE analysis request had speci?cally requested data fromthe randomized, double-blind, controlled portions of the trials, out to measurement of theprimary endpoint. However, in four of the Phase 2/3 trials of liraglutide, a comparator arm wasopen-label prior to the primary endpoint. These arms were not excluded from the aboveanalyses, and that was the intent of the FDA request. Novo did comply completely with therequest, and performed additional analyses excluding these open-label arms, and submitted theanalyses on 13 Feb 2009. However, the Agency considers these analyses less useful than thosewhich include all arms up to measurement of the primary endpoint.A series of tables follows, which presents the data and analyses described above for the MACEanalyses.Table 7 .1.3.3.1.3.2: Incidence Ratio, Liraglutide versus Pooled Comparator (Placebo Active Comparator), Novo Strati?ed CMH AnalysisMACE Endpoint Type of Events PopPoint EstimateFDA Broad Narrow All Serious A (95% CI)Custom SMQ SMQ TEAE Only0.72 (0.32, 1.61)0.87 (0.57, 1.34)0.87 (0.45, 1.69)0.69 (0.29, 1.62)0.67 (0.32, 1.41)0.64 (0.30, 1.34)0.79 (0.41, 1.54)0.88 (0.61, 1.28)0.89 (0.52, 1.52)0.76 (0.37, 1.57)0.83 (0.44, 1.56)0.30 (0.42, 1.51)Source: Applicant's Table 3, pg 23, NDA 22341 subm stamp date 13 Feb 2009Abbreviations: C1 con?dence interval, Pop time period population, SMQ Medical Dictionary for Regulatory Activities Standard Query, TEAE treatment-emergent adverse events; CMH Cochran Mantel-I-laenszelPage 56 of249	424533	426890
227	1	2	16	1	204	Clinical Safety ReviewKaren Murry Mahoney, MD, FACENDA 2234] Submission 000Victoza? (liraglutide injection)Examples 0Analysis ScenarioNumbers of5Patients.-with Events, and--Effect of I 1 LGT A,Tioita_1  6 PBO AReason for Decrease Scenario with largest numbers of patients with eventsScenario with smallest numbers of patients with events. Ana_lys_is'_ - . in?# of . .   Scen_a_rio -jSc'enario*f'- '3 Row A'bove?.Br?ads 4 A 3 All MACEPop (1.89) 5 Broad Broad, .:   SMQ All MACE(0.99) does not include extensionPopA  (1.47) . ?f'f  dataBroad,  I, i;Serious All MACE to -T 16 .- (0.33) I. does not includeMACE, Serious MACE (0.67)  A  nonserious CPK eventsPopA . . . . .Custom, --All MACE, n/a 17 i CPK events not in CustomPop (0.71) 3'FDA Custom? 373:?Custom All MACEdoes not include extensionPopA (0.55) . dataCustom,    Serious All MACE to '12 does not includeMACE, Serious MACE  (0.50)  3 . nonserious non-CPKPop 'eventsIn this table, the top row contains the analysis scenario with the largest number of events of anyscenario (Broad SMQ, serious nonserious MACE, Pop B), and the number of events goesdown as one moves down the table. One should not compare the percentages in the variouscells; they are only raw numbers used to illustrate event rates, and do not re?ect strati?cation bytrial. As an example of event rates, one can look at the middle (green-shaded) column forliraglutide group events. Even in the top row, with the highest number of events, one can seethat the event rates were low, with only 69, or of liraglutide-treated patients experiencingan event. As one moves down to the next LGT cell (change from Pop to Pop A), event ratesdrop due to omission of extension data. The clinical safety and statistical reviewersconsider Pop A to be more interpretable than Pop B, but less observation time results in fewerevents (69 to 51). Moving down to the next LGT cell, there is a large drop (from 51 to 16 events), as this cell no longer includes nonserious events, but only those that were characterizedas serious. This is because about half the events in the Broad SMQ were events of increasedCPK, and the vast majority were nonserious events. The bottom 3 rows of the table includeevent numbers contributing to the FDA Custom endpoint, rather than to the Broad MACEendpoint. The FDA Custom endpoint tended to be more specific, and therefore to have fewerevents (all other scenario elements being equal), than did the Broad MACE endpoint. Forexample, the scenario of Custom MACE, serious nonserious events, Pop B, had 21 events,while there were 69 events in the corresponding Broad MACE scenario. Taking out extensiondata dropped the number of liraglutide FDA Custom events from 21 to 13. Taking outPage 62 of 249	432345	435072
681	1	1	81	1	1	INVOICEDate: 4/23/15Invoice # 014Rob Williams2243 N Shallowford RdAtlanta, GA 30341404-421-4862RobertTDev@gmail.comDESCRIPTIONData ExtractionTOBill Denney Consulting51 Holyoke Rd #2Somerville, MA 02144Bill@Denney.wsNO. OFHOURSHRLY RATETOTAL27451215View Only945405Data Entry14545Supplemental Data Entry445180TOTAL$1845	0	316
686	1	1	87	1	1	INVOICEDate: 5/1/15Invoice # 015Rob Williams2243 N Shallowford RdAtlanta, GA 30341404-421-4862RobertTDev@gmail.comDESCRIPTIONData ExtractionSupplemental Data EntryTOBill Denney Consulting51 Holyoke Rd #2Somerville, MA 02144Bill@Denney.wsNO. OF HOURSHRLY RATETOTAL24451080945405TOTAL$1485	0	286
692	1	1	93	1	1	TestdocumentPDFLoremipsumdolorsitamet,consecteturadipiscingelit.Nullaestpurus,ultricesinporttitorin,accumsannonquam.Namconsecteturporttitorrhoncus.Curabitureuestetleofeugiatauctorvelquislorem.Utetliguladolor,sitametconsequatlorem.Aliquamportaerossedvelitimperdietegestas.Maecenastempuserosutdiamullamcorperiddictumliberotempor.Donecquisauguequismagnacondimentumlobortis.Quisqueimperdietipsumvelmagnaviverrarutrum.Crasviverramolestieurna,vitaevestibulumturpisvariusid.Vestibulummollis,arcuiaculisbibendumvarius,velitsapienblanditmetus,acposuereloremnullaacdolor.Maecenasurnaelit,tinciduntindapibusnec,vehiculaeudui.Duislaciniafringillamassa.Cumsociisnatoquepenatibusetmagnisdisparturientmontes,nasceturridiculusmus.Utconsequatultriciesest,nonrhoncusmauriscongueporta.Vivamusviverrasuscipitfelisegetcondimentum.Cumsociisnatoquepenatibusetmagnisdisparturientmontes,nasceturridiculusmus.Integerbibendumsagittisligula,nonfaucibusnullavolutpatvitae.Cumsociisnatoquepenatibusetmagnisdisparturientmontes,nasceturridiculusmus.Inaliquetquametvelitbibendumaccumsan.Cumsociisnatoquepenatibusetmagnisdisparturientmontes,nasceturridiculusmus.Vestibulumvitaeipsumnecarcusemperadipiscingataclacus.Praesentidpellentesqueorci.Morbicongueviverranislnecrhoncus.Integermattis,ipsumatinciduntcommodo,lacusarcuelementumelit,atmolliserosanteacrisus.Involutpat,anteatpretiumultricies,velitmagnasuscipitenim,aliquetblanditmassaorcineclorem.Nullafacilisi.Duiseuvehiculaarcu.Nullafacilisi.Maecenaspellentesquevolutpatfelis,quistristiqueligulaluctusvel.Sednecmieros.Integeraugueenim,sollicitudinullamcorpermattiseget,aliquaminest.Morbisollicitudinliberonecauguedignissimutconsecteturduivolutpat.Nullafacilisi.Maurisegestasvestibulumnequecursustincidunt.Donecsitametpulvinarorci.Quisquevolutpatpharetratincidunt.Fuscesapienarcu,molestieegetvariusegestas,faucibusacurna.Sedatnisiinvelitegestasaliquamutafelis.Aeneanmalesuadaiaculisnisl,uttemporlacusegestasconsequat.Namnibhlectus,gravidasedegestasut,feugiatquisdolor.Doneceuleoenim,nonlaoreetante.Morbidictumtemporvulputate.Phasellusultriciesrisusvelauguesagittiseuismod.Vivamustinciduntplaceratnisiinaliquam.Crasquismiacnuncpretiumaliquam.Aeneanelementumeratacmetuscommodorhoncus.Aliquamnullaaugue,portanonsagittisquis,accumsanvitaesem.Phasellusidlectustortor,egetpulvinaraugue.Etiamegetvelitacpurusfringillablandit.Donecodioodio,sagittissediaculissed,consecteturegetsem.Loremipsumdolorsitamet,consecteturadipiscingelit.Maecenasaccumsanvelitvelturpisrutruminsodalesdiamplacerat.Quisqueluctusullamcorpervelitsitametlobortis.Etiamligulafelis,vulputatequisrhoncusnec,fermentumegetodio.Vivamusvelipsumacauguesodalesmolliseuismodnectellus.Fusceetauguerutrumnuncsempervehiculavelsempernisl.Namlaoreeteuismodquamatvarius.Sedaliquetauctornibh.Curabiturmalesuadafermentumlacusvelaccumsan.Duisornarescelerisquenulla,acpulvinarligulatempussitamet.Inplaceratnullaacantescelerisqueposuere.Phasellusatantefelis.Sedhendreritrisusametusposuererutrum.Phaselluseuauguedui.Proininvestibulumipsum.Aeneanaccumsanmollissapien,uteleifendsemblanditat.Vivamusluctusmiegetloremlobortispharetra.Phasellusattortorquam,avolutpatpurus.Etiamsollicitudinarcuvelelitbibendumetimperdietrisustincidunt.Etiamelitvelit,posuereutpulvinarac,condimentumegetjusto.Fusceaeratvelit.Vivamusimperdietultricesorciinhendrerit.	0	3876
693	1	1	95	1	1	Trade Agreements Cannot be Allowedto Undermine Financial ReregulationForeclosed homes. Lost jobs. Collapsing banks. Thegreatest government involvement in the economy ingenerations. While these headlines dominated thenews of 2008-2009, a root cause of the crisis haslargely been ignored: over the last severaldecades, the U.S. government and corporationspushedextremefinancialderegulationworldwide using trade agreements.Stiglitz-led United Nations Commission Callsfor Reform of WTOs Regulatory CeilingThe UN Commission of Experts, chaired by Nobel Prizewinning economist Joseph Stiglitz, noted that: Theframework for financial market liberalization under theFinancial Services Agreement of the General Agreement onTrade in Services (GATS) under the WTO and, even more,similar provisions in bilateral trade agreements may restrictthe ability of governments to change the regulatory structurein ways which support financial stability, economic growth,and the welfare of vulnerable consumers and investors.Starting in the late 1970s, the U.S. governmentand corporations pushed to redefine financefrom a service that supports the real economyto a tradable commodity whose flow acrossborders should be uninhibited. Starting in thelate 1980s, they successfully pushed for financial services to be included in trade negotiations,including those establishing the World Trade Organization (WTO). The sector was truly unique inthat respect, and there is little doubt within the trade policy community that financial sector support inthe European Union and the United States was a determining force in concluding the FSA [WTOFinancial Services Agreement], notes a study posted on the WTOs own website.The WTOs General Agreement on Trade in Services (GATS) and the financial servicechapters of U.S. Free Trade Agreements (FTAs) limit the regulation of financial servicesectors subject to these agreements. The United States bound most banking and securities servicesto comply with these rules and made sizeable commitments in insurance. The trade pact rulessimply ban many common forms of financial regulation, even if such policies apply to domestic andforeign firms equally. U.S. government and corporate efforts in trade negotiations complementeddomestic lobbying to weaken and eventually repeal the New Deals system of banking regulation. Forinstance, the Glass-Steagall Act created a firewall between commercial and investment banks toprevent the former from speculating with consumers savings. But the 1997 U.S. WTO commitmentsnoted an intent to change Glass-Steagall to conform with WTO rules. The Gramm-Leach-Bliley Act,which did so, passed in 1999  the year the WTOs Financial Services Agreement (FSA) took effect.Many people still assume trade pacts are about traditional matters, such as tariff cuts. In fact, theWTO, North American Free Trade Agreement (NAFTA) and other U.S. FTAs require signatories including the United States  to conform domestic policies to a broad non-trade deregulatory agenda.Few in Congress read the legislation implementing the WTO in 1994 or NAFTA in 1993, much lessthe pacts actual 900-page texts. Congress didnt even get a vote on the expanded U.S. financial servicederegulation commitments contained in the subsequent WTO FSA. But if any countrys laws fail tocomply with WTO, NAFTA or FTA rules, the laws can be challenged before foreign tribunals, andthe country can be subjected to indefinite trade sanctions until its laws meet trade pact dictates.While Congress has worked to reregulate banks and other financial firms since the crisis, it must alsoconfront trade agreement rules that conflict with those reforms and require domestic law toconform to the now-rejected model of extreme deregulation that caused the global economic crisis.For more information, contact Public Citizens Global Trade Watch: 202-546-4996, www.TradeWatch.org	0	3901
694	1	1	95	1	2	The Problem: Overreaching Trade Agreement RulesSo-called trade agreements  both existing and proposed  limit the domestic-policy optionslawmakers can pursue in areas that are not trade-related. The WTO enforces 17 different agreements,only a handful of which relate to tariffs and quotas  the traditional terrain of trade policy. Others limitsubsidies governments can provide to green industries, forbid domestic economic stimulus funds frombeing directed to domestic workers and firms, set parameters for how our health-care system is managed,and even constrain how our federal and state governments can expend our tax dollars in governmentprocurement. NAFTA and similar FTAs contain analogous provisions, and also empower foreigninvestors to directly challenge governments for alleged violations.One of the most controversial WTO agreements is the GATS, which sets out rules for how countries canregulate their economies service sectors. Whats a service? Basically anything you cant drop on yourfoot, from banking to energy, education to healthcare. The WTO Secretariat was unusually direct indescribing the GATS implications: Governments are free in principle to pursue any national policy objectivesprovided the relevant measures are compatible with the GATS.One of the most controversial service sectors covered by the GATS is finance. When many countriesinitially rejected the extreme banking, securities and insurance deregulation pushed by U.S. and Europeangovernments and corporations, additional negotiations were launched after the WTO was established topush for deeper commitments. In all, over 100 countries have WTO financial services commitments.The United States and other rich countries also committed to even greater deregulation by adopting anadditional WTO agreement, called the Understanding on Commitments in Financial Services. When allwas said and done, the United States was bound to extremely broad WTO obligations to stay out ofregulation of banking, other financial services and insurance. Consider just one sector that hasgained notoriety for contributing to the financial meltdown: derivatives. In the expansive WTO categorycalled Trading of Securities and Derivative Products and Services Related Thereto, the only policy spacethat the United States preserved for regulating derivatives was for onion futures. Really.Taken as a whole, the WTOs limits on financial service sector regulation are expansive. These rules notonly guarantee foreign financial firms and their products access to U.S. markets, but also include numerousadditional rules that limit how our domestic governments may regulate foreign firms operating here:No new regulation: The United States agreed to a standstill provision which requires that we notcreate new regulations (or reverse liberalization) for the list of financial services bound to comply withWTO rules. This means that the United States has bound itself not to do what Congress and regulatorshave tried to do in the crisiss wake  to create new financial service regulations.Certain forms of regulation banned outright: The United States agreed that it would not set limits onthe size of financial firms, the types of financial services one entity may provide or the types of legalentities through which a financial service may be provided in the broad array of financial services signedup to the WTO. These WTO rules conflict with countries efforts to put size limitations on banks (so thatthey do not become too big too fail) and to firewall different financial services (a policy tool used tolimit the spread of risk across sectors, as Glass-Steagall did between commercial and investment banking).No bans on risky financial service products in committed sectors: A WTO tribunal has alreadyruled that a ban, even if it applies to domestic and foreign firms, constitutes a forbidden zero quota thatviolates service sector market access obligations. This restriction conflicts with proposals to limit variousrisky investment instruments, such as certain derivatives.2	3902	7976
695	1	1	95	1	3	Treating foreign and domestic firms alike is not sufficient: The GATS market access limits on U.S.domestic regulation apply in absolute terms. In other words, even if a policy applies to domestic andforeign firms alike, if it goes beyond what WTO rules permit, it is forbidden. And, forms of regulation notoutright banned by these rules must not inadvertently modify the conditions of competition in favor ofservices or service suppliers of the United States, even if they apply identically to foreign and domesticfirms. Might aspects of the Wall Street bailout have changed the conditions of competition in favor ofU.S. firms? Other WTO members have begun reviewing just this question.Other non-discriminatory domestic regulations also subject to review: GATS subjects policies ofgeneral application that may affect service sector firms to review, with WTO tribunals empowered todetermine if they are reasonable, whether they could not reasonably have been expected and whether licensingand qualification requirements and technical standards limit foreign firms access.The only exception to these rules is viewed by many to be useless: WTO, NAFTA and other U.S.FTAs contain a prudential exception that can be invoked as a defense if a financial policy is challenged.However, the provision contains a clause that many deem self-cancelling. That is to say, theeffectiveness of the provision is at best contested in that its acceptable use is explicitly limited tocircumstances where invoking the exception does not contradict a countrys trade pact commitments.But a country would not use the exception unless it felt that a financial policy did just that.New WTO Trade in Services Agreementand Trans-Pacific Partnership FTAWould Require More Financial DeregulationEven as regulators worked to reregulate financial firms after the 2008-2009 crisis, U.S. tradenegotiators were trying to revive a beleaguered WTO expansion called the Doha Round. TheBush administration led a push to expand financial deregulation through this Round, which started in 2001.The Obama administration continued with the Bush agenda. The Doha Round has been deadlocked, andsome consider it altogether derailed. However, the United States has joined a small bloc of WTO countriesin trying to revive the financial deregulation agenda from the Doha Round by pushing for new Trade inServices Agreement (TISA) negotiations. Congress was notified of these negotiations in January 2013.The agenda of the TISA negotiations may include these Doha leftover initiatives:A new agreement setting additional constraints on domestic regulation. It seems unimaginablethat, in the current context, WTO negotiations would be underway to establish an agreement imposingnew, additional limits on regulation. But a GATS Working Party on Domestic Regulations is tryingto complete new rules that would do just that. The rules could empower WTO tribunals to secondguess governments on the subjective questions of whether policies are really necessary and whetherless trade-restrictive means to meet policy goals could be employed.A new agreement imposing limits on accountancy sector regulation. Arthur Andersen, of Enronaccounting scandal fame, helped formulate a WTO agreement establishing new disciplines on nondiscriminatory regulations in the accounting sector. These rules would pressure governments toderegulate accounting, rather than better regulate it, as multiple G-20 Communiqus have called for.In praising the launch of the TISA, the U.S. Chamber of Commerce noted that banks and other firmshave seen trade and regulatory barriers multiply in ways that could not be foreseen two decades ago whenthe General Agreement on Trade in Services was negotiated. The Chamber welcomed the TISA as achance to tackle emerging trade barriers  a euphemism for post-crisis efforts to reregulate finance.3	7977	11860
696	1	1	95	1	4	The draft text of the Trans-Pacific Partnership (TPP), a NAFTA-style FTA under negotiationbetween the United States and 11 Pacific Rim countries, contains the same limits on financialregulation as the WTO, and more. In addition, foreign financial firms would be empowered to suethe U.S. government over financial regulations in foreign tribunals, which would be empowered to orderpayment of unlimted sums of U.S. taxpayer money if they saw new financial policies as undermining suchfirms expectations. Also, even as the International Monetary Fund has officially shifted from oppositionto qualified endorsement of capital controls, which are used to avoid destabilizing floods of speculativemoney into and out of countries, the TPP would ban the use of these important regulatory tools. Despiteyears of pressure from former House Financial Services Committee Chair Rep. Barney Frank to permitcapital controls, the Obama administration is the strongest promoter of this ban in the TPP.The Solution: Shrink or Sink (and Ignore) Trade PactLimits on Financial RegulationUnfortunately, some existing trade pact rules do limit the policy space nations need to prevent financialcrises. Other rules are at best unclear and can chill needed reforms. These rules must be changed.However, in the interim we cannot allow trade agreement rules to inhibit needed reform. Heres ablueprint for change:First, do no further harm: no additionalfinancial deregulation via the TISA or the TPP.Demands for nations to add financial sectorcommitments must be jettisoned along with newregulation-limiting agreements.Fix existing WTO, NAFTA and FTA rules toremove financial deregulation requirements andadd safeguards for economic stability policies:The changes needed are straightforward. The issueis whether the political will exists. The neededchanges include removing automatic deregulationrequirements from trade pact service sectorliberalization rules, and adding a meaningfulsafeguard to protect prudential policies.WTO Rules Have Been Modified Before toAddress a Global CrisisIn the past, when WTO rules conflicted with global policypriorities, nations negotiated changes. The 2001 DohaDeclaration on TRIPS and Public Health countered WTOdrug-patent rules limits to a global response to theHIV/AIDS crisis. Like that pandemic, dealing with thefinancial crisis and avoiding future such crises is a globalemergency. Scores of WTO countries are seeking to implementthe very financial stabilization policies that could be attackedas WTO violations. With so many countries facing the sameWTO problems, changes could find wide support.It takes years for a trade agreement challenge to get an initial ruling, so policymakers should notallow threats of challenges to be used as a tool to scale back reregulation: Industry groups like theU.S. Chamber of Commerce are already using the deregulatory WTO rules to threaten new financialregulations by trying to raise the specter that their implementation could spark trade disputes. But even if anew financial regulation would conflict with trade pact rules, a country must formally challenge thepolicy for dispute resolution action to be initiated. After a challenge is brought, it typically takes more thanfive years before issuance of a final WTO ruling that could result in trade sanctions. Thus, the way to gois to ignore the threats, implement robust financial regulations, and see if it draws an actual challenge.For access to a database detailing U.S. GATS service-sector commitments,along with fact sheets and other informational material about trade pactrules affecting financial regulation, please contact Public Citizens GlobalTrade Watch at 202-546-4996, or visit our website: www.TradeWatch.org.4	11861	15614
697	1	1	96	1	1	PREDICTION OF LONG-TERM EFFICACY OF ANTIDIABETIC DRUGS ON HBA1C USING LONGITUDINAL MODEL-BASEDMETA-ANALYSIS (MBMA) OF LITERATURE DATAJing Liu1, Rebecca Boyd1, William Denney2, Kevin Sweeney1, Beesan Tan2, Clare Buckeridge1, Gianluca Nucci2, Jaap Mandema31Clinical Pharmacology, Pfizer, Groton CT and 2Cambridge MA; 3Certara Strategic Consulting, Menlo Park, CABackground and ObjectivesModel-based meta-analysis (MBMA) has been applied in theassessments of comparative efficacy1,2 and time course of glucoseeffect3 with anti-diabetic drugs in Type 2 diabetes mellitus (T2DM).However, there has been no systematic quantitative meta-analysis ofhow early efficacy in glycemic endpoints translates to longer termefficacy. We previously published a preliminary MBMA of literaturedata on the predictability of HbA1c treatment effect at Week 12 fromWeek 4 HbA1c response using summary-level data.4 The objectivesof this expanded MBMA were to characterize the time course ofantidiabetic drug effect on HbA1c and the predictability of long-termefficacy from short-term data in T2DM.MethodsThe database included study-level longitudinal aggregate data from334 blinded, randomized, active- or placebo-controlled trials inT2DM of 2 to 260 weeks in duration, with metformin and 27 otherdrugs in 5 drug classes (DPP4: dipeptidyl peptidase-4 inhibitors;GLP1: glucagon-like peptide-1 receptor agonists; SGLT2: sodiumglucose co-transporter 2 inhibitors; SU: sulfonylureas; TZD:thiazolidinediones).HbA1c change from baseline (CFB) was described by:Yijt  Eoit Emax ,class  f (t )  (1   i ,drug )  DoseijtDoseijt  ED50 ,drug ijt Yijt is the mean HbA1c CFB in the ith trial, jth arm, at time t. Eoit is the non-parametric fixed placebo effect for the ith trial at time t. Emax,class is the maximal treatment effect specific to each drug class,except for SGLT2 inhibitors, which were adjusted to account fordifferent degrees of non-selective SGLT1 inhibition by each drug. f(t) is the time course function for Emax,class . ED50,drug is the drug-specific dose to achieve 50% of Emax.class . i,drug is a trial- and drug-specific random effect to describe betweentrial and drug heterogeneity in treatment effects. ijt is the residual variability in the ith trial, jth arm, at time t.Since not all trials reported the variability of the mean HbA1c CFB,SDit was calculated using the following Equation:Table 1. Summary of key drug class-specific parameters (mean [95% CI]).log( SDit )  nij  log( SDo )  SLPBSL  log( BSLij / 8)  SLPtime  time  nij SD0 is the intercept. SLPBSL is the log-linear slope for the effect of HbA1c baseline (BSL)normalized to a typical value of 8%. SLPtime is the linear slope for the time effect.The following covariates were evaluated on the time-course oftreatment effects: HbA1c BSL, placebo response, eGFR (for SGLT2only), background treatments, prior treatment/washout, the diseaseduration, and Japan vs. non-Japan studies. For combinationtreatments, an interaction coefficient was estimated for each drugclass combination.The final model was evaluated by visual predictive check acrossdoses and drugs in all drug classes and time.Prediction from shorter-term to long-term efficacy: One thousandsimulations of the time-course of treatment effects for each drugclass were performed by random sampling of the fixed effectparameters (multivariate normal distribution) and the random effect(normal distribution) from the final model. The ratios of treatmenteffects at the selected time points were calculated, and the meanand the 95% confidence interval (CI) of the ratios were summarized.R3.0.2 was used for data processing, modeling and simulations.ResultsObserved (symbols an whiskers, weighted mean and 95% CI) and modelpredicted mean (solid line) time-course of treatment effects on HbA1c byrepresentative drugs at respective median doses across trials.Emax (%, diet background)ET50 (weeks)ntTdurDPP4-0.919 [-0.998 to -0.840]8.60 [7.53 to 9.82]0.550 [0.516 to 0.583]-0.411 [-0.491 to -0.333]GLP1-1.69 [-1.88 to -1.50]9.25 [7.90 to 10.8]0.480 [0.445 to 0.515]-0.408 [-0.486 to -0.331]SGLT2-0.917 [-1.01 to -0.828]4.16 [3.71 to 4.67]0.660 [ 0.551 to 0.769]-0.050 [-0.104 to 0.004]Metformin-1.81 [-2.08 to -1.53]10.9 [8.74 to 13.7]0.469 [0.413 to 0.525]-0.306 [-0.408 to -0.204]SU-1.68 [-1.86 to -1.50]13.6 [12.1 to 15.4]0.589 [0.559 to 0.620]-0.685 [-0.768 to -0.602]TZD-1.78 [-2.07 to -1.50]10.7 [9.91 to 11.6]0.916 [0.844 to 0.988]-0.201 [-0.264 to -0.137]The model predicted a drug class dependent Emax, and drug class dependent onset and loss oftreatment effects.HbA1c BSL was found to be a significant covariate on Emax, e.g. a 36% higher Emax for HbA1c BSL of9% vs. 8%. Background treatments with oral anti-diabetic drugs and insulin were predicted to resultin mean decreases in Emax relative to diet background by 5.5%21.3% and 16.4%65.5%,respectively, across drug classes. Studies conducted in Japan were estimated to have 55.7% and49.0% higher Emax in DPP4 and GLP1 drug classes, respectively, relative to studies conducted outsideof Japan.Table 3. Model predicted ratios of treatment effects on HbA1c at selected time points by drug class*.Drug ClassDPP4GLP1SGLT2MetforminSUTZDf (t ) time ntclasstime nt  ET50 ,classntclass time  24  ET50,class is the class-specific onset time to reach 50% of the Emax,class. ntclass is the class-specific steepness of the onset of effect. Tdurclass describes the class-specific loss of effect relative to Week 24.The variance of ijt is it2/nij, where it2 is the SDit2 of the HbA1c CFBin the ith trial at time t, and nij is the number of subjects in the ithtrial and the jth arm.Predicted Drug Effect Ratio (Mean [95% CI])Week 26/12Week 52/120.99 [0.97 to 1.01]0.81 [0.78 to 0.87]1.01 [1.00 to 1.03]0.86 [0.82 to 0.89]1.06 [1.04 to 1.08]1.04 [1.00 to 1.10]1.18 [1.14 to 1.21]1.10 [1.04 to 1.15]1.01 [0.99 to 1.04]0.76 [0.73 to 0.80]1.36 [1.31 to 1.40]1.28 [1.22 to 1.35]Week 52/260.82 [0.80 to 0.86]0.84 [0.82 to 0.87]0.99 [0.96 to 1.02]0.93 [0.91 to 0.97]0.75 [0.73 to 0.77]0.95 [0.92 to 0.98]* Each ratio was predicted assuming the same drug treatment for the longer-term as for the shorter-term.The ratios of longer term to shorter term efficacy were precisely estimated within drug class. Thetreatment effects at Week 26 were predicted to be similar to those at Week 12. For drug classeswith loss of efficacy over time (e.g. SU, DPP4, GLP1), this was predicted to be more evident at Week52 than Week 26. The longitudinal model can also predict efficacy with different treatments in adrug class and in different populations, e.g. patients with different background treatments and/orwith different HbA1c BSL. The model also provides benchmarks of efficacy time-course for newantidiabetic drug classes.ConclusionsThe time course function was described by:Tdur classWeek 12/41.94 [1.89 to 2.00]1.88 [1.83 to 1.93]1.74 [1.68 to 1.80]2.30 [2.17 to 2.42]2.11 [2.03 to 2.19]5.84 [4.99 to 6.90]The longitudinal MBMA adequately characterized the time courses of antidiabetic drug effects inT2DM. Long-term efficacy may be confidently predicted from short-term efficacy within a drugclass. A 26-week trial duration may not add value over 12 weeks to understand peak treatmenteffect, and may not be sufficient to discern durability of treatment effect.References1.2.3.4.Mandema J, et al. Diabetes. 61(suppl. 1): A1015, 2012Gross, JL, et al. BMJ Open. 3(3): e001844, 2013Denney, WS, et al. JPKPD. 40: S141, 2013Liu, J, et al. JPKPD. 41:S7-S8, 2014AcknowledgementsWe thank Vaishali Sahasarabudhe, Vikas Kumar andArthur Bergman for their consultation on modelparameter interpretation.	0	7669
\.


--
-- Name: pages_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('pages_id_seq', 697, true);


--
-- Data for Name: pending_memberships; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY pending_memberships (id, first_name, last_name, email, organization_name, usage, editor, website, validated, notes, organization_id, fields, created_at, updated_at) FROM stdin;
\.


--
-- Name: pending_memberships_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('pending_memberships_id_seq', 1, false);


--
-- Data for Name: processing_jobs; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY processing_jobs (id, account_id, cloud_crowd_id, title, document_id) FROM stdin;
74	1	35	Denney Invoice 015	86
75	1	36	Denney Invoice 015	87
\.


--
-- Name: processing_jobs_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('processing_jobs_id_seq', 83, true);


--
-- Data for Name: project_memberships; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY project_memberships (id, project_id, document_id) FROM stdin;
\.


--
-- Name: project_memberships_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('project_memberships_id_seq', 1, false);


--
-- Data for Name: projects; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY projects (id, account_id, title, description, hidden) FROM stdin;
\.


--
-- Name: projects_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('projects_id_seq', 1, false);


--
-- Data for Name: remote_urls; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY remote_urls (id, document_id, url, hits) FROM stdin;
\.


--
-- Name: remote_urls_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('remote_urls_id_seq', 1, false);


--
-- Data for Name: repositories; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY repositories (id, repo_name, disabled) FROM stdin;
8	Test2	\N
\.


--
-- Name: repositories_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('repositories_id_seq', 8, true);


--
-- Data for Name: reviews; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY reviews (id, document_id, qc_id, de_one_id, de_one_rating, de_two_id, de_two_rating, qc_note, created_at, updated_at, qa_id, qc_rating, iteration, qa_note) FROM stdin;
2	42	6	7	5	4	2	There was a lot of data missing from DE2	2014-10-30 02:42:18.192572	2014-10-30 02:42:18.192572	5	3	1	This looks good
3	50	17	14	5	15	3		2014-11-06 22:54:04.986735	2014-11-06 22:54:04.986735	\N	\N	1	\N
5	48	17	7	2	14	4	DE2 was so good I didn't need any from DE1.	2015-01-21 02:22:04.029675	2015-01-21 02:22:04.029675	20	4	1	Looks excellent!
7	47	17	20	3	14	1	DE2 was not done	2015-01-26 22:14:35.528489	2015-01-26 22:14:35.528489	21	4	1	
11	46	17	1	3	14	3		2015-05-12 18:07:21.499846	2015-05-12 18:07:21.499846	\N	\N	1	\N
14	93	17	1	3	14	3		2015-06-15 20:11:44.477205	2015-06-15 20:11:44.477205	20	3	1	meh
15	93	17	14	3	\N	\N		2015-06-30 21:35:14.839015	2015-06-30 21:35:14.839015	\N	\N	2	\N
16	93	17	14	3	\N	\N		2015-06-30 21:48:32.338786	2015-06-30 21:48:32.338786	20	3	3	
17	93	17	14	3	\N	\N		2015-07-07 20:38:24.454082	2015-07-07 20:38:24.454082	20	3	4	
\.


--
-- Name: reviews_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('reviews_id_seq', 17, true);


--
-- Data for Name: schema_migrations; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY schema_migrations (version) FROM stdin;
1
20100108163304
20100108172251
20100109025746
20100109035508
20100112143144
20100114170350
20100120194128
20100120205426
20100125165305
20100208131000
20100208151651
20100212130932
20100218193708
20100219175757
20100301200857
20100304154343
20100316001441
20100317145034
20100317181051
20100401192921
20100413132825
20100607182008
20100624142442
20100625143140
20100630131224
20100701132413
20100823172339
20100928204710
20101025202334
20101028194006
20101101192020
20101103173409
20101110170100
20101207203607
20101209175540
20101214171909
20110111192934
20110113204915
20110114143536
20110207212034
20110216180521
20110217161649
20110217171353
20110224153154
20110303200824
20110303202721
20110304213500
20110308170707
20110310000919
20110429150927
20110502200512
20110505172648
20110512193718
20110603223356
20111026200513
20120131180323
20120927202457
20121108160450
20130107193641
20130108201748
20130109194211
20130327170939
20130716200416
20140226151713
20140301191427
20140301191704
20140301192243
20140301192400
20140417132052
20140417171446
20140429184510
20140430200314
20140604213826
20140604220150
20140605190022
20140701175538
20140704154025
20140730203154
20140813163126
20140814194013
20140904170250
20140905183032
20140911183140
20140911185636
20140919173300
20140925203205
20140929133607
20141010155400
20141010180742
20141014200020
20150107191612
20150325205011
20150429175735
20150529205731
20150609172330
20150708200432
20150716201936
20160615194758
20160624200630
20161013165748
\.


--
-- Data for Name: sections; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY sections (id, organization_id, account_id, document_id, title, page_number, access) FROM stdin;
\.


--
-- Name: sections_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('sections_id_seq', 1, false);


--
-- Data for Name: security_keys; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY security_keys (id, securable_type, securable_id, key) FROM stdin;
2	Account	3	3ea7f0913c6c43723e41
\.


--
-- Name: security_keys_id_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('security_keys_id_seq', 22, true);


--
-- Data for Name: subtemplate_fields; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY subtemplate_fields (id, subtemplate_id, field_id, created_at, updated_at) FROM stdin;
1	1	1	2014-05-02 11:09:32.733598	2014-05-02 11:09:32.733598
2	1	2	2014-05-02 11:09:34.96013	2014-05-02 11:09:34.96013
3	1	3	2014-05-02 11:09:37.87872	2014-05-02 11:09:37.87872
4	2	1	2014-05-02 11:09:59.850628	2014-05-02 11:09:59.850628
5	2	4	2014-05-02 11:10:02.116601	2014-05-02 11:10:02.116601
6	2	5	2014-05-02 11:10:02.876594	2014-05-02 11:10:02.876594
7	2	13	2014-05-02 11:11:41.766556	2014-05-02 11:11:41.766556
8	3	4	2014-05-02 11:12:06.372705	2014-05-02 11:12:06.372705
9	3	1	2014-05-02 11:12:06.414791	2014-05-02 11:12:06.414791
10	3	10	2014-05-02 11:12:07.317037	2014-05-02 11:12:07.317037
11	3	11	2014-05-02 11:12:08.446895	2014-05-02 11:12:08.446895
12	3	12	2014-05-02 11:12:09.413189	2014-05-02 11:12:09.413189
13	4	1	2014-05-02 11:13:04.968171	2014-05-02 11:13:04.968171
14	4	6	2014-05-02 11:13:08.162743	2014-05-02 11:13:08.162743
15	4	7	2014-05-02 11:13:08.530495	2014-05-02 11:13:08.530495
16	4	8	2014-05-02 11:13:09.154568	2014-05-02 11:13:09.154568
17	4	14	2014-05-02 11:13:47.416724	2014-05-02 11:13:47.416724
18	4	15	2014-05-02 11:13:47.999216	2014-05-02 11:13:47.999216
19	5	1	2014-07-03 19:26:50.071134	2014-07-03 19:26:50.071134
20	5	19	2014-07-03 19:26:51.235516	2014-07-03 19:26:51.235516
21	2	43	2014-07-03 19:34:25.830394	2014-07-03 19:34:25.830394
22	4	43	2014-07-03 19:34:35.263683	2014-07-03 19:34:35.263683
23	3	43	2014-07-03 19:34:39.702115	2014-07-03 19:34:39.702115
24	1	43	2014-07-03 19:34:46.144302	2014-07-03 19:34:46.144302
25	5	43	2014-07-03 19:34:53.787482	2014-07-03 19:34:53.787482
26	2	44	2014-07-03 21:04:22.201666	2014-07-03 21:04:22.201666
27	4	44	2014-07-03 21:04:26.322733	2014-07-03 21:04:26.322733
28	3	44	2014-07-03 21:04:30.359902	2014-07-03 21:04:30.359902
29	1	44	2014-07-03 21:04:36.420976	2014-07-03 21:04:36.420976
30	6	46	2014-07-16 11:41:49.720274	2014-07-16 11:41:49.720274
31	5	49	2014-10-22 04:04:57.092369	2014-10-22 04:04:57.092369
32	7	50	2014-12-20 23:50:13.260198	2014-12-20 23:50:13.260198
33	7	51	2014-12-20 23:50:14.107832	2014-12-20 23:50:14.107832
34	7	52	2014-12-20 23:50:16.107645	2014-12-20 23:50:16.107645
41	2	69	2015-01-12 00:57:30.956896	2015-01-12 00:57:30.956896
42	2	70	2015-01-12 00:57:31.186422	2015-01-12 00:57:31.186422
43	4	69	2015-01-12 00:57:35.689581	2015-01-12 00:57:35.689581
44	4	70	2015-01-12 00:57:36.106666	2015-01-12 00:57:36.106666
45	3	69	2015-01-12 00:57:40.810127	2015-01-12 00:57:40.810127
46	3	70	2015-01-12 00:57:42.400131	2015-01-12 00:57:42.400131
47	1	69	2015-01-12 00:57:46.319549	2015-01-12 00:57:46.319549
48	1	70	2015-01-12 00:57:46.72136	2015-01-12 00:57:46.72136
49	5	69	2015-01-12 00:57:50.301133	2015-01-12 00:57:50.301133
50	5	70	2015-01-12 00:57:50.60938	2015-01-12 00:57:50.60938
51	2	71	2015-01-16 03:36:02.472585	2015-01-16 03:36:02.472585
52	4	71	2015-01-16 03:36:08.982728	2015-01-16 03:36:08.982728
53	3	71	2015-01-16 03:36:38.658351	2015-01-16 03:36:38.658351
54	1	71	2015-01-16 03:36:42.916456	2015-01-16 03:36:42.916456
55	5	71	2015-01-16 03:36:47.365712	2015-01-16 03:36:47.365712
56	10	75	2015-01-18 15:11:45.514623	2015-01-18 15:11:45.514623
57	10	76	2015-01-18 15:11:45.900213	2015-01-18 15:11:45.900213
58	10	77	2015-01-18 15:11:46.416061	2015-01-18 15:11:46.416061
59	10	73	2015-01-18 15:11:47.964882	2015-01-18 15:11:47.964882
60	11	1	2015-01-24 18:45:31.681085	2015-01-24 18:45:31.681085
61	11	7	2015-01-24 18:45:33.633569	2015-01-24 18:45:33.633569
62	11	8	2015-01-24 18:45:34.694268	2015-01-24 18:45:34.694268
63	11	43	2015-01-24 18:45:43.093913	2015-01-24 18:45:43.093913
64	11	71	2015-01-24 18:45:44.021832	2015-01-24 18:45:44.021832
65	11	69	2015-01-24 18:45:45.623096	2015-01-24 18:45:45.623096
66	11	70	2015-01-24 18:45:45.965721	2015-01-24 18:45:45.965721
67	11	44	2015-01-24 18:45:48.335577	2015-01-24 18:45:48.335577
\.


--
-- Name: subtemplate_fields_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('subtemplate_fields_id_seq', 67, true);


--
-- Data for Name: subtemplates; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY subtemplates (id, template_id, sub_name, created_at, updated_at) FROM stdin;
1	1	Mean and SD	2014-05-02 11:09:32.66859	2014-05-02 11:09:32.66859
2	1	Geometric Mean and CV or SD	2014-05-02 11:09:59.799755	2014-05-02 11:11:44.976585
3	1	Mean and Confidence Interval	2014-05-02 11:11:59.298006	2014-05-02 11:11:59.298006
4	1	Inter-quartile Range	2014-05-02 11:13:04.92146	2014-05-02 11:13:04.92146
7	10	Year-Month-Day	2014-12-20 23:50:10.475475	2014-12-20 23:50:10.475475
5	1	Percent/Count	2014-07-03 19:26:49.942006	2014-12-22 02:21:26.929502
10	16	Counts only	2015-01-18 15:11:45.450466	2015-01-18 15:11:45.450466
11	1	Range	2015-01-24 18:45:31.617468	2015-01-24 18:45:31.617468
\.


--
-- Name: subtemplates_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('subtemplates_id_seq', 11, true);


--
-- Data for Name: template_fields; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY template_fields (id, template_id, field_name, created_at, updated_at) FROM stdin;
1	1	Number of Subjects Included in Measurement	2014-05-02 11:07:19.468721	2014-05-02 11:07:19.468721
2	1	Arithmetic Mean	2014-05-02 11:07:19.512048	2014-05-02 11:07:19.512048
3	1	Standard Deviation	2014-05-02 11:07:19.515946	2014-05-02 11:07:19.515946
6	1	Median	2014-05-02 11:07:19.52914	2014-05-02 11:07:19.52914
7	1	Minimum	2014-05-02 11:07:19.53279	2014-05-02 11:07:19.53279
8	1	Maximum	2014-05-02 11:07:19.536455	2014-05-02 11:07:19.536455
9	1	Standard Error	2014-05-02 11:07:19.540014	2014-05-02 11:07:19.540014
10	1	Confidence Interval Lower Bound	2014-05-02 11:07:19.543656	2014-05-02 11:07:19.543656
11	1	Confidence Interval Upper Bound	2014-05-02 11:07:19.547817	2014-05-02 11:07:19.547817
12	1	% Confidence Interval	2014-05-02 11:07:19.551949	2014-05-02 11:07:19.551949
4	1	Geometric Mean	2014-05-02 11:07:19.520582	2014-05-02 11:11:30.475701
5	1	Geometric Coefficient of Variation	2014-05-02 11:07:19.524888	2014-05-02 11:11:30.481119
13	1	Geometric Standard Deviation	2014-05-02 11:11:30.486382	2014-05-02 11:11:30.486382
14	1	25th Percentile	2014-05-02 11:13:43.46399	2014-05-02 11:13:43.46399
15	1	75th Percentile	2014-05-02 11:13:43.468973	2014-05-02 11:13:43.468973
19	1	Percent	2014-05-29 23:46:50.238271	2014-05-29 23:46:50.238271
21	6	Type of Reference	2014-06-29 02:31:40.455597	2014-06-29 02:31:40.455597
22	6	Publication Date	2014-06-29 02:31:40.465069	2014-06-29 02:31:40.465069
24	6	DOI (Digital Object Identifier)	2014-06-29 02:31:40.515944	2014-06-29 02:31:40.515944
26	6	Journal	2014-06-29 02:31:40.531112	2014-06-29 02:31:40.531112
27	6	Volume	2014-06-29 02:31:40.537568	2014-06-29 02:31:40.537568
28	6	Issue	2014-06-29 02:31:40.544186	2014-06-29 02:31:40.544186
29	6	Pages	2014-06-29 02:31:40.571375	2014-06-29 02:31:40.571375
30	6	Title	2014-06-29 02:31:40.578224	2014-06-29 02:31:40.578224
33	7	Last Name	2014-06-29 02:32:50.141316	2014-06-29 02:32:50.141316
34	7	First Name or Initial	2014-06-29 02:32:50.148592	2014-06-29 02:32:50.148592
35	7	Middle Name or Initial(s)	2014-06-29 02:32:50.156272	2014-06-29 02:32:50.156272
36	9	Start Time	2014-07-03 19:21:18.123878	2014-07-03 19:21:18.123878
37	9	Start Time Unit	2014-07-03 19:21:18.134867	2014-07-03 19:21:18.134867
38	9	End Time	2014-07-03 19:21:18.142299	2014-07-03 19:21:18.142299
39	9	End Time Unit	2014-07-03 19:21:18.149444	2014-07-03 19:21:18.149444
40	9	Drug Name	2014-07-03 19:21:18.15639	2014-07-03 19:21:18.15639
41	9	Drug Amount	2014-07-03 19:21:18.163879	2014-07-03 19:21:18.163879
42	9	Drug Amount Unit	2014-07-03 19:21:18.171032	2014-07-03 19:21:18.171032
43	1	Measurement Name	2014-07-03 19:34:08.965711	2014-07-03 19:34:08.965711
44	1	Measurement Unit	2014-07-03 21:04:16.160495	2014-07-03 21:04:16.160495
45	9	Frequency	2014-07-03 21:24:33.585342	2014-07-03 21:24:33.585342
49	1	Count	2014-10-22 04:04:49.273623	2014-10-22 04:04:49.273623
50	10	Year	2014-12-20 23:49:57.553476	2014-12-20 23:49:57.553476
51	10	Month	2014-12-20 23:49:57.561996	2014-12-20 23:49:57.561996
52	10	Day	2014-12-20 23:49:57.568678	2014-12-20 23:49:57.568678
53	10	Season	2014-12-20 23:49:57.575068	2014-12-20 23:49:57.575068
54	11	Blinding	2014-12-21 00:01:45.087265	2014-12-21 00:01:45.087265
55	11	Randomization	2014-12-21 00:01:45.095835	2014-12-21 00:01:45.095835
56	11	Cross-over/Parallel	2014-12-21 00:01:45.101989	2014-12-21 00:01:45.101989
57	9	Route	2014-12-21 22:16:59.947198	2014-12-21 22:16:59.947198
58	9	Formulation	2014-12-21 22:38:53.677847	2014-12-21 22:38:53.677847
59	8	Number of subjects	2014-12-21 22:41:34.358986	2014-12-21 22:41:34.358986
62	12	ClinicalTrials.gov Identifier	2015-01-10 18:55:52.434814	2015-01-10 18:55:52.434814
63	12	Sponsor Study Number	2015-01-10 18:55:52.444824	2015-01-10 18:55:52.444824
64	12	Study Name	2015-01-10 18:55:52.455855	2015-01-10 18:55:52.455855
69	1	Measurement Time	2015-01-12 00:57:27.034776	2015-01-12 00:57:27.034776
70	1	Measurement Time Unit	2015-01-12 00:57:27.043561	2015-01-12 00:57:27.043561
71	1	Measurement Type	2015-01-16 03:35:56.572281	2015-01-16 03:35:56.572281
72	16	Adverse Event Name	2015-01-18 15:11:15.336001	2015-01-18 15:11:15.336001
73	16	Severity (Mild/Moderate/Severe)	2015-01-18 15:11:15.346621	2015-01-18 15:11:15.346621
74	16	Serious/SAE	2015-01-18 15:11:15.353004	2015-01-18 15:11:15.353004
75	16	Subject Count	2015-01-18 15:11:15.359181	2015-01-18 15:11:15.359181
76	16	Subject Percent	2015-01-18 15:11:15.366067	2015-01-18 15:11:15.366067
77	16	Event Count	2015-01-18 15:11:15.372717	2015-01-18 15:11:15.372717
78	16	Description	2015-01-18 15:11:15.379409	2015-01-18 15:11:15.379409
79	17	Planned Number of Subjects Randomized	2015-01-24 17:39:54.277248	2015-01-24 17:39:54.277248
80	17	Planned Number of Subjects Completing the Study	2015-01-24 17:39:54.286282	2015-01-24 17:39:54.286282
81	18	Patient	2015-01-24 18:45:09.21999	2015-01-24 18:45:09.21999
82	18	Race	2015-01-24 18:45:09.228109	2015-01-24 18:45:09.228109
83	16	Related	2015-01-25 22:27:06.545441	2015-01-25 22:27:06.545441
\.


--
-- Name: template_fields_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('template_fields_id_seq', 83, true);


--
-- Data for Name: view_only_accesses; Type: TABLE DATA; Schema: public; Owner: documentcloud
--

COPY view_only_accesses (id, document_id, account_id, created_at, updated_at) FROM stdin;
1	42	23	2015-03-27 00:00:00	2015-03-27 00:00:00
2	47	23	2015-03-27 00:00:00	2015-03-27 00:00:00
3	48	23	2015-03-27 00:00:00	2015-03-27 00:00:00
4	42	23	2015-03-27 00:00:00	2015-03-27 00:00:00
5	47	23	2015-03-27 00:00:00	2015-03-27 00:00:00
6	48	23	2015-03-27 00:00:00	2015-03-27 00:00:00
7	42	23	2015-03-27 00:00:00	2015-03-27 00:00:00
8	47	23	2015-03-27 00:00:00	2015-03-27 00:00:00
9	48	23	2015-03-27 00:00:00	2015-03-27 00:00:00
10	42	23	2015-03-27 00:00:00	2015-03-27 00:00:00
11	47	23	2015-03-27 00:00:00	2015-03-27 00:00:00
12	48	23	2015-03-27 00:00:00	2015-03-27 00:00:00
13	42	23	2015-03-30 00:00:00	2015-03-30 00:00:00
14	47	23	2015-03-30 00:00:00	2015-03-30 00:00:00
15	48	23	2015-03-30 00:00:00	2015-03-30 00:00:00
\.


--
-- Name: view_only_accesses_id_seq; Type: SEQUENCE SET; Schema: public; Owner: documentcloud
--

SELECT pg_catalog.setval('view_only_accesses_id_seq', 15, true);


--
-- Name: accounts_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY accounts
    ADD CONSTRAINT accounts_pkey PRIMARY KEY (id);


--
-- Name: annotation_groups_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY annotation_groups
    ADD CONSTRAINT annotation_groups_pkey PRIMARY KEY (id);


--
-- Name: annotation_notes_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY annotation_notes
    ADD CONSTRAINT annotation_notes_pkey PRIMARY KEY (id);


--
-- Name: annotations_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY annotations
    ADD CONSTRAINT annotations_pkey PRIMARY KEY (id);


--
-- Name: app_constants_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY app_constants
    ADD CONSTRAINT app_constants_pkey PRIMARY KEY (id);


--
-- Name: collaborations_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY collaborations
    ADD CONSTRAINT collaborations_pkey PRIMARY KEY (id);


--
-- Name: docdata_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY docdata
    ADD CONSTRAINT docdata_pkey PRIMARY KEY (id);


--
-- Name: document_reviewers_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY document_reviewers
    ADD CONSTRAINT document_reviewers_pkey PRIMARY KEY (id);


--
-- Name: documents_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY documents
    ADD CONSTRAINT documents_pkey PRIMARY KEY (id);


--
-- Name: entities_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY entities
    ADD CONSTRAINT entities_pkey PRIMARY KEY (id);


--
-- Name: entity_dates_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY entity_dates
    ADD CONSTRAINT entity_dates_pkey PRIMARY KEY (id);


--
-- Name: featured_reports_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY featured_reports
    ADD CONSTRAINT featured_reports_pkey PRIMARY KEY (id);


--
-- Name: file_status_histories_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY file_status_histories
    ADD CONSTRAINT file_status_histories_pkey PRIMARY KEY (id);


--
-- Name: graph_groups_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY graph_groups
    ADD CONSTRAINT graph_groups_pkey PRIMARY KEY (id);


--
-- Name: graphs_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY graphs
    ADD CONSTRAINT graphs_pkey PRIMARY KEY (id);


--
-- Name: group_templates_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY group_templates
    ADD CONSTRAINT group_templates_pkey PRIMARY KEY (id);


--
-- Name: groups_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY groups
    ADD CONSTRAINT groups_pkey PRIMARY KEY (id);


--
-- Name: memberships_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY memberships
    ADD CONSTRAINT memberships_pkey PRIMARY KEY (id);


--
-- Name: organizations_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY organizations
    ADD CONSTRAINT organizations_pkey PRIMARY KEY (id);


--
-- Name: pages_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY pages
    ADD CONSTRAINT pages_pkey PRIMARY KEY (id);


--
-- Name: pending_memberships_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY pending_memberships
    ADD CONSTRAINT pending_memberships_pkey PRIMARY KEY (id);


--
-- Name: processing_jobs_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY processing_jobs
    ADD CONSTRAINT processing_jobs_pkey PRIMARY KEY (id);


--
-- Name: project_memberships_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY project_memberships
    ADD CONSTRAINT project_memberships_pkey PRIMARY KEY (id);


--
-- Name: projects_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY projects
    ADD CONSTRAINT projects_pkey PRIMARY KEY (id);


--
-- Name: qc_reviews_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY reviews
    ADD CONSTRAINT qc_reviews_pkey PRIMARY KEY (id);


--
-- Name: remote_urls_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY remote_urls
    ADD CONSTRAINT remote_urls_pkey PRIMARY KEY (id);


--
-- Name: repositories_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY repositories
    ADD CONSTRAINT repositories_pkey PRIMARY KEY (id);


--
-- Name: sections_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY sections
    ADD CONSTRAINT sections_pkey PRIMARY KEY (id);


--
-- Name: security_keys_pkey; Type: CONSTRAINT; Schema: public; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY security_keys
    ADD CONSTRAINT security_keys_pkey PRIMARY KEY (id);


--
-- Name: subtemplate_fields_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY subtemplate_fields
    ADD CONSTRAINT subtemplate_fields_pkey PRIMARY KEY (id);


--
-- Name: subtemplates_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY subtemplates
    ADD CONSTRAINT subtemplates_pkey PRIMARY KEY (id);


--
-- Name: template_fields_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY template_fields
    ADD CONSTRAINT template_fields_pkey PRIMARY KEY (id);


--
-- Name: view_only_accesses_pkey; Type: CONSTRAINT; Schema: public; Owner: documentcloud; Tablespace: 
--

ALTER TABLE ONLY view_only_accesses
    ADD CONSTRAINT view_only_accesses_pkey PRIMARY KEY (id);


--
-- Name: foo2; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX foo2 ON documents USING btree (organization_id);


--
-- Name: index_accounts_on_email; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE UNIQUE INDEX index_accounts_on_email ON accounts USING btree (email);


--
-- Name: index_accounts_on_identites; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_accounts_on_identites ON accounts USING gin (identities);


--
-- Name: index_annotation_group; Type: INDEX; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE INDEX index_annotation_group ON annotation_groups USING btree (group_id);


--
-- Name: index_annotations_on_document_id; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_annotations_on_document_id ON annotations USING btree (document_id);


--
-- Name: index_docdata_on_data; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_docdata_on_data ON docdata USING gin (data);


--
-- Name: index_documents_on_access; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_documents_on_access ON documents USING btree (access);


--
-- Name: index_documents_on_account_id; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_documents_on_account_id ON documents USING btree (account_id);


--
-- Name: index_documents_on_file_hash; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_documents_on_file_hash ON documents USING btree (file_hash);


--
-- Name: index_documents_on_hit_count; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_documents_on_hit_count ON documents USING btree (hit_count);


--
-- Name: index_documents_on_public_note_count; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_documents_on_public_note_count ON documents USING btree (public_note_count);


--
-- Name: index_group_document; Type: INDEX; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE INDEX index_group_document ON groups USING btree (document_id);


--
-- Name: index_labels_on_account_id; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_labels_on_account_id ON projects USING btree (account_id);


--
-- Name: index_memberships_on_account_id; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_memberships_on_account_id ON memberships USING btree (account_id);


--
-- Name: index_memberships_on_organization_id; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_memberships_on_organization_id ON memberships USING btree (organization_id);


--
-- Name: index_metadata_dates_on_document_id_and_date; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE UNIQUE INDEX index_metadata_dates_on_document_id_and_date ON entity_dates USING btree (document_id, date);


--
-- Name: index_metadata_on_document_id; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_metadata_on_document_id ON entities USING btree (document_id);


--
-- Name: index_metadata_on_kind; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_metadata_on_kind ON entities USING btree (kind);


--
-- Name: index_organizations_on_name; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE UNIQUE INDEX index_organizations_on_name ON organizations USING btree (name);


--
-- Name: index_organizations_on_slug; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE UNIQUE INDEX index_organizations_on_slug ON organizations USING btree (slug);


--
-- Name: index_pages_on_document_id; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_pages_on_document_id ON pages USING btree (document_id);


--
-- Name: index_pages_on_page_number; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_pages_on_page_number ON pages USING btree (page_number);


--
-- Name: index_pages_on_start_offset_and_end_offset; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_pages_on_start_offset_and_end_offset ON pages USING btree (start_offset, end_offset);


--
-- Name: index_parent_group; Type: INDEX; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE INDEX index_parent_group ON groups USING btree (parent_id);


--
-- Name: index_processing_jobs_on_account_id; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_processing_jobs_on_account_id ON processing_jobs USING btree (account_id);


--
-- Name: index_project_memberships_on_document_id; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_project_memberships_on_document_id ON project_memberships USING btree (document_id);


--
-- Name: index_project_memberships_on_project_id; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_project_memberships_on_project_id ON project_memberships USING btree (project_id);


--
-- Name: index_sections_on_document_id; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_sections_on_document_id ON sections USING btree (document_id);


--
-- Name: index_status; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE INDEX index_status ON documents USING btree (status);


--
-- Name: index_template_used; Type: INDEX; Schema: public; Owner: documentcloud; Tablespace: 
--

CREATE INDEX index_template_used ON groups USING btree (template_id);


--
-- Name: unique_schema_migrations; Type: INDEX; Schema: public; Owner: postgres; Tablespace: 
--

CREATE UNIQUE INDEX unique_schema_migrations ON schema_migrations USING btree (version);


--
-- Name: public; Type: ACL; Schema: -; Owner: postgres
--

REVOKE ALL ON SCHEMA public FROM PUBLIC;
REVOKE ALL ON SCHEMA public FROM postgres;
GRANT ALL ON SCHEMA public TO postgres;
GRANT ALL ON SCHEMA public TO PUBLIC;


--
-- PostgreSQL database dump complete
--

